=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehab368.pdf",
  "converted_date": "2026-01-31T14:45:21.643421",
  "file_size_bytes": 5230394,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehab368.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
EuropeanHeartJournal(2021)42,3599(cid:2)3726
doi:10.1093/eurheartj/ehab368
2021 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure
Developed by the Task Force for the diagnosis and treatment of acute
and chronic heart failure of the European Society of Cardiology (ESC)
With the special contribution of the Heart Failure Association
(HFA) of the ESC
Authors/Task Force Members: Theresa A. McDonagh* (Chairperson) (United
Kingdom), Marco Metra * (Chairperson) (Italy), Marianna Adamo (Task Force
Coordinator) (Italy), Roy S. Gardner (Task Force Coordinator) (United Kingdom),
Andreas Baumbach (United Kingdom), Michael Bo¨hm (Germany), Haran Burri
(Switzerland), Javed Butler (United States of America), Jelena C(cid:2) elutkiene_
(Lithuania), Ovidiu Chioncel (Romania), John G.F. Cleland (United Kingdom),
Andrew J.S. Coats (United Kingdom), Maria G. Crespo-Leiro (Spain),
Dimitrios Farmakis (Greece), Martine Gilard (France), Stephane Heymans
*Correspondingauthors:Thetwochairpersonscontributedequallytothedocument.
TheresaMcDonagh,CardiologyDepartment,King’sCollegeHospital,DenmarkHill,London,SE59RS,UnitedKingdom.Tel:þ44203299325,
E-mail:theresa.mcdonagh@kcl.ac.uk;
MarcoMetra,InstituteofCardiology,ASSTSpedaliCivilidiBresciaandDepartmentofMedicalandSurgicalSpecialties,RadiologicalSciencesandPublicHealth,Universityof
Brescia,Brescia,Italy.Tel:þ3930307221,E-mail:metramarco@libero.it
Author/TaskForceMemberaffiliations:listedinAuthorinformation.
ESCClinicalPracticeGuidelinesCommittee(CPG):listedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AssociationforAcuteCardioVascularCare(ACVC),AssociationofCardiovascularNursing&AlliedProfessions(ACNAP),EuropeanAssociationof
CardiovascularImaging(EACVI),EuropeanAssociationofPreventiveCardiology(EAPC),EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),European
HeartRhythmAssociation(EHRA),HeartFailureAssociation(HFA).
Councils:CouncilofCardio-Oncology,CouncilonBasicCardiovascularScience,CouncilonValvularHeartDisease.
WorkingGroups:AdultCongenitalHeartDisease,CardiovascularPharmacotherapy,CardiovascularRegenerativeandReparativeMedicine,CardiovascularSurgery,
e-Cardiology,MyocardialandPericardialDiseases,MyocardialFunction.
PatientForum
ThecontentoftheseEuropeanSocietyofCardiology(ESC)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.Nopartof
theESCGuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESC.Permissioncanbeobtaineduponsubmissionofawrittenrequestto
OxfordUniversityPress,thepublisheroftheEuropeanHeartJournalandthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.permissions@oup.com).
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavailableat
thetimeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancyand/orambiguitybetweentheESCGuidelinesandanyotherofficialrecommen-
dationsorguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsareencouraged
totaketheESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasinthedeterminationandtheimplementationofpreventive,diagnosticortherapeutic
medicalstrategies;however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedeci-
sionsinconsiderationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scaregiver.NordotheESC
Guidelinesexempthealthprofessionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublic
healthauthorities,inordertomanageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itisalsothehealth
professional’sresponsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
Thisarticlehasbeenco-publishedwithpermissionintheEuropeanHeartJournalandEuropeanJournalofHeartFailure.VC theEuropeanSocietyofCardiology2021.Allrightsreserved.
Thearticlesareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournal’sstyle.Eithercitationcanbeusedwhencitingthisarticle.Forpermissions,
pleaseemailjournals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 2 ---
3600 ESCGuidelines
(Netherlands), Arno W. Hoes (Netherlands), Tiny Jaarsma (Sweden), Ewa A.
Jankowska (Poland), Mitja Lainscak (Slovenia), Carolyn S.P. Lam (Singapore),
Alexander R. Lyon (United Kingdom), John J.V. McMurray (United Kingdom),
Alexandre Mebazaa (France), Richard Mindham (United Kingdom), Claudio
Muneretto (Italy), Massimo Francesco Piepoli (Italy), SusannaPrice (United
Kingdom), Giuseppe M.C. Rosano (United Kingdom), FrankRuschitzka(Switzer
land), Anne Kathrine Skibelund (Denmark), ESC Scientific Document Group
DocumentReviewers:RudolfA.deBoer(CPGReviewCoordinator)(Netherlands),P.ChristianSchulze
(CPGReviewCoordinator)(Germany),MagdyAbdelhamid(Egypt),VictorAboyans(France),
StamatisAdamopoulos(Greece),StefanD.Anker(Germany),ElenaArbelo(Spain),RiccardoAsteggiano
(Italy),JohannBauersachs(Germany),AntoniBayes-Genis(Spain),MichaelA.Borger(Germany),
WernerBudts(Belgium),MajaCikes(Croatia),KevinDamman(Netherlands),VictoriaDelgado
(Netherlands),PaulDendale(Belgium),PolychronisDilaveris(Greece),HeinzDrexel(Austria),
JustinEzekowitz(Canada),VolkmarFalk(Germany),LaurentFauchier(France),GerasimosFilippatos
(Greece),AlanFraser(UnitedKingdom),NorbertFrey(Germany),ChrisP.Gale(UnitedKingdom),
FinnGustafsson(Denmark),JulieHarris(UnitedKingdom),BernardIung(France),StefanJanssens
(Belgium),MariellJessup(UnitedStatesofAmerica),AleksandraKonradi(Russia),DipakKotecha(United
Kingdom),EkateriniLambrinou(Cyprus),PatrizioLancellotti(Belgium),UlfLandmesser(Germany),
ChristopheLeclercq(France),BasilS.Lewis(Israel),FranciscoLeyva(UnitedKingdom),Ale(cid:2)sLinhart
(CzechRepublic),Maja-LisaLøchen(Norway),LarsH.Lund(Sweden),DonnaMancini(UnitedStatesof
America),JosepMasip(Spain),DavorMilicic(Croatia),ChristianMueller(Switzerland),HolgerNef
(Germany),Jens-CosedisNielsen(Denmark),LisNeubeck(UnitedKingdom),MichelNoutsias(Germany),
SteffenE.Petersen(UnitedKingdom),AnnaSoniaPetronio(Italy),PiotrPonikowski(Poland),
EvaPrescott(Denmark),AminaRakisheva(Kazakhstan),DimitriosJ.Richter(Greece),EvgenySchlyakhto
(Russia),PetarSeferovic(Serbia),MicheleSenni(Italy),MartaSitges(Spain),MiguelSousa-Uva(Portugal),
CarloG.Tocchetti(Italy),RhianM.Touyz(UnitedKingdom),CarstenTschoepe(Germany),
JohannesWaltenberger(Germany/Switzerland)
Allexpertsinvolvedinthedevelopmentoftheseguidelineshavesubmitteddeclarationsofinterest.
Thesehavebeencompiledinareportandpublishedinasupplementarydocumentsimultaneouslytothe
guidelines.ThereportisalsoavailableontheESCwebsitewww.escardio.org/guidelines
FortheSupplementaryDatawhichincludebackgroundinformationanddetaileddiscussionofthedata
thathaveprovidedthebasisfortheguidelinesseeEuropeanHeartJournalonline
Onlinepublish-ahead-of-print27August2021
...................................................................................................................................................................................................
Keywords Guidelines (cid:129) heartfailure (cid:129) natriureticpeptides (cid:129) ejectionfraction (cid:129) diagnosis (cid:129) pharmacotherapy (cid:129)
neuro-hormonalantagonists (cid:129) cardiacresynchronizationtherapy (cid:129) mechanicalcirculatorysupport (cid:129)
transplantation (cid:129) arrhythmias (cid:129) comorbidities (cid:129) hospitalization (cid:129) multidisciplinarymanagement (cid:129)
advancedheartfailure (cid:129) acuteheartfailure
.
.
Table of contents . 3.2.2Rightventriculardysfunction ........................... 3613
.
.
. 3.2.3Othercommonterminologyusedinheartfailure ....... 3613
.
.
1Preamble ...................................................... 3607 .. 3.2.4Terminologyrelatedtothesymptomaticseverityof
.
2Introduction ................................................... 3609 .. heartfailure ................................................ 3613
.
2.1Whatisnew .............................................. 3609 .. 3.3Epidemiologyandnaturalhistoryofheartfailure ............ 3613
.
3Definition,epidemiologyandprognosis ......................... 3612 .. 3.3.1Incidenceandprevalence............................... 3613
.
3.1Definitionofheartfailure .................................. 3612 .. 3.3.2Aetiologyofheartfailure .............................. 3614
.
3.2Terminology .............................................. 3612 .. 3.3.3Naturalhistoryandprognosis.......................... 3614
.
3.2.1Heartfailurewithpreserved,mildlyreduced,andreduced .. 4Chronicheartfailure ........................................... 3614
.
ejectionfraction ............................................ 3612 . 4.1Keystepsinthediagnosisofchronicheartfailure ........... 3614
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 3 ---
ESCGuidelines 3601
.
.
4.2Natriureticpeptides ....................................... 3616 . 8Heartfailurewithpreservedejectionfraction ................... 3630
.
.
4.2.1Useinthenon-acutesetting ........................... 3617 . 8.1Thebackgroundtoheartfailurewithpreservedejection
.
.
4.3Investigationstodeterminetheunderlyingaetiologyof . fraction ....................................................... 3630
.
.
chronicheartfailure........................................... 3617 . 8.2Clinicalcharacteristicsofpatientswithheartfailurewith
.
.
5Heartfailurewithreducedejectionfraction ..................... 3619 . preservedejectionfraction .................................... 3630
.
.
5.1Thediagnosisofheartfailurewithreducedejectionfraction . 3619 . 8.3Thediagnosisofheartfailurewithpreservedejection
.
.
5.2Pharmacologicaltreatmentsforpatientswithheart . fraction ....................................................... 3630
.
.
failurewithreducedejectionfraction .......................... 3619 . 8.4Treatmentofheartfailurewithpreservedejectionfraction .. 3631
.
.
5.2.1Goalsofpharmacotherapyforpatientswithheart .. 9Multidisciplinaryteammanagementforthepreventionand
.
failurewithreducedejectionfraction ........................ 3619 .. treatmentofchronicheartfailure ................................ 3633
.
5.2.2Generalprinciplesofpharmacotherapyforheart .. 9.1Preventionofheartfailure ................................. 3633
.
failurewithreducedejectionfraction ........................ 3619 .. 9.2Multidisciplinarymanagementofchronicheartfailure ....... 3633
. 5.3Drugsrecommendedinallpatientswithheartfailurewith .. 9.2.1Modelsofcare ........................................ 3633
.
reducedejectionfraction ...................................... 3620 .. 9.2.2Characteristicsandcomponentsofaheartfailure
.
5.3.1Angiotensin-convertingenzymeinhibitors .............. 3621 .. managementprogramme ................................... 3633
.
5.3.2Beta-blockers ......................................... 3621 .. 9.3Patienteducation,self-careandlifestyleadvice .............. 3633
. 5.3.3Mineralocorticoidreceptorantagonists ................ 3621 .. 9.4Exerciserehabilitation ..................................... 3636
.
5.3.4Angiotensinreceptor-neprilysininhibitor ............... 3621 .. 9.5Follow-upofchronicheartfailure .......................... 3636
.
5.3.5Sodium-glucoseco-transporter2inhibitors ............ 3622 .. 9.5.1Generalfollow-up ..................................... 3636
.
5.4Otherdrugsrecommendedortobeconsidered .. 9.5.2Monitoringwithbiomarkers ........................... 3636
.
.
inselectedpatientswithheartfailurewithreduced . 9.6Telemonitoring............................................ 3636
.
.
ejectionfraction .............................................. 3622 . 10Advancedheartfailure ........................................ 3637
.
.
5.4.1Diuretics.............................................. 3623 . 10.1Epidemiology,diagnosis,andprognosis .................... 3637
.
.
5.4.2AngiotensinIItypeIreceptorblockers ................. 3623 . 10.2Management ............................................. 3639
.
.
5.4.3I-channelinhibitor .................................... 3623 . 10.2.1Pharmacologicaltherapyandrenalreplacement ....... 3639
f .
.
5.4.4Combinationofhydralazineandisosorbidedinitrate .... 3623 . 10.2.2Mechanicalcirculatorysupport ....................... 3639
.
.
5.4.5Digoxin ............................................... 3623 . 10.2.3Hearttransplantation ................................ 3643
.
.
5.4.6Recentlyreportedadvancesfromtrialsinheart . 10.2.4Symptomcontrolandend-of-lifecare ................. 3644
.
.
failurewithreducedejectionfraction ........................ 3624 . 11Acuteheartfailure............................................ 3644
.
.
5.5Strategicphenotypicoverviewofthemanagementof . 11.1Epidemiology,diagnosisandprognosis .................... 3644
.
.
heartfailurewithreducedejectionfraction ..................... 3624 .. 11.2Clinicalpresentations..................................... 3646
.
6Cardiacrhythmmanagementforheartfailurewithreduced .. 11.2.1Acutelydecompensatedheartfailure ................. 3646
.
ejectionfraction ................................................. 3624 .. 11.2.2Acutepulmonaryoedema ............................ 3647
.
6.1Implantablecardioverter-defibrillator....................... 3625 .. 11.2.3Isolatedrightventricularfailure ....................... 3647
.
6.1.1Secondarypreventionofsuddencardiacdeath ......... 3626 .. 11.2.4Cardiogenicshock ................................... 3647
.
6.1.2Primarypreventionofsuddencardiacdeath ............ 3626 .. 11.3Management ............................................. 3649
.
6.1.3Patientselectionforimplantablecardioverter- .. 11.3.1Generalaspects ...................................... 3649
.
defibrillatortherapy ........................................ 3626 .. 11.3.2Oxygentherapyand/orventilatorysupport ........... 3650
.
6.1.4Implantablecardioverter-defibrillatorprogramming..... 3626 .. 11.3.3Diuretics ............................................ 3652
. 6.1.5Subcutaneousandwearableimplantable .. 11.3.4Vasodilators ......................................... 3654
. cardioverter-defibrillators .................................. 3626 .. 11.3.5Inotropes ............................................ 3655
. 6.2Cardiacresynchronizationtherapy ......................... 3627 .. 11.3.6Vasopressors ........................................ 3655
.
.
6.3Devicesunderevaluation .................................. 3628 . 11.3.7Opiates.............................................. 3655
.
.
7Heartfailurewithmildlyreducedejectionfraction .............. 3628 . 11.3.8Digoxin.............................................. 3656
.
.
7.1Thediagnosisofheartfailurewithmildlyreducedejection . 11.3.9Thromboembolismprophylaxis ...................... 3656
.
.
fraction ....................................................... 3628 . 11.3.10Short-termmechanicalcirculatorysupport .......... 3656
.
.
7.2Clinicalcharacteristicsofpatientswithheartfailure . 11.3.11Pre-dischargeassessmentandpost-discharge
.
.
withmildlyreducedejectionfraction........................... 3629 . managementplanning....................................... 3657
.
.
7.3Treatmentsforpatientswithheartfailurewithmildly . 12Cardiovascularcomorbidities ................................. 3657
.
.
reducedejectionfraction ...................................... 3629 . 12.1Arrhythmiasandconductiondisturbances ................. 3657
.
.
7.3.1Angiotensin-convertingenzymeinhibitors .............. 3629 . 12.1.1Atrialfibrillation...................................... 3657
.
.
7.3.2AngiotensinreceptorIItype1receptorblockers ....... 3629 . 12.1.2Ventriculararrhythmias .............................. 3660
.
.
7.3.3Beta-blockers ......................................... 3629 .. 12.1.3Symptomaticbradycardia,pausesandatrio-ventricular
.
7.3.4Mineralocorticoidreceptorantagonists ................ 3629 .. block ...................................................... 3660
.
7.3.5Angiotensinreceptor-neprilysininhibitor ............... 3629 .. 12.2Chroniccoronarysyndromes ............................. 3660
.
7.3.6Otherdrugs .......................................... 3630 .. 12.2.1Medicaltherapy ...................................... 3661
.
7.3.7Devices ............................................... 3630 . 12.2.2Myocardialrevascularization .......................... 3662
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 4 ---
3602 ESCGuidelines
.
.
12.3Valvularheartdisease .................................... 3662 . Recommendationsforspecializeddiagnostictestsforselected
.
.
12.3.1Aorticstenosis ....................................... 3662 . patientswithchronicheartfailuretodetectreversible/treatable
.
.
12.3.2Aorticregurgitation .................................. 3664 . causesofheartfailure ............................................ 3618
.
.
12.3.3Mitralregurgitation................................... 3664 . Pharmacologicaltreatmentsindicatedinpatientswith
.
.
12.3.4Tricuspidregurgitation ............................... 3666 . (NYHAclassII(cid:2)IV)heartfailurewithreducedejectionfraction
.
.
12.4Hypertension ............................................ 3666 . (LVEF<_40%) .................................................... 3620
.
.
12.5Stroke ................................................... 3666 . Otherpharmacologicaltreatmentsindicatedinselected
.
.
13Non-cardiovascularcomorbidities ............................ 3666 .. patientswithNYHAclassII(cid:2)IVheartfailurewithreducedejection
.
13.1Diabetes ................................................. 3666 .. fraction(LVEF<_40%)............................................ 3622
.
13.2Thyroiddisorders ........................................ 3667 .. Recommendationsforanimplantablecardioverter-defibrillator
.
13.3Obesity .................................................. 3668 .. inpatientswithheartfailure ...................................... 3625
.
13.4Frailty,cachexia,sarcopenia............................... 3668 .. Recommendationsforcardiacresynchronizationtherapy
. 13.5Irondeficiencyandanaemia ............................... 3668 .. implantationinpatientswithheartfailure ......................... 3627
.
13.6Kidneydysfunction ....................................... 3669 .. Pharmacologicaltreatmentstobeconsideredinpatientswith
.
13.7Electrolytedisorders:hypokalaemia,hyperkalaemia, .. (NYHAclassII(cid:2)IV)heartfailurewithmildlyreducedejection
.
hyponatraemia,hypochloraemia ............................... 3670 .. fraction ......................................................... 3629
. 13.8Lungdisease,sleep-disorderedbreathing .................. 3671 .. Recommendationsforthetreatmentofpatientswithheartfailure
.
13.9Hyperlipidaemiaandlipid-modifyingtherapy............... 3671 .. withpreservedejectionfraction.................................. 3632
.
13.10Goutandarthritis ....................................... 3672 .. Recommendationsfortheprimarypreventionofheartfailurein
.
13.11Erectiledysfunction ..................................... 3672 .. patientswithriskfactorsforitsdevelopment ..................... 3632
.
.
13.12Depression ............................................. 3672 . Multidisciplinaryinterventionsrecommendedforthemanagement
.
.
13.13Cancer ................................................. 3672 . ofchronicheartfailure........................................... 3633
.
.
13.14Infection ................................................ 3675 . Recommendationsforexerciserehabilitationinpatientswith
.
.
14Specialconditions ............................................ 3675 . chronicheartfailure ............................................. 3636
.
.
14.1Pregnancy ............................................... 3675 . Recommendationsfortelemonitoring ............................ 3637
.
.
14.1.1Pregnancyinpre-existingheartfailure ................. 3675 . Recommendationsforthetreatmentofpatientswithadvanced
.
.
14.1.2Newheartfailurepresentingduringpregnancy ........ 3675 . heartfailure ..................................................... 3643
.
.
14.2Cardiomyopathies ....................................... 3677 . Recommendationsfortheinitialtreatmentofacuteheartfailure... 3655
.
.
14.2.1Epidemiologyanddiagnosis ........................... 3677 . Recommendationsfortheuseofshort-termmechanicalcirculatory
.
.
14.2.2Treatment ........................................... 3677 . supportinpatientswithcardiogenicshock ........................ 3656
.
.
14.3Leftventricularnon-compaction .......................... 3681 .. Recommendationsforpre-dischargeandearlypost-discharge
.
14.4Atrialdisease............................................. 3682 .. follow-upofpatientshospitalizedforacuteheartfailure ........... 3657
.
14.4.1Definition............................................ 3682 .. Recommendationsforthetreatmentofatrialfibrillationin
.
14.4.2Diagnosis ............................................ 3682 .. patientswithheartfailure ........................................ 3660
.
14.4.3Management ......................................... 3682 .. Recommendationsformyocardialrevascularizationinpatients
.
14.5Myocarditis .............................................. 3682 .. withheartfailurewithreducedejectionfraction .................. 3662
.
14.5.1Epidemiologyanddiagnosis ........................... 3682 .. Recommendationsforthemanagementofvalvularheart
.
14.5.2Treatment ........................................... 3682 .. diseaseinpatientswithheartfailure .............................. 3665
.
14.6Amyloidosis.............................................. 3682 .. Recommendationsforthetreatmentofdiabetesinheartfailure ... 3667
. 14.6.1Epidemiologyanddiagnosis ........................... 3682 .. Recommendationsforthemanagementofanaemiaandirondeficiency
. 14.6.2Therapyofamyloidosisandheartfailure .............. 3685 .. inpatientswithheartfailure ...................................... 3669
. 14.7Ironoverloadcardiomyopathy ............................ 3685 .. Recommendationsforthemanagementofpatientswithcancer
.
.
14.8Adultcongenitalheartdisease ............................ 3686 . andheartfailure ................................................. 3675
.
.
15Keymessages ................................................ 3688 . Recommendationsforthetreatmentoftransthyretin
.
.
16Gapsinevidence ............................................. 3689 . amyloidosis-cardiacamyloidosis .................................. 3686
.
.
17‘Whattodo’and‘whatnottodo’messagesfromtheguidelines . 3690 .
.
.
18Qualityindicators ............................................ 3693 .. List of tables
.
19Supplementarydata .......................................... 3694 .
.
.
20Authorinformation........................................... 3694 .. Table1Classesofrecommendations ............................. 3608
.
21Appendix .................................................... 3694 .. Table2Levelsofevidence ....................................... 3608
.
22References ................................................... 3695 .. Table3Definitionofheartfailurewithreducedejectionfraction,
.
.. mildlyreducedejectionfractionandpreservedejectionfraction ... 3613
.
.. Table4NewYorkHeartAssociationfunctionalclassification
.
List of recommendations .. basedonseverityofsymptomsandphysicalactivity ............... 3614
.
.. Table5Causesofheartfailure,commonmodesofpresentation
.
Recommendeddiagnostictestsinallpatientswith .. andspecificinvestigations ........................................ 3616
.
suspectedchronicheartfailure ................................... 3617 . Table6Symptomsandsignstypicalofheartfailure ................ 3617
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 5 ---
ESCGuidelines 3603
.
.
Table7Causesofelevatedconcentrationsofnatriuretic . Table37MainEuropeanSocietyofCardiologyQualityIndicatorsfor
.
.
peptides ........................................................ 3618 . theevaluationofcareandoutcomesforpatientswithheartfailure . 3693
.
.
Table8Evidence-baseddosesofdisease-modifyingdrugsinkey .
.
randomizedtrialsinpatientswithheartfailurewithreduced .. List of figures
.
.
ejectionfraction ................................................. 3621 .
.
. Figure1Thediagnosticalgorithmforheartfailure ................. 3615
Table9Objectiveevidenceofcardiacstructural,functionaland .
.
. Figure2TherapeuticalgorithmofClassITherapyIndicationsfora
serologicalabnormalitiesconsistentwiththepresenceof .
.
. patientwithheartfailurewithreducedejectionfraction ........... 3620
leftventriculardiastolicdysfunction/raisedleftventricularfilling .
.
pressures ....................................................... 3631
... Figure3CentralillustrationStrategicphenotypicoverviewofthe
Table10Riskfactorsforthedevelopmentofheartfailureand
... managementofheartfailurewithreducedejectionfraction........ 3624
potentialcorrectiveactions ...................................... 3632
... Figure4Algorithmforthetreatmentofpatientswithadvanced
Table11Importantcharacteristicsandcomponentsinaheart
... heartfailure ..................................................... 3640
failuremanagementprogramme ................................. 3634
... Figure5Triageofpatientswithadvancedheartfailureand
Table12Patienteducationandself-care .......................... 3634
... appropriatetimingofreferral .................................... 3641
Table13Criteriafordefinitionofadvancedheartfailure ........... 3638
... Figure6Diagnosticworkupofnewonsetacuteheartfailure....... 3645
Table14InteragencyRegistryforMechanicallyAssisted
... Figure7Managementofacutedecompensatedheartfailure ....... 3648
CirculatorySupportprofiledescriptionsofpatientswithadvanced
... Figure8Managementofpulmonaryoedema ...................... 3649
heartfailure ..................................................... 3638
... Figure9Managementofrightventricularfailure ................... 3650
Table15Termsdescribingvariousindicationsformechanical
... Figure10Managementofcardiogenicshock ...................... 3651
.
circulatorysupport .............................................. 3642 .. Figure11Stagesofmanagementofpatientswithacute
.
. heartfailure ..................................................... 3652
Table16Patientspotentiallyeligibleforimplantationofaleft .
.
. Figure12Initialmanagementofacuteheartfailure ................ 3653
ventricularassistdevice .......................................... 3642 .
.
. Figure13Diuretictherapy(furosemide)inacuteheartfailure...... 3654
Table17Hearttransplantation:indicationsand .
.
. Figure14Managementofatrialfibrillationinpatientswithheart
contraindications ................................................ 3643 .
.
. failurewithreducedejectionfraction ............................. 3658
Table18Patientswithheartfailureinwhomend-of-lifecare .
.
. Figure15Algorithmforthemedicaltreatmentofchronic
shouldbeconsidered ............................................ 3644 .
.
. coronarysyndromeinpatientswithheartfailurewithreduced
Table19Keycomponentsofpalliativecareservicein .
.
. ejectionfraction ................................................. 3661
patientswithadvancedheartfailure .............................. 3644 .
.
. Figure16Managementofpatientswithseverelow-flow
Table20Diagnostictestsinpatientswithacuteheartfailure ....... 3646 .
.
. low-gradientaorticstenosisandheartfailure ..................... 3663
Table21Clinicalpresentationsofacuteheartfailure .............. 3647 .
.
Table22Inotropesand/orvasopressorsusedtotreatacuteheart
... Figure17Managementofsecondarymitralregurgitationinpatients
failure ........................................................... 3655
... withheartfailurewithreducedejectionfraction .................. 3664
Table23Cancerdrugscausingheartfailure ....................... 3673
... Figure18Managementofpatientswithcancerandheartfailure .... 3674
Table24Infectionsinpatientswithheartfailure ................... 3675
... Figure19Managementofpatientswithheartfailurebeforeand
Table25Possiblecausesanddiseasemodifiersofmostfrequent
... duringpregnancy ................................................ 3676
cardiomyopathies ............................................... 3678
... Figure20Managementofpatientswithheartfailureandacute
Table26Initialdiagnosticassessmentinpatientswithsuspected
... myocarditis ..................................................... 3684
cardiomyopathy ................................................. 3678 ... Figure21Diagnosisandtreatmentofcardiacamyloidosisin
Table27Dilatedcardiomyopathyorhypokineticnon-dilated
... heartfailurepatients ............................................. 3687
. cardiomyopathy:specificaspectsofdiagnosisandtreatment ....... 3679 ..
. Table28Hypertrophiccardiomyopathy:specificaspectsof .. Abbreviations and acronyms
. diagnosisandtreatment ......................................... 3680 ..
.
Table29Arrhythmogeniccardiomyopathy:specificaspectsof .. 6MWT 6-minutewalktest
.
diagnosisandTreatment ......................................... 3681 .. 99mTc-PYP Technetium-labelledpyrophosphate
.
Table30Aetiologiestobeconsideredtriggeringacute .. AATAC Ablationvs.AmiodaroneforTreatmentof
.
myocarditis ..................................................... 3682 .. AtrialFibrillationinPatientsWith
.
Table31Diagnosticworkupinsuspectedacutemyocarditis ....... 3683 .. CongestiveHeartFailureandanImplanted
.
Table32Endomyocardialbiopsyinpatientswithsuspected .. ICD/CRTD(trial)
.
myocarditis ..................................................... 3684 .. AC Arrhythmogeniccardiomyopathy
.
Table33Cardiacmagneticresonanceinpatientswithsuspected .. ACE Angiotensin-convertingenzyme
.
myocarditis ..................................................... 3685 .. ACE-I Angiotensin-convertingenzymeinhibitor
.
Table34Treatmentandfollow-upofacutemyocarditis ........... 3685 .. ACHD Adultcongenitalheartdisease
.
Table35“Redflags”formostcommonformsofcardiac ... ACS Acutecoronarysyndrome
amyloidosis ..................................................... 3686 ... ADHF Acutelydecompensatedheartfailure
Table36Treatmentofadultcongenitalheartdiseaseandheart ... AF Atrialfibrillation
.
failureinspecializedcentres ...................................... 3688 .. AF-CHF Atrialfibrillation(cid:2)CongestiveHeart
.
. Failure(trial)
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 6 ---
3604 ESCGuidelines
.
AFFIRM AtrialFibrillationFollow-upInvestigationof .. CHARM CandesartaninHeartFailure-Assessment
.
RhythmManagement(trial) .. ofmoRtalityandMorbidity(trial)
.
AFFIRM-AHF ARandomized,Double-blindPlacebo- .. CHF Chronicheartfailure
.
controlledTrialComparingtheEffectof .. CI Confidenceinterval
.
IntravenousFerricCarboxymaltoseon .. CKD Chronickidneydisease
.
.
HospitalizationsandMortalityinIron- . CMP Cardiomyopathy
.
.
deficientSubjectsAdmittedforAcuteHeart . CMR Cardiacmagneticresonance
.
.
Failure(trial) . CMV Cytomegalovirus
.
.
AHF Acuteheartfailure . COAPT CardiovascularOutcomesAssessmentof
.
.
AL Lightchainimmunoglobulin . theMitraClipPercutaneousTherapyforHF
.
.
AL-CA Lightchainimmunoglobulincardiac . patientswithfunctionalmitralregurgitation
.
.
amyloidosis . (trial)
. .
AMICA AtrialFibrillationManagementinCongestive . COC Cardio-OncologyCouncil(partofthe
.
.
HeartFailureWithAblation(trial) . EuropeanSocietyofCardiology)
.
.
ANCA Antineutrophilcytoplasmicantibody . COMMANDER-HF AStudytoAssesstheEffectivenessand
.
.
ARB Angiotensin-receptorblocker . SafetyofRivaroxabaninReducingtheRisk
. .
ARNI Angiotensinreceptor-neprilysininhibitor .. ofDeath,MyocardialInfarctionorStrokein
.
ARVC Arrhythmogenicrightventricular .. ParticipantsWithHeartFailureand
.
cardiomyopathy .. CoronaryArteryDiseaseFollowingan
.
ATTR Transthyretinamyloidosis .. EpisodeofDecompensatedHeartFailure
.
AV Atrio-ventricular .. (trial)
.
b.i.d. Bisindie(twicedaily) .. COMPASS RivaroxabanforthePreventionofMajor
.
BAG3 Bcl2-associatedathanogene3 .. CardiovascularEventsinCoronaryor
.
BiVAD Biventricularassistdevice .. PeripheralArteryDisease(trial)
.
BMI Bodymassindex .. COPD Chronicobstructivepulmonarydisease
.
BNP B-typenatriureticpeptide .. CORONA COntrolledROsuvastatinmultiNAtional
.
BP Bloodpressure .. (trial)
.
.
b.p.m. Beatsperminute . COVID-19 Coronavirusdisease2019
.
.
BTB Bridgetobridge . CR Controlledrelease
.
.
BTC Bridgetocandidacy . CREDENCE CanagliflozinandRenalEndpointsin
.
.
BTD Bridgetodecision . DiabeteswithEstablishedNephropathy
.
.
BTR Bridgetorecovery . ClinicalEvaluation(trial)
.
.
BTT Bridgetotransplantation . CRT Cardiacresynchronizationtherapy
.
.
CA Cardiacamyloidosis(oramyloid . CRT-D Cardiacresynchronizationtherapywith
.
.
cardiomyopathy) . defibrillator
.
.
CABANA CatheterABlationvs.ANti-arrhythmicdrug . CRT-P Cardiacresynchronizationtherapypacemaker
.
. therapyforAtrialfibrillation(trial) . CSA Centralsleepapnoea
.
.
CABG Coronaryarterybypassgraft . CT Computedtomography
.
.
CAD Coronaryarterydisease .. CTCA Computedtomographycoronary
.
CANVAS-R CANagliflozincardioVascularAssessment .. angiography
.
Study-Renal .. CV Cardiovascular
.
CARE-HF CArdiacREsynchronizationinHeartFailure .. DAPA-HF DapagliflozinAndPreventionofAdverse-
.
CASTLE-AF CatheterAblationversusStandard .. outcomesinHeartFailure(trial)
.
conventionalTreatmentinpatientswithLEft .. DCM Dilatedcardiomyopathy
.
ventricularandAtrialFibrillation(trial) .. DECLARE- DapagliflozinEffectonCardiovascuLAR
.
CCB Calciumchannelblocker .. TIMI58 Events(ThrombolysisinMyocardial
.
CCS Chroniccoronarysyndrome .. Infarction)(trial)
.
CHA 2DS 2-VASc Congestiveheartfailureorleftventricular ... DIAMOND PatiromerfortheManagementof
dysfunction,Hypertension,Age>_75 .. HyperkalemiainSubjectsReceivingRAASi
.
(doubled),Diabetes,Stroke(doubled)- .. MedicationsfortheTreatmentofHeart
.
.
Vasculardisease,Age65(cid:2)74,Sexcategory . Failure(trial)
.
.
(female)(score) . DIG DigitalisInvestigationGroup(trial)
.
.
CHAMPIT AcuteCoronarysyndrome/Hypertension . DNA Deoxyribonucleicacid
.
.
emergency/Arrhythmia/acuteMechanical . DOAC Direct-actingoralanticoagulant
.
.
cause/Pulmonaryembolism/Infections/ . DPD 3,3-diphosphono-1,2-propanodicarboxylic
.
.
Tamponade . acid
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 7 ---
ESCGuidelines 3605
.
DPP-4 Dipeptidylpeptidase-4 .. HCM Hypertrophiccardiomyopathy
.
DSC2 Desmocollin2 .. HEART HeartFailureRevascularisationTrial
.
DSG2 Desmoglein2 .. HER2 Humanepidermalgrowthfactorreceptor2
.
DSP Desmoplakin .. HF Heartfailure
.
DT Destinationtherapy .. HFA HeartFailureAssociation
.
E/e0(ratio) E/e0(ratio)=earlyfillingvelocityon .. HFA-PEFF HeartFailureAssociationofESCdiagnostic
.
.
transmitralDoppler/earlyrelaxationvelocity . algorithm,P(cid:2)InitialWorkup(Step1:
.
.
ontissueDoppler . PretestAssessment),E-Diagnostic
.
.
EACVI EuropeanAssociationofCardiovascular . Workup(Step2:Echocardiographicand
.
.
Imaging(partoftheEuropeanSocietyof . NatriureticPeptidescore),F1(cid:2)Advanced
.
.
Cardiology) . Workup(Step3:FunctionaltestinginCase
.
.
EAST-AFNET4 EarlyTreatmentofAtrialFibrillationfor . ofUncertainty),F2(cid:2)AetiologicalWorkup
. .
StrokePreventionTrial4(trial) . (Step4:FinalAetiology)
.
.
ECG Electrocardiogram . HF-MP Heartfailuremanagementprogramme
.
.
EchoCRT EchocardiographyGuidedCardiac . HFmrEF Heartfailurewithmildlyreducedejection
.
.
ResynchronizationTherapy(trial) . fraction
. .
ECLS Extracorporeallifesupport .. HFpEF Heartfailurewithpreservedejectionfraction
.
ECMO Extracorporealmembraneoxygenation .. HFrEF Heartfailurewithreducedejectionfraction
.
EF Ejectionfraction .. HHV Humanherpesvirus
.
eGFR Estimatedglomerularfiltrationrate .. HIV Humanimmunodeficiencyvirus
.
EHRA EuropeanHeartRhythmAssociation .. HLA-DR Humanleukocyteantigen-DRisotype
.
EMA EuropeanMedicinesAgency .. HMDP Hydroxyl-methylene-diphosphonate
.
EMB Endomyocardialbiopsy .. HR Hazardratio
.
EMPA-REG EmpagliflozinCardiovascularOutcome .. HT Hearttransplantation
.
OUTCOME EventTrialinType2DiabetesMellitus .. HTM Hometelemonitoring
.
Patients(trial) .. i.v. Intravenous
.
EMPEROR- EMPagliflozinoutcomEtRialinPatients .. IABP Intra-aorticballoonpump
.
.
Reduced WithchrOnicheaRtFailureWithReduced . ICCU Intensivecoronarycareunit
.
.
EjectionFraction(trial) . ICD Implantablecardioverter-defibrillator
.
.
EROA Effectiveregurgitantorificearea . ICU Intensivecareunit
.
.
ESC EuropeanSocietyofCardiology . IHD Ischaemicheartdisease
.
.
EU EuropeanUnion . INR Internationalnormalizedratio
.
.
EuroSCOREII EuropeanSystemforCardiacOperative . INTERMACS InteragencyRegistryforMechanically
.
.
RiskEvaluationII(score) . AssistedCirculatorySupport
.
.
FDA FoodandDrugAdministration . INTrEPID InvestigationofNontransplant-Eligible
.
.
FDG Fluorodeoxyglucose . PatientsWhoAreInotropeDependent
.
. FiO Fractionofinspiredoxygen . (trial)
2 .
.
FLN Filamin . IOCM Ironoverloadcardiomyopathy
.
.
FLNC FilaminC .. IPD Individualpatientdata
.
GGT Gamma-glutamyltransferase .. I-PRESERVE IrbesartaninPatientswithHeartFailureand
.
GISSI-HF GruppoItalianoperloStudiodella .. PRESERVEdEjectionFraction(trial)
.
Streptochinasinell’InfartoMiocardico(cid:2) .. KCNH2 Potassiumvoltage-gatedchannelsubfamily
.
HeartFailure(trial) .. Hmember2
.
GLP-1 Glucagon-likepeptide-1 .. KCNQ1 Potassiumvoltage-gatedchannelsubfamily
.
GUIDE-HF Hemodynamic-GUIDEdManagementof .. Qmember1
.
HeartFailure(trial) .. LA Leftatrium/atrial
.
h Hour/hours .. LAE Leftatrialenlargement
.
H 2FPEF Heavy(BMI>30kg/m2),Hypertensive(useof ... LBBB Leftbundlebranchblock
>_2antihypertensivemedications),atrial .. LDB3 LIMdomainbinding3
.
Fibrillation(paroxysmalorpersistent), .. LFT Liverfunctiontest
.
.
Pulmonaryhypertension(Doppler . LGE Lategadoliniumenhancement
.
.
EchocardiographicestimatedPulmonary . LMNA LaminA/C
.
.
ArterySystolicPressure>35mmHg),Elderly . LMWH Low-molecular-weightheparin
.
.
(age>60years),Fillingpressure(Doppler . LUS Lungultrasound
.
EchocardiographicE/e0>9)(score) .. LV Leftventricular/ventricle
.
.
HbA1c Glycatedhaemoglobin . LVAD Leftventricularassistdevice
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 8 ---
3606 ESCGuidelines
.
LVEDP Leftventricularend-diastolicpressure .. PLN Phospholamban
.
LVEF Leftventricularejectionfraction .. PPCM Peripartumcardiomyopathy
.
LVESD Leftventricularend-systolicdiameter .. PREVEND PreventionofREnalandVascularENd-stage
.
LVH Leftventricularhypertrophy .. Disease(trial)
.
LVNC Leftventricularnon-compaction .. PV Pulmonaryvein
.
.
LVOT Leftventricularoutflowtract . PVC Prematureventricularcontraction
.
.
LVOTO Leftventricularoutflowtractobstruction . PVI Pulmonaryveinisolation
.
.
MADIT-CRT MulticenterAutomaticDefibrillator . pVO Peakexerciseoxygenconsumption
. 2
.
ImplantationTrialwithCardiac . QI Qualityindicator
.
.
ResynchronizationTherapy(trial) . QOL Qualityoflife
.
.
MADIT-II MulticenterAutomaticDefibrillator . QRS Q,R,andSwavesofanECG
.
.
ImplantationTrialII(trial) . RAAS Renin-angiotensin-aldosteronesystem
. .
MADIT-RIT MulticenterAutomaticDefibrillator . RACEII RateControlEfficacyinPermanentAtrial
.
.
ImplantationTrial(cid:2)ReduceInappropriate . Fibrillation:aComparisonbetweenLenient
.
.
Therapy(trial) . versusStrictRateControlII(trial)
.
.
MAGGIC Meta-AnalysisGlobalGroupinChronic . RAFT Resynchronization/Defibrillationfor
. .
HeartFailure .. AmbulatoryHeartFailureTrial(trial)
.
MCS Mechanicalcirculatorysupport .. RASi Renin-angiotensinsysteminhibitor
.
MEK Mitogen-activatedproteinkinase .. RATE-AF RateControlTherapyEvaluationin
.
MI Myocardialinfarction .. PermanentAtrialFibrillation(trial)
.
MITRA-FR PercutaneousRepairwiththeMitraClip .. RBM20 Ribonucleicacidbindingmotif20
.
DeviceforSevereFunctional/Secondary .. RCT Randomizedcontrolledtrial
.
MitralRegurgitation(trial) .. REMATCH RandomizedEvaluationofMechanical
.
MMR Mismatchrepair .. AssistancefortheTreatmentofCongestive
.
MR Mitralregurgitation .. HeartFailure(trial)
.
MRA Mineralocorticoidreceptorantagonist .. REVERSE REsynchronizationreVErsesRemodeling
.
MRI Magneticresonanceimaging .. inSystolicleftvEntriculardysfunction
.
.
mRNA Messengerribonucleicacid . (trial)
.
.
MR-proANP Mid-regionalpro-atrialnatriureticpeptide . REVIVED REVascularizationforIschaemicVEntricular
.
.
MT Medicaltherapy . Dysfunction(trial)
.
.
MV Mitralvalve . RNA Ribonucleicacid
.
.
mWHO ModifiedWorldHealthOrganization . RRT Renalreplacementtherapy
.
.
MYPC Myosin-bindingproteinC . RV Rightventricular/ventricle
.
.
NICM Non-ischaemiccardiomyopathy . RVAD Rightventricularassistdevice
.
.
NKX2-5 NK2transcriptionfactorrelated,locus5 . RVEDP Rightventricularend-diastolicpressure
.
.
NP Natriureticpeptide . SARS-CoV-2 Severeacuterespiratorysyndrome
.
. NSAID Non-steroidalanti-inflammatorydrug . coronavirus2
.
.
NSVT Non-sustainedventriculartachycardia . SAVR Surgicalaorticvalvereplacement
.
.
NT-proBNP N-terminalpro-B-typenatriureticpeptide .. SBP Systolicbloodpressure
.
NYHA NewYorkHeartAssociation .. SCORED EffectofSotagliflozinonCardiovascularand
.
o.d Omneindie(oncedaily) .. RenalEventsinPatientswithType2
.
OMT Optimalmedicaltherapy .. DiabetesandModerateRenalImpairment
.
OSA Obstructivesleepapnoea .. WhoAreatCardiovascularRisk(trial)
.
PA Pulmonaryartery .. SCN5a Sodiumchannelalphasubunit5
.
PaO
2
Partialpressureofoxygen ... SENIORS StudyoftheEffectsofNebivololIntervention
PARADIGM-HF ProspectivecomparisonofARNIwithACEI .. onOutcomesandRehospitalizationsin
.
toDetermineImpactonGlobalMortality .. SeniorswithHeartFailure(trial)
.
andmorbidityinHeartFailure(trial) .. SERVE-HF TreatmentofSleep-DisorderedBreathing
.
pCO
2
Partialpressureofcarbondioxide ... withPredominantCentralSleepApneaby
PCI Percutaneouscoronaryintervention .. AdaptiveServoVentilationinPatientswith
.
.
PCR Polymerasechainreaction . HeartFailure(trial)
.
.
PCWP Pulmonarycapillarywedgepressure . SGLT2 Sodium-glucoseco-transporter2
.
.
PEP-CHF PerindoprilinElderlyPeoplewithChronic . S-ICD Subcutaneousimplantablecardioverter-
.
.
HeartFailure(trial) . defibrillator
.
.
PET Positronemissiontomography . SMR Secondarymitralregurgitation
.
.
PKP2 Plakophilin2 . SPECT Single-photonemissioncomputedtomography
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 9 ---
ESCGuidelines 3607
.
.
SpO
2
Transcutaneousoxygensaturation ... societiesandorganizations.Becauseoftheirimpactonclinicalprac-
SR Sinusrhythm .. tice, quality criteria for the development of guidelines have been
.
STEMI ST-elevationmyocardialinfarction .. established in order to make all decisions transparent to the user.
.
STICH SurgicalTreatmentforIschemicHeart .. The recommendations for formulating and issuing ESC Guidelines
.
Failure(trial) .. can be found on the ESC website (https://www.escardio.org/
.
STICHES Extendedfollow-upofpatientsfromthe .. Guidelines).TheESCGuidelinesrepresenttheofficialpositionofthe
.
STICHtrial .. ESConagiventopicandareregularlyupdated.
.
STS-PROM SocietyofThoracicSurgeonsPredictedRisk .. InadditiontothepublicationofClinicalPracticeguidelines,theESC
.
ofMortality .. carriesouttheEURObservationalResearchProgrammeofinternational
.
SZC Sodiumzirconiumcyclosilicate .. registriesofcardiovascular(CV)diseasesandinterventionswhichare
.
T2DM Type2diabetesmellitus .. essential to assess diagnostic/therapeutic processes, use of resources
.
TAVI Transcatheteraorticvalveimplantation .. andadherencetoguidelines.Theseregistriesaimatprovidingabetter
. TFT Thyroidfunctiontest .. understanding of medical practice in Europe and around the world,
.
t.i.d. Terindie(threetimesaday) .. basedonhigh-qualitydatacollectedduringroutineclinicalpractice.
.
TKI Tyrosinekinaseinhibitor .. Furthermore,theESChasdevelopedandembeddedinthisdocu-
.
TMEM43 Transmembraneprotein43 .. mentasetofqualityindicators(QIs),whicharetoolstoevaluatethe
. TNNT Troponin-T ... level of implementation of the guidelines and may be used by the
TR Tricuspidregurgitation ... ESC, hospitals, healthcare providers and professionals to measure
TRPM4 Transientreceptorpotentialcationchannel ... clinicalpracticeaswellasusedineducationalprogrammes,alongside
subfamilyMmember4 ... thekeymessagesfromtheguidelines,toimprovequalityofcareand
.
TSAT Transferrinsaturation .. clinicaloutcomes.
.
TSH Thyroid-stimulatinghormone .. TheMembersofthisTaskForcewereselectedbytheESC,includ-
.
TTN Titin .. ing representation from its relevant ESC sub-specialty groups, in
.
TTR Transthyretin .. order to representprofessionalsinvolved withthe medicalcare of
.
UK UnitedKingdom .. patientswiththispathology.Selectedexpertsinthefieldundertooka
.
US UnitedStates .. comprehensivereviewofthepublishedevidenceformanagementof
.
VAD Ventricularassistdevice .. a given condition according to ESC Clinical Practice Guidelines
.
Val-HeFT ValsartanHeartFailureTrial(trial) .. (CPG)Committeepolicy.Acriticalevaluationofdiagnosticandther-
.
VEGF Vascularendothelialgrowthfactor .. apeutic procedures was performed, including assessment of the
.
VERTIS-CV CardiovascularOutcomesFollowing .. risk(cid:2)benefitratio.Thelevelofevidenceandthestrengthoftherec-
.
ErtugliflozinTreatmentinType2Diabetes .. ommendationofparticularmanagementoptionswereweighedand
.
MellitusParticipantsWithVascularDisease .. gradedaccordingtopredefinedscales,asoutlinedbelow.
.
(trial) .. Theexpertsofthewritingandreviewingpanelsprovideddeclara-
.
VEST VestPreventionofEarlySuddenDeathTrial .. tionofinterestformsforallrelationshipsthatmightbeperceivedas
.
(trial) .. realorpotentialsourcesofconflictsofinterest.Theirdeclarationsof
.
VKA VitaminKantagonist .. interestwerereviewedaccordingtotheESCdeclarationofinterest
.
VO Oxygenconsumption .. rulesandcanbefoundontheESCwebsite(http://www.escardio.org/
2 .
VPB Ventricularprematurebeat .. guidelines) and have been compiled in a report and published in a
.
vs Versus ... supplementarydocumentsimultaneouslytotheguidelines.
VVinterval Interventriculardelayinterval ... Thisprocessensurestransparencyandpreventspotentialbiasesin
WARCEF WarfarinandAspirininReducedCardiac ... thedevelopmentandreviewprocesses.Anychangesindeclarationsof
EjectionFraction(trial) ... interestthatariseduringthewritingperiodwerenotifiedtotheESC
.
wtTTR-CA Wild-typetransthyretincardiacamyloidosis .. andupdated.TheTaskForcereceiveditsentirefinancialsupportfrom
.
XL Extendedrelease .. theESCwithoutanyinvolvementfromthehealthcareindustry.
.
. TheESCCPGsupervisesandcoordinatesthepreparationofnew
.
.
. guidelines.TheCommitteeisalsoresponsiblefortheendorsement
.
.
1 Preamble . processoftheseGuidelines.TheESCGuidelinesundergoextensive
.
.
. reviewbytheCPGandexternalexperts.Afterappropriaterevisions
.
.
Guidelinessummarizeandevaluateavailableevidencewiththeaimof . theguidelinesaresigned-offbyalltheexpertsinvolvedintheTask
.
.
assistinghealthprofessionalsinproposingthebestmanagementstrat- .. Force.Thefinalizeddocumentissigned-offbytheCPGforpublica-
.
egies for an individual patient with a given condition. Guidelines and .. tionintheEuropeanHeartJournal.Theguidelinesweredeveloped
.
theirrecommendationsshouldfacilitatedecisionmakingofhealthpro- .. after careful consideration of the scientific and medical knowledge
.
fessionalsintheirdailypractice.However,thefinaldecisionsconcerning .. andtheevidenceavailableatthetimeoftheirdating.
.
anindividualpatientmustbemadebytheresponsiblehealthprofessio- .. ThetaskofdevelopingESCGuidelinesalsoincludesthecreationof
.
nal(s)inconsultationwiththepatientandcaregiverasappropriate. .. educationaltoolsandimplementationprogrammesfortherecommen-
.
Agreatnumberofguidelineshavebeenissuedinrecentyearsby .. dationsincludingcondensedpocketguidelineversions,summaryslides,
.
the European Society of Cardiology (ESC), as well as by other . summarycardsfornon-specialistsandanelectronicversionfordigital
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 10 ---
3608 ESCGuidelines
Table1 Classesofrecommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table2 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
.
.
applications(smartphones,etc.).Theseversionsareabridgedandthus, . judgment,aswellasinthedeterminationandtheimplementation
.
.
formoredetailedinformation,theusershouldalwaysaccesstothefull . of preventive, diagnostic, or therapeutic medical strategies.
.
.
textversionoftheguidelines,whichisfreelyavailableviatheESCweb- . However,theESCGuidelinesdonotoverrideinanywaywhatso-
.
.
siteandhostedontheEHJwebsite.TheNationalCardiacSocietiesof . everthe individual responsibility of healthprofessionals to make
.
.
theESCareencouragedtoendorse,adopt,translateandimplementall . appropriate and accurate decisions in consideration of each
.
.
ESC Guidelines. Implementation programmes are needed because it . patient’shealthconditionandinconsultationwiththatpatientor
.
.
hasbeenshownthattheoutcomeofdiseasemaybefavourablyinflu- .. the patient’s caregiver where appropriate and/or necessary. It is
.
encedbythethoroughapplicationofclinicalrecommendations. .. alsothehealthprofessional’sresponsibilitytoverifytherulesand
.
Health professionals are encouraged to take the ESC .. regulationsapplicableineachcountrytodrugsanddevicesatthe
.
Guidelines fully into account when exercising their clinical . timeofprescription.
snoitadnemmocer
fo
sessalC
1202
CSE©
1202
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 11 ---
ESCGuidelines 3609
2 Introduction ..
. Newrecommendations
.
.
.
TheaimofthisESCGuidelineistohelphealthprofessionalsmanage ... Recommendations Class
people with heart failure (HF) according to the best available evi- ..
.
. RecommendationsforthediagnosisofHF
dence.Fortunately,wenowhaveawealthofclinicaltrialstohelpus .
.
select the best management to improve the outcomes for people .. Rightheartcatheterizationshouldbeconsideredinpatients
.
with HF; for many, it is now both preventable and treatable. This .. whereHFisthoughttobeduetoconstrictivepericarditis,
. IIa
guidelineprovidespractical,evidence-basedrecommendations. .. restrictivecardiomyopathy,congenitalheartdisease,andhigh
.
We have revised the format of the previous 2016 ESC HF .. outputstates.
.
Guidelines1tomakeeachphenotypeofHFstand-aloneintermsof .. Rightheartcatheterizationmaybeconsideredinselected
. IIb
.
itsdiagnosisandmanagement.Thetherapyrecommendationsmen- . patientswithHFpEFtoconfirmthediagnosis.
.
.
tionthetreatmenteffectsupportedbytheclassandlevelofevidence . RecommendationsfortreatmentofchronicHF
.
. and are presented in tables.For HFwithreducedejectionfraction .. HFrEF
.
(HFrEF),thetabularrecommendationsfocusonmortalityandmor- .. Dapagliflozinorempagliflozinarerecommendedforpatients
.
bidityoutcomes.Wherethereare symptomaticbenefits,these are .. withHFrEFtoreducetheriskofHFhospitalizationand I
.
highlightedinthetextand/orinthewebappendices.Detailedsum- .. death.
. mariesofthetrialsunderpinningtherecommendationsareavailable ...
VericiguatmaybeconsideredinpatientsinNYHAclassII(cid:2)IV
inthewebappendices.Fordiagnosticindications,wehavesuggested ... whohavehadworseningHFdespitetreatmentwithanACE-I
investigationsthatallpatientswithHFshouldreceive,andinvestiga- ...
(orARNI),abeta-blockerandanMRAtoreducetheriskof
IIb
tions that can be targeted to specific circumstances. As diagnostic ...
CVmortalityorHFhospitalization.
tests have rarely been subject to randomized controlled trials ..
. HFmrEF
(RCTs), most of the evidence would be regarded as level C. ..
. AnACE-ImaybeconsideredforpatientswithHFmrEFto
However,thatdoesnotmeanthattherehasnotbeenappropriate .. IIb
. reducetheriskofHFhospitalizationanddeath.
rigorousevaluationofdiagnostictests. ..
In this guideline, we have decided to focus on thediagnosis and
... AnARBmaybeconsideredforpatientswithHFmrEFto
IIb
treatmentofHF,notonitsprevention.ManagementofCVriskand
... reducetheriskofHFhospitalizationanddeath.
.
. Abeta-blockermaybeconsideredforpatientswithHFmrEF
manyCVdiseases[especiallysystemichypertension,diabetesmelli- .. IIb
. toreducetheriskofHFhospitalizationanddeath.
tus,coronaryarterydisease,myocardialinfarction(MI),atrialfibrilla- .
.
tion(AF),andasymptomaticleftventricular(LV)systolicdysfunction] ... AnMRAmaybeconsideredforpatientswithHFmrEFto
IIb
will reduce the riskofdevelopingHF, whichis addressedbymany .. reducetheriskofHFhospitalizationanddeath.
.
otherESCGuidelinesandinsection9.1ofthecurrentguideline.2(cid:2)7 .. Sacubitril/valsartanmaybeconsideredforpatientswith
. IIb
.
This guideline is the result of a collaboration between the Task . HFmrEFtoreducetheriskofHFhospitalizationanddeath.
.
.
Force(includingtwopatientrepresentatives),thereviewers,andthe . HFpEF
.
.
ESCCPGCommittee.Assuch,itisaconsensus/majorityopinionof .. Screeningfor,andtreatmentof,aetiologies,andCVandnon-
.
theexpertsconsultedinitsdevelopment. .. CVcomorbiditiesarerecommendedinpatientswithHFpEF I
.
.. (seerelevantsectionsofthisdocument).
.
. . Preventionandmonitoring
.
2.1 What is new .... Self-managementstrategiesarerecommendedtoreducethe
I
Inadditiontotherecommendationslistedbelow,thefollowingtable .. riskofHFhospitalizationandmortality.
.
listssomenewconceptscomparedwiththe2016version. .. Eitherhome-basedand/orclinic-basedprogrammesimprove
.
.. outcomesandarerecommendedtoreducetheriskofHF I .
Newconcepts .. hospitalizationandmortality.
.
Achangeoftheterm‘heartfailurewithmid-rangeejectionfraction’to .. Influenzaandpneumococcalvaccinationsshouldbeconsid-
‘heartfailurewithmildlyreducedejectionfraction’(HFmrEF). ... eredinordertopreventHFhospitalizations. IIa
.
.
AnewsimplifiedtreatmentalgorithmforHFrEF. .. Asupervised,exercise-based,cardiacrehabilitationpro-
.
TheadditionofatreatmentalgorithmforHFrEFaccordingto .. grammeshouldbeconsideredinpatientswithmoresevere IIa
.
phenotypes. .. disease,frailty,orwithcomorbidities.
.
ModifiedclassificationforacuteHF. .. Non-invasiveHTMmaybeconsideredforpatientswithHFin
.
.
Updatedtreatmentsformostnon-cardiovascularcomorbidities . ordertoreducetheriskofrecurrentCVandHFhospitaliza- IIb
.
.
includingdiabetes,hyperkalaemia,irondeficiency,andcancer. . tionsandCVdeath.
.
.
Updatesoncardiomyopathiesincludingtheroleofgenetictestingand .. Recommendationsformanagementofpatientswithadvanced
.
newtreatments. .. HF
.
.
Theadditionofkeyqualityindicators. . Patientsbeingconsideredforlong-termMCSmusthavegood
.
.. compliance,appropriatecapacityfordevicehandlingandpsy- I
.
HF=heartfailure. .
. chosocialsupport.
.
.
. Continued
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 12 ---
3610 ESCGuidelines
.
Hearttransplantationisrecommendedforpatients .. RecommendationsformanagementofpatientswithHFand
.
withadvancedHF,refractorytomedical/devicetherapyand I .. diabetes
.
whodonothaveabsolutecontraindications. .. SGLT2inhibitors(canagliflozin,dapagliflozin,empagliflozin,
.
Continuousinotropesand/orvasopressorsmaybeconsidered ... ertugliflozin,sotagliflozin)arerecommendedinpatientswith
I
inpatientswithlowcardiacoutputandevidenceoforganhypo- IIb .. T2DMatriskofCVeventstoreducehospitalizationsforHF,
.
. majorCVevents,end-stagerenaldysfunction,andCVdeath.
perfusionasbridgetoMCSorhearttransplantation. .
.
RecommendationsformanagementofpatientsafterHF
... SGLT2inhibitors(dapagliflozin,empagliflozin,andsotagliflo-
hospitalization
... zin)arerecommendedinpatientswithT2DMandHFrEFto I
ItisrecommendedthatpatientshospitalizedforHFbecare-
... reducehospitalizationsforHFandCVdeath.
fullyevaluatedtoexcludepersistentsignsofcongestion I ... TheDPP-4inhibitorsaxagliptinisnotrecommendedin
III
beforedischargeandtooptimizeoraltreatment. .. patientswithHF.
.
.
Itisrecommendedthatevidence-basedoralmedicaltreat-
I
... RecommendationsformanagementofpatientswithHFand
mentbeadministeredbeforedischarge. .. irondeficiency
.
Anearlyfollow-upvisitisrecommendedat1(cid:2)2weeksafter .. ItisrecommendedthatallpatientswithHFareperiodically
.
dischargetoassesssignsofcongestion,drugtolerance,and I .. screenedforanaemiaandirondeficiencywithafullblood I
.
startand/oruptitrateevidence-basedtherapy. .. count,serumferritinconcentration,andTSAT.
.
. RecommendationsformanagementofpatientswithHFand . Intravenousironsupplementationwithferriccarboxymaltose
.
.
atrialfibrillation .. shouldbeconsideredinsymptomaticHFpatientsrecentlyhospi-
.
Long-termtreatmentwithanoralanticoagulantshouldbe .. talizedforHFandwithLVEF<_50%andirondeficiency,defined IIa
.
consideredforstrokepreventioninAFpatientswitha IIa .. asserumferritin<100ng/mLorserumferritin100(cid:2)299ng/mL
.
CHA 2DS 2-VAScscoreof1inmenor2inwomen. ... withTSAT<20%,toreducetheriskofHFhospitalization.
RecommendationsformanagementofpatientswithHFand .. TreatmentofanaemiainHFwitherythropoietinstimulating
.
CCS .. agentsisnotrecommendedintheabsenceofotherindica- III
.
CABGshouldbeconsideredasthefirst-choicerevasculariza- .. tionsforthistherapy.
.
.
tionstrategy,inpatientssuitableforsurgery,especiallyifthey IIa . RecommendationsformanagementofpatientswithHFand
.
.
havediabetesandforthosewithmultivesseldisease. . cancer
.
.
InLVADcandidatesneedingcoronaryrevascularization,
IIa
... Itisrecommendedthatcancerpatientsatincreasedriskforcardi-
CABGshouldbeavoided,ifpossible. .. otoxicity,definedbyahistoryorriskfactorsofCVdisease,pre-
.
Coronaryrevascularizationmaybeconsideredtoimproveout- .. viouscardiotoxicityorexposuretocardiotoxicagents,undergo I
.
comesinpatientswithHFrEF,CCS,andcoronaryanatomysuit- .. CVevaluationbeforescheduledanticancertherapy,preferablyby
.
ableforrevascularization,aftercarefulevaluationoftheindividual IIb .. acardiologistwithexperience/interestinCardio-Oncology.
risktobenefitratio,includingcoronaryanatomy(i.e.proximal ..
. TreatmentwithanACE-Iandabeta-blocker(preferablycarvedi-
stenosis>90%oflargevessels,stenosisofleftmainorproximal ..
. lol)shouldbeconsideredincancerpatientsdevelopingLVsystolic
LAD),comorbidities,lifeexpectancy,andpatient’sperspectives. .. IIa
. dysfunction,definedasa10%ormoredecreaseinLVEFandtoa
PCImaybeconsideredasalternativetoCABG,basedon ..
. valuelowerthan50%,duringanthracyclinechemotherapy.
HeartTeamevaluation,consideringcoronaryanatomy, IIb ..
comorbidities,andsurgicalrisk.
... AbaselineCVriskassessmentshouldbeconsideredinall
.. cancerpatientsscheduledtoreceiveacancertreatmentwith IIa
RecommendationsformanagementofpatientswithHFand .
.. thepotentialtocauseHF.
valvularheartdisease .
.. RecommendationsfortreatmentofpatientswithHFand Aorticvalveintervention,TAVIorSAVRisrecommendedin ..
. amyloidosis patientswithHFandseverehigh-gradientaorticstenosisto I ..
. Tafamidisisrecommendedinpatientswithgenetictestingpro-
reducemortalityandimprovesymptoms. ..
. venhTTR-CAandNYHAclassIorIIsymptomstoreduce I
.
ItisrecommendedthatthechoicebetweenTAVIandSAVR .
.. symptoms,CVhospitalizationandmortality.
bemadebytheHeartTeam,accordingtoindividualpatient .
.. TafamidisisrecommendedinpatientswithwtTTR-CAand
preferenceandfeaturesincludingage,surgicalrisk,clinical, I .
.. NYHAclassIorIIsymptomstoreducesymptoms,CVhospi- I
anatomicalandproceduralaspects,weighingtherisksand .
.. talizationandmortality.
benefitsofeachapproach. .
.
.
Percutaneousedge-to-edgemitralvalverepairshouldbeconsid- .. ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor
eredincarefullyselectedpatientswithsecondarymitralregurgi- ... blocker; ARNI=angiotensin receptor-neprilysin inhibitor; CABG=coronary
tation,noteligibleforsurgeryandnotneedingcoronary IIa .... ga ert se tir vy eb hyp eaa rs tsg far ia luft r; eC oC rS= lec fthr vo en nic tric co ur lao rna dr yy sfs uy nn cd tr ioo nm ,e H;C ypH eA rt2 eD nsS i2 o- nV ,A ASc ge=c >_o 7n 5-
revascularization,whoaresymptomaticdespiteOMTandwho .. (doubled),Diabetes,Stroke(doubled)-Vasculardisease,Age65(cid:2)74,Sexcate-
.
fulfilcriteriatoachieveareductioninHFhospitalizations. .. gory (female) (score); CMP=cardiomyopathy; CV=cardiovascular; DPP-4=
. dipeptidyl peptidase-4; HF=heart failure; HFmrEF=heart failure with mildly
Percutaneousedge-to-edgemitralvalverepairmaybecon- ... reducedejectionfraction;HFpEF=heartfailurewithpreservedejectionfraction;
sideredtoimprovesymptomsincarefullyselectedpatients .. HFrEF=heartfailurewithreducedejectionfraction;HTM=hometelemonitor-
.
w anit dh ns oe tco nen ed da ir ny gm coitr ra ol nr ae rg yu rr eg vit aa st cio un la, rn izo at tie ol nig ,ib wle hofo ar resu hr ig ge hr ly
y
IIb
.... i ln efg t; vh eT nT tR ric= ulh ae rr ;e Ld Vit Aa Dry =tr la en ftst vh ey nr te rt ii cn u; laL rA aD ss= istle dft ea vn ict ee ;ri Lo Vr Ed Fe =sc le en ftd vin eg nta rr icte ur lay r;L eV je=
c-
.. tion fraction; MCS=mechanical circulatory support; MRA=mineralocorticoid
symptomaticdespiteOMTandwhodonotfulfilcriteriafor .
. receptor antagonist; NYHA=New York Heart Association; OMT=optimal
reducingHFhospitalization. .. medical therapy; PCI=percutaneous coronary intervention; SAVR=surgical
.
Continued aortic valve replacement; SGLT2=sodium-glucose co-transporter 2; T2DM=
type2diabetesmellitus;TAVI=transcatheteraorticvalveimplantation;TSAT=
transferrinsaturation;wtTTR-CA=wild-typetransthyretincardiacamyloidosis.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 13 ---
ESCGuidelines 3611
Changesinrecommendations
2021 Class 2016 Class
RecommendationsfordiagnosisofHF
Invasivecoronaryangiographymaybeconsideredin Invasivecoronaryangiographyshouldbeconsideredin
patientswithHFrEFwithanintermediatetohighpre-test patientswithHFandintermediatetohighpre-testproba-
probabilityofCADandthepresenceofischaemiainnon- bilityofCADandthepresenceofischaemiainnon-inva-
IIb IIa
invasivestresstests. sivestresstests(whoareconsideredsuitableforpotential
coronaryrevascularization)inordertoestablishthediag-
nosisofCADanditsseverity.
CTCAshouldbeconsideredinpatientswithalowto CardiacCTmaybeconsideredinpatientswithHFand
intermediatepre-testprobabilityofCADorthosewith lowtointermediatepre-testprobabilityofCADorthose
IIa IIb
equivocalnon-invasivestresstestsinordertoruleout withequivocalnon-invasivestresstestsinordertorule
coronaryarterystenosis. outcoronaryarterystenosis.
RecommendationsfordevicetherapyinHFrEF
AnICDshouldbeconsideredtoreducetheriskofsud- Primaryprevention
dendeathandall-causemortalityinpatientswithsympto- AnICDisrecommendedtoreducetheriskofsudden
maticHF(NYHAclassII(cid:2)III)ofanon-ischaemic deathandall-causemortalityinpatientswithsymptomatic
aetiology,andanLVEF<_35%despite>_3monthsofOMT, IIa HF(NYHAclassII(cid:2)III),andanLVEF<_35%despite>_3 I
providedtheyareexpectedtosurvivesubstantiallylonger monthsofOMT,providedtheyareexpectedtosurvive
than1yearwithgoodfunctionalstatus. substantiallylongerthan1yearwithgoodfunctionalsta-
tus,andtheyhaveDCM.
CRTshouldbeconsideredforsymptomaticpatientswith CRTisrecommendedforsymptomaticpatientswithHF
HFinsinusrhythmwithaQRSdurationof130(cid:2)149ms insinusrhythmwithaQRSdurationof130(cid:2)149msand
andLBBBQRSmorphologyandwithLVEF<_35%despite IIa LBBBQRSmorphologyandwithLVEF<_35%despite I
OMTinordertoimprovesymptomsandreducemorbid- OMTinordertoimprovesymptomsandreducemorbid-
ityandmortality. ityandmortality.
PatientswithanLVEF<_35%whohavereceivedaconven- PatientswithHFrEFwhohavereceivedaconventional
tionalpacemakeroranICDandsubsequentlydevelop pacemakeroranICDandsubsequentlydevelop
worseningHFdespiteOMTandwhohaveasignificant worseningHFdespiteOMTandwhohaveahigh
IIa IIb
proportionofRVpacingshouldbeconsideredfor proportionofRVpacingmaybeconsideredfor
‘upgrade’toCRT. upgradetoCRT.Thisdoesnotapplytopatientswith
stableHF.
RecommendationsformanagementofpatientswithacuteHF
Combinationofaloopdiureticwiththiazide-typediuretic Combinationofloopdiureticwitheitherthiazide-typediu-
shouldbeconsideredinpatientswithresistantoedema reticorspironolactonemaybeconsideredinpatientswith
IIa IIb
whodonotrespondtoanincreaseinloopdiuretic resistantoedemaorinsufficientsymptomaticresponse.
doses.
InpatientswithAHFandSBP>110mmHg,i.v.vasodila- InpatientswithhypertensiveAHF,i.v.vasodilatorsshould
torsmaybeconsideredasinitialtherapytoimprove IIb beconsideredasinitialtherapytoimprovesymptomsand IIa
symptomsandreducecongestion. reducecongestion.
Routineuseofopiatesisnotrecommended,unlessin Opiatesmaybeconsideredforcautioususetorelieve
selectedpatientswithsevere/intractablepainoranxiety. III dyspnoeaandanxietyinpatientswithseveredyspnoea IIb
butnauseaandhypopneamayoccur.
Short-termMCSshouldbeconsideredinpatientswith Short-termMCSmaybeconsideredinrefractorycardio-
cardiogenicshockasaBTR,BTD,BTB.Furtherindica- genicshockdependingonpatientage,comorbidities,and
IIa IIb
tionsincludetreatmentofthecauseofcardiogenicshock neurologicalfunction.
orlong-termMCSortransplantation.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 14 ---
3612 ESCGuidelines
RecommendationsformanagementofpatientswithHFandAF
DOACsarerecommendedinpreferencetoVKAsin ForpatientswithHFandnon-valvularAFeligibleforanti-
patientswithHF,exceptinthosewithmoderateor coagulationbasedonaCHADS-VAScscore,NOACs
2 2
severemitralstenosisormechanicalprostheticheart ratherthanwarfarinshouldbeconsideredforanticoagula-
I IIa
valves. tionasNOACsareassociatedwithalowerriskofstroke,
intracranialhaemorrhage,andmortality,whichoutweigh
theincreasedriskofgastrointestinalhaemorrhage.
Beta-blockersshouldbeconsideredforshort-andlong- ForpatientsinNYHAclassI(cid:2)III,abeta-blocker,usually
termratecontrolinpatientswithHFandAF. givenorally,issafeandthereforeisrecommendedasfirst-
IIa I
linetreatmenttocontrolventricularrate,providedthe
patientiseuvolaemic.
Incasesofaclearassociationbetweenparoxysmalor AVnodecatheterablationmaybeconsideredtocontrol
persistentAFandworseningofHFsymptoms,which heartrateandrelievesymptomsinpatientsunresponsive
persistdespitemedicaltherapy,catheterablationshould IIa orintoleranttointensivepharmacologicalrateandrhythm IIb
beconsideredforthepreventionofAF. controltherapy,acceptingthatthesepatientswillbecome
pacemaker-dependent.
RecommendationsformanagementofpatientswithHFandCCS
Coronaryrevascularizationshouldbeconsideredto Myocardialrevascularizationisrecommendedwhenangina
relievepersistentsymptomsofangina(oranangina- persistsdespitetreatmentwithanti-anginaldrugs.
equivalent)inpatientswithHFrEF,CCS,andcoronary IIa I
anatomysuitableforrevascularization,despiteOMT
includinganti-anginaldrugs.
RecommendationsformanagementofpatientswithHFanddiabetes
SGLT2inhibitors(canagliflozin,dapagliflozin,empagliflo- EmpagliflozinshouldbeconsideredinpatientswithT2DM
zin,ertugliflozin,sotagliflozin)arerecommendedin inordertopreventordelaytheonsetofHFandprolong
patientswithT2DMatriskofCVeventstoreducehospi- I life. IIa
talizationsforHF,majorCVevents,end-stagerenaldys-
function,andCVdeath.
AF=atrialfibrillation;AHF=acuteheartfailure;AV=atrio-ventricular;BTB=bridgetobridge;BTD=bridgetodecision;BTR=bridgetocardiacrecovery;CAD=coronary
arterydisease;CCS=chroniccoronarysyndrome;CHA2DS2-VASc=congestiveheartfailureorleftventriculardysfunction, Hypertension,Age>_75(doubled),Diabetes,
Stroke(doubled)-Vasculardisease,Age65(cid:2)74,Sexcategory(female)(score);CRT= cardiacresynchronizationtherapy;CT=computedtomography;CTCA=computed
tomography coronary angiography; CV=cardiovascular; DCM=dilated cardiomyopathy; DOAC=direct oral anticoagulant; HF=heart failure; HFrEF=heart failure with
reducedejectionfraction;ICD=implantablecardioverter-defibrillator;LBBB=leftbundlebranchblock;LVEF=leftventricularejectionfraction;MCS=mechanicalcirculatory
support;NOAC=non-vitaminKantagonistoralanticoagulant;NYHA=NewYorkHeartAssociation;OMT=optimalmedicaltherapy;QRS=Q,R,andSwavesofanECG;
RV=rightventricular/ventricle;SBP=systolicbloodpressure;SGLT2=sodium-glucoseco-transporter2;T2DM=type2diabetesmellitus;VKA=vitaminKantagonist.
.
3 Definition, epidemiology and .. 3.2 Terminology
. .
prognosis .. 3.2.1 Heart failure with preserved, mildly reduced, and
.
.. reducedejectionfraction
.
3.1 Definition of heart failure .. Traditionally,HFhasbeendividedintodistinctphenotypesbasedon
.
Heartfailureisnotasinglepathologicaldiagnosis,butaclinicalsyn-
... the measurement of left ventricular ejection fraction (LVEF)
drome consisting of cardinal symptoms (e.g. breathlessness, ankle
... (Table3).Therationalebehindthisrelatestotheoriginaltreatment
swelling,andfatigue)thatmaybeaccompaniedbysigns(e.g.elevated
... trials in HF that demonstrated substantially improved outcomes in
jugular venous pressure, pulmonary crackles, and peripheral
... patients with LVEF <_40%. However, HF spans the entire range of
.
. LVEF(anormallydistributedvariable),andmeasurementbyechocar-
oedema).Itisduetoastructuraland/orfunctionalabnormalityofthe .
.
. diographyissubjecttosubstantialvariability.Wehavedecidedonthe
heart that results in elevated intracardiac pressures and/or inad- .
.
. followingclassificationofHF(Table3):
equatecardiacoutputatrestand/orduringexercise. .
.
.
Identificationoftheaetiologyoftheunderlyingcardiacdysfunction .. • Reduced LVEF is defined as <_40%, i.e. those with a significant
.
is mandatory in the diagnosis of HF as the specific pathology can .. reductioninLVsystolicfunction.ThisisdesignatedasHFrEF.
.
determine subsequent treatment. Most commonly, HF is due to .. • PatientswithaLVEFbetween41%and49%havemildlyreduced
.
myocardialdysfunction:eithersystolic,diastolic,orboth.However, .. LV systolic function, i.e. HFmrEF. Retrospective analyses from
.
pathologyofthevalves,pericardium,andendocardium,andabnor- .. RCTsinHFrEForHFwithpreservedejectionfraction(HFpEF)
.
malitiesofheartrhythmandconductioncanalsocauseorcontribute .. that have included patients with ejection fractions in the
.
toHF. .. 40(cid:2)50% range suggest that they may benefit from similar
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 15 ---
ESCGuidelines 3613
Table3 Definitionofheartfailurewithreducedejectionfraction,mildlyreducedejectionfractionandpreservedejection
fraction
TypeofHF HFrEF HFmrEF HFpEF
1 Symptoms±Signsa Symptoms±Signsa Symptoms±Signsa
2 LVEF<_40% LVEF41(cid:2)49%b LVEF>_50%
3 (cid:2) (cid:2) Objectiveevidenceofcardiacstructuraland/orfunctional
abnormalitiesconsistentwiththepresenceofLVdiastolic
dysfunction/raisedLVfillingpressures,includingraisednatriureticpeptidesc
HF=heartfailure;HFmrEF=heartfailurewithmildlyreducedejectionfraction;HFpEF=heartfailurewithpreservedejectionfraction;HFrEF=heartfailurewithreducedejec-
tionfraction;LV=leftventricle;LVEF=leftventricularejectionfraction.
aSignsmaynotbepresentintheearlystagesofHF(especiallyinHFpEF)andinoptimallytreatedpatients.
bForthediagnosisofHFmrEF,thepresenceofotherevidenceofstructuralheartdisease(e.g.increasedleftatrialsize,LVhypertrophyorechocardiographicmeasuresof
impairedLVfilling)makesthediagnosismorelikely.
cForthediagnosisofHFpEF,thegreaterthenumberofabnormalitiespresent,thehigherthelikelihoodofHFpEF.
.
therapies to those with LVEF <_40%.8(cid:2)13 This supports the .. slowly,theepisodemaybedescribedas‘decompensated’HF.This
.
.
renamingofHFmrEFfrom‘heartfailurewithmid-rangeejection . canresultinahospitaladmissionortreatmentwithintravenous(i.v.)
.
.
fraction’to‘heartfailurewithmildlyreducedejectionfraction’.14 . diuretictherapyintheoutpatientsetting.Inaddition,HFcanpresent
.
.
• Those with symptoms and signs of HF, with evidence of .. moreacutely.BothoftheseareconsideredinthesectiononAHF
.
structuraland/or functional cardiac abnormalities and/or raised .. (section11).
.
natriureticpeptides(NPs),andwithanLVEF>_50%,haveHFpEF. .. SomeindividualswithHFmayrecovercompletely[e.g.thosedue
.
.. to alcohol-induced cardiomyopathy (CMP), viral myocarditis,
ThediagnosisofHFrEF,HFmrEF,andHFpEFiscoveredinmore ...
Takotsubo syndrome, peripartum cardiomyopathy (PPCM), or
detailintheirrespectivesections(sections5,7,and8,respectively). ...
tachycardiomyopathy]. Other patients with LV systolic dysfunction
These definitions are consistent with a recent report on the ...
may show a substantial or even complete recovery of LV systolic
UniversalDefinitionofHeartFailure.15 ...
functionafterreceivingdruganddevicetherapy.
Patientswithnon-CVdisease,e.g.anaemia,pulmonary,renal,thy- ..
.
roid,orhepaticdiseasemayhavesymptomsandsignsverysimilarto ...
3.2.4 Terminology related to the symptomatic severityof
thoseofHF,butintheabsenceofcardiacdysfunction,theydonot ...
heartfailure
fulfilthecriteriaforHF.However,thesepathologiescancoexistwith ...
ThesimplestterminologyusedtodescribetheseverityofHFisthe
HFandexacerbatetheHFsyndrome. ..
. New York Heart Association (NYHA) functional classification
.
.
. (Table 4). However, this relies solely on symptoms and there are
3.2.2Rightventriculardysfunction ...
many other better prognostic indicators in HF.19 Importantly,
Heartfailurecanalsobearesultofrightventricular(RV)dysfunc- ..
. patientswithmildsymptomsmaystillhaveahighriskofhospitaliza-
. tion.RVmechanicsandfunctionarealteredinthesettingofeither .. tion and death.20 Predicting outcome is particularly important in
pressure or volume overload.16 Although the main aetiology of ..
. advancedHFtoguideselectionofcardiactransplantationanddevice
.
chronicRVfailureisLVdysfunction-inducedpulmonaryhyperten- .
. therapies.Thiswillbecoveredindetailinthesectiononadvanced
.
sion,thereareanumberofothercauses ofRVdysfunction[e.g. .
. HF(section10). .
MI,arrhythmogenicrightventricularcardiomyopathy(ARVC),or .
. valve disease].17 The diagnosis is determined by a quantitative ..
.
.
assessment of global RV function, most commonly by echocar- .
.. 3.3 Epidemiology and natural historyof
diography,usingatleastoneofthefollowingmeasurements:frac- . .
tional area change (FAC); tricuspid annular plane systolic
.. heart failure
.
.
excursion(TAPSE);andDopplertissueimaging-derivedsystolicS0 . 3.3.1Incidenceandprevalence
.
.
velocityofthetricuspid annulus.Thediagnosisandmanagement . Indevelopedcountries,theage-adjustedincidenceofHFmaybefall-
.
.
ofRVdysfunctioniscoveredcomprehensivelyinarecentHeart .. ing,presumablyreflectingbettermanagementofCVdisease,butdue
.
FailureAssociation(HFA)positionpaper.18 .. toageing,theoverallincidenceisincreasing.21(cid:2)24Currently,theinci-
.
.. denceofHFinEuropeisabout3/1000person-years(allage-groups)
.
3.2.3Othercommonterminologyusedinheartfailure .. or about 5/1000 person-years in adults.25,26 The prevalence of HF
.
Heartfailureisusuallydividedintotwopresentations:chronicheart .. appearstobe1(cid:2)2%ofadults.21,27(cid:2)31Asstudiesonlyusuallyinclude
.
failure (CHF) and acute heart failure (AHF). CHF describes those .. recognized/diagnosed HF cases, the true prevalence is likely to be
.
whohave hadanestablished diagnosis ofHForwho have a more .. higher.32 The prevalence increases with age: from around 1% for
.
gradualonsetofsymptoms.IfCHFdeteriorates,eithersuddenlyor . thoseaged<55yearsto>10%inthoseaged70yearsorover.33(cid:2)36It
AIRETIRC
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 16 ---
3614 ESCGuidelines
.
.. those who remainstableortransitionto a higherejectionfraction
Table4 NewYorkHeartAssociationfunctional .
.. category.48(cid:2)52
classificationbasedonseverityofsymptomsand .
physicalactivity ... HFpEF is generally considered to confer a better survival than
.. HFrEF, but most observational studies show that this difference is
.
ClassI Nolimitationofphysicalactivity.Ordinaryphysicalactivity .. negligible.45,46 In contrast, the large MAGGIC meta-analysis con-
.
doesnotcauseunduebreathlessness,fatigue,or .. cludedthattheadjustedmortalityriskforpatientswithHFpEFwas
.
palpitations. .. considerablylowerthaninpatientswithHFrEF.53
.
ClassII Slightlimitationofphysicalactivity.Comfortableatrest, .. Studiesfromseveralcountrieshaveshownthatbetween1980and
.
butordinaryphysicalactivityresultsinunduebreathless- .. 2000 survival in HF patients has improved markedly.41,54(cid:2)57
.
ness,fatigue,orpalpitations. .. However,thispositivetrendmayhavelevelledoffsincethen.45
.
.
ClassIII Markedlimitationofphysicalactivity.Comfortableatrest, . Aftertheinitialdiagnosis,HFpatientsarehospitalizedonceevery
.
butlessthanordinaryactivityresultsunduebreathless- .. yearonaverage.54From2000to2010,themeanrateofhospitaliza-
.
.
ness,fatigue,orpalpitations. . tion in the Olmsted County cohort was 1.3 per person-year.
.
.
ClassIV Unabletocarryonanyphysicalactivitywithoutdiscom- .. Interestingly,themajority(63%)ofhospitalizationswererelatedto
fort.Symptomsatrestcanbepresent.Ifanyphysicalactiv-
... non-CVcauses.45StudiesfromseveralEuropeancountriesandthe
.
ityisundertaken,discomfortisincreased. .. UnitedStates(US)haveshownthatHFhospitalizationratespeaked
.
.. in the 1990s, and then declined.54,55*,58(cid:2)60 However, in a recent
.
.. study of incident HF conducted between 1998 and 2017 in the
.
.. United Kingdom (UK), age-adjusted rates of first hospitalizations
.
.. increasedby28%forbothall-causeandHFadmissions,andby42%
.
isgenerallybelievedthat,ofthosewithHF,about50%haveHFrEF .. for non-CV admissions.61 These increases were higher in women,
.
and50%haveHFpEF/HFmrEF,mainlybasedonstudiesinhospitalized .. perhapsrelatedtohighercomorbidityrates.TheriskofHFhospital-
patients.32,35,37,38TheESCLong-TermRegistry,intheoutpatientset- ...
izationis1.5timeshigherinpatientswithdiabetescomparedtocon-
.
ting,reportsthat60%haveHFrEF,24%haveHFmrEF,and16%have .. trols. AF, a higher body mass index (BMI), and higher glycated
HFpEF.39Somewhatmorethan50%ofHFpatientsarefemale.21,40,41 ...
haemoglobin(HbA1c),aswellasalowestimatedglomerularfiltra-
.
.. tionrate(eGFR)arestrongpredictorsofHFhospitalizations.29
.
3.3.2Aetiologyofheartfailure .. Duetopopulationgrowth,ageing,andtheincreasingprevalence
.
The most common causes (as well as some key investigations) .. ofcomorbidities,theabsolutenumberofhospitaladmissionsforHF
.
ofHFareshowninTable5.TheaetiologyofHFvariesaccording .. is expected to increase considerably in the future, perhaps by as
.
to geography. In Western-type and developed countries, .. muchas50%inthenext25years.24,62
.
coronary artery disease (CAD) and hypertension are predomi- ..
.
nantfactors.27 ..
.
With regard to ischaemic aetiology, HFmrEF resembles HFrEF, ...
4 Chronic heart failure
withahigherfrequencyofunderlyingCADcomparedtothosewith ..
.
HFpEF.38,42,43 ...
4.1 Key steps in the diagnosis of chronic
.
.
3.3.3Naturalhistoryandprognosis
... heart failure
.
TheprognosisofpatientswithHFhasimprovedconsiderablysince .. The diagnosis of CHF requires the presence of symptoms and/or
.
the publication of the first treatment trials a few decades ago. .. signsofHFandobjectiveevidenceofcardiacdysfunction(Figure1).
.
However,itremainspoor,andqualityoflife(QOL)isalsomarkedly .. Typicalsymptomsincludebreathlessness,fatigue,andankleswelling
.
reduced.Theimprovementinprognosishasbeenconfinedtothose .. (Table 6). Symptoms and signs lack sufficient accuracy to be used
.
withHFrEF.
.. alonetomakethediagnosisofHF.63(cid:2)66
.
Mortalityratesarehigherinobservationalstudiesthaninclinical .. ThediagnosisofCHFismademorelikelyinpatientswithahistory
.
trials.44IntheOlmstedCountycohort,1-yearand5-yearmortality .. ofMI,arterialhypertension,CAD,diabetesmellitus,alcoholmisuse,
.
ratesafterdiagnosis,foralltypesofHFpatients,were20%and53%, .. chronic kidney disease (CKD), cardiotoxic chemotherapy, and in
.
respectively, between 2000 and 2010.45 A study combining the .. thosewithafamilyhistoryofCMPorsuddendeath.
.
Framingham Heart Study (FHS) and Cardiovascular Health Study .. The following diagnostic tests are recommended for the assess-
.
(CHS)cohortsreporteda67%mortalityratewithin5yearsfollowing .. mentofpatientswithsuspectedchronicHF:
.
diagnosis.46Despitereceivinglessevidence-basedtreatment,women ..
haveabettersurvivalthanmen.47
... (1) Electrocardiogram(ECG).A normal ECGmakesthediagnosisof
.. HF unlikely.63 The ECG may reveal abnormalities such as AF, Q
OverallprognosisisbetterinHFmrEFcomparedtoHFrEF.39Of .
.. waves, LV hypertrophy (LVH), and a widened QRS complex
note,transitioninejectionfractionovertimeiscommon,andpatients ...
(Table7)thatincreasethelikelihoodofadiagnosisofHFandalso
whoprogressfromHFmrEFtoHFrEFhaveaworseprognosisthan ..
mayguidetherapy.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 17 ---
ESCGuidelines 3615
Diagnostic algorithm for heart failure
Suspected heart failure
Risk factors
Symptoms and/or signs
Abnormal ECG
NT-proBNP ≥ 125 pg/mL
N or BNP ≥ 35 pg/mL
or if HF strongly suspected
YY
or if NT-proBNP/BNP unavailable
Echocardiography
N Abnormal findings
YY
Heart failure confirmed
Define heart failure phenotype
based on LVEF measurement
≤40% 41–49% ≥50%
(HFrEF) (HFmrEF) (HFpEF)
Determine aetiology and
Heart failure unlikely
commence treatment
Consider other diagnoses
Figure 1 Thediagnosticalgorithmforheartfailure.BNP=B-typenatriureticpeptide;ECG=electrocardiogram;HFmrEF=heartfailurewithmildly
reducedejectionfraction;HFpEF=heartfailurewithpreservedejectionfraction;HFrEF=heartfailurewithreducedejectionfraction;LVEF=leftventricu-
larejectionfraction;NT-proBNP=N-terminalpro-Btypenatriureticpeptide.Theabnormalechocardiographicfindingsaredescribedinmoredetailin
therespectivesectionsonHFrEF(section5),HFmrEF(section7),andHFpEF(section8).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 18 ---
3616 ESCGuidelines
Table5 Causesofheartfailure,commonmodesofpresentationandspecificinvestigations
Cause Examplesofpresentations Specificinvestigations
CAD Myocardialinfarction Invasivecoronaryangiography
Anginaor“angina-equivalent” CTcoronaryangiography
Arrhythmias Imagingstresstests(echo,nuclear,CMR)
Hypertension Heartfailurewithpreservedsystolicfunction 24hambulatoryBP
Malignanthypertension/acutepulmonaryoedema Plasmametanephrines,renalarteryimaging
Reninandaldosterone
Valvedisease Primaryvalvediseasee.g.,aorticstenosis Echo(cid:2)transoesophageal/stress
Secondaryvalvedisease,e.g.functionalregurgitation
Congenitalvalvedisease
Arrhythmias Atrialtachyarrhythmias AmbulatoryECGrecording
Ventriculararrhythmias Electrophysiologystudy,ifindicated
CMPs All CMR,genetictesting
Dilated
Hypertrophic
Restrictive Rightandleftheartcatheterization
ARVC
Peripartum
Takotsubosyndrome CMR,angiography
Toxins:alcohol,cocaine,iron,copper Traceelements,toxicology,LFTs,GGT
Congenitalheartdisease Congenitallycorrected/repairedtranspositionofgreatarteries CMR
Shuntlesions
RepairedtetralogyofFallot
Ebstein’sanomaly
Infective Viralmyocarditis CMR,EMB
Chagasdisease
HIV Serology
Lymedisease
Drug-induced Anthracyclines
Trastuzumab
VEGFinhibitors
Immunecheckpointinhibitors
Proteasomeinhibitors
RAFþMEKinhibitors
Infiltrative Amyloid Serumelectrophoresisandserumfreelightchains,Bence
Jonesprotein,bonescintigraphy,CMR,CT-PET,EMB
Sarcoidosis SerumACE,CMR,FDG-PET,chestCT,EMB
Neoplastic CMR,EMB
Storagedisorders Haemochromatosis Ironstudies,genetics,CMR(T2*imaging),EMB
Fabrydisease a-galactosidaseA,genetics,CMR(T1mapping)
Glycogenstoragediseases
Endomyocardialdisease Radiotherapy CMR
Endomyocardialfibrosis/eosinophilia EMB
Carcinoid 24hurine5-HIAA
Pericardialdisease Calcification ChestCT,CMR,rightandleftheartcatheterisation
Infiltrative
Metabolic Endocrinedisease TFTs,plasmametanephrines,reninandaldosterone,cortisol
Nutritionaldisease(thiamine,vitaminB1andseleniumdeficiencies) Specificplasmanutrients
Autoimmunedisease ANA,ANCA,rheumatologyreview
Neuromusculardisease Friedreich’sataxia Nerveconductionstudies,electromyogram,genetics
Musculardystrophy CK,electromyogram,genetics
5-HIAA=5-hydroxyindoleaceticacid;ACE=angiotensin-convertingenzyme;ANA=anti-nuclearantibody;ANCA=anti-nuclearcytoplasmicantibody;ARVC=arrhythmogenic
rightventricularcardiomyopathy;BP=bloodpressure;CAD=coronaryarterydisease;CMP=cardiomyopathy;CMR=cardiacmagneticresonance;CK=creatininekinase;CT
=computedtomography;ECG=electrocardiogram;Echo=echocardiography;EMB=endomyocardialbiopsy;FDG=fluorodeoxyglucose;GGT=gamma-glutamyltransferase;
HIV=humanimmunodeficiencyvirus;h=hour;LFT=liverfunctiontest;LGE=lategadoliniumenhancement;MEK=mitogen-activatedproteinkinase;PET=positronemission
tomography;TFT=thyroidfunctiontest;VEGF=vascularendothelialgrowthfactor.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 19 ---
ESCGuidelines 3617
(2) Measurement of NPs are recommended, if available. A plasma ..
concentration of B-type natriuretic peptide (BNP) <35 pg/mL,
... Table6 Symptomsandsignstypicalofheartfailure
.
N-terminalpro-B-typenatriureticpeptide(NT-proBNP)<125pg/ .. Symptoms Signs
.
.
mL, or mid-regional pro-atrial natriuretic peptide (MR-proANP) . Typical Morespecific
.
<40 pmol/L68makea diagnosisofHFunlikely.Thesewillbedis- .. Breathlessness Elevatedjugularvenouspressure
.
cussedinmoredetailinsection4.2.69,70 .. Orthopnoea Hepatojugularreflux
.
.
(3) Basicinvestigationssuchasserumureaandelectrolytes,creatinine, .. Paroxysmalnocturnaldyspnoea Thirdheartsound(galloprhythm)
.
fullbloodcount,liverandthyroidfunctiontestsarerecommended .. Reducedexercisetolerance Laterallydisplacedapicalimpulse
.
to differentiate HF from other conditions, to provide prognostic .. Fatigue,tiredness,increased
.
information,andtoguidepotentialtherapy. .. timetorecoverafterexercise
.
(4) Echocardiographyisrecommendedasthekeyinvestigationforthe .. Ankleswelling
.
assessmentofcardiacfunction.Aswellasthedeterminationofthe .. Lesstypical Lessspecific
. LVEF,echocardiographyalsoprovidesinformationonotherparam- .
. Nocturnalcough Weightgain(>2kg/week)
.
eterssuchaschambersize,eccentricorconcentricLVH,regional ..
Wheezing Weightloss(inadvancedHF)
.
wall motion abnormalities (that may suggest underlying CAD, ...
Bloatedfeeling Tissuewasting(cachexia)
Takotsubo syndrome, or myocarditis), RV function, pulmonary ...
Lossofappetite Cardiacmurmur
hypertension, valvular function, and markers of diastolic ...
Confusion(especiallyintheelderly) Peripheraloedema(ankle,
function.16,71 ... Depression sacral,scrotal)
(5) AchestX-rayisrecommendedtoinvestigateotherpotentialcauses ...
Palpitation Pulmonarycrepitations
ofbreathlessness(e.g.pulmonarydisease).Itmayalsoprovidesup- ...
Dizziness Pleuraleffusion
portive evidence of HF (e.g. pulmonary congestion or ...
Syncope Tachycardia
cardiomegaly). ... Bendopneaa Irregularpulse
.
.. Tachypnoea
.
.. Cheyne-Stokesrespiration
.
Recommendeddiagnostictestsinallpatientswith .. Hepatomegaly
.
suspectedchronicheartfailure .. Ascites
.
.
. Coldextremities
Recommendations Classa Levelb ..
. Oliguria .
.
BNP/NT-proBNPc I B .. Narrowpulsepressure
.
12-leadECG I C ..
.
Transthoracicechocardiography I C .. HF=heartfailure.
.. aThissymptomofadvancedHFcorrespondstoshortnessofbreathwhenleaning
Chestradiography(X-ray) I C .. forward.67
.
Routinebloodtestsforcomorbidities,including ..
.
.
fullbloodcount,ureaandelectrolytes,thyroid . I C .
function,fastingglucoseandHbA1c,lipids,iron .
. . 4.2.1Useinthenon-acutesetting
status(TSATandferritin) ..
. The diagnosticvalueofNPs,inadditiontosignsand symptoms and
. .
BNP=B-type natriuretic peptide; ECG=electrocardiogram; HbA1c=glycated . otherdiagnostictests,suchasanECG,hasbeenassessedinseveral
.
haemoglobin;NT-proBNP=N-terminalpro-B-typenatriureticpeptide;TSAT= .. studies in the primary care setting.68,76(cid:2)80 The aim of these studies transferrinsaturation. ..
aClassofrecommendation. .. wastoeitherexcludeorestablishadiagnosisofHF.TheTaskForce
.
bLevelofevidence. . consideredstudiesofadequatequalitythatincludedNPcut-offpoints .
cReferencesarelistedinsection4.2forthisitem. ..
intheirdiagnosticalgorithms,belowwhichtheprobabilityofhavingHF
.
.
.. wasextremelylow.Theupperlimitsofnormalinthenon-acutesetting
.
.. are35pg/mLforBNP,and125pg/mLforNT-proBNP.Inthesestud-
.
4.2 Natriuretic peptides .. ies,thenegativepredictivevaluesofNPconcentrationsbelowthese
.
.. thresholds range from 0.94 to 0.98.76(cid:2)78 Fewer data are available
PlasmaconcentrationsofNPsarerecommendedasinitialdiagnostic .
.. forMR-proANPinCHFthaninAHF.Aconcentrationof<40pmol/L
testsinpatientswithsymptomssuggestiveofHFtoruleoutthediag- .
.. canbeusedtoruleoutHF.68
nosis.ElevatedconcentrationssupportadiagnosisofHF,areuseful .
.
forprognostication,72andmayguidefurthercardiacinvestigation.73 ..
.. 4.3 Investigations to determine the
However,itshouldbenotedthattherearemanycausesofanele- .
.
. underlying aetiologyof chronic heart
vatedNP—bothCVandnon-CV—thatmightreducetheirdiagnostic .
.
accuracy(Table7).ThesecausesincludeAF,increasingage,andacute .. failure
.
orchronickidneydisease.74Conversely,NPconcentrationsmaybe ...
RecommendedteststodeterminetheunderlyingaetiologyofCHF
disproportionatelylowinobesepatients.75 ..
aresummarizedinTable5.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 20 ---
3618 ESCGuidelines
.
.
Table7 Causesofelevatedconcentrationsofnatriuretic .. Recommendationsforspecializeddiagnostictestsfor
peptides86-88 .. selectedpatientswithchronicheartfailuretodetect
.
. reversible/treatablecausesofheartfailure
.
.
Heartfailure .
.
ACS .. Recommendations Classa Levelb
.
.
Pulmonaryembolism .
. CMR
.
Myocarditis .
.. CMRisrecommendedfortheassessmentof
Leftventricularhypertrophy .
.. myocardialstructureandfunctioninthosewith I C
Hypertrophicorrestrictivecardiomyopathy ...
poorechocardiogramacousticwindows.
Cardiac Valvularheartdisease ..
. CMRisrecommendedforthecharacterization
Congenitalheartdisease ..
. ofmyocardialtissueinsuspectedinfiltrativedis-
Atrialandventriculartachyarrhythmias ..
. ease,Fabrydisease,inflammatorydisease(myo- I C Heartcontusion ..
. carditis),LVnon-compaction,amyloid,
Cardioversion,ICDshock ..
. sarcoidosis,ironoverload/haemochromatosis.
Surgicalproceduresinvolvingtheheart ..
Pulmonaryhypertension
... CMRwithLGEshouldbeconsideredinDCMto
.. distinguishbetweenischaemicandnon-ischae- IIa C
Advancedage .
.. micmyocardialdamage.
Ischaemicstroke .
.
. Invasivecoronaryangiography(inthosewhoareconsidered
Subarachnoidhaemorrhage .
.
. eligibleforpotentialcoronaryrevascularization)
Renaldysfunction .
.
. Invasivecoronaryangiographyisrecommendedin
Liverdysfunction(mainlylivercirrhosiswithascites) .
.
Paraneoplasticsyndrome
.. patientswithanginadespitepharmacologicalther- I B
.
Non-cardiac COPD
... apyorsymptomaticventriculararrhythmias.5
Severeinfections(includingpneumoniaandsepsis) ... Invasivecoronaryangiographymaybeconsidered
Severeburns ... inpatientswithHFrEFwithanintermediatetohigh
IIb B
Anaemia ... pre-testprobabilityofCADandthepresenceof
Severemetabolicandhormoneabnormalities
... ischaemiainnon-invasivestresstests.89
.
(e.g.thyrotoxicosis,diabeticketosis) .. Non-invasivetesting
.
.. CTCAshouldbeconsideredinpatientswitha
.
ACS=acute coronary syndrome; COPD=chronic obstructive pulmonary dis- ... lowtointermediatepre-testprobabilityofCAD IIa C
ease;ICD=implantablecardioverter-defibrillator. .. orthosewithequivocalnon-invasivestresstests
.
.. inordertoruleoutcoronaryarterystenosis.
.
.
. Non-invasivestressimaging(CMR,stressechocar-
.
.
Exerciseorpharmacologicalstressechocardiographymaybeused . diography,SPECT,PET)maybeconsideredforthe
.
.
fortheassessmentofinducibleischaemiainthosewhoareconsid- .. assessmentofmyocardialischaemiaandviabilityin IIb B
.
ered suitable for coronary revascularization.81 In patients with .. patientswithCADwhoareconsideredsuitablefor
. HFpEF,valvedisease,orunexplaineddyspnoea,stressechocardiogra- .. coronaryrevascularization.90(cid:2)93
.
phymighthelpclarifythediagnosis.82 .. Exercisetestingmaybeconsideredtodetect
.
Cardiac magnetic resonance (CMR) imaging with late gadoli- .. reversiblemyocardialischaemiaandinvestigate IIb C
.
nium enhancement (LGE), T1 mapping and extracellular volume .. thecauseofdyspnoea.94(cid:2)96
.
willidentifymyocardialfibrosis/scar,whicharetypicallysubendo- .. Cardiopulmonaryexercisetesting .
cardialforpatientswithischaemicheartdisease(IHD)incontrast ... Cardiopulmonaryexercisetestingisrecom-
tothemid-wallscartypicalofdilatedcardiomyopathy(DCM).In ... mendedasapartoftheevaluationforheart I C
addition,CMRallowsmyocardialcharacterizationin,e.g.myocar- ... transplantationand/orMCS.94(cid:2)96
ditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease, LV ...
Cardiopulmonaryexercisetestingshouldbe
non-compaction CMP, haemochromatosis, and arrhythmogenic ...
consideredtooptimizeprescriptionofexercise IIa C
cardiomyopathy(AC).83,84 ...
training.94(cid:2)96
.
Computed tomography coronary angiography (CTCA) may be .
. Cardiopulmonaryexercisetestingshouldbe
.
consideredinpatientswithalowtointermediatepre-testprobability .
. consideredtoidentifythecauseofunexplained IIa C
.
ofCAD,orthosewithequivocalnon-invasivestresstestsinorderto .
excludethediagnosisofCAD.5
... dyspnoeaand/orexerciseintolerance.94(cid:2)96
.. Rightheartcatheterization
Single-photon emission CT (SPECT) can also be used to assess .
.
. Rightheartcatheterizationisrecommendedin
myocardial ischaemiaand viability,myocardialinflammationor infil- .
.
. patientswithsevereHFbeingevaluatedfor I C
tration. Scintigraphy with technetium (Tc)-labelled bisphosphonate .
.
. hearttransplantationorMCS.
has shown high sensitivity and specificity for imaging cardiac trans- .
.
thyretinamyloid.85 .. Continued
.
.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 21 ---
ESCGuidelines 3619
.
.
. AnalgorithmforthediagnosisofHFrEFisdepictedinFigure1.For
Rightheartcatheterizationshouldbeconsidered .
.
. theinvestigationoftheunderlyingaetiology,pleaserefertoTable5.
inpatientswhereHFisthoughttobedueto .
.
.
constrictivepericarditis,restrictivecardiomyop- IIa C .
.
athy,congenitalheartdisease,andhighoutput .. 5.2 Pharmacological treatments for
.
.
states. . patients with heart failurewith reduced
.
.
Rightheartcatheterizationshouldbeconsidered .. ejection fraction
.
inpatientswithprobablepulmonaryhyperten- ...
5.2.1 Goalsofpharmacotherapyforpatientswithheart
sion,assessedbyechoinordertoconfirmthe IIb C ...
failurewithreducedejectionfraction
diagnosisandassessitsreversibilitybeforethe ...
Pharmacotherapy is the cornerstone of treatment for HFrEF and
correctionofvalve/structuralheartdisease. ...
should be implemented before considering device therapy, and
.
Rightheartcatheterizationmaybeconsideredin .. alongsidenon-pharmacologicalinterventions.
.
selectedpatientswithHFpEFtoconfirmthe IIb C .. TherearethreemajorgoalsoftreatmentforpatientswithHFrEF:
.
diagnosis. .. (i)reductioninmortality,(ii)preventionofrecurrenthospitalizations
.
EMB .. due to worseningHF,and (iii) improvementinclinicalstatus,func-
.
EMBshouldbeconsideredinpatientswithrap- .. tionalcapacity,andQOL.100(cid:2)102
.
. idlyprogressiveHFdespitestandardtherapy . Thekeyevidencesupportingtherecommendationsinthissection
.
whenthereisaprobabilityofaspecificdiagnosis, IIa C .. forpatientswithsymptomaticHFrEFisgiveninSupplementaryTable1. .
.
whichcanbeconfirmedonlyinmyocardial . Figure2depictsthealgorithmforthetreatmentstrategy,including
. samples.97,98 .. drugsanddevicesinpatientswithHFrEF,forClassIindicationsfor
.
.
. thereductionofmortality(eitherall-causeorCV).Therecommen-
CAD=coronary artery disease; CMR=cardiac magnetic resonance; CTCA= ..
. dationsforeachtreatmentaresummarizedbelow.
computed tomography coronary angiography; DCM=dilated cardiomyopathy; .
.
EMB=endomyocardialbiopsy;HF=heartfailure;HFpEF=heartfailurewithpre- .
.
served ejection fraction; HFrEF=heart failure with reduced ejection fraction; ..
.
LGE=lategadoliniumenhancement;LV=leftventricular;MCS=mechanicalcir- .
culatory support; PET=positron emission tomography; SPECT=single-photon .. 5.2.2 Generalprinciplesofpharmacotherapyforheart
.
emissioncomputedtomography. .. failurewithreducedejectionfraction
a bC Lela vs es lo of fr ee vc ido em nm cee .ndation. .... Modulationoftherenin-angiotensin-aldosterone(RAAS)andsympa-
.. thetic nervous systems with angiotensin-converting enzyme inhibi-
.
.. tors(ACE-I)oranangiotensinreceptor-neprilysininhibitor(ARNI),
.
CoronaryangiographyisrecommendedinpatientswithHF,who .. beta-blockers, and mineralocorticoid receptor antagonists (MRA)
.
haveanginapectorisoran‘anginaequivalent’despitepharmacological .. hasbeenshowntoimprovesurvival,reducetheriskofHFhospital-
.
therapy,inordertoestablishthediagnosisofCADanditsseverity. .. izations,andreducesymptomsinpatientswithHFrEF.Thesedrugs
.
Coronary angiography may also be considered in patients with .. serve as the foundations of pharmacotherapy for patients with
.
HFrEFwhohaveanintermediatetohighpre-testprobabilityofCAD .. HFrEF.ThetriadofanACE-I/ARNI,abeta-blocker,andanMRAis
.
.
and who are considered potentially suitable for coronary .. recommended as cornerstone therapies for these patients, unless
revascularization.5 ... thedrugsarecontraindicatedornottolerated.103(cid:2)105Theyshould
.
. beuptitratedtothedosesusedintheclinicaltrials(ortomaximally .
.
. tolerated doses if that is not possible). This guideline still recom-
.
.
5 Heart failure with reduced . mends the use of ARNI as a replacement for ACE-I in suitable
.
. . patientswhoremainsymptomaticonACE-I,beta-blocker,andMRA
ejection fraction ..
. therapies;however,anARNImaybeconsideredasafirst-linether-
.
.. apy instead of an ACE-I.106,107 The recommended doses of these
.
5.1 The diagnosis of heart failurewith .
. drugsaregiveninTable8.Angiotensin-receptorblockers(ARBs)still
.
reduced ejection fraction ..
havearoleinthosewhoareintoleranttoACE-IorARNI.
.
.
ThediagnosisofHFrEFrequiresthepresenceofsymptomsand/or . Thesodium-glucoseco-transporter2(SGLT2)inhibitorsdapagli-
.
.
signsofHFandareducedejectionfraction(LVEF<_40%).Thisis .. flozin and empagliflozin added to therapy with ACE-I/ARNI/beta-
.
most usually obtained by echocardiography. Details about the .. blocker/MRA reduced the risk of CV death and worsening HF in
.
qualitystandardsthatshouldbeadheredtowhendeterminingthe .. patientswithHFrEF.108,109Unlesscontraindicatedornottolerated,
.
presence of reduced LV systolic function by echocardiography .. dapagliflozinorempagliflozinarerecommendedforallpatientswith
.
can be found in the European Association of Cardiovascular .. HFrEFalreadytreatedwithanACE-I/ARNI,abeta-blocker,and an
.
Imaging(EACVI)positionpaper.99IfassessmentofEFisnotpossi- .. MRA,regardlessofwhethertheyhavediabetesornot.
.
blebyechocardiography,thenCMRorrarely,nucleartechniques .. OtherdrugsmaybeusedforselectedpatientswithHFrEF.These
.
canbeemployed. . arediscussedinsection5.4.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 22 ---
3620 ESCGuidelines
Management of patients with HFrEF
ACE-I/ARNIa
Beta-blocker
MRA
Dapagliflozin/Empagliflozin
Loop diuretic for fluid retention
(Class I)
LVEF ≤35% and LVEF >35% or device SR and
QRS <130 ms and therapy not indicated LVEF ≤35% and
where appropriate or inappropriate QRS ≥130 ms
ICD CRT-Db/-P
Non-ischaemic Ischaemic QRS 130–149 ms QRS ≥150 ms
(Class IIa) (Class I) (Class IIa) (Class I)
If symptoms persist, consider therapies
with Class II recommendations
Figure2 TherapeuticalgorithmofClassITherapyIndicationsforapatientwithheartfailurewithreducedejectionfraction.ACE-I=angiotensin-con-
vertingenzymeinhibitor;ARNI=angiotensinreceptor-neprilysininhibitor;CRT-D=cardiacresynchronizationtherapywithdefibrillator;CRT-P=cardiac
resynchronizationtherapypacemaker;ICD=implantablecardioverter-defibrillator;HFrEF=heartfailurewithreducedejectionfraction;MRA=mineralo-
corticoidreceptorantagonist;QRS=Q,R,andSwavesofanECG;SR=sinusrhythm.aAsareplacementforACE-I.bWhereappropriate.ClassI=green.
ClassIIa=Yellow.
5.3 Drugs recommended in all patients with heart failurewith reduced ejection
fraction
Pharmacologicaltreatmentsindicatedinpatientswith(NYHAclassII–IV)heartfailurewithreducedejectionfraction
(LVEF<_40%)
Recommendations Classa Levelb
AnACE-IisrecommendedforpatientswithHFrEFtoreducetheriskofHF
I A
hospitalizationanddeath.110(cid:2)113
Abeta-blockerisrecommendedforpatientswithstableHFrEFtoreducetheriskof
I A
HFhospitalizationanddeath.114(cid:2)120
AnMRAisrecommendedforpatientswithHFrEFtoreducetheriskofHFhospitalizationanddeath.121,122 I A
DapagliflozinorempagliflozinarerecommendedforpatientswithHFrEFtoreducetherisk
I A
ofHFhospitalizationanddeath.108,109
Sacubitril/valsartanisrecommendedasareplacementforanACE-IinpatientswithHFrEFtoreducetheriskofHF
I B
hospitalizationanddeath.105
ACE-I=angiotensin-convertingenzymeinhibitor;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;LVEF=leftventricularejectionfraction;MRA=miner-
alocorticoidreceptorantagonist;NYHA=NewYorkHeartAssociation.
aClassofrecommendation.
bLevelofevidence.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 23 ---
ESCGuidelines 3621
.
.
. PracticalguidanceonhowtouseACE-IsisgiveninSupplementary
Table8 Evidence-baseddosesofdisease-modifyingdrugs ..
. Table2.
inkeyrandomizedtrialsinpatientswithheartfailurewith .
.
reducedejectionfraction ..
.
.
.
Startingdose Targetdose . 5.3.2 Beta-blockers
.
.
ACE-I . Beta-blockershavebeenshowntoreducemortalityandmorbidityin
.
.
Captoprila 6.25mgt.i.d. 50mgt.i.d. .. patientswithHFrEF,inadditiontotreatmentwithanACE-Ianddiu-
.
Enalapril 2.5mgb.i.d. 10(cid:2)20mgb.i.d. .. retic.114(cid:2)120 They also improve symptoms.123 There is consensus
.
Lisinoprilb 2.5(cid:2)5mgo.d. 20(cid:2)35mgo.d. .. thatACE-Iandbeta-blockerscanbecommencedtogetherassoon
.
Ramipril 2.5mgb.i.d. 5mgb.i.d.
... asthediagnosisofsymptomaticHFrEFisestablished.Thereisnoevi-
Trandolaprila 0.5mgo.d. 4mgo.d.
... dencefavouringtheinitiationofabeta-blockerbeforeanACE-Iand
.. vice versa.124 Beta-blockers should be initiated in clinically stable,
ARNI .
.. euvolaemic, patients at a low dose and gradually uptitrated to the
Sacubitril/valsartan 49/51mgb.i.d.c 97/103mgb.i.d. ...
maximum tolerated dose. In patients admitted with AHF, beta-
.
Beta-blockers .. blockersshouldbecautiouslyinitiatedinhospital,oncethepatientis
.
Bisoprolol 1.25mgo.d. 10mgo.d. .. haemodynamicallystabilized.
.
Carvedilol 3.125mgb.i.d. 25mgb.i.d.e .. An individual patient data (IPD) meta-analysis of all major beta-
.
Metoprololsuccinate 12.5(cid:2)25mgo.d. 200mgo.d. .. blockertrialsinHFrEFhasshownnobenefitonhospitaladmissions
.
(CR/XL) .. and mortality in the subgroup of patients with HFrEF with AF.125
.
.
Nebivolold 1.25mgo.d. 10mgo.d. .. However,sincethisisaretrospectivesubgroupanalysis,andbecause
.
MRA .. beta-blockersdidnotincreaserisk,theguidelinecommitteedecided
.
. nottomakeaseparaterecommendationaccordingtoheartrhythm.
Eplerenone 25mgo.d. 50mgo.d. .
.
. Practical guidance on how to use beta-blockers is given in
Spironolactone 25mgo.d.f 50mgo.d. ..
. SupplementaryTable3.
SGLT2inhibitor ..
.
.
Dapagliflozin 10mgo.d. 10mgo.d. .
.
.
Empagliflozin 10mgo.d. 10mgo.d. .. 5.3.3 Mineralocorticoidreceptorantagonists
.
Otheragents .. MRAs(spironolactoneoreplerenone)arerecommended,inaddition
.
Candesartan 4mgo.d. 32mgo.d.
.. toanACE-Iandabeta-blocker,inallpatientswithHFrEFtoreduce
.
Losartan 50mgo.d. 150mgo.d.
... mortalityandtheriskofHFhospitalization.121,122Theyalsoimprove
.. symptoms.121MRAsblockreceptorsthatbindaldosteroneand,with
Valsartan 40mgb.i.d. 160mgb.i.d. .
.. differentdegreesofaffinity,othersteroidhormones(e.g.corticoste-
Ivabradine 5mgb.i.d. 7.5mgb.i.d. .
.. roidandandrogen)receptors.Eplerenoneismorespecificforaldos-
Vericiguat 2.5mgo.d. 10mgo.d. ...
teroneblockadeand,therefore,causeslessgynaecomastia.
.
Digoxin 62.5mgo.d. 250mgo.d. .. CautionshouldbeexercisedwhenMRAsareusedinpatientswith
.
Hydralazine/ 37.5mgt.i.d./20mgt.i.d. 75mgt.i.d./40mgt.i.d. .. impairedrenalfunctionandinthosewithserumpotassiumconcen-
.
Isosorbidedinitrate .. trations>5.0mmol/L.
. ACE-I=angiotensin-converting enzyme inhibitor; ARNI=angiotensin receptor- .. PracticalguidanceonhowtouseMRAsisgiveninSupplementary
.
neprilysininhibitor;b.i.d.=bisindie(twicedaily);CR=controlledrelease;CV= .. Table4.
cardiovascular;MRA=mineralocorticoidreceptorantagonist;o.d.=omneindie ..
. (oncedaily);SGLT2=sodium-glucoseco-transporter2;t.i.d.=terindie(three .
.
timesaday);XL=extendedrelease. . .
aIndicates an ACE-I where the dosing target is derived from post-myocardial .. 5.3.4 Angiotensinreceptor-neprilysininhibitor
infarctiontrials. .. InthePARADIGM-HFtrial,sacubitril/valsartan,anARNI,wasshown
bIndicatesdrugswhereahigherdosehasbeenshowntoreducemorbidity/mor- ..
. tobesuperiortoenalaprilinreducinghospitalizationsforworsening
talitycomparedwithalowerdoseofthesamedrug,butthereisnosubstantive ..
randomized,placebo-controlledtrialandtheoptimumdoseisuncertain. .. HF,CVmortality,andall-causemortalityinpatientswithambulatory
cSacubitril/valsartanmayhaveanoptionallowerstartingdoseof24/26mgb.i.d. .. HFrEFwithLVEF<_40%(changedto<_35%duringthestudy).Patients
.
forthosewithahistoryofsymptomatichypotension. .
. inthetrialhadelevatedplasmaNPconcentrations,aneGFR>_30mL/
wdIn itd hic ha et ae rs ta fat ir lue ra etm (oe rnt shn oo wt nsh to ow bn et no onre -id nu fec re ioC rV too ar ta rl el- ac ta mus ee ntm to hart ta dli oty esin ).patients ....
min/1.73m2andwereabletotolerateenalaprilandthensacubitril/
eAmaximumdoseof50mgtwicedailycanbeadministeredtopatientsweighing .. valsartanduringtherun-inperiod.105Additionalbenefitsofsacubitril/
.
over85kg. .. valsartan included an improvement in symptoms and QOL,105 a
fSpironolactonehasanoptionalstartingdoseof12.5mginpatientswhererenal ..
statusorhyperkalaemiawarrantcaution.
.. reductionintheincidenceofdiabetesrequiringinsulintreatment,126
.
.. andareductioninthedeclineineGFR,127aswellasareducedrateof
.
5.3.1 Angiotensin-convertingenzymeinhibitors .. hyperkalaemia.128 Additionally, the use of sacubitril/valsartan may
.
ACE-Iswerethefirstclassofdrugsshowntoreducemortalityand .. allow a reduction in loop diuretic requirement.129 Symptomatic
.
morbidityinpatientswithHFrEF.110(cid:2)113Theyhavealsobeenshown .. hypotensionwasreportedmorecommonlyinpatientstreatedwith
.
to improve symptoms.111 They are recommended in all patients .. sacubitril/valsartanascomparedtoenalapril,butdespitedeveloping
.
unlesscontraindicatedornottolerated.Theyshouldbeuptitratedto .. hypotension,thesepatientsalsogainedclinicalbenefitsfromsacubi-
.
themaximumtoleratedrecommendeddoses. . tril/valsartantherapy.128,130
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 24 ---
3622 ESCGuidelines
.
Therefore,itisrecommendedthatanACE-IorARBisreplacedby .. isexpectedandisreversibleandshouldnotleadtoprematuredis-
.
.
sacubitril/valsartan in ambulatory patients with HFrEF, who remain . continuationofthedrug.
.
.
symptomaticdespiteoptimaltreatmentoutlinedabove.Twostudies . PracticalguidanceonhowtousetheSGLT2inhibitorsdapagliflo-
.
.
have examined the use of ARNI in hospitalized patients, some of . zinandempagliflozinaregiveninSupplementaryTable6.
.
.
whomhadnotbeenpreviouslytreatedwithACE-I.Initiationinthis .
.
.
settingappearssafeandreducessubsequentCVdeathorHFhospi- . 5.4 Other drugs recommended or to be
.
talizationsby42%comparedtoenalapril.106,107,131Assuch,initiation ...
considered in selected patients with
.
ofsacubitril/valsartaninACE-Inaive(i.e.denovo)patientswithHFrEF .
. heart failurewith reduced ejection
.
maybeconsidered(classofrecommendationIIb,levelofevidence .
.
. fraction
B).Patientsbeingcommencedonsacubitril/valsartanshouldhavean ..
.
adequatebloodpressure(BP),andaneGFR>_30mL/min/1.73m2.A ..
Otherpharmacologicaltreatmentsindicatedinselected
.
washout period of at least 36 h after ACE-I therapy is required in .. patientswithNYHAclassII–IVheartfailurewith
. ordertominimizetheriskofangioedema. .. reducedejectionfraction(LVEF(cid:3)40%)
.
PracticalguidanceonhowtouseARNIisgiveninSupplementary ..
Table5.
... Recommendations Classa Levelb
.
.
.. Loopdiuretics
.
.. Diureticsarerecommendedinpatientswith
.
5.3.5 Sodium-glucoseco-transporter2inhibitors .. HFrEFwithsignsand/orsymptomsofcongestion
TheDAPA-HFtrialinvestigatedthelong-termeffectsofdapagliflozin .. I C
. toalleviateHFsymptoms,improveexercise
.
(SGLT2inhibitor)comparedtoplaceboinadditiontooptimalmedi- .. capacity,andreduceHFhospitalizations.137
.
caltherapy(OMT),onmorbidityandmortalityinpatientswithambu- .
. ARB
latory HFrEF.108 Patients participated in the trial if they were in ..
.. AnARBcisrecommendedtoreducetheriskof
NYHA class II(cid:2)IV, and had an LVEF <_40% despite OMT. Patients .
.. HFhospitalizationandCVdeathinsymptomatic
werealsorequiredtohaveanelevatedplasmaNT-proBNPandan .
eGFR>_30mL/min/1.73m2.108
... patientsunabletotolerateanACE-IorARNI I B
.. (patientsshouldalsoreceiveabeta-blockerand
Therapywithdapagliflozinresultedina26%reductioninthepri- .
.. anMRA).138
maryendpoint:acompositeofworseningHF(hospitalizationoran ..
. I-channelinhibitor
urgentvisitresultingini.v.therapyforHF)orCVdeath.Bothofthese .. f
components were significantly reduced. Moreover, dapagliflozin
... Ivabradineshouldbeconsideredinsymptomatic
reduced all-cause mortality,108 alleviated HF symptoms, improved ... patientswithLVEF<_35%,inSRandaresting
physical functionand QOLinpatients with symptomatic HFrEF.132 ... heartrate>_70b.p.m.despitetreatmentwithan
Benefitswereseenearlyaftertheinitiationofdapagliflozin,andthe
... evidence-baseddoseofbeta-blocker(ormaxi- IIa B
absoluteriskreductionwaslarge.Survivalbenefitswereseentothe
... mumtolerateddosebelowthat),ACE-I/(or
sameextentinpatientswithHFrEFwithandwithoutdiabetes,and
... ARNI),andanMRA,toreducetheriskofHF
acrossthewholespectrumofHbA1cvalues.108
... hospitalizationandCVdeath.139
.
Subsequently,theEMPEROR-Reducedtrialfoundthatempagliflo- .. Ivabradineshouldbeconsideredinsymptomatic
.
zinreducedthecombinedprimaryendpointofCVdeathorHFhos- .. patientswithLVEF<_35%,inSRandaresting
.
pitalizationby25%inpatientswithNYHAclassII(cid:2)IVsymptoms,and .. heartrate>_70b.p.m.whoareunabletotolerate
.
anLVEF<_40%despiteOMT.109Thistrialincludedpatientswithan .. orhavecontraindicationsforabeta-blockerto IIa C
. eGFR >20 mL/min/1.73 m2 and there was also a reduction in the .. reducetheriskofHFhospitalizationandCV
. declineineGFRinindividualsreceivingempagliflozin.Itwasalsoasso- .. death.PatientsshouldalsoreceiveanACE-I(or
. ciatedwithanimprovementinQOL.133 Althoughtherewas nota .. ARNI)andanMRA.140
.
significantreductioninCVmortalityintheEMPEROR-Reducedtrial, .. Solubleguanylatecyclasestimulator
.
.
arecentmeta-analysisoftheDAPA-HFandEMPEROR-Reducedtri- . Vericiguatmaybeconsideredinpatientsin
.
alsfoundnoheterogeneityinCVmortality.134 .. NYHAclassII(cid:2)IVwhohavehadworseningHF
.
.
Therefore, dapagliflozin or empagliflozin are recommended, in . despitetreatmentwithanACE-I(orARNI),a IIb B
.
.
additiontoOMTwithanACE-I/ARNI,abeta-blockerandanMRA, . beta-blockerandanMRAtoreducetheriskof
.
.
for patients with HFrEF regardless of diabetes status. Thediuretic/ . CVmortalityorHFhospitalization.141
.
.
natriureticpropertiesofSGLT2inhibitorsmayofferadditionalbene- .. Hydralazineandisosorbidedinitrate
.
fitsinreducingcongestionandmayallowareductioninloopdiuretic .. Hydralazineandisosorbidedinitrateshouldbe
.
requirement.135 ..
consideredinself-identifiedblackpatientswith
.
ThecombinedSGLT-1and2inhibitor,sotagliflozin,hasalsobeen .. LVEF<_35%orwithanLVEF<45%combined
.
studiedinpatientswithdiabeteswhowerehospitalizedwithHF.The .. withadilatedleftventricleinNYHAclassIII(cid:2)IV IIa B
.
drugreducedCVdeathandhospitalizationforHF.136Itisdiscussed ..
despitetreatmentwithanACE-I(orARNI),a
.
furtherintheAHFandcomorbiditysections. .. beta-blockerandanMRAtoreducetheriskof
.
TherapywithSGLT2inhibitorsmayincreasetheriskofrecurrent .. HFhospitalizationanddeath.142
.
genitalfungalinfections.AsmallreductionineGFRfollowinginitiation . Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 25 ---
ESCGuidelines 3623
.
.
. 5.4.3 I -channelinhibitor
Hydralazineandisosorbidedinitratemaybecon- . f
.
. IvabradineslowsheartratebyinhibitionoftheI channelinthesinus
sideredinpatientswithsymptomaticHFrEFwho . f
.
. node and is therefore only effective in patients in SR. Ivabradine
cannottolerateanyofanACE-I,anARB,or IIb B .
.
. reducedthecombinedendpointofCVmortalityandHFhospitaliza-
ARNI(ortheyarecontraindicated)toreduce .
.
theriskofdeath.143 .. tioninpatientswithsymptomaticHFrEFwithanLVEF<_35%,withHF
.
. hospitalizationinrecent12months,insinusrhythm(SR)andwitha
Digoxin ..
. heartrate>_70b.p.m.whowereonevidence-basedtherapyincluding
.
Digoxinmaybeconsideredinpatientswith .
.. anACE-I(orARB),abeta-blocker,andanMRA.139,140Ourrecom-
symptomaticHFrEFinsinusrhythmdespite .
.. mendationisbasedontheheartrateof>_70b.p.m.usedintheSHIFT
treatmentwithanACE-I(orARNI),abeta- .
IIb B .. trial. However, the European Medicines Agency (EMA) approved
blockerandanMRA,toreducetheriskofhospi- . .. ivabradineforuseinEuropeinpatientswithHFrEFwithLVEF<_35%
talization(bothall-causeandHF .
hospitalizations).144
... andinSRwitharestingheartrate>_75b.p.m.,becauseinthisgroup
.. ivabradine conferred a survival benefit148 based on a retrospective
.
ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor .. subgroup analysis. Every effort should be made to commence and
.
blocker; ARNI=angiotensin receptor-neprilysin inhibitor; b.p.m.=beats per .. uptitratebeta-blockertherapytoguidelinerecommended/maximally
m rei dn uu cte e; deC jeV ct= ioc nar frd aio ctv ia os nc ;u Lla Vr E; F=HF le= fth ve ea nr tt ricf ua li alu rr ee j; ectH ioF nrE frF a= cth ioe na ;rt MRfa Ailu =r me inw erit ah
-
....
tolerateddosespriortoconsideringivabradine.
locorticoid receptor antagonist; NYHA=New York Heart Association; SR= .. Practical guidance on how to use ivabradine is given in
.
sinusrhythm. .. SupplementaryTable8.
aClassofrecommendation. ..
bLevelofevidence. ..
cTheARBswithevidenceinHFrEFarecandesartan,losartan,andvalsartan. .. 5.4.4 Combinationofhydralazineandisosorbide
.
.
. dinitrate
.
.
5.4.1 Diuretics .. Thereisnoclearevidencetosuggesttheuseofthisfixed-dosecom-
.
Loopdiureticsarerecommendedtoreducethesignsand/orsymp- .. binationtherapyinallpatientswithHFrEF.AsmallRCTconductedin
.
toms of congestion in patients with HFrEF. The quality of the evi- .. self-identifiedblackpatientsshowedthatanadditionofthecombina-
.
denceregardingdiureticsispoorandtheireffectsonmorbidityand .. tionofhydralazineandisosorbidedinitratetoconventionaltherapy
.
mortalityhavenotbeenstudiedinRCTs.However,itshouldalsobe .. (anACE-I,abeta-blocker,and anMRA)reduced mortalityandHF
remembered that the major disease-modifying treatment trials for
... hospitalizationsinpatientswithHFrEFandNYHAclassesIII(cid:2)IV.142
.
HFrEFwereconductedwithahighbackgrounduseofloopdiuretic .. Theseresultsaredifficulttotranslatetopatientsofotherracialor
.
therapy.Onemeta-analysis has shown that in patients with HFrEF, .. ethnicorigins.
.
loop and thiazide diuretics appear to reduce the risk of death and .. Additionally,acombinationofhydralazineandisosorbidedinitrate
.
worsening HF compared with a placebo, and compared with an .. maybeconsideredinsymptomaticpatientswithHFrEFwhocannot
.
activecontrol,diureticsimproveexercisecapacity.137 .. tolerateanyofanACE-I,ARNI,oranARB(oriftheyarecontraindi-
.
Loopdiureticsproduceamoreintenseandshorterdiuresisthan .. cated)toreducemortality.However,thisrecommendationisbased
.
thiazides,althoughtheyactsynergistically(sequentialnephronblock- .. on the results of the relatively small Veterans Administration
.
ade)andthecombinationmaybeusedtotreatdiureticresistance. .. CooperativeStudy,whichincludedonlymalepatientswithsympto-
.
However, adverse effects are more likely, and these combinations
.. maticHFrEFwhoweretreatedwithdigoxinanddiuretics.143
.
. should only be used with care. Of note, ARNI, MRAs, and SGLT2 .
.
inhibitorsmayalsopossessdiureticproperties.129,145 ... 5.4.5 Digoxin
.
Theaimofdiuretictherapyistoachieveandmaintaineuvolaemia .. DigoxinmaybeconsideredinpatientswithHFrEFinSRtoreduce
with the lowest diuretic dose. In some euvolaemic/hypovolaemic ... the risk of hospitalization,144 although its effect on those routinely
.
patients,the use of a diuretic drug might be reduced ordiscontin- .. treatedwithbeta-blockershasnotbeentested.IntheDIGtrial,the
.
ued.146 Patients should be trained to self-adjust their diuretic dose .. overalleffectonmortalitywithdigoxinwasneutral.
.
based on monitoring of symptoms/signs of congestion and daily .. TheeffectsofdigoxininpatientswithHFrEFandAFhavenotbeen
.
weightmeasurements. .. studied in RCTs. Some studies have suggested a potentially higher
Practical guidance on how to use diuretics is given in ... risk of events in patients with AF receiving digoxin,149,150 whereas
.
SupplementaryTable7. .. another meta-analysis concluded, on the basis of non-RCTs, that
.
. digoxinhasnodeleteriouseffectonmortalityinpatientswithAFand
.
.. HF,mostofwhomhadHFrEF.151Therefore,inpatientswithsympto-
.
.
5.4.2 AngiotensinIItypeIreceptorblockers . maticHFandAF,digoxinmaybeusefulforthetreatmentofpatients
.
.
Theplace of ARBsinthemanagementofHFrEFhaschangedover .. withHFrEFandAFwithrapidventricularrate,whenothertherapeu-
.
thelastfewyears.Theyarenowrecommendedforpatientswhocan- .. ticoptionscannotbepursued.150,152(cid:2)155
.
not tolerate ACE-I or ARNI because of serious side effects. .. Digoxinhasanarrowtherapeuticwindowandsolevelsshouldbe
.
Candesartan in the CHARM-Alternative study reduced CV deaths .. checkedaimingforaserumdigoxinconcentration<1.2ng/mL.156,157
.
andHFhospitalizationsinpatientswhowerenotreceivinganACE-I .. Cautionshouldalsobeexercisedwhenusingitinfemales,theelderly,
.
duetopreviousintolerance.138Valsartan,inadditiontousualtherapy, .. frail, hypokalaemic, and malnourished subjects. In patients with
.
includingACE-I,reducedHFhospitalizationsintheVal-HeFTtrial.147 .. reducedrenalfunction,digitoxincouldbeconsidered.Digitoxinuse
.
However,noARBhasreducedall-causemortalityinanytrial. . inHFandSRiscurrentlybeinginvestigated.158
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 26 ---
3624 ESCGuidelines
Management of HFrEF
To reduce mortality - for all patients
ACE-I/ARNI BB MRA SGLT2i
To reduce HF hospitalization/mortality - for selected patients
Volume overload
Diuretics
SR with LBBB ≥ 150 ms SR with LBBB 130–149 ms or non LBBB ≥ 150 ms
CRT-P/D CRT-P/D
Ischaemic aetiology Non-ischaemic aetiology
ICD ICD
Atrial fibrillation Atrial fibrillation Coronary artery disease Iron deficiency
Anticoagulation Digoxin PVI CABG Ferric carboxymaltose
Aortic stenosis Mitral regurgitation Heart rate SR>70 bpm Black Race ACE-I/ARNI intolerance
SAVR/TAVI TEE MV Repair Ivabradine Hydralazine/ISDN ARB
For selected advanced HF patients
Heart transplantation MCS as BTT/BTC Long-term MCS as DT
To reduce HF hospitalization and improve QOL - for all patients
Exercise rehabilitation
Multi-professional disease management
Figure3 Centralillustration.Strategicphenotypicoverviewofthemanagementofheartfailurewithreducedejectionfraction.ACE-I=angiotensin-convert-
ingenzymeinhibitor;ARB=angiotensinreceptorblocker;ARNI=angiotensinreceptor-neprilysininhibitor;BB=beta-blocker;b.p.m.=beatsperminute;BTC
=bridgetocandidacy;BTT=bridgetotransplantation;CABG=coronaryarterybypassgraft;CRT-D=cardiacresynchronizationtherapywithdefibrillator;
CRT-P=cardiacresynchronizationtherapypacemaker;DT=destinationtherapy;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;ICD=
implantablecardioverter-defibrillator;ISDN=isosorbidedinitrate;LBBB=leftbundlebranchblock;MCS=mechanicalcirculatorysupport;MRA=mineralocor-
ticoidreceptorantagonist;MV=mitralvalve;PVI=pulmonaryveinisolation;QOL=qualityoflife;SAVR=surgicalaorticvalvereplacement;SGLT2i=sodium-
glucoseco-transporter2inhibitor;SR=sinusrhythm;TAVI=transcatheteraorticvalvereplacement;TEE=transcatheteredgetoedge.Colourcodeforclasses
ofrecommendation:GreenforClassofrecommendationI;YellowforClassofrecommendationIIa(seeTable1forfurtherdetailsonclassesofrecommenda-
tion).TheFigureshowsmanagementoptionswithClassIandIIarecommendations.SeethespecificTablesforthosewithClassIIbrecommendations.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 27 ---
ESCGuidelines 3625
.
..
5.4.6 Recentlyreportedadvancesfromtrialsinheart .. prevent bradycardia. Some antiarrhythmic drugs might reduce the
..
..
failurewithreducedejectionfraction .. rateoftachyarrhythmiasandsuddendeath,buttheydonotreduce
..
.. .. overallmortality,161andmayincreaseit.
Solubleguanylatecyclasestimulator ...
.
The VICTORIA study assessed the efficacy and safety of the oral ..
.
soluble guanylate cyclase stimulator, vericiguat, in patients with a .. Recommendationsforanimplantablecardioverter-
reduced EF and recently decompensated CHF. The incidence of ... defibrillatorinpatientswithheartfailure
.
the primaryendpoint of death from CV causes or hospitalization ..
for HF was lower among those who received vericiguat than
... Recommendations Classa Levelb
.
amongthosewhoreceivedplacebo.141Therewasnoreductionin .. Secondaryprevention
.
either all-cause or CV mortality. Thus, vericiguat may be consid- ... AnICDisrecommendedtoreducetheriskof
ered,inadditiontostandardtherapyforHFrEF,toreducetherisk ... suddendeathandall-causemortalityinpatients
ofCVmortalityandhospitalizationsforHF. ... whohaverecoveredfromaventriculararrhyth-
.
.. miacausinghaemodynamicinstability,andwho
. I A
Cardiacmyosinactivator .. areexpectedtosurvivefor>1yearwithgood
.
TheGALACTIC-HFstudyassessedtheefficacyandsafetyofthecar- .. functionalstatus,intheabsenceofreversible
.
diacmyosinactivator,omecamtivmecarbil,inHFrEFpatients,enroll- .. causesorunlesstheventriculararrhythmiahas
.
ingpatientsinboththeinpatientandoutpatientsettings.Theprimary .. occurred<48hafteraMI.162(cid:2)164
.
endpointofafirstHFeventorCVdeathwasreducedby8%.There .
. Primaryprevention
.
wasnosignificantreductioninCVmortality.Currently,thisdrugis .
.. AnICDisrecommendedtoreducetheriskof
notlicensedforuseinHF.However,inthefutureitmaybeableto .
.. suddendeathandall-causemortalityinpatients
beconsidered,inadditiontostandardtherapyforHFrEFtoreduce .
theriskofCVmortalityandhospitalizationforHF.159
... withsymptomaticHF(NYHAclassII(cid:2)III)ofan
.. ischaemicaetiology(unlesstheyhavehadaMIin
. I A
.. theprior40days—seebelow),andanLVEF
5.5 Strategic phenotypic overviewof the .
.. <_35%despite>_3monthsofOMT,provided
management of heart failurewith ...
theyareexpectedtosurvivesubstantiallylonger
.
reduced ejection fraction .. than1yearwithgoodfunctionalstatus.161,165
.
.
In addition to the general therapies considered in section 5, other . AnICDshouldbeconsideredtoreducetherisk
.
.
therapiesareappropriatetoconsiderinselectedpatients.Theseare . ofsuddendeathandall-causemortalityin
.
.
coveredindetailinlatersections.Someofthemainones(i.e.those . patientswithsymptomaticHF(NYHAclass
.
.
withClassIandIIaMortality/Hospitalizationindications)aredepicted .. II(cid:2)III)ofanon-ischaemicaetiology,andanLVEF IIa A
.
inFigure3.Theeffectofsomeinterventionsonsymptoms/QOLare .. <_35%despite>_3monthsofOMT,provided
.
outlinedinSupplementaryTable9. .. theyareexpectedtosurvivesubstantiallylonger
.
. than1yearwithgoodfunctionalstatus.161,166,167
.
.
.. Patientsshouldbecarefullyevaluatedbyan
.
.. experiencedcardiologistbeforegenerator
6 Cardiac rhythm management ... replacement,becausemanagementgoals,the IIa B
.
for heart failure with reduced .. patient’sneedsandclinicalstatusmayhave
.
.. changed.168(cid:2)172
ejection fraction ..
. AwearableICDmaybeconsideredforpatients
. .
. withHFwhoareatriskofsuddencardiacdeath
This section provides recommendations on the use of implantable .. IIb B
. foralimitedperiodorasabridgetoan
cardioverter-defibrillators(ICD)andcardiacresynchronizationther- ..
. implanteddevice.173(cid:2)176
.
apy(CRT).Otherimplantabledeviceswillbediscussedattheendof .
.. ICDimplantationisnotrecommendedwithin40
thissection. .
.. daysofaMIasimplantationatthistimedoesnot III A
.
.. improveprognosis.177,178
6.1 Implantable cardioverter- .
.
. ICDtherapyisnotrecommendedinpatientsin
defibrillator ..
. NYHAclassIVwithseveresymptomsrefractory
.
A high proportion of deaths among patients with HF, especially in .. topharmacologicaltherapyunlesstheyarecan- III C
.
those with milder symptoms, occur suddenly and unexpectedly. ..
didatesforCRT,aVAD,orcardiac
. Manyofthesemaybeduetoelectricaldisturbances,includingven- .. transplantation.179(cid:2)183
.
tricular arrhythmias, bradycardia, and asystole, although some are ..
.
duetootheracutevascularevents.Treatmentsthatimproveordelay .. CRT=cardiac resynchronization therapy; HF=heart failure; ICD=implantable
. cardioverter-defibrillator;LVEF=leftventricularejectionfraction;MI=myocar-
theprogressionofCVdiseasehavebeenshowntoreducetheannual ...
dial infarction; NYHA=New York Heart Association; OMT=optimal medical
rateofsuddendeath,105,160buttheydonottreatarrhythmicevents .. therapy;VAD=ventricularassistdevice.
whentheyoccur.ICDsareeffectiveatcorrectingpotentiallylethal
... aClassofrecommendation.
ventriculararrhythmias,andinthecaseoftransvenoussystems,also
.. bLevelofevidence.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 28 ---
3626 ESCGuidelines
.
.
6.1.1 Secondarypreventionofsuddencardiacdeath . In patients with moderate or severe HF, a reduction in sudden
.
.
Compared with amiodarone treatment, ICDs reduce mortality in . deathmaybepartiallyorwhollyoffsetbyanincreaseindeathdueto
.
survivorsofcardiacarrestandinpatientswhohaveexperiencedsus- .. worsening HF.161 As such, ICD therapy is not recommended in
.
.
tained symptomatic ventricular arrhythmias. An ICD is recom- . patientsinNYHAclassIV,withseveresymptomsrefractorytophar-
.
.
mendedinsuchpatientswhentheintentistoincreasesurvival;the . macologicaltherapy,whoarenotcandidatesforaventricularassist
.
.
decisiontoimplantshouldtakeintoaccountthepatient’sviewand . device (VAD) orcardiactransplantation.Suchpatients have a very
.
.
theirQOL,theLVEF(survivalbenefitisuncertainwhenLVEF>35%) . limited life expectancy and are likely to die from pump failure.
.
.
andtheabsenceofotherdiseaseslikelytocausedeathwithinthefol- .. Similarly,patientswithseriouscomorbiditieswhoareunlikelytosur-
.
lowingyear.162(cid:2)164,184 .. vivesubstantiallymorethan1yearwithgoodQOLareunlikelyto
.
.. obtainsubstantialbenefitfromanICD.179(cid:2)183
.
.. AlthoughtheDANISHtrialdidnotshowasignificantbenefitfrom
6.1.2 Primarypreventionofsuddencardiacdeath .
.. ICDtherapyinpatientswithNICM,itshouldberememberedthat
Inananalysisofover40000patientsfrom12pivotalHFtrials,rates . .. NICMisaheterogeneouscondition,andcertainsubgroups(e.g.lami-
ofsuddencardiacdeathdecreasedby44%overthe20-yearperiod .
(from the mid-1990s to 2015).160 This is almost certainly due to
... nopathies,sarcoidosis)areathigherriskofsuddendeathandthere-
.. foremeritcarefulconsiderationofICDimplantation.Toolstohelp
advances in HF treatment, as many key guideline-recommended .
.. riskstratification (e.g. scarburden on magnetic resonanceimaging)
therapies, including beta-blockers, MRAs, sacubitril/valsartan, and . .. canbehelpfulinthatregard.190(cid:2)192
CRTpacemakers(CRT-P),reducetheriskofsuddendeath.While ...
Patients should be counselled as to the purpose of an ICD and
theafore-mentionedHFtherapieshavebeenshowntoreducemor- ...
involvedinthedecision-makingprocess.Theyshouldalsobeawareof
talityinpatientswithHFrEF,amiodaronehasnot.161However,ifitis ...
thepotentialcomplicationsrelatedtoimplantation,anyadditionalimpli-
tobeused,itshouldbewithcautionduetoitssignificantside-effect ..
. cationsfordriving,andtheriskofinappropriateshocks.Furthermore,
profile. Conversely, dronedarone185 and the class I antiarrhythmic ..
. patientsshouldbeinformedaboutthecircumstanceswherethedefib-
agentsdisopyramide,encainide,andflecainide186shouldnotbeused ..
. rillator(ordefibrillatorcomponentofaCRT-D)mightbedeactivated
forpreventionofarrhythmiasduetotheincreaseinmortalityseenin ..
. (e.g. terminal disease) or explanted (e.g. infection or recovery of LV
clinicalstudies. ...
function).193 Subsequent timely conversations regarding defibrillator
Although an ICD reduces the rate of sudden arrhythmic death in ..
. deactivationshouldbeheldwiththepatientandcaregiver(s).
patients with HFrEF,187 it would be expected that, in well-managed ..
. WhenanICDgeneratorreachesitsendoflifeorrequiresexplan-
patients,theadditionalbenefitaffordedbyanICDwouldbelower.In ..
. tation,itshouldnotbereplacedautomatically.Rather,shareddeci-
theDANISHtrial,ratesofsuddendeathwerelowinpatientswithnon- ...
sion making should be undertaken.168(cid:2)172 Patients should be
.
ischaemiccardiomyopathy(NICM);only70patientsoutof1116fol- .
. carefullyevaluatedbyanexperiencedcardiologistastreatmentgoals
lowedupover5yearshadsuddendeath.166Whilsttherewasamodest ..
.. may have changed since implantation (the risk of fatal arrhythmia
absolute reduction in sudden death with a defibrillator-containing .
.. maybelower,ortheriskofnon-arrhythmicdeathmaybehigher).
device,thisdidnot significantlyimprove the overall risk of mortality. .
.. It is a matter of some controversy whether patients whose
However,subgroupanalysissuggestedtherewasabenefitinthose<_70 .
years.188Inarecentmeta-analysisofstudiesthatexaminedtheeffectof
... LVEFhasgreatlyimprovedandwhohavenotrequireddevicether-
.. apy during the lifetime of the ICD should have another device
ICDsinNICMasurvivalbenefitwasstillseen,althoughtheeffectwas .
significantlyweakenedbytheinclusionoftheDANISHtrial.167
... implanted.168(cid:2)172
. .
Onaverage,patientswithIHDareatgreaterriskofsuddendeath .
.
.
thanpatientswithNICMandtherefore,althoughtherelativebenefits . 6.1.4 Implantablecardioverter-defibrillator
.
.
aresimilar,theabsolutebenefitisgreaterinpatientswithIHD.187Two . programming .
.
RCTsshowednobenefitinpatientswhohadanICDimplantedwithin .. Routine defibrillation threshold testing is no longer performed fol-
.
40 days after a MI.177,178 Although sudden arrhythmic deaths were .. lowing implantation of an ICD or CRT-D as it does not improve
.
reduced, this was balanced by an increase in non-arrhythmic deaths. .. shockefficacyorreducearrhythmicdeath.194Conservativeprogram-
.
Accordingly,anICDforprimarypreventioniscontraindicatedinthis .. mingwithlongdelays195betweendetectionandtheICDdelivering
.
timeperiod.Furthermore,ICDimplantationisrecommendedonlyifa .. therapy dramatically reduces the risk of both inappropriate and
.
minimum of 3 months of OMT has failed to increase the LVEF to .. appropriatebutunnecessaryshocks.194,196,197Generally,forprimary
.
>35%.OMTideallyincludestheuseofClassIrecommendeddrugsfor .. prevention, defibrillators are programmed to minimize pacing (e.g.
.
HFrEF.However,theICDtrialswecitepredatetheuseofARNIand .. ventricular demand pacing VVI at 40/min), and with a tachycardia
.
SGLT2inhibitors.WhetherimplantationofICDsreducesmortalityin .. treatment zone >200/min.194,198 Ultimately—and particularly for
.
thosewithanLVEF>35%isunknown.ThereisanongoingtrialofICD .. secondary prevention—programming should be adapted according
.
therapyinsuchpatientswiththepresenceofscaronCMRimaging.189 .. tothepatient’sspecificneeds.
.
.
.
.
.
.
6.1.3 Patientselectionforimplantablecardioverter- .. 6.1.5 Subcutaneousandwearableimplantable
.
defibrillatortherapy .. cardioverter-defibrillators
.
PatientswithHFrEFandaQRSduration>_130mscanbeconsidered .. Subcutaneous ICDs (S-ICDs) appear to be as effective as conven-
.
forCRTwithadefibrillator(CRT-D)ratherthanICD.Seethesec- .. tionaltransvenous ICDs with a similar complicationrate.Although
.
tiononCRTforfurtherdetails(section6.2). . the risk of inappropriate shocks appeared to be higher initially,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 29 ---
ESCGuidelines 3627
.
improved patient selection has shown S-ICDs are non-inferior to .
. CRTmaybeconsideredforsymptomatic
transvenousICDsinthisregard.199(cid:2)202Theymaybethepreferred ..
. patientswithHFinSRwithaQRSdurationof
.
optionforpatientswithdifficultvenousaccessorthosewhorequire .
. 130(cid:2)149msandnon-LBBBQRSmorphology
ICD explantation due to infection. Patients must be carefully .. IIb B
. andwithLVEF<_35%despiteOMTinorderto
.
selected,asS-ICDscannottreatbradyarrhythmia(exceptpost-shock .
. improvesymptomsandreducemorbidityand
.
pacing) and cannot deliver either anti-tachycardia pacing or CRT. .. mortality.208,213
.
Substantial RCTs with these devices and more long-term data on .
.. CRTisnotrecommendedinpatientswitha
safetyandefficacyareawaited. .
.. QRSduration<130mswhodonothaveanindi-
A wearable cardioverter-defibrillator that is able to recognize ...
cationforpacingduetohighdegreeAV
III A
and treat ventricular arrhythmias may be considered for a limited ...
block.222(cid:2)224
period of time in selected patients with HF who are at high risk ..
.
for sudden death but otherwise are not suitable for ICD .. AF=atrial fibrillation; AV=atrio-ventricular; CRT=cardiac resynchronization
implantation.162,175,176,203 However, the large VEST trial failed to ... therapy;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;
. ICD=implantable cardioverter-defibrillator; LBBB=left bundle branch block;
show that the wearable cardioverter-defibrillator reduced arrhyth- .. LVEF=leftventricularejectionfraction;NYHA=NewYorkHeartAssociation;
.
micdeathin patientswith anLVEF <_35% followinga recentacute .. OMT=optimalmedicaltherapy(classIrecommendedmedicaltherapiesforat
.
MI.204 .. least3months);QRS=Q,R,andSwavesofanECG;RV=rightventricular;SR=
. sinusrhythm. For more detailed recommendations on the use/indications of ... aClassofrecommendation.
ICD we refer the reader to the ESC/European Heart Rhythm .. bLevelofevidence.
.
Association(EHRA)Guidelinesonventriculartachyarrhythmiasand ..
.
suddencardiacdeath.201 ..
.
.. Inappropriatelyselectedindividuals,CRTreducesmorbidityand
.
6.2 Cardiac resynchronization therapy .. mortality.211 Furthermore, CRT improves cardiac function, and
.
.. enhancesQOL.209,225
.
.. WhilsttheCARE-HF206,208andCOMPANION210trialscompared
Recommendationsforcardiacresynchronizationther- .
.
apyimplantationinpatientswithheartfailure .. theeffectofCRTwithmedicaltherapy(MT),themajorityofCRT
.
. studieshavecomparedCRT-DwithICD,andafewhavecompared
.
.
Recommendations Classa Levelb .. CRT-Pwithbackuppacing.Thepreventionoffatalbradycardiamight
.
. beanimportantmechanismofbenefitsharedbyallpacingdevices.In
.
CRTisrecommendedforsymptomaticpatients .
. CARE-HF,atbaseline,25%ofpatientshadarestingheartrateof<_60
.
withHFinSRwithaQRSduration>_150msand .. b.p.m.206,208,209Ifpreventionofbradycardiaisimportant,theeffectof
.
LBBBQRSmorphologyandwithLVEF<_35% I A .
. CRTwillappeargreaterintrialswherethereisnodeviceinthecon-
.
despiteOMTinordertoimprovesymptoms .
. trolgroup.However,inMADIT-II,35% ofthosewhodiedwithan
andreducemorbidityandmortality.205(cid:2)215 ..
. ICD did sosuddenly even though they were protected from both
.
CRTratherthanRVpacingisrecommendedfor .. brady-andtachyarrhythmia.226
.
patientswithHFrEFregardlessofNYHAclassor ..
MoststudiesofCRThavespecifiedthattheLVEFshouldbe<_35%,
.
QRSwidthwhohaveanindicationforventricu-
I A
... butRAFT212andMADIT-CRT213,214specifiedanLVEF<_30%,while
larpacingforhighdegreeAVblockinorderto ... REVERSE207,215,227 specified <_40% and BLOCK-HF216 <_50%.
reducemorbidity.Thisincludespatientswith ... RelativelyfewpatientswithanLVEFof35(cid:2)40%havebeenrandom-
AF.216(cid:2)219 ...
ized,butanIPDmeta-analysissuggestsnodiminutionoftheeffectof
. CRTshouldbeconsideredforsymptomatic .. CRTinthisgroup.211
. patientswithHFinSRwithaQRSduration .. Assessingthe‘response’toCRTischallenging.Indeed,manywho
. >_150msandnon-LBBBQRSmorphologyand
IIa B
... donotappearto‘respond’favourablyintermsoftheirsymptomsor
withLVEF<_35%despiteOMTinorderto .. LVfunctionmaywellhaveexperiencedthemortalitybenefit.Several
.
improvesymptomsandreducemorbidityand .. characteristicspredictimprovementinmorbidityandmortality.The
.
mortality.205(cid:2)215 .. extentofreverseremodellingisoneofthemostimportantmecha-
.
CRTshouldbeconsideredforsymptomatic .. nismsofactionofCRT.PatientswithHFrEFofanischaemicaetiology
.
patientswithHFinSRwithaQRSdurationof .. havelessimprovementinLVfunctionduetomyocardialscartissue,
.
130(cid:2)149msandLBBBQRSmorphologyand .. whichislesslikelytoundergofavourableremodelling.228Conversely,
IIa B .
withLVEF<_35%despiteOMTinorderto .. women may be more likely to respond than men, possibly due to
.
improvesymptomsandreducemorbidityand .. smaller body and heart size.220,224,229 QRS width predicts CRT
.
mortality.211,220 .. responseandwastheinclusioncriterioninallrandomizedtrials,211
.
.
PatientswithanLVEF<_35%whohavereceived . butQRSmorphologyhasalsobeenrelatedtoabeneficialresponse
.
.
aconventionalpacemakeroranICDandsubse- . to CRT. Several studies have shown that patients with left bundle
.
.
quentlydevelopworseningHFdespiteOMTand IIa B .. branchblock(LBBB)morphologyaremorelikelytorespondfavour-
.
whohaveasignificantproportionofRVpacing .. ablytoCRT,whereasthereislesscertaintyaboutpatientswithnon-
shouldbeconsideredfor‘upgrade’toCRT.221 ... LBBBmorphology.230Thislattergroupisalsounderrepresentedin
.
Continued . the large CRT trials.206,210,213 However, patients with LBBB
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 30 ---
3628 ESCGuidelines
.
.
morphologyoftenhavewiderQRSdurations,andthereisacurrent . Earlystudiessuggestedthatimagingtestsfordyssynchronywere
.
debate about whether QRS durations or QRS morphology is the .. notofvalueinselectingpatientsforCRT.233However,arecentstudy
.
.
mainpredictorofabeneficialresponsetoCRT.Evidencefromtwo . hassuggestedthattwonovelmarkersofdyssynchrony(apicalrock-
.
.
IPDmeta-analysesindicatesthatafteraccountingforQRSduration, . ingandseptalflash)areassociatedwitharesponsetoCRT,butthese
.
.
thereislittleevidencetosuggestthatQRSmorphologyoraetiology . have not been tested as selection criteria or as prespecified sub-
.
of disease influence the effect of CRT on morbidity or mortal- .. groups ina randomized trial.234 Patientswith extensive myocardial
.
ity.211,220Inaddition,noneofthelandmarktrialsselectedpatientsfor .. scarwillhavelessimprovementinLVfunctionwithCRT,butthisis
.
.
inclusionaccordingtoQRSmorphology,sex,orischaemicaetiology, . true ofany treatment forHFrEF and doesnot reliably predict less
.
.
norweretheypoweredforsubgroupanalyses. .. clinicalbenefit.Pacingthresholdsarehigherinscarredmyocardium
.
TheEcho-CRTtrial222,223andanIPDmeta-analysis213suggestpos- .. and, if possible, lead placement should avoid such regions.235,236
.
sibleharmfromCRTwhenQRSdurationis<130ms,thusimplanta- .. Althoughpatientswithextensivescarringhaveanintrinsicallyworse
.
tionofCRTisnotrecommendedifQRSdurationis<130ms. .. prognosis, there is little evidence that they obtain less prognostic
. Ifapatientisscheduled toreceiveanICDandisinSR,witha .. benefitfromCRT.211
.
LBBB, CRT-D should be considered if the QRS is between 130 .. The value of trying to optimize AV intervals or interventricular
.
and 149 ms and is recommended if QRS is >_150 ms. However, .. delayintervals(VVintervals)afterimplantationusingecho-orelec-
.
clinicalpracticevarieswidelyamongcountriesandiftheprimary .. trocardiographiccriteriaorBPresponseisuncertainbutmaybecon-
. reasonforimplantingCRTisforthereliefofsymptoms,thenthe .. sidered for patients who have had a disappointing response to
.
clinician should choose CRT-P or CRT-D, whichever they con- .. CRT.237,238OtheroptionstoconsidertooptimizeresponsetoCRT
.
sider appropriate. The only randomized trial to compare CRT-P .. arecoveredinarecentlypublishedpracticalarticle.239
.
and CRT-D210 did not demonstrate a difference in morbidity or .. FollowingCRTimplantation,areviewofdiuretictherapyisadvised
.
.
mortalitybetweenthesetechnologies(althoughthetrialwasnot . asareductionindoseoritsdiscontinuationmayberequired.Inaddi-
.
.
powered to show such a difference). Furthermore, in the . tion,CRTimplantationmayaffordanopportunitytofurtheroptimize
.
DANISH study in patients with NICM where 58% of patients .. MTforHFrEF.240
.
.
received CRT there was no suggestion from subgroup analysis . ThereaderisdirectedtoguidelinesonpacingandCRTforrecom-
.
thatCRT-PwasinferiortoCRT-D.166,167 .. mendationsondeviceimplantationprocedures.240a
.
.
WhenLVEFisreduced,RVpacingmayexacerbatecardiacdyssyn- .
.
.
chrony.ThiscanbepreventedbyCRT,whichmightimprovepatient . 6.3 Devices under evaluation
.
outcomes.216(cid:2)218,231 However, a difference in outcome was not ..
. Cardiac contractility modulation (CCM) has been evaluated in
.
observed between CRT and RV pacing in a subgroup analysis of .
. patientswithNYHAclassIII(cid:2)IVHF,withanLVEF>_25%to<_45%
.
RAFT.212Onbalance,CRTratherthanRVpacingisrecommended .
. andQRSduration<130ms,andwasassociatedwithasmallimprove-
.
forpatientswithHFrEFregardlessofNYHAclasswhohaveanindi- ... mentinexercisetoleranceandQOL.241,242
cationforventricularpacinginordertoreducemorbidity,although ...
Technologiesthatinvolvemodificationoftheactivityoftheauto-
nocleareffectonmortalitywasobserved.PatientswithHFrEFwho ... nomicnervoussystem,e.g.baroreflexactivationtherapy,243,244have
havereceivedaconventionalpacemakeroranICDandsubsequently ...
alsobeenshowntoofferamodestimprovementineffortcapacity
developworseningHFwithahighproportionofRVpacing,despite ...
andQOL.However,currently,theevidenceisconsideredinsufficient
OMT,shouldbeconsideredfor‘upgrading’toCRT. ...
to support specific guideline recommendations for a reduction in
Only two small trials have compared pharmacological therapy ...
mortalityorhospitalizationfortheseandavarietyofotherimplant-
alonevs.CRTinpatientswithAF,withconflictingresults.Several ...
ableelectricaltherapeutictechnologies(seealsoGapsinEvidencein
studieshaveindicatedthatCRTissuperiortoRVpacinginpatients ...
section16).
undergoing atrio-ventricular (AV) node ablation.217,218,231 ..
. However,AFisnotanindicationtocarryoutAVnodeablationin ..
. patients with CRT except in a few cases when ventricular rate .. 7 Heart failure with mildly
.
.
remainspersistentlyhighdespiteattemptsatpharmacologicalrate .
.. reduced ejection fraction
control. A subgroup analysis of patients with AF from the RAFT .
.
.
studyfoundnobenefitfromCRT-DcomparedwithICD,although .
.
lessthanhalfofpatientshad>90%biventricularcapture.219Inview .. 7.1 The diagnosis of heart failurewith
.
ofthepaucityofevidencefortheefficacyofCRTinpatientswith .. mildly reduced ejection fraction
.
.
AF, it may be an option in selected patients—particularly those . ThediagnosisofHFmrEFrequiresthepresenceofsymptomsand/or
.
.
withaQRS>_150ms—ensuringaproportionofbiventricularpac- .. signsofHF,andamildlyreducedEF(41(cid:2)49%)Thepresenceofele-
.
ingashighaspossible. .. vatedNPs(BNP>_35pg/mLorNT-proBNP>_125pg/mL)andother
.
Observational studies report that when biventricular capture is .. evidenceofstructuralheartdisease[e.g.increasedleftatrial(LA)size,
.
<98%,theprognosisofpatientswithCRTdeclines.218,232Whether .. LVHorechocardiographicmeasuresofLVfilling]makethediagnosis
.
thisassociationreflectsalossofresynchronization(whichmightbe .. morelikelybutarenotmandatoryfordiagnosisifthereiscertainty
.
remediedbydeviceprogramming),poorplacementoftheLVlead, .. regardingthemeasurementofLVEF.
.
orgreaterdifficultyinpacingseverelydiseasedmyocardiumisuncer- .. AnalgorithmforthediagnosisofHFmrEFisdepictedinFigure1.
.
tain. This observation has not been confirmed in any randomized .. For the investigation of the underlying aetiology, please refer to
.
trial. . Table5(whichreferstoinvestigationsregardlessofLVEF).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 31 ---
ESCGuidelines 3629
.
7.2 Clinical characteristics of patients .
.. 7.3.1 Angiotensin-convertingenzymeinhibitors
with heart failurewith mildly reduced ...
There are no specific trials of ACE-I in patients with HFmrEF.
.
ejection fraction .. Although,thePEP-CHFtrialwasconductedinpatientswithHFpEF
.
Thereisa substantialoverlapofclinicalcharacteristics,riskfactors, .. andincludedpatientswithanLVEF>40%,itdidnotreportoutcomes
.
patternsofcardiacremodelling,andoutcomesamongtheLVEFcate-
.. accordingtoLVEF.11
.
gories inHF. Patientswith HFmrEFhave, onaverage,features that .. However, in patients with HFmrEF, many will also have CAD,
.
aremoresimilartoHFrEFthanHFpEF,inthattheyaremorecom- .. hypertension,orpost-MILVsystolicdysfunctionandwill,therefore,
.
monly men, younger, and are more likely to have CAD .. alreadybetreatedwithACE-I.
.
(50(cid:2)60%),38,42,43andlesslikelytohaveAFandnon-cardiaccomor- .. Therefore,ACE-IusemaybeconsideredinpatientswithHFmrEF.
.
.
bidities(SupplementaryTable10).However,ambulatorypatientswith .
.
.
HFmrEFhavealowermortalitythanthosewithHFrEF,moreakinto . 7.3.2 AngiotensinreceptorIItype1receptorblockers
.
.
thosewithHFpEF. .. There are no specific trials of ARBs in HFmrEF. The CHARM-
.
Patients with HFmrEF may include patients whose LVEF has .. PreservedtrialmisseditsprimaryendpointofCVdeathorHFhospi-
.
improvedfrom<_40%ordeclinedfrom>_50%.50 .. talizations.245However,aretrospectiveanalysisshowedthatcande-
.
.. sartan reduced the number of patients hospitalized for HF among
.
7.3 Treatments for patients with heart
... thosewithHFmrEF(withsimilartrendsforCVandall-causemortal-
.. ity).8Moreover,arecurrent-eventanalysissuggestedareductionin
failurewith mildly reduced ejection .
.. hospitalizationsforHFamongtheentireCHARM-Preservedcohort,
fraction ... includingthosewithHFmrEF.248
.
AsinotherformsofHF,diureticsshouldbeusedtocontrolconges- .. AsforACE-I,manywithHFmrEFwillalreadybeonanARBfor
.
tion.NosubstantialprospectiveRCThasbeenperformedexclusively .. otherCVindications.Therefore,treatmentwithARBsmaybecon-
.
inpatientswithHFmrEF(SupplementaryTable11).Somedatacanbe .. sideredinpatientswithHFmrEF.
.
gleaned from subgroup analysis of trials in HFpEF, none of which ..
.
havemettheirprimaryendpoint.Althoughstrongrecommendations ... 7.3.3 Beta-blockers
cannotbemadeaboutspecifictherapiesatthispointintime,wehave ... Thereisnospecifictrialofbeta-blockadeinHFmrEF.AnIPDmeta-
includedaTableofRecommendationstohelpguidethemanagement ... analysisoflandmarktrialsofbeta-blockerssuggestedsimilarreduc-
.
ofpatientsinthiscategory. .. tionsinCVandall-causemortality(of50%)forpatientsinSRwith
.
.. HFrEFandHFmrEF.12ThisIPDmeta-analysisincludedtheSENIORS
Pharmacologicaltreatmentstobeconsideredin ...
trialwherenebivololreducedthecompositeprimaryendpointofall-
patientswith(NYHAclassII–IV)heartfailurewith .
mildlyreducedejectionfraction
... causemortalityorCVhospitaladmissionsintheoverallpopulation.
.. No interaction between LVEF (35% of patients had an LVEF of
.
Recommendations Classa Levelb .. 35(cid:2)50%)andtheeffectofnebivololontheprimaryoutcomewas
.
.. observed.119,249ManypatientswithHFmrEFmayhaveanotherCV
Diureticsarerecommendedinpatientswith ...
indication,suchasAForangina,forabeta-blocker.Therefore,treat-
congestionandHFmrEFinordertoalleviate I C ...
mentwithbeta-blockersmaybeconsideredinpatientswithHFmrEF.
symptomsandsigns.137 ..
. .
AnACE-Imaybeconsideredforpatientswith .
.. 7.3.4 Mineralocorticoidreceptorantagonists
HFmrEFtoreducetheriskofHFhospitalization IIb C .
anddeath.11
... ThereisnospecifictrialofMRAsinHFmrEF.Inaretrospectiveanaly-
.. sisoftheTOPCATtrialinpatientswithanLVEF>_45%,9spironolac-
AnARBmaybeconsideredforpatientswith ...
tone reduced hospitalizationsfor HFin those withanLVEF <55%.
HFmrEFtoreducetheriskofHFhospitalization IIb C ...
TherewasasimilartrendforCVbutnotall-causemortality.
anddeath.245 ...
Treatment with an MRA may be considered in patients with
.
Abeta-blockermaybeconsideredforpatients .. HFmrEF.
.
withHFmrEFtoreducetheriskofHFhospital- IIb C .
.
izationanddeath.12,119 ..
. 7.3.5 Angiotensinreceptor-neprilysininhibitor
.
AnMRAmaybeconsideredforpatientswith ..
ThereisnospecifictrialofARNIinHFmrEF.InthePARAGON-HF
.
HFmrEFtoreducetheriskofHFhospitalization IIb C ..
trial,whichincludedpatientswithEF>_45%,althoughthetrialmissed
.
anddeath.246 ..
itsprimaryendpointoverall,asignificantEF-by-treatmentinteraction
.
.
Sacubitril/valsartanmaybeconsideredfor .. wasobserved.Sacubitril/valsartan,comparedwithvalsartan,reduced
patientswithHFmrEFtoreducetheriskofHF IIb C ... thelikelihoodoftheprimarycompositeoutcomeofCVdeathand
hospitalizationanddeath.13,247 ...
totalHFhospitalizationsby22%inthosewithanEFbeloworequal
.
ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor
... tothemedianof57%.13Furtherdataareavailablefromacombined
blocker;HF=heartfailure;HFmrEF=heartfailurewithmildlyreducedejection .. analysis of the PARADIGM-HF and PARAGON-HF trials showing
.
fraction; MRA=mineralocorticoid receptor antagonist; NYHA=New York .. thatsacubitril/valsartan,comparedtootherformsofRAASblockade,
H aCe la ar st sA ofss ro ec ci oa mtio mn e.
ndation.
....
hasabeneficialeffect,especiallyonhospitalizationsforHFinthose
bLevelofevidence. . withHFmrEF.247
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 32 ---
3630 ESCGuidelines
.
.
Treatment with an ARNI may be considered in patients with . ofaveryhighEF(e.g.above65(cid:2)70%)shouldalsopromptasearch
.
.
HFmrEF. . forpathology,suchascardiacamyloidosis(CA)orhypertrophiccar-
.
.
. diomyopathy (HCM), where a ‘supra-normal’ EF may result from
.
7.3.6 Otherdrugs
... shrinkageoftheLVend-diastolicvolume(denominatorofEF).256,257
.
IntheDIGtrial,10forthosewithHFmrEFinSR,therewasatrendto ..
.
fewer hospitalizations for HF in those assigned to digoxin, but no .. 8.2 Clinical characteristics of patients
.
reduction in mortality and a trend to an excess of CV deaths. .. with heart failurewith preserved ejection
.
.
Therefore,thereareinsufficientdatatorecommenditsuse. . fraction
.
.
TherearealsoinsufficientdataonivabradineinHFmrEFtodraw .
. HFpEF differs from HFrEF and HFmrEF in that HFpEF patients are
.
anyconclusions. .
. olderandmoreoftenfemale.AF,CKD,andnon-CVcomorbidities
.
.
. are more common in patients with HFpEF than in those with
.
.
7.3.7 Devices .. HFrEF.258
.
While post hoc analyses of landmark CRT trials suggest that CRT .. There are numerous potential causes of HFpEF (Table 5). The
.
maybenefitpatientswithLVEF>35%,trialsofCRTforHFmrEFwere .. pathophysiologyofvariousHFpEFsyndromesdiffers,andthusthey
abandonedduetopoorrecruitment.250Therearenosubstantialtri- ...
requiredistincttherapies.RedflagsforthepotentialpresenceofCA
.
als of ICDs for primary prevention of ventricular arrhythmias for .. include low normal BP in patients with a history of hypertension,
.
HFmrEF;trialsconductedmorethan20yearsagosuggestednobene- .. intolerancetobeta-blockersorACE-I,historyofbilateralcarpaltun-
.
fit from ICD implantation for secondary prevention of ventricular .. nel syndrome, low voltage on ECG and echocardiographic features
.
arrhythmiasforHFmrEF. .. suchasthickeningoftheseptum,posteriorwall,orRVwall,enlarged
.
Therefore, there is insufficient evidence to advise CRT or ICD .. atria,asmallpericardialeffusion,orvalvethickening[formoredetails
.
therapyinpatientswithHFmrEF. .. seethesectiononCMP(section14.2)].Furthermore,itisimportant
.
InHFpatientswithanLVEF>_40%,theimplantationofanintera- .. toexcludeotherconditionsthatmightmimictheHFpEFsyndrome
.
trialshuntdevicewasfoundtobesafe,andthisdeviceissubjectto .. (e.g.lungdisease,anaemia,obesity,anddeconditioning).Foramore
.
investigationinalargerstudybeforeanyrecommendationontheir .. comprehensive overview on HFpEF, see the ESC/HFA position
.
useinHFpEForHFmrEFcanbegiven.251 .. statement.259
.
.
.
.
.
. 8.3 The diagnosis of heart failurewith
8 Heart failure with preserved ..
.. preserved ejection fraction
.
ejection fraction .
.. ThediagnosisofHFpEFremainschallenging.Severaldiagnosticcriteria
.
.. havebeenproposedbysocietiesandinclinicaltrials.260Thesecriteria
8.1 The background to heart failurewith .
.. varywidelyintheirsensitivitiesandspecificitiesfordiagnosingHFpEF.
preserved ejection fraction ....
Morerecently,twoscore-basedalgorithms(H 2FPEFandHFA-PEFF)
Thisguidelineacknowledgesthehistoricalchangesinnomenclature .. havebeenproposedtoaidthediagnosis.259,261Whilethegeneraliz-
.
andthelackofconsensusontheoptimalLVEFcut-offtodefinethe .. abilityofthescoreshasbeentestedinvarioustrialandobservational
.
groupofpatientswithHFwithoutovertlyreducedEF.Theterm‘pre- .. cohorts,theirdiagnosticperformancehasvaried.262(cid:2)269
.
served’wasoriginallyproposedintheCandesartaninHeartfailure: .. Both scores assign a substantial proportion of suspected HFpEF
.
Assessment of Reduction in Mortality and morbidity (CHARM) .. patientsasintermediatelikelihood,whereinadditionaldiagnosticsare
.
.
Programme to refer to patients with an EF (>40%) that was not . proposed.Thus,dependingonwhichscoreisused,differentpatients
. clearly‘reduced’orcompletely‘normal’.252Whilethecurrentguide- .. willbereferredforadditionaltestingorallocatedashavingHFpEF.
. .
lineshavedesignatedpatientswithanLVEF41(cid:2)49%asHFmrEF,we . Furthermore, physicians may not have access to all the specialized
. .
recognize that there will be debate about what constitutes ‘mildly . testsrecommendedbythespecificdiagnosticalgorithms.Thislimits
.
.
reduced’ EF, what these EF cut-offs should be, and whether they . the broad clinical applicability of the scores and demonstrates the
.
shouldbedifferentformenandwomen.14,253TheEACVIdefinessys- .. ongoingdiagnosticuncertaintyinHFpEF.267
.
tolicdysfunctionasbeing<52%formalesand<54%forfemales.16 .. To facilitate broad clinical application, this guideline recom-
.
.
Whether patients with higher EFs and HF should be named HF . mends a simplified pragmatic approach that distils the common
.
with‘normal’EFhasalsobeenconsidered.14,254However,giventhe .. major elements in prior diagnostic criteria and emphasizes the
.
.
known variability of echocardiographic measurements of LVEF, the . most frequently used variables widely available to clinicians. Some
.
.
difficulties in interpreting LVEF measured using different imaging . of these variables, in particular, LA size (LA volume index
.
.
modalities,andremainingcontroversiesregardingthepreciseLVEF .. >32 mL/m2), mitral E velocity <90 cm/s, septal e0 velocity <9 cm/
.
cut-offtodefine‘normal’,whichmayvarynotonlywithsexbutalso .. s,E/e0 ratio>9havebeenshowntobepivotpointsbeyondwhich
.
withotherfactorssuchasageandethnicity,255thisguidelinehaskept .. the risk of CV mortality is increased, underscoring their value.270
.
thenomenclatureofHFpEFusinganEFcut-offof50%.Importantly, .. This recommendation is therefore consistent with the consensus
.
cliniciansshouldbeawarethatLVEFisacontinuousvariablewitha .. document of the HFA, and does not represent a new algorithm
.
normal distribution in the general population, and the EF cut-offs .. or diagnostic score but rather a simplified approach. Physicians
.
usedindefinitionsarethereforearbitrary.Moreover,whiletheLVEF .. with access to expertise may refer to the full diagnostic approach
.
cut-offtodefine‘normal’willlikelybehigherthan50%,thepresence . recommendedbytheHFA.259
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 33 ---
ESCGuidelines 3631
.
.
Thissimplifieddiagnosticapproachstartswithassessmentofpre- . (PCWP)of>_15mmHg(atrest)or>_25mmHg(withexercise)orLV
.
.
test probability (see clinical characteristics above). The diagnosis . end-diastolic pressure >_16 mmHg (at rest) is generally considered
.
shouldincludethefollowing: .. diagnostic.266However,insteadofanexercisePCWPcut-off,some
.
.
.. haveusedanindexofPCWPtocardiacoutputfortheinvasivediag-
(1) SymptomsandsignsofHF. .
.. nosisofHFpEF260,276.Recognizingthatinvasivehaemodynamicexer-
(2) AnLVEF>_50%.* .
.. cise testing is not available in many centres worldwide, and is
(3) Objective evidence of cardiac structural and/or functional abnor- .
.. associatedwithrisks,itsmainuseislimitedtotheresearchsetting.In
malities consistentwith the presenceofLV diastolic dysfunction/ .
.
. theabsenceofanydisease-modifyingtreatments,thecurrentguide-
raisedLVfillingpressures,includingraisedNPs(Table9). .
.
. linesdonotmandategoldstandardtestingineverypatienttomake
.
.
*Ofnote,patientswithahistoryofovertlyreducedLVEF(<_40%), . thediagnosis,butemphasizethatthegreaterthenumberofobjective
.
.
wholaterpresent with LVEF>_50%, should be considered tohave . non-invasive markers of raised LV filling pressures (Table 9), the
.
.
recoveredHFrEFor‘HFwithimprovedLVEF’(ratherthanHFpEF). .. highertheprobabilityofadiagnosisofHFpEF.
.
ContinuedtreatmentforHFrEFisrecommendedinthesepatients.271 ..
.
ItisnotknownwhetherstartingHFtherapyinpatientswithrecov- ...
8.4 Treatment of heart failurewith
eredLVEFisbeneficial.PatientswithHFpEFtendtohavestabletra- ..
. preserved ejection fraction
jectory of LVEF over time.272 However, in those who develop a ..
.
clinical indication for a repeat echo during follow-up, around one .. To date, no treatment has been shown to convincingly reduce
.
thirdhaveadeclineinLVEF.273 .. mortalityand morbidityin patientswithHFpEF,althoughimprove-
.
InthepresenceofAF,thethresholdforLAvolumeindexis>40 .. ments have been seen for some specific phenotypes of patients
.
mL/m2. Exercise stress thresholds include E/e0 ratio at peak .. within the overall HFpEF umbrella. However, none of the large
.
stress >_15 or tricuspid regurgitation (TR) velocity at peak stress .. RCTs conducted in HFpEF have achieved their primary endpoints.
>3.4 m/s.275 LV global longitudinal strain <16% has a sensitivity of ... These include PEP-CHF (perindopril),277 CHARM-Preserved (can-
.. desartan),245 I-PRESERVE (irbesartan),278 TOPCAT (spironolac-
62%andaspecificityof56%forthediagnosisofHFpEFbyinvasive .
testing.261 ... tone),246 DIG-Preserved (digoxin),279 and PARAGON-HF
.. (sacubitril/valsartan)13 (see Supplementary Table 12 for the details
Theapproachtothediagnosisshouldinvolveadditionalconfirma- .
.
. about these and additional trials). Hospitalizations for HF were
torytestsincasesofdiagnosticuncertainty,suchascardiopulmonary .
.
exercisetesting(toconfirmareductioninexercisecapacityandto
... reducedbycandesartanandspironolactone andtherewasatrend
helpdifferentiatethecauseofdyspnoea),exercisestresstesting,and
... towards reduction with sacubitril/valsartan, although asthese trials
invasivehaemodynamictesting.259 ... were neutral for their primary endpoints, these are hypothesis-
Ifrestingechocardiographicandlaboratorymarkersareequivocal,
... generating findings only. Although nebivolol significantly reduced
adiastolicstresstestisrecommended.259,274Theconfirmatorytest ... thecombinedprimaryendpointofall-causemortalityorCVhospi-
forthediagnosisofHFpEFisinvasivehaemodynamicexercisetesting.
... taladmissionintheSENIORStrial,thistrialincludedonly15%with
.. anLVEF >50%.119,249 Trials targeting the nitric oxide-cyclic guano-
An invasively measured pulmonary capillary wedge pressure .
. sinemonophosphatepathwayhavealsofailed toimprove exercise
Table9 Objectiveevidenceofcardiacstructural,functionalandserologicalabnormalitiesconsistentwiththepresence
ofleftventriculardiastolicdysfunction/raisedleftventricularfillingpressures259,261
Parametera Threshold Comments
LVmassindex >_95g/m2(Female),>_115g/m2(Male) AlthoughthepresenceofconcentricLVremodellingorhypertrophyis
Relativewallthickness >0.42 supportive,theabsenceofLVhypertrophydoesnotexcludethediagno-
sisofHFpEF
LAvolumeindexa >34mL/m2(SR) IntheabsenceofAForvalvedisease,LAenlargementreflectschronically
elevatedLVfillingpressure(inthepresenceofAF,thethresholdis
>40mL/m2)
E/e’ratioatresta >9 Sensitivity78%,specificity59%forthepresenceofHFpEFbyinvasive
exercisetesting,althoughreportedaccuracyhasvaried.Ahighercut-off
of13hadlowersensitivity(46%)buthigherspecificity(86%).71,259,274
NT-proBNP >125(SR)or Upto20%ofpatientswithinvasivelyprovenHFpEFhaveNPsbelow
BNP >365(AF)pg/mL diagnosticthresholds,particularlyinthepresenceofobesity
>35(SR)or
>105(AF)pg/mL
PAsystolicpressure >35mmHg Sensitivity54%,specificity85%forthepresenceofHFpEFbyinvasive
TRvelocityatresta >2.8m/s exercisetesting259,261
AF=atrialfibrillation;BNP=B-typenatriureticpeptide;E/e’ratio=earlyfillingvelocityontransmitralDoppler/earlyrelaxationvelocityontissueDoppler;HFpEF=heartfailure
withpreservedejectionfraction;LA=leftatrial;LV=leftventricular;NP=natriureticpeptide;NT-proBNP=N-terminalpro-B-typenatriureticpeptide;PA=pulmonaryartery;
SR=sinusrhythm;TR=tricuspidregurgitation.
Note:Thegreaterthenumberofabnormalitiespresent,thehigherthelikelihoodofHFpEF.
aOnlycommonlyusedindicesarelistedinthetable;forlesscommonlyusedindicesrefertotheconsensusdocumentoftheESC/HFA.259
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 34 ---
3632 ESCGuidelines
capacity orQOL in HFpEF, e.g. NEAT-HFpEF,280 INDIE-HFpEF,281 ..
VITALITY-HFpEF,282andCAPACITY-HFpEF(praliciguat).283
... Table10 Riskfactorsforthedevelopmentofheart
. failureandpotentialcorrectiveactions
.
Despitethelackofevidenceforspecificdisease-modifyingthera- .
.
piesinHFpEF,asthevastmajorityofHFpEFpatientshaveunderlying .. Riskfactorsforheart Preventivestrategies
.
. failure
hypertension and/or CAD, many are already treated with ACE-I/ .
.
. Sedentaryhabit Regularphysicalactivity
ARB,beta-blockers,orMRAs.InthePARAGON-HFstudyatbase- .
.
line,morethan86%ofpatientswereonACE-I/ARBs,80%wereon .. Cigarettesmoking Cigarettesmokingcessation
.
.
beta-blockers,andmorethan24%wereonMRAs.13 . Obesity Physicalactivityandhealthydiet
.
.
The Task Force acknowledge that the treatment options for .. Excessivealcoholintake286 Generalpopulation:no/lightalcohol
.
HFpEFarebeingrevisedasthisguidelineisbeingpublished.Wenote .. intakeisbeneficial
.
thattheFoodandDrugAdministration(FDA)hasendorsedtheuse .. Patientswithalcohol-inducedCMP
.
ofsacubitril/valsartanandspironolactoneinthosewithanLVEF‘less .. shouldabstainfromalcohol
. than normal’. These statements relate to patients within both the .. Influenza Influenzavaccination
.
HFmrEFandHFpEFcategories.Forsacubitril/valsartan,thisdecision .. Microbes(e.g.Trypanosoma Earlydiagnosis,specificantimicrobial
.
wasbasedonthesubgroupanalysisfromthePARAGON-HFstudy, .. cruzi,Streptococci) therapyforeitherpreventionand/or
.
which showed a reduction in HF hospitalizations in those with an .. treatment
. LVEF <57%, and a meta-analysis of the PARADIGM-HF and ...
Cardiotoxicdrugs(e.g., Cardiacfunctionandsideeffectmoni-
PARAGON-HF studies, showing a reduction in CV death and HF ... anthracyclines) toring,doseadaptation,changeof
hospitalization in those with an LVEF below the normal range.247 ...
chemotherapy
Regarding spironolactone, the subgroup of individuals in the ..
. Chestradiation Cardiacfunctionandsideeffectmoni-
.
TOPCAT study recruited in the Americas had a significant reduc- .
. toring,doseadaptation
.
tion in the primary endpoint of CV death and HF hospitalization, .
.. Hypertension Lifestylechanges,antihypertensive
and a subsequent post hoc analysis by EF showed a significant .
reductioninoutcomesforthosewithanLVEF<55%.9,247Thereare
... therapy
.. Dyslipidaemia Healthydiet,statins
alsoongoingtrialswithSGLT2inhibitors.Thesedevelopmentsmay .
.
. Diabetesmellitus Physicalactivityandhealthydiet, wellacceleratearedefinitionofHFpEFinthefutureandhavethera- .
.
. SGLT2inhibitors
peuticimplications. . .
In the absence of recommendations regarding disease-modifying .. CAD Lifestylechanges,statintherapy
.
.
therapies,treatmentshouldbeaimedatreducingsymptomsofcon- . CAD=coronary artery disease; CMP=cardiomyopathy; SGLT2=sodium-glu-
.
gestionwithdiuretics.Loopdiureticsarepreferred,althoughthiazide
.. coseco-transporter2.
.
.
diuretics may be useful for managing hypertension. Reducing body ..
.
weightinobesepatientsandincreasingexercisemayfurtherimprove ..
.
symptomsandexercisecapacityandshouldthereforebeconsidered ..
.
inappropriatepatients.284,285 .. Recommendationsfortheprimarypreventionofheart
Itisimportanttoidentifyandtreattheunderlyingriskfactors,aeti-
... failureinpatientswithriskfactorsforitsdevelopment
.
ology, and coexisting comorbidities in HFpEF (e.g. hypertension in ...
Recommendations Classa Levelb
section12.4,CADinsection12.2,amyloidosisinsection14.6,AFin ..
.
section 12.1.1, and valvular heart disease in section 12.3). .. Treatmentofhypertensionisrecommendedto
.
Undoubtably,treatmentofsomeoftheunderlyingphenotypesofthe .. preventordelaytheonsetofHF,andtoprevent I A
. theHFpEFsyndromeleadstoimprovedoutcomes. .. HFhospitalizations.287(cid:2)290
. .
. Treatmentwithstatinsisrecommendedin
. .
. patientsathighriskofCVdiseaseorwithCV
.. I A
Recommendationsforthetreatmentofpatientswith .. diseaseinordertopreventordelaytheonsetof
.
heartfailurewithpreservedejectionfraction .. HF,andtopreventHFhospitalizations.291,292
.
.. SGLT2inhibitors(canagliflozin,dapagliflozin,
Recommendations Classa Levelb ...
empagliflozin,ertugliflozin,sotagliflozin)arerec-
.
Screeningfor,andtreatmentof,aetiologies,and
... ommendedinpatientswithdiabetesathighrisk I A
.
cardiovascularandnon-cardiovascularcomor- .. ofCVdiseaseorwithCVdiseaseinorderto
biditiesisrecommendedinpatientswithHFpEF
I C ... preventHFhospitalizations.293(cid:2)297
.
(seerelevantsectionsofthisdocument). .. Counsellingagainstsedentaryhabit,obesity,ciga-
.
. rettesmoking,andalcoholabuseisrecom-
Diureticsarerecommendedincongested .. I C
patientswithHFpEFinordertoalleviatesymp- I C .. mendedtopreventordelaytheonsetof . tomsandsigns.137 .. HF.298(cid:2)302
.
.
.
HFpEF=heartfailurewithpreservedejectionfraction. .. CV=cardiovascular;HF=heartfailure;SGLT2=sodium-glucoseco-transporter2.
aClassofrecommendation. .. aClassofrecommendation.
bLevelofevidence. ... bLevelofevidence.
1202
CSE
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 35 ---
ESCGuidelines 3633
.
9 Multidisciplinary team .. system,availableresources(infrastructure,facilities,staff,andfinan-
.
management for the prevention
... ces),administrativepolicies,andtailoredtothepatient’sneeds.
.
. ManypatientswithHFwouldderivebenefitfromtheearlyintegra-
.
and treatment of chronic heart .
. tionofapalliativeandsupportiveapproachwithinthecareprovided
.
failure .. byallmembersoftheHFmultidisciplinaryteam.312,313Palliativeand
.
.
. supportive care should be thought about for all patients with HF,
.
.
9.1 Prevention of heart failure .. regardlessofstageoftheirillness.Patientsintheadvancedstagesand
.
. thoseconsideredformechanicalcirculatorysupport(MCS)orheart
General advice about risk factors for the development of HF (see ..
. transplantation should receive a palliative care consultation before
SupplementaryFigure1)andstrategiestopreventHFearlyintheCV ..
. suchinterventionsasamatterofprotocol(seesection10.2.4).
continuumaresummarizedinTable10. ..
.
Itiswidelyrecognizedthat,inadditiontooptimizingmedicaland ...
9.2.2Characteristicsandcomponentsofaheartfailure
devicetherapiesforHF,attentionshouldalsobe giventohowHF ...
managementprogramme
care is delivered. The HFA of the ESC has issued several position ...
Clinicaltrialshaveincludedcomplex,bundledinterventions,making
papersthatcovernon-pharmacologicalmanagement,dischargeplan- ...
itdifficulttodeterminetheefficiencyandeffectivenessofeachspe-
ning,andstandardsfordeliveringHFcare.303(cid:2)305Ithasalsounder- ...
cificcomponent.Table11presentsanoverviewofcharacteristicsand
scored the need for specialist HF cardiologists and specialist HF ... componentsthatareimportanttoconsiderinaHF-MP.
nurses to help provide care. Detailed curricula, to aid training of ..
.
these,areavailabletobeadaptedfornationalimplementation.306,307 ..
.
.
Thissectionfocusesonareaswhererecommendationswithanevi- .
. Multidisciplinaryinterventionsrecommendedforthe
.
dencelevelcanbegiven:multidisciplinaryteammanagement,lifestyle .. managementofchronicheartfailure
.
advice,exercisetraining,follow-up,andmonitoring. .
.
.. Recommendations Classa Levelb
.
.
9.2 Multidisciplinary management of ...
ItisrecommendedthatHFpatientsareenrolled
.
chronic heart failure .. inamultidisciplinaryHFmanagementpro-
. I A
9.2.1Modelsofcare .. grammetoreducetheriskofHFhospitalization
.
Inordertoreducehospitalizationsandmortality,earlierguidelines1 ... andmortality.309,314,315,316
.
recommended the use of multidisciplinary HF management .. Self-managementstrategiesarerecommended
.
programmes (HF-MPs), which enable patients to have the correct .. toreducetheriskofHFhospitalizationand I A
investigations, an accurate diagnosis, appropriate evidence-based ... mortality.309
.
therapy,education,andsuitablefollow-up.Theoptimalimplementa- .. Eitherhome-basedand/orclinic-basedpro-
.
tionofaHF-MPrequiresamultidisciplinaryteamthatisactivealong .. grammesimproveoutcomesandarerecom-
. I A
thewholeHFtrajectory;fromonset,throughcriticalevents,periods .. mendedtoreducetheriskofHFhospitalization
.
ofapparentstability,anditsterminalstages.303Sincethe2016guide- .. andmortality.310,317
.
lines,newstudieshavebeenpublishedthatunderscoretheneedfor .. Influenzaandpneumococcalvaccinationsshould .
HF-MPsandrevealmoreinsightsintohowcarecanbedelivered. .. beconsideredinordertopreventHF IIa B
. Anetworkmeta-analysisincluding53randomizedtrialspublished .. hospitalizations.315,316
.
in2017,concludedthatbothdisease-managementclinicsandhome ..
.
. HF=heartfailure.
visitsbynursesreducedall-causemortalitycomparedtousualcare; .. aClassofrecommendation.
homevisitsbeingmosteffective.308AnIPDmeta-analysisof20stud- ... bLevelofevidence.
.
ies,including5624patients,concludedthatself-managementinterven- .
. .
tionsinHFpatientsimproveoutcomesdespiteheterogeneityinthe .
.
intensity,content,andthepersonnelwhodelivertheinterventions.309 ..
.. 9.3 Patient education, self-care and
HF-MPsvaryintheircomponentsandcanapplydifferentservice .
.
. lifestyle advice
models, such asclinic-based approaches (in primary, secondary, or .
.
tertiary care), home-based programmes, case management, or .. Adequatepatientself-careisessentialintheeffectivemanagementof
.
.
hybrids of these. Components used in the services vary, e.g. some . HFandallowspatientstounderstandwhatisbeneficial,andtoagree
.
HF-MPsusetelemonitoringthatmaybeappliedatalocal,regional,
.. toself-monitoringandmanagementplans.319HFpatientswhoreport
.
.
or national level. No service model has been shown to be consis- . moreeffectiveself-carehaveabetterQOL,lowerreadmissionrates,
.
tently superior to others.310 While home visits and HF clinics do ... andreducedmortality.309
.
reduceall-causeadmissionsandmortality,educationalprogrammes, .. Misunderstandings,misconceptions,andlackofknowledgeallcon-
.
usedalone,donot.308,309HF-MPsshouldbepatient-centredandtake .. tributetoinsufficientself-careandthereforepatienteducationisvital.
.
aholisticapproachtothepatientratherthanfocussingsolelyonHF; .. Improvingpatients’knowledgeoftheirconditionisfundamentalfor
managementofcomorbidconditions,suchasarrhythmias,hyperten-
... thedevelopmentofself-careskills.304
.
sion, diabetes, renal dysfunction, and depression, improve patient .. Educationtoimproveself-careshouldbetailoredtotheindividual
.
well-being and self-management, leading to better outcomes.309,311 .. patientandbasedon,whereavailable,scientificevidenceorexpert
.
The organization of a HF-MP should be adapted to the healthcare . opinion.Thereislittleevidencethatspecificlifestyleadviceimproves
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 36 ---
3634 ESCGuidelines
Table11 Importantcharacteristicsandcomponentsinaheartfailuremanagementprogramme
Characteristics
1. Patient/person-centred318
2. Multidisciplinary
3. Thefocusoftheprogrammeshouldbeflexibleandinclude:
• preventionofdiseaseprogression
• symptomcontrol
• maintainingpatientsintheirpreferredplaceofcareforend-stageheartfailure
4. Competentandprofessionallyeducatedstaff
5. Encouragepatient/carerengagementintheunderstandingandmanagementoftheircondition
Components
1. Optimizedmanagement;lifestylechoices,pharmacological,anddevices
2. Patienteducation,withspecialemphasisonself-careandsymptommanagement
3. Provisionofpsychosocialsupporttopatientsandfamilycaregivers
4. Follow-upafterdischarge(clinic;homevisits;telephonesupportortelemonitoring)
5. Easyaccesstohealthcare,especiallytopreventandmanagedecompensation
6. Assessmentof(andappropriateinterventioninresponseto)anunexplainedchangeinweight,nutritionalandfunctionalstatus,qualityoflife,sleep
problems,psychosocialproblemsorotherfindings(e.g.,laboratoryvalues)
7. Accesstoadvancedtreatmentoptions;supportiveandpalliativecare
Table12 Patienteducationandself-care
Educationtopic Goalforthepatientandcaregiver Professionalbehaviourandeducationaltools
ExplanationaboutHF TounderstandthecauseoftheirHF,symptomsandtreat- Providetailoredinformation.
mentchoice.
TheHFtrajectory Tounderstandprognosisandthedifferentpossiblephases Sensitivelycommunicateinformationonprognosisattimeofdiag-
intheHFtrajectory. nosis,duringdecisionmakingabouttreatmentoptions,when
Tomakejointtreatmentdecisionsthatrecognisethe thereisachangeintheclinicalconditionandwheneverthe
patient’spositionontheHFtrajectory. patientrequests.
Medicaltreatment
Medication Tobeabletomakejointdecisionsaboutmedication. Providewrittenandoralinformationonindication,benefits,dos-
Tounderstandtheindications,benefits,theneedforlong- ing,effectsandsideeffects.
termadherencetocertaindrugs,andthedosingand Discusspracticalissuessuchasoptimaltime-schedule,whattodo
sideeffectsofmedication. incaseofamisseddoseetc.
Tobeabletorecognizethecommonsideeffectsofmedi- Discusspossiblebarriersformedicationtaking.
cationandknowwhatactionstotake. Adviseonsupportaidssuchasdosettebox,electronicreminders
etc.whenappropriate.320
Implanteddevices Tobeabletomakejointdecisionsondeviceimplantation. Providewrittenandoralinformationabouttheimportanceand
Tounderstandtheindications,importance,expectations expectationsofimplanteddevices,andpossiblewaysoffollow-
andcheck-uproutineforimplanteddevices,andany up(remotemonitoring).
exceptionmanagement. Discussexpectationsandanypossibleimpactondriving.
Tobeabletorecognizethecommoncomplications Clearlyidentifysituationswherethedevicemightbedeactivated
(includingtheriskofinappropriatedefibrillatorshocks), orexplanted.
andknowwhatactionstotake. Involvepatientandcaregiverindecisionmaking.
Self-careaspects
Activityandexercise Toundertakeregularexerciseandbephysicallyactive. Adviseonexercisethatrecognizesphysicalandfunctionallimita-
Tobeabletoadaptphysicalactivitytosymptomstatus tions,suchasfrailty,comorbidities.
andpersonalcircumstances. Refertoexerciseprogrammeorotheractivitymodes.
Discusspossiblebarriers,side-effectsandopportunities.
Sleepandbreathing Torecognizetheimportanceofsleepandrestfor(CV) Reviewsleephistory.
health. Adviseanddiscusstheimportanceofgoodsleepandprovide
Tobeabletorecognizeproblemswithsleepingandhow adviceon‘sleephealth’(includingtimingofdiuretics).
tooptimizesleep.
Continued
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 37 ---
ESCGuidelines 3635
Table12 Continued
Educationtopic Goalforthepatientandcaregiver Professionalbehaviourandeducationaltools
Considerandcarefullydiscussthebenefitsanddeleteriouseffects
ofsleepmedication.
Fluids Toavoidlargevolumesoffluidintake.Afluidrestriction Provideinformationanddiscusstheadvantagesanddisadvantages
of1.5(cid:2)2L/daymaybeconsideredinpatientswith offluidrestriction.
severeHF/hyponatraemiatorelievesymptomsand Advisetoadaptfluidintaketoweight,andintimesofhighheat
congestion. andhumidity,nausea/vomiting.
Toavoiddehydration:wherefluidsarerestricted,increase Adjustadviceduringperiodsofacutedecompensationandcon-
intakeduringperiodsofhighheat/humidityand/ornau- sideralteringthisadvicetowardsend-of-life.
sea/vomiting.
Healthydiet Tobeabletopreventmalnutritionandknowhowtoeat Discusscurrentfoodintake,roleofsalt,roleofmicronutrients.
healthily,avoidingexcessivesaltintake(>5g/day)and Discusstheneedforsupplementingincaseofnutrientdeficien-
maintainingahealthybodyweight. ciesbutthereisnoclearroleforroutinemicronutrient
supplementation.321
Discussmaintainingahealthybodyweight.
Alcohol Tobeabletoabstainfromoravoidexcessivealcohol TailoralcoholadvicetoaetiologyofHF;e.g.abstinenceinalco-
intake,especiallyforalcohol-inducedCMP. holicCMP.
TorestrictalcoholaccordingtoCVpreventionguidelines. InformanddiscussalcoholintakeaccordingtoCVprevention
guidelines(2unitsperdayinmenor1unitperdayinwomen)a.
Immunization Tobeawareoftheneedforimmunizationforinfluenza Discussbenefitsandpossiblebarriers.
andpneumococcaldisease. Adviseonlocalimmunizationpractice.
Smokingandrecrea- Tobeawareoftheconsequencesforhealthofsmoking Inform,discussandhelpindecisionmaking.
tionaldrugs anduseofrecreationaldrugs. Referforspecialistadviceforsmokingcessationanddrugwith-
Stopsmoking(includinge-cigarettes)andtakingrecrea- drawalandreplacementtherapy.
tionaldrugs. Considerreferralforcognitivebehaviouraltheoryand
psychologicalsupportifpatientwishestostopsmokingor
takingdrugs.
Travel,leisure,driving Tobeabletopreparetravelandleisureactivitiesaccord- Informanddiscusspracticalissuesrelatedtolonghaultravel,stay-
ingtophysicalcapacity. ingabroad,exposuretosun(amiodaroneeffects),highhumidity
Tobeabletotakeaninformeddecisionaboutdriving. orheat(dehydration),andhighaltitude(oxygenation).
Providepracticaladvicerelatedtotravelwithmedication/devices
(keepmedicinesinhandluggage,havealistwithmedication,
devicename/cardandtreatingcentres).
Informaboutlocal/national/internationalregulationrelatedto
driving.
Sexualactivity Tobeabletoresumeoradaptsexualactivityaccordingto InformanddiscussthatsexualactivityissafeforstableHF
physicalcapacity. patients.
Torecognizepossibleproblemswithsexualactivityand Provideadviceoneliminatingfactorspredisposingtosexual
theirrelationshipwithHForitstreatment. problems.
Discussandprovideavailablepharmacologicaltreatmentforsex-
ualproblems.
Refertospecialistforsexualcounsellingwhennecessary.
Symptommonitoring Monitorandrecognizechangeinsignsandsymptoms. Provideindividualizedinformationtosupportself-management
andsymptomself- Beingabletoreactadequatelytochangeinsignsand suchas:
management symptoms. Inthecaseofincreasingdyspnoeaoroedemaorasuddenunex-
Knowhowandwhentocontactahealthcareprofessional. pectedweightgainof>2kgin3days,patientsmayincrease
theirdiureticdoseand/oralerttheirhealthcareteam.
LivingwithHF
Psychologicalissues TobeabletoliveagoodlifewithHF. Regularlycommunicateinformationondisease,treatmentoptions
Tobeabletoseekhelpincaseofpsychologicalproblems andself-care.
suchasdepressivesymptoms,anxietyorlowmood Regularlydiscusstheneedforsupport.
whichmayoccurinthecourseoftheHFtrajectory. Treatorreferraltospecialistforpsychologicalsupportwhen
necessary.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 38 ---
3636 ESCGuidelines
Table12 Continued
Educationtopic Goalforthepatientandcaregiver Professionalbehaviourandeducationaltools
Torecognisethatthecarerorfamilymembersmaybe
greatlyaffectedandneedtoseekhelp.
Familyandinformal Tobeabletoaskforsupport. Discussthepreferenceofcaregiver/familyinvolvement.
caregivers Involvepatientsandcaregiversinarespectfulway.
CMP=cardiomyopathy;CV=cardiovascular;HF=heartfailure.
a1unitis10mLofpurealcohol(e.g.,1glassofwine,1=2pintofbeer,1measureofspirit).
.
.
QOLorprognosis;however,providingthisinformationhasbecome .. exercise-basedrehabilitationshouldbeconsideredinthosewhoare
.
akeycomponentofeducationforself-care. .. frail,whohavemoreseverediseaseorcomorbidities.95
.
Generaleducationalapproachesinclude: .. Physical conditioning also improves exercise capacity and
.
.. QOL.332(cid:2)335 No data on HFmrEF are available, but benefits
• Providing information in a variety of formats that take into .
.. observedintheothergroupsofHFshouldalsoapplytothisgroup.
account educational grade and health literacy. Consider .
.
.
approacheswithactiverolesforpatientsandcaregiverssuchas .
.. 9.5 Follow-up of chronic heart failure
‘ask-tell-ask’,‘teachback’,ormotivationalinterviewing.Reinforce .
.
messagesatregulartimeintervals. .. 9.5.1Generalfollow-up
.
• Recognizing barriers to communication (language, social skills, .. Thisisarelativelyunderstudiedarea.PatientswithHF,evenifsymp-
.
cognition,anxiety/depression,hearingorvisualchallenges). .. tomsarewellcontrolledandstable,requirefollow-uptoensurecon-
.
• Recommending‘HFmatters.org’.Offerhelpandguidancetouse .. tinuedoptimizationoftherapy,todetectasymptomaticprogressionof
.
itandofferdiscussionofquestionsarising. .. HForitscomorbiditiesandtodiscussanynewadvancesincare.These
.
.
• Invitingpatientstobeaccompaniedbyafamilymemberorfriend. . guidelinesrecommendfollow-upatintervalsnolongerthan6months
.
.
. tochecksymptoms,heartrateandrhythm,BP,fullbloodcount,elec-
.
KeytopicstoincludearerecommendedinTable12. .
. trolytes,andrenalfunction.Forpatientsrecentlydischargedfromhos-
.
.
. pital, or in those undergoing uptitration of medication, follow-up
.
.
. intervalsshouldbemorefrequent.Whethersuchstablepatientsneed
.
.
9.4 Exercise rehabilitation . tobefollowed-upbycardiologistsisuncertain.Somestudiessuggest
.
There is consistent evidence that physical conditioning by exercise ... that follow-up in primary care may be appropriate.303,339 However,
training improves exercise tolerance, and health-related QOL in
... uptakeofevidence-basedinterventionsispoorinmanysettings340,104
.
. and several studies suggest that care and follow-up provided by HF
patients with HF. Clinical trials and meta-analyses in people with .
.
HFrEFshowthatexerciserehabilitationimprovesexercisecapacity .. specialists,anduseofqualityimprovementregistriescanleadtohigher
.
andQOL.Severalmeta-analysesalsoshowthatitreducesall-cause
.. ratesofoptimaltherapyandimprovedoutcomes.341(cid:2)343
.
andHFhospitalizations,althoughuncertaintypersistsaboutitseffects
.. AnECGshouldbedoneannuallytodetectQRSprolongation344
.
on mortality.322(cid:2)328 The effect on hospitalization is seen in those .. as such patients may become candidates for CRT. Furthermore, it
.
who are highly adherent to the exercise programme.329 High- .. mayidentifyconductiondisturbancesandAF.
.
intensity interval training, in patients who are able and willing,
.. Serial echocardiography is generally not necessary, although an
. may improve peak oxygen consumption (VO ).330,331 Supervised .. echocardiogramshouldberepeatediftherehasbeenadeterioration
2 . .. inclinicalstatus.Anechocardiogramisalsoadvised3(cid:2)6monthsafter
Recommendationsforexerciserehabilitationinpatients ...
optimizationofstandardtherapiesforHFrEFtodeterminetheneed
withchronicheartfailure .
.. foradditionofnewerpharmacologicalagentsandimplanteddevices.
.
.
Recommendations Classa Levelb ..
. 9.5.2Monitoringwithbiomarkers
.
.
Exerciseisrecommendedforallpatientswhoare . Trials investigating the use of biomarkers (particularly BNP and/or
.
.
ableinordertoimproveexercisecapacity,QOL, I A . NT-proBNP) to guide pharmacotherapy for HFrEF have produced
.
andreduceHFhospitalization.c324(cid:2)328,335(cid:2)337 .. conflicting results.345(cid:2)352 They are undoubtedly good prognostic
.
.
Asupervised,exercise-based,cardiacrehabilita- .. markers.72,353,354 Conceptually, it is not clear what a biomarker-
.
tionprogrammeshouldbeconsideredin .. supportedstrategymightofferinadditiontoassiduousapplicationof
IIa C .
patientswithmoreseveredisease,frailty,or .. guideline-recommendedtherapy.Currentevidence,therefore,does
.
withcomorbidities.95,324(cid:2)327,338 .. not support the routine measurement of BNP or NT-proBNP to
.
.. guidetitrationoftherapy.
HF=heartfailure;QOL=qualityoflife. ..
aClassofrecommendation. ..
bLevelofevidence. .. 9.6 Telemonitoring
.
cInthosewhoareabletoadheretotheexerciseprogramme. .
.. Telemonitoringenablespatientstoprovide,remotely,digitalhealth
.
. information to support and optimize their care. Data such as
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 39 ---
ESCGuidelines 3637
.
.
symptoms, weight, heart rate, and BP, can be collected frequently, . Thus,non-invasiveHTMmaybeconsideredforpatientswithHF
.
.
stored in an electronic health record and used to guide patients . inordertoreducetheriskofrecurrentCVandHFhospitalizations
.
.
(directlyorthroughahealthcareprofessional),toadjusttherapyor . andCVdeath;furtherevidenceonmanagementguidedbyimplanted
.
toseekfurtheradvice.Hometelemonitoring(HTM)canhelpmain- .. systemsisawaited.374
.
.
tain quality of care, facilitate rapid access to care when needed, .
.
.
reducepatienttravelcosts,andminimizethefrequencyofclinicvis- .
.
its.355Enforcedcessationofface-to-faceconsultationsinmanycoun- ...
Recommendationsfortelemonitoring
.
triesduringtherecentCOVID-19pandemichavehighlightedsome .
.
.
ofthepotentialadvantagesofHTM.356 .. Recommendations Classa Levelb
.
TrialsofHTMarediverse.Patientsareusuallyrequiredtomake ..
. Non-invasiveHTMmaybeconsideredfor
measurementsand,asformanyotheraspectsofHFmanagement, ..
. patientswithHFinordertoreducetheriskof
adherencemaybeincomplete.HTMmaybeprovidedasalocal, .. IIb B
. recurrentCVandHFhospitalizationsandCV regional, or national service. Systems that focus on optimizing ...
death.374
management rather than detecting and managing medical emer- ..
gencies need only to be staffed during standard working hours.
... Monitoringofpulmonaryarterypressureusinga
Some systems are designed also to offer support at any time
... wirelesshaemodynamicmonitoringsystemmay
IIb B
requestedbythepatient.Thecomparativeeffectivenessandcost
... beconsideredinsymptomaticpatientswithHF
effectivenessofeachstrategyisuncertain.Systemsthatfocuson
... inordertoimproveclinicaloutcomes.372
.
continuousoptimizationofcare(ahealthmaintenanceapproach) .. CV=cardiovascular;HF=heartfailure;HTM=hometelemonitoring;LVEF=left
.
ratherthantryingtoanticipateandmanageepisodesofworsening .. ventricularejectionfraction.
.. aClassofrecommendation.
(a strategy that is plagued by a large number of false-positive .. bLevelofevidence.
alerts),appearmoresuccessful.357HTMisanefficientmethodfor ..
.
.
providingpatienteducationandmotivationandaidingdeliveryof .
.
.
care, but it should be adapted to work in synergy with existing .
.
healthcareprovision.358 ..
.
.
A Cochrane systematic review conducted in 2017 identified 39 .
.. 10 Advanced heart failure
relevant trialsofHTM, largely basedonassessments ofsymptoms, .
.
.
weight,heartrateandrhythm,andBPandfoundthatHTMwasasso- .
.
. 10.1 Epidemiology, diagnosis, and
ciatedwithareductioninall-causemortalityof20%andHFhospital- .
.
izationof37%.359Sincethen,severalneutraltrialsandatleastone .. prognosis
.
.
positive trial have been published.357,360(cid:2)364 These are unlikely to .. ManypatientswithHFprogressintoaphaseofadvancedHF,charac-
.
changethe positiveresultsofthe systematicreview.Importantly,if .. terizedbypersistentsymptomsdespitemaximaltherapy.375(cid:2)377The
.
social distancing and the ‘green’ agenda are important, HTM only .. prevalenceofadvancedHFisincreasingduetothegrowingnumber
.
needs to show that it is not inferior to contemporary methods of .. ofpatientswithHF,ageingofthepopulation,andbettertreatment
.
deliveringcaretobeanappropriatemeansofsupportingcare.356 .. andsurvivalofHF.Prognosisremainspoor,witha1-yearmortality
.
Whether wearable technologies for monitoring heart rate and .. rangingfrom25%to75%.378(cid:2)380
.
rhythmorlungcongestion(bio-impedanceorlungradar)offeraddi- .. TheupdatedHFA-ESC2018criteriaforthedefinitionofadvanced
.
tional benefits to conventional HTM described above is .. HFarereportedinTable13.376AseverelyreducedLVEFiscommon
.
uncertain.365(cid:2)367 .. butnotrequiredforadiagnosisofadvancedHFasitmaydevelopin
. Many implanted therapeutic devices can provide, wirelessly and .. patients with HFpEF as well. In addition to the reported criteria,
. remotely,informationeitheronthedeviceitself(generatorandlead .. extra-cardiac organ dysfunction due to HF (e.g. cardiac cachexia,
. function),arrhythmias,oronpatientphysiology(heartrate,activity, .. liver or kidney dysfunction) or type II pulmonary hypertension
.
heart sounds,bio-impedance).Thereisstrongevidencethatmoni- .. maybepresent,butarenotrequiredforthedefinitionofadvanced
.
toring can detect device malfunction earlier than by conventional .. HF.376
.
.
monitoringandthatitmaybeusefulfordetectingarrhythmiassuch . TheInteragencyRegistryforMechanicallyAssistedCirculatory
.
.
as AF. However, there is little evidence that device monitoring . Support (INTERMACS) profiles, developed to classify patients
.
reducesadmissionsforHFormortality.368(cid:2)370,371 .. with a potential indication for durable MCS devices, describes
.
.
Devicesthatonlyprovideamonitoringfunctionarealsoavailable. . clinicalparametersandcharacteristicsconsistentwithaneedfor
.
Implantableloop-recorderscanbeinjectedsubcutaneouslyandused .. advancedtherapies(Table14).381Thisclassificationhasalsobeen
.
.
to monitor heart rate and rhythm, activity, and bio-impedance. . showntobeusefulinestimatingtheprognosisofpatientsunder-
.
Monitoring devices can also be placed in the pulmonary artery to .. goingurgenthearttransplantation382orLVassistdevice(LVAD)
.
monitorpressurewirelessly,althoughtheexternalreaderrequired .. implantation,383 and for risk assessment inambulatory advanced
.
to detect thedevicesignalis rather bulky and requires patient co- .. HFpatients.384
.
.
operation.Ariseindiastolicpulmonaryarterypressuremaybeone .. Prognostic stratification is important to identify the ideal time for
.
oftheearliestsignsofcongestion.Apreliminary,butfairlysubstantial, .. referral to an appropriate centre (i.e. one capable of providing
.
trialshowedareductionintheriskofrecurrentHFhospitalization.372 .. advancedHFtherapies),toproperlyconveyexpectationstopatients
.
Amuchlargertrialhascompletedrecruitment(GUIDE-HF).373 . and families, and to plan treatment and follow-up strategies
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 40 ---
3638 ESCGuidelines
Table13 Criteriafordefinitionofadvancedheartfailure
Allthefollowingcriteriamustbepresentdespiteoptimalmedicaltreatment:
1.Severeandpersistentsymptomsofheartfailure[NYHAclassIII(advanced)orIV].
2.Severecardiacdysfunctiondefinedbyatleastoneofthefollowing:
• LVEF<_30%
• IsolatedRVfailure(e.g.,ARVC)
• Non-operableseverevalveabnormalities
• Non-operableseverecongenitalabnormalities
• Persistentlyhigh(orincreasing)BNPorNT-proBNPvaluesandsevereLVdiastolicdysfunctionorstructuralabnormalities(accordingtothedefinitions
ofHFpEF).
3.Episodesofpulmonaryorsystemiccongestionrequiringhigh-dosei.v.diuretics(ordiureticcombinations)orepisodesoflowoutputrequiringinotropes
orvasoactivedrugsormalignantarrhythmiascausing>1unplannedvisitorhospitalizationinthelast12months.
4.Severeimpairmentofexercisecapacitywithinabilitytoexerciseorlow6MWTdistance(<300m)orpVO <12mL/kg/minor<50%predictedvalue,
2
estimatedtobeofcardiacorigin.
6MWT=6-minute walk test; ARVC=arrhythmogenic right ventricular cardiomyopathy; BNP=B-type natriuretic peptide; HFpEF=heart failure with preserved ejection
fraction;i.v.=intravenous;LV=leftventricular;LVEF=leftventricularejectionfraction;NT-proBNP=N-terminalpro-B-typenatriureticpeptide;NYHA=NewYorkHeart
Association;pVO2=peakoxygenconsumption;RV=rightventricular.Modifiedfrom376.
Table14 InteragencyRegistryforMechanicallyAssistedCirculatorySupportprofiledescriptionsofpatientswith
advancedheartfailure
Profile Timeframeforintervention
Profile1.Criticalcardiogenicshock
Patientwithlife-threateninghypotensiondespiterapidlyescalatinginotropicsupport, Definitiveinterventionneededwithinhours.
criticalorganhypoperfusion,oftenconfirmedbyworseningacidosisand/orlactatelev-
els.“Crashandburn.”
Profile2.Progressivedecline
Patientwithdecliningfunctiondespitei.v.inotropicsupport,maybemanifestbywor- Definitiveinterventionneededwithinfewdays.
seningrenalfunction,nutritionaldepletion,inabilitytorestorevolumebalance.“Sliding
oninotropes.”Alsodescribesdecliningstatusinpatientsunabletotolerateinotropic
therapy.
Profile3.Stableoninotropeorinotrope-dependent
Patientwithstablebloodpressure,organfunction,nutrition,andsymptomsoncontinu- Definitiveinterventionelectiveoveraperiodofweeksto
ousi.v.inotropicsupport(oratemporarycirculatorysupportdeviceorboth)butdem- fewmonths.
onstratingrepeatedfailuretoweanfromsupportduetorecurrentsymptomatic
hypotensionorrenaldysfunction.“Dependentstability.”
Profile4.FrequentFlyer
Patientcanbestabilizedclosetonormalvolumestatusbutexperiencesdailysymptoms Definitiveinterventionelectiveoveraperiodofweeksto
ofcongestionatrestorduringactivitiesofdailyliving.Dosesofdiureticsgenerallyfluc- fewmonths.
tuateatveryhighlevels.Moreintensivemanagementandsurveillancestrategiesshould
beconsidered,whichmayinsomecasesrevealpoorcompliancethatwouldcompro-
miseoutcomeswithanytherapy.Somepatientsmayshuttlebetween4and5.
Profile5.Housebound
Comfortableatrestandwithactivitiesofdailylivingbutunabletoengageinanyother Variableurgency,dependsuponmaintenanceofnutrition,
activity,livingpredominantlywithinthehouse.Patientsarecomfortableatrestwithout organfunction,andactivity.
congestivesymptoms,butmayhaveunderlyingrefractoryelevatedvolumestatus,often
withrenaldysfunction.Ifunderlyingnutritionalstatusandorganfunctionaremarginal,
patientsmaybemoreatriskthanINTERMACS4,andrequiredefinitiveintervention.
Profile6.Exertionlimited
Patientwithoutevidenceoffluidoverload,comfortableatrestandwithactivitiesof Variable,dependsuponmaintenanceofnutrition,organ
dailylivingandminoractivitiesoutsidethehomebutfatiguesafterthefirstfewminutes function,andactivitylevel.
ofanymeaningfulactivity.Attributiontocardiaclimitationrequirescarefulmeasure-
mentofpeakoxygenconsumption,insomecaseswithhaemodynamicmonitoring,to
confirmseverityofcardiacimpairment.“Walkingwounded.”
Continued
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 41 ---
ESCGuidelines 3639
Table14 Continued
Profile Timeframeforintervention
Profile7.AdvancedNYHAclassIIIsymptoms
Patientwithoutcurrentorrecentepisodesofunstablefluidbalance,livingcomfortably HearttransplantationorMCSmaynotbecurrently
withmeaningfulactivitylimitedtomildphysicalexertion. indicated.
Modifiersforprofiles Possibleprofilesthatcanbemodified
TemporaryMCScanmodifyprofileonlyinhospitalizedpatients.TheyincludeIABP, 1,2,3
ECMO,TandemHeart,LVAD,Impella.
Arrhythmiacanmodifyanyprofile.Theyincluderecurrentventriculartachyarrhythmias 1(cid:2)7
thathaverecentlycontributedsubstantiallytoclinicalcompromise,frequentICDshocks
orrequirementforexternaldefibrillation,usuallymorethantwiceweekly.
FrequentepisodesofHFdecompensationcharacterizepatientsrequiringfrequent 3ifathome,4,5,6.Rarelyforprofile7.
emergencyvisitsorhospitalizationsfordiuretics,ultrafiltration,ortemporaryi.v.vaso-
activetherapy.Frequentepisodesmaybeconsideredasatleasttwoemergencyvisits/
admissionsinthepast3monthsorthreeinthepast6months.
ECMO=extracorporealmembraneoxygenation;HF=heartfailure;IABP= intra-aorticballoonpump;ICD=implantablecardioverter-defibrillator;INTERMACS=Interagency
RegistryforMechanicallyAssistedCirculatorySupport;i.v.=intravenous;LVAD=leftventricularassistdevice;MCS=mechanicalcirculatorysupport;NYHA=NewYork
HeartAssociation.Modifiedfrom381.
.
(Figure 4).376 Patients with contraindications to MCS or heart trans- .. withdiureticresistanceevenifdataaboutitseffectsonoutcomesare
.
plantationshouldbeconsideredforpalliativecare(seesection10.2.4). .. unsettled.391,392
.
.
Despite many prognostic parameters (Supplementary Table 13), .
.
.
predictingoutcomesremainsdifficultandpatientsareoftenreferred .
.
.
toadvancedHFcentrestoolate.Identifyingwarningsignsinpatients . 10.2.2 Mechanicalcirculatorysupport
.
.
withnon-advancedsymptomsmayallowearlyreferralsothatMCS . MCScanimprovesurvivalandsymptomsofpatientswithadvanced
.
.
andhearttransplantationmaybeofferedbeforethedevelopmentof .. HF.376,393TheuseofMCSshouldbeconsideredforthedifferentsce-
.
end-organfailure(Figure5;SupplementaryTable14).376,386Anorgani- .. narioslisted in Table15. Indications for short- and long-term MCS
.
zational model between centres with different levels of care com- .. shouldbebasedontheINTERMACSprofiles(Table14,Figure4).
.
plexity, based on a ‘Hub and Spoke’ network is the key to good ..
.
patientmanagement.376 .. Short-termmechanicalcirculatorysupport
.
.. Short-term MCS devices are indicated to reverse critical end-
.
.. organ hypoperfusion and hypoxia in the setting of cardiogenic
.
.. shock.Theycanbeusedforashort,limited,periodoftime,froma
10.2 Management ...
few days up to several weeks. The aim is to support the central
.
In patients with advanced HF, pharmacological therapy and short- .. nervous system and organ perfusion, to reverse acidosis and
.
termMCSmaybeneededuntiltheimplantationoflong-termMCS .. multi-organ failure until the patient’s outcome becomes clearer
.
orhearttransplantationbecomesavailable. .. be that of cardiac recovery, transition to durable MCS or heart
.
.
. transplantation, or, in some cases, towards a more palliative
.
.
. approach.Thecareofpatientsonshort-termMCSiscomplexand .
.
10.2.1 Pharmacologicaltherapyandrenalreplacement . requires dedicated expertise including having specific plans for
.
.
Inotropes may improve haemodynamic parameters, reducing con- . stoppingsupportwhenneithercardiacnorbraininjuryrecovers.
.
.
gestion,augmentingcardiacoutput,andaidingperipheralperfusion. . Short-term MCS should be used in patients with INTERMACS
.
.
Althoughnotproven,thismayhelptopreventworseningend-organ . profiles1or2asabridgetodecision(BTD),bridgetorecovery
. .
function. Conversely, traditional inotropes may favor myocardial . (BTR),bridgetobridge(BTB)foreitherlong-termMCSorurgent
.
ischaemia and/or tachyarrhythmias and worsen the clinical .. heart transplantation (Figure 4).394 Further details about short-
.
course.387,388Theycanbeusedaspalliativetherapyforthereliefof .. termMCSarereportedintheSupplementarytext11.4.
.
.
symptomsinpatientswithoutothertreatmentoptions.Intermittent .
.
.
long-term use of inotropes may be considered in outpatients to . Long-termmechanicalcirculatorysupport
.
.
improvefunctionalclassandQOL.389,390 .. Long-termMCSisindicatedinselectedpatientswhenMTisinsuffi-
.
Kidneydysfunctionandloopdiureticresistanceoftencharacterize .. cientorwhenshort-term MCShasnotled to cardiacrecovery or
.
the clinical course of patients with advanced HF. Doubling of the .. clinicalimprovement,toprolonglifeandimproveQOL,ortokeep
.
loopdiureticdoseisproposed,inthefirstinstance,followedbycon- .. thepatientaliveuntiltransplantation(bridgetotransplantation,BTT)
.
comitant administration of thiazides or metolazone (see section .. or to reverse contraindications to heart transplantation (bridge to
.
11.3.3).145Inpatientswhofailtorespondtodiuretic-basedstrategies, .. candidacy,BTC),orasdestinationtherapy(DT)(Table15).
.
renalreplacementtherapies shouldbe considered.Ultrafiltration is .. Long-term MCS should be considered in patients with
.
oneofthemostcommonapproaches.Itmaybeconsideredinthose . INTERMACSprofiles2to4andalsoinpatientswithINTERMACS
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 42 ---
3640 ESCGuidelines
Management of patients with advanced heart failurea
INTERMACS INTERMACS INTERMACS INTERMACS
1 2 3–4 >4“Stable ambulatory”
Short-term MCS
BTD/BTR/BTB/BTT
(Class IIa)
Persistence of
severe brain Neurological
Cardiac,
damage and and end-organ
neurological Contraindications
severe recovered Y High riskb
and end-organ for HT
irreversible but no cardiac
recovered
end-organ recovery
damage Y N N
Potentially
N
reversible
Y
LVAD-BTC
(Class IIa)
Contraindication
reversed
List for HT or
de-listing with Advanced HF
N Y very close therapies
Withdrawal of Weaning from LVAD-DT follow-up in (HT/LVAD) can
MCS support MCS support (Class IIa) case of be deferred.
meaningful Very close
improvement follow-up
(Class I)
Figure 4 Algorithmforthetreatmentofpatientswithadvancedheartfailure.BTB=bridgetobridge;BTC=bridgetocandidacy;BTD=bridgeto
decision; BTR=bridge to recovery; BTT=bridge to transplantation; CA=cardiac amyloidosis; DT=destination therapy; ESC=European Society of
Cardiology; HCM=hypertrophic cardiomyopathy; HF=heart failure; HFA=Heart Failure Association; HT=heart transplantation; INTERMACS=
InteragencyRegistryforMechanicallyAssistedCirculatorySupport;LVAD=leftventricularassistdevice;LVAD-BTC=leftventricularassistdevice (cid:2)
bridgetocandidacy;LVAD-DT=leftventricularassistdevice(cid:2)destinationtherapy;MCS=mechanicalcirculatorysupport.aThisalgorithmcanbeapplied
toallpatientswithadvancedHFdefinedaccordingtotheESC/HFAcriteria,376withexceptionofHCM,CA,arrhythmicstorm,adultcongenitalheartdis-
ease,refractoryangina.bRecurrenthospitalization,progressiveend-organfailure,refractorycongestion,inabilitytoperformcardiopulmonaryexercisetest
orpeakoxygenconsumption<12mL/min/kgor<50%ofexpectedvalue.385Colourcodeforclassesofrecommendation:GreenforClassofrecommen-
dationIandYellowforClassofrecommendationIIa(seeTable1forfurtherdetailsonclassesofrecommendation).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 43 ---
ESCGuidelines 3641
Triage of patients with advanced heart failure and appropriate timing of referral
Very limited life expectancy and/or
poor QOL conditions that may impair follow-up and/or
worsened prognosis after advanced HF therapies (HT/LT-MCS)a
N YY
NYHA III–IV despite optimal
medical therapy NYHA class II
(including ICD/CRT when indicated)
Any of these characteristics
>1 admission or unplanned visit to HF clinic
within last 12 months
Prior inotropic use
Intolerant to beta-blocker or RASi/ARNI
LVEF <20%
Worsening RV function
YY
Worsening renal function
Worsening liver function
Ventricular arrhythmias/ICD shocks
Need for escalating diuretic doses
for persistent congestion
SBP <90 mmHg and/or signs of
peripheral hypoperfusion
N
Manage in local HF service
Refer to or discuss with Re-evaluation every
Palliative care
advanced HF centre 3–6 months
Figure5 Triageofpatientswithadvancedheartfailureandappropriatetimingofreferral.376ARNI=angiotensinreceptor-neprilysininhibitor;CRT=
cardiac resynchronization therapy; HF=heart failure; HT=heart transplantation; ICD=implantable cardioverter-defibrillator; LT-MCS=long-term
mechanicalcirculatorysupport;LVEF=leftventricularejectionfraction;NYHA=NewYorkHeartAssociation;RASi=renin-angiotensinsysteminhibitor;
RV=rightventricular;SBP=systolicbloodpressure;QOL=qualityoflife.aLimitedlifeexpectancymaybeduebymajorcomorbiditiessuchascancer,
dementia,end-stageorgandysfunction;otherconditionsthatmayimpairfollow-uporworsenpost-treatmentprognosisincludefrailty,irreversiblecogni-
tivedysfunction,psychiatricdisorder,orpsychosocialissues.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 44 ---
3642 ESCGuidelines
Table15 Termsdescribingvariousindicationsformechanicalcirculatorysupport
Bridgetodecision(BTD)/ Useofshort-termMCS(ECMOorImpella)inpatientswithcardiogenicshockuntilhaemodynamicsandend-organ
Bridgetobridge(BTB) perfusionarestabilized,contraindicationsforlong-termMCSareexcluded(braindamageafterresuscitation)and
additionaltherapeuticoptionsincludinglong-termVADtherapyorhearttransplantcanbeevaluated.
Bridgetocandidacy(BTC) UseofMCS(usuallyLVAD)toimproveend-organfunctionand/ortomakeanineligiblepatienteligibleforheart
transplantation.
Bridgetotransplantation(BTT) UseofMCS(LVAD,BiVADorTAH)tokeepapatientalivewhoisotherwiseathighriskofdeathbeforetrans-
plantationuntiladonororganbecomesavailable.
Bridgetorecovery(BTR) UseofMCS(short-termorlong-term)tokeepapatientaliveuntilcardiacfunctionrecoverssufficientlytoremove
MCS.
Destinationtherapy(DT) Long-termuseofMCS(LVAD)asanalternativetotransplantationinpatientswithend-stageHFineligiblefor
transplantation.
BiVAD=biventricularassistdevice;ECMO=extracorporealmembraneoxygenation;HF=heartfailure;LVAD=leftventricularassistdevice;MCS=mechanicalcirculatory
support;TAH=totalartificialheart;VAD=ventricularassistdevice.
.
.
. transplantation, although adverse events negatively affect QOL.
Table16 Patientspotentiallyeligibleforimplantationof ..
. AmongpatientswithcontinuousflowLVADs,actuarialsurvivalwas
aleftventricularassistdevice ..
. reportedof80%at1yearand70%at2years.403,404Two-yearsur-
.
.
Patientswithpersistenceofseveresymptomsdespiteoptimalmedical .. vivalwas84.5%andsurvivalfreeofdisablingstrokeorneedofreop-
.
anddevicetherapy,withoutsevererightventriculardysfunctionand/or .. eration for LVAD malfunction was 76.9% with a centrifugal-flow
.
severeTR,withastablepsychosocialbackgroundandabsenceofmajor .. LVAD in MOMENTUM 3.405 The fully magnetically levitated
.
contraindications*,andwhohaveatleastoneofthefollowing: .. centrifugal-flowLVADhassignificantlyreducedpumpthrombosis.In
.
(cid:4) LVEF<25%andunabletoexerciseforHFor,ifabletoperformcardi- .. MOMENTUM3,theneedforreoperationtoreplaceamalfunction-
.
opulmonaryexercisetesting,withpeakVO 2<12mL/kg/minand/or ... ingdevicewas2.3%per24months,withonly0.6%per24months
<50%predictedvalue. .. risk of pump replacement because of pump thrombosis. Stroke
.
(cid:4) >_3HFhospitalizationsinprevious12monthswithoutanobviouspre- .. (namely, disabling stroke),majorbleeding, and gastrointestinal hae-
.
cipitatingcause. .. morrhagewerealsolowerinthecentrifugal-flowpumpgroupthanin
.
(cid:4) Dependenceoni.v.inotropictherapyortemporaryMCS.
... the axial-flow pump group. However, the incidence of all bleeding
.. events,thromboembolismanddrivelineinfectionremainedsimilarto
(cid:4) Progressiveend-organdysfunction(worseningrenaland/orhepatic .
.. thatwitholderdevices.402
function,typeIIpulmonaryhypertension,cardiaccachexia)dueto .
.
. Dataonfullymagneticallycentrifugal-flowLVADuseinreal-world
reducedperfusionandnottoinadequatelylowventricularfilling . .
. studies with the 2-year outcomes from the ELEVATE registry
pressure(PCWP>_20mmHgandSBP<_90mmHgorcardiacindex .
. <_2L/min/m2). .. showedanoverallsurvivalof74.5%,withgastrointestinalbleedingin
.. 9.7%,strokein10.2%,andpumpthrombosisin1.5%ofpatients.406
.
HF=heartfailure;i.v.=intravenous;LVAD=leftventricularassistdevice;LVEF= .
. AccordingtotheIMACSRegistry,anewcompositeendpointinclud- leftventricularejectionfraction;MCS=mechanicalcirculatorysupport;PCWP= .
.
pulmonarycapillarywedgepressure;SBP=systolicbloodpressure;TR=tricuspid .. ingQOLandadverseeventsbeyondsurvivalwasproposedtohelp
regurgitation;VO2=oxygenconsumption. ... in guiding decision making. In this sense ‘living well at one year’
*Stable psychosocial background includes demonstrated understanding of the . . definedasfreedomfromdeath,stroke,bleedingrequiringoperation,
technologyandpatientlivinginthesamehouseholdwithacaregiverthatwill .
. helpthepatient(i.e.livingaloneandpoorpsychosocialbackgroundisLVADcon- .. RV assist device, pump replacement, or device-related infection
traindication).Majorcontraindicationsincludecontraindicationtolong-termoral .. within the first year, was 56.8% after isolated, centrifugal flow-
.
anticoagulation,infection,severerenaldysfunction,ventriculararrhythmias. .
.. LVAD.383
.
.. Although now outdated, REMATCH was the only RCT
.
profile5(cid:2)6, whentheyhave high-riskcharacteristics. Patientswith .. comparinganLVADasDTwithOMTinpatientswithadvancedHF,
.
noirreversibleend-organfailureotherthancardiac,recoveringfrom .. NYHAclassIVandacontraindicationtotransplantation.REMATCH
.
INTERMACSlevel1whileonshort-termMCS,mayalsoqualifyfor .. showed lower all-cause mortality with LVAD therapy when com-
.
long-term MCS (Figure 4).376,378,383,395(cid:2)402 The characteristics of .. pared with medical treatment (primary endpoint). However, there
.
patientspotentiallyeligibleforimplantationofanLVADarereported .. werehighmortalityratesat2yearsinbotharms.378Otherstudies
.
inTable16. .. were not randomized (INTrEPID, ROADMAP)396,407,408 or com-
.
Thedetailsofthedevicesandstudiesonlong-termMCSaresum- .. pareddifferentdevices(ADVANCE,ENDURANCE,MOMENTUM
.
marizedinSupplementaryTable15. .. 3).399,402,409ThetwostrategiesofearlyLVADimplantationvs.medi-
.
Current 2-year survival rates in patients receiving the latest .. caltreatmentwithLVADimplantationonlyafterseriousdeteriora-
.
continuous-flow LVADs are comparable to those after heart .. tion of the patient’s condition are currently being compared in a
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 45 ---
ESCGuidelines 3643
.
prospective trial, Early-VAD (ClinicalTrials.gov Identifier: .. pre-transplant and post-transplant life expectancy (both are influ-
.
.
NCT02387112).Also,theSwedishevaluationofLVAD(SweVAD) . encedbypre-operativestatusandcomorbidities).
.
.
studyiscomparingthesurvivalofpatientswithadvancedHFineligible . Themainindicationsandcontraindicationsforhearttransplanta-
.
forhearttransplantationprospectivelyrandomizedtoLVADasDT .. tionarelistedinTable17.376,385
.
vs.MT(ClinicalTrials.govIdentifier:NCT02592499).410 .. Activeinfectionisarelativecontraindicationtotransplantbutin
.
.
. somecasesofinfectedLVADsitmayactuallybeanindication.Elderly
.
.
10.2.3 Hearttransplantation . ageisnotanabsolutecontraindication.Althoughpatientsaged<65
.
.
Hearttransplantationremainsthegoldstandardforthetreatmentof . yearsmightbemoreappropriatecandidatesduetotheiroveralllife
.
.
advancedHFintheabsenceofcontraindications.Post-transplant1- . expectancy,mostprogrammesacceptpatientsupto70yearsofage,
.
.
year survival is around 90% with a median survival of 12.5 . and biological age as well as chronological age must be taken into
.
years.385,411,412TransplantationsignificantlyimprovesQOLandfunc- .. account. Surgical complexity [previous sternotomies, mediastinal
.
.
tionalstatus,although,forunclearreasons,thepercentageofpatients . radiation, adult congenital heart disease (ACHD)] should also be
.
. returning to work is lower than expected.412 Apart from primary .. considered.
.
graft dysfunction, the main challenges after heart transplantation .. The decision pathway to transplantation or LVAD is never
.
relate to either the efficacy or side effects of immunosuppression .. straightforward and is unique to each patient. Eligibility for each
.
(e.g.rejection,infection,cardiacallograftvasculopathy,lategraftdys- .. option may change according to the particular conditions of each
.
function,malignancy,renalfailure,hypertension,diabetesmellitus). .. patient,whichmayalsochangeovertime.Otherfactors,notrelated
.
Organdonorshortageremainsthemainlimitationtohearttrans- ... tothepatient,suchastimeonthehearttransplantwaitinglist,the
.
plantation.Thus,thedonorheartcriteriahavenowbeenextended ..
.
to allow an increased upper limit of the donor age, particularly in ..
.
Europe. Moreover, careful recipient selection is needed, based on .. Recommendationsforthetreatmentofpatientswith
.
. advancedheartfailure
.
.
.
.
.. Recommendations Classa Levelb
Table17 Hearttransplantation:indicationsand .
.
contraindications .. Patientsbeingconsideredforlong-termMCSmust
.
.
. havegoodcompliance,appropriatecapacityfor I C
Indications ..
. devicehandlingandpsychosocialsupport.414(cid:2)416
AdvancedHF376 ..
.. Hearttransplantationisrecommendedfor
Noothertherapeuticoption,exceptforLVADasBTT ...
patientswithadvancedHF,refractorytomedi-
Contraindications ...
cal/devicetherapyandwhodonothaveabsolute
I C
Activeinfectiona ...
contraindications.
.
Severeperipheralarterialorcerebrovasculardisease .. Long-termMCSshouldbeconsideredinpatients
.
Pharmacologicirreversiblepulmonaryhypertension(LVADshouldbe .. withadvancedHFrEFdespiteoptimalmedicaland
.
.
consideredtoreverseelevatedpulmonaryvascularresistancewithsubse- . devicetherapy,noteligibleforhearttransplantation
.. IIa A
quentre-evaluationtoestablishcandidacy) . orothersurgicaloptions,andwithoutsevereright
.
.
Malignancywithpoorprognosis(acollaborationwithoncologyspecialists . ventriculardysfunction,toreducetheriskofdeath
.
. shouldoccurtostratifyeachpatientasregardstheirriskoftumourpro- . andimprovesymptoms.378,396,397,401,402,404,417
.
.
gressionorrecurrencewhichincreaseswiththeuseof .. Long-termMCSshouldbeconsideredinpatients
.
immunosuppression) .. withadvancedHFrEFrefractorytooptimalmed-
.
Irreversibleliverdysfunction(cirrhosis)orirreversiblerenaldysfunction .. icalanddevicetherapyasabridgetocardiac
. IIa B
(e.g.creatinineclearance<30mL/min/1.73m2).Combinedheart-liveror .. transplantationinordertoimprovesymptoms, .
heart-kidneytransplantmaybeconsidered .. reducetheriskofHFhospitalizationandtherisk
.
Systemicdiseasewithmultiorganinvolvement .. ofprematuredeath.398(cid:2)400,402,404
.
.
Otherseriouscomorbiditywithpoorprognosis .. Renalreplacementtherapyshouldbeconsidered
.
Pre-transplantBMI>35kg/m2(weightlossisrecommendedtoachievea .. inpatientswithrefractoryvolumeoverloadand IIa C
.
BMI<35kg/m2) .. end-stagekidneyfailure.
.
Currentalcoholordrugabuse .. Continuousinotropesand/orvasopressorsmay
.
Psychologicalinstabilitythatjeopardizesproperfollow-upandintensive
... beconsideredinpatientswithlowcardiacout-
IIb C
therapeuticregimeafterhearttransplantation
... putandevidenceoforganhypoperfusionas
.. bridgetoMCSorhearttransplantation.389,390
Insufficientsocialsupportstoachievecompliantcareintheoutpatient .
. . Ultrafiltrationmaybeconsideredinrefractory setting .
.
. volumeoverloadunresponsivetodiuretic IIb C
BMI=body mass index; BTT=bridge to transplantation; HF=heart failure; ..
. treatment.391,392
LVAD=leftventricularassistdevice. .
.
aActive infection is a relative contraindication to transplant although in some .
.
casesofinfectedLVADsitmayactuallybeanindication. .. HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;MCS=
AdaptedfromCrespo-Leiroetal.376 .. mechanicalcirculatorysupport.
.. aClassofrecommendation.
bLevelofevidence.
1202
CSE 1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 46 ---
3644 ESCGuidelines
.
.
centre’ssurgicalexperience,andresources,canalsoinfluencedeci- . Treatment for symptoms needs to be considered and might
.
sionmaking.413 .. includeadditionalinterventionontopofOMT:
.
.
.
.. • Breathlessness: repeat doses of opioids may be considered for
.
10.2.4 Symptomcontrolandend-of-lifecare .. thereliefofdyspnoea;however,theireffectivenessisnotdemon-
.
WhilethediseasetrajectoryofeachpatientwithHFisunique,there .. strated.422,423Whileusingopioids,allpatientsshouldbeguided
.
isageneralizablepatternofgradualdecline,punctuatedbyepisodes .. aboutopioidsideeffectssuchasconstipationandnausea,urinary
.
ofacutedeteriorationleadingeithertosuddendeathordeathdueto .. retention, and mental status changes. Benzodiazepines may be
.
progressive HF. Communication about the disease trajectory and .. considered as a second- or third-line treatment, when opioids
.
anticipatory planning should start whena patient is diagnosed with .. andnon-pharmacologicalmeasureshavefailedtocontrolbreath-
.
advancedHF.Indicationsforandkeycomponentsofapalliativecare .. lessness.Increasingtheinspiredoxygenconcentrationmaypro-
.
servicearereportedinTables18and19.312,418 ..
videreliefofdyspnoea.
.
A team-based approach to palliative and end-of-life care for .. • Pain:non-pharmacologicmanagementcanbehelpful.Inaddition, .
patientswithHFhasbeenproposed.419Specificmodelsofpalliative ..
opioid,oxycodone,hydromorphone,andfentanyl are generally
.
careforpatientswithadvancedHFhavebeenalsoreported.They .. viewedassafeoptionsandcanbeprovidedorally,intravenously,
.
reducehospitalizations,withoutacleareffectonsurvival,andhave .. andtransdermally,especiallyinthehospitalorinpatientpalliative
.
someeffectsonQOLandsymptomburden.420,421 .. careorhospicesetting.424
.
Symptomassessmentshouldbeperformedonaregularbasis.In .. • Anxietyanddepression:adequateconventionaltreatmentshould
.
addition to clinical assessment, symptoms can be assessed using .. beoffered.
.
.
the Numeric Rating Scale, the Edmonton Symptom Assessment .
.
Scale(ESAS)orESAS-HF,ortheIntegratedPalliativecareOutcome .. Proactivedecisionsandadvancedplanningwithregardtopalliative
.
Scale. .. and end-of-life care discussions should be documented, regularly
.
.. reviewed, and routinelycommunicated to all those involved in the
.
.. patient’scare.Healthcareprovidersshouldmakesurethatpatients’
.
Table18 Patientswithheartfailureinwhomend-of-life .. andcarerpreferencesarefollowed,whereverpossible.Theyshould
careshouldbeconsidered ... alsotakeintoaccountthatpatientsmaychoosenotto,ormaynot
.
Progressivefunctionaldecline(physicalandmental)anddependencein
... be in a position to, express preferences (e.g. due to symptoms of
mostactivitiesofdailyliving.
... depressionorcognitiveimpairment).
.
.
SevereheartfailuresymptomswithpoorQOLdespiteoptimalpharma- .
.
.
cologicalandnon-pharmacologicaltherapies. . 11 Acute heart failure
.
.
Frequentadmissionstohospitalorotherseriousepisodesofdecompen- ..
.
sationdespiteoptimaltreatment. .. 11.1 Epidemiology, diagnosis and
.
.
HearttransplantationandMCSruledout. . prognosis
. .
Cardiaccachexia. .. AHFreferstorapidorgradualonsetofsymptomsand/orsignsof
.
Clinicallyjudgedtobeclosetoendoflife. .. HF,severeenoughforthepatienttoseekurgentmedicalatten-
.
MCS=mechanicalcirculatorysupport;QOL=qualityoflife. ... tion,leadingtoanunplannedhospitaladmissionoranemergency
. . department visit. Patients with AHF require urgent evaluation
.
. . withsubsequentinitiationorintensificationoftreatment,includ-
.
.
. ingi.v.therapiesorprocedures.AHFisaleadingcauseofhospital-
.
.
. izations in subjects aged >65 years and is associated with high
Table19 Keycomponentsofpalliativecareservicein ..
. mortalityandrehospitalizationrates.In-hospitalmortalityranges
patientswithadvancedheartfailure . .. from 4% to 10%.425(cid:2)428 Post-discharge 1-year mortality can be
.
.
FocusonimprovingormaintainingtheQOLofapatientandhis/herfam- . 25(cid:2)30% with up to more than 45% deaths or readmission
.
ilyaswellaspossibleuntilhe/shedies. .. rates.104,426,427,429,430 .
.
Frequentassessmentofsymptoms(includingdyspnoeaandpain)result- .. AHFmaybethefirstmanifestationofHF(newonset)or,more
.
ingfromadvancedheartfailureandothercomorbiditiesandfocuson .. frequently, be due to an acute decompensation of chronic HF.
.
symptomrelief. .. Compared to patients with acutely decompensated CHF, those
.
Accessforthepatientandhis/herfamilytopsychologicalsupportandspi- .. with new onset HF may have a higher in-hospital mortality425 but
.
ritualcareaccordingtoneed. .. have lower post-discharge mortality and rehospitalization
.
Advancedcareplanning,takingintoaccountpreferencesforplaceof
... rates.425,428,431,432 Specific extrinsic factors may precipitate, but
deathandresuscitation(whichmayincludedeactivatingdevices,suchas
... not cause, AHF in patients with pre-existing cardiac dysfunction
ICDorlong-termMCSthatmayrequireamultidisciplinaryteam
... (Supplementary Table 16). Clinical severity and in-hospital trajec-
decision).
... tory are determined by the complex interplay between precipi-
.. tants, the underlying cardiac substrate, and the patient’s
ICD=implantable cardioverter-defibrillator; MCS=mechanical circulatory sup- .
. comorbidities.
port;QOL=qualityoflife.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 47 ---
ESCGuidelines 3645
Diagnostic workup of new onset acute heart failure
Patient history, signs and/or
symptoms suspected of acute HF
Electrocardiogram
Pulse oximetry
Echocardiography
Initial laboratory investigationsa
Chest X-ray
Lung ultrasound
Other specific evaluationsb
Natriuretic peptide testing
BNP <100 pg/mL BNP ≥ 100 pg/mL
NT-proBNP <300 pg/mL NT-proBNP ≥300 pg/mLc
MR-proANP <120 pg/mL MR-proANP ≥120 pg/mL
Acute heart failure ruled out Acute heart failure confirmed
Comprehensive echocardiography
Figure 6 Diagnosticworkupofnewonsetacuteheartfailure.ACS =acutecoronarysyndrome;BNP=B-typenatriureticpeptide;CT=computed
tomography;HF=heartfailure;MR-proANP=mid-regionalpro-atrialnatriureticpeptide;NT-proBNP=N-terminalpro-B-typenatriureticpeptide;TSH
=thyroid-stimulatinghormone.aInitiallaboratoryexamsincludetroponin,serumcreatinine,electrolytes,bloodureanitrogenorurea,TSH,liverfunction
testsaswellasD-dimerandprocalcitoninwhenpulmonaryembolismorinfectionaresuspected,arterialbloodgasanalysisincaseofrespiratorydistress,
andlactateincaseofhypoperfusion.bSpecificevaluationincludescoronaryangiography,incaseofsuspectedACS,andCTincaseofsuspectedpulmonary
embolism.cRule-invaluesforthediagnosisofacuteHF:>450pg/mLifaged<55years,>900pg/mLifagedbetween55and75yearsand>1800pg/mLif
aged>75years.433,434
.
.
ThediagnosticworkupofAHFstartsatthetimeofthefirstmedi- .. pg/mL, NT-proBNP <300 pg/mL and MR-proANP <120 pg/
.
calcontact,andiscontinuedthroughouttheinitialpatientpathway, .. mL.74,433(cid:2)435 However, elevated NP values are associated with a
.
aiming to identify the clinical presentation and to diagnose and .. widerangeofcardiacandnon-cardiacconditions(Table6).Lowcon-
.
manage any potentially reversible causes/precipitants/coexisting .. centrationscanbedetectedinsomepatientswithadvanceddecom-
.
life-threateningconditions ina timelymanner (Figure6).Diagnostic .. pensated end-stage HF, obesity, flash pulmonary oedema or right-
.
testsareoutlinedatTable20.Inadditiontoclinicalsignsandsymp- .. sidedAHF.Higherlevelscanbefoundinthepatientswithconcomi-
.
toms,diagnosticworkupincludesECGandechocardiography,ifpos- .. tantAFand/orreducedrenalfunction.74
.
sible. Additional investigations, i.e. chest X-ray and lung ultrasound .. Amongotherlaboratorytests,troponinisusefulforthedetection
.
maybeusedtoconfirmAHFdiagnosis,especiallywhenNPtestingis .. of acute coronary syndrome (ACS) although elevated levels are
.
not available. Plasma NP levels (BNP or NT-proBNP or MR- .. detectedinthevastmajorityofpatientswithAHF.436(cid:2)438Bloodurea
.
.
proANP) should be measured if the diagnosis is uncertain and a . nitrogenorurea,serumcreatinine,electrolytes(sodium,potassium,
.
.
point-of-careassayisavailable.NormalconcentrationsofNPsmake . chloride), and antigen carbohydrate 125 may help tailor treat-
.
thediagnosisofAHFunlikely.Cut-offsforacuteHFare:BNP<100 .. ment.439,440 Detectionofabnormalliver functionidentifiespatients
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 48 ---
3646 ESCGuidelines
Table20 Diagnostictestsinpatientswithacuteheartfailure
Exam Timeofmeasurement Possiblefindings Diagnosticvaluefor Indication
AHF
ECG Admission,duringhospitali- Arrhythmias,myocardial ExclusionofACSor Recommended
zation,a,bpre-discharge ischaemia arrhythmias
Chest-Xray Admission,during Congestion,lunginfection Confirmatory Maybeconsidered
hospitalizationa
LUS Admission,duringhospitali- Congestion Confirmatory Maybeconsidered
zation,apre-discharge
Echocardiography Admission,duringhospitali- Congestion,cardiacdys- Major Recommended
zation,apre-discharge function,mechanicalcauses
Natriureticpeptides Admission,pre-discharge Congestion Highnegativepredictive Shouldbeconsidered
(BNP,NT-proBNP, value
MR-proANP)
Serumtroponin Admission Myocardialinjury ExclusionofACS Recommended
Serumcreatinine Admission,duringhospitali- Renaldysfunction None Recommendedforprognos-
zation,apre-discharge ticassessment
Serumelectrolytes Admission,duringhospitali- Electrolytedisorders None Recommendedforprognos-
(sodium,potassium, zation,apre-discharge ticassessmentand
chloride) treatment
Ironstatus(transferrin, Pre-discharge Irondepletion None Recommendedforprognos-
ferritin) ticassessmentand
treatment
TSH Admission Hypo-hyperthyroidism None Recommendedwhenhypo-
hyperthyroidismis
suspected
D-dimer Admission Pulmonaryembolism Usefultoexcludepulmo- Recommendedwhenpul-
naryembolism monaryembolismis
suspected
Procalcitonin Admission Pneumonia Usefulfordiagnosisof Maybedonewhenpneu-
pneumonia moniaissuspected
Lactate Admission,during Lacticacidosis Usefultoassessperfusion Recommendedwhen
hospitalizationa status peripheralhypoperfusionis
suspected
Pulseoximetryand Admission,during Respiratoryfailure Usefultoassessrespiratory Recommendedwhenrespi-
arterialbloodgas hospitalizationa function ratoryfailureissuspected
analysis
ACS=acutecoronarysyndrome;AHF=acuteheartfailure;BNP=B-typenatriureticpeptide;ECG=electrocardiogram;LUS=lungultrasound;MR-proANP=mid-regional
pro-atrialnatriureticpeptide;NT-proBNP=N-terminalpro-B-typenatriureticpeptide;TSH=thyroid-stimulatinghormone.
aBasedonclinicalconditions.
bContinuousECGmonitoringcanbeconsideredbasedonclinicalconditions.
.
withapoorprognosis.441Sincebothhypothyroidismandhyperthyr- .. AHFandcontinuousmonitoringmaybeneededinthefirsthoursor
.
oidism may precipitate AHF, thyroid-stimulating hormone (TSH) .. days.443,444
.
should be assessed in those with newly diagnosed AHF. Arterial ..
.
bloodgasanalysisshouldbeperformedwhenaprecisemeasurement .. 11.2 Clinical presentations
.
ofO 2andCO 2partialpressureisneeded(i.e.patientswithrespira- ... Four major clinical presentations can be described with possible
torydistress).LactateandpHlevelsshouldbemeasuredinpatients ... overlapsbetweenthem(Table21).1,425,445Clinicalpresentationsare
with cardiogenic shock. D-dimer should be measured when acute ... mainlybasedonthepresenceofsignsofcongestionand/orperiph-
.
pulmonaryembolismissuspected.Procalcitoninmaybeusedforthe .. eral hypoperfusion and require different treatments (Table
.
diagnosisofpneumoniaandantibiotictherapymayhaveanindication .. 21).1,425(cid:2)427,432,446,447
.
whenplasmalevelsare>0.2lg/L.However,noimpactofastrategy .
.
.
based on routine procalcitonin measurements on outcomes was .. 11.2.1 Acutedecompensatedheartfailure
showninaprospective,controlled,trial.442Pulseoximetryshouldbe ...
Acutedecompensatedheartfailure(ADHF)isthemostcommon
.
measuredroutinelyatthetimeoffirstpresentationofpatientswith . formofAHF,accountingfor50(cid:2)70%ofpresentations.426,427,432It
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 49 ---
ESCGuidelines 3647
Table21 Clinicalpresentationsofacuteheartfailure
Acutedecompensated Acutepulmonary Isolatedright Cardiogenicshock
heartfailure oedema ventricularfailure
Mainmechanisms LVdysfunction Increasedafterloadand/or RVdysfunctionand/or Severecardiacdysfunction
Sodiumandwaterrenal predominantLVdiastolic pre-capillarypulmonary
retention dysfunction hypertension
Valvularheartdisease
Maincauseof Fluidaccumulation,increased Fluidredistributiontothe Increasedcentralvenous Systemichypoperfusion
symptoms intraventricularpressure lungsandacuterespira- pressureandoftensys-
toryfailure temichypoperfusion
Onset Gradual(days) Rapid(hours) Gradualorrapid Gradualorrapid
Mainhaemodynamic IncreasedLVEDPandPCWPa IncreasedLVEDPand IncreasedRVEDP IncreasedLVEDPand
abnormalities Lowornormalcardiacoutput PCWPa Lowcardiacoutput PCWPa
NormaltolowSBP Normalcardiacoutput LowSBP Lowcardiacoutput
NormaltohighSBP LowSBP
Mainclinical WetandwarmORWetand Wetandwarmb Wetandcold Wetandcold
presentations1,446 cold
Maintreatment Diuretics Diuretics Diureticsforperipheral Inotropicagents/
Inotropicagents/vasopressors Vasodilatorsb congestion vasopressors
(ifperipheralhypoperfu- Inotropicagents/vasopres- Short-termMCS
sion/hypotension) sors(ifperipheralhypo- RRT
Short-termMCSorRRTif perfusion/hypotension)
needed Short-termMCSorRRTif
needed
LV=leftventricular;LVEDP=leftventricularend-diastolicpressure;MCS=mechanicalcirculatorysupport;PCWP=pulmonarycapillarywedgepressure;RV=rightventricular;
RVEDP=rightventricularend-diastolicpressure;RRT=renalreplacementtherapy;SBP=systolicbloodpressure.
aMaybenormalwithlowcardiacoutput.
bWetandcoldprofilewithneedofinotropesand/orvasopressorsmayrarelyoccur.
.
.
usuallyoccursinpatientswithhistoryofHFandpreviouscardiac . ultimately reduce systemic cardiac output, through ventricular
.
dysfunctionacrossthespectrumofLVEFandmayincludeRVdys- .. interdependence.449
.
.
function.Distinctfromtheacutepulmonaryoedemaphenotype,it . Diureticsareoftenthefirstoptionoftherapyforvenousconges-
.
.
has a more gradual onset, and the main alteration is progressive . tion. Noradrenalineand/or inotropes are indicated for low cardiac
.
.
fluid retention responsible for systemic congestion. Sometimes, . outputandhaemodynamicinstability.Inotropesreducingcardiacfill-
.
congestionisassociatedwithhypoperfusion.426Theobjectivesof .. ingpressuresmaybepreferred(i.e.levosimendan,phosphodiester-
.
.
treatment are identification of precipitants, decongestion, and in . asetypeIIIinhibitors).Sinceinotropicagentsmayaggravatearterial .
.
rareinstances,correctionofhypoperfusion(Figure7). . hypotension,theymaybecombinedwithnorepinephrineifneeded
.
.
.. (Figure9).449
. .
11.2.2 Acutepulmonaryoedema .
. .
Acutepulmonaryoedemaisrelatedtolungcongestion.Clinicalcrite- .
. .
ria for acute pulmonary oedema diagnosis include dyspnoea with . 11.2.4 Cardiogenicshock
.
.
orthopnoea, respiratory failure (hypoxaemia-hypercapnia), tachyp- . Cardiogenicshockisasyndromeduetoprimarycardiacdysfunction
.
noea,>25breaths/min,andincreasedworkofbreathing.448 .. resulting in an inadequate cardiac output, comprising a life-
.
.
Threetherapiesshouldbecommenced,ifindicated.First,oxygen, . threateningstateoftissuehypoperfusion,whichcanresultinmulti-
.
givenascontinuouspositiveairwaypressure,non-invasivepositive- .. organfailureanddeath.450(cid:2)452Cardiacinsultcausingsevereimpair-
.
.
pressure-ventilation and/or high-flow nasal cannula, should be . mentofcardiacperformancemaybeacute,asaresultoftheacute
.
.
started. Second, i.v. diuretics shouldbe administered, and third, i.v. . lossofmyocardialtissue(acuteMI,myocarditis)ormaybeprogres-
.
.
vasodilatorsmaybegivenifsystolicBP(SBP)ishigh,toreduceLV . sive as seen in patients with chronic decompensated HFwho may
.
.
afterload(Figure8).InafewcasesofadvancedHF,acutepulmonary .. experienceadeclineindiseasestabilityasaresultofthenaturalpro-
.
oedemamaybeassociatedwithlowcardiacoutputand,inthiscase, .. gressionofadvancedHFand/orspecificprecipitants.426
.
inotropes,vasopressors,and/orMCSareindicatedtorestoreorgan .. Diagnosisofcardiogenicshockmandatesthepresenceofclini-
.
perfusion. .. calsignsofhypoperfusion,suchascoldsweatedextremities,oli-
.
.. guria, mental confusion, dizziness, narrow pulse pressure. In
.
11.2.3 Isolatedrightventricularfailure .. addition, biochemical manifestations of hypoperfusion, elevated
.
RV failure is associated with increased RV and atrial pressure .. serum creatinine, metabolic acidosis and elevated serum lactate
.
and systemic congestion. RV failure may also impair LV filling, and . are present and reflect tissue hypoxia and alterations of cellular
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 50 ---
3648 ESCGuidelines
Management of patients with acute decompensated heart failure
Congestion/Fluid overload
N Hypoperfusion Y
Loop diureticsa (Class I)
Loop diureticsa
and consider
(Class I)
inotropes (Class IIb)
Hypoperfusion and
Congestion relief Y Y
congestion relief
N NN
Increase diuretic doses Consider vasopressors
(Class I) and/or combine (i.e. norepinephrine)
diuretics (Class IIa) (Class IIb)
Diuretic resistance or Medical therapy optimization Persistent hypoperfusion
N N
end-stage renal failure (Class I) Organ damage
Y Y
Renal replacement
MCS
therapy
(Class IIa)
(Class IIa)
OR AND/OR
Renal replacement
Consider
therapy
palliative care
(Class IIa)
OR
Consider
palliative care
Figure 7 Managementofacutedecompensatedheartfailure.MCS=mechanicalcirculatorysupport.aAdequatediureticdosestorelievecongestion
andclosemonitoringofdiuresisisrecommended(seeFigure13)regardlessofperfusionstatus.
.
metabolismleadingtoorgandysfunction.437,453Ofnote,hypoper- .. Management of cardiogenic shock should start as early as pos-
.
.
fusion is not always accompanied by hypotension, as BP may . sible. Early identification and treatment of the underlying cause,
.
.
be preserved by compensatory vasoconstriction (with/without . concomitant with haemodynamic stabilization and management of
.
.
pressoragents),albeitatthecostofimpairedtissueperfusionand . organ dysfunction, are key components of its management (Figure
.
oxygenation.426,427,450,454 .. 10, Supplementary text 11.1; Supplementary Figure 2).
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 51 ---
ESCGuidelines 3649
Management of patients with pulmonary oedema
Oxygen (Class I) or
ventilatory support
(Class IIa)
Y SBP ≥110 mmHg
N
Signs of hypoperfusion N
Y
Loop diuretics (Class I) Loop diuretics (Class I) Loop diuretics
and/or vasodilators and inotropes/vasopressors
(Class I)
(Class IIb) (Class IIb)
N Congestion relief Y
Medical therapy optimization
Consider RRT, MCS,
(Class I)
other devices (Class IIa)
OR
Consider
palliative care
Figure8Managementofpulmonaryoedema.MCS=mechanicalcirculatorysupport;RRT= renalreplacementtherapy;SBP=systolicbloodpressure.
11.3 Management .
.. to be proven in randomized clinical trials.455 Furthermore, pre-
11.3.1 Generalaspects ... hospital management should not delay the rapid transfer of AHF
Managementcanbesubdividedinthreestages(pre-hospital,in-hos- ... patientstothemostappropriatemedicalsetting.455,456
.
pital,andpre-discharge),havingdifferentgoalsandrequiringdifferent .
.
. approaches(Figure11). . In-hospitalmanagement
.
.
. Diagnostic workup and appropriate pharmacological and non-
.
.
Pre-hospitalphase . pharmacologicaltreatmentmustbestartedpromptlyandinparallel
.
.
In the pre-hospital setting, AHF patients should benefit from non- .. (Figure12).AHFpatientsaretriagedtotheappropriatelevelofcare
.
invasivemonitoring,includingpulseoximetry,BP,heartraterespira- .. accordingtothedegreeofhaemodynamicinstabilityandseverityof
.
toryrate,andacontinuousECG,institutedwithinminutesofpatient .. the criticalillness.Dispositiondecisionsare importantcomponents
contactandintheambulanceifpossible.305Oxygentherapymaybe ... oftheinitialphaseofmanagement(seeSupplementarytext11.2and
.
givenbasedonclinicaljudgmentunlessoxygensaturationis<90%in .. SupplementaryTables17(cid:2)19).
.
whichcaseitshouldbeadministered.Inpatientswithrespiratorydis- .. Thetypeandintensityofin-hospitalmonitoringdependsonclinical
.
tress, respiratory rate >25 breaths/min, oxygen saturation <90%, .. severity, settings of care and in-hospital course (see Supplementary
.
non-invasiveventilationshouldbeinitiated.444,448Althoughtherapeu- .. text11.3).AsAHFisaheterogeneouscondition,managementmay
.
tictoolsmaybeavailablein the prehospitalsetting, whether more .. differaccordingtothemainclinicalpresentation.Managementstarts
.
effectivepre-hospitalcarewouldaltertheclinicaloutcomeremains .. with the search for specific causes of AHF.1,305,430 These include
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 52 ---
3650 ESCGuidelines
Management of patients with isolated right ventricular failure
ACS with RV involvement or
N Y
acute pulmonary embolism
Optimize fluid status Specific treatments
Marked congestion N
Y
Loop diuretics Consider careful
(Class I) fluid administration
Peripheral hypoperfusion/
N
persistent hypotension
Y
Vasopressors
and/or inotropesa
(Class IIb)
Relief of signs and symptoms
Y N
Follow-up
RVAD
AND/OR
Renal replacement
therapy
OR
Consider
palliative care
Figure 9 Management of right ventricular failure. ACS=acute coronary syndrome; RV=right ventricular; RVAD=right ventricular assist device.
aInotropesaloneincaseofhypoperfusionwithouthypotension.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 53 ---
ESCGuidelines 3651
Management of patients with cardiogenic shock
ACS and/or mechanical
Y N
complications
Emergency PCI or Identify and treat
surgical treatmenta other specific causesb
Consider oxygen Consider inotropes/ Consider short-term
(Class I) or ventilatory AND vasopressors AND MCS
support (Class IIa) (Class IIb) (Class IIa)
Improvement of hypoperfusion
Y N
and organ dysfunction
Weaning from
inotropes/vasopressors
MCS
and/or MCS
(Class IIa)
AND/OR
Continue aetiological
Renal replacement
treatment if needed and
therapy
medical therapy optimization
(Class IIa)
(Class I)
OR
Consider
palliative care
Figure10Managementofcardiogenicshock.ACS=acutecoronarysyndrome;BTT=bridgetotransplantation;MCS=mechanicalcirculatorysupport;
PCI=percutaneouscoronaryintervention.aPCIinACS,pericardiocentesisintamponade,mitralvalvesurgeryinpapillarymusclerupture.Incaseofinter-
ventricularseptumrupture,MCSasBTTshouldbeconsidered.bOthercausesincludeacutevalveregurgitation,pulmonaryembolism,infection,acute
myocarditis,arrhythmia(seeFigure12).
.
.
ACS,ahypertensiveemergency,rapidarrhythmiasorseverebrady- . Pre-dischargephase
.
.
cardia/conductiondisturbance,acutemechanicalcausessuchasacute . Detailsonthisphaseareshowninsection11.3.11.
.
.
valveregurgitationoracutepulmonaryembolism,infection,including .
.
.
myocarditis,andtamponade(CHAMPIT)(Figure12).Afterexclusion .. 11.3.2 Oxygentherapyand/orventilatorysupport
.
of these conditions, which need to be treated/corrected urgently, .. In AHF, oxygen should not be used routinely in non-hypoxaemic
.
management of AHF differs according to the clinical presentations .. patients,asitcausesvasoconstrictionandareductionincardiacout-
.
(Figures7(cid:2)10). . put.457OxygentherapyisrecommendedinpatientswithAHFand
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 54 ---
3652 ESCGuidelines
Goals PPhhaasseess Procedures
Determine aetiology Close monitoring of vital signs and
Alleviate symptoms grading severity of symptoms/signs
Improve congestion and organ Disposition decisions: ICU/ICCU
perfusion ward
Restore oxygenation Immediate Initial treatment to support
Limit organ damage (cardiac, circulatory and respiratory
renal, hepatic, gut) functions (vasodilators,
Prevent thromboembolism vasopressors, inotropes,
diuretics, supplemental O)
2
Determine aetiology Identify aetiology and relevant
Improve signs and symptoms co-morbidities and start targeted
Limit organ damage treatment
Prevent thromboembolism Titrate therapy to control
symptoms and to relieve
Intermediate congestion, manage hypoperfusion
and optimize blood pressure
Initiate and up-titrate disease-
modifying pharmacological therapy
Consider device therapy in
appropriate patients
Improve symptoms and quality Initiate and up-titrate disease-
of life modifying pharmacological and
Achieve full congestion relief device therapy
Prevent early readmission Develop a care plan with the
Improve survival Pre-discharge identification of caregivers, a
and long-term schedule for up-titration and
monitoring of pharmacological
therapy,review of device therapy
Enrolment in a disease
management programme
Figure11Stagesofmanagementofpatientswithacuteheartfailure.ICCU=intensivecoronarycareunit;ICU=intensivecareunit.
.
. SpO <90%orPaO <60mmHgtocorrecthypoxaemia.Inchronic . Bloodpressureshouldbemonitoredregularlyduringnon-invasive
2 2 .
. obstructive pulmonary disease (COPD), hyper-oxygenation may .. positivepressureventilation.Theincreaseinintrathoracicpressure
. increase ventilation(cid:2)perfusion mismatch, suppress ventilation and .. with non-invasive positive pressure ventilation decreases venous
.
leadtohypercapnia.Duringoxygentherapy,acid-base balanceand .. returnandrightandleftventricularpreload.Itmayalsodecreasecar-
.
SpO 2shouldbemonitored. ... diac output and BP and should therefore be used with caution in
Non-invasivepositivepressureventilation,eithercontinuousposi- .. patientswithreducedpreloadreserveandhypotension.Theincrease
.
tiveairwaypressureandpressuresupport,improvesrespiratoryfail- .. inpulmonaryvascularresistanceandRVafterloadmayalsobedetri-
.
ure, increases oxygenation and pH, and decreases the partial .. mentalinRVdysfunction.448
.
pressureofcarbondioxide(pCO 2)andworkofbreathing.Although ... Intubation is recommended for progressive respiratory failure
alargerandomizedtrialhadneutralresults,meta-analysessuggestit .. in spite of oxygen administration or non-invasive ventilation
.
may improve dyspnoea and reduce the need for intubation and .. (SupplementaryTable20).448
.
mortality, compared with traditional oxygen therapy.1,458,459 Non- ..
.
.
invasive positive pressure ventilation should be started as soon as .
.
.
possible in patients with respiratory distress (respiratory rate >25 .. 11.3.3 Diuretics
.
breaths/min,SpO 2<90%)toimprovegasexchangeandreducethe .. Intravenous diuretics are thecornerstoneofAHF treatment.They
rateofendotrachealintubation.448,459Thefractionofinspiredoxygen ...
increaserenalexcretionofsaltandwaterandareindicatedforthe
.
(FiO 2) should be increased up to 100%, if necessary, according to .. treatment of fluid overload and congestion in the vast majority of
.
oxygensaturationlevel. . AHFpatients.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 55 ---
ESCGuidelines 3653
Management of patients with suspected acute heart failure
Pharmacological support
Urgent phase after Cardiogenic shock and/or
Y Ventilatory support
first medical contact respiratory failure
MCS
N
Identification of acute aetiology
C acute Coronary syndrome
H Hypertension emergency
A Arrhythmia
Immediate phase Immediate initiation
M Mechanical causea Y
(initial 60–120 min) of specific treatment
P Pulmonary embolism
I Infections
T Tamponade
N
Further treatmentb
Figure12 Initialmanagementofacuteheartfailure.MCS=mechanicalcirculatorysupport.aAcutemechanicalcause:myocardialrupturecomplicating
acutecoronarysyndrome(freewallrupture,ventricularseptaldefect,acutemitralregurgitation),chesttraumaorcardiacintervention,acutenativeor
prostheticvalveincompetencesecondarytoendocarditis,aorticdissectionorthrombosis.bSeeFigures7(cid:2)10forspecifictreatmentsaccordingtodifferent
clinicalpresentations.
.
. Loop diuretics are commonly used due to their rapid onset of .. correspondingto1(cid:2)2timesthedailyoraldosetakenbythepatient
. action and efficacy. Data defining their optimal dosing, timing, and .. beforeadmission.Ifthepatientwasnotonoraldiuretics,astarting
.
methodofadministrationarelimited.Nodifferenceintheprimary .. doseof20(cid:2)40mgoffurosemide,orabolusof10(cid:2)20mgi.v.torase-
.
efficacy outcome of patients’ symptoms global assessment was .. mide, can be used.145,467 Furosemide can be given as 2(cid:2)3 daily
.
shown with a high-dose regimen, compared with a low-dose regi- .. bolusesorasacontinuousinfusion.Dailysinglebolusadministrations
.
men,intheDOSEtrial.However,therewasagreaterreliefofdysp- .. are discouraged because of the possibility of post-dosing sodium
.
noea,changeinweightandnetfluidloss(withnoprognosticrolefor .. retention.145,461 With continuous infusion, a loading dose may be
.
increases in serum creatinine) in the higher-dose regimen.460(cid:2)462 .. used to achieve steady state earlier. Diuretic response should be
.
Highdiureticdosesmaycausegreaterneurohormonalactivationand .. evaluatedshortlyafterstartofdiuretictherapyandmaybeassessed
.
electrolyteabnormalitiesandareoftenassociatedwithpoorerout- .. byperformingaspoturinesodiumcontentmeasurementafter2or
.
comes, although a cause and effect relation cannot be proven by .. 6hand/orbymeasuringthehourlyurineoutput.Asatisfactorydiu-
.
theseretrospectiveanalyses.463(cid:2)466Basedontheseobservations,it .. retic response can be defined as a urine sodium content
.
.
maybeappropriate,whenstartingi.v.diuretictreatment,touselow . >50(cid:2)70mEq/Lat2hand/orbyaurineoutput>100(cid:2)150mL/hdur-
.
doses,toassessthe diureticresponse and increasethe dosewhen .. ingthefirst6h.145,468Ifthereisaninsufficientdiureticresponse,the
.
.
thatisinsufficient. . loopdiuretici.v.dosecanbedoubled,withafurtherassessmentof
.
Diuretic treatment should be started with an initial i.v. dose of .. diureticresponse.145Ifthediureticresponseremainsinadequate,e.g.
.
.
furosemide, or equivalent dose of bumetanide or torasemide, . <100 mL hourly diuresis despite doubling loop diuretic dose,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 56 ---
3654 ESCGuidelines
Management of diuretic therapy in patients with acute heart failure
N On oral loop diuretic Y
≥20–40 mg i.v. 1–2 times daily
furosemide oral dose i.v.
Urinary spot sodium after 2 h ≥50–70 mEq/L
Urine output after 6 h ≥100–150 mL/h
Y N
Repeat similar dose Double dose i.v. until
i.v. every 12 h maximum i.v. dosea
Urinary spot sodium ≥50–70 mEq/L at 2–6 h
Urine output ≥100–150 mL/h
Y N
Check serum
Continue until Combination
creatinine and
complete diuretic
electrolytes at least
decongestion therapiesb
every 24 h
Figure13 Diuretictherapy(furosemide)inacuteheartfailure.i.v.=intravenous.aThemaximaldailydosefori.v.loopdiureticsisgenerallyconsidered
furosemide400(cid:2)600mgthoughupto1000mgmaybeconsideredinpatientswithseverelyimpairedkidneyfunction.bCombinationtherapyistheaddi-
tiontotheloopdiureticofadiureticwithadifferentsiteofaction,e.g.thiazidesormetolazoneoracetazolamide.Modifiedfrom145.
.
concomitantadministrationofotherdiureticsactingatdifferentsites, .. 11.3.4 Vasodilators
.
namely thiazides or metolazone or acetazolamide, may be consid- .. Intravenous vasodilators, namely nitrates or nitroprusside (Supple-
. ered. However, this combination requires careful monitoring of .. mentary Table 21), dilate venous and arterial vessels leading to a
. serumelectrolytesandrenalfunction(Figure13).145,469,470Thisstrat- .. reductioninvenousreturntotheheart,lesscongestion,lowerafter-
. .
egy, based on early and frequent assessment of diuretic response, . load, increased stroke volume and consequent relief of symptoms.
.
.
allowsstartingtreatmentwithrelativelylowdosesofloopdiuretics, . Nitrates act mainly on peripheral veins whereas nitroprusside is
.
withfrequentdoseadjustmentsthatmaybelesslikelytocausedehy- .. moreabalancedarterialandvenousdilator.474,475Becauseoftheir
.
.
dration and increase in serum creatinine. The loop diuretic dose . mechanisms of action, i.v. vasodilators may be more effective than
.
.
should be progressively decreased when a significant negative fluid . diureticsinthosepatientswhoseacutepulmonaryoedemaiscaused
.
.
balancehasbeenobtained.However,itshouldbepointedoutthat . by increased afterload and fluid redistribution to the lungs in the
.
thisalgorithmisentirelybasedonexpertopinion,todate.145,461 .. absence or with minimal fluid accumulation.427,476(cid:2)478 However,
.
.
Transition to oral treatment should be commenced when the . tworecentrandomizedtrialscomparingusualcarewithearlyinten-
.
.
patient’s clinical condition is stable. It is recommended that, after . siveandsustainedvasodilationfailedtoshowabeneficialeffectofi.v.
.
.
achievementofcongestionrelief,oralloopdiureticsarecontinuedat .. vasodilators vs. high-dose diuretics.479,480 No recommendation
.
thelowestdosepossibletoavoidcongestion.463,471Caremustalso .. favouringaregimenbasedonvasodilatortreatmentvs.usualcarecan
.
betakentoavoidpatientsbeingdischargedfromhospitalwithpersis- .. thusbegiven,todate.
.
tentcongestion,asthisisamajorpredictorofincreaseddeathsand .. IntravenousvasodilatorsmaybeconsideredtorelieveAHFsymp-
.
rehospitalizations.462,472 Hence, care should be taken to achieve .. tomswhenSBPis>110mmHg.Theymaybestartedatlowdoses
.
adequatedecongestionandestablishanappropriatelong-termdiu- .. and uptitrated to achieve clinical improvement and BP control.
.
reticdosebeforedischarge.427,473 . Nitratesaregenerallyadministeredwithaninitialbolusfollowedby
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 57 ---
ESCGuidelines 3655
.
.. arrhythmiceventsandwithagreatermortalityinpatientswithcar-
Table22 Inotropesand/orvasopressorsusedtotreat ...
diogenicshockbutnotinthosewithhypovolaemicorsepticshock.
acuteheartfailure .
.. Althoughthetrialincluded1679patients,significancewasseenonly
.
Drug Infusionrate .. inasubgroupanalysisofthe280patientswithcardiogenicshockand
.
Dobutamine 2(cid:2)20lg/kg/min(betaþ) .. <10%ofthepatientshadMI.Astherewerenodataregardingrevas-
.
Dopamine 3(cid:2)5lg/kg/min;inotropic(betaþ) .. cularization,thislimitsthegeneralizabilityoftheresults.485Inanother
.
>5lg/kg/min:inotropic(betaþ),vasopressor(alphaþ) .. prospectiverandomizedtrialepinephrinewascomparedwithnore-
.
Milrinone 0.375(cid:2)0.75lg/kg/min .. pinephrineinpatientswithcardiogenicshockduetoacuteMI.486The
.
.
Enoximone 5(cid:2)20lg/kg/min .. trialwasstoppedprematurelyduetoahigherincidenceofrefractory
.
Levosimendan 0.1lg/kg/min,whichcanbedecreasedto0.05 .. shockwithepinephrine.Epinephrinewasalsoassociatedwithhigher
.
orincreasedto0.2lg/kg/min .. heartrateandlacticacidosis.Despitelimitationsrelatedtoitsrela-
. . tively small sample size, short time of follow-up and lack of data
Norepinephrine 0.2(cid:2)1.0lg/kg/min .
. . regarding the maximum reached dose, the study suggests superior
Epinephrine 0.05(cid:2)0.5lg/kg/min ..
. efficacy and safety with norepinephrine. These data are consistent
.
.
. withameta-analysisincluding2583patientswithcardiogenicshock
.
.
. showingathree-foldincreaseintheriskofdeathwithepinephrine,
.
.
continuous infusion. However, they may also be given as repeated .. compared with norepinephrine, in patients with cardiogenic
.
boluses.Nitroglycerinecanbegivenas1(cid:2)2mgbolusesinseverely .. shock.487However,thelackofinformationaboutdose,durationof
.
hypertensivepatientswithacutepulmonaryoedema.477Careshould .. treatment,andaetiology,makestheseresultspartiallyexplorative.
.
be taken to avoid hypotension due to an excessive decrease in ..
.
preload and afterload. For this reason, they should be used with ..
extremecautioninpatientswithLVHand/orsevereaorticstenosis.
... 11.3.7 Opiates
However,favorableeffectsweredescribedinpatientswithLVsys-
... Opiatesrelievedyspnoeaandanxiety.Theymaybeusedassedative
tolic dysfunction and aortic stenosis when vasodilators were given
... agentsduringnon-invasivepositive pressure ventilationto improve
withcarefulmonitoringofhaemodynamicparameters.481 ... patient adaptation. Dose-dependent side effects include nausea,
.. hypotension,bradycardia,andrespiratorydepression.Retrospective
.
.
.
.
11.3.5 Inotropes .. Recommendationsfortheinitialtreatmentofacute
.
Inotropesarestillneededfortreatmentofpatientswithlowcardiac . heartfailure
.
.
output and hypotension (Table 22). They should be reserved for .
.
patientswithLVsystolicdysfunction,lowcardiacoutputandlowSBP .. Recommendations Classa Levelb
.
.
(e.g.<90mmHg) resultinginpoorvitalorganperfusion.However, .
. Oxygenandventilatorysupport
.
theymustbeusedwithcautionstartingatlowdosesanduptitrating .
themwithclosemonitoring.387,388
... OxygenisrecommendedinpatientswithSpO
2
Inotropes,especiallythosewithadrenergicmechanisms,cancause
..... < hy9 p0 o% xao er mP ia aO
.
2<60mmHgtocorrect I C
sinus tachycardia, increase ventricular rate in patients with AF, ..
. Intubationisrecommendedforprogressiveres-
mayinducemyocardialischaemiaandarrhythmias,andincreasemor- ..
. piratoryfailurepersistinginspiteofoxygen I C tality.387,388,430,478 Levosimendan or type-3-phosphodiesterase ...
administrationornon-invasiveventilation.448
inhibitors may be preferred over dobutamine for patients on ..
beta-blockers as they act through independent mechanisms.482,483 ... Non-invasivepositivepressureventilation
Excessiveperipheralvasodilationandhypotensioncanbemajorlimi-
... shouldbeconsideredinpatientswithrespiratory
tations of type-3-phosphodiestaerase inhibitors or levosimendan,
... distress(respiratoryrate>25breaths/min,SpO
2 IIa B
especiallywhenadministeredathighdosesand/orwhencommenced
... <90%)andstartedassoonaspossibleinorder
withabolusdose.482,484 ... todecreaserespiratorydistressandreducethe
.. rateofmechanicalendotrachealintubation.448
.
.
11.3.6 Vasopressors . Diuretics
.
.
VasopressorsusedforthetreatmentofAHFarereportedinTable22. .. Intravenousloopdiureticsarerecommendedfor
.
Amongdrugswithaprominentperipheralarterialvasoconstrictor .. allpatientswithAHFadmittedwithsigns/symp- I C
.
action, norepinephrine may be preferred in patients with severe .. tomsoffluidoverloadtoimprovesymptoms.145
.
hypotension. The aim is to increase perfusion to the vital organs. .. Combinationofaloopdiureticwiththiazide-
.
However, this is at the expense of an increase in LV afterload. .. typediureticshouldbeconsideredinpatients
Therefore, a combination of norepinephrine and inotropic agents
...
withresistantoedemawhodonotrespondto
IIa B
.
maybeconsidered,especiallyinpatientswithadvancedHFandcar- .. anincreaseinloopdiureticdoses.145
.
diogenicshock. ...
Vasodilators
Somestudies,thoughwithlimitations,supporttheuseofnorepi- ...
InpatientswithAHFandSBP>110mmHg,i.v.
nephrine as first choice, compared with dopamine or epinephrine. ...
vasodilatorsmaybeconsideredasinitialtherapy
Dopamine was compared with norepinephrine as a first-line vaso- ...
toimprovesymptomsandreduce
IIb B
pressortherapyinpatientswithshockandwasassociatedwithmore .
congestion.475(cid:2)477,479,480
Continued
1202
CSE Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 58 ---
3656 ESCGuidelines
.
.
. 11.3.10 Short-termmechanicalcirculatorysupport
Inotropicagents .
.
. Inpatientspresentingwithcardiogenicshock,short-termMCSmay
Inotropicagentsmaybeconsideredinpatients .
.
. benecessarytoaugmentcardiacoutputandsupportend-organper-
withSBP<90mmHgandevidenceofhypoperfu- ...
fusion.Short-termMCScanbeusedasaBTR,BTDorBTB.450-452
sionwhodonotrespondtostandardtreatment, IIb C ..
. The initial improvements in cardiac output, BP and arterial lactate
includingfluidchallenge,toimproveperipheral ..
. may be counterbalanced by significant complications. High-quality
perfusionandmaintainend-organfunction.387 ..
. evidenceregardingoutcomesremainsscarce.Hence,theunselected
.
Inotropicagentsarenotrecommendedrou- .
.. useofMCSinpatientswithcardiogenicshockisnotsupportedand
tinely,duetosafetyconcerns,unlessthepatient .
III C .. they require specialist multidisciplinary expertise for implantation
hassymptomatichypotensionandevidenceof .
hypoperfusion.387,467,478
... andmanagement, similar to that outlined for advanced HFcentres
.. (Supplementary text 11.4; Supplementary Table 22, see also section
Vasopressors ... 10.2.2).376,496 Recentstudiesshow thata ‘standardized team-based
Avasopressor,preferablynorepinephrine,may ...
approach’usingpredefinedalgorithmsforearlyMCSimplantcoupled
beconsideredinpatientswithcardiogenicshock
IIb B
...
withclosemonitoring(invasivehaemodynamics,lactate,markersof
toincreasebloodpressureandvitalorgan ...
end-organ damage) may potentially translate into improved
perfusion.485(cid:2)487 ...
survival.497(cid:2)499
. Otherdrugs .. The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-
.
Thromboembolismprophylaxis(e.g.with .. SHOCK-II)trialshowednodifferencein30-day,aswellasinlong-
.
LMWH)isrecommendedinpatientsnotalready .. term,mortalitybetweenintra-aorticballoonpump(IABP)andOMT
.
anticoagulatedandwithnocontraindicationto .. inpatientswithcardiogenicshockfollowingacuteMIwhounderwent
I A .
anticoagulation,toreducetheriskofdeep .. earlyrevascularization.500(cid:2)502Accordingtotheseresults,IABPisnot
.
venousthrombosisandpulmonary .. routinely recommended in cardiogenic shock post-MI. However, it
.
embolism.494,495 .. maystillbeconsideredincardiogenicshock,especiallyifnotdueto
.
.
Routineuseofopiatesisnotrecommended, . ACS,andrefractorytodrugtherapy,asaBTD,BTR,orBTB.
.
.
unlessinselectedpatientswithsevere/intract- III C . Other short-term MCS were compared with IABP in small,
. ablepainoranxiety.488,489 .. randomizedtrialsandpropensity-matchedanalyseswithinconclusive
.
.. results.503(cid:2)507Similarly,RCTscomparingextracorporealmembrane
.
AHF=acuteheartfailure;i.v.=intravenous;LMWH=low-molecular-weighthep- .
. oxygenation(ECMO)withIABPorMTarelacking.Ameta-analysis
arin;PaO2=partialpressureofoxygen;SBP=systolic bloodpressure;SpO2= ..
transcutaneousoxygensaturation. .. includingonlyobservationalstudiesshowedfavourableoutcomesin
a bC Lela vs es lo of fr ee vc ido em nm cee .ndation. .... patientswithcardiogenicshockorcardiacarresttreatedwithveno-
.. arterial(VA)-ECMOcomparedtocontrols.508VA-ECMOmayalso
.
.. beconsideredinfulminantmyocarditisandotherconditionscausing
.
analyses suggest that morphine administration is associated with a .. severecardiogenicshock.509Dependingontheseverityofmyocar-
.
greaterfrequencyofmechanicalventilation,prolongedhospitalization, .. dial dysfunction and/or concomitant mitral or aortic regurgitation,
.
more intensive care unitadmissions, and increased mortality.488(cid:2)491 . VA-ECMO may increase LV afterload with an increase in LV end-
Thus, routine use of opiates in AHF is not recommended although
.
they may be considered in selected patients, particularly in case of .. Recommendationsfortheuseofshort-termmechanical
severe/intractablepainoranxietyorinthesettingofpalliation. ... circulatorysupportinpatientswithcardiogenicshock
.
.
.. Recommendations Classa Levelb .
11.3.8 Digoxin .
. DigoxinshouldbeconsideredinpatientswithAFwitharapidven- .. Short-termMCSshouldbeconsideredin
. .
tricular rate (>110 b.p.m.) despite beta-blockers (see also section .. patientswithcardiogenicshockasaBTR,BTD,
12.1.1).151,492,493Itcanbegiveninbolusesof0.25(cid:2)0.5mgi.v.,ifnot ... BTB.Furtherindicationsincludetreatmentof IIa C
.
usedpreviously.However,inpatientswithcomorbidities(i.e.CKD) .. thecauseofcardiogenicshockorlong-term
.
orotherfactorsaffectingdigoxinmetabolism(includingotherdrugs) .. MCSortransplantation.
.
and/ortheelderly,themaintenancedosemaybedifficulttoestimate .. IABPmaybeconsideredinpatientswithcardio-
.
theoretically and measurements of serum digoxin concentrations .. genicshockasaBTR,BTD,BTB,includingtreat-
.
shouldbeperformed.Digitoxinisapotentialalternativetodigoxin .. mentofthecauseofcardiogenicshock(i.e. IIb C
.
andiscurrentlybeingevaluatedinarandomizedplacebo-controlled .. mechanicalcomplicationofacuteMI)orlong-
.
trial(ClinicalTrials.govIdentifier:NCT03783429).158 .. termMCSortransplantation.450
.
.
. IABPisnotroutinelyrecommendedinpost-MI
. III B
11.3.9 Thromboembolismprophylaxis
... cardiogenicshock.500(cid:2)502
.
Thromboembolism prophylaxis with heparin (e.g. low-molecular- ...
BTB=bridge to bridge; BTD=bridge to decision; BTR=bridge to recovery;
weight heparin) or another anticoagulant is recommended, unless .. IABP=intra-aortic balloon pump; MCS=mechanical circulatory support; MI=
.
contraindicatedorunnecessary(becauseofexistingtreatmentwith .. myocardialinfarction.
oralanticoagulants).494,495 .... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 59 ---
ESCGuidelines 3657
.
diastolic pressure and pulmonary congestion. In these cases, LV ...
Recommendationsforpre-dischargeandearlypost-dis-
unloadingismandatoryandcanbeachievedbymeansoftranseptal/ .. chargefollow-upofpatientshospitalizedforacuteheart
.
ventricular apex vent or adding an unloading device such as the .. failure
.
Impelladevice.510,511 ..
.. Recommendations Classa Levelb
.
.
11.3.11Pre-dischargeassessmentandpost-discharge .
.. Itisrecommendedthatpatientshospitalizedfor
managementplanning .
.. HFbecarefullyevaluatedtoexcludepersistent
A significant proportion of patients with AHF are discharged with ...
signsofcongestionbeforedischargeandtoopti-
I C
minimalornoweightlossand,moreimportantly,persistentconges- ...
mizeoraltreatment.427,472
tion.427,472Persistentcongestionbeforedischargeisassociatedwith ..
. Itisrecommendedthatevidence-basedoral
ahigherriskofreadmissionandmortality.426,472Treatment,including ..
. medicaltreatmentbeadministeredbefore I C
diuretic dose, should therefore be optimized in order to keep the ...
discharge.103,513
patientfreeofcongestion. ..
In those admitted with ADHF, oral OMT should be continued,
... Anearlyfollow-upvisitisrecommendedat1(cid:2)2
exceptforpossibledosereductionorwithdrawalifthereishaemo-
... weeksafterdischargetoassesssignsofconges-
I C
dynamic instability (symptomatic hypotension), severely impaired
... tion,drugtoleranceandstartand/oruptitrate
renalfunctionorhyperkalaemia.Oncehaemodynamicstabilizationis
... evidence-basedtherapy.517,518
.
achievedwithi.v.therapy,treatmentshouldbeoptimizedbeforedis- .. Ferriccarboxymaltoseshouldbeconsideredfor .
charge.467 Treatment optimization has three major aims. First, to .. irondeficiency,definedasserumferritin<100
.
relievecongestion.Second,totreatcomorbidities,suchasirondefi- .. ng/mLorserumferritin100(cid:2)299ng/mLwith IIa B
.
ciency,thathaveanimpactonpost-dischargeoutcome.512Third,to .. TSAT<20%,toimprovesymptomsandreduce
.. rehospitalizations.512
initiate, or restart oral, OMT with beneficial effects on outcome. .
.
.
Dosesmaybeuptitratedbeforedischargeand/orintheearlypost- .
. HR=heartfailure;TSAT=transferrinsaturation.
.
dischargephase. . aClassofrecommendation.
.
Studieshaveshownthatsuchoptimizationofmedicaltreatmentis
.. bLevelofevidence.
.
.
associatedwithalowerriskof30-dayreadmission,althoughprospec- .
.
tive randomized trials have not been performed, to date.103,467,513 ...
impairment.519(cid:2)523TheproportionofpatientswithHFwhodevelop
Retrospectiveanalysesshowthatdiscontinuationordosereduction ..
. AFincreaseswithageandHFseverity.WhenAFcausesHFtheclini-
ofbeta-blockertherapyduringanAHFhospitalizationisassociated ..
. calcourseseemsmorefavourablethanwithothercausesofHF(so
withworseoutcomes.514InitiationofARNIinrecentlyhospitalized ...
called tachycardiomyopathy).524 In contrast, development of AF in
.
stable patients with HFrEF, including those who are ACE-I/ARB .
. patientswithchronicHFisassociatedwithworseprognosis,includ-
na¨ıve,issafeandmaybeconsideredinthissetting.106,107Safetyand ..
.. ingstrokeandincreasedmortality.525,526
better outcome have also been recently shown in a prospective .
.. ThemanagementofpatientswithconcomitantHFandAFissum-
randomizedtrialwithsotagliflozinindiabeticpatientshospitalizedfor .
HF,irrespectiveoftheirLVEF.136
... marizedinFigure 14.7,521Itincludes:
.
.
Itisrecommendedtohaveonefollow-upvisitwithin1to2weeks .. (1) IdentificationandtreatmentofpossiblecausesortriggersofAF
after discharge.515,516 Components of this follow-up visit should ... (2) ManagementofHF
.
includemonitoringofsignsandsymptomsofHF,assessmentofvol- .. (3) Preventionofembolicevents
.
ume status, BP, heart rate, and laboratory measurements including .. (4) Ratecontrol
. renalfunction,electrolytes,andpossiblyNPs.Ironstatusandhepatic .. (5) Rhythmcontrol
. function should also be assessed when not done before discharge. ..
. Basedonclinicalevaluationandlaboratoryexams,furtheroptimiza- .. Identificationoftriggersandmanagementofheartfailure
.
tion and/or initiation of disease-modifying treatment for HFrEF .. Potential causes or precipitating factors such as hyperthyroidism,
.
shouldoccur.Retrospectivestudiesshowthatsuchanapproachis .. electrolyte disorders, uncontrolled hypertension, mitral valve dis-
.
associatedwithlower30-dayreadmissionratesalthoughprospective .. ease,andinfectionshouldbeidentifiedandcorrected.
.
randomizedtrialshavenotbeenperformed,todate.513,516(cid:2)518 .. Worsening congestion due to AF should be managed with diu-
.
.. retics.Congestionreliefmayreducesympatheticdriveandventricu-
.
.. larrateandincreasethechanceofspontaneousreturntoSR.The
.
.. presence of AF may reduce or abolish the prognostic benefits of
.
12 Cardiovascular comorbidities .. beta-blockers and renders ivabradine ineffective.12,125 Some treat-
.
.
. ments for HF decrease the risk of developing AF, including ACE-I,
.
12.1 Arrhythmias and conduction .. slightly,andCRT,probably.7,527
.
disturbances ..
.
.
12.1.1 Atrialfibrillation .. Preventionofembolicevents
.
AFand HFfrequentlycoexist.519,520Theycancauseorexacerbate .. Unless contraindicated, an oral, long-term anticoagulant is recom-
.
eachotherthroughmechanismssuchasstructuralcardiacremodel- .. mendedinallpatientswithHFandparoxysmal,persistent,orperma-
.
ling, activation of neurohormonal systems, and rate-related LV . nent AF. Direct-acting oral anticoagulants (DOACs) are preferred
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 60 ---
3658 ESCGuidelines
Management of atrial fibrillation in patients with HFrEF
Anticoagulation for preventing embolic events (Class I)
Treatment of trigger(s) (Class I)
Optimization of heart failure therapies (Class I)
Haemodynamic
instability
Y N
Rhythm control Rate control
ECV Beta-blockers
(Class I) (Class IIa)
OR
Digoxin/digitoxin
Sinus rhythm N (Class IIa)
OR
Amiodarone i.v.
(Class IIa)
Y
Symptom
Y
improvement
N Follow-up
Rhythm control Rhythm control
PV ablation PV ablation
(Class IIa) (Class IIa)
OR OR
Amiodarone Amiodarone
(Class IIb) (Class IIb)
OR
ECV
(Class IIb)
Rate control
AVN ablation
(Class IIb)
N Sinus rhythm Y
Figure14 Managementofatrialfibrillationinpatientswithheartfailurewithreducedejectionfraction.AF=atrialfibrillation;AVN=atrioventricular
node;ECV=electricalcardioversion;HF=heartfailure;i.v.=intravenous;PV=pulmonaryvein.Colourcodeforclassesofrecommendation:Greenfor
ClassofrecommendationI;YellowforClassofrecommendationIIa;OrangeforClassofrecommendationIIb;RedforClassofrecommendationIII(see
Table1forfurtherdetailsonclassesofrecommendation).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 61 ---
ESCGuidelines 3659
.
.
forthepreventionofthromboemboliceventsinpatientswithAFand . dronedarone) are associated with worse outcomes in
.
withoutseveremitralstenosisand/ormechanicalvalveprosthesis,as .. HFrEF.186,534,541(cid:2)544 Amiodarone can help maintain HF patients in
.
theyhavesimilarefficacytovitaminKantagonists(VKAs)butalower .. SRaftercardioversion.545,546
.
riskofintracranialhaemorrhage.528 .. TrialsincludingpatientswithHFandcomparingratecontroland
.
.
LAappendageclosurecanbeconsideredinpatientswithHFand . rhythm control strategies with the latter based on antiarrhythmic
.
.
AFwhohaveacontraindicationtooralanticoagulationthoughdata . drugs failed to show any benefit of one strategy over the oth-
.
fromrandomizedtrialshavenotincludedpatientswithcontraindica- .. er.547(cid:2)550 More recently, EAST-AFNET 4, enrolling patients with
.
.
tionstooralanticoagulants.529,530 . earlyAF,28.6%withHF,wasstoppedearlyafteramedianfollow-up
.
.
.. of5.1yearsforaloweroccurrenceoftheprimaryoutcomeofdeath,
.
Ratecontrol .. stroke, orhospitalizationfor worseningHForACS in thepatients
.
Dataregardingratecontrolarenotconclusiveforthepatientswith .. assignedtoearlyrhythmcontrolvs.thoseassignedtousualcare.551
.
AFand HF. A strategyoflenient rate control, defined by a resting .. However,thepatientsassignedtotherhythmcontrolstrategyhada
. heartrate<110b.p.m.,wascomparedtoastrategyofstrictratecon- .. closerfollow-up,whichmayhave influenced theirbetteroutcome.
.
trol,definedbyaheartrate<80b.p.m.atrestand<110b.p.m.during .. Catheterablationwasperformedinaminorityofthepatientsinthe
.
moderateexercise,inRACEIIandinapooledanalysisofRACEand .. rhythmcontrolarm(19.4%).551
.
AFFIRM.152,531 The studies showed no differences in outcome .. LAcatheterablationwascomparedwithMT,rateorrhythmcon-
. between the two strategies. However, only 10% of the patients in .. trolstrategy,in363patientswithpersistentorparoxysmalAF,LVEF
.
RACEIIand17%ofthoseinthepooledanalysishadahistoryofHF .. <35% and an implanted device (ICD or CRT-D) enrolled in the
.
hospitalizationorNYHAclassII(cid:2)III,respectively.152,531Higherheart .. CASTLE-AFtrial.552Theprimaryendpointofall-causedeathorHF
.
rates are associated with worse outcomes in observational stud- .. hospitalizationsoccurredinfewerpatientsintheablationgroupvs.
.
ies.532,533Thus,alenientratecontrolisanacceptableinitialapproach .. theMTgroup,51patients(28.5%)vs.82(44.6%)[hazardratio(HR);
.
.
with,however,treatmenttargetingalowerheartrateincaseofper- . 95%confidenceinterval(CI),0.62;0.43(cid:2)0.87;P=0.007].Also,other
.
.
sistentsymptomsorcardiacdysfunctionlikelyrelatedtotachycardia . endpoints,all-causeorCVdeathorworseningHF,werereducedby
.
(e.g.tachycardia-inducedcardiomyopathy).7,534 .. catheter ablation.552 This trial suggests that catheter ablation can
.
.
Beta-blockerscanbeusedforratecontrolinpatientswithHFrEF . improvetheprognosisofpatientswithHFrEF.However,itenrolleda
.
.
orHFmrEFbecauseoftheirestablishedsafetyinthesepatients(see . highlyselectedpopulation,363of3013patients,wasnotblinded,had
.
section5.3.2).7,534,535Digoxinordigitoxincanbeconsideredwhen .. crossoversbetweenthetwotreatmentstrategiesandthenumberof
.
.
the ventricular rate remains high, despite beta-blockers, or when . eventsobservedwaslow:24(13.4%)vs.46(25.0%)all-causedeaths
.
beta-blockersarecontraindicatedornottolerated.151,493,536Itmay .. and37(20.7%)vs.66(35.9%)HFhospitalizationsintheablationand
.
.
therefore be considered also an alternative to beta-blockers. For . MTgroups,respectively.552
.
.
patients with NYHA class IV and/or haemodynamic instability, i.v. .. TheCABANAtrialwasaninvestigator-initiated,open-label,multi-
.
amiodarone can be considered to reduce ventricular rate.537 For .. centre, randomized trial enrolling 2204 patients with symptomatic
.
HFpEF,thereisapaucityofevidencetodemonstrateefficacyofany .. AF. The trial failed to show a benefit of AF ablation strategy over
.
agent. The RATE-AF trial compared digoxin with bisoprolol in .. medicalcareontheprimarycompositeendpointofdeath,disabling
.
patients with persistent AF and NYHA class II(cid:2)IV symptoms. .. stroke,seriousbleeding,orcardiacarrestintheoverallpopulation.553
.
Comparedwithbisoprolol,digoxinhadthesameeffectonQOLat6 .. Inananalysisofthe778patients(35%)withNYHAclasssymptoms
.
months(primaryendpoint)andabettereffectonEHRAandNYHA .. >II,theprimaryoutcomeoccurredin34patients(9.0%)inthecathe-
.
functionalclass.536Only19%ofthepatientshadLVEF<50%sothat .. terablationgroupvs.49(12.3%)inthedrugtherapygroup(HR;95%
.
most of the patients can be considered as having HFmrEF or .. CI, 0.64; 0.41(cid:2)0.99).554 However, also in this trial, the number of
. HFpEF.536 .. eventswassmallandHFwasdefinedbasedonlyonsymptomswith
. AVnodeablationcanbeconsideredinpatientswithpoorventric- .. LVEFavailablein73%ofthepatientsand>50%and40(cid:2)49%in79%
. ularrate control despite medicaltreatmentnot eligibleforrhythm .. and 11.7% of the cases, respectively.554 Both CASTLE-AF and
.
.
control by catheter ablation or in patients with biventricular . CABANAshowedahighlysignificanteffectofcatheterablationon
.
pacing.7,538(cid:2)540 .. patients’symptoms.552(cid:2)554
.
.
. Two other prospective trials enrolled patients with HFrEF and
.
.
Rhythmcontrol . persistentAF,whowererandomizedtocatheterablationorMTin
.
.
Urgent electrical cardioversion is recommended in the setting of . onetrial(AMICAtrial,n = 140),andtocatheterablationoramio-
.
acuteworseningHFinpatientspresentingwithrapidventricularrates .. daroneintheotherone(AATACtrial,n = 203).555,556Thefirsttrial
.
.
andhaemodynamicinstability,afterconsiderationofthethromboem- . failedtoshowanydifferenceintheLVEFincreasebetweenthetwo
.
bolicrisk.Cardioversionshouldbeconsideredalsotoimprovesymp- .. groups.555Thesecondtrialshowedsuperiorityofcatheterablation
.
.
tomsinpatientswhohave persistentandsymptomaticAF,despite . with respect of AF recurrence, the primary endpoint, with also a
.
.
optimal pharmacological management. In patients who do not . reductioninunplannedhospitalizationsandmortality.556Incontrast
.
.
receive chronic therapy with oral anticoagulant and with AF onset . with the AMICA trial,555 but in accordance with CASTLE-AF,552
.
.
>48h,atleast3weeksoftherapeuticanticoagulationoratransoeso- .. AATACalsoshowedabenefitofcatheterablationonLVEF.556
.
phageal echocardiography is needed before cardioversion.7 When .. Inconclusion,thereisinsufficientevidenceinfavourofastrategy
.
pharmacologicalcardioversionispreferred,amiodaroneisthedrug .. of rhythm control with antiarrhythmic drugs vs. rate control in
.
ofchoiceasotherantiarrhythmicdrugs(i.e.propafenone,flecainide, . patientswithHFandAF.547(cid:2)551Theresultsofrandomizedtrialswith
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 62 ---
3660 ESCGuidelines
.
.
. lead toreversiblesystolic dysfunction.Possiblefactors mayinclude
Recommendationsforthetreatmentofatrialfibrilla- .
tioninpatientswithheartfailure
... dyssynchronyandabnormalcalciumhandling.560
.
. InitialmanagementofventriculararrhythmiasinHFshouldinclude
.
Recommendations Classa Levelb .. correctionofpotentialprecipitants(includingelectrolyteabnormal-
.
.
. ities, particularlyhypo/hyperkalaemia,and pro-arrhythmicdrugs)as
Anticoagulation ..
. wellastheoptimizationofHFdrugtherapy.Althoughischaemiamay
.
Long-termtreatmentwithanoralanticoagulant .
. beatriggeringfactor,revascularizationhasnotbeenshowntoreduce
.
isrecommendedinallpatientswithAF,HF,and .
I A .. riskofventriculararrhythmias.561
CHADS-VAScscore>_2inmenor>_3in .
wome2 n.72 ... Amiodarone is effective also for suppression of ventricular
.. arrhythmias.However,itdoesnotreduce theincidenceof sudden
DOACsarerecommendedinpreferenceto ... cardiac death or overall mortality.161 For patients with premature
VKAsinpatientswithHF,exceptinthosewith
I A
...
ventricularcontraction(PVC)-inducedCMP,amiodaroneadministra-
moderateorseveremitralstenosisormechani- ...
tion may be considered to reduce recurrent arrhythmias and
calprostheticheartvalves.528,558 ...
improvesymptomsandLVfunction,althoughitssideeffectsshould
.
Long-termtreatmentwithanoralanticoagulant .. be taken into consideration. Other drugs are discussed in
.
shouldbeconsideredforstrokepreventionin IIa B ... Supplementarytext12.1.
AFpatientswithaCHA 2DS 2-VAScscoreof1in .. Radiofrequency ablation of VPBs may improve LV function and,
menor2inwomen.7,559 ...
possibly,outcomesinpatientswithtachycardiomyopathywhenVPBs
.
Ratecontrol .. contributetoLVdysfunction.562Asustainedreductioninthebaseline
.
Beta-blockersshouldbeconsideredforshort- .. PVCburdenhasbeenassociatedwithalowerriskofcardiacmortal-
.
andlong-termratecontrolinpatientswithHF IIa B .. ity,cardiactransplantation, orhospitalization for HFduring follow-
.
andAF.535 .. up.563,564
.
.
Digoxinshouldbeconsideredwhentheventric- .
.
.
ularrateremainshigh,despitebeta-blockers,or .
IIa C ..
whenbeta-blockersarecontraindicatedornot . 12.1.3 Symptomaticbradycardia,pausesandatrio-
.
.
tolerated.536 . ventricularblock
.
.
Cardioversion .. IndicationsforpacemakertherapydonotdifferinpatientswithHF
.
UrgentECVisrecommendedinthesettingof .. fromthosewithotherCVdisease.ThereisampleevidencethatRV
.
acuteworseningofHFinpatientspresenting .. pacingmayhaveanadverseeffectonLVsystolicfunctionleading,in
withrapidventricularratesandhaemodynamic
I C ... thelongterm,toHF.565PatientswithHFrEFrequiringfrequentven-
.
instability. .. tricularpacing,e.g.withAVblockorslowAF,andwhohavesystolic
.
Cardioversionmaybeconsideredinpatientsin
... dysfunction, should be implanted with CRT rather thana standard
whomthereisanassociationbetweenAFand
... pacemakertoavoidadverseoutcomes,asshownintheBLOCK-HF
worseningofHFsymptomsdespiteoptimal
IIb B ... (Biventricular versus Right Ventricular Pacing in Heart Failure
medicaltreatment.7,541
... PatientswithAtrioventricularBlock)trial.216Inthequestforamore
.. physiological alternative to RV pacing, physiological pacing is being
AFcatheterablation .
.. increasinglyadopted.566Inanon-randomizedcomparisonof304con-
Incasesofaclearassociationbetweenparoxys- ...
secutivepatientswithHisbundlepacingand433consecutivepatients
malorpersistentAFandworseningofHFsymp- ..
. withRVpacing,theformergrouphadlessHFhospitalizationanda
toms,whichpersistdespiteMT,catheter IIa B ... trendinreducedmortality.567Althoughthetechniqueispromising,
ablationshouldbeconsideredfortheprevention ..
. moredataareneededtoconfirmitsrole.
ortreatmentofAF.552(cid:2)554,557 ..
.
.
.
AF=atrialfibrillation;CHA2DS2-VASc=congestiveheartfailureorleftventricu- ..
lardysfunction,Hypertension,Age>_75(doubled),Diabetes,Stroke(doubled)- .. 12.2 Chronic coronary syndromes
Vascular disease, Age 65(cid:2)74, Sex category (female) (score); DOAC=direct- ..
. CAD is the most common cause of HF in industrialized, middle-
actingoralanticoagulant;ECV=electricalcardioversion;HF=heartfailure;MT= .
.
medicaltherapy;VKA=vitaminKantagonist. .. income,andincreasinglyinlow-income,countries.Itshouldbecon-
aClassofrecommendation. ..
sidered aspossiblecause ofHFinall patients presentingwithnew
bLevelofevidence. ..
. onsetHF.
.
.
. ThediagnosticworkupofpatientswithHFandchroniccoronary
.
.
catheterablationvs.MTshowedaconsistentimprovementinsymp- .. syndromes(CCS)isreportedintherecent2019ESCGuidelineson
.
toms whereas the results on mortality and hospitalization were .. CCS.5PatientswithHFshouldbecarefullyevaluatedtoassesssigns
.
obtainedwitharelativelysmallnumberofeventsnotpermittingto .. and/or symptoms of CCS. Clinical and family histories, physical
drawdefinitiveconclusions.152,548(cid:2)550,552(cid:2)554,557 ... examination, ECG and imaging tests are recommended.5
.
.. Documentationofischaemiausingnon-invasiveandinvasivetestscan
.
12.1.2 Ventriculararrhythmias .. be difficult in patients with HF because of the possible exercise
.
Ventriculararrhythmiasmaybeacomplication,andinsomeinstan- .. intoleranceandthe effectsofincreased end-diastolicLV pressures.
.
ces,acauseofHF.Frequentventricularprematurebeats(VPBs)may . CoronaryangiographyorCTCAcanbeperformedtoestablishthe
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 63 ---
ESCGuidelines 3661
presenceandextentofCADandevaluatethepotentialindicationfor ..
. Beta-blockers, long-acting nitrates, calcium channel blockers
revascularization(seesection4.3).5 ..
. (CCBs), ivabradine, ranolazine, trimetazidine, nicorandil and
.
.
. their combinations should be considered in HFpEF for angina
.
12.2.1Medicaltherapy .
. relief but without a foreseen benefit on HF and coronary end
.
Beta-blockersarethemainstayoftherapyinpatientswithHFrEFand .
CADbecauseoftheirprognosticbenefit.116(cid:2)120,568Ivabradineshould
... points.
.. Low-doseofrivaroxaban[2.5mgtwicedaily(b.i.d.)]didnotadd
be considered as an alternative to beta-blockers (when contraindi- .
.. prognostic benefit in patients with HFrEF and CCS in the
cated) or as additional anti-anginal therapy in patients in SR whose .
heartrateis>_70b.p.m.139,569Otheranti-anginaldrugs(e.g.amlodipine,
... COMMANDER-HF trial, a study to assess the effectiveness and
.. safetyof rivaroxabaninreducing theriskofdeath, MI orstrokein
felodipine,nicorandil,ranolazine,andoralortransdermalnitrates)are .
.. participants with HFand CAD followinganepisode ofdecompen-
effective fortreating symptoms,althoughdata abouttheireffectson .
outcomesareneutralorlacking.5,570(cid:2)574Trimetazidineseemstohave
... sated HF.579 This trial included patients with HFrEF and a recent
.. episode of worsening HF occurring within 21 days from the time additive effects, such as improvement of LV function and exercise .
.. of enrolment. These patients are at high risk of HF-related events
capacity, in patients with HFrEF and CCS already on beta-block- .
.. and these were the main cause of deaths and hospitalizations in
ers.575(cid:2)577Trimetazidineandotheranti-anginaldrugsmaybeconsid- ...
thetrial.Rivaroxabanhadnoeffectontheseevents.Incontrast,in
ered in patients with HF and angina despite beta-blocker and/or ...
a non-pre-specified subgroup analysis of the COMPASS trial, low
ivabradine.Short-actingnitratesshouldbeusedwithcautioninpatients ..
. doseofrivaroxaban,ontopofaspirin,wasassociatedwithareduc-
withHFastheycausehypotension.Diltiazemandverapamilincrease ..
. tion in ischaemic events in patients with HF, mainly HFmrEF or
HF-relatedeventsinpatientswithHFrEFandarecontraindicated.578 ...
HFpEF.580Basedonthesedata,low-doserivaroxabanmaybecon-
An algorithm for the use of anti-anginal medications in patients ..
. sidered in patients with CAD (or peripheral artery disease) and
withHFrEFisreportedinFigure15. ..
Use of anti-anginal medications in patients with CCS and HFrEF
Beta-blockers
(Class I)
Persistence of
CCS symptoms
HR ≥70 bpm, and HR <70 bpm, and/or
sinus rhythm atrial fibrillation
Trimetazidine Ranolazine
OR
(Class IIb) (Class IIb)
In absence of
Ivabradine improvement Nicorandil Nitrates
OR
(Class IIa) (Class IIb) (Class IIb)
Felopidine Amlodipine
OR
(Class IIb) (Class IIb)
Diltiazem (Class III)
Verapamil (Class III)
Figure 15 Algorithmforthemedicaltreatmentofchroniccoronarysyndromeinpatientswithheartfailurewithreducedejectionfraction.CCS=
chroniccoronarysyndrome;HFrEF=heartfailurewithreducedejectionfraction;HR=heartrate.Colourcodeforclassesofrecommendation:Greenfor
ClassofrecommendationI;YellowforClassofrecommendationIIa;OrangeforClassofrecommendationIIb;RedforClassofrecommendationIII(see
Table1forfurtherdetailsonclassesofrecommendation).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 64 ---
3662 ESCGuidelines
HF,LVEF>40%andSR,whenathighriskofstrokeandwithalow ...
Recommendationsformyocardialrevascularizationin
haemorrhagicrisk. .. patientswithheartfailurewithreducedejection
.
.. fraction
.
.
12.2.2Myocardialrevascularization .
.
Dataonthebenefitofmyocardialrevascularizationinpatientswith .. Recommendations Classa Levelb
.
.
HFarelimited. .
. CABGshouldbeconsideredasthefirst-choice
.
STICH compared coronary artery bypass grafting (CABG) with .
. revascularizationstrategy,inpatientssuitablefor
MTinpatientswithCAD,amenablebyCABG,andwithreducedLV .. IIa B
. surgery,especiallyiftheyhavediabetesandfor
.
function(EF<_35%).Atamedianfollow-upof56months,therewas .. thosewithmultivesseldisease.581,587,588,590
.
nosignificantdifferencebetweentheCABGgroupandtheMTgroup .
intherateofdeathfromanycause,primaryoutcomeofthetrial.89
... Coronaryrevascularizationshouldbeconsidered
.. torelievepersistentsymptomsofangina(oran
The extended follow-up report showed a significant reduction of .
.. angina-equivalent)inpatientswithHFrEF,CCS, IIa C
deathintheCABGgroupvs.thecontrolgroup(58.9%vs.66.1%;HR .
.. andcoronaryanatomysuitableforrevasculariza-
0.84;95%CI,0.73(cid:2)0.97;P = 0.02)over10years.581CVdeathand ...
tion,despiteOMTincludinganti-anginaldrugs.
the combined endpoint of all-cause death or hospitalization for ..
. InLVADcandidatesneedingcoronaryrevascula-
CV causes were also significantly reduced after CABG at 10 years .. IIa C
. rization,CABGshouldbeavoided,ifpossible.
of follow-up.581 Post hoc analyses of the STICH trial suggested ..
. Coronaryrevascularizationmaybeconsidered
thatneithermyocardialviability,angina,norischaemiawererelated ..
with outcomes after revascularization.92,93,582 The Heart Failure
... toimproveoutcomesinpatientswithHFrEF,
RevascularisationTrial(HEART)wasunder-powered,withonly138
... CCS,andcoronaryanatomysuitableforrevas-
oftheplanned800patientstobeenrolled,andfailedtoshowdiffer-
... cularization,aftercarefulevaluationoftheindi-
encesinoutcomesbetweenHFpatientsreceivingCABGorMT.583
... vidualrisktobenefitratio,includingcoronary IIb C
TherearecurrentlynoreportedRCTscomparingpercutaneous
... anatomy(i.e.proximalstenosis>90%oflarge
coronary intervention (PCI) with MT in patients with HFrEF.
... vessels,stenosisofleftmainorproximalLAD),
However, the REVIVED-BCIS2 trial has finished recruitment
... comorbidities,lifeexpectancy,andpatient’s
(ClinicalTrials.gov Identifier: NCT01920048).584 There are also no
... perspectives.
.
. PCImaybeconsideredasanalternativeto
randomizedstudiescomparingPCIwithCABGassuchrandomized .
.
. CABG,basedonHeartTeamevaluation,consid- trials excluded patients with HFrEF. In one prospective registry, .. IIb C
. eringcoronaryanatomy,comorbidities,andsur-
including 4616 patients with multivessel disease and HFrEF, . .
. gicalrisk.
propensity-score matched comparisons showed similar survival .
.
.
(meanfollow-up2.9years)inPCIvs.CABGgroupwithPCIsassoci- .
. CABG=coronaryarterybypassgraft;CCS=chroniccoronarysyndrome;HFrEF
.
atedwithahigherriskofMI,particularlyinpatientswithincomplete . =heart failure with reduced ejection fraction; LAD=left anterior descending
.
revascularization, and CABG associated with a higher risk of .. artery;LVAD=leftventricularassistdevice;OMT=optimalmedicaltherapy;PCI
stroke.585 A propensity-matched analysis showed a significantly
.... = aCp lae sr scu ot fa rn ee co ou ms mco er no dn aa tr ioy ni .ntervention.
.
lowerriskofdeathormajorCVeventsindiabeticpatientswithLV .. bLevelofevidence.
.
dysfunction and multivessel disease treated with CABG compared .. .
..
with PCI.586 CABG was associated with better outcome than PCI .. .. corrected (i.e. anaemia, hyperthyroidism, arteriovenous shunts)
alsoinpatientswithmoderateorsevereLVdysfunctionandleftmain ... ... before proceeding to aortic valve intervention.592 An aortic valve
..
or complex coronary disease.587,588 Two meta-analyses confirmed . .. intervention is recommended in patients with HF symptoms and
. thatCABGisassociatedwithbetteroutcomes,includingmortality, .. severe, high-gradient aortic stenosis, regardless of LVEF.
. MI, and repeated revascularization, compared with PCI .. Managementofpatientswithlow-flowlow-gradientaorticstenosisis
. and/orMT.589,590 .. reportedinFigure16.592
.
.. Interventionisrecommendedinpatientswithalifeexpectancy>1
.
.. year,avoidingfutility.Transcatheteraorticvalveimplantation(TAVI)
.
12.3 Valvular heart disease .. hasbeenshowntobenon-inferiortosurgicalaorticvalvereplace-
.
12.3.1 Aorticstenosis .. ment(SAVR)inreducingclinicalevents(includingmortalityanddis-
.
.
AorticstenosismaycauseorworsenHFbyincreasingLVafterload . abling stroke) in patients at high and intermediate risk for
.
and causing LV hypertrophy and remodelling.591 When HF symp- .. surgery.593(cid:2)600Inlow-riskpatients,meanageintheRCTscomparing
.
.
toms occur in patients with severe aortic stenosis, prognosis is . TAVI and SAVR was >70 years and follow-up was restricted to
.
.
extremelypoor.NoMTforaorticstenosiscanimproveoutcomes. .. 2years.Therefore,SAVRisrecommendedinpatientsaged<75years
.
HFmedicaltreatmentshouldbegiventoallHFpatientswithsympto- .. andatlowsurgicalrisk(STS-PROMscoreorEuroSCOREII<4%),
.
maticsevereaorticstenosis.Caremustbetakenusingvasodilators .. whereasTAVIisrecommendedinthoseaged>75yearsorathigh/
.
to avoid hypotension. Importantly, possibleimprovementofsymp- .. prohibitivesurgicalrisk(STS-PROMscoreorEuroSCOREII>8%).In
.
tomsafterMTshouldnotdelayintervention. .. alltheothercases,thechoicebetweenTAVIandSAVRshouldbe
.
In the presence of suspected symptomatic and severe high- .. madebytheHeartTeam,weighingtheprosandconsofeachproce-
.
gradient aortic stenosis (valve area <_1 cm2, mean gradient >_40 .. dure,accordingtoage,lifeexpectancy,individualpatientpreference
.
mmHg), other causes of high flow status must be excluded and . and other features including clinical and anatomical aspects. Aortic
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 65 ---
ESCGuidelines 3663
Management of patients with heart failure and suspected severe low-flow low-gradientASa
LVEF < 50%
Y N
Clinical and
Dobutamine echo
echo criteriab
High calcium scored
Flow reservec N
by CT
Y
Severe low-flow
low-gradientAS
e f
N Y Y Y N
f
Y
Medical therapy
HeartTeamg HeartTeamg
optimization Follow-up
(Class I) (Class I)
(Class I)
SAVR SAVR
(Class I) (Class IIa)
OR OR
TAVI TAVI
(Class I) (Class IIa)
Figure16 Managementofpatientswithseverelow-flowlow-gradientaorticstenosisandheartfailure.AS=aorticstenosis;CT =computedtomogra-
phy;EuroSCOREII=EuropeanSystemforCardiacOperativeRiskEvaluationII;LVEF=leftventricularejectionfraction;OMT=optimalmedicaltherapy;
SAVR=surgical aortic valve replacement; STS-PROM=Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI=transcatheter aortic valve
implantation.aValvearea<_1cm2,peakvelocity<4.0m/s,meangradient<40;strokevolumeindex<_35mL/m2.bAge>70years,typicalsymptomswithout
otherexplanations,leftventricularhypertrophyorreducedleftventricularlongitudinalfunction,meangradient30(cid:2)40mmHg,valvearea<_0.8cm2,stroke
volumeindex<_35mL/m2assessedbytechniquesotherthanstandardDoppler.cFlowreserveisdefinedasstrokevolumeindexincrease>20%.dASis
verylikelyifcalciumscoreis>_3000inmenand>_1600inwomen.ASislikelyifcalciumscoreis>_2000inmenand>_1200inwomen.ASisunlikelyifcalcium
scoreis<1600inmenand<800inwomen.eIncreaseinvalveareato>1.0cm2inresponsetoflowincrease(flowreserve)duringdobutamineecho.
fIncreaseinmeangradienttoatleast40mmHgwithoutsignificantchangeinvalveareainresponsetoflowincrease(flowreserve)duringdobutamine
echo.gSAVRisrecommendedinpatientsaged<75yearsandlowsurgicalrisk(STS-PROMscoreorEuroSCOREII<4%),whereasTAVIinthoseaged
>75yearsorathigh/prohibitivesurgicalrisk(STS-PROMscoreorEuroSCOREII>8%).Inalltheothercases,thechoicebetweenTAVIandSAVRisrec-
ommendedtobedecidedbytheHeartTeam,weighingtheprosandconsofeachprocedure,accordingtoage,lifeexpectancy,individualpatientprefer-
enceandfeaturesincludingclinicalandanatomicalaspects.Colourcodeforclassesofrecommendation:GreenforClassofrecommendationI;Yellowfor
ClassofrecommendationIIa(seeTable1forfurtherdetailsonclassesofrecommendation).
.
.
valveinterventionsshouldbeperformedonlyincentreshavingboth .. Balloonaorticvalvuloplastymaybeconsideredinhighlysympto-
.
interventionalcardiologyandcardiacsurgeryservicesonsiteanda .. maticpatientswithAHF(i.e.cardiogenicshock)asbridgetoTAVIor
.
structuredcollaborativeHeartTeamapproach. . SAVR,orinadvancedHFasBTRorDT.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 66 ---
3664 ESCGuidelines
.
12.3.2 Aorticregurgitation .. ofhighorprohibitivesurgicalrisk,TAVIhasbeenusedtotreatalso
.
SevereaorticregurgitationcanleadtoprogressiveLVdilationwith .. aorticregurgitation.604
.
subsequentdysfunction,HF,andpoorprognosis. ..
.
MT can improve HF symptoms in patients with severe aortic ... 12.3.3 Mitralregurgitation
regurgitation.Inparticular,inhibitorsofthe RAAScanbeuseful.601 ... Primary(organic)mitralregurgitation
Beta-blockersshouldbecautiouslyusedastheyprolongdiastoleand ... Primarymitralregurgitation(MR)iscausedbyabnormalitiesofthe
.
mayworsenaorticregurgitation. .. valveapparatusandcancauseHF.
.
Aorticvalvesurgeryisrecommendedinpatientswithsevereaortic .. Surgery, preferably repair, is recommended in patients with
regurgitationandHFsymptomsregardlessofLVEF.592,602,603Incase ..
severeprimaryMRandHFsymptoms.Ifsurgeryiscontraindicated
Management of secondary mitral regurgitation in patients with HFrEF
HeartTeam
(Class I)
Need for coronary OMT including CRT
revascularization if indicated
Y N Y N
High surgical risk
Y N
CABG and mitral MT optimization and
PCI
valve surgery implantCRTifindicated
(Class IIb)
(Class IIa) (Class I)
Persistence of HF symptomsa
and significant SMRb
Y N
HeartTeam
Follow-up
(Class I)
Echocardiographic and clinical criteria for outcome
improvement after percutaneous EE mitral valve repairc
Y N
Consider percutaneous
Maintain ongoing therapy.
Consider surgery Percutaneous EE EE mitral valve repair
Consider palliative care
if low-risk mitral valve repair to improve symptoms
and/or MCS or HT,
(Class IIb) (Class IIa) or as BTT or to LVAD
if possible
(Class IIb)
Figure17 Managementofsecondarymitralregurgitationinpatientswithheartfailurewithreducedejectionfraction.BTT=bridgetotransplantation;
CABG=coronaryarterybypassgraft;CRT=cardiacresynchronizationtherapy;EE=edge-to-edge;EROA=effectiveregurgitantorificearea;HF=heart
failure;LVAD=leftventricularassistdevice;LVEF=leftventricularejectionfraction;LVESD=leftventricularend-systolicdiameter;MCS=mechanicalcir-
culatorysupport;MT=medicaltherapy;NYHA=NewYorkHeartAssociation;OMT=optimalmedicaltherapy;PCI=percutaneouscoronaryinterven-
tion;SMR=secondarymitralregurgitation;TR=tricuspidregurgitation.aNYHAclassII(cid:2)IV.bModerate-to-severeorsevere(EROA>_30mm2).cAllofthe
followingcriteriamustbefulfilled:LVEF20(cid:2)50%,LVESD<70mm,systolicpulmonarypressure<70mmHg,absenceofmoderateorsevererightventricu-
lardysfunctionorsevereTR,absenceofhaemodynamicinstability.612Colourcodeforclassesofrecommendation:GreenforClassofrecommendationI;
YellowforClassofrecommendationIIa;OrangeforClassofrecommendationIIb(seeTable1forfurtherdetailsonclassesofrecommendation).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 67 ---
ESCGuidelines 3665
.
.
or considered at high risk, then percutaneous repair may be . different procedures once it is performed. A sham-controlled
.
considered.592,605 .. randomizedtrialtestingatranscatheterindirectmitralannuloplasty
.
.
. devicemetitsprimaryendpointofmitralregurgitantvolumereduc-
.
Secondary(functional)mitralregurgitation .. tionwithreverse LVandLAremodelling at12months.618Further
.
.
Secondarymitralregurgitation(SMR)ismostlyadiseaseoftheleft . studiesconfirmedfavourableresultsonLAvolumesandLVremodel-
.
.
ventricle. It can also be caused by mitral annulus enlargement due . lingwithtrendstowardsimprovementinmean6MWTdistanceand
.
to LA dilation.606 Moderate or severe SMR is associated with an .. symptomsandareductioninHFhospitalizationsinanIPDmeta-ana-
.
extremely poor prognosis in patients with HF.607,608 The assess- .. lysis.619(cid:2)622Transcathetermitralvalvereplacementisalsoemerging
.
.
ment of MR aetiology and severity should be performed by an . as a possible alternative option, but randomized trials are still
.
.
experienced echocardiographer applying a multi-parametric . lacking.623
.
.
approach,andideallyinstablepatientconditions,afteroptimization .. Mitralvalveinterventionsarenotrecommendedinpatientswitha
.
of medical and resynchronization therapies. Being SMR a dynamic .. lifeexpectancyof<1yearduetoextra-cardiacconditions.592
. condition, echocardiographicquantification duringexercisemay be ..
. Recommendationsforthemanagementofvalvular
helpfulinpatientswithmoderateSMRatrestandsymptomsduring ...
heartdiseaseinpatientswithheartfailure
physicalactivity.609EarlyreferralofpatientswithHFandmoderate ..
.
orsevereMRtoamultidisciplinaryHeartTeam,includingHFspe- ... Recommendations Classa Levelb
cialists, is recommended for assessment and treatment planning. ..
.
The Heart Team has to verify, first of all, that the patient is on .. Aorticstenosis
.
optimaltherapy,includingCRT,whenindicated(Figure17). .. Aorticvalveintervention,TAVIorSAVR,isrec-
.
InpatientswithsevereSMRandHFrEFrequiringrevascularization, ... ommendedinpatientswithHFandseverehigh-
I B
mitralvalvesurgeryandCABGshouldbeconsidered.Isolatedmitral .. gradientaorticstenosistoreducemortalityand
.
valvesurgerymaybeconsideredinsymptomaticpatientswithsevere
.. improvesymptoms.594
.
SMRdespiteoptimaltherapyandlowsurgicalrisk.592 .. Itisrecommendedthatthechoicebetween
.
.
Two randomized trials, MITRA-FR and COAPT, evaluated the . TAVIandSAVRbemadebytheHeartTeam,
.
.
effectivenessofpercutaneousedge-to-edgemitralvalverepairplus . accordingtoindividualpatientpreferenceand
. I C
.
OMT compared to OMT alone, in symptomatic patients with . featuresincludingage,surgicalrisk,clinical,ana-
.
.
reducedLVEF(15(cid:2)40%inMITRA-FRand20(cid:2)50%inCOAPT)and . tomicalandproceduralaspects,weighingthe
.
moderate-to-severeorsevereSMR[effectiveregurgitantorificearea .. risksandbenefitsofeachapproach.592
.
(EROA) >_ 20 mm2 in MITRA-FR and EROA >_ 30 mm2 in ... Secondarymitralregurgitation
.
COAPT].610(cid:2)612 MITRA-FR failed to show any benefit from the .. Percutaneousedge-to-edgemitralvalverepair
.
intervention on all-cause mortality or HF hospitalization at 12 .. shouldbeconsideredincarefullyselected
.
months(primaryendpoint;HR1.16,95% CI0.73(cid:2)1.84)andat24 .. patientswithsecondarymitralregurgitation,not
.
months.610,611Incontrast,COAPTshowedasignificantreductionin .. eligibleforsurgeryandnotneedingcoronary IIa B
.
hospitalizationforHFat24months(primaryendpoint;HR0.53,95% .. revascularization,whoaresymptomaticcdespite
.
CI0.40(cid:2)0.70)andmortality(secondaryendpoint;HR0.62,95%CI .. OMTandwhofulfilcriteriadforachievinga
.
0.46(cid:2)0.82).612 Differences in patient selection, concomitant MT, .. reductioninHFhospitalizations.612
.
echocardiographic assessment, procedural issues and severity of ...
InpatientswithHF,severesecondarymitral
S thM eR di in ver re gla inti gon reto sut lth se od feg tr he ee Mof ITLV RAd -il Fa Rtat aio nn dm Ca Oy Abe PTres tp rio an lss .6ib 13le (cid:2)f 6o 15r ......
r tie og nu ,r Cgi Ata Bti Gon anan dd mC itA raD lvw alh vo en sue re gd err yev sa hs oc uu ll dar biz ea-
IIa C
Thus,percutaneousedge-to-edgemitralvalverepairshouldbecon- ...
considered.
sideredforoutcomeimprovementonlyincarefullyselectedpatients ..
. Percutaneousedge-to-edgemitralvalverepair who remain symptomatic (NYHA class II(cid:2)IV) despite OMT, with ..
. maybeconsideredtoimprovesymptomsin
moderate-to-severe or severe SMR (EROA >_30 mm2), favourable ..
. carefullyselectedpatientswithsecondarymitral
.
anatomical conditions, and fulfilling the inclusion criteria of the . . regurgitation,noteligibleforsurgeryandnot IIb C
.
COAPT study (i.e. LVEF 20(cid:2)50%, LV end-systolic diameter <70 .
. needingcoronaryrevascularization,highlysymp-
.
mm,systolicpulmonarypressure<70mmHg,absenceofmoderate .
. tomaticdespiteOMTandwhodonotfulfilcrite-
. orsevereRVdysfunction,absenceofsevereTR,absenceofhaemo- .. riaforreducingHFhospitalization.617
dynamicinstability)(Figure17).615,616 ..
.
.
Percutaneous edge-to-to edge mitral valve repair may also be . CABG=coronaryarterybypassgraft;CAD=coronaryarterydisease;LVEF=left
.
. ventricular ejection fraction; LVESD=left ventricular end-systolic diameter;
considered to improve symptoms in patients with advanced HF, .
.. NYHA=NewYorkHeartAssociation;OMT=optimalmedicaltherapy;SAVR=
severe SMRand severesymptomsdespiteOMT. Inthesepatients, .. surgicalaorticvalvereplacement;TAVI=transcatheteraorticvalveimplantation;
.
cardiac transplantation or LVAD implantation must also be . TR=tricuspidregurgitation.
.
considered.376,617
.. aClassofrecommendation.
.. bLevelofevidence.
Otherpercutaneousmitralvalverepairsystems,suchasindirect .. cNYHAclassII(cid:2)IV.
annuloplasty,areavailablefortreatmentofSMR.Thisapproachhasa ... dAllofthefollowingcriteriamustbefulfilled:LVEF20(cid:2)50%,LVESD<70mm,
shorterlearningcurveandlessertechnicalrequirementsthanpercu-
.... s vy es nt to rl ii cc ulp au rl dm yo sfn ua nr cy tip or ne oss ru sr ee ve< r7 e0 Tm R,m aH bsg e, na cb es oen fc he aeo mf om do ynd ae mra icte ino sr tabse ilv ite yr .6e 12right
taneousedge-to-toedgemitralvalverepairanddoesnotpreclude .
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 68 ---
3666 ESCGuidelines
.
.
12.3.4 Tricuspidregurgitation . BPtargetsareuncertaininbothHFrEFandHFpEF.However,eval-
.
.
Tricuspidregurgitation(TR)canbecausedbyorbeaconsequence . uationofpatient’sageandcomorbidities(i.e.diabetes,CKD,CAD,
.
.
ofRVdysfunctionandHF.ThemanagementofHFwithTRincludes . valvularheartdiseaseandstroke)canbehelpfultopersonalizethe
.
MT (i.e. diuretics,neurohormonalantagonists).Transcatheter ther- .. BP target.4 Every effort should be made to reach target doses of
.
apyandsurgerymaybeconsideredinselectedcases.592Amultidisci- .. evidence-based medications in HFrEF patients, despite slight hypo-
.
plinary Heart Team, including HF specialists, should be considered .. tension.4,633Conversely,inHFpEFpatientswithLVHandlimitedpre-
.
.
forassessmentandtreatmentplanning. . loadreserve,hypotensionshouldbeavoided.
.
.
Tricuspid valve surgery is recommended in patients with severe ..
.
TRrequiringleft-sidedcardiacsurgery.Itshouldbealsoconsidered ..
. 12.5 Stroke
inpatientswithmoderateTRandtricuspidannulusdilatationrequir- ..
.
ingleft-sided cardiacsurgeryand in symptomatic patients withiso- .. HFandstrokefrequentlycoexistbecauseofanoverlapofsharedrisk
latedsevereTR.592However,surgeryinisolatedTRisburdenedby ... factorsandsubsequentmechanisms.519,634Ahigherriskofstrokeis
highin-hospitalmortality(8.8%)althoughtheadvancedstageofHF ... present also in HF patients in SR.39,426,635(cid:2)637 AF confers an addi-
.
may have influenced these data.624 Transcatheter techniques have .. tionalriskandpatientswithHFandAFhaveafive-foldincreasedrisk
.
recentlyemergedaspotentialtreatmentoptionsofTR.Preliminary .. comparedtothecontrolpopulation.519,634,638
.
results show improvement in TR severity and symptoms with low .. Asatemporaltrend,theincidenceofstrokeishigherinthefirst
. complication rates.625 Further prospective studies are needed to .. 30daysafterHFdiagnosisoranepisodeofHFdecompensationand
.
showtheprognosticimpactofthesetreatmentsinHFpatients. .. decreases in the first 6 months following the acute event.637,639
.
.. PatientswithstrokeandHFhavehighermortality,moresevereneu-
.
.. rological deficits and longer hospital stays than those without
.
12.4 Hypertension .. HF.637,640Similarly,patientswithHFandstrokehaveahighermortal-
.
Arterialhypertensionisaleadingriskfactorforthedevelopmentof
.. itythanpatientswithoutstroke.640InCOMMANDER-HF,47.5%of
.
HF.Almosttwo-thirdsofHFpatientshaveapasthistoryofhyperten-
.. strokeswereeitherdisabling,16.5%,orfatal,31%.637
.
sion.104,626ClinicaltrialsevaluatingantihypertensivestrategiesandBP .. Patients with HF and concomitant AF, including paroxysmal AF,
.
targets in patients with HF and hypertension have not been ... haveaCHA 2DS 2-VAScscoreofatleast1andhavethereforeanindi-
performed. .. cationtoanticoagulation.Theindicationtoantithromboticstrategies
.
.
Treatmentof HFrEFissimilarinhypertensiveandnormotensive .. in patients with HF and SR is controversial. In the Warfarin and
.
patients. Recommended medications, including neurohormonal .. AspirininReducedCardiacEjectionFraction(WARCEF)trial,war-
.
antagonistsanddiuretics,loweralsoBP.Lifestylemodifications,such .. farin reduced ischaemic stroke as compared with aspirin, but
.
asweightloss,reducedsodiumintake,andincreasedphysicalactivity, .. increased major haemorrhages and did not influence the primary
.
are useful adjunctive measures.4 Uncontrolled hypertension in .. endpoint of ischaemic stroke, intracerebral haemorrhage, or
patientswithHFrEFisrare,providedthepatientisreceivingOMTat ... death.641 Meta-analyses confirm an increased risk of bleeding out-
.
recommended doses for HF. If further BP lowering is required, in .. weighingischaemicstrokepreventioninplacebo-controlledtrialsin
absence of signs of fluid overload, amlodipine and felodipine have ... patients with HFrEF and SR.642 In COMMANDER-HF, rivaroxaban
.
beenshowntobesafeinHFrEFandmaybeconsidered.570,571Non- .. 2.5 mg b.i.d. did not improve the composite outcome of all-cause
.
dihydropyridineCCBs(diltiazemandverapamil)andcentrallyacting .. mortality, MI or stroke, nor did it favourably influence HF-related
.
agents,suchasmoxonidine,arecontraindicatedastheyareassoci- .. deathsorHFhospitalizations.579Therearenodatatosupportarou-
.
atedwithworseoutcomes.627Alpha-blockershavenoeffectsonsur- .. tinestrategyofanticoagulationinpatientswithHFrEFinSRwhodo
.
vival and are therefore not indicated.143 They can be used for the .. nothavehistoryofparoxysmalAF.However,low-doserivaroxaban
. treatmentofconcomitantprostatichyperplasiabutshouldbewith- .. maybeconsideredinpatientswithconcomitantCCSorperipheral
. drawnincasesofhypotension. .. arterydisease,ahighriskofstrokeandnomajorhaemorrhagicrisk
. HypertensionisthemostimportantcauseofHFpEF,withapreva- .. (seesection12.2).
.
lenceof60%to89%.39PatientswithHFpEFalsofrequentlyhavean .. Patients with visibleintraventricularthrombus orathighthrom-
.
exaggerated hypertensive response to exercise and may present .. boticrisk,suchasthosewithhistoryofperipheralembolismorsome
.
withhypertensiveacutepulmonaryoedema.628,629Antihypertensive .. patientswithPPCMorLVnon-compaction(LVNC),shouldbecon-
.
agents, including ACE-I, ARBs, beta-blockers, CCB, and diuretics
.. sideredforanticoagulation.3,643(cid:2)645
.
reduce the incidence of HF.630,631 Reducing BP leads also to LVH ..
.
regression,thedegreeofwhichdependsontheclassofdrugused.4 ..
.
.
ARBs,ACE-I,andCCBscause moreeffectiveLVHregressionthan .
. 13 Non-cardiovascular
.
beta-blockers or diuretics.632 Poorly controlled hypertension may ..
precipitateepisodesofdecompensation.Causesofsecondaryhyper-
... comorbidities
.
tension,suchasrenalvascularorparenchymaldisease,primaryaldos- ..
teronismandobstructivesleepapnoea(OSA),shouldberuledout
... 13.1 Diabetes
.
or,ifconfirmed,consideredfortreatment.Treatmentofhyperten- .. TreatmentofHFissimilarinpatientswithandwithoutdiabetes.6,646
.
sion is an important issue in patients with HFpEF, but the optimal .. Conversely,antidiabeticdrugsdifferintheireffectsinpatientswith
.
treatment strategy is uncertain. The treatment strategy used in .. HF and preference must be given to drugs that are both safe and
.
HFrEFshouldalsobeconsideredinHFpEF.4 . reduceHF-relatedevents.6,646,647
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 69 ---
ESCGuidelines 3667
.
The SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin, .. analyses.658,659 These drugs are therefore not recommended to
.
ertugliflozinandsotagliflozinwerestudiedinpatientswithestablished .. reduceCVeventsindiabeticpatientswithHF.
.
CV disease in the EMPA-REG OUTCOME and VERTIS-CV trials, .. Glucagon-likepeptide-1(GLP-1)receptoragonistsreducetherisk
.
withestablishedCVdiseaseorCVriskfactorsintheCANVASand .. ofMI,stroke,andCVdeathinpatientswithdiabetes,althoughprob-
.
DECLARE-TIMI58trials,andwithCKDandCVriskintheSCORED .. ably do not reduce incident HF.6,660 Liraglutide had no effect on
.
trial,respectively.293(cid:2)297Asmallproportionofpatientshadahistory .. LVEF,increasedheartrate,andincreasedseriouscardiaceventsina
.
ofHF.Empagliflozinandcanagliflozinreducedtheprimarycomposite .. randomizedplacebo-controlledtrialin241patientswithHFrEFwith
.
endpointofmajorCVadverse events, including CVdeath ornon- .. and without diabetes.661 Neutral results on the primary endpoint
.
.
fatal MI or non-fatal stroke, and HF hospitalizations in EMPA-REG . werefoundinanothertrialin300patientswithanumericalincrease
.
OUTCOME and CANVAS, respectively.293,294 Empagliflozin also .. indeathsandHFhospitalizations,comparedwithplacebo.662GLP-1
.
reducedall-causedeathorCVdeathalone.293Theeffectsonthepri- .. receptoragonistsarethereforenotrecommendedforthepreven-
.
.
mary endpoint were driven by the reduction in HF-related . tionofHFevents.
.
events.293,294 In DECLARE-TIMI 58, dapagliflozin did not reduce .. Insulinis needed in patientswithtype 1diabetesand tocontrol
.
.
majorCVeventsbutreducedtheco-primaryefficacyendpointofCV . hyperglycaemia in some patients with type 2 diabetes, especially
.
death or HF hospitalization and HF hospitalization alone.295 In .. when beta-cell function is exhausted. It is a sodium-retaining hor-
.
.
VERTIS-CV,neithertheprimarymajorCVeventendpointnorthe . moneandconcernhasbeenraisedthatitmayexacerbatefluidreten-
.
.
key secondary outcome of CV death or HF hospitalization were . tioninpatientswithHF.However,inaRCTthatincludedpatients
.
.
reducedsignificantlybyertugliflozin,althoughtherewasastatistically . withtype2diabetes,impairedglucosetolerance,orimpairedfasting .
.
significant reduction in HFhospitalization and repeated hospitaliza- . glucose, insulin did not increase the risk of incident HF.663 Use of
.
.
tions.297,648 In SCORED, sotagliflozin reduced CV deaths and HF .. insulinwasassociatedwithpooreroutcomesinretrospectiveanaly-
.
hospitalizations.296Inameta-analysisofthesetrialsandonefurther .. sesofrandomizedtrialsandadministrativedatabases.664,665Ifinsulin
.
trial in patients with CKD (CREDENCE), overall SGLT2 inhibitors .. isneededinapatientwithHF,thepatientshouldbemonitoredfor
.
reduced HF and CV hospitalization by 22%.649 SGLT2 inhibitors .. evidenceofworseningofHFaftertreatmentinitiation.
.
werewelltolerated,althoughtheymaycausegenitalfungalskininfec- .. Sulfonylureaswere associated with a higher risk ofHFeventsin
.
tionsand,rarely,diabeticketoacidosis.293(cid:2)295Trialresultswithdapa- .. someanalyses.666,667Therefore,theyarenotapreferredtreatment
.
gliflozin and empagliflozin in patients with HFrEF, with or without .. inpatientswithHFand,ifneeded,patientsshouldbemonitoredfor
.
diabetes,andwiththeSGLT1/2inhibitorsotagliflozininpatientswith .. evidence of worsening of HF after treatment initiation.6,646
.
type2diabetesstabilizedafterhospitalizationforacuteHForwithin .. Thiazolidinediones (glitazones) cause sodium and water retention
.
3 days after discharge, further support the administration of these .. andanincreased riskof worsening HFand hospitalization.668 They
.
agents(seesection5.3.5andsection11.3.11).108,109,136 .. arecontraindicatedinpatientswithHF.
.
.
EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and
VERTIS-CV also showed a reduction in worsening renal function, ..
end-stage renal disease or death from renal causes, with SGLT2
... Recommendationsforthetreatmentofdiabetesin
. heartfailure
inhibitors. ..
.
Basedontheseresults,theSGLTinhibitorscanagliflozin,dapagli- ...
Recommendation Classa Levelb
flozin, empagliflozin, ertugliflozin or sotagliflozin are recommended ..
.
to prevent HF and CV death and worsening kidney function in .. SGLT2inhibitors(canagliflozin,dapagliflozin,
.
patientswithtype2diabetesandCVdiseaseand/orCVriskfactors, .. empagliflozin,ertugliflozin,sotagliflozin)arerec-
.
or CKD. Dapagliflozin and empagliflozin are also indicated for the ... ommendedinpatientswithT2DMatriskofCV
I A
treatment of patients with type 2 diabetes and HFrEF (see .. eventstoreducehospitalizationsforHF,major
. section 5.3.5 and section 11.2.4) and sotagliflozin was shown to .. CVevents,end-stagerenaldysfunction,andCV
. reduceCVdeathsandHFrehospitalizationsinpatientsrecentlyhos- .. death.293(cid:2)297
.
pitalizedforHF.6,296,646,647,650 .. SGLT2inhibitors(dapagliflozin,empagliflozin,
.
.
Metformin is thought to be safe in patients with HF, compared . andsotagliflozin)arerecommendedinpatients . I A
withinsulinandsulfonylureas,basedonobservationalstudies.651,652 .. withT2DMandHFrEFtoreducehospitalizations
.
However,itisnotrecommendedinpatientswithaneGFR<30mL/ .. forHFandCVdeath.108,109,136
.
min/1.73m2orhepaticimpairmentbecauseoftheriskoflacticacido- ..
sis.Ithasnotbeenstudiedincontrolledoutcometrials,todate.6,646
... CV=cardiovascular;HF=heartfailure;HFrEF=heartfailurewithreducedejec-
. tionfraction;SGLT2=sodium-glucoseco-transporter2;T2DM=type2diabetes
.
Regardingdipeptidylpeptidase-4(DPP-4)inhibitors,HFhospital- . mellitus.
.
izationswereincreasedby27%inonetrialwithsaxagliptininpatients
.. aClassofrecommendation.
withdiabetes.653However,nodifferenceoverplaceboforHFevents
... bLevelofevidence.
.
.
wasfoundwithalogliptin,sitagliptin,andlinagliptin.654(cid:2)656Vidagliptin .
.
.
was associated with an increase in LV volumes and a numerically . 13.2 Thyroid disorders
.
.
greaternumberofdeathsandCVeventsinasmalltrialinpatients .. AssessmentofthyroidfunctionisrecommendedinallpatientswithHF
.
with diabetes and HF.657 Overall, the effects on mortality or CV .. as both hypo- and hyperthyroidism may cause or precipitate HF.669
.
events were neutral in the DPP-4 inhibitor trials and meta- .. Subclinical hypothyroidism and isolated low triiodothyronine levels
.
.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 70 ---
3668 ESCGuidelines
.
.
were associated with poorer outcomes in observational studies in . Cachexiaisdefinedasa‘complexmetabolicsyndromeassociated
.
patients with HF.670,671 Treatment of thyroid disorders should be .. with underlying illnessand characterized by loss of muscle withor
.
guidedbygeneralendocrineguidelines.Therearenorandomizedtrials .. without loss of fat mass’.694 Its major clinical feature is a >5%
.
.
evaluating the efficacy of thyroid replacement therapy in subclinical . oedema-free body weight loss during the previous 12 months or
.
hypothyroidism,butthereisageneralagreementtocorrectitwhen .. less.694,695Cachexiaisageneralizedwastingprocessthatmaycoexist
.
.
theTSHis>10mIU/L,particularlyinpatients<70years.Correction . withfrailtyandmayoccurin5(cid:2)15%ofpatientswithHF,especially
.
mayalsobeconsideredatlowerTSHlevels(7(cid:2)10mIU/L).672(cid:2)674 .. thosewithHFrEFandmoreadvanceddiseasestatus.Itisassociated
.
.
. withreducedfunctionalcapacityanddecreasedsurvival.695(cid:2)698Asit
.
13.3 Obesity ...
isassociatedwithotherchronicdiseases,suchascancer,alternative,
.
ObesityisariskfactorforhypertensionandCADandisalsoassoci- .. non-cardiaccausesforcachexiashouldalwaysbeinvestigated.699
.
atedwithanincreasedriskofHF.Thereispossiblyastrongerassocia- .. Sarcopeniaisdefinedbythepresenceoflowmusclemasstogether
.
tionwithHFpEF.258,675(cid:2)677OnceobesepatientshaveHF,anobesity .. with low muscle function, strength, or performance.698 It is usually
. paradoxhasbeendescribedsuchthatoverweightormildly/moder- .. identifiedbyanappendicularskeletalmusclemass,definedasthesum
.
atelyobesepatientshaveabetterprognosisthanleanerpatients,par- .. ofthemusclemassofthefourlimbs,2standarddeviationbelowthe
.
ticularlycomparedwiththosewhoareunderweight.678,679However, .. meanofahealthyreferencegroupaged18(cid:2)40yearswithacut-off
.
othervariablesmayinfluencethisrelationshipandtheobesitypara- .. value of 7.26 kg/m2 for men.688,700,701 It occurs physiologically with
. dox is not observed in patients with diabetes.680,681 Second, BMI .. aging.However,itisacceleratedbychronicdiseases,suchascancer
.
does not take into account body composition, e.g. the relation .. andHF.Sarcopeniacanbefoundin20(cid:2)50%ofpatientswithHFrEF
.
betweenleanskeletalmusclemassandfatmass.Obesepatientswho .. andisoftenassociatedwithfrailtyandincreasedmorbidityandmortal-
.
arefitandhaveapreservedskeletalmusclemasshavebetterprogno- .. ity.Itisamajordeterminantofoutcomesoutweighingtheeffectof
.
sis than obese sarcopenic patients.682 Waist circumference or the .. bodyweightandBMI.684,698,701,702Sofar,themosteffectivestrategy
.
.
waist-to-hip ratio, measuring visceral obesity, is less influenced by . forsarcopeniatreatmentisresistanceexercisetraining,possiblycom-
.
muscle mass and may have a stronger relationship with outcomes .. binedwithaproteinintakeof1(cid:2)1.5g/kg/day.698,703Drugtreatments,
.
thanBMI,especiallyinfemalepatients.683,684 .. including anabolic compounds like testosterone, growth hormone,
.
.
Bodyfathasamajorimpactonthediagnosticandprognosticvalue . ghrelinreceptoragonists,weretestedinsmallstudies,showingfavour-
.
.
ofmultipleparameters.ObesepatientswithHFhavelowerNPcon- . able results mostly in terms of exercise capacity and muscle
.
centrationsduetoincreasedexpressionofclearancereceptorsand .. strength.697,703(cid:2)705Therearenodatashowingafavourableimpactof
.
.
augmentedpeptidedegradationbytheadiposetissue.74Peakoxygen . sarcopenia treatment on outcomes. However, exercise training has
.
consumption adjusted for body weight underestimates exercise ... favourableeffectsinpatientswithHF(seesection9.4).95,323(cid:2)329
.
capacity in obese patients and an adjustment for lean body mass ..
shouldbeusedforriskstratification.96 ... 13.5 Iron deficiency and anaemia
.
ObesitymaybeamajorcauseofHFpEFandobeseHFpEFpatients .. IrondeficiencyandanaemiaarecommoninpatientswithHF,being
.
display several pathophysiologic mechanisms that differ from non- .. independentlyassociatedwithreducedexercisecapacity,recurrent
.
obese patients with HFpEF.258,675(cid:2)677,685 Caloric restriction and .. HF hospitalizations, and high CV and all-cause mortality.706,707
.
exercisetraininghadadditivebeneficialeffectsonexercisecapacity .. According to the World Health Organization criteria, anaemia is
.
andQOLofpatientswithobesityandHFpEFinarandomizedtrial.337 .. defined as a haemoglobin concentration <12 g/dL in women and
.
.. <13 g/dL in men. In patients with HF, iron deficiency is defined as
.
13.4 Frailty, cachexia, sarcopenia .. eitheraserumferritinconcentration<100ng/mLor100(cid:2)299ng/
.
Frailty is a multidimensional dynamic state, independent of age, that .. mL with transferrin saturation (TSAT) <20%.708(cid:2)710 Ferritin tissue
. makestheindividualmorevulnerabletotheeffectofstressors.686HF .. expressionandconcentrationintheperipheralbloodisincreasedby
. .
andfrailtyaretwodistinctyetcommonlyassociatedconditions.The . inflammationandseveraldisorderssuchasinfection,cancer,liverdis-
. .
assessmentof frailtyin patientswithHF is crucial as itis associated . ease,andHFitself.Hence,highercut-offvalueshavebeenappliedfor
.
withbothunfavourableoutcomesandreducedaccessto,andtoler- .. thedefinitionofirondeficiencyinpatientswithHF.709(cid:2)711Another
.
.
ance of, treatments. Several tools have been proposed for frailty . markerreflectingdepletedintracellularironcanbehighserumsolu-
.
.
screeningandassessmentindifferentchronicconditions,includingHF. . bletransferrinreceptors,whichderivesfromproteolysisofthemem-
.
.
TheHFAofESChasdevelopedaHF-specifictoolbasedonfourmajor . branetransferrinreceptor.Its synthesisisincreased incase ofiron
.
domains,clinical,psycho-cognitive,functional,andsocial.686 .. deficiency and is not affected by inflammation. High serum soluble
.
.
FrailtyismoreprevalentinpatientswithHFthaninthegeneralpop- . transferrin receptors identify patients at high risk of death beyond
.
.
ulationand may occur in up to 45% of the patients, according to a . standard prognostic variables.711,712 However, its applicability for
.
.
recentmeta-analysis.687,688PatientswithHFareuptosixtimesmore .. ironsupplementationtherapyhasnotbeendemonstratedyet.
.
likelytobefrail,andfrailpeoplehaveasignificantlyincreasedriskof .. Irondeficiency,whichcanbepresentindependentlyofanaemia,is
.
developingHF.689,690Frailtyisassociatedwithahigherriskofdeath, .. presentinupto55%ofchronicHFpatientsandinupto80%ofthose
.
hospitalizations,andfunctionaldeclineaswellaswithalongerdura- .. withAHF.713(cid:2)716Itmaybecausedbyincreasedloss,reducedintake
.
tionofhospitalstay.691(cid:2)693ThetreatmentoffrailtyinHFshouldbe .. orabsorption(i.e.malnutrition,gutcongestion)and/orimpairediron
.
multifactorialandtargetedtoitsmaincomponentsandmayinclude .. metabolism caused by the chronic inflammatory activation of HF,
.
physicalrehabilitationwithexercisetraining,nutritionalsupplementa- .. althoughtheexactcauseofirondeficiencyinHFremainsunknown.
.
tionaswellasanindividualizedapproachtotreatingcomorbidities.686 . Irondeficiencymayimpairfunctionalcapacity,precipitatecirculatory
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 71 ---
ESCGuidelines 3669
.
decompensation,promoteskeletalmuscledysfunction,andisassoci- .. offirstHFhospitalizationorCVdeath(HR0.80,95%CI0.66(cid:2)0.98,
.
atedwithfrailty,irrespectiveofanaemia.716(cid:2)718 .. P = 0.030) and total HF hospitalizations (rate ratio 0.74, 95% CI
.
ItisrecommendedthatallpatientswithHFareregularlyscreened .. 0.58(cid:2)0.94,P = 0.013).512Therefore,ironsupplementationwithi.v.
.
foranaemiaandirondeficiencywithfullbloodcount,serumferritin .. ferriccarboxymaltoseshouldbeconsideredfortheimprovementof
.
concentration,andTSAT.Thedetectionofanaemiaand/orirondefi- .. symptoms,exercisecapacity,andQOLinpatientswithHFandLVEF
.
ciencyshouldpromptappropriateinvestigationtodefinetheircause. .. <45%.ItshouldalsobeconsideredforthereductionofHFrehospi-
.
Darbepoetin-alphafailedtoreduceall-causedeathorHFhospital- .. talizationsinpatientswithLVEF<50%recentlyhospitalizedforwor-
.
izationandincreasedtheriskofthromboemboliceventsintheonly .. seningHF.Ongoingtrialsareexpectedtoprovidemoreevidenceon
.
.
large-scalerandomizedtrialinpatientswithHFrEFandmildtomod- . theeffectsofferriccarboxymaltoseinpatientswithHFpEF.Inaddi-
.
erate anaemia.719 As a result, erythropoietin stimulating agents are .. tion,largeoutcomestrialswithotherironformulationsareongoing
.
notindicatedforthetreatmentofanaemiainHF. .. in HFrEF, HFpEF, and AHF.727 Oraliron therapy isnot effectivein
.
.
. ironrepletionanddidnotimproveexercisecapacityinpatientswith
.
.. HFrEFandirondeficiency.728Itis thereforenotrecommended for
.
Recommendationsforthemanagementofanaemiaand .. thetreatmentofirondeficiencyinthepatientswithHF.
.
irondeficiencyinpatientswithheartfailure .
.
.
.
.
Recommendations Classa Levelb ..
. 13.6 Kidney dysfunction
.
.
ItisrecommendedthatallpatientswithHFbe .. CKDandHFfrequentlycoexist.471,707,729Theysharecommonrisk
.
periodicallyscreenedforanaemiaandirondefi- I C ... factors,suchasdiabetesorhypertension.CKDmayworsenCVfunc-
ciencywithafullbloodcount,serumferritin .. tioncausinghypertensionandvascularcalcification.HFmayworsen
.
concentration,andTSAT. .. renalfunction,throughtheeffectsofneurohormonalandinflamma-
.
Intravenousironsupplementationwithferric .. tory activation, increased venous pressure and hypoperfusion.
.
carboxymaltoseshouldbeconsideredinsymp- .. Oxidative stress and fibrosis likely play a major role as pathogenic
.
tomaticpatientswithLVEF<45%andirondefi- .. mechanismsinHFwithCKD.730,731
.
ciency,definedasserumferritin<100ng/mLor IIa A .. While CKD and worsening renal function both appear more
.
.
serumferritin100(cid:2)299ng/mLwithTSAT . commoninHFpEFascomparedtoinHFmrEFandHFrEF,perhaps
.
.
<20%,toalleviateHFsymptoms,improveexer- .. duetosharedpathophysiologicalmechanisms,theyappeartobeless
cisecapacityandQOL.720,722,724 ... associated with worse outcomes in HFpEF than in HFmrEF and
.
Intravenousironsupplementationwithferric .. HFrEF.732,733
.
carboxymaltoseshouldbeconsideredinsymp- .. CKDisamajorindependentdeterminantofincreasedmortalityand
.
tomaticHFpatientsrecentlyhospitalizedforHF .. morbidity in HF.471,734(cid:2)736 However, there are settings in which
.
andwithLVEF<50%andirondeficiency,defined IIa B .. changesinserumcreatininearenotassociatedwithworseoutcomes.
.
asserumferritin<100ng/mLorserumferritin .. WhenRAASinhibitors,ARNIorSGLT2inhibitorsarestarted,theini-
.
100(cid:2)299ng/mLwithTSAT<20%,toreduce .. tialdecreaseintheglomerularfiltrationpressuremaydecreaseGFR
.
theriskofHFhospitalization.512 .. andincreaseserumcreatinine.However,thesechangesaregenerally
.
.. transient and occur despite improvement in patient outcomes and
H TSF A= Th =ea tr rt anfa si fl eu rr re in;L sV atE uF ra= til oe nft .ventricularejectionfraction;QOL=qualityoflife; ....
slowerworseningofrenalfunctioninthelongterm.Forinstance,in
aClassofrecommendation. .. EMPEROR-Reduced, the placebo-corrected eGFR dip induced by
.
bLevelofevidence. .. empagliflozinatweek4wasof2.4mL/min/1.73m2forpatientswith
.
.. CKDand2.7mL/min/1.73m2forthosewithoutCKD,corresponding
.
.
. toadecreasefrombaselineof5.2%and3.8%,respectively.Thiswas
.
RCTs haveshown that iron supplementation with i.v. ferric car- .. followedbyaslowerslopeofeGFRdeclineandbyareducedrateof
.
boxymaltoseissafeandimprovessymptoms,exercisecapacity,and .. thecompositekidneyoutcomewithempagliflozinvs.placebo,withno
.
QOL of patients with HFrEF and iron deficiency.720(cid:2)723 Meta- .. differencebetweenpatientswithorwithoutCKDatbaseline.109,737
.
analysesofRCTsshowedalsoareductionintheriskofthecombined .. Thus, with respect to the initiation of RAAS inhibitors, ARNI or
.
endpointsofall-causedeathorCVhospitalization,CVdeathorHF .. SGLT2 inhibitors, a transient decrease in renal function should not
.
hospitalization, CV death or recurrent CV or HF hospitaliza- .. prompttheirinterruption.Anincreaseinserumcreatinineof<50%
.
tions.724,725 The favourable effects of iron supplementation were .. abovebaseline,aslongasitis<266lmol/L(3mg/dL),oradecreasein
.
independentfromanaemiacoexistence.726InAFFIRM-AHF,patients ... eGFRof<10%frombaseline,aslongaseGFRis>25mL/min/1.73m2,
.
hospitalizedforHFwithLVEF<50%andconcomitantirondeficiency .. canbeconsideredasacceptable(seesection5.3andSupplementary
.
wererandomizedtoi.v.ferriccarboxymaltoseorplacebo,repeated .. Table 8).Also, with respect to diuretic therapy, small and transient
.
at6-andthen12-weekintervalsifindicatedaccordingtorepeatiron .. risesinserumcreatinineduringtreatmentofacuteHFarenotassoci-
studies.512 Administration of ferric carboxymaltose did not signifi- ... ated with poorer outcomes when the patient is free of
.
cantlyreducetheprimarycompositeoutcomeoftotalHFhospital- .. congestion.108,109,460(cid:2)462,471,729,737(cid:2)740
.
izations and CV death at 52 weeks (rate ratio 0.79, 95% CI .. RandomizedtrialshaveshownthatpatientswithHFandconcomi-
.
0.62(cid:2)1.01,P = 0.059).However,itreducedthecompositeendpoint . tantCKDareathigherriskofeventsbutthebeneficialeffectsofMT
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 72 ---
3670 ESCGuidelines
.
aresimilar,ifnotgreater,thaninthepatientswithnormalrenalfunc- .. with HF appears to be less than 5%,757 but the incidence is much
.
tion.206,471,741,742 Beta-blockers reduce mortality in HFrEF patients .. higher,atupto40%inchronicHFand73%inCKDoverfollow-up
.
.
with moderate (eGFR 45(cid:2)59 mL/min/1.73 m2) and moderately .. durationsofapproximately1year.753,756,757,763(cid:2)765InPARADIGM-
.
severe (eGFR 30(cid:2)44 mL/min/1.73 m2) renal dysfunction, whereas .. HF,treatmentwithsacubitril/valsartanwasassociatedwithlowerrisk
.
limited evidence is available regarding patients with severe renal .. ofseverehyperkalaemia,comparedwithenalapril.128Life-threatening
.
impairment (eGFR <30 mL/min/1.73 m2).743 Sacubitril/valsartan, .. hyperkalaemiarequiresimmediatetreatmentwithacombinationof
.
compared with enalapril, led to a slower decline in renal function, .. calciumcarbonateand/orsodiumbicarbonate,insulin,withorwith-
.
despiteaslightincreaseintheurinaryalbumin/creatinineratio,and .. out glucose, and beta adrenoceptor agonists [e.g. salbutamol, off-
.
improvedCVoutcomestoasimilarextentinpatientswithCKDvs. .. label use in some European Union (EU) countries]. These agents
.
theothersinPARADIGM-HF.127SGLT2inhibitorsleadtoaslower .. favourpotassiumentryintothecellsanddonotincreasepotassium
.
decline in renal function, compared with placebo, both in patients .. excretion.Thus,theyonlyprovidetemporarybenefitandrebound
.
with HFrEF and in those with CKD.108,109,737,738,744 The improve- .. hyperkalaemia can occur after few hours. Loop diuretics can be
.
ment in cardiac output after CRT or LVAD implantation may be .. administeredtofacilitatepotassiumloss.
.
associated with, at least, a transient improvement in renal func- .. Potassiumbindersbindtopotassiuminthe gastrointestinaltract
.
tion.471,745,746ThebenefitsofICDsmaybereducedinpatientswith .. reducing its absorption. They can be used for acute and chronic
.
.
severe renal dysfunction because of the competing risk of non- . potassiumlowering.Theyincludesodiumpolystyrenesulfonate,cal-
. arrhythmiccausesofdeath.747(cid:2)749 .. ciumpolystyrenesulfonate,andthemuchbettertoleratedpatiromer
.
.
There is little direct evidence to support any recommendations . sorbitexcalciumandsodiumzirconiumcyclosilicate(SZC).Sodium
.
.
for treatment of HF patients with severe CKD as to date, RCTs . polystyrene sulfonate is still indicated in anuric or severely oliguric
.
.
excludedpatientswithadvancedstagesofCKD,i.e.eGFR<30mL/ . patients,butitshouldnotbeusedinthemediumorlongtermasit
.
min/1.73 m2 (Supplementary Table 23). Cut-off values for inclusion .. may cause severe gastrointestinal side effects, including bowel
.
were lower in recent trials: 25 mL/min/1.73 m2 in DAPA-CKD, .. necrosis.760 Patiromer or SZC increase faecal potassium excretion
.
20mL/min/1.73m2inEMPEROR-ReducedandGALACTIC-HF,and .. andactmainlyinthecolon.Bothcompoundsareeffectiveinnormal-
.
15 mL/min/1.73 m2 in VICTORIA, respectively.109,141,737,738,750 .. izingelevatedpotassiumlevels,maintainingnormokalaemiaovertime
.
.
Despitedifferencesinbaselinecharacteristicsbetweenpatientswith . andpreventingtherecurrenceofhyperkalaemiaandcanbeconsid-
.
.
severely impaired renal function and the others, no interaction .. eredfortreatmentofhyperkalaemia766(cid:2)768(seeSupplementaryTable
.
betweendrugeffectsandrenalfunctionwasnotedinsubgroupanaly- .. 24).
.
sisofthesetrials.109,141,738,750 .. Renal dysfunction and hyperkalaemia are the major causes of
.
.. underuse of RAAS inhibitors, particularly MRA, in clinical
.
13.7 Electrolyte disorders:
... practice.342,753,758,769(cid:2)771 Administrationofthe potassium-lowering
.. agents,patiromerorSZC,mayallowtheirinitiationoruptitrationin
hypokalaemia, hyperkalaemia, .
.. alargerproportionofpatients.Thishypothesiswastestedindouble-
hyponatraemia, hypochloraemia ...
blind, placebo-controlled, randomized trials with patiromer or pla-
.
Electrolyte disturbances are frequent in patients with HF and may .. ceboadministrationtopatientswithCKDandhyperkalaemia,ordis-
.
oftenbeiatrogenic.751SerumpotassiumlevelshaveaU-shapedrela- .. continuation of RAAS inhibitors for hyperkalaemia, and with an
.
tionwithmortalitywiththelowestriskofdeathwithinarelatively .. indication forspironolactone for HFand/or resistant hypertension.
.
narrowrangeof4to5mmol/L.752(cid:2)758 .. Patiromerwasmorelikelytolowerserumpotassiumanddecreased
.
. Hypokalaemia is defined as serum potassium <3.5 mmol/L and . episodes of hyperkalaemia than spironolactone initiation and
.
mayoccurinupto50%ofpatientswithHF.759Hypokalaemiaisoften .. uptitration.772(cid:2)775 The ongoing RCT DIAMOND (NCT03888066)
.
.
induced by loop and thiazide diuretic administration. It may cause . is testing the impact on clinical outcomes of a strategy based on
. .
lethal ventricular arrhythmias and increase CV mortality. Its treat- . patiromer administration, compared with placebo, in patients with
. .
ment includes the use of RAAS inhibitors, potassium-sparing diu- . HFrEF who are hyperkalaemic while on RAAS inhibitors orwith a
.
.
retics,andprescriptionoforalpotassiumsupplements(i.e.potassium . historyofhyperkalaemiawithsubsequentreductionordiscontinua-
.
chloridetablets).Whenoraladministrationisnotpossible,potassium .. tionofaRAASinhibitor776,777(seeSupplementarytext13.1). .
.
supplementation by infusion may be necessary (20 to 40 mmol of . Hyponatraemiaisdefinedasaserumsodiumconcentrationlower
.
.
potassiumin250(cid:2)1000mLofnormalsaline).Potassium-richsolu- . than136mmol/L.ItiscommoninHFandmaybepresentinupto
.
.
tionshouldbeinfusedatslowratethroughalargeveinusingavenous . 30%ofpatientsadmittedtohospitalwithHF.Itreflectsneurohormo-
.
.
catheter. .. nal activation and is a powerful independent marker of poor out-
.
Hyperkalaemiaisdefinedasserumpotassium>5mmol/Landcan .. comesinpatientswithacuteorchronicHF.778,779
.
be classified as mild (>5.0 to <5.5 mmol/L), moderate (5.5 to 6.0 .. Severehyponatraemiamaycauseneurologicsymptoms(seizures,
.
mmol/L), or severe (>6.0 mmol/L).760 It is associated with an .. obtundation, delirium) due to cerebral oedema and may require
.
increased risk of hospitalization and death.752,753,755,756,761,762 .. immediate treatment with hypertonic saline with serum sodium
.
Hyperkalaemia can be associated with the administration of RAAS .. increases by 1(cid:2)2 mmol/L per hour, thoughless than 8 mmol/Lin
.
inhibitors, CKD and increased absorption.760 Among patients with .. 24 h as a more rapid correction increases the risk of myelinolysis.
.
HF,theprevalenceofhyperkalaemiaatanygiventimeamongpatients . Intravenous treatment is not required when hyponatraemia is less
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 73 ---
ESCGuidelines 3671
.
.
severe,e.g.>124mmol/L,andintheabsenceofsymptoms.Asthe . seem to increase CV events, including HF, in patients at high
.
pathogenesis of hyponatraemia in HF is dilutional, e.g. caused by .. risk.803,804Moreover,optimalCOPDmanagementcanimprovecar-
.
water retention induced by increased vasopressin secretion, treat- .. diacfunction.805
.
.
mentisbasedonwaterrestrictionorvasopressinantagonists.Fluid . Sleep-disordered breathing occurs in more than one third of
.
.
restrictions to less than 800(cid:2)1000 mL/day may be indicated to . patientswithHFandisevenmoreprevalentinpatientswithAHF.
.
.
achieve a negative water balance and treat hyponatraemia. Water . Themostcommontypesare:centralsleepapnoea(CSA,similarto
.
.
restrictionwasassociatedwithimprovedQOLinasmall,random- . Cheyne-Stokesrespiration),OSA,andamixedpatternofthetwo.
.
.
izedstudybutwithonlyslightincreasesinserumsodiuminanobser- . CSAandOSAhavebeenshowntobeassociatedwithaworseprog-
.
.
vationalregistry.780,781 Tolvaptan, an orally active selective arginine .. nosisinHF.OSAisassociatedwithanincreasedriskofincidentHFin
.
vasopressin V2 receptor antagonist, can be considered to increase .. men.CSAisthemostcommonformofsleep-disorderedbreathing
.
serumsodiumanddiuresisinpatientswithpersistenthyponatraemia .. inHFrEFandHFmrEFisthemostcommoncauseofCSA.806,807
.
andcongestion.However,noeffectsonoutcomeshavebeenshown .. PatientswithHFcanbeinvestigatedforsleep-disorderedbreath-
. inRCTs782(cid:2)785(seeSupplementarytext13.1).Theinfusionofhyper- .. ing.Historytakingshouldinvolvepartners.Questionnairesareinstru-
.
tonic saline combined with loop diuretics was associated with an .. mental in identifying patients at risk. Home monitoring can usually
.
increaseinserumsodiumlevelsandgreaterdiureticefficacyinsmall .. identifyanddistinguishthetypeofsleepapnoea.However,overnight
.
trialsandobservationalstudies.786(cid:2)788 .. polysomnographyremainsthedefinitiveinvestigation.807Theuseof
. Hypochloraemia(<96mmol/L)isapowerfulindependentpredic- .. adaptiveservo-ventilationinpatientswithHFrEFandpredominantly
.
tor of mortality in patients with acute and chronic HF.439,789(cid:2)792 .. CSAisnotrecommended,basedontheresultsofSERVE-HF,which
.
Serumchloridemayhaveadirectroleinthecontrolofreninsecre- .. wasneutralregardingthecompositeprimaryendpointofdeathfrom
.
tion and the response tolooporthiazide diuretics.439,793 Thecar- .. anycause orlifesavingCVintervention, but showed anincrease in
.
.
bonic anhydrase inhibitor acetazolamide increases chloride . bothall-causemortalityandCVmortalitywithadaptiveservo-venti-
.
reabsorptioncausingagreaterbicarbonateandsodiumexcretionin .. lation.808Transvenousphrenicnervestimulationwastestedinapro-
.
.
theproximaltubuleofthenephron.Itcanincreaseserumchloride . spective, multicentre, randomized trial involving 151 patients with
.
levelsanddiuresisinpatientswithsevereHFatriskofdiureticresist- .. CSA.809 The primary efficacy endpoint was the reduction of the
.
ance.145,794Itiscurrentlybeingtestedinamulticentrerandomized .. apnoea-hypopnoea index from baseline to 6 months and was
.
studyindecompensatedHF.469 .. achievedbyalargerpercentageofpatientswiththeactivetreatment.
.
.
. OthermeasurementsofsleepqualityandQOLwereimprovedand
.
.
. nodifferenceinanysafetyendpointwasfoundbetweenactivetreat-
.
13.8 Lung disease, sleep-disordered .. mentandcontrol.809Similarresultswereobservedinthe96patients
.
breathing .. withHF.810
.
.
Overall,COPDaffectsabout20%ofpatientswithHFandhasamajor .. Patients with HFrEF being considered for a sleep-disordered
.
impact on symptoms and outcomes.795(cid:2)797 Due to the overlap in .. breathing treatment with positive pressure airway mask must
.
symptomsandsigns,thedifferentiationbetweenHFandCOPDmay .. undergo formalsleep study to document thepredominant type of
.
be difficult. Pulmonary function testing with spirometry is recom- .. sleep apnoea (central vs. obstructive). When sleep-disordered
.
mended as the first diagnostic tool and should be considered in .. breathing is caused by OSA, nocturnalhypoxaemia can be treated
.
patients with suspected COPD. For adequate interpretation, it .. withnocturnaloxygensupplementation,continuouspositiveairway
.
shouldbeperformedinstableandeuvolaemicpatientstoavoidcon- .. pressure, bi-level positive airway pressure, and adaptive servo-
.
gestionrelatedtoobstructivepulmonaryfunctionpatterns.Ifthereis .. ventilation.However,noneoftheseinterventionshasbeenshownto
.
uncertaintyaboutthereversibilityofairflowobstruction,pneumol- .. have beneficial effects on outcomes in HF.807 When sleep-
. ogy referral for more sophisticated tests (bronchodilatatory test, .. disordered breathing is caused by CSA, positive pressure airway
. bronchialprovocationtests,diffusioncapacity)iswarranted.798,799 .. masks are contraindicated in HFrEF patients.808 In these patients,
. Treatment of HF is generally well tolerated in COPD.800 Beta- .. implantablephrenicnervestimulationcanbeconsideredforsympto-
.
.
blockers can worsen pulmonary function in individual patients but . maticrelief.
.
.
arenotcontraindicatedineitherCOPDorasthma,asstatedinthe .
.
.
GlobalinitiativeforchronicObstructiveLungDisease(GOLD)and .
.
. 13.9 Hyperlipidaemia and lipid-modifying
theGlobal INitiative for Asthma (GINA), respectively.801,802 GINA .
.
statesthatasthmashouldnotberegardedasanabsolutecontraindi-
... therapy
.
cationtotheuseofcardioselectivebeta-blockers(bisoprolol,meto- .. TwolargeRCTs,includingmainlypatientswithHFrEF,aswellasa
.
prololsuccinate,ornebivolol)withconsiderationofrelativerisksand .. meta-analysisof24RCTs,showednobenefitofstatintreatmenton
.
benefits.Inclinicalpractice,startingwithlowdosesofcardioselective .. CVmortalityorstrokeinpatientswithHFrEF.811,812Areductionin
.
beta-blockers combined with close monitoring for signs of airway .. HFhospitalizationsaswellasasmallreductioninMIwasobservedin
.
obstruction(wheezing,shortnessofbreathwithlengtheningofthe .. ameta-analysisoftheCORONAandGISSI-HFtrials.813(cid:2)815Based
.
expiration) should be encouraged. Although not tested in HF .. oncurrentevidence,routineadministrationofstatinsinpatientswith
.
patients,inhaledcorticosteroidsandbeta-adrenergicagonistsdonot . HF without other indications for their use (e.g. CAD) is not
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 74 ---
3672 ESCGuidelines
.
recommended.Becausethereisnoevidenceofharminpatientson .. studieshaveshownoneagenttobemoreeffectiveorsaferthanthe
.
statintreatmentaftertheoccurrenceofHF,thereisnoneedforsta- .. others.However,phosphodiesterasetype5inhibitorsshouldnotbe
.
tindiscontinuationforpatientsalreadytreated. .. usedinpatientsreceivingnitratesandnitratesshouldnotbeadminis-
.
.. teredtopatientswithin24hofsildenafilorvardenafiladministration
.
13.10 Gout and arthritis .. orwithin48hoftadalafiladministration.834
.
.
HyperuricemiaisacommonfindinginpatientswithCHFwithaprev- .
.
alenceupto50%.816,817Hyperuricemiamaybecausedoraggravated ...
13.12 Depression
.
bydiuretictreatmentanditisrelatedtosymptoms,exercisecapacity, .
.. Depressionaffects20% ofpatientswithHFandissevereinhalfof
severityofdiastolicdysfunctionandlong-termprognosis.817,818For .
.. them. Its occurrence is higher in women and it is associated with
every1mg/dLincreaseinserumuricacidlevelstheriskofall-cause ...
worseclinicalstatusandapoorprognosis.836(cid:2)838Screeningusinga
mortalityandofHFhospitalizationincreasesby4%and28%,respec- ..
. validatedquestionnaireisrecommendedwhenthereisaclinicalsus-
tively.819 Both febuxostat and allopurinol reduce uric acid levels. ..
. picion of depression. The Beck Depression Inventory and Cardiac
However,allopurinolwasassociatedwitha lower rate ofall-cause ..
. DepressionScalearethetoolsformallyvalidatedfortheassessment
death and CV death, compared with febuxostat, in a prospective, ..
. of depression in patients with HF. Other questionnaires (e.g.
multicentre,double-blind,non-inferioritytrialenrolling6190patients ..
. Geriatric Depression Scale, Hamilton Depression Scale, Hospital
withgoutandCVdisease,20%withHF,withamedianfollow-upof ...
AnxietyandDepressionScale)canalsobeused.837,838
32 months.820 Allopurinol is therefore recommended as the first- ..
. There is still no consensus on the best therapy for HF patients
choiceurate-loweringdruginHFpatientswithnocontraindication. ..
. withdepression.Psychosocialinterventionmayimprovedepressive
Thereisnoevidencethaturicacid-loweringtreatmenthasbeneficial ..
. symptomsbuthasnoeffectonprognosisofdepressedpatientswith
effects on LV function, symptoms or outcomes of patients with ..
. HF.839Depressivesymptomsmayimprovewithselectiveserotonin
HF.821(cid:2)823 ..
.. reuptakeinhibitorsbuttrialsspecificallydesignedtoassesstheeffect
With respect to treatment of acute gout attacks, non-steroidal .
.. ofthesedrugsinpatientswithHFanddepressionhavefailedtoshow
anti-inflammatory drugs (NSAIDs) can worsen renal function and .
.. any significant benefit over placebo on both symptoms and out-
precipitate acute HF decompensation. Colchicine should be pre- .
ferred asit isassociated withlessside effects.824 However,it,too,
... comes.840,841Interestingly,patientsimprovedalsointheplaceboarm
.. showingtheimportanceofbettercareinthesepatients.Bothtrials
shouldbeusedwithcautioninpatientswithsevererenaldysfunction .
.. showedthesafetyofsertralineandescitalopram,respectively.840,841
andiscontraindicatedinpatientsondialysis.Anincreaseinventricu- .
larvulnerabilitywasshowninexperimentalmodels.825
... Tricyclic antidepressants should be avoided for the treatment of
.. depressioninHFastheymaycausehypotension,worseningHF,and
Arthritisisacommoncomorbidityandisacommoncauseofboth .
.. arrhythmias.837,838
self-takenandprescribedNSAIDs.Theseagentsarerelativelycontra- .
.
.
indicatedastheymayprecipitateacutedecompensationinpatients .
.
withHF.826Rheumatoidarthritisisassociatedwithatwo-tothree- ... 13.13 Cancer
.
foldincreaseintheriskofHFandthisincreasedriskisindependent .. HFoccursinpatientswithcancerasaresultoftheinteractionamong
.
ofischaemicheartdisease,suggestingadirectroleinHFpathophysi- .. anticancertherapy,canceritself,and patients’ CVbackground (risk
.
ology.827,828Thesafetyofdisease-modifyingdrugsusedforthetreat- .. factorsandcoexistingCVdisease).842(cid:2)846Severalanticancerthera-
.
ment of rheumatoid arthritis has not been established in HF. High .. piesmaycauseHFdirectly,thoroughtheircardiotoxiceffects(Table
.
doses of anti-tumour necrosis factor alpha agents were associated .. 23), or, indirectly, through other mechanisms, such as myocarditis,
. withworseningHFininitialtrialsandshouldbeusedwithcaution. .. ischaemia,systemicorpulmonaryhypertension,arrhythmiasorvalve
.
Noadverseeffectswerenotedwithlowerdoses.829(cid:2)831 .. disease.844,845,847(cid:2)852 HF, in turn, may affect cancer outcomes by
. .. depriving patients of effective anticancer therapies.699 Some epide-
.
13.11 Erectile dysfunction .
. miological and experimental evidence suggests a further reciprocal
.
.
Erectile dysfunction is a serious problem in HF patients due to its . interactionbetweencancerandHFwithsome,thoughnotall,studies
.
association with CV risk factors, comorbidities (e.g. diabetes), life- .. showingahigherincidencerateofcancerinpatientswithHF.853(cid:2)858
.
style(e.g.inactivity),andtreatment(e.g.drugs).832Inthegeneralpop- .. ThepreventionofHFinpatientswithcancerundergoingpotential
.
.
ulation,theprevalenceoferectiledysfunctionisestimatedtobe50% . cardiotoxictherapiesrequirescarefulpatient’sassessmentandman-
.
.
in men aged >_60,buterectile dysfunction canbe present inup to . agementbefore, during,and aftercancer therapy, preferablyinthe
.
.
81%ofcardiacpatientsacrossdifferentculturesandethnicgroups.833 . context of an integrated Cardio-Oncology service
.
.
Optimal assessment should include both questions assessing the .. (Figure 18).845,859,860 A CV baseline risk assessment for all patients
.
presence oferectiledysfunctionand factors that canbe related to .. scheduled to receive potentially cardiotoxic cancer therapies using
.
erectiledysfunction.NumerousclassesofCVdrugs,particularlydiu- .. the HFA-ICOS risk assessment is advisable.846 Baseline CV risk
.
reticsandbeta-blockers,havebeenimplicatedcausingerectiledys- .. assessmentformshavebeendevelopedfordifferentpotentiallycar-
.
function. However, the relationships between many contemporary .. diotoxic cancer therapies. History of HF or CMP characterizes
.
CVdrugsanderectiledysfunctionisnotclear.834Forthetreatment .. patientsasbeingatveryhighriskorathighriskforallcancerthera-
.
oferectiledysfunction,phosphodiesterasetype5inhibitorsaregen- .. pies,exceptanti-androgentreatmentsforprostatecancer.AnLVEF
.
erallysafeandeffectiveinpatientswithcompensatedHF.834,835No . <50%isanadditionalfactorforhigh-riskpatientsandelevatedlevels
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 75 ---
ESCGuidelines 3673
Table23 Cancerdrugscausingheartfailure
Cancertherapy Indication
Anthracyclinechemotherapy Breastcancer,lymphoma,acuteleukaemia,sarcoma
(doxorubicin,epirubicin,daunorubicin,idarubicin)
HER2-targetedtherapies HER2þbreastcancer
(trastuzumab,pertuzumab,trastuzumabemtansineT-DM1,lapatinib,neratinib, HER2þgastriccancer
tucatinib)
VEGFinhibitors VEGFTKIs:renalcancer,hepatocellularcancer,thyroidcancer,colon
TKIs(sunitinib,pazopanib,sorafenib,axitinib,tivozanib,cabozantinib,regorafenib, cancer,sarcoma,GIST
lenvatinib,vandetinib)andantibodies(bevacizumab,ramucirumab) Antibodies:breastcancer,ovariancancer,gastriccancer,gastro-oesopha-
gealcancer,coloncancer
Multi-targetedkinaseinhibitors: Chronicmyeloidleukaemia
secondandthirdgenerationBCR-ABLTKIs(ponatinib,nilotinib,dasatinib,
bosutinib)
Proteasomeinhibitors Multiplemyeloma
(carfilzomib,bortezomib,ixazomib)
Immunomodulatorydrugs
(lenalidomide,pomalidomide)
CombinationRAFandMEKinhibitors RAFmutantmelanoma
(dabrafenibþtrametinib,vemurafenibþcobimetinib,encorafenibþ
binimetinib)
Androgendeprivationtherapies Prostatecancer,breastcancer
GnRHagonists(goserelin,leuprorelin)
Antiandrogrens(abiraterone)
Immunecheckpointinhibitors: Melanoma(metastaticandadjuvant)
anti-programmedcelldeath1inhibitors Metastaticrenalcancer,non-smallcelllungcancer,smallcelllungcancer,
(nivolumab,pembrolizumab) refractoryHodgkin’slymphoma,metastatictriplenegativebreastcancer,
anti-cytotoxicT-lymphocyte-associated metastaticurothelialcancer,livercancer,MMR-deficientcancer
protein4inhibitor(ipilimumab)
anti-programmeddeath-ligand1inhibitors
(avelumab,atezolizumab,durvalumab)
GIST=gastrointestinalstromaltumour;GnRH=gonadotropin-releasinghormone;HER2=humanepidermalgrowthfactorreceptor2;MEK=mitogen-activatedproteinkinase;
MMR=mismatchrepair;TKI=tyrosinekinaseinhibitor;VEGF=vascularendothelialgrowthfactor.
.
ofNPsortroponinatbaselineareadditionalcriteriaofmediumrisk .. Promisingresultsfortheearlydetectionofcardiacdysfunctionhave
.
formostofthecancertreatments.846 .. alsobeenobtainedthroughmonitoringofbiomarkers,suchasNPs
.
Duringcancertreatmentwithpotentialcardiotoxictherapies,LV .. andtroponin.868,869Patientsonimmunotherapywithimmunecheck-
.
systolic function can be monitored through echocardiography. .. point inhibitors are at increased risk of myocarditis and should be
. ChemotherapyshouldbereconsideredandtreatmentwithanACE-I .. monitoredforrelatedsymptomsandsignsandbyweeklyassessment
.
and a beta-blocker (preferably carvedilol) should be started in .. ofcardiactroponinduringatleastthefirst6weeksoftherapyand
.
patients who develop LV systolic dysfunction, defined as 10% or .. managedaccordingly.870 .
more absolutereduction in LVEF to a value below 50%.844,861(cid:2)864 .. Timing of the imaging procedures and biomarkers assessment
.
.
Globallongitudinalstraincandetectcardiacdysfunctionatanearlier . depend on the anticancer treatment and patient’s risk profile
.
stage.865,866 A >_12% relative reduction in global longitudinal strain .. (Figure18).865Ingeneral,allpatientsscheduledforpotentialcardi-
.
.
wascomparedwithanLVEFdeclineinaprospectiverandomizedtrial . otoxic therapies must undergo a baseline evaluation that would
.
.
in high-risk patients undergoing potentially cardiotoxic chemother- . define the level of risk for cardiotoxicity(low, medium, or high)
.
.
apy. Compared to treatment based on LVEF, treatment based on . and the intensity of monitoring and follow-up during and after
.
changesingloballongitudinalstrainledtothesamedecreaseinLVEF .. cancer treatment.865 Cancer survivors exposed to potentially
.
.
(primaryendpoint)butwithfewerpatientswhodevelopedcardiac . cardiotoxic therapies should be periodically monitored in the
.
.
dysfunction at the end of the study, thus suggesting usefulness of . long term as HF may develop several years after cancer
.
globallongitudinalstrainfortheearlydetectionofcardiotoxicity.867 .. therapy.865,871
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 76 ---
3674 ESCGuidelines
Management of patients receiving potential cardiotoxic treatments
Before cardiotoxic
cancer treatmenta
Baseline risk assessment including clinical
assessment, ECG,resting echocardiogram and
cardiac biomarkers (NP, troponin)
Pre-existing heart failure or high-risk
cardiovascular disease
Medium- and high-risk patientb Low-risk patientb
During cardiotoxic
cancer treatmenta
Increasedc surveillance with ECG
and cardiac biomarkers Standard surveillanced
during treatment
Reassessment at Reassessment at
3 months and 12 months 12 months
after completion of cancer therapy after completion of cancer therapy
After cardiotoxic
cancer treatmenta
Surveillance every 5 years following therapies
with established cardiotoxicity
(e.g. high-dose anthracycline chemotherapy)e
Follow-up by heart failure or cardio-oncology team for
new heart failure or left ventricular systolic dysfunction
Figure18 Managementofpatientswithcancerandheartfailure.ECG=electrocardiogram;HER2=humanepidermalgrowthfactorreceptor2;HF=
heartfailure;HFA=HeartFailureAssociation;ICOS=InternationalCardio-OncologySociety;MEK=mitogen-activatedproteinkinase;NP=natriuretic
peptide; VEGF=vascular endothelial growth factor. aAnthracycline chemotherapy, trastuzumab and HER2 targeted therapies, VEGF inhibitors,
proteasomeinhibitors,combinationRAFþMEKinhibitors.bLow,mediumandhighriskmaybecalculatedusingtheHFA-ICOSbaselinecardiovascular
riskproformas.846cIncreasedsurveillanceisintendedbetween1and4weeks.dStandardsurveillanceisintendedevery3months.e5yearlysurveillanceat
follow-up=clinicalreviewevery5yearswithhistory,examination,NPandtroponinlevels,andechocardiogram.865
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 77 ---
ESCGuidelines 3675
.
Recommendationsforthemanagementofpatientswith ...
Table24 Infectionsinpatientswithheartfailure
cancerandheartfailure ..
.
.. PatientswithHFareatincreasedriskofinfectionsandhavepoorerout-
Recommendation Classa Levelb ... comesonceinfected.
.
.
Itisrecommendedthatcancerpatientsat .. Telemonitoringavoidstherisksofinfectionscausedbyclosecontact.Itis
.
increasedriskforcardiotoxicity,definedbya .. usefulduringpandemicconditions.
.
historyorriskfactorsofCVdisease,previous .. Telemonitoringmaybeimplementedforpatients’follow-upinpandemic
.
cardiotoxicityorexposuretocardiotoxic .. conditions.
I C .
agents,undergoCVevaluationbeforesched- .. Duringpandemics,HFpatientsshouldbescreenedforinfectionatthe
.
uledanticancertherapy,preferablybyacardi- .. timeofhospitalization,incaseofurgentadmissions,orbeforeelective
.
ologistwithexperience/interestinCardio- .. hospitalizations.
.
.
Oncology. . Carefulassessmentoffluidstatus,inadditiontoclinicalsignsofHF,is .
.
TreatmentwithanACE-Iandabeta-blocker . mandatoryduringhospitalizationinpatientswithconcomitantsepsis.
.
.
(preferablycarvedilol)shouldbeconsideredin . Repeatedmeasuresofinferiorvenacavadiameterandcollapsibilityby
.
.
cancerpatientsdevelopingLVsystolicdys- . echocardiographymaybeusedtoassessfluidstatus.
IIa B ..
function,definedasa10%ormoredecrease .. OMT(includingbeta-blocker,ACE-I,ARBorARNI,MRAandSGLT2
.
inLVEFandtoavaluelowerthan50%,during .. inhibitors),shouldbecontinuedinchronicHFpatientswheneverBPand .
anthracyclinechemotherapy.861,862 .. haemodynamicconditionspermitandconsideringdruginteractionwith
.
AbaselineCVriskassessmentshouldbecon- .. infectionrelatedtherapiesandsideeffectprofile.
.
sideredinallcancerpatientsscheduledto IIa C ... ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor
receiveacancertreatmentwiththepotential .. blocker; ARNI=angiotensin receptor-neprilysin inhibitor; BP=blood pressure;
.
tocauseheartfailure.846,865 .. HF=heartfailure;MRA=mineralocorticoidreceptorantagonist;OMT=optimal
. medicaltherapy;SGLT2=sodium-glucoseco-transporter2.
.
.
ACE-I=angiotensin-converting enzyme inhibitor; CV=cardiovascular; LV=left ..
.
ventricular;LVEF=leftventricularejectionfraction. .
aClassofrecommendation. .. algorithmforthemanagementofHFpatientsbeforeandduringpreg-
.
bLevelofevidence. .. nancyisreportedinFigure19.
.
.. Pre-pregnancy management includes the modification ofexisting
.
.. HF medications to avoid foetal harm. ACE-Is, ARBs, ARNI, MRAs,
.
.. ivabradine,andSGLT2inhibitorsarecontraindicatedandshouldbe
.
.. stopped prior to conception with close clinical and echocardio-
.
13.14 Infection .. graphicmonitoring.Beta-blockersshouldbecontinuedandswitched
.
Infective disordersmayworsenHFsymptomsand be a precipitant .. to beta-1-selective blockers (bisoprolol, metoprolol succinate).
.
factorforAHF.872,873Severesepsisandpneumoniacancausemyo- .. Hydralazine,oralnitratesandmethyldopacanbestartedifrequired.
.
.
cardialinjuryanddepresscardiacfunctionleadingtocardiacdysfunc- . Therapeutic anticoagulation with low-molecular-weight heparin
.
.
tion and HF and this risk is greater in patients with a history of . (LMWH),inthefirstandlasttrimesters,andVKAs,withtheusualtar-
.
HF.873(cid:2)875 More recently, the coronavirus disease 2019 (COVID- .. getinternationalnormalizedratios(INRs)orLMWHforthesecond
. .
19)pandemichasemergedasamajorcauseofmorbidityandmortal- . trimester, is recommended for patients with HF and AF. DOACs
.
ityaswellasofHFdecompensation.873,876(cid:2)878Specificguidanceis .. shouldbeavoided.884
.
available.879 General recommendations related to infections are .. AssessmentofpatientswithHFinpre-pregnancyoratpresenta- .
.
giveninTable24. . tion with a new pregnancy should include a clinical assessment .
.
Influenzavaccinationisassociatedwithareducedriskofall-cause . (symptoms,clinicalexamination,BP,SaO ),ECGandrestingecho- . 2
.
deathinpatientswithHFinobservationalstudiesandretrospective .. cardiography.Themodalitiesofdeliveryshouldbeplannedbycardi-
.
analyses.880(cid:2)882Influenzaandpneumococcalvaccination,aswellas .. ologists,obstetricians,and anaesthesiologistsaround 35 weeksin a
.
COVID-19 vaccination, when available, should be considered in .. multidisciplinaryPregnancyHeartTeam.Bimonthlyassessmentsfor
.
patientswithHF.879,883 .. womeninmWHOII(cid:2)III,andmonthlyassessmentsforwomenwith
.
.. pre-existing HF in mWHO III, must be performed. Women with
.
.. advancedHF(LVEF<30%,NYHAclassIII(cid:2)IV)inmWHOIVwho
.
14 Special conditions
... are pregnant can be referred to a specialist centre for counselling
.. regardinganyconsiderationofterminationofpregnancy.Thedeci-
.
14.1 Pregnancy
... sionregardingmodalitiesofdeliverycanbeplannedbycardiologists,
.. obstetricians,andanaesthesiologistsaround35weeksinamultidisci-
14.1.1 Pregnancyinpre-existingheartfailure ...
plinaryPregnancyHeartTeamanddiscussedwiththepatient.884
Womenwithpre-existingHFhaveahigherriskofpregnancy-related ..
.
CV complications including HF decompensation. Moderate- and ..
.
high-risk patients according to the modified World Health .. 14.1.2 Newheartfailurepresentingduringpregnancy
.
Organization(mWHO)classIII(cid:2)IVshouldbereferredtoaspecialist .. Theincreaseddemandsonventricularfunctionduetotheincreased
.
centre with a multidisciplinary Pregnancy Heart Team.884 An . circulatingvolumeandcardiacoutputofpregnancycanunmaskpre-
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 78 ---
3676 ESCGuidelines
Management of patients with heart failure before and during pregnancy
Pre-pregnancy
Counselling including risk
assessment and educationa
At pregnancy
diagnosis or planning
Cardiac assessment including clinical
assessment, ECG, echocardiogram
Review HF therapy and switch to
non-teratogenic HF medication
During pregnancy
Moderate and
Low-risk HF patients
high-risk HF patients
(mWHO I)
(mWHO II, II–III and IV)
Referral to a specialist centre for
Discuss with a specialist centre
high-risk pregnancies with
for high-risk pregnancies
multidisciplinary Pregnancy HeartTeam
Reassessment at the
beginning of the second
trimester i.e. 20 weeks
Reassessment at the
Reassessment
beginning of the second
at 20 weeks
trimester i.e. 20 weeks
Bi-monthly or Monthly
monthly review review
(mWHO II) (mWHO III)
Urgent counselling for consideration
of pregnancy termination
(mWHO IV)
Figure19 Managementofpatientswithheartfailurebeforeandduringpregnancy.ECG=electrocardiogram;HF=heartfailure;mWHO=modified
WorldHealthOrganization.aAdviceregardingcontraception,HFmedication,tocontactHFspecialistwhenplanningpregnancy.
.
existing,butpreviouslyundiagnosed,causesofHFsuchasCMPsand .. PPCMpresentsasHFsecondarytoLVsystolicdysfunction,usually
.
valvediseases.885Symptomsaremorelikelytooccurinthesecond .. shownbyanLVEF<45%,occurringtowardstheendofpregnancy
.
.
trimester when the demand for anincreased cardiac output is the . (third trimester) or in the months following delivery without any
.
.
highest.Severeemotionallystressfulepisodesduringpregnancyand . otheridentifiablecause.ThemajorityofPPCMcasesarediagnosedin
.
deliverycanalsocauseTakotsubosyndrome.884,885 .. post-partum.Theprevalencerangesfrom1:100inNigeriato1:1000
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 79 ---
ESCGuidelines 3677
.
inSouthAfricaand1:1500inGermany.643Prospectivelargecohort .. consider this key interaction between genetic and acquired causes
.
studiesreporta6-monthmortalityrangingfrom2.0%inGermanyto .. duringthediagnosticworkup.897Identificationofanacquiredcause
.
12.6%ina206PPCMpatientcohortfromSouthAfrica.643 .. oftheCMPdoesnotexcludeanunderlyingpathogenicgenevariant,
.
.
PPCM frequently presents with acute HF but may also present . whereasthelattermayrequireanadditionalacquiredcauseand/or
.
.
with ventricular arrhythmiasand/or cardiacarrest.AnLVEF <30%, . disease modifier to become manifest clinically. The commonest
.
.
marked LV dilatation, LV end-diastolic diameter >6.0 cm, and RV . causesanddiseasemodifiersareshowninTable25.
.
.
involvement are associated with adverse outcomes.643 Cardiac .. ThekeyelementsofthediagnosticworkupforallpatientswithHF
.
recovery may occur in the first 3(cid:2)6 months though it may be .. andCMParereportedinTable26.892,894,895,898,899Specificsaspects
.
delayedtoupto2years.Recoveryratesvaryamongregions,from .. ofdiagnosisandtreatmentaresummarizedinTables27(cid:2)29.Clinical
.
75%tolessthan50%.886(cid:2)888 .. history,laboratorytests,andimagingarethefirst-lineinvestigations.
.
Assessmentandmanagementofpregnantpatientspresentingwith .. Echocardiography is central for the diagnosis and monitoring of
.
HF depends upon the clinical setting and severity of presentation. .. HCM,DCM,andAC.CMRimagingprovidesmoredetailedmorpho-
. Detailedcardiacassessmentwithechocardiography,NPlevels,foetal .. logical and prognostic information and should be performed
.
ultrasoundandfoetalmonitoringisrecommended.Incasesofnew .. at baseline. The prevalence of gene mutations may vary according
.
HF or if there is diagnostic uncertainty non-contrast CMR may be .. to the morphological phenotype or the underlying acquired
.
considered. .. cause. Gene mutations occur in up to 40% of DCM, 60% of
. Milder cases can be treated with oral diuretics, beta-blockers, .. HCM, and 15% in chemotherapy-induced, alcoholic or peripartum
.
hydralazineandoralnitrates.Pregnantwomenpresentingwithsigns .. CMPs.895,898,900(cid:2)905 The prevalence of genetic mutations is over
.
ofacuteHFrequireurgenthospitaladmission.IncaseofPPCMpre- .. 10%alsoinnon-familialDCM.898,906Findingapathogenicgenevar-
.
.
sentingwithsevereHFandcardiogenicshockrequiringinotropicor . iantinapatientwithCMPallowsbetterpredictionofthediseaseout-
.
.
vasopressor support, transfer to an advanced HF centre, where . comeandprogression,maycontributetotheindicationsfordevice
.
.
ECMO, LVAD and/or cardiac transplantation can be performed, is . implantationandinformgeneticcounsellingforfamilies.
.
.
recommended.Urgentdeliverybycaesareansection(irrespectiveof . Endomyocardialbiopsy(EMB)withimmunohistochemicalquantifi-
.
.
gestation)shouldbeconsideredwithMCSimmediatelyavailable. . cationofinflammatorycellsremainsthegoldstandardinvestigation
.
.
Adrenergicagents(dobutamine,adrenaline)mayhavedetrimental . fortheidentificationofcardiacinflammation.Itmayconfirmthediag-
.
effects.889WhenaPPCMpatientishaemodynamicallyunstable,levo- .. nosisofauto-immunediseaseinpatientswithDCMandsuspected
.
.
simendanorMCSmaybeconsidered.LVADimplantationasaBTT . giantcellmyocarditis,eosinophilicmyocarditis,vasculitisandsarcoi-
.
.
or BTR should be considered in refractory cases of cardiogenic . dosis.893,907 It may also help for the diagnosis of storage diseases,
.
.
shock.643Bromocriptinehasbeenproposedforpatientswithacute .. includingamyloidorFabrydisease,ifimagingorgenetictestingdoes
.
PPCMtoreducetheproductionofacleaved16kDaprolactinfrag- .. notprovideadefinitivediagnosis(seealsosection14.6).EMBmight
.
ment, which may contribute to the pathophysiology of PPCM. .. beconsideredalsoinHCMifgeneticoracquiredcausescannotbe
.
Bromocriptinewastestedinarandomizedtrialin63patientscom- .. identified.TherisksandbenefitsofEBMshouldbeevaluatedandthis
.
paringitslong-term,8weeks,withitsshort-term,1-week,treatment. .. procedureshouldbereservedforspecificsituationswhereitsresults
.
It was associated with recovery of LV function, with no difference .. mayaffecttreatment.
.
betweenthetworegimensandinlinewiththeresultsofaprevious ..
.
internationalPPCMregistry.890,891Bromocriptinemaybeconsidered ..
.
for treatment of PPCM. Untoward effects of treatment, including .. 14.2.2 Treatment
.
deepvenousthrombosisandcessationoflactation,mustbeconsid- .. ThecurrentpharmacologicaltreatmentofHFinDCM,HCM,orAC
.
eredifitisinitiated.Itshouldthereforebeaccompaniedbyprophy- .. patients does not differ from general HF management, except for
. lactic(ortherapeutic)anticoagulation. .. peculiaraspectsreportedinTables27(cid:2)29.Apilotrandomizedstudy,
. .
. TRED-HF,investigatedthepossibilityofwithdrawingmedicaltreat-
. .
. mentinthosepatientswithnon-ischaemicDCMwhohadhadpartial
.
14.2 Cardiomyopathies .
. to completerecovery ofLVEF(>40%).However,relapse ofDCM
.
.
14.2.1 Epidemiologyanddiagnosis . within 6 months was observed in 44% of patients, and rapid LV
.
.
CMPscanbeeitherinherited(genetic/familial)and/oracquired.They . remodellingwithearlytissueandfunctionalchanges,evenamongst
.
canalsobeacceleratedbydiseasemodifiers.892(cid:2)894Theyareaheter- .. patientswhodidnotrelapse,wasfound.271,908
.
.
ogeneousgroupofdiseasesandaremajorcausesofHF.895DCMhas . In a phase 3, randomized, double-blind, placebo-controlled trial
.
.
anestimatedprevalenceof1in250to1in500ofthegeneralpopula- .. (EXPLORER-HCM),treatmentwithmavacamtenimprovedexercise
.
tion,HCMrangesbetween1in500to1in5000,andACisestimated .. capacity,LVOTobstruction,NYHAfunctionalclass,andhealthstatus
.
tobepresentinaround1in1000to1in5000persons.895,896 .. in patients with obstructive HCM. This offers the possibility of
.
Direct causes of CMPs include pathogenic gene variants (muta- .. disease-specifictreatmentforinheritedCMPs.909
.
tions), toxins, auto-immunity, storage diseases, infections, and .. ICD implantation should be considered for patients with DCM,
.
tachyarrhythmias. Disease modifiers, conditions that may aggravate .. HCM,orAC(seesection6).895,910(cid:2)912Thestrengthoftheindication
.
ortriggeraCMP,includeepigeneticfactorsandacquiredmodifiers, .. variesaccordingtotheclinicalriskfactorsforsuddencardiacdeath
.
such as pregnancy and most CV comorbidities. It is important to . withhigherprioritybeinggiventothosepatientswithsignificantLGE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 80 ---
3678 ESCGuidelines
Table25 Possiblecausesanddiseasemodifiersofmostfrequentcardiomyopathies
Cause Diseasemodifier Phenotype
Geneticmutations
LMNA x DCM
TTN x x DCM,(HCM)
RBM20 x DCM
MYH7 x DCM,HCM
MYPC x DCM,HCM
TNNT x DCM,HCM
PLN x DCM,HCM,AC
DSP x x AC,DCM,myocarditis
SCN5a x x AC,(DCM)
Tropomyosin-1 x DCM
Haemochromatosis(HFEgene,C282Y) x HCM,DCM
Galactosidase-A(Fabrydisease) x HCM
Neuromusculardisorders
Duchennemusculardystrophy,Beckermusculardystrophy, x DCM
myotonicdystrophy
Syndromicdisorders
MitochondrialX-linkedmutations x DCM
Acquireddiseases
Infection(viruses) x x Myocarditis,DCM
Immuno-mediateddiseases(rheumathoidarthritis,systemic x x Myocarditis,DCM
lupuserythematosus,dermatomyositis)
Toxic(alcohol,amphetamines,cocaine) x x DCM,myocarditis
Drugs(anthracyclines,trastuzumab,immunecheckpointinhibitors) x x DCM,myocarditis
Overload(haemochromoatosis) x x HCM,DCM
Peripartum(pregnancy) x x DCM
Comorbiditieswithpossibleinteractionswiththegenemutationsandaneffectonphenotypeandoutcome
Tachy-arrhythmias x x DCM
Diabetesmellitus x x DCM,HCM
Hypertension x x DCM,HCM
Hypo-andhyperthyroidism x DCM,HCM,myocarditis
AC=arrhythmogeniccardiomyopathy;DCM=dilatedcardiomyopathy;DSP=desmoplakin;HCM=hypertrophiccardiomyopathy;LMNA=laminA/C;MYH7(gene)=myosin
heavychain7;MYPC=myosin-bindingproteinC;PLN=phospholamban;RBM20=ribonucleicacidbindingmotif20;SCN5a=sodiumchannelalphaunit5;TTN=titin;TNNT
=troponin-T.
Table26 Initialdiagnosticassessmentinpatientswithsuspectedcardiomyopathy
Historyincludingdetailedquestionsonanysystemicdisease,toxicagents(chemotherapy,alcohol,drugs),andfamilialhistoryofcardiacorneuromuscular
disease,orsuddencardiacdeathinfamilymembersatyoungage(<50years).
Laboratoryexamsincludingcardiacandmuscularenzymes,liverandrenalfunction,haemoglobin,whitebloodcellcount(includingdifferentialwhite
bloodcellcounttodetecteosinophilia),natriureticpeptides,thyroidfunctiontests,ironstatus,andmarkersofsystemicauto-immunedisease(hsCRP,anti-
nuclearantibodies,solubleIL-2receptor).
Standard12-leadECGandechocardiographytodetectarrhythmiasandassesscardiacstructureandfunctionandconcomitantabnormalities.
InvasivecoronaryangiographyorCTCAtoruleoutsignificantCADinpatientswithcardiacdysfunction.
CMRimagingwithT1andT2sequencingandLGEtovisualizestructuralchanges,storage,infiltration,inflammation,fibrosisandscarring.
Geneticcounsellingandgenetictestingshouldbeperformeddependingonage,familyhistory,cardiacphenotype.
24or48-hourambulatoryECGmonitoringtodetectatrialandventriculararrhythmias.
CAD=coronaryarterydisease;CMR=cardiacmagneticresonance;CTCA=computedtomographycoronaryangiography;ECG=electrocardiogram;hsCRP=high-sensitivity
C-reactiveprotein;IL-2=interleukin-2;LGE=lategadoliniumenhancement.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 81 ---
ESCGuidelines 3679
Table27 Dilatedcardiomyopathyorhypokineticnon-dilatedcardiomyopathy:specificaspectsofdiagnosisand
treatment
Diagnosticcriteriaanddefinitions894,895
DCM:LVdilatationandsystolicdysfunctionintheabsenceofknownabnormalloadingconditionsorsignificantCAD.
HNDC:LVorbiventricularglobalsystolicdysfunction(LVEF<45%)withoutdilatationintheabsenceofknownabnormalloadingconditionsorsignificant
CAD.
DCMandHNDCcanbeconsidered“familial”iftwoormorefirst-orsecond-degreerelativeshaveDCMorHNDC,orafirst-degreerelativehasautopsy
provenDCMandsuddendeathat<50yearsofage.
Geneticcounsellingandtesting892,894,898,916
Indication.AllpatientswithadiagnosisofDCMorHNDCandallfirst-degreeadultrelativesofthesepatientsandadefinitedisease-causingmutation,
regardlessoftheirphenotype,inordertoidentifygeneticallyaffectedindividualsatapreclinicalphase.
First-degreeadultrelativesshouldhavetheirevaluationrepeatedevery5yearsorlesswhenaged<50yearsornon-diagnosticabnormalitiesarefound.
Clinicalevaluation,ECG,echocardiographyandpossiblyCMR,mustbeperformedinfirst-degreerelativesofpatients.
Results.CanidentifypatientswithDCMorHNDCathighestriskofarrhythmiaand/ordeservingotherspecifictreatments.
EarlyidentificationofasymptomaticrelativesmayleadtoearlytreatmentandpreventionofprogressiontoHFandpropergeneticcounseling.
Minimalsetofgenesa:TTN,LMNA,MHC,TNNT,troponin-C,MYPC,RBM20,PLN,sodiumchannelalphaunit,BAG3,actinalphacardiacmuscle,
nexilin,tropomyosin-1,vinculin.
Theuseofadditionalsequencingfortheanalysisofverylargepanelofgenesmaybeconsideredwhenthereisaclearfamilialhistoryorstructuralpheno-
type,bypreferencecombinedwithfamilysegregation.
Endomyocardialbiopsy97,907,917(cid:2)919
Indication.Insuspectedphenotypesrequiringspecifictreatments(i.e.giantcellmyocarditis,eosinophilicmyocarditis,sarcoidosis,vasculitis,SLE,other
systemic,auto-immuneinflammatoryconditions,orstoragediseases).
Numberofsamples.Aminimumof5butpossiblyatleast7samples:3forpathology,2forinfection(DNA,PCR)and2forRNAviruses/viral
replication.918,919
Aetiology.Searchforcommoncardiotrophicviruses(parvovirusB19,HHV4,HHV6,enteroviruses,adenovirusandcoxsackie)byquantitativertPCR
whenaviralaetiologyissuspected.ViralmRNAforactiveviralreplicationshouldbeassessed,ifpossible.
Furtherassessmentifindicated:CMV,HIV,Borreliaburgdorferi(Lymedisease),Coxiellaburnetii(Q-fever),Trypanosomacruzi(Chagasdisease)and
SARS-CoV-2.
Immunohistochemistry.QuantificationofCD3-,CD4-,CD8-orCD45-staininglymphocytesandCD68macrophagespermm2;anti-HLA-DR.
Histology.Haematoxylinandeosinstaining,fibrosisassessmentwithMasson’sTrichromeandPicrosiriusRed,amyloidfibrilsdetectionwithCongoRed.
Therapeuticoptions895,917
HFtreatmentforHFrEF(seesections5and6)
LMNA,RBM20,PLNandFLNmutation.Higherriskofsuddencardiacdeath:earlyindicationforprimarypreventionbyICDimplantationshouldbe
considered(guidedbyriskfactorsasdetailed).920
TTNmutation.HigherrateofLVreverseremodeling(inupto70%),butahigherriskofatrialandventriculartachyarrhythmias.
Lymedisease(Borrelia).Treatmentwithdoxycycline.
Chagasdisease(Trypanosomacruzi).Specifictreatmentaccordingtocurrentrecommendations.921,922
Auto-immune/inflammatory.Considerimmunosuppressivetherapyingiantcellmyocarditis,eosinophilicmyocarditis,sarcoidosisorvasculitis,andin
highlyselectedpatientswithincreasedcardiacinflammationofunknownoriginbaseduponmultidisciplinarycounselling(cardiologyandimmunology).
BAG3=Bcl2-associatedathanogene3;CAD=coronaryarterydisease;CMR=cardiacmagneticresonance;CMV=cytomegalovirus;DCM=dilatedcardiomyopathy;DNA=
deoxyribonucleicacid;ECG=electrocardiogram;FLN=filamin;HF=heartfailure;HFrEF=heartfailurewithreducedejectionfraction;HHV=humanherpesvirus;HIV=
humanimmunodeficiencyvirus;HLA-DR=humanleukocyteantigen-DRisotype;HNDC=hypokineticnon-dilatedcardiomyopathy;ICD=implantablecardioverter-defibrilla-
tor;LMNA=laminA/C;LV=leftventricular;LVEF=leftventricularejectionfraction;MHC=myosinheavychain;MYPC=myosin-bindingproteinC;mRNA=messengerribo-
nucleic acid; NSVT=non-sustained ventricular tachycardia; PCR=polymerase chain reaction; PLN=phospholamban; RBM20=ribonucleic acid binding motif 20; RNA=
ribonucleicacid;rtPCR=reversetranscriptasepolymerasechainreaction;SARS-CoV-2=severeacuterespiratorysyndromecoronavirus2;SLE=systemiclupuserythemato-
sus;TNNT=troponin-T;TTN=titin.
aThislistofgenesisnotexhaustive,andwillchangeovertime,withincreasingknowledgeofthepathogenicity.Contactthegeneticdepartmenttoaskwhichcorepanelofgenes
theyareusing.
bRiskfactorsinpatientswithaconfirmedLMNAmutation:NSVTduringambulatoryECGmonitoring,LVEF<45%atfirstevaluation,malesexandnon-missensemutations
(insertion,deletion,truncations,ormutationsaffectingsplicing).
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 82 ---
3680 ESCGuidelines
Table28 Hypertrophiccardiomyopathy:specificaspectsofdiagnosisandtreatment
Definition895,896,923
Wallthickness>14mminoneormoreLVmyocardialsegmentsnotsufficientlyexplainedsolelybyabnormalloadingconditions.
LVOTO>_30mmHgatrestorexercise,asymmetrichypertrophy,orincreasedLGEinapatchymid-wallpatterninthemosthypertrophiedsegment,
furthersuggestthepresenceofHCM.
Itcanbeconsideredfamilialwhentwoormorefirst-orsecond-degreerelativeswithHCMorafirst-degreerelativewithautopsyprovenHCMand
suddendeathat<50yearsofagearedetected.
Differentialdiagnosis
Itmightbedifficultwithphysiologicalhypertrophyinducedbyintenseathletictraining,severehypertensionoraorticstenosisandwithisolatedseptal
hypertrophy.ConsiderageneticHCMifthedegreeofLVhypertrophyisdisproportionatewithrespecttotheacquiredtrigger.
Consideramyloidosisasacausewhenincreasedthicknessoftheinteratrialseptum,AVvalveand/orRVfreewallaredetected(seesection14.6).
Geneticcounsellingandtesting
Indication.MustbeofferedtoallpatientswithadiagnosisofHCMtoidentifyapossibleunderlyinggeneticcauseandtoallfirst-degreeadultrelativesof
patientswithHCMandadefinitedisease-causingmutation,regardlessoftheirphenotype,inordertoidentifygeneticallyaffectedindividualsatapreclinical
phase.
Clinicalevaluation,ECGandechocardiography,mustbeperformedinfirst-degreerelativeswhohavethesamedefinitedisease-causingmutationasthe
indexpatient.
Whennodefinitegeneticmutationisidentifiedintheindexpatientorgenetictestingisnotperformed,clinicalevaluationwithECGandechocardiography
shouldbeconsideredinfirst-degreeadultrelativesandrepeatedevery2(cid:2)5yearsorlessifnon-diagnosticabnormalitiesarepresent.
Minimalsetofgenesa(sarcomericgenemutationinupto60%ofcases):TTN,LMNA,MHC,TNNT,Troponin-C,MYPC,RMB20,PLN,Sodiumchannel
alphaunit,BAG3,ActinAlphaCardiacMuscle,Nexilin,Tropomyosin-1,Vinculin.898,924(cid:2)926
Theuseofadditionalsequencingfortheanalysisofverylargepanelofgenesmaybeconsideredifthereisaclearfamilialhistoryorstructuralphenotype,
bypreferencecombinedwithfamilysegregation.
Specificconditions.
Muscularweakness:considermitochondrialX-linkedmutations,glycogenstoragedisorders,FHLImutations,Friedreich’sataxia.
Syndromicconditions(cognitive,visualimpairment,droopingeyelid):considermitochondrialX-linkedmutations,Noonansyndrome,Danondisease.
Cafe´aulaitspots(lentigines):considerLeopard/Noonansyndrome
Endomyocardialbiopsy
Indication.Itmaybeconsideredwhenthebaselineclinicalassessmentsuggestscardiacinflammationorstoragediseasewhichcannotbediagnosedby
othermeans896(seealsoSection14.6).
Therapeuticoptions895,896,923
WithLVOTO
Avoidhypovolaemia(dehydration),arterialandvenousdilators(nitratesandphosphodiesterasetype5inhibitors),anddigoxin.
Usenon-vasodilatingbeta-blockersoruseverapamilifbeta-blockersnon-toleratedorineffective.
Low-doselooporthiazidediureticsmustbeusedwithcautiontoimprovedyspnoeaassociatedwithLVOTO,butavoidinghypovolaemia.
Invasivetreatment(septalreductiontherapybyalcoholablationormyomectomy),inexperiencedcentres,maybeconsideredinthosepatientswitha
restingormaximumprovokedLVOT>_50mmHgand/orwhoremainsymptomatic(NYHAclassIIIorIV,syncope)despiteOMT.
Noveldrugsordevicesmaybeconsideredonceavailable.909,927
SymptomaticwithoutLVOTO
Cautioususeoflow-doselooporthiazidediureticsavoidinghypovolaemia.
Verapamil/diltiazemifLVEF>50%andbeta-blockersarenottoleratedorineffective.
IndicationtoICD
Basedonsuddencardiacdeathriskmodels.928(cid:2)930
ConsiderICDimplantationif:
- familyhistoryofsuddencardiacdeathinoneormorefirstdegreerelativesunder40yearsofageorsuddencardiacdeathinafirstdegreerelative
withconfirmedHCMatanyage;
- NSVT;
- unexplainedsyncope.931
Fabrydisease
Enzymereplacementtherapy(alpha-galactosidaseAdeficiency).895
Amyloidosis.Seesection14.6andFigure21.
AV=atrio-ventricular;BAG3=Bcl2-associatedathanogene3;ECG=electrocardiogram;HCM=hypertrophiccardiomyopathy;ICD=implantablecardioverter-defibrillator;LGE=
lategadoliniumenhancement;LMNA=laminA/C;LV=leftventricular;LVEF=leftventricularejectionfraction;LVOT=leftventricularoutflowtract;LVOTO=leftventricularout-
flowtractobstruction;MHC=myosinheavychain;MYPC=myosin-bindingproteinC;NSVT=non-sustainedventriculartachycardia;NYHA=NewYorkHeartAssociation;OMT
=optimalmedicaltherapy;PLN=phospholamban;RMB20=ribonucleicacidbindingmotif20;RV=rightventricular;TNNT=troponin-T;TTN=titin.
aThelistofgenesisnotexhaustive,andwillchangeovertime,withincreasingknowledgeofthepathogenicity.Contactthegeneticdepartmenttoaskwhichcorepanelofgenes
theyareusing.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 83 ---
ESCGuidelines 3681
Table29 Arrhythmogeniccardiomyopathy:specificaspectsofdiagnosisandtreatment912,915,932
Definition
InheritedheartmusclediseasecharacterizedbyprogressivefibrofattyreplacementoftheRVmyocardiumwhichmayactasasubstrateforventricular
arrhythmias,unexplainedsyncopeand/orsuddencardiacdeath.
LVinvolvementandsystolicdysfunctionoccursin>30%ofACpatients,thereforeitsphenotypemayoverlapwithDCM.
Diagnosis933
Basedupontheevaluationofacombinationofthegeneticfactors(mostcasesautosomaldominantdesmosomalmutations),documentationofventricular
arrhythmiasandimagingcriteria(echocardiographyandMRI)ofRVdysplasiawiththefibrofattyreplacementeitherornotconfirmedbyEMB.SpecificECG
abnormalitiescanbepresentorabsent.
Geneticcounselling/testing898,912
Indication.MustbeofferedtoallpatientswithasuspectedACandhas tobeofferedtoallfirst-degreeadultrelativesofpatientswithACandadefinite
disease-causingmutation,regardlessoftheirphenotypeinordertoidentifygeneticallyaffectedindividualsatapreclinicalphase.
Geneticfamilyscreeningcanbealsoindicatedforarrhythmicriskstratificationpurposes.
Clinicalevaluation,ECG,echocardiographyandpossiblyCMRhavetobeperformedinfirst-degreerelativeswhohavethesamedefinitedisease-causing
mutationastheindexpatient.
Whennodefinitegeneticmutationisidentifiedintheindexpatientorgenetictestingisnotperformed,clinicalevaluationwithECGandechocardiography
shouldbeconsideredinfirst-degreeadultrelativesandrepeatedevery2(cid:2)5yearsorlessifnon-diagnosticabnormalitiesarepresent.
Minimalsetofgenes:
Desmosomal,mostlywithisolatedRVinvolvement:plakoglobin,DSP,PKP2,DSG2andDSC2a
WithfrequentLVinvolvement/DCM:DSP,FLNC,SCN5A,TMEM43,FLN,LDB3,desmin,a-actinin,BAG3,NKX2-5,RBM20,SCN5A,KCNQ1,KCNH2,
TRPM4orPLNvariantsinparticular.
IfmildLVhypertrophy:considerTNNTvariants.
Cutaneousabnormalities,palmarandplantarhyperkeratosis:considerrarerecessivemutationsleadingtoCarvajalsyndromeandNaxosdisease.Plakoglobin
(JUP).
WithCMRpresentationofmyocarditisalongAC:considerDSPgenevariants.934,935
Endomyocardialbiopsy
Itshouldbereservedtohighlyselectedcasesafterallnon-invasivestudieshavebeenassessed.Fibrofattyreplacementwithorwithoutreplacementtypefib-
rosisatRVseptalbiopsiesarethecharacteristicfindings.EMBhaslowsensitivityforthediagnosisofACincasesoffocaldistribution.
Therapeuticoptions
HFtreatmentforHFrEF(seesections5and6).
Competitivesportsshouldbeavoided,limitactivitiestoleisure-timeactivities.936
Inpatientswithventriculararrhythmias:beta-blockersmustbetitratedtothemaximallytolerateddoseasfirst-linetherapy.Amiodaronecanbeconsidered
inadditiontobeta-blockersorifbeta-blockerscontraindicatedornottolerated;ICDimplantationisindicatedifhistoryofabortedsuddencardiacdeathor
sustainedand/orhaemodynamicallypoorlytoleratedventriculartachycardia.910(cid:2)912
Inpatientswithnoventriculararrhythmias:ICDcanbeconsidered(seesection6.1)eveninpatientswithLMNAorFLNCgenemutationsandLVEF
<45%.912
AC=arrhythmogenic cardiomyopathy; BAG3=Bcl2-associated athanogene 3; CMR=cardiac magnetic resonance; DCM=dilated cardiomyopathy; DSC2=desmocollin 2;
DSG2=desmoglein2;DSP=desmoplakin;ECG=electrocardiogram;EMB=endomyocardialbiopsy;FLN=filamin;FLNC=filaminC;HF=heartfailure;HFrEF=heartfailure
withreducedejectionfraction;ICD=implantablecardioverter-defibrillator;JUP=junctionplakoglobin;KCNH2=potassiumvoltage-gatedchannelsubfamilyHmember2;
KCNQ1=potassiumvoltage-gatedchannelsubfamilyQmember1;LDB3=LIMdomainbinding3;LMNA=laminA/C;LV=leftventricular;LVEF=leftventricularejectionfrac-
tion;MRI=magneticresonanceimaging;NKX2-5=NK2transcriptionfactorrelated,locus5;PLN=phospholamban;PKP2=plakophilin2;RMB20=ribonucleicacidbinding
motif20;RV=rightventricular;SCN5A=sodiumchannelalphasubunit5;TMEM43=transmembraneprotein43;TNNT=troponin-T;TRPM4=transientreceptorpotential
cationchannelsubfamilyMmember4.
.
onCMR, younger age,or witha specific familial/geneticphenotype .. 14.3 Left ventricular non-compaction
.
(Tables27(cid:2)29).RiskmodelsforthepredictionofICDbenefitswere ...
LVNCisaveryrarecongenitalCMPcharacterizedbyendomyo-
appliedtothepatientsenrolledinDANISHandmayhelpfortheindi- ...
cardialtrabeculationsthatincreaseinnumberandprominence.In
cation to ICD implantation in DCM.166,913 Treatment of HCM and ...
mostcases,includingwhentheconditioniscausedbymutations
.
AC, including indications for ICD, are detailed in previous .. intheMYH7orMYBPC3gene,LVNCisinheritedinanautosomal
documents.895,896,899,912,914,915 ...
dominantpattern.644,937,938Aclearoverlapexistsinfamilieswith
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 84 ---
3682 ESCGuidelines
.
DCM and HCM phenotypes. Quite commonly individuals with .. diseaseappearstoresultfromtheintersectionofsharedriskfactors
.
featuresofLVNCarefoundinfamilieswhereotheraffectedrela- .. andcomorbiditiespredisposingtobothAFandHF,diabetesmellitus,
.
tiveshavetypicalHCMorDCM.Therefore,LVNCisnottreated .. hypertension,obesity,smoking,andphysicalinactivitymaybeofpara-
.
asaseparatediseaseentity,butasaseparaterarepresentationof .. mountimportanceforitsdevelopment.7,950Effectivemanagementof
.
ageneticsusceptibilitytoeitherHCMorDCM.939 .. HFandAF(seesection12.1.1),aswellastreatmentofmitralregurgi-
.
.. tation(seesection12.3.3),mayalsobeimportanttocounteractatrial
.
14.4 Atrial disease .. diseaseprogression.
.
.
14.4.1 Definition .
.
.
Atrialdisease,alsotermedatrialfailureormyopathy,canbedefined .
.
. 14.5 Myocarditis
asacomplexofsubclinicalstructural,electrophysiological,andfunc- .
.
.
tional changes that affect the atria with the potential to produce .. 14.5.1 Epidemiologyanddiagnosis
.
clinicalconsequences.606,940,941Ithasbeensuggestedthatatrialdis- .. Theincidenceofacutemyocarditisisestimatedtobe1.5millioncases
easelinksthepathophysiologyofHF,especiallyHFpEF,withAF,as
... peryearglobally.951ThecontributionofmyocarditisasacauseofHF
theyoftencoexist,arecloselyinter-relatedandsharecommonrisk ... varies by age and region from approximately 0.5% to 4.0%.918,952
.
factors.606,685,942,943 .. Chronic,EMBproven,inflammationcanbefoundin9%to30%ofadult
.. patients with a DCM.918,953 The most frequent potential aetiologies
.
.
. triggeringacutemyocarditisinEuropearereportedinTable30.
14.4.2 Diagnosis .
.
. Theclinicalpresentationofacutemyocarditismayvaryfrommild Atrialsizeandfunctioncanbeevaluatedbymultimodalityimaging .
.
. symptomstocardiogenicshock.Workupforthediagnosisofacute
includingtwo-andthree-dimensionalechocardiography,myocar- .
.
dial deformation, computed tomography (CT) and CMR.944 .. myocarditisinpatientswithHFisreportedinTable31andFigure20.
.
. SpecificcriteriaaboutbiopsiesandCMRare reportedinTables32
Cardiac biomarkers, including high-sensitivity cardiac troponins ..
and NPs, may assess pathophysiological aspects of atrial dis-
... and33.
.
ease.945(cid:2)947TheincreasedlevelsofNPsinAFmayalsobeanindi- ..
.
cator of an underlying atrial disease.942,948 A comprehensive .. 14.5.2 Treatment
.
characterizationofatrialdiseasecombiningclinical,imaging,bio- .. Hospitalizationforatleast48hmaybeusefulforpatientswithacute
.
chemicalandmolecularfeaturesis,however,stilllacking. .. myocarditis and HF, especially when troponins are elevated and
.
.
. when cardiac dysfunction, and/or arrhythmias are present at initial
.
.
14.4.3 Management . presentation.
.
.
Atrialdiseaseisanemergingtherapeutictargetinthepreventionof . Despitethelackofevidenceinthespecificsettingofacutemyocar-
.
.
AF, systemic thromboembolism, and perhaps HFpEF.949 As atrial . ditis,treatmentofHFrEFisrecommendedinthepresenceofsystolic
.
.
. LV dysfunction. Immunosuppression is only indicated in selected
.
.
. cases of acute myocarditis (Table 34). Once cardiac enzymes
.
Table30 Aetiologiestobeconsideredtriggeringacute .. decrease,arrhythmiasareabsent,andcardiacsystolicdysfunctionis
myocarditis917 ..
. stabilized, standard HF therapy should be continued for at least
.
.
Infectious .. 6months(seealsoFigure20).
.
. Immunosuppressionhasbeenconsideredfortreatmentofpatients
Viral ParvovirusB19,humanherpesvirus-6,Epstein- . .
Barrvirus,enteroviruses,(coxsackievirus,
... withchroniccardiacinflammationatEMBandnoevidenceofactive
adenovirus),CMV,HIV,SARS-CoV-2
... viralinfection.918,919Thiswasassociatedwithanimprovementincar-
Others Borrelia,Coxiellaburnetii(Q-fever)
... diacfunctioninsmallstudiesand withbetteroutcomesina retro-
.. spectiveobservationalstudy.953,963,964Prospectivetrialswitholdor
Systemicdisease .
.. newerimmunosuppressive/immunomodulatorydrugsareneeded.A
Auto-immune Sarcoidosis,giantcellmyocarditis,eosinophilic ...
placebo-controlledtrialtestingtheeffectsofimmunoadsorptionwith
andothers myocarditis,SLE,ANCA-positivevasculitis, ...
i.v.immunoglobulinsonLVfunctionisongoingandothertreatment
rheumatoidarthritis,anyotherauto-immune ... optionsarebeingtested.919
disease ..
.
.
Toxic .. 14.6 Amyloidosis
.
Medications Immunecheckpointinhibitors,anthracyclines, .
.. 14.6.1 Epidemiologyanddiagnosis
clozapine,adrenergicdrugs,5-fluorouracil .
.. CA oramyloid cardiomyopathy is stillanunderdiagnosed causeof
Otheragents Alcohol,amphetamines,cocaine ... HF.895,965,966 The two most prevalent forms of CA are light chain
.
ANCA=antineutrophil cytoplasmic antibody; CMV=cytomegalovirus; HIV= .. immunoglobulin (AL)and transthyretin (ATTR) amyloidosis.ATTR
human immunodeficiency virus; SARS-CoV-2=severe acute respiratory syn- ...
includesthewild-type(>90%ofcases),andthehereditaryorvariant
dromecoronavirus2;SLE=systemiclupuserythematosus. .
. type(<10%ofcases).Itisestimatedthat6%to16%ofallpatients
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 85 ---
ESCGuidelines 3683
Table31 Diagnosticworkupinsuspectedacutemyocarditis
Definitionofsuspectedacutemyocarditis
Clinicalpresentationþ>_1mandatorydiagnostictestbeingpositive(bypreferenceCMR)intheabsenceofsignificantcoronaryartery,
valvularorcongenitalheartdisease,orothercauses.
Sensitivity Specificity
Clinicalpresentation
Acute/newonsetchestpain,dyspnoea,signsofleftand/orrightHF,and/orunexplainedarrhythmiasorabortedsuddendeath. Low Low
Mandatorydiagnostictests
ECG NewanddynamicST-Tabnormalities,includingpseudo-infarctSTseg- High Low
mentelevation,atrialorventriculararrhythmias,AVblocks,QRS
abnormalities.
Laboratorytests Elevatedtroponinswithdynamicchangesconsistentwithmyocardial Intermediate Low
necrosis.
Standardtestsincludingwhitebloodcellscounttoexclude
eosinophilia.919,954
Echocardiography Newstructuralorfunctionabnormalities,regionalwallmotionabnormal- High Low
itiesorglobalventriculardysfunctionwithoutventriculardilatationor
with,generallymild,dilatation,increasedwallthicknessduetomyocardial
oedema,pericardialeffusion,intracardiacthrombi,notexplainedbyother
conditions(e.g.,CAD,ACSorvalvularheartdisease).
CMR Oedema,inflammationandfibrosisdetection,quantificationandlocaliza- High Intermediate
tionthroughT1andT2mapping,extracellularvolumeassessmentand
LGE(seeTable33).955,956
Additionaldiagnostictests
CoronaryangiographyorCTCA ExcludessignificantCADorACSinclinicallysuspectedmyocarditis. High High
Endomyocardialbiopsy Fordiagnosisandindicationtospecifictreatment(seeTable32). Intermediate High
CardiacPET MaybeusefulinpatientswhocannotundergoCMRorwithsuspected Low Low
systemicautoimmunediseaseorcardiacsarcoidosis.919,957
Additionallaboratorytest Skeletalmuscleenzymes,liverandrenalfunction,natriureticpeptides, Low Low
thyroidfunctiontests,ironstatus,markersofsystemicautoimmune
disease.
CRPelevatedin80(cid:2)90%patients.919,954 Intermediate Low
PCRtestingofcommoncardiotrophicviruses.Itcandetectsystemic Low Low
infectionbutdoesnotprovecardiacinfectionandcannotsubstitute
viralgenomeanalysisonEMBsamples.917
CirculatingIgGantibodiestocardiotrophicvirusesarecommoninthe
absenceofviralmyocarditis.Verylimiteddiagnosticusefulness.917,918
SpecifictestforSARS-CoV-2,Borrelia,HIVorCMVifclinicalsuspicion.
ACS=acutecoronarysyndrome;AV=atrio-ventricular;CAD=coronaryarterydisease;CMR=cardiacmagneticresonance;CMV=cytomegalovirus;CRP=C-reactivepro-
tein;CTCA=computedtomographycoronaryangiography;ECG=electrocardiogram;EMB=endomyocardialbiopsy;HF=heartfailure;HIV=humanimmunodeficiencyvirus;
IgG=immunoglobulinG;LGE=lategadoliniumenhancement;PCR=polymerasechainreaction;PET=positronemissiontomography;QRS=Q,RandSwaves(combination
ofthreeofthegraphicaldeflections);SARS-CoV-2=severeacuterespiratorysyndromecoronavirus2;ST=STsegmentoftheelectrocardiogram;ST-T=STsegmentandT
waveoftheelectrocardiogram.
.
.
withunexplainedLVHorHFpEFathospitalizationorsevereaortic . in patients with abnormal haematological tests (Figure 21).
.
.
stenosisundergoingaorticvalvereplacement,agedabove65years, .. Technetium-labelled99mTc-PYPorDPDorHMDPscintigraphywith
.
mayhavewtTTR-CA.967(cid:2)972 .. planar and SPECT imaging has a specificity and positive predictive
.
Diagnosis and treatment of CA were recently reviewed.973 Age .. valueforTTR-CAofupto100%.975Incontrast,CMRhasasensitivity
.
>65yearsandHFalongwithaLVwallthickness>12mmatechocar- .. and specificity of 85% and 92%, respectively.966,976 The hereditary
.
diographyaremajorcriteriaforthesuspicionofCA.973Criteriafora .. formshouldbeexcludedbygenetictesting.EMBisthegoldstandard
.
suspicionofCAandtoconfirmdiagnosisarereportedinTable35, .. forthediagnosisofTTR-CAwithnearly100%sensitivityandspecific-
.
Supplementary Table 25, and Figure 21.973,974 Cardiac imaging and .. ityifspecimensarecollectedfrom>4multiplesitesandtestedfor
.
EMBorextra-cardiacbiopsyareneededforthediagnosisofAL-CA . amyloiddepositsbyCongoredstaining.966However,abiopsyisnot
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 86 ---
3684 ESCGuidelines
Management of patients with heart failure and suspected myocarditis
Clinical history, signs and symptoms, ECG, laboratory,
echocardiography, CMR imaging, coronary CT/CAGa
Treatment of CAD if present Suspected auto-immunity,
and indicated infectious, toxic
HF treatment
EMB if any doubt
Clinical stabilization N
about diagnosis
Y
Consider immunosuppressive
Maintain HF treatment Consider MCS
therapy or anti-infection
Figure20 Managementofpatientswithheartfailureandacutemyocarditis.ACS=acutecoronarysyndrome;CAD=coronaryarterydisease;CAG=
coronaryarteryangiogram;CMR=cardiacmagneticresonance;CT=computedtomography;ECG=electrocardiogram;EMB=endomyocardialbiopsy;
HF=heartfailure;MCS=mechanicalcirculatorysupport.aToexcludeCAD/ACS.
Table32 Endomyocardialbiopsyinpatientswithsuspectedmyocarditis
Indication(seealsoSection4.3).
Progressiveorpersistentseverecardiacdysfunctionand/orlife-threateningventriculararrhythmiasand/orMobitztype2second-degreeorhigherAVblock
withlackofshort-term(<1-2weeks)expectedresponsetousualmedicaltreatment.
Theaimistoidentifyaetiologyandtoindicatespecifictreatment(e.g.giantcellmyocarditis,eosinophilicmyocarditis,cardiacsarcoidosis,systemicinflamma-
torydisorders).97,98,917,918,958
Numberandsitesofthesamples
Aminimumof5butpossiblyatleast7samples,3forpathology,2forinfections(DNA,PCR)and2forRNAviruses/viralreplication.Leftand/orrightven-
tricle.CMRorPETguidedsamplingmaybeconsidered.919
Aetiology
QuantitativePCRviralgenomeanalysisforcommoncardiotrophicviruses(parvovirusB19,HHV4,HHV6,enteroviruses,adenovirusandcoxsackievirus)by
rtPCR.
ViralmRNAforactiveviralreplicationmaybeassessedalthoughithaslowsensitivity.
Onindication,searchforCMV,HIV,Borrelia,Coxiellaburnetii(Q-fever)andSARS-CoV-2.
Diagnosisofinflammation
Immunohistochemistrywithstainingforanti-CD3-,CD4-,CD8-orCD45antibodiesforlymphocytesandanti-CD68antibodiesformacrophagesandanti-
HLA-DRantibodies.907,917,918,959
Therapeuticimplications
ImmunosuppressivetherapymaybeindicatedbasedontheresultsofEMBasingiantcellmyocarditisoreosinophilicmyocarditisand,possibly,alsoin
sarcoidosis,vasculitisorselectedpatientswithincreasedcardiacinflammationofunknownoriginbaseduponmultidisciplinarycounselling.98,917(cid:2)919,954
Antibiotics:Borrelia(Lymedisease).
Antiviraltherapy:HIV,CMV,HHV6pendingonloadandviralreplication(mRNA).
CMR=cardiacmagneticresonance;CMV=cytomegalovirus;DNA=deoxyribonucleicacid;EMB=endomyocardialbiopsy;HHV=humanherpesvirus;HIV=humanimmuno-
deficiencyvirus;HLA-DR=humanleucocyteantigen-DRisotype;mRNA=messengerribonucleicacid;PCR=polymerasechainreaction;PET=positronemissiontomography;
RNA=ribonucleicacid;rtPCR=reversetranscriptasepolymerasechainreaction;SARS-CoV-2=severeacuterespiratorysyndromecoronavirus2.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 87 ---
ESCGuidelines 3685
.
Table33 Cardiacmagneticresonanceinpatientswith .. Table34 Treatmentandfollow-upofacutemyocarditis
.
suspectedmyocarditis955,956 .
.
.. HFtherapyshouldbestartedifLVsystolicdysfunctionispresentatpre-
.
Indication .. sentationandshouldbecontinuedforatleast6monthsuponcomplete
.
Indicatedatbaseline,inallpatientswithclinicalhistoryþECG,elevated .. functionalrecovery(EF>50%).918,919
.
troponinorechocardiographicabnormalities,andsignificantCAD .
. Immunosuppressionforatleast6(cid:2)12monthsisrequiredinacutemyo-
.
excludedorunlikely. ..
carditiswithclinicalorEMBevidenceofauto-immunedisease,including
.
Advisedatfollow-upinpatientswithpersistentdysfunctionatechocar- .. giantcellmyocarditis,vasculitisorsarcoidosis.98,917(cid:2)919,953,954,961
.
diography,arrhythmiasorECGabnormalities.a ...
Immunosuppressionisnotadvisedonaroutinebasisinacutemyocarditis
Mainfindings ... withoutclinicalorEMB-basedevidenceofauto-immunedisease.917Initial
Atbaseline:T1-weighted(inflammation,injury)andT2-weighted(oedema) ...
empiricaladministrationofi.v.corticosteroidsmaybetakenintoconsid-
.
sequences,extracellularvolumeandLGEwithin2weeksaftersymptom .. erationincasesofhighsuspicionofimmune-mediatedmyocarditisespe-
onset.956,960 ...
ciallyifcomplicatedbyacuteHF,malignantarrhythmiasand/orhigh
.
Atfollowup:LGEtoevaluatethedegreeofscarring,T1andT2toidentify .. degreeAVblock.954,962
persistentinflammation.a ..
. Intensesportingactivitiesshouldbeavoidedaslongassymptoms,cardiac
.
Diagnosticsignificance ..
enzymeselevatedorECG/imagingabnormalitiesarepresentandlastfor .
AtleastoneT2-basedcriterion(globalorregionalincreaseofmyocardial .. atleast6monthssincecompleterecovery.936
.
T2relaxationtimeoranincreasedsignalintensityinT2-weightedimages), ...
Yearlyfollow-upforatleast4years,withanECGandechocardiography,
withatleastoneT1-basedcriterion(increasedmyocardialT1,extracellu- ...
isneededasacutemyocarditismayleadtoDCMinupto20%of
larvolume,orLGE)intheacutephase. ...
cases.
Onlyone(i.e.,T2-basedorT1-based)markermaystillsupportadiagnosis ..
ofacutemyocardialinflammationinanappropriateclinicalscenario,albeit
.... A grV am= ;a Et Frio =- ev je en ct tr ioic nul fa rr a; ctiD onC ;M EM= Bd =ila ete nd domca yr od ci ao rm diy ao lp ba ioth py s; y;HEC FG =h= ee al re tc ft ar io luc ra er ;d ii .o v.-
withlessspecificityintheacutephase. .. =intravenous;LV=leftventricular.
.
AnegativeT1/T2scandoesnotexcludeastillongoinginflammatoryproc- ..
essinthechronicphase.a
.
.. TherapyofAL-CAisbasedontreatmentoftheunderlyinghaema-
.
.. tological problem with chemotherapy or autologous stem-cell
CAD=coronaryarterydisease;CMR=cardiacmagneticresonance;ECG=elec- .
trocardiogram;LGE=lategadoliniumenhancement.
... transplant.
aIttakesatleast3monthsbeforeCMRsignsofoedema(secondarytoinflamma- .. TTRstabilizationandreductionofitsproductionarethebasis
.
tion in the acute phase/baseline) disappear. At 6 months, T1 or T2 signs of .. ofTTR-CAtreatment.Liverand/orcardiactransplantationcanbe
o Ste ild l,em tha es ah bo su el nd ceha ove
f
Tdi 1sap op re Tar 2ed oeif dein mfla am dm oa et sio nn otwo eu xl cd lub de ec co hm rop nl ie cte ll oy wa -b gs re an dt e. ....
considered only in end-stage disease of familial TTR-CA.
inflammation. .. Tafamidis reduced all-cause mortality and CV hospitalizations in
.
.. cardiacornon-cardiacbiopsy-provenhereditaryandwtTTR-CA,
.
.
. mainly in those patients with NYHA class I and II at baseline.
.
needed with a grade 2(cid:2)3 positivity of scintigraphy with SPECT .
. Functionalimprovementoccurredwithin6months,whereasthe
(Figure21).973 ...
decrease in mortality took nearly 2 years to occur.979,980
.
.
. Intravenouspatisiran,asmallRNAinterferingmolecule,orsubcu- .
.
14.6.2 Therapyofamyloidosisandheartfailure . taneousinotersen,antisenseoligonucleotideagainstTTR,maybe
.
.
Maintenanceofeuvolaemiaiscentraltomanagementbutischal- . considered in those patients with combined hTTR-
.
lengingduetothemarkedlyreducedventricularcapacitance.977If .. polyneuropathy and CA (Figure 21).981,982 Off-label use of diflu-
.
. HFsymptomsarepresent,aloopdiuretic,possiblywithanMRA, . nisalmaybeconsideredinwtTTR-CAincombinationwithapro-
.
maybegiven,butorthostatichypotensionmaycauseintolerance. .. tonpumpinhibitor.983
.
.
Beta-blockers,digitalis,ACE-I,ARBs,orARNImaynotbewelltol- .
.
.
eratedbecauseofhypotension,andtheirplaceinCAtreatmentis .
.
.
unsettled. Their withdrawal must be often considered due to .
.
hypotensionand/orbradycardia.973,974CCBshouldbeavoidedas .. 14.7 Iron overload cardiomyopathy
.
.
they may cause severe hypotension and fatigue, or form com- .. Ironoverloadresultseitherfromgeneticallydeterminedincreased
.
plexeswithamyloid.966 .. intestinalironabsorptioninthecontextofhereditaryhaemochro-
.
Amyloid infiltration of the atrial wall leads to atrial myopathy .. matosis (primary iron overload) or from multiple blood transfu-
.
and electromechanical dissociation with high embolic risk. .. sions required for the management of haematological conditions
.
PatientswithCAandhistoryofAFshouldreceiveanticoagulation. .. such as beta-thalassaemia (secondary iron overload).984 In iron
.
There is no evidence to support anticoagulation for patients .. overload, the iron binding capacity of transferrin is saturated and
.
in SR, yet.7,978 Amiodarone is the preferred antiarrhythmic .. non-transferrin-bound iron enters cardiomyocytes through L-
.
agent.973 . type calcium channels, causing oxidative myocardial damage.985
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 88 ---
3686 ESCGuidelines
.
Table35 “Redflags”formostcommonformsofcardiac
... Recommendationsforthetreatmentoftransthyretin
. amyloidosis-cardiacamyloidosis
amyloidosis .
.
.
.
Type RedFlag TTR AL .. Recommendations Classa Levelb
.
Extracardiac Polyneuropathy X X ..
.. Tafamidisisrecommendedinpatientswith
Dysautonomia X X .
.. genetictestingprovenhTTR-CAandNYHA
Skinbruising X .
.. classIorIIsymptomsto I B
Macroglossia X ...
reducesymptoms,CVhospitalizationand
.
Deafness X .. mortality.979
.
Bilateralcarpaltunnelsyndrome X .. Tafamidisisrecommendedinpatientswith
.
Rupturedbicepstendon X .. wtTTR-CAandNYHAclassIorIIsymptomsto
.. I B
Lumbarspinalstenosis X . reducesymptoms,CVhospitalizationand .
Vitreousdeposits Xa .. mortality.979
.
.
Familyhistory Xa ..
. CA=cardiacamyloidosis; CV=cardiovascular; hTTR=hereditary transthyretin;
.
Renalinsufficiency X . NYHA=NewYorkHeartAssociation;wtTTR=wild-typetransthyretin.
.
Proteinuria X
.... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
Cardiac Clinical ..
.
Hypotensionornormotensiveif X X ..
.
previouslyhypertensive
.
.
ECG . cardiomyopathy(IOCM),whichmayhaveeitherarestrictiveora
.
.
Pseudo-infarctECGpattern X X .. dilatedphenotype,theformerpotentiallyevolvingtothelatteras
.
Low/decreasedQRSvoltageto X X .. the disease advances. Myocardial iron deposition can be accu-
.
degreeofLVthickness .. ratelyestimatedbytheCMRT2*technique;T2*valuesarecorre-
.
AVconductiondisease X X .. lated with left and right ventricular systolic function and predict
.
Laboratory .. the development of iron-induced HF or arrhythmias.984
.
DisproportionallyelevatedNT- X X .. PreventionofIOCMissuccessfullyaccomplishedwithironchela-
.
proBNPtodegreeofHF .. tors,includingdeferoxamine,deferiprone,anddeferasirox,while
.
Persistingelevatedtroponinlevels X X .. establishedIOCMmaybecompletelyreversedbyintensifiedand
.
Echocardiography
.. combinedironchelationtherapy.985
.
.
Granularsparklingofmyocardium X X ..
.
Increasedrightventricularwall X X ..
.
thickness ..
.
IncreasedAVvalvethickness X X .. 14.8 Adult congenital heart disease
.
Pericardialeffusion X X .. ThemanagementofACHDhasbeenreviewedindetailinarecent
.
Reducedlongitudinalstrainwith X X .. ESCguideline.988HFisacommonproblemaffecting20(cid:2)50%of
. apicalsparingpattern .. the ACHD population, and an important cause of death.989 The
.
.
CMR . pathophysiologyofcardiacdysfunctioninACHDisoftendifferent
.
.
SubendocardialLGE X X . from non-congenital (acquired) heart disease, in particular in .
.
ElevatednativeT1values X X . thosewith:asystemicrightventricle(RV),afailingsubpulmonary .
Increasedextracellularvolume X X .. ventricle, a single ventricle,988 surgery-related injury, chronic .
.
Abnormalgadoliniumkinetics X X . pressure/volume overload in systemic and sub-pulmonary
. .
. ventricles, and those with hypertrophy or non-compaction
.
.
AL=lightchainimmunoglobulin;AV=atrio-ventricular;CA=cardiacamyloido- .. induced by gene mutations. Therefore, extrapolation
.
sis;CMR=cardiacmagneticresonance;ECG=electrocardiogram;HF=heartfail- . of current HF treatment guidelines to ACHD patients is not
.
u ter re m;L inG alE p= rola -t Be -tg ya pd eo nli an tiu rim uree tn icha pn ec pe tm ide e;n Qt; RLV S== Qle ,ft Rv ae nn dtr Sicu wla ar v; eN s(T c- op mro bB inN atP io= nN o-
f
....
alwaysappropriate.Inaddition,thefewavailabledataonHFtreat-
threeofthegraphicaldeflections);TTR=transthyretin. .. ments in ACHD patients are often inconclusive and are derived
.
Modifiedfrom973. .. from small patient cohorts. As a consequence, ACHD specific
aHereditaryTTR-CA. ...
recommendations are mostly based on clinical experience or
.
.. positionstatements.990
.
Additional iron-induced complications, such as liver disease and .. Importantly,ACHDpatientswithHFshouldbereferredtoexpert
.
endocrineabnormalities,furthercontributetocardiacdeteriora- .. centres.Thegeneralprinciplesofmanagement,whileawaitingtrans-
.
tion.986,987 The end result is the development of iron overload . fertospecialistcentres,issummarizedinTable36.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 89 ---
ESCGuidelines 3687
Diagnosis and treatment of cardiac amyloidosis in heart failure patients
Cardiac amyloidosis suspected
HF and LV wall thickness ≥12 mm
AND age ≥65 or at least 1 red flaga
Serum free light-chain assay
99mTc-PYP, DPD or HMDP
Serum and urine protein electrophoresis
scintigraphy with SPECT
with immunofixation
Abnormalhaematology Normalhaematology Normalhaematology
Both abnormal All normal
No myocardialuptake Grade 1 uptake Grade2–3 uptake
Cardiac amyloidosis
ATTR
on CMR imaging
Genetic counselling
Positive or
Negative
inconclusive
Tafamidis
(Class I)
Histological
Histological
confirmation
confirmation Amyloidosis Consider patisiran Amyloidosis
of diagnosis
to subtype unlikely orinotersen if unlikely (cardiac/
(usually cardiac)b hereditaryATTR
extracardiac)c
and polyneuropathy
Figure21 Diagnosisandtreatmentofcardiacamyloidosisinheartfailurepatients.Basedon.973ATTR= transthyretinamyloidosis;CMR= car-
diacmagneticresonance;DPD= 3,3-diphosphono1,2-propanodicarboxylicacid;HF= heartfailure;HMDP= hydroxymethylenediphosphonate;
LV=left ventricular; SPECT= single-photon emission computed tomography; 99mTc-PYP= technetium-labelled 99mTc-pyrophosphate. aRed
flagsarelistedinTable35.bGenerallyrequiresendomyocardialbiopsyforadiagnosisofthecardiacsubtype.cRequiresbiopsythatmaybecardiac
orabdominal.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 90 ---
3688 ESCGuidelines
.
.
. (3) ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are
Table36 Treatmentofadultcongenitalheartdisease ..
. recommendedascornerstonetherapiesforpatientswithHFrEF.
andheartfailureinspecializedcentres .
.
. (4) ICDs are recommended in selected patients with HFrEF of an
.
.
ACHDpatientswithchronicHFshouldbereferredtospecialized . ischaemicaetiologyandshouldbeconsideredinthosewithanon-
.
.
centres. . ischaemicaetiology.
.
.
SpecificguidelinesformedicaltreatmentofchronicHFinACHDare .. (5) CRT-P/DisrecommendedinthosepatientswithHFrEF,insinus
.
lacking,andpractitionersshouldfollowthecurrentguidelinesformedical .. rhythm,withaLBBB>_150msandshouldbeconsideredinthose
.
treatmentofHF.Itremainsunknownwhetherthelong-termuseofneu- .. withaLBBB>_130(cid:2)149msornon-LBBB>_150ms.
.
rohormonalmodulatorsaffectsclinicaloutcomesandprognosisin .. (6) Advanced HF strategies (heart transplantation/MCS) may be
.
ACHD. .. appropriateinselectedpatients.
.
Sacubitril/valsartanmaydecreasemorbidity,991(cid:2)993however,norecom- .. (7) ACE-I/ARNI, beta-blockers, and MRA may be considered in
.
mendationcanbemadeatthismomentbasedontheretrospectiveor .. patientswithHFmrEF.
. anecdoticalnatureoftheseobservations. .. (8) The diagnosis of HFpEF requires objective evidence of cardiac
.
Co-morbiditiesinHFsuchasdiabetesmellitus,AF,CSA,irondeficiency,
... structural,orfunctionalabnormalitiesaswellaselevatedplasma
andcachexiashouldbetreatedaccordingtospecificrecommendations
... NP concentrations consistent with the presence of LV diastolic
reportedinthisdocument.
... dysfunctionandraisedLVfillingpressures.Adiastolicstresstestis
.. recommendedwhenthesemarkersareequivocal.
Inabiventricularcirculation,patientswithanimpairedsystemicLV .
.. (9) Todate,notreatmenthasbeenshowntoreducemortalityand
shouldbetreatedwithconventionalHFtherapy;thismayalsobeconsid- .
.. morbidityinpatientswithHFpEF.
eredinsymptomaticpatientswithafailingsystemicrightventricle. .
.. (10) ItisrecommendedthatallpatientswithHFbeenrolledinamulti-
Diureticsarerecommendedtocontrolsymptomsoffluidretention. .
.. disciplinaryHF-MP.
Treatmentofsymptomaticpatientswithafailingsingleventricleina ..
. (11) Exerciseisrecommendedforallpatientswhoareable,toimprove
Fontancirculation,orinthecaseofapersistentright-to-leftshunt,should ..
. exercisecapacityandQOL,andreduceHFhospitalization.
alwaysbecarefullyinitiated,takingthelabilebalanceofventricularpre- ..
. (12) Patients withadvanced HF refractory to medical/device therapy
loadandsystemicafterloadintoaccount. ..
. and who do not have absolute contraindications should be
.
CRTmaybeatherapeuticoptioninACHDpatientswithHF,butevi- .
. referred for consideration of heart transplantation. MCS should
.
denceinthisspecificsettingisstilllacking.EfficacyofCRTwilldependon .
. alsobeconsideredasBTTorDTinselectedpatients.
.
theunderlyingstructuralandfunctionalsubstrate,suchasanatomyofthe .
. (13) FourmajorclinicalpresentationsofacuteHFmayoccur:ADHF,
.
systemicventricle(left,right,orfunctionallysingle),presenceanddegree .
. acutepulmonaryoedema,RVfailure,andcardiogenicshock.
.
ofstructuralsystemicAVvalveregurgitation,primarymyocardialdisease ..
(14) TreatmentofacuteHFisbasedondiureticsforcongestion,ino-
.
orscarring,andtypeofelectricalconductiondelay.988 ..
tropes,andshort-termMCSforperipheralhypoperfusion.
.
TreatmentofacuteHFinACHDpatientsshouldbeinanexpertcentre, ... (15) Patients hospitalized for HF should be carefully evaluated to
withproperknowledgeofinotropes,theavailabilityofextracorporeal ... excludepersistentsignsofcongestion.Oraltreatmentshouldbe
membraneoxygenation,andadvancedbridgingtechniques.988,994 ...
optimizedbeforedischarge.
.
TimelyevaluationfortransplantationbyACHDHFspecialistsinatrans- .. (16) Inaddition to oral anticoagulation, a strategy of rhythm control
.
plantcentrewithACHDexpertiseisrecommended. .. includingcatheterablationshouldbeconsideredinpatientswhose
.
Ventricularassistdevicescanbridgepatientstotransplantation,orina .. symptomsand/orcardiacdysfunctionareassociatedwithAF.
.
subgroupofpatients,maybeanoptionasdestinationtherapy. .. (17) SAVRorTAVI,asadvisedbytheHeartTeam,arerecommended
.
ACHD=adultcongenitalheartdisease;AF=atrialfibrillation;AV=atrioventricu- .. inpatientswithsymptomaticsevereaorticvalvestenosis.
. lar;CRT=cardiacresynchronizationtherapy;CSA=centralsleepapnoea;HF= .. (18) PatientswithisolatedsignificantSMRandCOAPTcriteriashould
. heartfailure;LV=leftventricular. .. be considered for percutaneous edge-to-edge repair, whereas
.
.. thosewithSMRandCAD,whoneedrevascularization,shouldbe
.
.. consideredforsurgery.
.
.
. (19) ItisrecommendedthatpatientswithtypeIIdiabetesaretreated
.
.
15 Key messages . withSGLT2inhibitors.
.
.
. (20) Patientsshouldbeperiodicallyscreenedforanaemiaandirondefi-
.
.
(1) PatientswithHFareclassifiedbasedontheirLVEF.Thosewitha . ciency and i.v. iron supplementation with ferric carboxymaltose
.
.
LVEFbetween41%and49%aredefinedas‘mildlyreducedLVEF’ . should be considered in symptomatic patients with LVEF <45%
.
.
(HFmrEF). . and iron deficiency, and in patients recently hospitalized for HF
.
.
(2) MeasurementofNPsandechocardiographyhavekeyrolesinthe . andwithLVEF<_50%andirondeficiency.
.
.
diagnosisofHF. .
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 91 ---
ESCGuidelines 3689
.
16 Gaps in evidence .. (6) AdvancedHF
.
.
. i. BetterdefinitionofriskprofilesaccordingtoINTERMACSand
.
Majoradvances inthe diagnosis and treatmentofpatientswith HF .. otherclassifications
.
haveoccurredoverrecentyears.Strongevidencefornewtreatment .. ii. RCTstoestablishtheeffectsonoutcomesoflong-termMCS
.
.
optionshavebeengivenbyrecentRCTsandHFmanagementmay . in hospitalized patients as well as in ambulatory outpatients
.
.
undergomajorchangesinthenextyears.Newdiscoveries,however, . (forinstanceINTERMACS4(cid:2)6profiles)
.
.
pose new challenges and many areas with lack of evidence still . iii. Advancesinlong-termMCS,includingstrategiestoreducethe
.
.
remain.Thefollowingisashortlistofselected,commonissuesthat . riskofbleeding,thromboembolicevents,andinfection
.
.
deservetobeaddressedinfutureclinicalresearch. .. iv. Advancesinmedicaltreatmentforthemanypatientswhocan-
.
.. notundergoMCSorhearttransplantationincludingdevelop-
(1) Definitionandepidemiology .
.. mentoftreatmentstrategies,novelinotropesormyotropes
i. Further research into the underlying characteristics, patho- .
.. forpatientswithadvancedHF
physiology,anddiagnosisofHFmrEFandHFpEF . .. (7) AHF
ii. Consensusaboutnormalvalues/rangesofEF .
.. i. Better definition and classification of patient phenotypes to
iii. BetterphenotypingofHFpEF .
.. facilitateimprovedtreatment
iv. More information on the incidence and prevalence of .
.. ii. Evidence-baseduseofimagingtechniquesandbiomarkersthat
‘recoveredLV’systolicfunction . .. haveanimpactonpatients’clinicalcourse
(2) Diagnosis .
.. iii. Developmentofbetterstrategiesforcongestionrelief,includ-
i. Definitivestudiesontheroleofbiomarkers,focusingontheir ...
ingmonitoringofdiureticadministration,and/ortoimprove
additivevalueinthediagnosisofHF ...
organperfusion
ii. More randomized studies on screening for HF in asympto- ..
. iv. Identificationoftreatmentswithanimpactonpost-discharge
maticsubjectsthatmaytranslateintoimprovedoutcomes ..
. outcomes
iii. Studiesonbiomarkersshowingtheimpactonoutcomeoftheir ..
. v. Newdevicesforshort-termMCS
measurementsfortheidentificationofsubjectsatriskofdevel- ..
. vi. Definitionofevidence-basedtreatmentoptionsandtherapeu-
opingHFaswellastoguidetreatmentinpatientswithHF ..
. ticalgorithmsforpatientswithcardiogenicshock
iv. Validated diagnostic protocols for the diagnosis of HFmrEF ..
andHFpEF
... (8) CVcomorbidities
(3) PharmacotherapyofCHF
... i. RCTsshowingbeststrategiesforthetreatmentofventricular
i. Pragmatic studies on the order of adding disease-modifying
... arrhythmias
drugsforHFrEF
... ii. RCTstoestablishtheroleofcoronaryrevascularizationpro-
.. ceduresindifferentpatientsubsets
ii. SpecifictherapiesforHFmrEFandHFpEFand,likely,theirdif- .
.
. iii. RCTs to establish the impact on patients’ outcomes and/or
ferentphenotypes .
.
. QOLofpercutaneoustreatmentofmitralortricuspidvalve
iii. MoredataandprospectiveclinicaltrialsofHFrEFtherapiesin .
.
patientswitheGFR<30mL/min/1.73m2 .. diseaseinpatientswithHF
.
. (9) Non-CVcomorbidities
iv. FurtherevidencefromprospectiveRCTsforthetreatmentof .
.
specificHFphenotypes:myocarditis,cardiotoxicity,inherited .. i. RCTs addressing cachexia and/or sarcopenia and/or frailty
.
CMPs,PPCM,amyloidosis .. and showing the impact of treatment on QOL and/or
. v. Managementstrategiesandtherapiesfor‘recoveredLV’sys- .. outcome
.
tolicfunction .. ii. RCTsofmedicaltherapiesordevicesinpatientswithsevere
.
vi. Moreevidenceontheeffectsoffluidrestriction,dietarysalt .. CKDandHF .
restriction,andnutrition ... iii. RCTsshowingtheeffectsonoutcomesofmedicaltreatment
(4) Devicesandinterventions ... ofelectrolyteabnormalities
.
i. IndicationsforICDsinspecificsubgroupsofHFmrEF/HFpEF .. iv. RCTs showing the effects on outcomes of treatment of
.
andoptimal selectionofICD candidates inHFrEF, including .. CSA
.
patientswithischaemicandnon-ischaemiccardiomyopathy .. v. Prospectivestudiesshowingtheimpactonoutcomesand/or
.
ii. MoreresearchonCRTefficacyinAF .. QOLofearlydiagnosis,betterpreventionandtreatmentof
.
iii. Furtherprospectiverandomizedstudiesshowingtheimpact .. cardiotoxicityofcancertherapies
.
onoutcomesofAFablationstrategiescomparedtoOMTin .. vi. Bettertreatmentofinfectionsandpreventionofcardiacinjury
.
HFpatients .. withinfection
.
iv. Further research on the percutaneous treatment of valve .. (10) Specialconditions
.
heartdiseaseanditsimpactonpatients’outcomesandQOL .. i. RCTsoftreatmentforPPCM
.
v. LargerRCTsonCCMandbaroreceptorstimulationinHFrEF .. ii. Better phenotyping of CMPs through genetic testing, bio-
.
(5) Diseasemanagement .. markersandimagingmodalities,andtailoringoftherapy
.
.
i. The role ofremote monitoring strategies in HF in the post . iii. RCTsoftreatmentofdifferenttypesofmyocarditis,including
.
.
COVID-19era . immunosuppressivetherapies
.
.
ii. Studiesonoptimalmodelsforfollow-upofstableHFpatients . iv. RCTsofnewtreatmentsofdifferentformsofcardiacamyloid
.
.
iii. Studiestodeterminespecificoptionsforpalliativecare . v. BetterdefinitionandtreatmentofLAmyopathy.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 92 ---
3690 ESCGuidelines
17 ‘What to do’ and ‘what not to do’ messages from the guidelines
Recommendations Classa Levelb
RecommendationsforthediagnosisofchronicHF
BNP/NT-proBNP.c I B
12-leadECG. I C
Transthoracicechocardiography. I C
Chestradiography(X-ray). I C
Routinebloodtestsforcomorbidities(includingfullbloodcount,ureaandelectrolytes,thyroidfunction,fastingglucoseand
I C
HbA1c,lipids.Ironstudies(TSATandferritin).
CMRisrecommendedfortheassessmentofmyocardialstructureandfunctioninthosewithpoorechocardiogramacoustic
I C
windows.
CMRisrecommendedforthecharacterizationofmyocardialtissueinsuspectedinfiltrativedisease,Fabrydisease,inflamma-
I C
torydisease(myocarditis),LVnon-compaction,amyloid,sarcoidosis,ironoverload/haemochromatosis.
Invasivecoronaryangiographyisrecommendedinpatientswithanginadespitepharmacologicaltherapyorsymptomaticven-
I B
triculararrhythmias.
Cardiopulmonaryexercisetestingisrecommendedasapartoftheevaluationforhearttransplantationand/orMCS. I C
RightheartcatheterizationisrecommendedinpatientswithsevereHFbeingevaluatedforhearttransplantationorMCS. I C
RecommendationsforthetreatmentofHFrEF
ACE-IisrecommendedforpatientswithHFrEFtoreducetheriskofHFhospitalizationanddeath. I A
Beta-blockerisrecommendedforpatientswithstableHFrEFtoreducetheriskofHFhospitalizationanddeath. I A
MRAisrecommendedforpatientswithHFrEFtoreducetheriskofHFhospitalizationanddeath. I A
DapagliflozinorempagliflozinarerecommendedforpatientswithHFrEFtoreducetheriskofHFhospitalizationanddeath. I A
Sacubitril/valsartanisrecommendedasareplacementforanACE-IinpatientswithHFrEFtoreducetheriskofHFhospitaliza-
I B
tionanddeath.
DiureticsarerecommendedinpatientswithHFrEFwithsignsand/orsymptomsofcongestiontoalleviateHFsymptoms,
I C
improveexercisecapacityandreduceHFhospitalizations.
AnARBcisrecommendedtoreducetheriskofHFhospitalizationandCVdeathinsymptomaticpatientsunabletotolerate
I B
anACE-IorARNI(patientsshouldalsoreceiveabeta-blockerandanMRA).
TheadditionofanARB(orrenininhibitor)tothecombinationofanACE-IandanMRAisnotrecommendedinpatientswith
III C
HF,becauseoftheincreasedriskofrenaldysfunctionandhyperkalaemia.
AnICDisrecommendedtoreducetheriskofsuddendeathandall-causemortalityinpatientswhohaverecoveredfroma
ventriculararrhythmiacausinghaemodynamicinstability,andwhoareexpectedtosurvivefor>1yearwithgoodfunctional I A
status,intheabsenceofreversiblecausesorunlesstheventriculararrhythmiahasoccurred<48hafteraMI.
AnICDisrecommendedtoreducetheriskofsuddendeathandall-causemortalityinpatientswithsymptomaticHF(NYHA
classII(cid:2)III)ofanischaemicaetiology(unlesstheyhavehadanMIintheprior40days—seebelow),andanLVEF<_35%despite I A
>_3monthsofOMT,providedtheyareexpectedtosurvivesubstantiallylongerthan1yearwithgoodfunctionalstatus.
ICDimplantationisnotrecommendedwithin40daysofanMIasimplantationatthistimedoesnotimproveprognosis. III A
ICDtherapyisnotrecommendedinpatientsinNYHAclassIVwithseveresymptomsrefractorytopharmacologicaltherapy
III C
unlesstheyarecandidatesforCRT,aVAD,orcardiactransplantation.
CRTisrecommendedforsymptomaticpatientswithHFinSRwithaQRSduration>_150msandLBBBQRSmorphologyand
I A
withLVEF<_35%despiteOMTinordertoimprovesymptomsandreducemorbidityandmortality.
CRTratherthanRVpacingisrecommendedforpatientswithHFrEFregardlessofNYHAclassorQRSwidthwhohavean
I A
indicationforventricularpacingforhighdegreeAVblockinordertoreducemorbidity.ThisincludespatientswithAF.
CRTisnotrecommendedinpatientswithaQRSduration<130mswhodonothaveanindicationforpacingduetohigh-
III A
degreeAVblock.
RecommendationsforthetreatmentofHFmrEFandHFpEF
DiureticsarerecommendedinpatientswithcongestionandHFmrEFinordertoalleviatesymptomsandsigns. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 93 ---
ESCGuidelines 3691
Screeningfor,andtreatmentof,aetiologies,andCVandnon-CVcomorbiditiesisrecommendedinpatientswithHFpEF(see
I C
relevantsectionsofthisdocument).
DiureticsarerecommendedincongestedpatientswithHFpEFinordertoalleviatesymptomsandsigns. I C
RecommendationsforthepreventionofchronicHF
TreatmentofhypertensionisrecommendedtopreventordelaytheonsetofHF,andtopreventHFhospitalizations. I A
TreatmentwithstatinsisrecommendedinpatientsathighriskofCVdiseaseorwithCVdiseaseinordertopreventordelay
I A
theonsetofHF,andtopreventHFhospitalizations.
SGLT2inhibitors(canagliflozin,dapagliflozin,empagliflozin,ertugliflozin,sotagliflozin)arerecommendedinpatientswithdia-
I A
betesathighriskofCVdiseaseorwithCVdiseaseinordertopreventHFhospitalizations.
Counsellingagainstsedentaryhabit,obesity,cigarettesmoking,andalcoholabuseisrecommendedtopreventordelaythe
I C
onsetofHF.
OtherrecommendationsforthemanagementofchronicHF
ItisrecommendedthatHFpatientsareenrolledinamultidisciplinaryHFmanagementprogrammetoreducetheriskofHF
I A
hospitalizationandmortality.
Self-managementstrategiesarerecommendedtoreducetheriskofHFhospitalizationandmortality. I A
Eitherhome-basedand/orclinic-basedprogrammesimproveoutcomesandarerecommendedtoreducetheriskofHFhospi-
I A
talizationandmortality.
ExerciseisrecommendedforallpatientswhoareableinordertoimproveexercisecapacityandQOL,andreduceHF
I A
hospitalization.d
RecommendationsfortreatmentofpatientswithadvancedHF
Patientsbeingconsideredforlong-termMCSmusthavegoodcompliance,appropriatecapacityfordevicehandlingandpsy-
I C
chosocialsupport.
HearttransplantationisrecommendedforpatientswithadvancedHF,refractorytomedical/devicetherapyandwhodonot
I C
haveabsolutecontraindications.
RecommendationsfortreatmentofpatientswithacuteHF
OxygenisrecommendedinpatientswithSpO <90%orPaO <60mmHgtocorrecthypoxaemia. I C
2 2
Intubationisrecommendedforprogressiverespiratoryfailurepersistinginspiteofoxygenadministrationornon-invasive
I C
ventilation.
IntravenousloopdiureticsarerecommendedforallpatientswithAHFadmittedwithsigns/symptomsoffluidoverloadto
I C
improvesymptoms.
Thromboembolismprophylaxis(e.g.withLMWH)isrecommendedinpatientsnotalreadyanticoagulatedandwithnocontra-
I A
indicationtoanticoagulation,toreducetheriskofdeepvenousthrombosisandpulmonaryembolism.
Inotropicagentsarenotrecommendedroutinely,duetosafetyconcerns,unlessthepatienthassymptomatichypotension
III C
andevidenceofhypoperfusion.
Routineuseofopiatesisnotrecommended,unlessinselectedpatientswithsevere/intractablepainoranxiety. III C
IABPisnotroutinelyrecommendedinpost-MIcardiogenicshock. III B
RecommendationsformanagementofpatientsafterHFhospitalization
ItisrecommendedthatpatientshospitalizedforHFbecarefullyevaluatedtoexcludepersistentsignsofcongestionbefore
I C
dischargeandtooptimizeoraltreatment.
Itisrecommendedthatevidence-basedoralmedicaltreatmentbeadministeredbeforedischarge. I C
Anearlyfollow-upvisitisrecommendedat1(cid:2)2weeksafterdischargetoassesssignsofcongestion,drugtolerance,andstart
I C
and/oruptitrateevidence-basedtherapy.
RecommendationsfortreatmentofpatientswithHFandAF
Long-termtreatmentwithanoralanticoagulantisrecommendedinallpatientswithAF,HF,andCHADS-VAScscore>2in
2 2 I A
menor>3inwomen.
DOACsarerecommendedinpreferencetoVKAsinpatientswithHF,exceptinthosewithmoderateorseveremitralsteno-
I A
sisormechanicalprostheticheartvalves.
UrgentECVisrecommendedinthesettingofacuteworseningofHFinpatientspresentingwithrapidventricularratesand
I C
haemodynamicinstability.
Treatmentwiththeanti-arrhythmicagentsflecainide,encainide,disopyramide,dronedarone,andD-sotalolisnotrecom-
III A
mendedduetosafetyconcerns.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 94 ---
3692 ESCGuidelines
DiltiazemorverapamilarenotrecommendedinpatientswithHFrEF,astheyincreasetheriskofHFworseningandHF
III C
hospitalization.
RecommendationsfortreatmentofpatientswithHFandaorticstenosis
Aorticvalveintervention,TAVIorSAVR,isrecommendedinpatientswithHFandseverehigh-gradientaorticstenosisto
I B
reducemortalityandimprovesymptoms.
ItisrecommendedthatthechoicebetweenTAVIandSAVRbemadebytheHeartTeam,accordingtoindividualpatientpref-
erenceandfeaturesincludingage,surgicalrisk,clinical,anatomicalandproceduralaspects,weighingtherisksandbenefitsof I C
eachapproach.
RecommendationsfortreatmentofpatientswithHFanddiabetes
SGLT2inhibitors(canagliflozin,dapagliflozin,empagliflozin,ertugliflozin,sotagliflozin)arerecommendedinpatientswith
I A
T2DMatriskofCVeventstoreducehospitalizationsforHF,majorCVevents,end-stagerenaldysfunction,andCVdeath.
SGLT2inhibitors(dapagliflozin,empagliflozin,andsotagliflozin)arerecommendedinpatientswithT2DMandHFrEFto
I A
reducehospitalizationsforHFandCVdeath.
Thiazolidinediones(glitazones)arenotrecommendedinpatientswithHF,astheyincreasetheriskofHFworseningandHF
III A
hospitalization.
TheDPP-4inhibitorsaxagliptinisnotrecommendedinpatientswithHF. III B
RecommendationsfortreatmentofpatientswithHFandirondeficiency
ItisrecommendedthatallpatientswithHFbeperiodicallyscreenedforanaemiaandirondeficiencywithafullbloodcount,
I C
serumferritinconcentration,andTSAT.
TreatmentofanaemiainHFwitherythropoietin-stimulatingagentsisnotrecommendedintheabsenceofotherindications
III B
forthistherapy.
RecommendationfortreatmentofpatientswithHFandsleepapnoea
Adaptiveservo-ventilationisnotrecommendedinpatientswithHFrEFandapredominantCSAbecauseofanincreasedall-
III A
causeandCVmortality.
RecommendationfortreatmentofpatientswithHFandarthritis
NSAIDsorCOX-2inhibitorsarenotrecommendedinpatientswithHF,astheyincreasetheriskofHFworseningandHF
III B
hospitalization.
RecommendationfortreatmentofpatientswithHFandcancer
Itisrecommendedthatcancerpatientsatincreasedriskforcardiotoxicity,definedbyahistoryorriskfactorsofCVdisease,
previouscardiotoxicityorexposuretocardiotoxicagents,undergoCVevaluationbeforescheduledanticancertherapy,pref- I C
erablybyacardiologistwithexperience/interestinCardio-Oncology.
RecommendationsfortreatmentofpatientswithHFandamyloidosis
TafamidisisrecommendedinpatientswithgenetictestingprovenhTTR-CAandNYHAclassIorIIsymptomstoreduce
I B
symptoms,CVhospitalizationandmortality.
TafamidisisrecommendedinpatientswithwtTTR-CAandNYHAclassIorIIsymptomstoreducesymptoms,CVhospitaliza-
I B
tionandmortality.
ACE-I=angiotensin-convertingenzymeinhibitor;AF=atrialfibrillation;AHF=acuteheartfailure;ARB=angiotensin-receptorblocker;ARNI=angiotensinreceptor-neprilysin
inhibitor;AV=atrio-ventricular;BNP=B-typenatriureticpeptide;CHA2DS2-VASc=congestiveheartfailureorleftventriculardysfunction,Hypertension,Age>_75(doubled),
Diabetes,Stroke(doubled)-Vasculardisease,Age65(cid:2)74,Sexcategory(female)(score);CMP=cardiomyopathy;CMR=cardiacmagneticresonance;CRT=cardiacresynchro-
nizationtherapy;CSA=centralsleepapnoea;CV=cardiovascular;DOAC=direct-actingoralanticoagulant;DPP-4=dipeptidylpeptidase-4;ECG=electrocardiogram;ECV=
electricalcardioversion;HbA1c=glycatedhaemoglobin;HF=heartfailure;HFmrEF=heartfailurewithmildlyreducedejectionfraction;HFpEF=heartfailurewithpreserved
ejectionfraction;HFrEF=heartfailurewithreducedejectionfraction;hTTR=hereditarytransthyretin;IABP=intra-aorticballoonpump;ICD=implantablecardioverter-defib-
rillator;LBBB=leftbundlebranchblock;LMWH=low-molecular-weightheparin;LV=leftventricular/ventricle;LVEF=leftventricularejectionfraction;MCS=mechanicalcir-
culatorysupport;MI=myocardialinfarction;MRA=mineralocorticoidreceptorantagonist;NSAID=non-steroidalanti-inflammatorydrug;NT-proBNP=N-terminalpro-B-
typenatriureticpeptide;NYHA=NewYorkHeartAssociation;OMT=optimalmedicaltherapy;PaO2=partialpressureofoxygen;QOL=qualityoflife;QRS=Q,R,andS
waves(onanECG);RV=rightventricular;SAVR=surgicalaorticvalvereplacement;SGLT2=sodium-glucoseco-transporter2;SpO2=transcutaneousoxygensaturation;SR
=sinusrhythm;T2DM=type2diabetesmellitus;TAVI=transcatheteraorticvalveimplantation;TSAT=transferrinsaturation;VAD=ventricularassistdevice;VKA=vitaminK
antagonist;wtTTR-CA=wild-typetransthyretincardiacamyloidosis.
aClassofrecommendation.
bLevelofevidence.
cReferencesarelistedinsection4.2forthisitem.
dInthosewhoareabletoadheretotheexerciseprogramme.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 95 ---
ESCGuidelines 3693
.
18 Quality indicators .. aredevelopedhasbeenpublished997and,todate,asuiteofQIsfor
.
.. aninitialtrancheofCVconditionshasbeenproduced.998,999Tofacili-
.
QIs are tools that may be used to evaluate care quality, including .. tatequalityimprovementinitiatives,thedisease-specificESCQIsare
.
that of processes of care and clinical outcomes.995 They may .. includedincorrespondingESCClinicalPracticeGuidelines.7,1000This
.
also serve as a mechanism for enhancing adherence to guideline .. isfurtherenhancedbywayoftheirintegrationintheESCregistries,
.
recommendations,throughqualityassuranceendeavoursandbench- .. suchastheEURObservationalResearchProgramme(EORP)andthe
.
markingofcareproviders.996Assuch,theroleofQIsindrivingqual- .. European Unified Registries On Heart Care Evaluation and
.
ityimprovementisincreasinglyrecognizedandattractsinterestfrom .. RandomizedTrials(EuroHeart)project.1001
.
.
healthcare authorities, professional organizations, payers, and the . ForpatientswithHF,QIsmayhelphealthcareproviderstosimul-
.
public.997 .. taneously operationalize discrete guideline recommendations and
.
.
TheESCrecognizestheneedformeasuringandreportingquality . enablethediscriminationbetweenmissedopportunitiesandappro-
.
.
andoutcomesofCVcare.ThemethodologybywhichtheESCQIs . priate care. Furthermore, QIs allow the capture of patients’
Table37 MainEuropeanSocietyofCardiologyqualityindicatorsfortheevaluationofcareandoutcomesforpatients
withheartfailure(afulllistispublishedinaseparatearticle)
Domain1.StructuralQIsa
Main(1):CentreshouldhaveadedicatedmultidisciplinaryteamtomanagepatientswithHF
Numerator:AvailabilityofadedicatedmultidisciplinaryteamtomanagepatientswithHF.
Domain2.Patientassessmentb
Main(1):ProportionofpatientswithHFwhohaveadocumentationoftheirHFclinicaltype(HFrEF,HFmrEF,HFpEF)
Numerator:NumberofpatientswithHFwhohaveadocumentationoftheirHFclinicaltype(HFrEF,HFmrEF,HFpEF).
Denominator:NumberofpatientswithHF.
Main(2):ProportionofpatientswithHFwhohaveadocumentationoftheirECGfindings
Numerator:NumberofpatientswithHFwhohaveadocumentationoftheirECGfindings.
Denominator:NumberofpatientswithHF.
Main(3):ProportionofpatientswithHFwhohavetheirNPsmeasured
Numerator:NumberofpatientswithHFwhohaveadocumentationoftheirNPslevels.
Denominator:NumberofpatientswithHF.
Domain3.Initialtreatment
Main(1).ProportionofpatientswithHFrEFwhoareprescribedthebeta-blockerbisoprolol,carvedilol,sustained-releasemetoprolol
succinate,ornebivololintheabsenceofanycontraindications
Numerator:NumberofpatientswithHFrEFwhoareprescribedthebeta-blockerbisoprolol,carvedilol,sustained-releasemetoprololsuccinate,or
nebivolol.
Denominator:NumberofpatientswithHFrEFwithoutanycontraindicationsforthebeta-blockerbisoprolol,carvedilol,sustained-releasemetoprolol
succinate,andnebivolol.
Main(2).ProportionofpatientswithHFrEFwhoareprescribedACEinhibitor,ARBorARNIintheabsenceofanycontraindications
Numerator:NumberofpatientswithHFrEFwhoareprescribedanACEinhibitor,ARBorARNI.
Denominator:NumberofpatientswithHFrEFwithoutanycontraindicationsforACEinhibitors,ARBsandARNI.
Main(3).ProportionofpatientswithHFwhoareprescribeddiuretictherapyiftheyhaveevidenceoffluidretention
Numerator:NumberofpatientswithHF,withevidenceoffluidretentionwhoareprescribeddiuretictherapy.
Denominator:NumberofpatientswithHFwhohaveevidenceoffluidretentionandnocontraindicationsfordiuretictherapy.
Main(4):ProportionofpatientswithHFrEFwhoareprescribedanMRAintheabsenceofanycontraindications
Numerator:NumberofpatientswithHFrEFwhoareprescribedanMRA.
Denominator:NumberofpatientswithHFrEFwithoutanycontraindicationsforMRA.
Main(5):ProportionofpatientswithHFrEFwhoareprescribedaSGLT2inhibitorintheabsenceofanycontraindications
Numerator:NumberofpatientswithHFrEFwhoareprescribedaSGLT2inhibitor.
Denominator:NumberofpatientswithHFrEFwithoutanycontraindicationsforSGLT2inhibitor.
ACE=angiotensin-convertingenzyme;ARB=angiotensin-receptorblocker;ARNI=angiotensinreceptor-neprilysininhibitor;HF=heartfailure;HFmrEF=heartfailurewith
mildlyreducedejectionfraction;HFpEF=heartfailurewithpreservedejectionfraction;HFrEF=heartfailurewithreducedejectionfraction;ICD=implantablecardioverter-
defibrillator;IHD=ischaemicheartdisease;LBBB=leftbundlebranchblock;LVEF=leftventricularejectionfraction;MRA=mineralocorticoidreceptorantagonist;NP=natriu-
reticpeptide;NYHA=NewYorkHeartAssociation;OMT=optimalmedicaltherapy;QI=qualityindicator;SGLT2=sodium-glucoseco-transporter2.
aStructuralQIsarebinarymeasurements(Yes/No),andthus,haveonlynumeratordefinitions.
bBloodtestsincludeurea,creatinine,electrolytes,fullbloodcount,glucose,glycatedhaemoglobin,thyroid-stimulatinghormone,liverfunctiontest,lipids,andironprofile.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 96 ---
3694 ESCGuidelines
.
.
experience. As such, and in parallel with the writing of these . Massimo Francesco Piepoli, Cardiology, Guglielmo da Saliceto
.
.
guidelines,asuiteofQIsfortheevaluationofcareandoutcomesfor . Hospital,AUSLPiacenza,Piacenza,Italy;SusannaPrice,Cardiology
.
.
patientswithHFwasdeveloped.TheseQIs,alongsidetheirspecifica- . & Adult Intensive Care Unit, Royal Brompton Hospital, London,
.
.
tionsanddevelopmentprocessarepublishedseparatelywithashort . United Kingdom; Giuseppe M.C. Rosano, IRCCS San Raffaele,
.
.
summaryshowninTable37. . Roma, Italy; Frank Ruschitzka, Department of Cardiology,
.
.
. University Hospital Zurich, Zurich, Switzerland; Anne Kathrine
.
.
. Skibelund,Denmark,ESCPatientForum,SophiaAntipolis,France.
.
.
.
.
19 Supplementary data .
.
.
. 21 Appendix
.
.
SupplementarydatawithadditionalSupplementaryFigures,Tables,and .
.
.
text complementing the full text are available on the European Heart .
.. ESCScientificDocumentGroup
JournalwebsiteandviatheESCwebsiteatwww.escardio.org/guidelines. . .. IncludesDocumentReviewersandESCNationalCardiacSocieties.
.
.
.
.
20 Author information .. Document Reviewers: Rudolf A. de Boer (CPG Review
.
.. Coordinator) (Netherlands), P. Christian Schulze (CPG Review
. .
Author/TaskForceMemberAffiliations:MariannaAdamo, . Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor
.
.
Medical and Surgical Specialties, Radiological Sciences and Public, . Aboyans(France),StamatisAdamopoulos(Greece),StefanD.Anker
.
.
ASSTSpedaliCivilidiBrescia,Brescia,Italy;AndreasBaumbach, . (Germany),ElenaArbelo(Spain),RiccardoAsteggiano(Italy),Johann
.
.
Barts Heart Centre, Queen Mary University of London, London, . Bauersachs (Germany), Antoni Bayes-Genis (Spain), Michael A.
.
.
United Kingdom; Michael Bo¨hm, Klinik fu¨r Innere Medizin III, . Borger (Germany), Werner Budts (Belgium), Maja Cikes (Croatia),
.
.
Saarland University, Homburg/Saar, Saarland, Germany; Haran . KevinDamman(Netherlands),VictoriaDelgado(Netherlands),Paul
.
.
Burri, Cardiology, University Hospital of Geneva, Geneva, . Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel
.
Switzerland; Jelena C(cid:2)elutkiene_, Clinic of Cardiac and Vascular .. (Austria), Justin Ezekowitz (Canada), Volkmar Falk (Germany),
.
.
Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania; . Laurent Fauchier (France), Gerasimos Filippatos (Greece), Alan
.
.
OvidiuChioncel,EmergencyInstituteforCardiovascularDiseases . Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale
.
.
‘Prof.Dr.C.C.Iliescu’,UniversityofMedicineCarolDavila,Bucuresti, .. (UnitedKingdom),FinnGustafsson(Denmark),JulieHarris(United
.
Romania; John G.F. Cleland, Robertson Centre for Biostatistics .. Kingdom),Bernard Iung(France),StefanJanssens (Belgium),Mariell
.
and Clinical Trials, Institute of Health & Wellbeing, Glasgow, .. Jessup (United States of America), Aleksandra Konradi (Russia),
.
Lanarkshire, United Kingdom; Andrew J.S. Coats, University of .. Dipak Kotecha (United Kingdom), Ekatirini Lambrinou (Cyprus),
.
Warwick, Coventry, United Kingdom; Maria G. Crespo-Leiro, .. Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany),
.
Cardiology, Complexo Hospitalario Universitario A Coru~na .. ChristopheLeclercq(France),BasilS.Lewis(Israel),FranciscoLeyva
.
(CHUAC),CIBERCV,UniversidadedaCoru~na(UDC),Institutode .. (UnitedKingdom),Ale(cid:2)sLinhart(CzechRepublic),Maja-LisaLøchen
.
Investigacio(cid:3)n Biomedica de A Coru~na (INIBIC), La Coru~na, Spain; .. (Norway),LarsH.Lund(Sweden),DonnaMancini(UnitedStatesof
.
Dimitrios Farmakis, University of Cyprus Medical School, .. America), Josep Masip (Spain), Davor Milicic (Croatia), Christian
.
Nicosia, Cyprus; Roy S. Gardner, Scottish National Advanced .. Mueller(Switzerland),HolgerNef(Germany),Jens-CosedisNielsen
.
HeartFailureService,GoldenJubileeNationalHospital,Clyderbank, .. (Denmark), Lis Neubeck (United Kingdom), Michel Noutsias
.
Glasgow, Scotland, United Kingdom; Martine Gilard, Cardiology, .. (Germany), Steffen E. Petersen (United Kingdom), Anna Sonia
.
.
BrestUniversity,Brest,France;StephaneHeymans,Department . Petronio(Italy),PiotrPonikowski(Poland),EvaPrescott(Denmark),
. .
of Cardiology, Maastricht University, CARIM School for . Amina Rakisheva (Kazakhstan), Dimitrios Richter (Greece), Evgeny
. .
CardiovascularDiseases,Maastricht,Netherlands;ArnoW.Hoes, . Schlyakhto (Russia), Petar Seferovic (Serbia), Michele Senni (Italy),
. .
University Medical Center Utrecht, Utrecht, Netherlands; Tiny . Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Carlo Gabriele
.
.
Jaarsma, Department of Health, Medicine and Caring Science, . Tocchetti(Italy),RhianTouyz(UnitedKingdom),CarstenTschoepe
.
.
Linko¨ping University, Linko¨ping, Sweden; Ewa A. Jankowska, . (Germany),JohannesWaltenberger(Germany).
.
.
Department of Heart Diseases, Wroclaw Medical University, .
.
.
Wroclaw,Poland;MitjaLainscak,DivisionofCardiology,General . ESCNationalCardiacSocietiesactivelyinvolvedinthereview
.
.
Hospital Murska Sobota, Murska Sobota, Slovenia; Carolyn S.P. . processofthe2021ESCGuidelinesforthediagnosisandtreatment
.
.
Lam, National Heart Centre Singapore and Duke-National . ofacuteandchronicheartfailure:
.
.
University of Singapore, Singapore; Alexander R. Lyon, .
.
.
Department of Cardiology, Royal Brompton Hospital, London, .. Algeria:AlgerianSocietyofCardiology,MessaadKrim;Armenia:
.
United Kingdom; John J.V. McMurray, British Heart Foundation .. ArmenianCardiologistsAssociation,HamletHayrapetyan;Austria:
.
Cardiovascular Research Centre, University of Glasgow, Glasgow, .. Austrian Society of Cardiology, Deddo Moertl; Azerbaijan:
.
Scotland, United Kingdom; Alexandre Mebazaa, Anesthesiology .. Azerbaijan Society of Cardiology, Isakh Mustafayev; Belarus:
.
and Critical Care, Universite´ de Paris - Hoˆpital Lariboisie`re, Paris, .. Belorussian Scientific Society of Cardiologists, Alena Kurlianskaya;
.
France; Richard Mindham, UnitedKingdom, ESC Patient Forum, .. Belgium: Belgian Society of Cardiology, Michel Depauw; Bosnia
.
Sophia Antipolis, France; Claudio Muneretto, Cardiothoracic .. and Herzegovina: Association of Cardiologists of Bosnia and
.
Surgery, Asst Spedali Civili University of Brescia, Brescia, Italy; . Herzegovina, Zumreta Ku(cid:2)sljugi(cid:3)c; Bulgaria: Bulgarian Society of
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 97 ---
ESCGuidelines 3695
.
.
Cardiology, Plamen Gatzov; Croatia: Croatian Cardiac Society, . (France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia),
.
.
Davor Milicic; Cyprus: Cyprus Society of Cardiology, Petros . Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United
.
.
Agathangelou; Czech Republic: Czech Society of Cardiology, . Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales
.
.
Vojt(cid:2)ech Melenovsk(cid:3)y; Denmark: Danish Society of Cardiology, . Linhart(CzechRepublic),Maja-LisaLøchen(Norway),Jens-Cosedis
.
.
BrianBridalLøgstrup;Egypt:EgyptianSocietyofCardiology,Ahmed . Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva
.
.
Magdy Mostafa; Estonia: Estonian Society of Cardiology, Tiina . Prescott (Denmark), Lis Neubeck (United Kingdom), Amina
.
.
Uuetoa; Finland: Finnish Cardiac Society, Johan Lassus; France: . Rakisheva(Kazakhstan),MartaSitges(Spain),RhianM.Touyz(United
.
.
FrenchSocietyofCardiology,DamienLogeart;Georgia:Georgian . Kingdom).
.
.
Society of Cardiology, Zviad Kipiani; Germany: German Cardiac ..
.
Society,JohannBauersachs;Greece:HellenicSocietyofCardiology, ..
.
ChristinaChrysohoou;Hungary:HungarianSocietyofCardiology, ...
22 References
Ro(cid:3)bert Sepp; Iceland: Icelandic Society of Cardiology, Inga Jo(cid:3)na ..
. Ingimarsdo(cid:3)ttir; Ireland: Irish Cardiac Society, Jim O’Neill; Israel: ...
1. Ponikowski P,VoorsAA, Anker SD, Bueno H,Cleland JGF,Coats AJS, FalkV,
Israel Heart Society, Israel Gotsman; Italy: Italian Federation of .. Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
.
Cardiology, Massimo Iacoviello; Kazakhstan: Association of .. Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Cardiologists of Kazakhstan, Amina Rakisheva; Kosovo (Republic
.... R ESu Csch Git uz ik da elF in, eR su ft ot ren thF eH d, iav ga nn od sie sr aM ndee trr eP at, mES eC ntS oc fie an cuti tfi ec aD ndoc cu hm roe nn it cG hero aru tp f. a2 ilu0 r1 e6
:
of): Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan: .. TheTaskForceforthediagnosisandtreatmentofacuteandchronicheartfailure
.
Kyrgyz Society of Cardiology, Olga Lunegova, Latvia: Latvian .. oftheEuropeanSocietyofCardiology(ESC).Developedwiththespecialcontri-
SocietyofCardiology,GintaKamzola;Lebanon:LebaneseSociety
.... b 20u 1ti 6o ;n 37:o 2f 12t 9h (cid:2)e 22H 0e 0a .rt Failure Association (HFA) of the ESC. Eur Heart J
of Cardiology, Tony Abdel Massih; Libya: Libyan Cardiac Society, .. 2. PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,CooneyMT,
.
Hisham Benlamin; Lithuania: Lithuanian Society of Cardiology, .. Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML,
DianaZ(cid:2)aliaduonyte_; Luxembourg: Luxembourg Society of ... Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,
. SmuldersY,TiberiM,vanderWorpHB,vanDisI,VerschurenWMM,BinnoS,
.
Cardiology,StephanieNoppe;Malta:MalteseCardiacSociety,Alice . ESCScientificDocumentGroup.2016EuropeanGuidelinesoncardiovasculardis-
.
Moore;Moldova(Republicof):MoldavianSocietyofCardiology, .. easepreventioninclinicalpractice:TheSixthJointTaskForceoftheEuropean
.. SocietyofCardiologyandOtherSocietiesonCardiovascularDiseasePrevention
Eleonora Vataman; Montenegro: Montenegro Society of .
. inClinicalPractice(constitutedbyrepresentativesof10societiesandbyinvited
.
Cardiology, Aneta Boskovic; Morocco: Moroccan Society of . experts)DevelopedwiththespecialcontributionoftheEuropeanAssociationfor
.
Cardiology, Ahmed Bennis; Netherlands: Netherlands Society of .. Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J
.. 2016;37:2315(cid:2)2381.
Cardiology, Olivier C. Manintveld; North Macedonia: North .
. 3. IbanezB,JamesS,AgewallS,AntunesMJ,Bucciarelli-DucciC,BuenoH,Caforio
.
MacedonianSociety ofCardiology, ElizabetaSrbinovskaKostovska; .. ALP,CreaF,GoudevenosJA,HalvorsenS,HindricksG,KastratiA,LenzenMJ,
Norway:NorwegianSocietyofCardiology,GeetaGulati;Poland: .. Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC
.
. ScientificDocumentGroup.2017ESCGuidelinesforthemanagementofacute
Polish Cardiac Society, Ewa Straburzy(cid:3)nska-Migaj; Portugal: ..
myocardialinfarctioninpatientspresentingwithST-segmentelevation:TheTask
.
Portuguese Society of Cardiology, Jose´ Silva-Cardoso; Romania: .. Forceforthemanagementofacutemyocardialinfarctioninpatientspresenting
RomanianSocietyofCardiology,RoxanaCristinaRimbas¸;Russian ... with ST-segment elevation of the European Society of Cardiology (ESC). Eur
. HeartJ2018;39:119(cid:2)177.
Federation: Russian Society of Cardiology, Yury Lopatin; San ..
4. WilliamsB,ManciaG,SpieringW,AgabitiRoseiE,AziziM,BurnierM,Clement
.
Marino:SanMarinoSocietyofCardiology,MarinaFoscoli;Serbia: .. DL,CocaA,deSimoneG,DominiczakA,KahanT,MahfoudF,RedonJ,Ruilope
.
Cardiology Society of Serbia, Sinisa Stojkovic; Slovakia: Slovak .. L,ZanchettiA,KerinsM,KjeldsenSE,KreutzR,LaurentS,LipGYH,McManusR,
. NarkiewiczK,RuschitzkaF,SchmiederRE,ShlyakhtoE,TsioufisC,Aboyans V,
Society of Cardiology, Eva Goncalvesova; Slovenia: Slovenian ...
DesormaisI,ESCScientificDocumentGroup.2018ESC/ESHGuidelinesforthe
Society of Cardiology, Zlatko Fras; Spain: Spanish Society of .. managementofarterialhypertension.EurHeartJ2018;39:3021(cid:2)3104.
.
Cardiology,JavierSegovia;Sweden:SwedishSocietyofCardiology, .. 5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
. PrescottE,StoreyRF,DeatonC,CuissetT,AgewallS,DicksteinK,EdvardsenT, KristerLindmark;Switzerland:SwissSocietyofCardiology,Micha ...
EscanedJ,GershBJ,SvitilP,GilardM,HasdaiD,HatalaR,MahfoudF,MasipJ,
T. Maeder; Syrian Arab Republic: Syrian Cardiovascular .. MunerettoC,ValgimigliM,AchenbachS,BaxJJ,ESCScientificDocumentGroup.
. Association, Walid Bsata; Tunisia: Tunisian Society of Cardiology .. 2019ESCGuidelinesforthediagnosisandmanagementofchroniccoronarysyn-
.. dromes.EurHeartJ2020;41:407(cid:2)477.
andCardio-VascularSurgery,LeilaAbid;Turkey:TurkishSocietyof .. 6. CosentinoF,GrantPJ,AboyansV,BaileyCJ,CerielloA,DelgadoV,FedericiM,
.
Cardiology, Hakan Altay; Ukraine: Ukrainian Association of . FilippatosG,GrobbeeDE,HansenTB,HuikuriHV,JohanssonI,JuniP,LettinoM,
.
. MarxN,MellbinLG,OstgrenCJ,RoccaB,RoffiM,SattarN,SeferovicPM,Sousa-
Cardiology, Leonid Voronkov; United Kingdom of Great .
.. Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC
Britain and Northern Ireland: British Cardiovascular Society, .. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in
.
Ceri Davies, Uzbekistan: Association of Cardiologists of . collaborationwiththeEASD.EurHeartJ2020;41:255(cid:2)323.
.
. 7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C,
Uzbekistan,TimurAbdullaev. .
.. BorianiG,CastellaM,DanGA,DilaverisPE,FauchierL,FilippatosG,KalmanJM,
.
. La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN,
.
ESCClinicalPracticeGuidelinesCommittee(CPG):Colin . ValgimigliM,VanGelderIC,VanPutteBP,WatkinsCL,ESCScientificDocument
.
N. Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
.. Group.2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillation
.. developed in collaboration with the European Association for Cardio-Thoracic
(Egypt), Victor Aboyans (France), Sotiris Antoniou (United .. Surgery(EACTS).EurHeartJ2021;42:373(cid:2)498.
.
Kingdom),ElenaArbelo(Spain),RiccardoAsteggiano(Italy),Andreas . 8. LundLH,ClaggettB,LiuJ,LamCS,JhundPS,RosanoGM,SwedbergK,YusufS,
.
B C(cid:2)a eu lum tkb ia ec nh e_(U (Ln iti hte ud anK iain ),gd Mo am ja), CM ikic eh sae (l CA ro. aB to iar )g ,e Jr ea( nG -e Pr hm ilia pn py e), CJe ole lln ea
t
...... G
r sa
ar
n
ra
tg
an
e
nge er
je ac
cC
t
riB oo,
sn
sP ff re
a
tf
c
hfe
t
eir onM
ei
nA
n
t,
iC
reM Hc AM
eR
ju eMr cr
:
ta
ic
oy
h
naJJ rV
a
f,
c rt
aS
e
co
r ti
il
s
oo
t
nm icso ,n
so pu
eS
t
cD
c to
r. umH mee .sar at
En
udf ra eilu
ff
Jr ee
ct
Hw
o
ei afth
rc
tanm
d
Fi ad
e
i--
l
.
(France),VolkmarFalk(Germany),LaurentFauchier(France),Chris .. 2018;20:1230(cid:2)1239.
.
P.Gale(UnitedKingdom),SigrunHalvorsen(Norway),BernardIung .
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 98 ---
3696 ESCGuidelines
.
.
9. SolomonSD,ClaggettB,LewisEF,DesaiA,AnandI,SweitzerNK,O’MearaE, . 23. RothGA,ForouzanfarMH,MoranAE,BarberR,NguyenG,FeiginVL,Naghavi
.
ShahSJ,McKinlayS,FlegJL,SopkoG,PittB,PfefferMA,TOPCATInvestigators. . M,MensahGA,MurrayCJ.Demographicandepidemiologicdriversofglobalcar-
.
Influence of ejection fraction on outcomes and efficacy of spironolactone in .. diovascularmortality.NEnglJMed2015;372:1333(cid:2)1341.
patients with heart failure with preserved ejection fraction. Eur Heart J .. 24. SavareseG,LundLH.Globalpublichealthburdenofheartfailure.CardFailRev
.
2016;37:455(cid:2)462. . 2017;3:7(cid:2)11.
.
10. Abdul-RahimAH,ShenL,RushCJ,JhundPS,LeesKR,McMurrayJJV,VICCTA- .. 25. MeyerS,BrouwersFP,VoorsAA,HillegeHL,deBoerRA,GansevoortRT,van
HeartFailureCollaborators.Effectofdigoxininpatientswithheartfailureand .. derHarstP,RienstraM,vanGelderIC,vanVeldhuisenDJ,vanGilstWH,van
.
mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail . der Meer P. Sex differences in new-onset heart failure. Clin Res Cardiol
.
2018;20:1139(cid:2)1145. . 2015;104:342(cid:2)350.
.
11. ClelandJG,TenderaM,AdamusJ,FreemantleN,PolonskiL,TaylorJ,PEP-CHF .. 26. BrouwersFP,deBoerRA,vanderHarstP,VoorsAA,GansevoortRT,Bakker
Investigators.Theperindoprilinelderlypeoplewithchronicheartfailure(PEP- .. SJ,HillegeHL,vanVeldhuisenDJ,vanGilstWH.Incidenceandepidemiologyof
.
CHF)study.EurHeartJ2006;27:2338(cid:2)2345. . new onset heart failure with preserved vs. reduced ejection fraction in a
.
12. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, . community-based cohort: 11-year follow-up of PREVEND. Eur Heart J
.
Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, .. 2013;34:1424(cid:2)1431.
.
BohmM, Andersson B,KjekshusJ, PackerM, Rigby AS,RosanoG, Wedel H, . 27. GBD2017DiseaseandInjuryIncidenceandPrevalenceCollaborators.Global,
.
Hjalmarson A, Wikstrand J, Kotecha D, Beta-blockers in Heart Failure . regional, and national incidence, prevalence, and years lived with disability for
. Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, .. 354diseasesandinjuriesfor195countriesandterritories,1990-2017:asystem-
and preserved ejection fraction: an individual patient-level analysis of double- .. atic analysis for the Global Burden of Disease Study 2017. Lancet
.
blindrandomizedtrials.EurHeartJ2018;39:26(cid:2)35. . 2018;392:1789(cid:2)1858.
.
13. SolomonSD,McMurrayJJV,AnandIS,GeJ,LamCSP,MaggioniAP,MartinezF, . 28. RogerVL.Epidemiologyofheartfailure.CircRes2013;113:646(cid:2)659.
.
Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, .. 29. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart
ZannadF,ZileMR,DesaiAS,ClaggettB,JhundPS,BoytsovSA,Comin-ColetJ, .. 2007;93:1137(cid:2)1146.
.
ClelandJ,DungenHD,GoncalvesovaE,KatovaT,KerrSaraivaJF,LelonekM, . 30. SmeetsM,VaesB,MamourisP,VanDenAkkerM,VanPottelberghG,Goderis
.
MerkelyB,SenniM,ShahSJ,ZhouJ,RizkalaAR,GongJ,ShiVC,LefkowitzMP, .. G,JanssensS,AertgeertsB,HenrardS.BurdenofheartfailureinFlemishgeneral
PARAGON-HFInvestigatorsandCommittees.Angiotensin-neprilysininhibition .. practices: a registry-based study in the Intego database. BMJ Open
.
in heart failure with preserved ejection fraction. N Engl J Med . 2019;9:e022972.
.
2019;381:1609(cid:2)1620. . 31. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP,
.
14. LamCSP,VoorsAA,PiotrP,McMurrayJJV,SolomonSD.Timetorenamethe .. Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV,
middlechildofheartfailure:heartfailurewithmildlyreducedejectionfraction. .. FergusonJF,FornageM,KhanSS,KisselaBM,KnutsonKL,KwanTW,Lackland
.
EurHeartJ2020;41:2353(cid:2)2355. . DT,LewisTT,LichtmanJH,LongeneckerCT,LoopMS,LutseyPL,MartinSS,
.
15. Bozkurt B,Coats AJS,Tsutsui H,Abdelhamid CM,AdamopoulosS,AlbertN, . MatsushitaK,MoranAE,MussolinoME,PerakAM,RosamondWD,RothGA,
.
Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G, .. Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL,
.
FilippatosG,FiuzatM,FonarowGC,Gomez-MesaJE,HeidenreichP,ImamuraT, . StokesA,TirschwellDL,VanWagnerLB,TsaoCW,AmericanHeartAssociation
.
JankowskaEA,JanuzziJ,KhazanieP,KinugawaK,LamCSP,MatsueY,MetraM, . Council on Epidemiology and Prevention Statistics Committee and Stroke
.
OhtaniT,FrancescoPiepoliM,PonikowskiP,RosanoGMC,SakataY,Seferovic .. Statistics Subcommittee. Heart disease and stroke statistics—2020 update: a
P,StarlingRC,TeerlinkJR,VardenyO,YamamotoK,YancyC,ZhangJ,Zieroth .. reportfromtheAmericanHeartAssociation.Circulation2020;141:e139(cid:2)e596.
.
S.Universaldefinitionandclassificationof heartfailure: areportofthe Heart . 32. vanRietEE,HoesAW,LimburgA,LandmanMA,vanderHoevenH,RuttenFH.
.
FailureSocietyofAmerica,HeartFailureAssociationoftheEuropeanSocietyof . Prevalence of unrecognized heart failure in older persons with shortness of
.
Cardiology, Japanese Heart Failure Society and Writing Committee of the .. breathonexertion.EurJHeartFail2014;16:772(cid:2)777.
UniversalDefinition ofHeartFailure:EndorsedbytheCanadianHeartFailure .. 33. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH.
.
Society,HeartFailureAssociationofIndia,CardiacSocietyofAustraliaandNew . Epidemiologyofheartfailure:theprevalenceofheartfailureandventriculardys-
.
Zealand, and Chinese Heart Failure Association. Eur J Heart Fail .. function in older adults over time. A systematic review. Eur J Heart Fail
2021;23:352(cid:2)380. .. 2016;18:242(cid:2)252.
.
16. GalderisiM,CosynsB,EdvardsenT,CardimN,DelgadoV,DiSalvoG,DonalE, . 34. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S,
.
SadeLE,ErnandeL,GarbiM,GrapsaJ,HagendorffA,KampO,MagneJ,Santoro . ChiuveSE,CushmanM,DellingFN,DeoR,deFerrantiSD,FergusonJF,Fornage
.
C,StefanidisA,LancellottiP,PopescuB,HabibG,EACVIScientificDocuments .. M,GillespieC,IsasiCR,JimenezMC,JordanLC,JuddSE,LacklandD,Lichtman
Committee.Standardizationofadulttransthoracicechocardiographyreportingin .. JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB,
.
agreementwithrecentchamberquantification,diastolicfunction,andheartvalve . MatsushitaK,MussolinoME,NasirK,O’FlahertyM,PalaniappanLP,PandeyA,
.
disease recommendations: an expert consensus document of the European . PandeyDK,ReevesMJ,RitcheyMD,RodriguezCJ,RothGA,RosamondWD, .
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging .. Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW,
2017;18:1301(cid:2)1310. .. Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P,
.
17. Arrigo M, Huber LC, Winnik S, Mikulicic F, Guidetti F, Frank M, Flammer AJ, . AmericanHeartAssociationCouncilonEpidemiologyandPreventionStatistics
. RuschitzkaF.Rightventricularfailure:pathophysiology,diagnosisandtreatment. .. CommitteeandStrokeStatisticsSubcommittee.Heartdiseaseandstrokestatis-
CardFailRev2019;5:140(cid:2)146. .. tics—2018 update: a report from the American Heart Association. Circulation
.
18. Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats . 2018;137:e67(cid:2)e492. .
AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, . 35. CeiaF,FonsecaC,MotaT,MoraisH,MatiasF,deSousaA,OliveiraA,EPICA
.
LamCSP,LundLH,LyonAR,MebazaaA,MuellerC,PaulusWJ,PieskeB,Piepoli .. Investigators. Prevalence of chronic heart failure in Southwestern Europe: the
MF,RuschitzkaF,RuttenFH,SeferovicPM,SolomonSD,ShahSJ,TriposkiadisF, .. EPICAstudy.EurJHeartFail2002;4:531(cid:2)539.
.
WachterR,TschopeC,deBoerRA.Rightheartdysfunctionandfailureinheart . 36. Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A,
.
failurewithpreservedejectionfraction:mechanismsandmanagement.Position .. Lewis CE, Williams OD, Hulley SB. Racial differences in incident heart failure
statementonbehalfoftheHeartFailureAssociationoftheEuropeanSocietyof .. amongyoungadults.NEnglJMed2009;360:1179(cid:2)1190.
.
Cardiology.EurJHeartFail2018;20:16(cid:2)37. . 37. BleuminkGS,Knetsch AM,SturkenboomMC,StrausSM,HofmanA,Deckers
.
19. CaraballoC,DesaiNR,MulderH,AlhantiB,WilsonFP,FiuzatM,FelkerGM, . JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: preva-
.
Pina IL, O’Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical .. lence,incidencerate,lifetimeriskandprognosisofheartfailureTheRotterdam
implicationsoftheNewYorkHeartAssociationclassification.JAmHeartAssoc .. Study.EurHeartJ2004;25:1614(cid:2)1619.
.
2019;8:e014240. . 38. KohAS,TayWT,TengTHK,VedinO,BensonL,DahlstromU,SavareseG,Lam
.
20. SolomonSD,ClaggettB,PackerM,DesaiA,ZileMR,SwedbergK,RouleauJ, . CSP,LundLH.Acomprehensivepopulation-basedcharacterizationofheartfail-
.
Shi V, Lefkowitz M, McMurray JJV. Efficacy of sacubitril/valsartan relative to a .. urewithmid-rangeejectionfraction.EurJHeartFail2017;19:1624(cid:2)1634.
prior decompensation: the PARADIGM-HF trial. JACC Heart Fail .. 39. ChioncelO,LainscakM,SeferovicPM,AnkerSD,Crespo-LeiroMG,HarjolaVP,
.
2016;4:816(cid:2)822. . ParissisJ,LarocheC,PiepoliMF,FonsecaC,MebazaaA,LundL,AmbrosioGA,
.
21. ConradN,JudgeA,TranJ,MohseniH,HedgecottD,CrespilloAP,AllisonM, .. CoatsAJ,FerrariR,RuschitzkaF,MaggioniAP,FilippatosG.Epidemiologyand
HemingwayH,ClelandJG,McMurrayJJV,RahimiK.Temporaltrendsandpat- .. one-year outcomes in patients with chronic heart failure and preserved, mid-
.
ternsinheartfailureincidence:apopulation-basedstudyof4millionindividuals. . rangeandreducedejectionfraction:ananalysisoftheESCHeartFailureLong-
.
Lancet2018;391:572(cid:2)580. . TermRegistry.EurJHeartFail2017;19:1574(cid:2)1585.
.
22. DunlaySM,RogerVL.Understandingtheepidemicofheartfailure:past,present, .. 40. ShahRU,KleinL,Lloyd-JonesDM.Heartfailureinwomen:epidemiology,biology
andfuture.CurrHeartFailRep2014;11:404(cid:2)415. . andtreatment.WomensHealth(Lond)2009;5:517(cid:2)527.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 99 ---
ESCGuidelines 3697
.
.
41. RogerVL,WestonSA,RedfieldMM,Hellermann-HomanJP,KillianJ,YawnBP, . with chronic heart failure: summary of updated NICE guidance. BMJ
.
JacobsenSJ.Trendsinheartfailureincidenceandsurvivalinacommunity-based . 2010;341:c4130.
.
population.JAMA2004;292:344(cid:2)350. .. 63. MantJ,DoustJ,RoalfeA,BartonP,CowieMR,GlasziouP,MantD,McManusRJ,
42. VedinO,LamCSP,KohAS,BensonL,TengTHK,TayWT,BraunOO,Savarese .. Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD.
.
G,DahlstromU,LundLH.Significanceofischemicheartdiseaseinpatientswith . Systematicreviewandindividualpatientdatameta-analysisofdiagnosisofheart
.
heartfailureandpreserved,midrange,andreducedejectionfraction:anation- .. failure,withmodellingofimplicationsofdifferentdiagnosticstrategiesinprimary
widecohortstudy.CircHeartFail2017;10:e003875. .. care.HealthTechnolAssess2009;13:1(cid:2)207,iii.
.
43. KapoorJR,KapoorR,JuC,HeidenreichPA,EapenZJ,HernandezAF,ButlerJ, . 64. DavieAP,FrancisCM,CaruanaL,SutherlandGR,McMurrayJJ.Assessingdiagno-
.
YancyCW,FonarowGC.Precipitatingclinicalfactors,heartfailurecharacteriza- . sisinheartfailure:whichfeaturesareanyuse?QJM1997;90:335(cid:2)339.
.
tion,andoutcomesinpatientshospitalizedwithheartfailurewithreduced,bor- .. 65. OudejansI,MosterdA,BloemenJA,ValkMJ,vanVelzenE,WieldersJP,Zuithoff
derline,andpreservedejectionfraction.JACCHeartFail2016;4:464(cid:2)472. .. NP,RuttenFH,HoesAW.Clinicalevaluationofgeriatricoutpatientswithsus-
.
44. HeiatA,GrossCP,KrumholzHM.Representationoftheelderly,women,and . pectedheartfailure:valueofsymptoms,signs,andadditionaltests.EurJHeart
.
minoritiesinheartfailureclinicaltrials.ArchInternMed2002;162:1682(cid:2)1688. .. Fail2011;13:518(cid:2)527.
45. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, ManemannSM, Jiang R, .. 66. KelderJC,CramerMJ,vanWijngaardenJ,vanToorenR,MosterdA,MoonsKG,
.
Killian JM, Roger VL. A contemporary appraisalof the heart failure epidemic in . LammersJW,CowieMR,GrobbeeDE,HoesAW.Thediagnosticvalueofphysi-
.
OlmstedCounty,Minnesota,2000to2010.JAMAInternMed2015;175:996(cid:2)1004. . cal examination and additional testingin primary carepatients with suspected
. 46. TsaoCW,LyassA,EnserroD,LarsonMG,HoJE,KizerJR,GottdienerJS,Psaty .. heartfailure.Circulation2011;124:2865(cid:2)2873.
BM,VasanRS.Temporaltrendsintheincidenceofandmortalityassociatedwith .. 67. ThibodeauJT,TurerAT,GualanoSK,AyersCR,Velez-MartinezM,MishkinJD,
.
heart failure with preserved and reduced ejection fraction. JACC Heart Fail . Patel PC, Mammen PP, Markham DW, Levine BD, Drazner MH.
.
2018;6:678(cid:2)685. . Characterizationofanovelsymptomofadvancedheartfailure:bendopnea.JACC
.
47. Motiejunaite J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ, .. HeartFail2014;2:24(cid:2)31.
KavoliunieneA,CelutkieneJ,ParenicaJ,LassusJ,KajimotoK,SatoN,MiroO, .. 68. Gohar A, Rutten FH, den Ruijter H, Kelder JC, von Haehling S, Anker SD,
.
PeacockWF,MatsueY,VoorsAA,LamCSP,EzekowitzJA,AhmedA,Fonarow . Mockel M, Hoes AW. Mid-regional pro-atrial natriuretic peptide for the early
.
GC,GayatE,Regitz-ZagrosekV,MebazaaA.Theassociationoflong-termout- .. detectionofnon-acuteheartfailure.EurJHeartFail2019;21:1219(cid:2)1227.
comeandbiologicalsexinpatientswithacuteheartfailurefromdifferentgeo- .. 69. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide
.
graphicregions.EurHeartJ2020;41:1357(cid:2)1364. . testingtoassistthediagnosticevaluationofheartfailureinsymptomaticprimary
.
48. DunlaySM,RogerVL,WestonSA,JiangR,RedfieldMM.Longitudinalchangesin . carepatients.AmJCardiol2008;101:25(cid:2)28.
.
ejection fraction inheartfailure patients with preservedand reduced ejection .. 70. Maisel A, Mueller C, Adams K, Jr., Anker SD, Aspromonte N, Cleland JG,
fraction.CircHeartFail2012;5:720(cid:2)726. .. Cohen-SolalA,DahlstromU,DeMariaA,DiSommaS,FilippatosGS,Fonarow
.
49. ClarkeCL,GrunwaldGK,AllenLA,BaronAE,PetersonPN,BrandDW,Magid . GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A,
.
DJ,MasoudiFA.Naturalhistoryofleftventricularejectionfractioninpatients . Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW,
.
withheartfailure.CircCardiovascQualOutcomes2013;6:680(cid:2)686. .. ZannadF,BraunwaldE.Stateoftheart:usingnatriureticpeptidelevelsinclinical
.
50. TsujiK,SakataY,NochiokaK,MiuraM,YamauchiT,OnoseT,AbeR,Oikawa . practice.EurJHeartFail2008;10:824(cid:2)839.
.
T,KasaharaS,SatoM,ShirotoT,TakahashiJ,MiyataS,ShimokawaH,CHART-2 . 71. LancellottiP,GalderisiM,EdvardsenT,DonalE,GoliaschG,CardimN,MagneJ,
.
Investigators.Characterizationofheartfailurepatientswithmid-rangeleftven- .. Laginha S, Hagendorff A, Haland TF, Aaberge L, Martinez C, Rapacciuolo A,
tricular ejection fraction–a report from the CHART-2 Study. Eur J Heart Fail .. Santoro C, Ilardi F, Postolache A, Dulgheru R, Mateescu AD, Beladan CC,
.
2017;19:1258(cid:2)1269. . DeleanuD,Marchetta S,AuffretV,SchwammenthalE,HabibG,PopescuBA.
.
51. RastogiA,NovakE,PlattsAE,MannDL.Epidemiology,pathophysiologyandclin- . Echo-Dopplerestimationofleftventricularfillingpressure:resultsofthemulti-
.
icaloutcomesforheartfailurepatientswithamid-rangeejectionfraction.EurJ .. centre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging
HeartFail2017;19:1597(cid:2)1605. .. 2017;18:961(cid:2)968.
.
52. Lupon J,Gavidia-BovadillaG,FerrerE, deAntonioM,Perera-LlunaA,Lopez- . 72. GardnerRS,OzalpF,MurdayAJ,RobbSD,McDonaghTA.N-terminalpro-brain
.
AyerbeJ,DomingoM,NunezJ,ZamoraE,MolinerP,Diaz-RuataP,Santesmases .. natriureticpeptide.Anewgoldstandardinpredictingmortalityinpatientswith
J, Bayes-Genis A. Dynamic trajectories of left ventricular ejection fraction in .. advancedheartfailure.EurHeartJ2003;24:1735(cid:2)1743.
.
heartfailure.JAmCollCardiol2018;72:591(cid:2)601. . 73. RobertsE,LudmanAJ,DworzynskiK,Al-MohammadA,CowieMR,McMurray
.
53. PocockSJ,AritiCA,McMurrayJJ,MaggioniA,KoberL,SquireIB,SwedbergK, . JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure. The
.
DobsonJ,PoppeKK,WhalleyGA,DoughtyRN,Meta-AnalysisGlobalGroupin .. diagnosticaccuracyofthenatriureticpeptidesinheartfailure:systematicreview
ChronicHeartFailure.Predictingsurvivalinheartfailure:ariskscorebasedon .. anddiagnosticmeta-analysisintheacutecaresetting.BMJ2015;350:h910.
.
39372patientsfrom30studies.EurHeartJ2013;34:1404(cid:2)1413. . 74. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N,
.
54. BarasaA,SchaufelbergerM,LappasG,SwedbergK,DellborgM,RosengrenA. . CoatsAJS,MetraM,MebazaaA,RuschitzkaF,LainscakM,FilippatosG,Seferovic .
Heart failure in young adults: 20-year trends in hospitalization, aetiology, and .. PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr, Heart
casefatalityinSweden.EurHeartJ2014;35:25(cid:2)32. .. Failure Association of the European Society of Cardiology. Heart Failure
.
55. JhundPS,MacintyreK,SimpsonCR,LewseyJD,StewartS,RedpathA,Chalmers . AssociationoftheEuropeanSocietyofCardiologypracticalguidanceontheuse
. JW,CapewellS,McMurrayJJ.Long-termtrendsinfirsthospitalizationforheart .. ofnatriureticpeptideconcentrations.EurJHeartFail2019;21:715(cid:2)731.
failureandsubsequentsurvivalbetween1986and2003:apopulationstudyof .. 75. MadamanchiC,AlhosainiH,SumidaA,RungeMS.Obesityandnatriureticpepti-
.
5.1millionpeople.Circulation2009;119:515(cid:2)523. . des,BNPandNT-proBNP:mechanismsanddiagnosticimplicationsforheartfail- .
56. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, . ure.IntJCardiol2014;176:611(cid:2)617.
.
RogerVL.Hospitalizationsafterheartfailurediagnosisacommunityperspective. .. 76. CowieMR,StruthersAD,WoodDA,CoatsAJ,ThompsonSG,Poole-Wilson
JAmCollCardiol2009;54:1695(cid:2)1702. .. PA,SuttonGC.Valueofnatriureticpeptidesinassessmentofpatientswithpos-
.
57. Taylor CJ, Ordonez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, . siblenewheartfailureinprimarycare.Lancet1997;350:1349(cid:2)1353.
.
HobbsFDR. TrendsinsurvivalafteradiagnosisofheartfailureintheUnited . 77. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T,
.
Kingdom2000-2017:populationbasedcohortstudy.BMJ2019;364:l223. .. HardmanSM,DargieHJ,CowieMR.ThediagnosticaccuracyofplasmaBNPand
.
58. LorenzoniG,AzzolinaD,LaneraC,BriantiG,GregoriD,VanuzzoD,BaldiI. . NTproBNPinpatientsreferredfromprimarycarewithsuspectedheartfailure:
.
Timetrendsinfirsthospitalizationforheartfailureinacommunity-basedpopula- . resultsoftheUKnatriureticpeptidestudy.EurJHeartFail2005;7:537(cid:2)541.
.
tion.IntJCardiol2018;271:195(cid:2)199. .. 78. KelderJC,CramerMJ,VerweijWM,GrobbeeDE,HoesAW.Clinicalutilityof
59. MosterdA,ReitsmaJB,GrobbeeDE.Angiotensinconvertingenzymeinhibition .. three B-type natriuretic peptide assays for the initial diagnostic assessment of
.
andhospitalisationratesforheartfailureintheNetherlands,1980to1999:the . newslow-onsetheartfailure.JCardFail2011;17:729(cid:2)734.
.
endofanepidemic?Heart2002;87:75(cid:2)76. . 79. Verdu JM, Comin-Colet J, Domingo M, Lupon J, Gomez M, Molina L,
.
60. ChenJ,HsiehAF,DharmarajanK,MasoudiFA,KrumholzHM.Nationaltrendsin .. Casacuberta JM,MunozMA, Mena A,Bruguera-CortadaJ.Rapidpoint-of-care
heartfailurehospitalizationafteracutemyocardialinfarctionforMedicarebenefi- .. NT-proBNPoptimalcut-offpointforheartfailurediagnosisinprimarycare.Rev
.
ciaries:1998-2010.Circulation2013;128:2577(cid:2)2584. . EspCardiol(EnglEd)2012;65:613(cid:2)619.
.
61. LawsonCA,ZaccardiF,SquireI,LingS,DaviesMJ,LamCSP,MamasMA,Khunti .. 80. Taylor CJ, Roalfe AK, Iles R, Hobbs FR, investigators R, Barton P, Deeks J,
K, Kadam UT. 20-year trends in cause-specific heart failure outcomes by sex, .. McCahon D, Cowie MR, Sutton G, Davis RC, Mant J, McDonagh T, Tait L.
.
socioeconomicstatus,andplace of diagnosis: apopulation-basedstudy.Lancet . PrimarycareREFerralforEchocaRdiogram(REFER)inheartfailure:adiagnostic
.
PublicHealth2019;4:e406(cid:2)e420. . accuracystudy.BrJGenPract2017;67:e94(cid:2)e102.
.
62. Al-Mohammad A, Mant J, Laramee P, Swain S, Chronic Heart Failure .. 81. SicariR,NihoyannopoulosP,EvangelistaA,KasprzakJ,LancellottiP,Poldermans
Guideline Development Group. Diagnosis and management of adults . D, Voigt JU, Zamorano JL, European Association of Echocardiography. Stress
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 100 ---
3698 ESCGuidelines
.
.
Echocardiography Expert Consensus Statement–Executive Summary: European . 98. CooperLTJr,BerryGJ,ShabetaiR.Idiopathicgiant-cellmyocarditis–naturalhis-
.
Association of Echocardiography (EAE) (a registered branch of the ESC). Eur . tory and treatment. Multicenter Giant Cell Myocarditis Study Group
.
HeartJ2009;30:278(cid:2)289. .. Investigators.NEnglJMed1997;336:1860(cid:2)1866.
82. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, .. 99. LangRM,BadanoLP,Mor-AviV,AfilaloJ,ArmstrongA,ErnandeL,Flachskampf
.
EdvardsenT,GarbiM,HaJW,KaneGC,KreegerJ,MertensL,PibarotP,Picano . FA,FosterE,GoldsteinSA,KuznetsovaT,LancellottiP,MuraruD,PicardMH,
.
E,RyanT,Tsutsui JM,VargaA.Theclinicaluseofstressechocardiographyin .. RietzschelER,RudskiL,SpencerKT,TsangW,VoigtJU.Recommendationsfor
non-ischaemicheartdisease:recommendationsfromtheEuropeanAssociation .. cardiacchamberquantificationbyechocardiographyinadults:anupdatefrom
.
of Cardiovascular Imaging and the American Society of Echocardiography. Eur . the American Society of Echocardiography and the European Association of
.
HeartJCardiovascImaging2016;17:1191(cid:2)1229. . CardiovascularImaging.EurHeartJCardiovascImaging2015;16:233(cid:2)270.
.
83. Gonzalez JA, KramerCM. Role of imaging techniques for diagnosis, prognosis .. 100.GheorghiadeM,ShahAN,VaduganathanM,ButlerJ,BonowRO,RosanoGM,
andmanagementofheartfailurepatients:cardiacmagneticresonance.CurrHeart .. TaylorS,KupferS,MisselwitzF,SharmaA,FonarowGC.Recognizinghospital-
.
FailRep2015;12:276(cid:2)283. . izedheartfailureasanentityanddevelopingnewtherapiestoimproveout-
.
84. MessroghliDR,MoonJC,FerreiraVM,Grosse-WortmannL,HeT,KellmanP, . comes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives.
.
Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, .. HeartFailClin2013;9:285(cid:2)290,v-vi.
.
UganderM,vanHeeswijkRB,FriedrichMG.Clinicalrecommendationsforcardi- . 101.AmbrosyAP,FonarowGC,ButlerJ,ChioncelO,GreeneSJ,VaduganathanM,
.
ovascularmagneticresonancemappingofT1,T2,T2andextracellularvolume:a . Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global
. consensus statement by the Society for Cardiovascular Magnetic Resonance .. health and economic burden of hospitalizations for heart failure: lessons
(SCMR) endorsed by the European Association for Cardiovascular Imaging .. learned from hospitalized heart failure registries. J Am Coll Cardiol
.
(EACVI).JCardiovascMagnReson2017;19:75. . 2014;63:1123(cid:2)1133.
.
85. WittelesRM,BokhariS,DamyT,ElliottPM,FalkRH,FineNM,GospodinovaM, . 102.Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A,
.
ObiciL,RapezziC,Garcia-PaviaP.Screeningfortransthyretinamyloidcardiomy- .. Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA,
opathyineverydaypractice.JACCHeartFail2019;7:709(cid:2)716. .. Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le
.
86. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J . Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M,
.
2015;79:1647(cid:2)1655. .. Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA,
87. ZoisNE,BartelsED,HunterI,KousholtBS,OlsenLH,GoetzeJP.Natriureticpepti- .. RuschitzkaF.Traditionalandnewcompositeendpointsinheartfailureclinical
.
desincardiometabolicregulationanddisease.NatRevCardiol2014;11:403(cid:2)412. . trials: facilitating comprehensive efficacy assessments and improving trial effi-
.
88. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, . ciency.EurJHeartFail2016;18:482(cid:2)489.
.
andclinicalrelevanceofnatriureticpeptides.JCardiol2011;57:131(cid:2)140. .. 103.GayatE,ArrigoM,LittnerovaS,SatoN,ParenicaJ,IshiharaS,SpinarJ,Muller
89. VelazquezEJ,LeeKL,DejaMA,JainA,SopkoG,MarchenkoA,AliIS,PohostG, .. C, Harjola VP, Lassus J, Miro O, Maggioni AP, AlHabib KF, Choi DJ, Park JJ,
.
Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie . Zhang Y, Zhang J, Januzzi JL, Jr., Kajimoto K, Cohen-Solal A, Mebazaa A,
.
MC,O’ConnorCM,PanchavinninP,SheL,BonowRO,RankinGR,JonesRH, . NetworkG.Heartfailureoraltherapiesatdischargeareassociatedwithbetter
.
RouleauJL,STICHInvestigators.Coronary-arterybypasssurgeryinpatientswith .. outcomeinacuteheartfailure:apropensity-scorematchedstudy.EurJHeart
.
leftventriculardysfunction.NEnglJMed2011;364:1607(cid:2)1616. . Fail2018;20:345(cid:2)354.
.
90. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing . 104.Crespo-LeiroMG,AnkerSD,MaggioniAP,CoatsAJ,FilippatosG,RuschitzkaF,
.
andimpactofrevascularizationonprognosisinpatientswithcoronaryarterydis- .. FerrariR,PiepoliMF,DelgadoJimenezJF,MetraM,FonsecaC,HradecJ,Amir
ease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol .. O,LogeartD,DahlstromU,MerkelyB,DrozdzJ,GoncalvesovaE,Hassanein
.
2002;39:1151(cid:2)1158. . M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A,
.
91. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, . Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C,
.
Hachamovitch R. Identification of therapeutic benefit from revascularization in .. MebazaaA,HeartFailureAssociationoftheEuropeanSocietyofCardiology.
patientswithleftventricularsystolicdysfunction:inducibleischemiaversushiber- .. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-
.
natingmyocardium.CircCardiovascImaging2013;6:363(cid:2)372. . LT):1-yearfollow-upoutcomesanddifferencesacrossregions.EurJHeartFail
.
92. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, .. 2016;18:613(cid:2)625.
DrozdzJ,FarskyPS,FeldmanAM,DoenstT,MichlerRE,BermanDS,NicolauJC, .. 105.McMurrayJJ,PackerM,DesaiAS,GongJ,LefkowitzMP,RizkalaAR,RouleauJL,
.
Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, . ShiVC,SolomonSD,SwedbergK,ZileMR,PARADIGM-HFInvestigatorsand
.
JonesRH,PanzaJA,STICHTrialInvestigators.Myocardialviabilityandsurvivalin . Committees.Angiotensin-neprilysininhibitionversusenalaprilinheartfailure.N
.
ischemicleftventriculardysfunction.NEnglJMed2011;364:1617(cid:2)1625. .. EnglJMed2014;371:993(cid:2)1004.
93. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, .. 106.VelazquezEJ,MorrowDA,DeVoreAD,DuffyCI,AmbrosyAP,McCagueK,
.
SopkoG,ChrzanowskiL,MarkDB,KukulskiT,FavaloroLE,MaurerG,Farsky . Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-neprilysin
.
PS,TanRS,AschFM,VelazquezEJ,RouleauJL,LeeKL,BonowRO.Myocardial . inhibition in acute decompensated heart failure. N Engl J Med 2019;380: .
viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med .. 539(cid:2)548.
2019;381:739(cid:2)748. .. 107.WachterR,SenniM,BelohlavekJ,Straburzynska-MigajE,WitteKK,Kobalava
.
94. Corra U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, . Z,FonsecaC,GoncalvesovaE,CavusogluY,FernandezA,ChaabanS,Bohmer
. Lambrinou E, Pieske B, Piotrowicz E, Schmid JP, Seferovic PM, Anker SD, .. E,PouleurAC,MuellerC,TribouilloyC,LonnE,BuraikiALJ,GniotJ,Mozheiko
FilippatosG,PonikowskiPP.Cardiopulmonaryexercisetestinginsystolicheart .. M, Lelonek M, Noe` A, Schwende H, Bao W, Butylin D, Pascual-Figal D,
.
failure in 2014: the evolving prognostic role: a position paper from the . TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynami- .
CommitteeonExercisePhysiologyandTrainingoftheHeartFailureAssociation . callystabilisedheartfailurepatientsinhospitalorearlyafterdischarge:primary
.
oftheESC.EurJHeartFail2014;16:929(cid:2)941. .. results of the randomised TRANSITION study. Eur J Heart Fail
95. PiepoliMF,ConraadsV,CorraU,DicksteinK,FrancisDP,JaarsmaT,McMurray .. 2019;21:998(cid:2)1007.
.
J,PieskeB,PiotrowiczE,SchmidJP,AnkerSD,SolalAC,FilippatosGS,Hoes . 108.McMurrayJJV,SolomonSD,InzucchiSE,KøberL,KosiborodMN,MartinezFA,
.
AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: . Ponikowski P, Sabatine MS, Anand IS, B(cid:2)elohl(cid:3)avek J, Bo¨hm M, Chiang C-E,
.
fromtheorytopractice.AconsensusdocumentoftheHeartFailureAssociation .. ChopraVK,deBoerRA,DesaiAS,DiezM,DrozdzJ,Duk(cid:3)atA,GeJ,Howlett
.
andtheEuropeanAssociationforCardiovascularPreventionandRehabilitation. . JG,KatovaT,KitakazeM,LjungmanCEA,MerkelyB,NicolauJC,O’MearaE,
.
EurJHeartFail2011;13:347(cid:2)357. . PetrieMC,VinhPN,SchouM,TereshchenkoS,VermaS,HeldC,DeMetsDL,
.
96. CorraU,AgostoniPG,AnkerSD,CoatsAJS,CrespoLeiroMG,deBoerRA, .. Docherty KF, Jhund PS, Bengtsson O, Sjo¨strand M, LangkildeAM, DAPA-HF
HairolaVP,HillL,LainscakM,LundLH,MetraM,PonikowskiP,RileyJ,Seferovic .. TrialCommitteesandInvestigators.Dapagliflozininpatientswithheartfailure
.
PM,PiepoliMF.Roleofcardiopulmonaryexercisetestinginclinicalstratification . andreducedejectionfraction.NEnglJMed2019;381:1995(cid:2)2008.
.
inheartfailure.ApositionpaperfromtheCommitteeonExercisePhysiology . 109.Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J,
.
and Training of the Heart Failure Association of the European Society of .. Verma S,TsutsuiH,BrueckmannM,JamalW,KimuraK,SchneeJ,Zeller C,
Cardiology.EurJHeartFail2018;20:3(cid:2)15. .. CottonD,BocchiE,BohmM,ChoiDJ,ChopraV,ChuquiureE,GiannettiN,
.
97. Cooper LT, BaughmanKL, FeldmanAM, Frustaci A,Jessup M,KuhlU,Levine . Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP,
.
GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial .. Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M,
biopsyinthemanagementofcardiovasculardisease:ascientificstatementfrom .. Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-
.
theAmericanHeartAssociation,theAmericanCollegeofCardiology,andthe . ReducedTrialInvestigators.Cardiovascularandrenaloutcomeswithempagli-
.
European Society of Cardiology Endorsed by the Heart Failure Society of . flozininheartfailure.NEnglJMed2020;383:1413(cid:2)1424.
.
America and the Heart Failure Association of the European Society of .. 110.TheCONSENSUSTrialStudyGroup.Enalaprilforcongestiveheartfailure.N
Cardiology.EurHeartJ2007;28:3076(cid:2)3093. . EnglJMed1987;317:1349(cid:2)1351.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 101 ---
ESCGuidelines 3699
.
.
111. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting . duringtreatment of heartfailure with mineralocorticoid receptor antagonists
.
enzyme inhibitors on mortality and morbidity in patients with heart failure. . byuseofsacubitril/valsartancomparedwithenalapril:asecondaryanalysisof
.
CollaborativeGrouponACEInhibitorTrials.JAMA1995;273:1450(cid:2)1456. .. thePARADIGM-HFTrial.JAMACardiol2017;2:79(cid:2)85.
112. PackerM,Poole-WilsonPA,ArmstrongPW,ClelandJG,HorowitzJD,Massie .. 129.VardenyO,ClaggettB,KachadourianJ,DesaiAS,PackerM,RouleauJ,ZileMR,
.
BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high . Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop
.
doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity .. diureticuseinpatientstakingsacubitril/valsartancomparedwithenalapril:the
and mortality in chronic heart failure. ATLAS Study Group. Circulation .. PARADIGM-HFtrial.EurJHeartFail2019;21:337(cid:2)341.
.
1999;100:2312(cid:2)2318. . 130.Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M,
.
113. SOLVDInvestigators,YusufS,PittB,DavisCE,HoodWB,CohnJN.Effectof . RouleauJ,ZileMR,SwedbergK,LefkowitzM,ShiV,McMurrayJJV,Solomon
.
enalaprilonsurvivalinpatientswithreducedleftventricularejectionfractions .. SD.Incidence,predictors,andoutcomesassociatedwithhypotensiveepisodes
andcongestiveheartfailure.NEnglJMed1991;325:293(cid:2)302. .. among heart failure patients receiving sacubitril/valsartan or enalapril: the
.
114. MERIT-HFStudyGroup.EffectofmetoprololCR/XLinchronicheartfailure: . PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor
.
MetoprololCR/XLRandomisedInterventionTrialinCongestiveHeartFailure . Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to
.
(MERIT-HF).Lancet1999;353:2001(cid:2)2007. .. Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ
.
115. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, . HeartFail2018;11:e004745.
.
ShustermanNH.Theeffectofcarvedilolonmorbidityandmortalityinpatients . 131.Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP,
. withchronicheartfailure.U.S.CarvedilolHeartFailureStudyGroup.NEnglJ .. Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients
Med1996;334:1349(cid:2)1355. .. withacutedecompensatedheartfailurerandomlyassignedtosacubitril/valsar-
.
116. Packer M,CoatsAJ, Fowler MB, Katus HA,Krum H,Mohacsi P,Rouleau JL, . tanorenalaprilinthePIONEER-HFtrial.Circulation2019;139:2285(cid:2)2288.
.
Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol . 132.KosiborodMN,JhundPS,DochertyKF,DiezM,PetrieMC,VermaS,Nicolau
.
ProspectiveRandomizedCumulativeSurvivalStudyGroup.Effectofcarvedilol .. JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA,
onsurvivalinseverechronicheartfailure.NEnglJMed2001;344:1651(cid:2)1658. .. PonikowskiP,SabatineMS,SolomonSD,BengtssonO,LindholmD,Niklasson
.
117. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, . A,SjostrandM,LangkildeAM,McMurrayJJV.Effectsofdapagliflozinonsymp-
.
WikstrandJ,ElAllafD,VitovecJ,AldershvileJ,HalinenM,DietzR,Neuhaus .. toms,function,andqualityoflifeinpatientswithheartfailureandreducedejec-
KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, .. tionfraction:resultsfromtheDAPA-HFtrial.Circulation2020;141:90(cid:2)99.
.
RickenbacherP,BallS,GottliebS,DeedwaniaP.Effectsofcontrolled-release . 133.ButlerJ,AnkerSD,FilippatosG,KhanMS,FerreiraJP,PocockSJ,GiannettiN,
.
metoprololontotalmortality,hospitalizations,andwell-beinginpatientswith . JanuzziJL,PinaIL,LamCSP,PonikowskiP,SattarN,VermaS,BrueckmannM,
.
heartfailure:theMetoprololCR/XLRandomizedInterventionTrialinconges- .. JamalW,VedinO,PeilB,ZellerC,ZannadF,PackerM,EMPEROR-Reduced
tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA .. TrialCommitteesandInvestigators.Empagliflozinandhealth-relatedqualityof
.
2000;283:1295(cid:2)1302. . lifeoutcomesinpatientswithheartfailurewithreducedejectionfraction:the
.
118. PackerM,FowlerMB,RoeckerEB,CoatsAJ,KatusHA,KrumH,MohacsiP, . EMPEROR-Reducedtrial.EurHeartJ2021;42:1203(cid:2)1212.
.
RouleauJL,TenderaM,StaigerC,HolcslawTL,Amann-ZalanI,DeMetsDL, .. 134.ZannadF,FerreiraJP,PocockSJ,AnkerSD,ButlerJ,FilippatosG,Brueckmann
.
CarvedilolProspectiveRandomizedCumulativeSurvivalStudyGroup.Effectof . M,OfstadAP,PfarrE,JamalW,PackerM.SGLT2inhibitorsinpatientswith
.
carvedilolonthemorbidityofpatientswithseverechronicheartfailure:results . heartfailurewithreducedejectionfraction:ameta-analysisoftheEMPEROR-
.
ofthecarvedilolprospectiverandomizedcumulativesurvival(COPERNICUS) .. ReducedandDAPA-HFtrials.Lancet2020;396:819(cid:2)829.
study.Circulation2002;106:2194(cid:2)2199. .. 135.JacksonAM,DewanP,AnandIS,BelohlavekJ,BengtssonO,deBoerRA,Bohm
.
119. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, . M,BoultonDW,ChopraVK,DeMetsDL,DochertyKF,DukatA,GreasleyPJ,
.
Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, . Howlett JG, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM,
.
Tavazzi L,SpinarovaL,TomanJ,BohmM,AnkerSD,ThompsonSG,Poole- .. LindholmD,LjungmanCEA,MartinezFA,O’MearaE,SabatineMS,Sjostrand
WilsonPA,SENIORSInvestigators.Randomizedtrialtodeterminetheeffectof .. M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV.
.
nebivololonmortalityandcardiovascularhospitaladmissioninelderlypatients . Dapagliflozinanddiureticuseinpatientswithheartfailureandreducedejection
.
withheartfailure(SENIORS).EurHeartJ2005;26:215(cid:2)225. .. fractioninDAPA-HF.Circulation2020;142:1040(cid:2)1054.
120. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol .. 136.BhattDL,SzarekM,StegPG,CannonCP,LeiterLA,McGuireDK,LewisJB,
.
StudyII(CIBIS-II):arandomisedtrial.Lancet1999;353:9(cid:2)13. . RiddleMC,VoorsAA,MetraM,LundLH,KomajdaM,TestaniJM,WilcoxCS,
.
121. PittB,ZannadF,RemmeWJ,CodyR,CastaigneA,PerezA,PalenskyJ,Wittes . Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial
.
J. The effect of spironolactone on morbidity and mortality in patients with .. Investigators.Sotagliflozininpatientswithdiabetesandrecentworseningheart
severe heartfailure.Randomized Aldactone Evaluation Study Investigators.N .. failure.NEnglJMed2021;384:117(cid:2)128.
.
EnglJMed1999;341:709(cid:2)717. . 137.FarisR,FlatherM,PurcellH,HeneinM,Poole-WilsonP,CoatsA.Currentevi-
.
122. ZannadF,McMurrayJJ,KrumH,vanVeldhuisenDJ,SwedbergK,ShiH,Vincent . dencesupportingtheroleofdiureticsinheartfailure:ametaanalysisofrando- .
J,PocockSJ,PittB,EMPHASIS-HFStudyGroup.Eplerenoneinpatients with .. misedcontrolledtrials.IntJCardiol2002;82:149(cid:2)158.
systolicheartfailureandmildsymptoms.NEnglJMed2011;364:11(cid:2)21. .. 138.Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B,
.
123. Fowler MB. Effects of beta blockers on symptoms and functional capacity in . OstergrenJ,PfefferMA,SwedbergK,CHARMInvestigatorsandCommittees.
. heartfailure.AmJCardiol1997;80:55L(cid:2)58L. .. Effectsofcandesartaninpatientswithchronicheartfailureandreducedleft-
124. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, .. ventricularsystolicfunctionintoleranttoangiotensin-converting-enzymeinhibi-
.
Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III . tors:theCHARM-Alternativetrial.Lancet2003;362:772(cid:2)776. .
Investigators. Effect on survival and hospitalization of initiating treatment for . 139.Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
.
chronicheartfailurewithbisoprololfollowedbyenalapril,ascomparedwith .. Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in
the opposite sequence: results of the randomized Cardiac Insufficiency .. chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
.
BisoprololStudy(CIBIS)III.Circulation2005;112:2426(cid:2)2435. . 2010;376:875(cid:2)885.
.
125. KotechaD,HolmesJ,KrumH,AltmanDG,ManzanoL,ClelandJG,LipGY, . 140.Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I,
.
Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, .. SHIFTInvestigators.Effectsonoutcomesofheartratereductionbyivabradine
.
Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure . inpatientswithcongestiveheartfailure:isthereaninfluenceofbeta-blocker
.
Collaborative Group. Efficacy of beta blockers in patients with heart failure . dose?: findings fromtheSHIFT(Systolic Heartfailure treatment with theI(f)
.
plus atrial fibrillation: an individual-patient data meta-analysis. Lancet .. inhibitorivabradineTrial)study.JAmCollCardiol2012;59:1938(cid:2)1945.
2014;384:2235(cid:2)2243. .. 141.ArmstrongPW,PieskeB,AnstromKJ,EzekowitzJ,HernandezAF,ButlerJ,Lam
.
126. SeferovicJP,ClaggettB,SeidelmannSB,SeelyEW,PackerM,ZileMR,Rouleau . CSP,PonikowskiP,VoorsAA,JiaG,McNultySE,PatelMJ,RoessigL,KoglinJ,
.
JL,SwedbergK,LefkowitzM,ShiVC,DesaiAS,McMurrayJJV,SolomonSD. . O’ConnorCM,VICTORIAStudyGroup.Vericiguatinpatientswithheartfail-
.
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients .. ureandreducedejectionfraction.NEnglJMed2020;382:1883(cid:2)1893.
withheartfailureanddiabetes: apost-hoc analysisfromthePARADIGM-HF .. 142.TaylorAL,ZiescheS,YancyC,CarsonP,D’AgostinoR,Jr.,FerdinandK,Taylor
.
trial.LancetDiabetesEndocrinol2017;5:333(cid:2)340. . M,AdamsK,SabolinskiM,WorcelM,CohnJN,African-AmericanHeartFailure
.
127. DammanK,GoriM,ClaggettB,JhundPS,SenniM,LefkowitzMP,PrescottMF, .. TrialInvestigators.Combinationofisosorbidedinitrateandhydralazineinblacks
ShiVC,RouleauJL,SwedbergK,ZileMR,PackerM,DesaiAS,SolomonSD, .. withheartfailure.NEnglJMed2004;351:2049(cid:2)2057.
.
McMurray JJV. Renal effects and associated outcomes during angiotensin- . 143.Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE,
.
neprilysininhibitioninheartfailure.JACCHeartFail2018;6:489(cid:2)498. . DunkmanWB,JacobsW,FrancisGS,FlohrKH.Effectofvasodilatortherapy
.
128. DesaiAS,VardenyO,ClaggettB,McMurrayJJ,PackerM,SwedbergK,Rouleau .. on mortality in chronic congestive heart failure. Results of a Veterans
JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced risk of hyperkalemia . AdministrationCooperativeStudy.NEnglJMed1986;314:1547(cid:2)1552.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 102 ---
3700 ESCGuidelines
.
.
144. DigitalisInvestigationGroup.Theeffectofdigoxinonmortalityandmorbidity . 161.BardyGH, LeeKL, Mark DB, PooleJE,Packer DL,BoineauR, Domanski M,
.
inpatientswithheartfailure.NEnglJMed1997;336:525(cid:2)533. . Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N,
.
145. MullensW,DammanK,HarjolaVP,MebazaaA,Brunner-LaRoccaHP,Martens .. Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac
P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, .. Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an
.
SeferovicPM,RuschitzkaF,CoatsAJ.Theuseofdiureticsinheartfailurewith . implantablecardioverter-defibrillatorforcongestiveheartfailure.NEnglJMed
.
congestion–apositionstatementfromthe HeartFailureAssociation ofthe .. 2005;352:225(cid:2)237.
EuropeanSocietyofCardiology.EurJHeartFail2019;21:137(cid:2)155. .. 162.ConnollySJ,HallstromAP,CappatoR,SchronEB,KuckKH,ZipesDP,Greene
.
146. RohdeLE,RoverMM,FigueiredoNetoJA,DanzmannLC,BertoldiEG,Simoes . HL,BoczorS,DomanskiM,FollmannD,GentM,RobertsRS, investigatorsof
.
MV,SilvestreOM,RibeiroALP,MouraLZ,Beck-da-SilvaL,PradoD,Sant’Anna . the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardi-
.
RT,BridiLH,ZimermanA,RauppdaRosaP,BioloA.Short-termdiureticwith- .. overter defibrillator secondary prevention trials. Eur Heart J
drawal in stable outpatients with mild heart failure and no fluid retention .. 2000;21:2071(cid:2)2078.
.
receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur . 163.AntiarrhythmicsversusImplantableDefibrillators(AVID)Investigators.Acom-
.
HeartJ2019;40:3605(cid:2)3612. .. parison of antiarrhythmic-drug therapy with implantable defibrillators in
147. CohnJN,TognoniG,ValsartanHeartFailureTrialInvestigators.Arandomized .. patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med
.
trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N . 1997;337:1576(cid:2)1583.
.
EnglJMed2001;345:1667(cid:2)1675. . 164.KuckKH,CappatoR,SiebelsJ,RuppelR.Randomizedcomparisonofantiar-
. 148. BohmM,Borer J,FordI,Gonzalez-JuanateyJR,Komajda M,Lopez-SendonJ, .. rhythmic drug therapy with implantable defibrillators in patients resuscitated
ReilJC,SwedbergK,TavazziL.Heartrateatbaselineinfluencestheeffectof .. from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation
.
ivabradine on cardiovascular outcomes in chronic heart failure: analysis from . 2000;102:748(cid:2)754.
.
theSHIFTstudy.ClinResCardiol2013;102:11(cid:2)22. . 165.Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP,
.
149. OuyangAJ,LvYN,ZhongHL,WenJH,WeiXH,PengHW,ZhouJ,LiuLL. .. Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator
Meta-analysisofdigoxinuseandriskofmortalityinpatientswithatrialfibrilla- .. ImplantationTrialIIInvestigators.Prophylacticimplantationofadefibrillatorin
.
tion.AmJCardiol2015;115:901(cid:2)906. . patientswithmyocardialinfarctionandreducedejectionfraction.NEnglJMed
.
150. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a .. 2002;346:877(cid:2)883.
systematic review and meta-analysis of the literature. Eur Heart J .. 166.Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G,
.
2015;36:1831(cid:2)1838. . HildebrandtP,SteffensenFH,BruunNE,EiskjaerH,BrandesA,ThogersenAM,
.
151. ZiffOJ,LaneDA,SamraM,GriffithM,KirchhofP,LipGY,SteedsRP,Townend . Gustafsson F, Egstrup K, Videbaek R, HassagerC, Svendsen JH, Hofsten DE,
.
J,KotechaD.Safetyandefficacyofdigoxin:systematicreviewandmeta-analysis .. Torp-PedersenC,PehrsonS,DANISHInvestigators.Defibrillatorimplantation
ofobservationalandcontrolledtrialdata.BMJ2015;351:h4451. .. in patients with nonischemic systolic heart failure. N Engl J Med
.
152. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, . 2016;375:1221(cid:2)1230.
.
HillegeHL,Bergsma-KadijkJA,CornelJH,KampO,TukkieR,BoskerHA,Van . 167.BeggsSAS, JhundPS, JacksonCE,McMurrayJJV, Gardner RS.Non-ischaemic
.
VeldhuisenDJ,VandenBergMP,RACEIIInvestigators.Lenientversusstrictrate .. cardiomyopathy, sudden death and implantable defibrillators: a review and
.
controlinpatientswithatrialfibrillation.NEnglJMed2010;362:1363(cid:2)1373. . meta-analysis.Heart2018;104:144(cid:2)150.
.
153. BavishiC,KhanAR,AtherS.Digoxininpatientswithatrialfibrillationandheart . 168.MerchantFM,JonesP,WehrenbergS,LloydMS,SaxonLA.Incidenceofdefib-
.
failure:ameta-analysis.IntJCardiol2015;188:99(cid:2)101. .. rillatorshocksafterelectivegeneratorexchangefollowinguneventfulfirstbat-
154. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, .. terylife.JAmHeartAssoc2014;3:e001289.
.
BorowskyLH,HarrisonTN,SingerDE,GoAS.Digoxinandriskofdeathin . 169.YapSC,SchaerBA,BhagwandienRE,KuhneM,DabiriAbkenariL,OsswaldS,
.
adultswithatrialfibrillation:theATRIA-CVRNstudy.CircArrhythmElectrophysiol . Szili-Torok T, Sticherling C, Theuns DA. Evaluation of the need of elective
.
2015;8:49(cid:2)58. .. implantablecardioverter-defibrillatorgeneratorreplacementinprimarypreven-
155. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, .. tion patients without prior appropriate ICD therapy. Heart
.
MahaffeyKW,HankeyGJ,BerkowitzSD,NesselCC,FoxKA,CaliffRM,Piccini . 2014;100:1188(cid:2)1192.
.
JP,PatelMR,ROCKETSteeringCommittee andInvestigators.Digoxinusein .. 170.KiniV,SoufiMK,DeoR,EpsteinAE,BalaR,RileyM,GroeneveldPW,Shalaby
patientswithatrialfibrillationAFandadversecardiovascularoutcomes:retro- .. A, Dixit S. Appropriateness of primary prevention implantable cardioverter-
.
spective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa . defibrillatorsatthetimeofgeneratorreplacement:areindicationsstillmet?J
.
Inhibition Compared with Vitamin a K Antagonism for Prevention of Stroke . AmCollCardiol2014;63:2388(cid:2)2394.
.
and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet .. 171.ErkapicD,SperzelJ,StillerS,MeltendorfU,MermiJ,WegscheiderK,HuglB,
2015;385:2363(cid:2)2370. .. InvestigatorsI.Long-termbenefitofimplantablecardioverter/defibrillatorther-
.
156. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of . apy after elective device replacement: results of the INcidence free SUrvival
.
serumdigoxinconcentrationandoutcomesinpatientswithheartfailure.JAMA . after ICD REplacement (INSURE) trial–a prospective multicentre study. Eur .
2003;289:871(cid:2)878. .. HeartJ2013;34:130(cid:2)137.
157. AdamsKF,Jr.,PattersonJH,GattisWA,O’ConnorCM,LeeCR,SchwartzTA, .. 172.Alsheikh-AliAA,HomerM,MaddukuriPV,KalsmithB,EstesNA,3rd,LinkMS.
.
GheorghiadeM.Relationshipofserumdigoxinconcentrationtomortalityand . Time-dependence of appropriate implantable defibrillator therapy in patients
. morbidityinwomenintheDigitalisInvestigationGrouptrial:aretrospective .. withischemiccardiomyopathy.JCardiovascElectrophysiol2008;19:784(cid:2)789.
analysis.JAmCollCardiol2005;46:497(cid:2)504. .. 173.OpreanuM,WanC,SinghV,SalehiN,AhmadJ,SzymkiewiczSJ,ThakurRK.
.
158. Bavendiek U, Berliner D, Davila LA, Schwab J, Maier L, Philipp SA, Rieth A, . Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a .
WestenfeldR,PiorkowskiC,WeberK,HanselmannA,OldhaferM,Schallhorn . nationaldatabaseanalysis.JHeartLungTransplant2015;34:1305(cid:2)1309.
.
S, von der Leyen H, Schroder C, Veltmann C, Stork S, Bohm M, Koch A, .. 174.ZishiriET,WilliamsS,CroninEM,BlackstoneEH,EllisSG,RoselliEE,Smedira
BauersachsJ,DIGIT-HFInvestigatorsandCommittees.Rationaleanddesignof .. NG,GillinovAM,GladJA,TchouPJ,SzymkiewiczSJ,ChungMK.Earlyriskof
.
theDIGIT-HFtrial(DIGitoxintoImproveouTcomesinpatientswithadvanced . mortalityaftercoronaryarteryrevascularizationinpatientswithleftventricular
.
chronic Heart Failure): a randomized, double-blind, placebo-controlled study. . dysfunction and potential role of the wearable cardioverter defibrillator. Circ
.
EurJHeartFail2019;21:676(cid:2)684. .. ArrhythmElectrophysiol2013;6:117(cid:2)128.
.
159. TeerlinkJR,DiazR,FelkerGM,McMurrayJJV,MetraM,SolomonSD,Adams . 175.Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, Zareba W,
.
KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, . GoldenbergI.Useofthewearablecardioverterdefibrillatorinhigh-riskcardiac
.
ClelandJGF,CorbalanR,Crespo-LeiroMG,DahlstromU,EcheverriaLE,Fang .. patients: data from the Prospective Registry of Patients Using the Wearable
JC,FilippatosG,FonsecaC,GoncalvesovaE,GoudevAR,HowlettJG,Lanfear .. Cardioverter Defibrillator (WEARIT-II Registry). Circulation
.
DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E, . 2015;132:1613(cid:2)1619.
.
ParkhomenkoA,PonikowskiP,RamiresFJA,SerpytisP,SliwaK,SpinarJ,Suter . 176.Kutyifa V, Moss AJ, Klein HU, McNitt S, Zareba W, Goldenberg I. One-year
.
TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, .. follow-up of the Prospective Registry of Patients Using the Wearable
ZannadF,SharpstenL,LeggJC,VarinC,HonarpourN,AbbasiSA,MalikFI, .. Defibrillator(WEARIT-IIRegistry).PacingClinElectrophysiol2018;41:1307(cid:2)1313.
.
KurtzCE,GALACTIC-HF Investigators.Cardiacmyosin activationwithome- . 177.HohnloserSH,KuckKH,DorianP,RobertsRS,HamptonJR,HatalaR,FainE,
.
camtivmecarbilinsystolicheartfailure.NEnglJMed2021;384:105(cid:2)116. .. GentM,ConnollySJ,DINAMITInvestigators.Prophylacticuseofanimplant-
160. ShenL,JhundPS, PetrieMC,ClaggettBL,BarleraS,ClelandJGF,DargieHJ, .. able cardioverter-defibrillator after acute myocardial infarction. N Engl J Med
.
Granger CB, Kjekshus J, Kuˆ¡ber L, Latini R, Maggioni AP, Packer M, Pitt B, . 2004;351:2481(cid:2)2488.
.
Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, . 178.SteinbeckG,AndresenD,SeidlK,BrachmannJ,HoffmannE,WojciechowskiD,
.
McMurray JJV. Declining risk of sudden death in heart failure. N Engl J Med .. Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgartner F, Lubinski A,
2017;377:41(cid:2)51. . Rosenqvist M, Habets A, Wegscheider K, Senges J, IRIS Investigators.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 103 ---
ESCGuidelines 3701
.
.
Defibrillator implantation early after myocardial infarction. N Engl J Med . ShocklessIMPLantEvaluationInvestigators.Cardioverterdefibrillatorimplanta-
.
2009;361:1427(cid:2)1436. . tionwithoutinductionofventricularfibrillation:asingle-blind,non-inferiority,
.
179. SandersGD,HlatkyMA,OwensDK.Cost-effectivenessofimplantablecardi- .. randomisedcontrolledtrial(SIMPLE).Lancet2015;385:785(cid:2)791.
overter-defibrillators.NEnglJMed2005;353:1471(cid:2)1480. .. 196.GaspariniM,ProclemerA,KlersyC,KloppeA,LunatiM,FerrerJB,HersiA,
.
180. SteinbergBA,Al-KhatibSM,EdwardsR,HanJ,BardyGH,BiggerJT,BuxtonAE, . Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A. Effect of long-detection
.
MossAJ,LeeKL,SteinmanR,DorianP,HallstromA,CappatoR,KadishAH, .. intervalvsstandard-detectionintervalforimplantablecardioverter-defibrillators
Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Outcomes of implantable .. on antitachycardia pacing and shock delivery: the ADVANCE III randomized
.
cardioverter-defibrillator use in patients with comorbidities: results from a . clinicaltrial.JAMA2013;309:1903(cid:2)1911.
.
combined analysis of 4 randomized clinical trials. JACC Heart Fail . 197.ClelandJG,BugaL.Devicetherapy:defibrillators–ashockingtherapyforcardio-
.
2014;2:623(cid:2)629. .. myopathy?NatRevCardiol2010;7:69(cid:2)70.
181. RaphaelCE,FinegoldJA,BarronAJ,WhinnettZI,MayetJ,LindeC,ClelandJG, .. 198.WilkoffBL,CookJR,EpsteinAE,GreeneHL,HallstromAP,HsiaH,KutalekSP,
.
LevyWC,FrancisDP.Theeffectofdurationoffollow-upandpresenceofcom- . SharmaA,DualChamberandVVIImplantableDefibrillatorTrialInvestigators.
.
petingriskonlifespan-gainfromimplantablecardioverterdefibrillatortherapy: . Dual-chamberpacingorventricularbackuppacinginpatientswithanimplant-
.
whobenefitsthemost?EurHeartJ2015;36:1676(cid:2)1688. .. abledefibrillator:theDualChamberandVVIImplantableDefibrillator(DAVID)
.
182. MillerRJ,HowlettJG,ExnerDV,CampbellPM,GrantAD,WiltonSB.Baseline . Trial.JAMA2002;288:3115(cid:2)3123.
.
functionalclassandtherapeuticefficacyofcommonheartfailureinterventions: . 199.BoersmaL,BarrC,KnopsR,TheunsD,EckardtL,NeuzilP,ScholtenM,Hood
. asystematicreviewandmeta-analysis.CanJCardiol2015;31:792(cid:2)799. .. M, Kuschyk J, Jones P, Duffy E, Husby M, Stein K, Lambiase PD, Group EI.
183. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, .. Implantandmidtermoutcomesofthesubcutaneousimplantablecardioverter-
.
Cappato R, Dorian P,Hallstrom A, Kadish AH, Kudenchuk PJ, LeeKL, Mark . defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol
.
DB,MossAJ,SteinmanR,InoueLY,SandersG.Survivalbenefitoftheprimary . 2017;70:830(cid:2)841.
.
prevention implantable cardioverter-defibrillator among older patients: does .. 200.BurkeMC,GoldMR,KnightBP,BarrCS,TheunsD,BoersmaLVA,KnopsRE,
agematter?Ananalysisofpooleddatafrom5clinicaltrials.CircCardiovascQual .. WeissR,LeonAR,HerreJM,HusbyM,SteinKM,LambiasePD.Safetyandeffi-
.
Outcomes2015;8:179(cid:2)186. . cacyofthetotallysubcutaneousimplantabledefibrillator:2-yearresultsfroma
.
184. ConnollySJ,GentM,RobertsRS,DorianP,RoyD,SheldonRS,MitchellLB, .. pooled analysis of the IDEstudy andEFFORTLESS registry. J Am Coll Cardiol
GreenMS,KleinGJ,O’BrienB.Canadianimplantabledefibrillatorstudy(CIDS): .. 2015;65:1605(cid:2)1615.
.
arandomizedtrialoftheimplantablecardioverterdefibrillatoragainstamiodar- . 201.PrioriSG,Blomstrom-LundqvistC,MazzantiA,BlomN,BorggrefeM,CammJ,
.
one.Circulation2000;101:1297(cid:2)1302. . ElliottPM,FitzsimonsD,HatalaR,HindricksG,KirchhofP,KjeldsenK,Kuck
.
185. KoberL,Torp-PedersenC,McMurrayJJ,GotzscheO,LevyS,CrijnsH,AmlieJ, .. KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van
Carlsen J, DronedaroneStudy Group. Increased mortality after dronedarone .. VeldhuisenDJ,ESCScientificDocumentGroup.2015ESCGuidelinesforthe
.
therapyforsevereheartfailure.NEnglJMed2008;358:2678(cid:2)2687. . managementofpatientswithventriculararrhythmiasandthepreventionofsud-
.
186. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, . den cardiac death: The Task Force for the Management of Patients with
.
Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in .. VentricularArrhythmiasandthePreventionofSuddenCardiacDeathofthe
.
patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia . EuropeanSocietyofCardiology(ESC).Endorsedby:AssociationforEuropean
.
SuppressionTrial.NEnglJMed1991;324:781(cid:2)788. . PaediatricandCongenitalCardiology(AEPC).EurHeartJ2015;36:2793(cid:2)2867.
.
187. TheunsDA,SmithT,HuninkMG,BardyGH,JordaensL.Effectivenessofpro- .. 202.KnopsRE,OldeNordkampLRA,DelnoyPHM,BoersmaLVA,KuschykJ,El-
phylacticimplantationofcardioverter-defibrillatorswithoutcardiacresynchro- .. ChamiMF,BonnemeierH,BehrER,BrouwerTF,KaabS,MittalS,QuastABE,
.
nization therapy inpatients with ischaemic ornon-ischaemicheartdisease: a . Smeding L, van der Stuijt W, de Weger A, de Wilde KC, Bijsterveld NR,
.
systematicreviewandmeta-analysis.Europace2010;12:1564(cid:2)1570. . RichterS, Brouwer MA, de Groot JR, Kooiman KM, Lambiase PD, Neuzil P,
.
188. ElmingMB,NielsenJC,HaarboJ,VidebaekL,KorupE,SignorovitchJ,Olesen .. Vernooy K, Alings M, Betts TR, Bracke F, Burke MC, de Jong J, Wright DJ,
LL,HildebrandtP,SteffensenFH,BruunNE,EiskjaerH,BrandesA,Thogersen .. TijssenJGP,WildeAAM,PRAETORIANInvestigators.Subcutaneousortrans-
.
AM,GustafssonF,EgstrupK,VidebaekR,HassagerC,SvendsenJH,Hofsten . venousdefibrillatortherapy.NEnglJMed2020;383:526(cid:2)536.
.
DE,Torp-PedersenC,PehrsonS,KoberL,ThuneJJ.Ageandoutcomesofpri- .. 203.DunckerD,KonigT,HohmannS,BauersachsJ,VeltmannC.Avoidinguntimely
mary prevention implantable cardioverter-defibrillators in patients with noni- .. implantable cardioverter/defibrillator implantation by intensified heart failure
.
schemicsystolicheartfailure.Circulation2017;136:1772(cid:2)1780. . therapyoptimizationsupportedbythewearablecardioverter/defibrillator–the
.
189. SelvanayagamJB,HartshorneT,BillotL,GroverS,HillisGS,JungW,KrumH, . PROLONGStudy.JAmHeartAssoc2017;6:e004512.
.
PrasadS,McGaviganAD.Cardiovascularmagneticresonance-GUIDEdmanage- .. 204.OlginJE,PletcherMJ,VittinghoffE,WraniczJ,MalikR,MorinDP,ZweibelS,
mentofmildtomoderateleftventricularsystolicdysfunction(CMRGUIDE): .. BuxtonAE,ElayiCS,ChungEH,RashbaE,BorggrefeM,HueTF,MaguireC,Lin
.
Studyprotocolforarandomizedcontrolledtrial.AnnNoninvasiveElectrocardiol . F, Simon JA, Hulley S, Lee BK, VEST Investigators. Wearable cardioverter-
.
2017;22:e12420. . defibrillatoraftermyocardialinfarction.NEnglJMed2018;379:1205(cid:2)1215. .
190. LeyvaF,ZegardA,AcquayeE,GubranC,TaylorR,FoleyPWX,UmarF,Patel .. 205.CazeauS,LeclercqC,LavergneT,WalkerS,VarmaC,LindeC,GarrigueS,
K,PantingJ,MarshallH,QiuT.Outcomesofcardiacresynchronizationtherapy .. Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC, Multisite
.
with or without defibrillation in patients with nonischemic cardiomyopathy. J . StimulationinCardiomyopathies(MUSTIC)StudyInvestigators.Effectsofmulti-
. AmCollCardiol2017;70:1216(cid:2)1227. .. sitebiventricularpacinginpatientswithheartfailureandintraventricularcon-
191. DiMarcoA,AngueraI,SchmittM,KlemI,NeilanTG,WhiteJA,SramkoM, .. ductiondelay.NEnglJMed2001;344:873(cid:2)880.
.
Masci PG, Barison A, McKenna P, Mordi I, Haugaa KH, Leyva F, Rodriguez . 206.ClelandJG,DaubertJC,ErdmannE,FreemantleN,GrasD,KappenbergerL, .
CapitanJ,SatohH,NabetaT,DallaglioPD,CampbellNG,SabateX,Cequier . Tavazzi L, Cardiac Resynchronization-Heart Failure (CARE-HF) Study
.
A. Late gadolinium enhancement and the risk for ventricular arrhythmias or .. Investigators.Theeffectofcardiacresynchronizationonmorbidityandmortal-
suddendeathindilatedcardiomyopathy:systematicreviewandmeta-analysis. .. ityinheartfailure.NEnglJMed2005;352:1539(cid:2)1549.
.
JACCHeartFail2017;5:28(cid:2)38. . 207.DaubertC,GoldMR,AbrahamWT,GhioS,HassagerC,GoodeG,Szili-Torok
.
192.GulatiA,JabbourA,IsmailTF,GuhaK,KhwajaJ,RazaS,MorarjiK,BrownTD, . T,LindeC,REVERSEStudyGroup.Preventionofdiseaseprogressionbycar-
.
IsmailNA,DweckMR,DiPietroE,RoughtonM,WageR,DaryaniY,O’HanlonR, .. diacresynchronizationtherapyinpatientswithasymptomaticormildlysympto-
.
Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, . matic left ventricular dysfunction: insights from the European cohort of the
.
PennellDJ,PrasadSK.Associationoffibrosiswithmortalityandsuddencardiacdeath . REVERSE(ResynchronizationReversesRemodelinginSystolicLeftVentricular
.
inpatientswithnonischemicdilatedcardiomyopathy.JAMA2013;309:896(cid:2)908. .. Dysfunction)trial.JAmCollCardiol2009;54:1837(cid:2)1846.
193. StewartGC,WeintraubJR,PratibhuPP,SemigranMJ,CamusoJM,BrooksK, .. 208.ClelandJG,DaubertJC,ErdmannE,FreemantleN,GrasD,KappenbergerL,
.
TsangSW,AnelloMS,NguyenVT,LewisEF,NohriaA,DesaiAS,GivertzMM, . TavazziL.Longer-termeffectsofcardiacresynchronizationtherapyonmortal-
.
StevensonLW.Patientexpectationsfromimplantabledefibrillatorstoprevent . ity in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF)
.
deathinheartfailure.JCardFail2010;16:106(cid:2)113. .. trialextensionphase].EurHeartJ2006;27:1928(cid:2)1932.
194. MossAJ,SchugerC,BeckCA,BrownMW,CannomDS,DaubertJP,EstesNA, .. 209.Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L,
.
3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, . DaubertJC.Long-termmortalitywithcardiacresynchronizationtherapyinthe
.
OlshanskyB,ShodaM,WilberD,ZarebaW,MADIT-RITTrialInvestigators. .. Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail
ReductionininappropriatetherapyandmortalitythroughICDprogramming.N .. 2012;14:628(cid:2)634.
.
EnglJMed2012;367:2275(cid:2)2283. . 210.BristowMR,SaxonLA,BoehmerJ,KruegerS,KassDA,DeMarcoT,CarsonP,
.
195. HealeyJS,HohnloserSH,GliksonM,NeuznerJ,MaboP,VinolasX,KautznerJ, . DiCarloL,DeMetsD,WhiteBG,DeVriesDW,FeldmanAM,Comparisonof
.
O’HaraG,VanErvenL,GadlerF,PogueJ,ApplU,GilkersonJ,PochetT,Stein .. Medical Therapy Pacing and Defibrillation in Heart Failure (COMPANION)
KM, Merkely B, Chrolavicius S, Meeks B, Foldesi C, Thibault B, Connolly SJ, . Investigators.Cardiac-resynchronizationtherapywithorwithoutanimplantable
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 104 ---
3702 ESCGuidelines
.
.
defibrillator in advanced chronic heart failure. N Engl J Med . therapy in mild heart failure: 5-year results from the REsynchronization
.
2004;350:2140(cid:2)2150. . reVErsesRemodelinginSystolicleftvEntriculardysfunction(REVERSE)study.
.
211. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, .. EurHeartJ2013;34:2592(cid:2)2599.
Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five .. 228.ClelandJG,MareevY,LindeC.Reflections onEchoCRT:soundguidanceon
.
randomizedtrialsassessingtheeffectsofcardiacresynchronizationtherapyon . QRSdurationandmorphologyforCRT?EurHeartJ2015;36:1948(cid:2)1951.
.
morbidityandmortalityinpatientswithsymptomaticheartfailure.EurHeartJ .. 229.Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U,
2013;34:3547(cid:2)3556. .. Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization
.
212. TangAS,WellsGA,TalajicM,ArnoldMO,SheldonR,ConnollyS,Hohnloser . therapy, and prognostic impact of QRS prolongation and left bundle branch
.
SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, . blockinheartfailure.Europace2015;17:424(cid:2)431.
.
Resynchronization-Defibrillation for Ambulatory Heart Failure Trial .. 230.Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A,
Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart .. Ahmed FZ, Mamas MA. Cardiac resynchronisation therapy is not associated
.
failure.NEnglJMed2010;363:2385(cid:2)2395. . with a reduction in mortality or heart failure hospitalisation in patients with
.
213. MossAJ,HallWJ,CannomDS,KleinH,BrownMW,DaubertJP,EstesNA, . non-left bundle branch block QRS morphology: meta-analysis of randomised
.
3rd,FosterE,GreenbergH,HigginsSL,PfefferMA,SolomonSD,WilberD, .. controlledtrials.Heart2015;101:1456(cid:2)1462.
.
ZarebaW,MADIT-CRTTrialInvestigators.Cardiac-resynchronizationtherapy . 231.DoshiRN,Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA,
.
forthepreventionofheart-failureevents.NEnglJMed2009;361:1329(cid:2)1338. . PAVEStudy Group. Leftventricular-basedcardiacstimulation postAV nodal
. 214. GoldenbergI,KutyifaV,KleinHU,CannomDS,BrownMW,DanA,Daubert .. ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol
JP,EstesNA,3rd,FosterE,GreenbergH,KautznerJ,KlempfnerR,KunissM, .. 2005;16:1160(cid:2)1165.
.
MerkelyB,PfefferMA,QuesadaA,ViskinS,McNittS,PolonskyB,GhanemA, . 232.KoplanBA,KaplanAJ,WeinerS,JonesPW,SethM,ChristmanSA.Heartfail-
.
Solomon SD, Wilber D, Zareba W, Moss AJ. Survival with cardiac- . uredecompensationandall-causemortalityinrelationtopercentbiventricular
.
resynchronization therapy in mild heart failure. N Engl J Med .. pacinginpatientswithheartfailure:isagoalof100%biventricularpacingneces-
2014;370:1694(cid:2)1701. .. sary?JAmCollCardiol2009;53:355(cid:2)360.
.
215. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, . 233.HawkinsNM,PetrieMC,BurgessMI,McMurrayJJ.Selectingpatientsforcardiac
.
REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular .. resynchronizationtherapy:thefallacyofechocardiographicdyssynchrony.JAm
dysfunction) Study Group. Randomized trial of cardiac resynchronization in .. CollCardiol2009;53:1944(cid:2)1959.
.
mildlysymptomaticheartfailurepatientsandinasymptomaticpatientswithleft . 234.BeelaAS,UnluS,DuchenneJ,CiarkaA,DarabanAM,KotrcM,AaronesM,
.
ventriculardysfunctionandpreviousheartfailuresymptoms.JAmCollCardiol . SzulikM,WinterS,PenickaM,NeskovicAN,KukulskiT,AakhusS,WillemsR,
.
2008;52:1834(cid:2)1843. .. Fehske W, Faber L, Stankovic I, Voigt JU. Assessment of mechanical dyssyn-
216. CurtisAB,WorleySJ,AdamsonPB,ChungES,NiaziI,SherfeseeL,ShinnT, .. chronycanimprovetheprognosticvalueofguideline-basedpatientselection
.
Sutton MS, Biventricular versus Right Ventricular Pacing in Heart Failure . for cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging
.
Patients with Atrioventricular Block (BLOCK AF) Trial Investigators. . 2019;20:66(cid:2)74.
.
Biventricularpacingforatrioventricularblockandsystolicdysfunction.NEnglJ .. 235.Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, Read PA,
.
Med2013;368:1585(cid:2)1593. . BegleyD,FynnSP,DutkaDP.Targetedleftventricularleadplacementtoguide
.
217. BrignoleM,Botto G,MontL,IacopinoS,DeMarchi G,OddoneD,LuziM, . cardiac resynchronization therapy: the TARGET study: a randomized, con-
.
Tolosana JM, Navazio A, Menozzi C. Cardiac resynchronization therapy in .. trolledtrial.JAmCollCardiol2012;59:1509(cid:2)1518.
patientsundergoingatrioventricularjunctionablationforpermanentatrialfibril- .. 236.SabaS,MarekJ,SchwartzmanD,JainS,AdelsteinE,WhiteP,OyenugaOA,
.
lation:arandomizedtrial.EurHeartJ2011;32:2420(cid:2)2429. . Onishi T, Soman P, Gorcsan J, 3rd. Echocardiography-guided left ventricular
.
218. StavrakisS,GarabelliP,ReynoldsDW.Cardiacresynchronizationtherapyafter . lead placement for cardiac resynchronization therapy: results of the Speckle
.
atrioventricularjunctionablationforsymptomaticatrialfibrillation:ameta-anal- .. Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ
ysis.Europace2012;14:1490(cid:2)1497. .. HeartFail2013;6:427(cid:2)434.
.
219. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, Djiane P, . 237.Kosmala W, Marwick TH. Meta-analysis of effects of optimization of cardiac
.
MaboP,LevyT,GadlerF,BailleulC,DaubertJC.Comparativeeffectsofper- .. resynchronization therapy on left ventricular function, exercise capacity, and
manent biventricular and right-univentricular pacing in heart failure patients .. qualityoflifeinpatientswithheartfailure.AmJCardiol2014;113:988(cid:2)994.
.
withchronicatrialfibrillation.EurHeartJ2002;23:1780(cid:2)1787. . 238.Whinnett ZI, Francis DP, Denis A, Willson K, Pascale P, van Geldorp I, De
.
220. WoodsB,HawkinsN,MealingS,SuttonA,AbrahamWT,BeshaiJF,KleinH, . Guillebon M, Ploux S, Ellenbogen K, Haissaguerre M, Ritter P, Bordachar P.
.
Sculpher M, Plummer CJ, Cowie MR. Individual patient data network meta- .. ComparisonofdifferentinvasivehemodynamicmethodsforAVdelayoptimiza-
analysis of mortality effects of implantable cardiac devices. Heart .. tioninpatientswithcardiacresynchronizationtherapy:implicationsforclinical
.
2015;101:1800(cid:2)1806. . trialdesignandclinicalpractice.IntJCardiol2013;168:2228(cid:2)2237.
.
221. GageRM,BurnsKV,BankAJ.Echocardiographicandclinicalresponsetocar- . 239.Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non- .
diacresynchronizationtherapyinheartfailurepatientswithandwithoutpre- .. responderstocardiacresynchronizationtherapy:apracticalguide.EurHeartJ
viousrightventricularpacing.EurJHeartFail2014;16:1199(cid:2)1205. .. 2017;38:1463(cid:2)1472.
.
222. RuschitzkaF,AbrahamWT,SinghJP,BaxJJ,BorerJS,BrugadaJ,DicksteinK, . 240.MullensW,AuricchioA,MartensP,WitteK,CowieMR,DelgadoV,Dickstein
. FordI,GorcsanJ,3rd,GrasD,KrumH,SogaardP,HolzmeisterJ,EchoCRT .. K,LindeC,VernooyK,LeyvaF,BauersachsJ,IsraelCW,LundLH,DonalE,
StudyGroup.Cardiac-resynchronizationtherapyinheartfailurewithanarrow .. Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis
.
QRScomplex.NEnglJMed2013;369:1395(cid:2)1405. . NielsenJ,SteffelJ,VardasP,CoatsA,SeferovicP,EdvardsenT,HeidbuchelH, .
223. Steffel J, Robertson M,Singh JP,Abraham WT, Bax JJ, Borer JS, DicksteinK, . RuschitzkaF,LeclercqC.Optimizedimplementationofcardiacresynchroniza-
.
FordI,GorcsanJ,3rd,GrasD,KrumH,SogaardP,HolzmeisterJ,BrugadaJ, .. tiontherapy:acallforactionforreferralandoptimizationofcare:ajointposi-
RuschitzkaF.TheeffectofQRSdurationoncardiacresynchronizationtherapy .. tion statement from the Heart Failure Association (HFA), European Heart
.
inpatientswithanarrowQRScomplex:asubgroupanalysisoftheEchoCRT . Rhythm Association (EHRA), and European Association of Cardiovascular
.
trial.EurHeartJ2015;36:1983(cid:2)1989. .. Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail
224. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM, .. 2020;22:2349(cid:2)2369.
.
CarpenterJL,PinaIL,StraussDG.Cardiacresynchronizationtherapyinwomen: . 240a.GliksonM, NielsenJC,MichowitzY,KronborgMB,AuricchioA,BarbashIM,
.
US Food and Drug Administration meta-analysis of patient-level data. JAMA . Barrabe´s JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS,
.
InternMed2014;174:1340(cid:2)1348. .. DeharoJC,DelgadoV,DillerGP,IsraelCW,KerenA,KnopsRE,KotechaD,
225. Sohaib SM, Finegold JA, Nijjer SS, Hossain R, Linde C, Levy WC, Sutton R, .. Leclercq C, Merkely B, Starck C, Thyle´n I, Tolosana JM; ESC Scientific
.
KanagaratnamP,FrancisDP,WhinnettZI.Opportunitytoincreaselifespanin . DocumentGroup.2021ESCGuidelinesoncardiacpacingandcardiacresynch-
.
narrowQRScardiacresynchronizationtherapyrecipientsbydeactivatingven- . ronization therapy. Eur Heart J 2021; doi: 10.1093/eurheartj/ehab364 [Epub
.
tricular pacing: evidence from randomized controlled trials. JACC Heart Fail .. aheadofprint].
2015;3:327(cid:2)336. .. 241.AbrahamWT,KuckKH,GoldsmithRL,LindenfeldJ,ReddyVY,CarsonPE,Mann
.
226. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, . DL, Saville B, PariseH,ChanR, WiegnP, Hastings JL,Kaplan AJ,EdelmannF,
.
MADIT-II Investigators. Analysis of mortality events in the Multicenter .. Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D,
Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol .. HasenfussG.Arandomizedcontrolledtrialtoevaluatethesafetyandefficacyof
.
2004;43:1459(cid:2)1465. . cardiaccontractilitymodulation.JACCHeartFail2018;6:874(cid:2)883.
.
227. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, . 242.NICE:NationalInstituteforHealthandCareExcellence.Interventionalproce-
.
DaubertC,REsynchronizationreVErsesRemodelinginSystolicleftvEntricular .. duresguidance.Cardiaccontractilitymodulationdeviceimplantationforheart
dysfunction Study Group. Long-term impact of cardiac resynchronization . failure.www.nice.org.uk/guidance/ipg655(28May2021).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 105 ---
ESCGuidelines 3703
.
.
243. AbrahamWT,ZileMR,WeaverFA,ButterC,DucharmeA,HalbachM,Klug . (HFA) of the European Society of Cardiology (ESC). Eur Heart J
.
D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, . 2019;40:3297(cid:2)3317.
.
LittleWC.Baroreflexactivationtherapyforthetreatmentofheartfailurewith .. 260.HoJE,ZernEK,WoosterL,BaileyCS,CunninghamT,EismanAS,HardinKM,
areducedejectionfraction.JACCHeartFail2015;3:487(cid:2)496. .. ZampierolloGA,JarolimP,PappagianopoulosPP,MalhotraR,NayorM,Lewis
.
244. ZileMR,LindenfeldJ,WeaverFA,ZannadF,GalleE,RogersT,AbrahamWT. . GD.Differentialclinicalprofiles,exerciseresponses,andoutcomesassociated
.
Baroreflexactivationtherapyinpatientswithheartfailurewithreducedejec- .. withexistingHFpEFdefinitions.Circulation2019;140:353(cid:2)365.
tionfraction.JAmCollCardiol2020;76:1(cid:2)13. .. 261.Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple,
245. YusufS,PfefferMA,SwedbergK,GrangerCB,HeldP,McMurrayJJ,Michelson .. evidence-basedapproachtohelpguidediagnosisofheartfailurewithpreserved
.
EL,OlofssonB,OstergrenJ,CHARMInvestigatorsandCommittees.Effectsof . ejectionfraction.Circulation2018;138:861(cid:2)870.
.
candesartaninpatientswithchronicheartfailureandpreservedleft-ventricular .. 262.SegarMW,PatelKV,BerryJD,GrodinJL,PandeyA.Generalizabilityandimpli-
ejectionfraction:theCHARM-Preservedtrial.Lancet2003;362:777(cid:2)781. .. cationsoftheH2FPEFscoreinacohortofpatientswithheartfailurewithpre-
.
246. PittB,PfefferMA,AssmannSF,BoineauR,AnandIS,ClaggettB,ClausellN, . servedejectionfraction.Circulation2019;139:1851(cid:2)1853.
.
DesaiAS,DiazR,FlegJL,GordeevI,HartyB,HeitnerJF,KenwoodCT,Lewis . 263.Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS,
.
EF,O’MearaE,ProbstfieldJL,ShaburishviliT,ShahSJ,SolomonSD,Sweitzer .. SweitzerNK,FangJC,O’MearaE,ShahSJ,ShahAM,LewisEF,RouleauJ,PittB,
NK,YangS,McKinlaySM,TOPCATInvestigators.Spironolactoneforheartfail- .. Solomon SD. Application of the H2 FPEF score to a global clinical trial of
.
urewithpreservedejectionfraction.NEnglJMed2014;370:1383(cid:2)1392. . patientswithheartfailurewithpreservedejectionfraction:theTOPCATtrial.
. 247. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, .. EurJHeartFail2019;21:1288(cid:2)1291.
RouleauJ,PfefferMA,DesaiA,LundLH,KoberL,AnandI,SweitzerN,Linssen .. 264.Sepehrvand N, Alemayehu W, Dyck GJB, Dyck JRB, Anderson T, Howlett J,
.
G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, . Paterson I, McAlister FA, Ezekowitz JA. External validation of the H2F-PEF
.
Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan . modelindiagnosingpatientswithheartfailureandpreservedejectionfraction.
.
across the spectrum of ejection fraction in heart failure. Circulation .. Circulation2019;139:2377(cid:2)2379.
2020;141:352(cid:2)361. .. 265.Sueta D, Yamamoto E, Nishihara T, Tokitsu T, Fujisue K, Oike F, Takae M,
.
248. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, . Usuku H, Takashio S, Arima Y, Suzuki S, Nakamura T, Ito M, Kanazawa H,
.
PfefferMA,SolomonSD,SwedbergK,YusufS.Analysingrecurrenthospitaliza- . SakamotoK,KaikitaK,TsujitaK.H2FPEFscoreasaprognosticvalueinHFpEF
.
tions inheartfailure: a review ofstatistical methodology, with applicationto .. patients.AmJHypertens2019;32:1082(cid:2)1090.
CHARM-Preserved.EurJHeartFail2014;16:33(cid:2)40. .. 266.BarandiaranAizpuruaA,Sanders-vanWijkS,Brunner-LaRoccaHP,Henkens
.
249. vanVeldhuisenDJ,Cohen-SolalA,BohmM,AnkerSD,BabalisD,RoughtonM, . M,HeymansS,Beussink-NelsonL,ShahSJ,vanEmpelVPM.Validationofthe
.
CoatsAJ,Poole-WilsonPA,FlatherMD,SENIORSInvestigators.Beta-blockade .. HFA-PEFFscoreforthediagnosisofheartfailurewithpreservedejectionfrac-
withnebivololinelderlyheartfailurepatientswithimpairedandpreservedleft .. tion.EurJHeartFail2020;22:413(cid:2)421.
.
ventricularejectionfraction:datafromSENIORS(StudyofEffectsofNebivolol . 267.Sanders-vanWijkS,BarandiaranAizpuruaA,Brunner-LaRoccaHP,Henkens
.
Intervention on Outcomes and Rehospitalization in Seniors With Heart . M, Weerts J, Knackstedt C, Uszko-Lencer N, Heymans S,van Empel V. The
.
Failure).JAmCollCardiol2009;53:2150(cid:2)2158. .. HFA-PEFFandH2FPEFscoreslargelydisagreeinclassifyingpatientswithsus-
250. Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, .. pected heart failure with preserved ejection fraction. Eur J Heart Fail
.
HolzmeisterJ,LamCS,PochetT,VincentA,LindeC.Cardiacresynchroniza- . 2021;23:838(cid:2)840.
.
tiontherapyinheartfailurepatientswithlesssevereleftventriculardysfunc- . 268.SelvarajS,MyhrePL,VaduganathanM,ClaggettBL,MatsushitaK,KitzmanDW,
.
tion.EurJHeartFail2015;17:135(cid:2)143. .. Borlaug BA, Shah AM, Solomon SD. Application of diagnostic algorithms for
.
251. ShahSJ,FeldmanT,RicciardiMJ,KahwashR,LillyS,LitwinS,NielsenCD,van . heartfailurewithpreservedejectionfractiontothecommunity.JACCHeartFail
.
derHarstP,HoendermisE,PenickaM,BartunekJ,FailPS,KayeDM,WaltonA, . 2020;8:640(cid:2)653.
.
PetrieMC,WalkerN,BasurayA,YakubovS,HummelSL,ChetcutiS,Forde- .. 269.OuwerkerkW,TrompJ,JinX,JaufeerallyF,YeoPSD,LeongKTG,OngHY,
McLeanR,HerrmannHC,BurkhoffD,MassaroJM,ClelandJGF,MauriL.One- .. LingLH,LohSY,SimD,LeeS,SoonD,ChinC,RichardsAM,LamCSP.Heart
.
yearsafetyandclinicaloutcomesofatranscatheterinteratrialshuntdevicefor . failurewithpreservedejectionfractiondiagnosticscoresinanAsianpopulation.
.
thetreatmentofheartfailurewithpreservedejectionfractionintheReduce . EurJHeartFail2020;22:1737(cid:2)1739.
.
ElevatedLeftAtrialPressureinPatientsWithHeartFailure(REDUCELAP-HF .. 270.PlayfordD,StrangeG,CelermajerDS,EvansG,ScaliaGM,StewartS,PriorD,
I)Trial:arandomizedclinicaltrial.JAMACardiol2018;3:968(cid:2)977. .. NEDAInvestigators.Diastolic dysfunctionandmortalityin436360menand
.
252. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, . women:theNationalEchoDatabaseAustralia(NEDA).EurHeartJCardiovasc
.
Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and .. Imaging2021;22:505(cid:2)515.
Committees. Effects of candesartan on mortality and morbidity in patients .. 271.HallidayBP,WassallR,LotaAS,KhaliqueZ,GregsonJ,NewsomeS,JacksonR,
.
with chronic heart failure: the CHARM-Overall programme. Lancet . Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W,
.
2003;362:759(cid:2)766. . Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, .
253. Dewan P, Jackson A, Lam CSP, Pfeffer MA, Zannad F, Pitt B, Solomon SD, .. Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of
McMurrayJJV.Interactionsbetweenleftventricularejectionfraction,sexand .. pharmacologicaltreatmentforheartfailureinpatientswithrecovereddilated
.
effect of neurohumoral modulators in heart failure. Eur J Heart Fail . cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet
. 2020;22:898(cid:2)901. . 2019;393:61(cid:2)73.
.
254. Campbell RT, Petrie MC, McMurray JJV. Redefining heart failure phenotypes .. 272.LuponJ,Gavidia-BovadillaG,FerrerE,deAntonioM,Perera-LlunaA,Lopez-
basedonejectionfraction.EurJHeartFail2018;20:1634(cid:2)1635. .. Ayerbe J, Domingo M, Nunez J, Zamora E, Moliner P, Santiago-Vacas E,
.
255. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart . Santesmases J, Bayes-Genis A. Heart failure with preserved ejection fraction
.
Collaboration.Ethnic-specificnormativereferencevaluesforechocardiographic .. infrequentlyevolvestowardareducedphenotypeinlong-termsurvivors.Circ
LAandLVsize,LVmass,andsystolicfunction:theEchoNoRMALStudy.JACC .. HeartFail2019;12:e005652.
.
CardiovascImaging2015;8:656(cid:2)665. . 273.SavareseG,VedinO,D’AmarioD,UijlA,DahlstromU,RosanoG,LamCSP,
.
256. WehnerGJ,JingL,HaggertyCM,SueverJD,LeaderJB,HartzelDN,Kirchner . LundLH.Prevalenceandprognosticimplicationsoflongitudinalejectionfrac-
.
HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, .. tionchangeinheartfailure.JACCHeartFail2019;7:306(cid:2)317.
FornwaltBK.Routinelyreportedejectionfractionandmortalityinclinicalprac- .. 274.Nauta JF, Hummel YM, van der Meer P, Lam CSP, Voors AA, van Melle JP.
.
tice:wheredoesthenadirofrisklie?EurHeartJ2020;41:1249(cid:2)1257. . Correlationwithinvasiveleftventricularfillingpressuresandprognosticrele-
.
257. StewartS,PlayfordD,ScaliaGM,CurrieP,CelermajerDS,PriorD,CoddeJ, .. vance of the echocardiographic diastolic parameters used in the 2016 ESC
Strange G, NEDA Investigators. Ejection fraction and mortality: a nationwide .. heartfailureguidelines andinthe2016 ASE/EACVIrecommendations:asys-
.
register-based cohort study of 499 153 women and men. Eur J Heart Fail . tematicreviewinpatientswithheartfailurewithpreservedejectionfraction.
.
2021;23:406(cid:2)416. . EurJHeartFail2018;20:1303(cid:2)1311.
.
258. BorlaugBA.Evaluationandmanagementofheartfailurewithpreservedejection .. 275.SharifovOF,SchirosCG,AbanI,DenneyTS,GuptaH.Diagnosticaccuracyof
fraction.NatRevCardiol2020;17:559(cid:2)573. .. tissueDopplerindexE/e’forevaluatingleftventricularfillingpressureanddia-
.
259. PieskeB,TschopeC,deBoerRA,FraserAG,AnkerSD,DonalE,Edelmann . stolic dysfunction/heart failure with preserved ejection fraction: a systematic
.
F,FuM,GuazziM,LamCSP,LancellottiP,MelenovskyV,MorrisDA,Nagel . reviewandmeta-analysis.JAmHeartAssoc2016;5:e002078.
.
E,Pieske-KraigherE,PonikowskiP,SolomonSD,VasanRS,RuttenFH,Voors .. 276.EismanAS,Shah RV,DhakalBP, PappagianopoulosPP,WoosterL,BaileyC,
AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose .. Cunningham TF, Hardin KM, Baggish AL, Ho JE, Malhotra R, Lewis GD.
.
heartfailurewithpreservedejectionfraction:theHFA-PEFFdiagnosticalgo- . Pulmonarycapillarywedgepressurepatternsduringexercisepredictexercise
.
rithm: a consensus recommendation from the Heart Failure Association . capacityandincidentheartfailure.CircHeartFail2018;11:e004750.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 106 ---
3704 ESCGuidelines
.
.
277. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, . Arandomizedtrialofintensiveversusstandardblood-pressurecontrol.NEngl
.
O’Mahony D, Polonski L, Taylor J. Perindopril for elderly people with . JMed2015;373:2103(cid:2)2116.
.
chronic heart failure: the PEP-CHF study. The PEP Investigators. Eur J Heart .. 289.SciarrettaS,PalanoF,TocciG,BaldiniR,VolpeM.Antihypertensivetreatment
Fail1999;1:211(cid:2)217. .. and development of heart failure in hypertension: a Bayesian network meta-
.
278. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, . analysis of studies in patients with hypertension and high cardiovascular risk.
.
Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE .. ArchInternMed2011;171:384(cid:2)394.
Investigators. Irbesartan in patients with heart failure and preserved ejection .. 290.Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D,
.
fraction.NEnglJMed2008;359:2456(cid:2)2467. . Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F,
.
279. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, . Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group. Treatment
.
AronowWS,AdamsKFJr,GheorghiadeM.Effectsofdigoxinonmorbidityand .. of hypertension in patients 80 years of age or older. N Engl J Med
mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group .. 2008;358:1887(cid:2)1898.
.
trial.Circulation2006;114:397(cid:2)403. . 291.SciricaBM,MorrowDA,CannonCP,RayKK,SabatineMS,JarolimP,ShuiA,
.
280. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, . McCabeCH,BraunwaldE,PROVEIT-TIMIInvestigators.Intensivestatinther-
.
LeWinterMM,JosephSM,ShahSJ,SemigranMJ,FelkerGM,ColeRT,Reeves .. apyandtheriskofhospitalizationforheartfailureafteranacutecoronarysyn-
.
GR,TedfordRJ,TangWH,McNultySE,VelazquezEJ,ShahMR,BraunwaldE, . dromeinthePROVEIT-TIMI22study.JAmCollCardiol2006;47:2326(cid:2)2331.
.
NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in . 292.KjekshusJ,PedersenTR,OlssonAG,FaergemanO,PyoralaK.Theeffectsof
. heart failure with preserved ejection fraction. N Engl J Med .. simvastatinontheincidenceofheartfailureinpatientswithcoronaryheartdis-
2015;373:2314(cid:2)2324. .. ease.JCardFail1997;3:249(cid:2)254.
.
281. BorlaugBA,AnstromKJ,LewisGD,ShahSJ,LevineJA,KoeppGA,GivertzMM, . 293.ZinmanB,WannerC,LachinJM,FitchettD,BluhmkiE,HantelS,MattheusM,
.
Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WHW, . Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG
.
Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, .. OUTCOMEInvestigators.Empagliflozin,cardiovascularoutcomes,andmortal-
Hernandez AF, Braunwald E, Redfield MM, National Heart, Lung, and Blood .. ityintype2diabetes.NEnglJMed2015;373:2117(cid:2)2128.
.
InstituteHeartFailureClinicalResearchNetwork.Effectofinorganicnitritevs . 294.NealB,PerkovicV,MahaffeyKW,deZeeuwD,FulcherG,EronduN,Shaw
.
placeboonexercisecapacityamongpatientswithheartfailurewithpreserved .. W,LawG,DesaiM,MatthewsDR,CANVASProgramCollaborativeGroup.
ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA .. Canagliflozinandcardiovascularandrenaleventsintype2diabetes.NEnglJ
.
2018;320:1764(cid:2)1773. . Med2017;377:644(cid:2)657.
.
282. ArmstrongPW,LamCSP,AnstromKJ,EzekowitzJ,HernandezAF,O’Connor . 295.WiviottSD,RazI,BonacaMP,MosenzonO,KatoET,CahnA,SilvermanMG,
.
CM,PieskeB,PonikowskiP,ShahSJ,SolomonSD,VoorsAA,SheL,VlajnicV, .. ZelnikerTA,KuderJF,MurphySA,BhattDL,LeiterLA,McGuireDK,Wilding
Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J, VITALITY-HFpEF .. JPH,RuffCT,Gause-NilssonIAM,FredrikssonM,JohanssonPA,LangkildeAM,
.
StudyGroup.Effectofvericiguatvsplaceboonqualityoflifeinpatientswith . SabatineMS,DECLARE-TIMI58Investigators.Dapagliflozinandcardiovascular
.
heartfailureandpreservedejectionfraction:theVITALITY-HFpEFrandomized . outcomesintype2diabetes.NEnglJMed2019;380:347(cid:2)357.
.
clinicaltrial.JAMA2020;324:1512(cid:2)1521. .. 296.Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB,
.
283. UdelsonJE,LewisGD,ShahSJ,ZileMR,RedfieldMM,BurnettJ,Jr.,ParkerJ, . RiddleMC,InzucchiSE,KosiborodMN,CherneyDZI,DwyerJP,SciricaBM,
.
SeferovicJP,WilsonP,MittlemanRS,ProfyAT,KonstamMA.Effectofpralici- . BaileyCJ,DiazR,RayKK,UdellJA,LopesRD,LapuertaP,StegPG,SCORED
.
guat onpeakrateof oxygenconsumptioninpatients with heartfailure with .. Investigators.Sotagliflozininpatientswithdiabetesandchronickidneydisease.
preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. .. NEnglJMed2020;384:129(cid:2)139.
.
JAMA2020;324:1522(cid:2)1531. . 297.Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U,
.
284. OmarW,PandeyA,HaykowskyMJ,BerryJD,LavieCJ.Theevolvingroleof . CharbonnelB,FrederichR,GalloS,CosentinoF,ShihWJ,GantzI,TerraSG,
.
cardiorespiratoryfitnessandexerciseinpreventionandmanagementofheart .. CherneyDZI,McGuireDK,VERTISCVInvestigators.Cardiovascularoutcomes
failure.CurrHeartFailRep2018;15:75(cid:2)80. .. withertugliflozinintype2diabetes.NEnglJMed2020;383:1425(cid:2)1435.
.
285. KitzmanDW,UpadhyaB,ReevesG.Hospitalizationsandprognosisinelderly . 298.SuskinN,ShethT,NegassaA,YusufS.Relationshipofcurrentandpastsmok-
.
patients with heart failure and preserved ejection fraction: time to treat the .. ingtomortalityandmorbidityinpatientswithleftventriculardysfunction.JAm
wholepatient.JACCHeartFail2015;3:442(cid:2)444. .. CollCardiol2001;37:1677(cid:2)1682.
.
286. WoodAM,KaptogeS,ButterworthAS,WilleitP,WarnakulaS,BoltonT,Paige . 299.Dorans KS, Mostofsky E, Levitan EB, Hakansson N, Wolk A, Mittleman MA.
.
E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, . Alcoholandincidentheartfailureamongmiddle-agedandelderlymen:cohort
.
SelmerRM,VerschurenWMM,SatoS,NjolstadI,WoodwardM,SalomaaV, .. ofSwedishmen.CircHeartFail2015;8:422(cid:2)427.
Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, .. 300.GoncalvesA,ClaggettB,JhundPS,RosamondW,DeswalA,AguilarD,Shah
.
MarmotM,KoenigW,CasigliaE,CooperC,ArndtV,FrancoOH,Wennberg . AM,ChengS,SolomonSD.Alcoholconsumptionandriskofheartfailure:the
.
P,GallacherJ,delaCamaraAG,VolzkeH,DahmCC,DaleCE,BergmannMM, . AtherosclerosisRiskinCommunitiesStudy.EurHeartJ2015;36:939(cid:2)945. .
CrespoCJ,vanderSchouwYT,KaaksR,SimonsLA,LagiouP,SchoufourJD, .. 301.PandeyA,GargS,KhungerM,DardenD,AyersC,KumbhaniDJ,MayoHG,de
Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, .. LemosJA,BerryJD.Dose-responserelationshipbetweenphysicalactivityand
.
SacerdoteC,WallaceRB,QuirosJR,TuminoR,BlazerDG,2nd,LinnebergA, . riskofheartfailure:ameta-analysis.Circulation2015;132:1786(cid:2)1794.
. DaimonM,PanicoS,HowardB,SkeieG,StrandbergT,WeiderpassE,Nietert .. 302.PadwalR,McAlisterFA,McMurrayJJ,CowieMR,RichM,PocockS,SwedbergK,
PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, .. MaggioniA,GambleG,AritiC,EarleN,WhalleyG,PoppeKK,DoughtyRN,
.
GrioniS,PalliD,HuertaJM,PriceJ,SundstromJ,ArriolaL,ArimaH,TravisRC, . Bayes-GenisA,Meta-analysisGlobalGroupinChronicHeartFailure(MAGGIC). .
Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE, . The obesity paradox in heart failure patients with preserved versus reduced
.
Barrett-ConnorE,vanSchoorN,BoeingH,OvervadK,KauhanenJ,Wareham .. ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond)
N,LangenbergC,ForouhiN,WennbergM,DespresJP,CushmanM,Cooper .. 2014;38:1110(cid:2)1114.
.
JA,RodriguezCJ,SakuraiM,ShawJE,KnuimanM,VoortmanT,MeisingerC, . 303.McDonaghTA,BlueL,ClarkAL,DahlstromU,EkmanI,LainscakM,McDonald
.
TjonnelandA,BrennerH,PalmieriL,DallongevilleJ,BrunnerEJ,AssmannG, .. K, Ryder M, StrombergA, Jaarsma T,European Society of Cardiology Heart
TrevisanM,GillumRF,FordI,SattarN,LazoM,ThompsonSG,FerrariP,Leon .. Failure Association Committee on Patient Care. European Society of
.
DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J, . CardiologyHeartFailureAssociationStandardsfordeliveringheartfailurecare.
.
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study . EurJHeartFail2011;13:235(cid:2)241.
.
Group. Risk thresholds for alcohol consumption: combined analysis of .. 304.LainscakM,BlueL,ClarkAL,DahlstromU,DicksteinK,EkmanI,McDonaghT,
individual-participantdatafor599912currentdrinkersin83prospectivestud- .. McMurrayJJ,RyderM,StewartS,StrombergA,JaarsmaT.Self-caremanage-
.
ies.Lancet2018;391:1513(cid:2)1523. . ment of heart failure: practical recommendations from the Patient Care
.
287. KostisJB,DavisBR,CutlerJ,GrimmRH,Jr.,BergeKG,CohenJD,LacyCR, . Committee of the Heart Failure Association of the European Society of
.
Perry HM, Jr., Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, .. Cardiology.EurJHeartFail2011;13:115(cid:2)126.
Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention .. 305.MebazaaA,YilmazMB,LevyP,PonikowskiP,PeacockWF,LaribiS,RisticAD,
.
ofheartfailurebyantihypertensivedrugtreatmentinolderpersonswithiso- . LambrinouE,MasipJ,RileyJP,McDonaghT,MuellerC,deFilippiC,HarjolaVP,
.
lated systolic hypertension. SHEP Cooperative Research Group. JAMA .. ThieleH,PiepoliMF,MetraM,MaggioniA,McMurrayJJ,DicksteinK,Damman
1997;278:212(cid:2)216. .. K,SeferovicPM,RuschitzkaF,Leite-MoreiraAF,BellouA,AnkerSD,Filippatos
.
288. Group SR, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, . G.Recommendationsonpre-hospitalandearlyhospitalmanagementofacute
.
RoccoMV,ReboussinDM,RahmanM,OparilS,LewisCE,KimmelPL,Johnson . heart failure: a consensus paper from the Heart Failure Association of the
.
KC,GoffDCJr,FineLJ,CutlerJA,CushmanWC,CheungAK,AmbrosiusWT. .. EuropeanSocietyofCardiology,theEuropeanSocietyofEmergencyMedicine
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 107 ---
ESCGuidelines 3705
.
.
and the Society of Academic Emergency Medicine–short version. Eur Heart J . 324.TaylorRS,WalkerS,SmartNA,PiepoliMF,WarrenFC,CianiO,WhellanD,
.
2015;36:1958(cid:2)1966. .. O’ConnorC,KeteyianSJ,CoatsA,DavosCH,DalalHM,DracupK,Evangelista
306. McDonaghTA,GardnerRS,LainscakM,NielsenOW,ParissisJ,FilippatosG, .. LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY,
.
Anker SD. Heart Failure Association of the European Society of Cardiology . ExTraMATCH II Collaboration. Impact of exercise rehabilitation on exercise
.
specialistheartfailurecurriculum.EurJHeartFail2014;16:151(cid:2)162. .. capacityandquality-of-lifeinheartfailure:individualparticipantmeta-analysis.J
307. Riley JP, Astin F, Crespo-Leiro MG, Deaton CM, Kienhorst J, Lambrinou E, .. AmCollCardiol2019;73:1430(cid:2)1443.
.
McDonagh TA, Rushton CA, Stromberg A, Filippatos G, Anker SD. Heart . 325.TaylorRS,WalkerS,SmartNA,PiepoliMF,WarrenFC,CianiO,O’ConnorC,
.
FailureAssociationoftheEuropeanSocietyofCardiologyheartfailurenurse . WhellanD,KeteyianSJ,CoatsA,DavosCH,DalalHM,DracupK,Evangelista
.
curriculum.EurJHeartFail2016;18:736(cid:2)743. .. L,JollyK,MyersJ,McKelvieRS,NilssonBB,PassinoC,WithamMD,YehGY,
308. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, .. ZwislerAO,ExTraMATCHIICollaboration.Impactofexercise-basedcardiac
.
KabaliC,CoppensM,BrianHaynesR,ConnollyS.Comparativeeffectiveness . rehabilitationinpatientswithheartfailure(ExTraMATCHII)onmortalityand
.
oftransitionalcareservicesinpatientsdischargedfromthehospitalwithheart . hospitalisation:anindividualpatientdatameta-analysisofrandomisedtrials.Eur
.
failure: a systematic review and network meta-analysis. Eur J Heart Fail .. JHeartFail2018;20:1735(cid:2)1743.
2017;19:1427(cid:2)1443. .. 326.PandeyA,ParasharA,KumbhaniD,AgarwalS,GargJ,KitzmanD,LevineB,
.
309. Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L, . DraznerM,BerryJ.Exercisetraininginpatientswithheartfailureandpreserved
.
Bruggink-AndredelaPortePW,DeWaltDA,HebertPL,HeislerM,JaarsmaT, .. ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail
Kempen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, Peters- .. 2015;8:33(cid:2)40.
.
Klimm F, Rich MW, Riegel B, Stromberg A, Tsuyuki RT, Trappenburg JC, . 327.TaylorRS,LongL,MordiIR,MadsenMT,DaviesEJ,DalalH,ReesK,SinghSJ,
.
SchuurmansMJ,HoesAW.Whatareeffectiveprogramcharacteristicsofself- . GluudC,ZwislerAD.Exercise-basedrehabilitationforheartfailure:Cochrane
.
managementinterventionsinpatientswithheartfailure?Anindividualpatient .. SystematicReview, meta-analysis,andtrialsequentialanalysis.JACC HeartFail
datameta-analysis.JCardFail2016;22:861(cid:2)871. .. 2019;7:691(cid:2)705.
. 310. TakedaA,MartinN,TaylorRS,TaylorSJ.Diseasemanagementinterventions . 328.Taylor RS, Walker S, Ciani O, Warren F, Smart NA, Piepoli M, Davos CH.
.
forheartfailure.CochraneDatabaseSystRev2019;1:CD002752. . Exercise-based cardiac rehabilitation for chronic heart failure: the
.
311. KalogirouF,ForsythF,KyriakouM,MantleR,DeatonC.Heartfailuredisease .. EXTRAMATCHIIindividualparticipantdatameta-analysis.HealthTechnolAssess
management: a systematic review of effectiveness in heart failure with pre- .. 2019;23:1(cid:2)98.
.
servedejectionfraction.ESCHeartFail2020;7:194(cid:2)212. . 329.CooperLB,MentzRJ,SunJL,SchultePJ,FlegJL,CooperLS,PinaIL,LeiferES,
.
312. HillL,PragerGellerT,BaruahR,BeattieJM,BoyneJ,deStoutzN,DiStolfoG, .. KrausWE,WhellanDJ,KeteyianSJ,O’ConnorCM.Psychosocialfactors,exer-
LambrinouE,SkibelundAK,UchmanowiczI,RuttenFH,CelutkieneJ,Piepoli .. cise adherence, and outcomes in heart failure patients: insights from Heart
.
MF,JankowskaEA,ChioncelO,BenGalT,SeferovicPM,RuschitzkaF,Coats . Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-
.
AJS,StrombergA,JaarsmaT.Integrationofapalliativeapproachintoheartfail- . ACTION).CircHeartFail2015;8:1044(cid:2)1051.
.
urecare:aEuropeanSocietyofCardiologyHeartFailureAssociationposition .. 330.Gomes Neto M, Duraes AR, Conceicao LSR, Saquetto MB, Ellingsen O,
paper.EurJHeartFail2020;22:2327(cid:2)2339. .. CarvalhoVO.Highintensityintervaltrainingversusmoderateintensitycontinu-
.
313. KyriakouM,MiddletonN,KtistiS,PhilippouK,LambrinouE.Supportivecare . oustrainingonexercisecapacityandqualityoflifeinpatientswithheartfailure
.
interventions to promote health-related quality of life in patients living with . with reduced ejection fraction: a systematic review and meta-analysis. Int J
.
heart failure: a systematic review and meta-analysis. Heart Lung Circ .. Cardiol2018;261:134(cid:2)141.
.
2020;29:1633(cid:2)1647. . 331.EllingsenO,HalleM,ConraadsV,StoylenA,DalenH,DelagardelleC,Larsen
.
314. FeltnerC,JonesCD,CeneCW, ZhengZJ,SuetaCA,Coker-SchwimmerEJ, . AI,HoleT,MezzaniA,VanCraenenbroeckEM,VidemV,BeckersP,Christle
.
ArvanitisM,LohrKN,MiddletonJC,JonasDE.Transitionalcareinterventions .. JW,WinzerE,MangnerN,WoitekF,HollriegelR,PresslerA,Monk-HansenT,
topreventreadmissionsforpersonswithheartfailure:asystematicreviewand .. Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S,
.
meta-analysis.AnnInternMed2014;160:774(cid:2)784. . KarlsenT, PrescottE, LinkeA, SMARTEX Heart FailureStudy Group. High-
.
315. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, Petrie . intensity interval training in patients with heart failure with reduced ejection
.
MC,ConnollyE,NorrieJ,RoundCE,FordI,MorrisonCE.Randomisedcon- .. fraction.Circulation2017;135:839(cid:2)849.
trolled trial of specialist nurse intervention in heart failure. BMJ .. 332.EdelmannF,GelbrichG,DungenHD,FrohlingS,WachterR,StahrenbergR,
.
2001;323:715(cid:2)718. . Binder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Loffler M,
.
316. LambrinouE,KalogirouF,LamnisosD,SourtziP.Effectivenessofheartfailure .. Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity
management programmes with nurse-led discharge planning in reducing re- .. anddiastolicfunctioninpatientswithheartfailurewithpreservedejectionfrac-
.
admissions: a systematic review and meta-analysis. Int J Nurs Stud . tion:resultsoftheEx-DHF(ExercisetraininginDiastolicHeartFailure)pilot
.
2012;49:610(cid:2)624. . study.JAmCollCardiol2011;58:1780(cid:2)1791.
.
317. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial .. 333.NolteK,Herrmann-LingenC,WachterR,GelbrichG,DungenHD,Duvinage
effectsofahome-basedinterventiononunplannedreadmissionsandmortality .. A, Hoischen N, von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B, .
among patients with congestive heart failure. Arch Intern Med . EdelmannF.Effectsofexercisetrainingondifferentqualityoflifedimensionsin
.
1999;159:257(cid:2)261. . heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev
.
318. EkmanI,WolfA,OlssonLE,TaftC,DudasK,SchaufelbergerM,SwedbergK. .. Cardiol2015;22:582(cid:2)593.
Effectsofperson-centredcareinpatientswithchronicheartfailure:thePCC- .. 334.Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical out-
.
HFstudy.EurHeartJ2012;33:1112(cid:2)1119. . comesandcardiovascularresponsestodifferentexercisetrainingintensitiesin .
319. Riegel B, Bennett JA, Davis A, Carlson B, Montague J, Robin H, Glaser D. .. patients with heart failure: asystematicreview and meta-analysis. JACC Heart
Cognitiveimpairmentinheartfailure:issuesofmeasurementandetiology.AmJ .. Fail2013;1:514(cid:2)522.
.
CritCare2002;11:520(cid:2)528. . 335.KitzmanDW,BrubakerPH,HerringtonDM,MorganTM,StewartKP,Hundley
. 320. LaufsU,Rettig-EwenV,BohmM.Strategiestoimprovedrugadherence. Eur . WG,AbdelhamedA,HaykowskyMJ.Effectofenduranceexercisetrainingon
.
HeartJ2011;32:264(cid:2)268. .. endothelialfunctionandarterialstiffnessinolderpatientswithheartfailureand
321. AbraityteA,AukrustP,KouL,AnandIS,YoungJ,McMurrayJJV,vanVeldhuisen .. preserved ejection fraction: a randomized, controlled, single-blind trial. J Am
.
DJ,GullestadL,UelandT.Tcellandmonocyte/macrophageactivationmarkers . CollCardiol2013;62:584(cid:2)592.
.
associate with adverse outcome, but give limited prognostic value in anemic .. 336.IsmailH,McFarlaneJ,SmartNA.Isexercisetrainingbeneficialforheartfailure
patients with heart failure: results from RED-HF. Clin Res Cardiol .. patientstakingbeta-adrenergicblockers?Asystematicreviewandmeta-analysis.
.
2019;108:133(cid:2)141. . CongestHeartFail2013;19:61(cid:2)69.
.
322. FlynnKE,PinaIL,WhellanDJ,LinL,BlumenthalJA,EllisSJ,FineLJ,HowlettJG, . 337.Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE,
.
Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, .. EggebeenJ,NicklasBJ.Effectofcaloricrestrictionoraerobicexercisetraining
O’Connor CM, Weinfurt KP, HF-ACTION Investigators. Effects of exercise .. onpeakoxygenconsumptionandqualityoflifeinobeseolderpatientswith
.
training on health status in patients with chronic heart failure: HF-ACTION . heartfailurewithpreservedejectionfraction:arandomizedclinicaltrial.JAMA
.
randomizedcontrolledtrial.JAMA2009;301:1451(cid:2)1459. . 2016;315:36(cid:2)46.
.
323. O’ConnorCM,WhellanDJ,LeeKL,KeteyianSJ,CooperLS,EllisSJ,LeiferES, .. 338.TaylorRS,SagarVA,DaviesEJ,BriscoeS,CoatsAJ,DalalH,LoughF,ReesK,
Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, .. SinghS.Exercise-basedrehabilitationforheartfailure.CochraneDatabaseSyst
.
Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators. . Rev2014:CD003331.
.
Efficacyandsafetyofexercisetraininginpatientswithchronicheartfailure:HF- .. 339.Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr
ACTIONrandomizedcontrolledtrial.JAMA2009;301:1439(cid:2)1450. . KnudsenA,EspersenG,MarkenvardJ,EgstrupK,UlriksenH,HildebrandtPR,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 108 ---
3706 ESCGuidelines
.
theNorthStarInvestigators,allmembersofTheDanishHeartFailureClinics .. 358.FrederixI,CaianiEG,DendaleP,AnkerS,BaxJ,BohmA,CowieM,Crawford
Network.Extendedheartfailureclinicfollow-upinlow-riskpatients:arandom- .. J, de Groot N, Dilaveris P, Hansen T, Koehler F, Krstacic G, Lambrinou E,
.
izedclinicaltrial(NorthStar).EurHeartJ2013;34:432(cid:2)442. . LancellottiP,MeierP,NeubeckL,ParatiG,PiotrowiczE,TubaroM,vander
.
340. ThorvaldsenT,BensonL,DahlstromU,EdnerM,LundLH.Useofevidence- .. VeldeE.ESCe-CardiologyWorkingGroupPositionPaper:Overcomingchal-
basedtherapyandsurvivalinheartfailureinSweden2003-2012.EurJHeartFail .. lenges in digital health implementation in cardiovascular medicine. Eur J Prev
.
2016;18:503(cid:2)511. . Cardiol2019;26:1166(cid:2)1177.
.
341. Lund LH, Braunschweig F, Benson L, Stahlberg M, Dahlstrom U, Linde C. . 359.LinMH,YuanWL,HuangTC,ZhangHF,MaiJT,WangJF.Clinicaleffectiveness
.
Associationbetweendemographic,organizational,clinical,andsocio-economic .. oftelemedicineforchronicheartfailure:asystematicreviewandmeta-analysis.
characteristicsandunderutilizationofcardiacresynchronizationtherapy:results .. JInvestigMed2017;65:899(cid:2)911.
.
fromtheSwedishHeartFailureRegistry.EurJHeartFail2017;19:1270(cid:2)1279. . 360.Adamson PB, Ginn G, Anker SD, Bourge RC, Abraham WT. Remote
.
342. SavareseG,CarreroJJ,PittB,AnkerSD,RosanoGMC,DahlstromU,LundLH. .. haemodynamic-guided care for patients with chronic heart failure: a meta-
Factorsassociatedwithunderuseofmineralocorticoidreceptorantagonistsin .. analysisofcompletedtrials.EurJHeartFail2017;19:426(cid:2)433.
.
heartfailurewithreducedejectionfraction:ananalysisof11215patientsfrom . 361.Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO,
.
theSwedishHeartFailureRegistry.EurJHeartFail2018;20:1326(cid:2)1334. . HodshonBV,CooperLS,KrumholzHM.Telemonitoringinpatientswithheart
.
343. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, .. failure.NEnglJMed2010;363:2301(cid:2)2309.
DahlstromU.Associationbetweenenrolmentinaheartfailurequalityregistry .. 362.Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, Boll H,
.
and subsequent mortality–a nationwide cohort study. Eur J Heart Fail . Baumann G, Honold M, Koehler K, Gelbrich G, Kirwan BA, Anker SD,
.
2017;19:1107(cid:2)1116. . TelemedicalInterventionalMonitoringinHeartFailureInvestigators.Impactof
.
344. ClarkAL,GoodeK,ClelandJG.Theprevalenceandincidenceofleftbundle .. remotetelemedical management onmortalityandhospitalizationsinambula-
branch block in ambulant patients with chronic heart failure. Eur J Heart Fail .. torypatientswithchronicheartfailure:thetelemedicalinterventionalmonitor-
.
2008;10:696(cid:2)702. . inginheartfailurestudy.Circulation2011;123:1873(cid:2)1880.
.
345. TroughtonRW,FramptonCM,YandleTG,EspinerEA,NichollsMG,Richards .. 363.Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S,
AM.Treatmentofheartfailureguidedbyplasmaaminoterminalbrainnatriu- .. VettorazziE,PolzeA,StanglK,HartmannO,MarxA,NeuhausP,ScherfM,
. reticpeptide(N-BNP)concentrations.Lancet2000;355:1126(cid:2)1130. . KirwanBA,AnkerSD.TelemedicalInterventionalManagementinHeartFailure
.
346. BergerR,MoertlD,PeterS,AhmadiR,HuelsmannM,YamutiS,WagnerB, . II(TIM-HF2),arandomised,controlledtrialinvestigatingtheimpactoftelemedi-
.
Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient .. cineonunplannedcardiovascularhospitalisationsandmortalityinheartfailure
managementinadditiontomultidisciplinarycareinchronicheartfailurea3- .. patients: study design and description of the intervention. Eur J Heart Fail
.
arm,prospective,randomizedpilotstudy.JAmCollCardiol2010;55:645(cid:2)653. . 2018;20:1485(cid:2)1493.
.
347. JourdainP,JondeauG,FunckF,GueffetP,LeHellocoA,DonalE,AupetitJF, . 364.Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA,
.
Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain .. WinklerS,VettorazziE,BruchL,OeffM,ZugckC,DoerrG,NaegeleH,Stork
natriuretic peptide-guided therapy to improve outcome in heart failure: the .. S,ButterC,SechtemU,AngermannC,Gola G,Prondzinsky R,Edelmann F,
.
STARS-BNPMulticenterStudy.JAmCollCardiol2007;49:1733(cid:2)1739. . SpethmannS,SchellongSM,SchulzePC,BauersachsJ,WellgeB,SchoebelC,
.
348. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, .. TajsicM,DregerH,AnkerSD,StanglK.Efficacyoftelemedicalinterventional
Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type .. managementinpatientswithheartfailure(TIM-HF2):arandomised,controlled,
.
natriureticpeptide-guidedtreatmentforchronicheartfailure:resultsfromthe . parallel-group,unmaskedtrial.Lancet2018;392:1047(cid:2)1057.
.
BATTLESCARRED(NT-proBNP-AssistedTreatmentToLessenSerialCardiac . 365.Kalter-Leibovici O, Freimark D, Freedman LS, Kaufman G, Ziv A, Murad H,
.
ReadmissionsandDeath)trial.JAmCollCardiol2009;55:53(cid:2)60. .. BenderlyM,SilvermanBG,FriedmanN,Cukierman-YaffeT,AsherE,Grupper
349. PfistererM,BuserP,RickliH,GutmannM,ErneP,RickenbacherP,Vuillomenet .. A,GoldmanD,AmitaiM,MatetzkyS,ShaniM,SilberH,IsraelHeartFailure
.
A,JekerU,DubachP,BeerH,YoonSI,SuterT,OsterhuesHH,SchieberMM, . DiseaseManagementStudyinvestigators.Diseasemanagementinthetreatment
.
HiltiP,SchindlerR,Brunner-LaRoccaHP,TIME-CHFInvestigators.BNP-guided .. ofpatientswithchronicheartfailurewhohaveuniversalaccesstohealthcare:
vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard .. arandomizedcontrolledtrial.BMCMed2017;15:90.
.
MedicalTherapyinElderlyPatientsWithCongestiveHeartFailure(TIME-CHF) . 366.JayaramNM,KharitonY,KrumholzHM,ChaudhrySI,MatteraJ,TangF,Herrin
.
randomizedtrial.JAMA2009;301:383(cid:2)392. . J, Hodshon B, Spertus JA. Impact of telemonitoring on health status. Circ
.
350. FelkerGM,AnstromKJ,AdamsKF,EzekowitzJA,FiuzatM,Houston-MillerN, .. CardiovascQualOutcomes2017;10:e004148.
JanuzziJL,Jr.,MarkDB,PinaIL,PassmoreG,WhellanDJ,YangH,CooperLS, .. 367.ShochatMK,ShotanA,BlondheimDS,KazatskerM,DahanI,AsifA,Rozenman
.
Leifer ES, Desvigne-Nickens P, O’Connor CM. Effect of natriuretic peptide- . Y,KleinerI,WeinsteinJM,FrimermanA,VasilenkoL,MeiselSR.Non-invasive
.
guided therapy on hospitalization or cardiovascular mortality in high-risk . lung IMPEDANCE-guided preemptive treatment in chronic heart failure
.
patientswithheartfailureandreducedejectionfraction:arandomizedclinical .. patients: a randomized controlled trial (IMPEDANCE-HF Trial). J Card Fail
trial.JAMA2017;318:713(cid:2)720. .. 2016;22:713(cid:2)722.
.
351. PorapakkhamP,PorapakkhamP,ZimmetH,BillahB,KrumH.B-typenatriu- . 368.vanVeldhuisenDJ,BraunschweigF,ConraadsV,FordI,CowieMR,JondeauG, .
retic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med .. KautznerJ,AguileraRM,LunatiM,YuCM,GerritseB,BorggrefeM,DOT-HF
2010;170:507(cid:2)514. .. Investigators. Intrathoracic impedance monitoring, audible patient alerts, and
. 352. TroughtonRW,FramptonCM,Brunner-LaRoccaHP,PfistererM,EurlingsLW, . outcomeinpatientswithheartfailure.Circulation2011;124:1719(cid:2)1726.
.
Erntell H, Persson H, O’Connor CM, Moertl D, Karlstrom P, Dahlstrom U, . 369.Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A,
.
GagginHK,JanuzziJL,BergerR,RichardsAM,PintoYM,NichollsMG.Effectof .. Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D,
B-type natriuretic peptide-guided treatment of chronic heart failure on total .. PiorkowskiC,SogaardP,IN-TIMEStudyGroup.Implant-basedmultiparameter
.
mortality and hospitalization: an individual patient meta-analysis. Eur Heart J . telemonitoring of patients with heart failure (IN-TIME): a randomised con-
.
2014;35:1559(cid:2)1567. .. trolledtrial.Lancet2014;384:583(cid:2)590.
353. AnandIS,FisherLD,ChiangYT,LatiniR,MassonS,MaggioniAP,GlazerRD, .. 370.MorganJM,KittS,GillJ,McCombJM,NgGA,RafteryJ,RoderickP,SeedA,
.
TognoniG,CohnJN,Val-HeFTInvestigators.Changesinbrainnatriureticpep- . WilliamsSG,WitteKK,WrightDJ,HarrisS,CowieMR.Remotemanagement
.
tideandnorepinephrineovertimeandmortalityandmorbidityintheValsartan . of heart failure using implantable electronic devices. Eur Heart J
.
HeartFailureTrial(Val-HeFT).Circulation2003;107:1278(cid:2)1283. .. 2017;38:2352(cid:2)2360.
354. Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, .. 371.BohmM,DrexlerH,OswaldH,RybakK,BoschR,ButterC,KleinG,Gerritse
.
SwedbergK,DesaiAS,GongJ,ShiVC,SolomonSD.Prognosticimplicationsof . B,MonteiroJ,IsraelC,BimmelD,KaabS,HueglB,BrachmannJ,OptiLinkHF
.
changesinN-terminalpro-B-typenatriureticpeptideinpatientswithheartfail- . StudyInvestigators.Fluidstatustelemedicinealertsforheartfailure:arandom-
.
ure.JAmCollCardiol2016;68:2425(cid:2)2436. .. izedcontrolledtrial.EurHeartJ2016;37:3154(cid:2)3163.
355. BrahmbhattDH,CowieMR.Remotemanagementofheartfailure:anoverview .. 372.AbrahamWT,StevensonLW,BourgeRC,LindenfeldJA,BaumanJG,Adamson
.
oftelemonitoringtechnologies.CardFailRev2019;5:86(cid:2)92. . PB, CHAMPION Trial Study Group. Sustained efficacy of pulmonary
.
356. ClelandJG,ClarkRA,PellicoriP,InglisSC.Caringforpeoplewithheartfailure .. arterypressuretoguideadjustmentofchronicheartfailuretherapy:complete
and many other medical problems through and beyond the COVID-19 pan- .. follow-up results from the CHAMPION randomised trial. Lancet
.
demic:theadvantagesofuniversalaccesstohometelemonitoring.EurJHeart . 2016;387:453(cid:2)461.
.
Fail2020;22:995(cid:2)998. . 373.Lindenfeld J, Abraham WT, MaiselA, Zile M, Smart F, Costanzo MR, Mehra
.
357. InglisSC,ClarkRA,DierckxR,Prieto-MerinoD,ClelandJG.Structuredtele- .. MR, Ducharme A, Sears SF, Desai AS, Paul S, Sood P, Johnson N, Ginn G,
phone supportor non-invasive telemonitoringfor patients with heart failure. .. Adamson PB.Hemodynamic-GUIDEd management of Heart Failure (GUIDE-
.
Heart2017;103:255(cid:2)257. HF).AmHeartJ2019;214:18(cid:2)27.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 109 ---
ESCGuidelines 3707
.
374. DierckxR,InglisSC,ClarkRA,Prieto-MerinoD,ClelandJG.Telemedicinein .. failedinchronicheartfailure?Lessonsfrompriorinotropetrials.EurJHeartFail
heart failure: new insights from the Cochrane meta-analyses. Eur J Heart Fail .. 2019;21:1064(cid:2)1078.
.
2017;19:304(cid:2)306. . 389.Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM,
.
375. FangJC,EwaldGA,AllenLA,ButlerJ,WestlakeCanaryCA,Colvin-AdamsM, . Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, Gonzalez-
.
Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ, .. Vilchez F, Lambert-Rodriguez JL, Grau M, Bruguera J, LION-HEART
Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE, .. Study Investigators. Efficacy and safety of intermittent intravenous outpatient
.
Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S, . administration of levosimendan in patients with advanced heart failure: the
.
RodgersJE,RogersJG,VestAR,GivertzMM,HeartFailureSocietyofAmerica . LION-HEART multicentre randomised trial. Eur J Heart Fail
.
GuidelinesCommittee.Advanced(stageD)heartfailure:astatementfromthe .. 2018;20:1128(cid:2)1136.
Heart Failure Society of America Guidelines Committee. J Card Fail .. 390.Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock
.
2015;21:519(cid:2)534. . DD,DunlaySM.Ambulatoryinotropeinfusionsinadvancedheartfailure:asys-
.
376. Crespo-LeiroMG,MetraM, LundLH,MilicicD, CostanzoMR, Filippatos G, .. tematicreviewandmeta-analysis.JACCHeartFail2018;6:757(cid:2)767.
GustafssonF,TsuiS,Barge-CaballeroE,DeJongeN,FrigerioM,HamdanR, .. 391.BartBA,GoldsmithSR,LeeKL,GivertzMM,O’ConnorCM,BullDA,Redfield
.
Hasin T, Hulsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, . MM,DeswalA,RouleauJL,LeWinterMM,OfiliEO,StevensonLW,Semigran
.
Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P, . MJ,FelkerGM,ChenHH,HernandezAF,AnstromKJ,McNultySE,Velazquez
.
RuschitzkaF.Advancedheartfailure:apositionstatementoftheHeartFailure .. EJ, Ibarra JC, Mascette AM, Braunwald E, Heart Failure Clinical Research
Association of the European Society of Cardiology. Eur J Heart Fail .. Network.Ultrafiltrationindecompensatedheartfailurewithcardiorenalsyn-
.
2018;20:1505(cid:2)1535. . drome.NEnglJMed2012;367:2296(cid:2)2304.
.
377. TrubyLK,RogersJG.Advancedheartfailure:epidemiology,diagnosis,andther- .. 392.CostanzoMR,GuglinME,SaltzbergMT,JessupML,BartBA,TeerlinkJR,Jaski
apeuticapproaches.JACCHeartFail2020;8:523(cid:2)536. .. BE,FangJC,FellerED,HaasGJ,AndersonAS,SchollmeyerMP,SobotkaPA,
.
378. RoseEA,GelijnsAC,MoskowitzAJ,HeitjanDF,StevensonLW,DembitskyW, . UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for
. LongJW,AscheimDD,TierneyAR,LevitanRG,WatsonJT,MeierP,Ronan . patients hospitalized foracute decompensated heartfailure.J Am CollCardiol
.
NS,ShapiroPA,LazarRM,MillerLW,GuptaL,FrazierOH,Desvigne-Nickens .. 2007;49:675(cid:2)683.
P,OzMC,PoirierVL,RandomizedEvaluationofMechanicalAssistanceforthe .. 393.GustafssonF,RogersJG.Leftventricularassistdevicetherapyinadvancedheart
.
TreatmentofCongestiveHeartFailure(REMATCH)StudyGroup.Long-term . failure:patientselectionandoutcomes.EurJHeartFail2017;19:595(cid:2)602.
.
useofaleftventricularassistdeviceforend-stageheartfailure.NEnglJMed . 394.Barge-Caballero E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez
.
2001;345:1435(cid:2)1443. .. JL,Gonzalez-CostelloJ,Segovia-CuberoJ,Castel-LavillaMA,Delgado-JimenezJ,
379. AmmarKA,JacobsenSJ,MahoneyDW,KorsJA,RedfieldMM,BurnettJC,Jr., .. Garrido-Bravo IP, Rangel-Sousa D, Martinez-Selles M, De la Fuente-Galan L,
.
Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: . Rabago-AracilJuan- G, Sanz-Julve M, Hervas-Sotomayor D, Mirabet-Perez S,
.
applicationoftheAmericanCollegeofCardiology/AmericanHeartAssociation .. MunizJ,Crespo-LeiroMG.Clinicaloutcomesoftemporarymechanicalcircula-
heartfailurestagingcriteriainthecommunity.Circulation2007;115:1563(cid:2)1570. .. torysupportasadirectbridgetohearttransplantation:anationwideSpanish
.
380. XanthakisV,EnserroDM,LarsonMG,WollertKC,JanuzziJL,LevyD,Aragam . registry.EurJHeartFail2018;20:178(cid:2)186.
.
J,BenjaminEJ,ChengS,WangTJ,MitchellGF,VasanRS.Prevalence,neurohor- . 395.Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan
.
monalcorrelates,andprognosisofheartfailurestagesinthecommunity.JACC .. MM, Kukucka M, de Jonge N, Loforte A, Lund LH, Mohacsi P, Morshuis M,
HeartFail2016;4:808(cid:2)815. .. Netuka I, Ozbaran M, Pappalardo F, Scandroglio AM, Schweiger M, Tsui S,
.
381. StevensonLW,PaganiFD,YoungJB,JessupM,MillerL,KormosRL,NaftelDC, . Zimpfer D, Gustafsson F. 2019 EACTS Expert Consensus on long-term
.
Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced .. mechanicalcirculatorysupport.EurJCardiothoracSurg2019;56:230(cid:2)270.
heartfailure:thecurrentpicture.JHeartLungTransplant2009;28:535(cid:2)541. .. 396.RogersJG,ButlerJ,LansmanSL,GassA,PortnerPM,PasqueMK,PiersonRN,
382. Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F, .. 3rd, INTrEPID Investigators. Chronic mechanical circulatory support for
.
Villa-Arranz A, Delgado-Jimenez J, Lage-Galle E, Perez-Villa F, Lambert- . inotrope-dependent heart failure patients who are not transplant candidates:
.
RodriguezJL,Manito-LoriteN,Arizon-DelPradoJM,Brossa-LoidiV,Pascual- .. resultsoftheINTrEPIDTrial.JAmCollCardiol2007;50:741(cid:2)747.
Figal D, Fuente-Galan Lde L, Sanz-Julve M, Muniz-Garcia J, Crespo-Leiro M. .. 397.SlaughterMS,RogersJG,MilanoCA,RussellSD,ConteJV,FeldmanD,SunB,
.
PreoperativeINTERMACSprofilesdeterminepostoperativeoutcomesincrit- . TatoolesAJ,DelgadoRM,3rd,LongJW,WozniakTC,GhummanW,FarrarDJ,
.
ically ill patients undergoing emergency heart transplantation: analysis of the . Frazier OH, HeartMate II Investigators. Advanced heart failure treated with
.
SpanishNationalHeartTransplantRegistry.CircHeartFail2013;6:763(cid:2)772. .. continuous-flow left ventricular assist device. N Engl J Med
383. GoldsteinDJ,MeynsB,XieR,CowgerJ,PettitS,NakataniT,NetukaI,ShawS, .. 2009;361:2241(cid:2)2251.
.
Yanase M, Kirklin JK. Third annual report from the ISHLT Mechanically . 398.StarlingRC,NakaY,BoyleAJ,Gonzalez-StawinskiG,JohnR,JordeU,Russell
.
Assisted Circulatory Support Registry: a comparison of centrifugal and axial .. SD,ConteJV,AaronsonKD,McGeeEC,Jr.,Cotts WG,DeNofrioD,Pham
continuous-flow left ventricular assist devices. J Heart Lung Transplant .. DT, Farrar DJ, Pagani FD. Results of the post-U.S. Food and Drug
.
2019;38:352(cid:2)363. . Administration-approval study with a continuous flow left ventricular assist .
384. KittlesonMM,ShahP,LalaA,McLeanRC,PamboukianS,HorstmanshofDA, . device as a bridge to heart transplantation: a prospective study using the
.
ThibodeauJ,ShahK,TeutebergJ,GilotraNA,Taddei-PetersWC,CascinoTM, .. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory
Richards B, Khalatbari S, Jeffries N, Stevenson LW, Mann D, Aaronson KD, .. Support).JAmCollCardiol2011;57:1890(cid:2)1898.
.
Stewart GC, REVIVAL Investigators. INTERMACS profiles and outcomes of . 399.RogersJG,PaganiFD,TatoolesAJ,BhatG,SlaughterMS,BirksEJ,BoyceSW,
.
ambulatory advanced heart failure patients: a report from the REVIVAL . Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, .
Registry.JHeartLungTransplant2020;39:16(cid:2)26. .. Aaronson KD, Frazier OH, Milano CA. Intrapericardial left ventricular assist
385. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, .. deviceforadvancedheartfailure.NEnglJMed2017;376:451(cid:2)460.
.
Danziger-IsakovL,KirklinJK,KirkR,KushwahaSS,LundLH,PotenaL,RossHJ, . 400.TrubyLK,FarrMA,GaranAR,GivensR,RestainoSW,LatifF,TakayamaH,
. TaylorDO,VerschuurenEAM,ZuckermannA,InternationalSocietyforHeart .. Naka Y, Takeda K, Topkara VK. Impact of bridge to transplantation with
LungTransplantation (ISHLT)InfectiousDiseases,PediatricandHeartFailure .. continuous-flowleftventricularassistdevicesonposttransplantationmortality.
.
andTransplantation Councils.The2016 International SocietyforHeartLung . Circulation2019;140:459(cid:2)469.
.
Transplantation listing criteria for heart transplantation: a 10-year update. J . 401.GoldsteinDJ,NakaY,HorstmanshofD,RavichandranAK,SchroderJ,Ransom
.
HeartLungTransplant2016;35:1(cid:2)23. .. J,ItohA,UrielN,ClevelandJC,Jr.,RavalNY,CogswellR,SuarezEE,Lowes
386. BaumwolJ."Ineedhelp"–amnemonictoaidtimelyreferralinadvancedheart .. BD,KimG,BondeP,SheikhFH,SoodP,FarrarDJ,MehraMR.Associationof
.
failure.JHeartLungTransplant2017;36:593(cid:2)594. . clinicaloutcomeswithleftventricularassistdeviceusebybridgetotransplant
.
387. Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, . or destination therapy intent: the Multicenter Study of MagLev Technology
.
Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, .. in Patients Undergoing Mechanical Circulatory Support Therapy With
.
BauersachsJ,BrutsaertD,CarrierL,ChlopickiS,ClelandJG,deBoerRA,Dietl . HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial. JAMA Cardiol
.
A,FischmeisterR,HarjolaVP,HeymansS,Hilfiker-KleinerD,HolzmeisterJ,de . 2020;5:411(cid:2)419.
.
KeulenaerG,LimongelliG,LinkeWA,LundLH,MasipJ,MetraM,MuellerC, .. 402.MehraMR,UrielN,NakaY,ClevelandJC,Jr.,YuzefpolskayaM,SalernoCT,
Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H, .. WalshMN,MilanoCA,PatelCB,HutchinsSW,RansomJ,EwaldGA,ItohA,
.
Zimmermann WH, Mebazaa A. Treatments targeting inotropy. Eur Heart J . RavalNY,SilvestrySC,CogswellR,JohnR,BhimarajA,BrucknerBA,Lowes
.
2019;40:3626(cid:2)3644. . BD,UmJY,JeevanandamV,SayerG,MangiAA,MolinaEJ,SheikhF,Aaronson
.
388. AhmadT,MillerPE,McCulloughM,DesaiNR,RielloR,PsotkaM,BohmM, .. K,PaganiFD,CottsWG,TatoolesAJ,BabuA,ChomskyD,KatzJN,Tessmann
AllenLA,TeerlinkJR,RosanoGMC,LindenfeldJ.Whyhaspositiveinotropy . PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 110 ---
3708 ESCGuidelines
.
.
MOMENTUM3Investigators.Afullymagneticallylevitatedleftventricularassist . RosanoG,SeferovicP,StrombergA.Self-careofheartfailurepatients:practical
.
device–finalreport.NEnglJMed2019;380:1618(cid:2)1627. . managementrecommendationsfromtheHeartFailureAssociationoftheEuropean
.
403. KirklinJK,NaftelDC,PaganiFD,KormosRL,StevensonLW,BlumeED,Myers .. SocietyofCardiology.EurJHeartFail2021;23:157(cid:2)174.
SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: .. 417.JordeUP,KushwahaSS,TatoolesAJ,NakaY,BhatG,LongJW,Horstmanshof
.
15,000patientsandcounting.JHeartLungTransplant2015;34:1495(cid:2)1504. . DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ,
.
404. TheochariCA, MichalopoulosG, Oikonomou EK,GiannopoulosS,Doulamis .. HeartMateIIClinicalInvestigators.Resultsofthedestinationtherapypost-food
IP,VillelaMA,KokkinidisDG.Hearttransplantationversusleftventricularassist .. anddrugadministrationapprovalstudywithacontinuousflowleftventricular
.
devicesasdestinationtherapyorbridgetotransplantationfor1-yearmortality: . assistdevice:aprospectivestudyusingtheINTERMACSregistry(Interagency
.
asystematicreviewandmeta-analysis.AnnCardiothoracSurg2018;7:3(cid:2)11. . Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol
.
405. MehraMR,GoldsteinDJ,UrielN,ClevelandJC,Jr.,YuzefpolskayaM,Salerno .. 2014;63:1751(cid:2)1757.
C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, .. 418.SahlollbeyN,LeeCKS,ShirinA,JosephP.Theimpactofpalliativecareonclini-
.
KrishnamoorthyA,CottsWG,TatoolesAJ,JordeUP,BrucknerBA,EstepJD, . calandpatient-centredoutcomesinpatientswithadvancedheartfailure:asys-
.
Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER, . tematic review of randomized controlled trials. Eur J Heart Fail
.
O’Connell JB, Heatley G, Sood P, Naka Y, MOMENTUM 3 Investigators. .. 2020;22:2340(cid:2)2346.
.
Two-yearoutcomeswithamagneticallylevitatedcardiacpumpinheartfailure. . 419.FendlerTJ,SwetzKM,AllenLA.Team-basedpalliativeandend-of-lifecarefor
.
NEnglJMed2018;378:1386(cid:2)1395. . heartfailure.HeartFailClin2015;11:479(cid:2)498.
. 406. Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M, .. 420.Brannstrom M, Boman K. Effects of person-centred and integrated chronic
Morshuis M, Shaw SM, Saeed D, Lavee J, Heatley G, Gazzola C, Garbade J. .. heartfailureandpalliativehomecare.PREFER:arandomizedcontrolledstudy.
.
Two-year outcome after implantation of a full magnetically levitated left . EurJHeartFail2014;16:1142(cid:2)1151.
.
ventricular assist device: results from the ELEVATE Registry. Eur Heart J . 421.O’DonnellAE,SchaeferKG,StevensonLW,DeVoeK,WalshK,MehraMR,
.
2020;41:3801(cid:2)3809. .. DesaiAS.Socialworker-aidedpalliativecareinterventioninhigh-riskpatients
407. EstepJD,Starling RC,HorstmanshofDA,MilanoCA,SelzmanCH,ShahKB, .. with Heart Failure (SWAP-HF):a pilotrandomizedclinical trial.JAMA Cardiol
.
LoebeM,MoazamiN,LongJW,StehlikJ,KasirajanV,HaasDC,O’ConnellJB, . 2018;3:516(cid:2)519.
.
BoyleAJ,FarrarDJ,RogersJG,ROADMAPStudyInvestigators.Riskassessment .. 422.JohnsonMJ,McDonaghTA,HarknessA,McKaySE,DargieHJ.Morphinefor
andcomparativeeffectivenessofleftventricularassistdeviceandmedicalman- .. thereliefofbreathlessnessinpatientswithchronicheartfailure–apilotstudy.
.
agement in ambulatory heart failure patients: results from the ROADMAP . EurJHeartFail2002;4:753(cid:2)756.
.
study.JAmCollCardiol2015;66:1747(cid:2)1761. . 423.OxberrySG,BlandJM,ClarkAL,ClelandJG,JohnsonMJ.Repeatdoseopioids
.
408. Starling RC, Estep JD, Horstmanshof DA, Milano CA, Stehlik J, Shah KB, .. may be effective for breathlessness in chronic heart failure if given for long
BrucknerBA,LeeS,LongJW,SelzmanCH,KasirajanV,HaasDC,BoyleAJ, .. enough.JPalliatMed2013;16:250(cid:2)255.
.
ChuangJ,FarrarDJ,RogersJG,ROADMAPStudyInvestigators.Riskassessment . 424.BlindermanCD,BillingsJA.Comfortcareforpatientsdyinginthehospital.N
.
andcomparativeeffectivenessofleftventricularassistdeviceandmedicalman- . EnglJMed2015;373:2549(cid:2)2561.
.
agement in ambulatory heart failure patients: the ROADMAP study 2-year .. 425.Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP,
.
results.JACCHeartFail2017;5:518(cid:2)527. . HochadelM,KomajdaM,LassusJ,Lopez-SendonJL,PonikowskiP,TavazziL,
.
409. SlaughterMS,PaganiFD,McGeeEC,BirksEJ,CottsWG,GregoricI,Howard . EuroHeart Survey Investigators, Heart Failure Association of the European
.
FrazierO,IcenogleT,NajjarSS,BoyceSW,AckerMA,JohnR,HathawayDR, .. SocietyofCardiology.EuroHeartFailureSurveyII(EHFSII):asurveyonhospi-
NajarianKB,AaronsonKD,HeartWareBridgetoTransplantADVANCETrial .. talized acute heart failure patients: description of population. Eur Heart J
.
Investigators. HeartWare ventricular assist system for bridge to transplant: . 2006;27:2725(cid:2)2736.
.
combined results of the bridge to transplant and continued access protocol . 426.ChioncelO,MebazaaA,HarjolaVP,CoatsAJ,PiepoliMF,Crespo-LeiroMG,
.
trial.JHeartLungTransplant2013;32:675(cid:2)683. .. LarocheC,SeferovicPM,AnkerSD,FerrariR,RuschitzkaF,Lopez-Fernandez
410. KarasonK,LundLH,DalenM,BjorklundE,GrinnemoK,BraunO,NilssonJ, .. S,MianiD,FilippatosG,MaggioniAP,ESCHeartFailureLong-TermRegistry
.
van der Wal H, Holm J, Hubbert L, Lindmark K, Szabo B, Holmberg E, . Investigators. Clinical phenotypes and outcome of patients hospitalized for
.
Dellgren G, SweVAD Investigators. Randomized trial of a left ventricular .. acuteheartfailure:theESCHeartFailureLong-TermRegistry.EurJHeartFail
assistdeviceasdestinationtherapyversusguideline-directedmedicaltherapy .. 2017;19:1242(cid:2)1254.
.
inpatientswithadvancedheartfailure.RationaleanddesignoftheSWEdish . 427.Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C,
.
evaluationofleftVentricularAssistDevice(SweVAD)trial.EurJHeartFail . Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G,
.
2020;22:739(cid:2)750. .. RuschitzkaF,SeferovicP,CoatsAJS,LundLH,ESC-EORP-HFAHeartFailure
411. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Jr., Hsich E, .. Long-TermRegistryInvestigators.Acuteheartfailurecongestionandperfusion
.
Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, . status–impactoftheclinicalclassificationonin-hospitalandlong-termout-
.
Zuckermann A, Stehlik J, International Society for Heart and Lung . comes:insightsfromtheESC-EORP-HFAheartfailurelong-termregistry.EurJ .
Transplantation.TheInternational ThoracicOrganTransplantRegistryofthe .. HeartFail2019;21:1338(cid:2)1352.
International Society for Heart and Lung Transplantation: Thirty-sixth adult .. 428.MiroO,GarciaSarasolaA,FuenzalidaC,CalderonS,JacobJ,AguirreA,Wu
.
heart transplantation report–2019; focus theme: donor and recipient size . DM,RizziMA,MalchairP,HaroA,HerreraS,GilV,Martin-SanchezFJ,Llorens
. match.JHeartLungTransplant2019;38:1056(cid:2)1066. .. P,HerreroPuenteP,BuenoH,DominguezRodriguezA,MullerCE,Mebazaa
412. LundLH,EdwardsLB,KucheryavayaAY,DipchandAI,BendenC,ChristieJD, .. A,ChioncelO,Alquezar-Arbe A,ICA-SEMES ResearchGroup. Departments
.
DobbelsF,KirkR,RahmelAO,YusenRD,StehlikJ,InternationalSocietyforH, . involvedduringthefirstepisodeofacuteheartfailureandsubsequentemer- .
HeartandLungTransplantation.TheRegistryoftheInternationalSocietyfor . gency department revisits and rehospitalisations: an outlook through the
.
HeartandLungTransplantation:Thirtiethofficialadulthearttransplantreport– .. NOVICAcohort.EurJHeartFail2019;21:1231(cid:2)1244.
2013;focustheme:age.JHeartLungTransplant2013;32:951(cid:2)964. .. 429.SolomonSD,DobsonJ,PocockS,SkaliH,McMurrayJJ,GrangerCB,YusufS,
.
413. GuglinM,ZuckerMJ,BorlaugBA,BreenE,ClevelandJ,JohnsonMR,Panjrath . SwedbergK,YoungJB,MichelsonEL,PfefferMA,CandesartaninHeartfailure:
.
GS, Patel JK, Starling RC, Bozkurt B, ACC Heart Failure and Transplant . Assessment of Reduction in Mortality and morbidity (CHARM) Investigators.
.
MemberSectionandLeadershipCouncil.Evaluationforhearttransplantation .. Influenceofnonfatalhospitalizationforheartfailureonsubsequentmortalityin
.
and LVAD implantation: JACC Council perspectives. J Am Coll Cardiol . patientswithchronicheartfailure.Circulation2007;116:1482(cid:2)1487.
.
2020;75:1471(cid:2)1487. . 430.TomasoniD,LombardiCM,SbolliM,CotterG,MetraM.Acuteheartfailure:
.
414. BernhardtAM,SchloglhoferT,LauenrothV,MuellerF,MuellerM,SchoedeA, .. morequestionsthananswers.ProgCardiovascDis2020;63:599(cid:2)606.
Klopsch C, Driveline Expert STagINg and carE DESTINE study group, a .. 431.Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC,
.
VentricularAssistDeviceDrivelineInfectionStudyGroup.Preventionandearly . Gustafsson F, Madelaire C, Kristensen SL, Gislason GH, Torp-Pedersen C,
.
treatment of driveline infections in ventricular assist device patients – the . KoberL,SchouM.Readmissionanddeathinpatientsadmittedwithnew-onset
.
DESTINEstagingproposalandthefirststandardofcareprotocol.JCritCare .. versusworseningofchronicheartfailure:insightsfrom anationwidecohort.
2020;56:106(cid:2)112. .. EurJHeartFail2020;22:1777(cid:2)1785.
.
415. DeFilippisEM,BreathettK,DonaldEM,NakagawaS,TakedaK,TakayamaH, . 432.Javaloyes P, Miro O, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K,
.
TrubyLK,SayerG,ColomboPC,YuzefpolskayaM,UrielN,FarrMA,Topkara .. Alquezar-Arbe A, Lopez Diez MP, Martin E, Bibiano C, Escoda R, Gil C,
VK.Psychosocialriskanditsassociationwithoutcomesincontinuous-flowleft .. Fuentes M, Llopis Garcia G, Alvarez Perez JM, Jerez A, Tost J, Llauger L,
.
ventricularassistdevicepatients.CircHeartFail2020;13:e006910. . Romero R, Garrido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis
.
416.JaarsmaT,HillL,Bayes-GenisA,LaRoccaHB,CastielloT,CelutkieneJ,Marques- . J, Mebazaa A, Chioncel O, Llorens P, ICA-SEMES Research Group. Clinical
.
SuleE,PlymenCM,PiperSE,RiegelB,RuttenFH,BenGalT,BauersachsJ,Coats .. phenotypesofacuteheartfailurebasedonsignsandsymptomsofperfusion
AJS,ChioncelO,LopatinY,LundLH,LainscakM,MouraB,MullensW,PiepoliMF, . and congestion at emergency department presentation and their relationship
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 111 ---
ESCGuidelines 3709
.
.
with patient management and outcomes. Eur J Heart Fail . Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M,
.
2019;21:1353(cid:2)1365. . ThygesenK,ESCCommitteforPracticeGuideline(CPG).Executivesummary
.
433. JanuzziJL,vanKimmenadeR,LainchburyJ,Bayes-GenisA,Ordonez-LlanosJ, .. oftheguidelinesonthediagnosisandtreatmentofacuteheartfailure:theTask
Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and .. ForceonAcuteHeartFailureoftheEuropeanSocietyofCardiology.EurHeart
.
short-termprognosisinacutedestabilizedheartfailure:aninternationalpooled . J2005;26:384(cid:2)416.
.
analysisof1256patients:theInternationalCollaborativeofNT-proBNPStudy. .. 446.NohriaA,TsangSW,FangJC,LewisEF,JarchoJA,MudgeGH,StevensonLW.
EurHeartJ2006;27:330(cid:2)337. .. Clinical assessment identifies hemodynamic profiles that predict outcomes in
.
434. JanuzziJLJr,Chen-TournouxAA,ChristensonRH,DorosG,HollanderJE,Levy . patientsadmittedwithheartfailure.JAmCollCardiol2003;41:1797(cid:2)1804.
.
PD,NagurneyJT,NowakRM,PangPS,PatelD,PeacockWF,RiversEJ,Walters . 447.Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG,
.
EL,GagginHK,ICON-RELOADEDInvestigators.N-terminalpro-B-typenatriu- .. Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL,
reticpeptideintheemergencydepartment:theICON-RELOADEDstudy.JAm .. MebazaaA,MetraM,NieminenM,PangPS,SeferovicP,StevensonLW,van
.
CollCardiol2018;71:1191(cid:2)1200. . Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G,
.
435. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, . EuropeanSocietyofCardiology,EuropeanSocietyofIntensiveCareMedicine.
.
MockelM,HoganC,WuAH,RichardsM,CloptonP,FilippatosGS,DiSomma .. Assessingandgradingcongestioninacuteheartfailure: ascientificstatement
.
S,AnandI,NgL,DanielsLB,NeathSX,ChristensonR,PotockiM,McCordJ, . fromtheacuteheartfailurecommitteeoftheHeartFailureAssociationofthe
.
Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, . European Society of Cardiology and endorsed by the European Society of
. MorgenthalerNG,AnkerSD.Mid-regionpro-hormonemarkersfordiagnosis .. IntensiveCareMedicine.EurJHeartFail2010;12:423(cid:2)433.
andprognosisinacutedyspnea:resultsfromtheBACH(BiomarkersinAcute .. 448.MasipJ,PeacockWF,PriceS,CullenL,Martin-SanchezFJ,SeferovicP,Maisel
.
HeartFailure)trial.JAmCollCardiol2010;55:2062(cid:2)2076. . AS,MiroO,FilippatosG,VrintsC,ChristM,CowieM,PlatzE,McMurrayJ,
.
436. HarjolaVP,ParissisJ,BauersachsJ,Brunner-LaRoccaHP,BuenoH,Celutkiene . DiSommaS,ZeymerU,BuenoH,GaleCP,LettinoM,TavaresM,RuschitzkaF,
.
J,ChioncelO,CoatsAJS,CollinsSP,deBoerRA,FilippatosG,GayatE,HillL, .. Mebazaa A, Harjola VP, Mueller C, AcuteHeart Failure Study Group of the
LaineM,LassusJ,LommiJ,MasipJ,MebazaaA,MetraM,MiroO,MortaraA, .. Acute Cardiovascular Care Association and the Committee on Acute Heart
.
Mueller C, Mullens W, Peacock WF, Pentikainen M, Piepoli MF, . FailureoftheHeartFailureAssociationoftheEuropeanSocietyofCardiology.
.
PolyzogopoulouE,RudigerA,RuschitzkaF,SeferovicP,SionisA,TeerlinkJR, .. Indicationsandpracticalapproachtonon-invasiveventilationinacuteheartfail-
ThumT,VarpulaM,WeinsteinJM,YilmazMB.Acutecoronarysyndromesand .. ure.EurHeartJ2018;39:17(cid:2)25.
.
acuteheartfailure:adiagnosticdilemmaandhigh-riskcombination.Astatement . 449.HarjolaVP,MebazaaA,CelutkieneJ,BettexD,BuenoH,ChioncelO,Crespo-
.
fromtheAcuteHeartFailureCommitteeoftheHeartFailureAssociationof . Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J,
.
theEuropeanSocietyofCardiology.EurJHeartFail2020;22:1298(cid:2)1314. .. MuellerC,MullensW,NaeijeR,NordegraafAV,ParissisJ,RileyJP,RisticA,
437. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, .. RosanoG,RudigerA,RuschitzkaF,SeferovicP,SztrymfB,Vieillard-BaronA,
.
ChioncelO,CollinsSP,DoehnerW,FilippatosGS,FlammerAJ,FuhrmannV, . YilmazMB,KonstantinidesS.Contemporarymanagementofacuterightventric-
.
LainscakM,LassusJ,LegrandM,MasipJ,MuellerC,PappZ,ParissisJ,PlatzE, . ularfailure:astatementfromtheHeartFailureAssociationandtheWorking
.
Rudiger A, Ruschitzka F, Schafer A, Seferovic PM, Skouri H, Yilmaz MB, .. Group on Pulmonary Circulation and Right Ventricular Function of the
.
Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from . EuropeanSocietyofCardiology.EurJHeartFail2016;18:226(cid:2)241.
.
pathophysiologytodiagnosisandmanagement.AreviewonbehalfoftheAcute . 450.ChioncelO,ParissisJ,MebazaaA,ThieleH,DeschS,BauersachsJ,HarjolaVP,
.
Heart Failure Committee of the Heart Failure Association (HFA) of the .. AntohiEL,ArrigoM,GalTB,CelutkieneJ,CollinsSP,DeBackerD,IliescuVA,
EuropeanSocietyofCardiology(ESC).EurJHeartFail2017;19:821(cid:2)836. .. JankowskaE,JaarsmaT,KeramidaK,LainscakM,LundLH,LyonAR,MasipJ,
.
438. HarjolaVP,ParissisJ,Brunner-LaRoccaHP,CelutkieneJ,ChioncelO,Collins . MetraM,MiroO,MortaraA,MuellerC,MullensW,NikolaouM,PiepoliM,
.
SP,DeBackerD,FilippatosGS,GayatE,HillL,LainscakM,LassusJ,MasipJ, . Price S, Rosano G, Vieillard-Baron A, Weinstein JM, AnkerSD, Filippatos G,
.
MebazaaA,MiroO,MortaraA,MuellerC,MullensW,NieminenMS,Rudiger .. RuschitzkaF,CoatsAJS,SeferovicP.Epidemiology,pathophysiologyandcon-
A, Ruschitzka F, Seferovic PM, Sionis A, Vieillard-Baron A, Weinstein JM, de .. temporarymanagementofcardiogenicshock–apositionstatementfromthe
.
Boer RA, Crespo-Leiro MG, Piepoli M, Riley JP. Comprehensive in-hospital . HeartFailureAssociationoftheEuropeanSocietyofCardiology.EurJHeart
.
monitoring in acute heart failure: applications for clinical practice and future .. Fail2020;22:1315(cid:2)1341.
directionsforresearch.AstatementfromtheAcuteHeartFailureCommittee .. 451.ThieleH,OhmanEM,deWaha-ThieleS,ZeymerU,DeschS.Managementof
.
oftheHeartFailureAssociation(HFA)oftheEuropeanSocietyofCardiology . cardiogenicshockcomplicatingmyocardialinfarction:anupdate2019.EurHeart
.
(ESC).EurJHeartFail2018;20:1081(cid:2)1099. . J2019;40:2671(cid:2)2683.
.
439.TerMaatenJM,DammanK,HanbergJS,GivertzMM,MetraM,O’ConnorCM, .. 452.MebazaaA,CombesA,vanDiepenS,HollingerA,KatzJN,LandoniG,Hajjar
Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, .. LA,LassusJ,LebretonG,MontalescotG,ParkJJ,PriceS,SionisA,Yannopolos
.
HillegeHL, vanVeldhuisen DJ, VoorsAA, TestaniJM. Hypochloremia, diuretic . D,HarjolaVP,LevyB,ThieleH.Managementofcardiogenicshockcomplicating
.
resistance,andoutcomeinpatientswithacuteheartfailure.CircHeartFail2016;9. . myocardialinfarction.IntensiveCareMed2018;44:760(cid:2)773. .
440. NunezJ,LlacerP,Garcia-BlasS,BonanadC,VenturaS,NunezJM,SanchezR, .. 453.Zymlinski R, Biegus J, Sokolski M, Siwolowski P, Nawrocka-Millward S, Todd J,
FacilaL,delaEspriellaR,VaquerJM,CorderoA,RoqueM,ChamorroC,Bodi .. JankowskaEA,BanasiakW,CotterG,ClelandJG,PonikowskiP.Increasedblood
.
V, Valero E, Santas E, Moreno MDC, Minana G, Carratala A, Rodriguez E, . lactateisprevalentandidentifiespoorprognosisinpatientswithacuteheartfailure
. MollarA,PalauP,BoschMJ,Bertomeu-GonzalezV,LuponJ,NavarroJ,Chorro .. withoutovertperipheralhypoperfusion.EurJHeartFail2018;20:1011(cid:2)1018.
FJ,GorrizJL,SanchisJ,VoorsAA,Bayes-GenisA.CA125-guideddiuretictreat- .. 454.MenonV,SlaterJN,WhiteHD,SleeperLA,CockeT,HochmanJS.Acutemyo-
.
mentversususualcareinpatientswithacuteheartfailureandrenaldysfunc- . cardialinfarctioncomplicatedbysystemichypoperfusionwithouthypotension: .
tion.AmJMed2020;133:370(cid:2)380e374. . reportoftheSHOCKtrialregistry.AmJMed2000;108:374(cid:2)380.
.
441. NikolaouM,ParissisJ,Yilmaz MB,SerondeMF,Kivikko M,LaribiS,Paugam- .. 455.HarjolaP,MiroO,Martin-SanchezFJ,EscaladaX,FreundY,PenalozaA,Christ
BurtzC,CaiD,PohjanjousiP,LaterrePF,DeyeN,PoderP,Cohen-SolalA, .. M,ConeDC,LaribiS,KuismaM,TarvasmakiT,HarjolaVP,EMS-AHFStudy
.
MebazaaA.Liverfunctionabnormalities,clinicalprofile,andoutcomeinacute . Group.Pre-hospitalmanagementprotocolsandperceiveddifficultyindiagnos-
.
decompensatedheartfailure.EurHeartJ2013;34:742(cid:2)749. .. ingacuteheartfailure.ESCHeartFail2020;7:289(cid:2)296.
442. Mockel M, de Boer RA, Slagman AC, von Haehling S, Schou M, Vollert JO, .. 456.TakahashiM,KohsakaS,MiyataH,YoshikawaT,TakagiA,HaradaK,Miyamoto
Wiemer JC, Ebmeyer S, Mart(cid:3)ın-S(cid:3)anchez FJ, Maisel AS, Giannitsis E. Improve .. T, Sakai T, Nagao K, Sato N, Takayama M, Tokyo CCU Network Council.
.
Managementof acuteheart failurewith ProcAlCiTonininEUrope:resultsof . Associationbetweenprehospitaltimeintervalandshort-termoutcomeinacute
.
therandomizedclinicaltrialIMPACTEUBiomarkersinCardiology(BIC)18. .. heartfailurepatients.JCardFail2011;17:742(cid:2)747.
EurJHeartFail2020;22:267(cid:2)275. .. 457.ParkJH,BalmainS,BerryC,MortonJJ,McMurrayJJ.Potentiallydetrimentalcar-
.
443. Masip J, De Mendoza D, Planas K, Paez J, Sanchez B, Cancio B. Peripheral . diovascular effectsof oxygen in patients with chronicleft ventricular systolic
.
venous blood gases and pulse-oximetry in acute cardiogenic pulmonary . dysfunction.Heart2010;96:533(cid:2)538.
.
oedema.EurHeartJAcuteCardiovascCare2012;1:275(cid:2)280. .. 458.Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, 3CPO
444. MasipJ,GayaM,PaezJ,BetbeseA,VecillaF,ManresaR,RuizP.Pulseoximetry .. TrialistsNoninvasiveventilationinacutecardiogenicpulmonaryedema.NEnglJ
.
in the diagnosis of acute heart failure. Rev Esp Cardiol (Engl Ed) . Med2008;359:142(cid:2)151.
.
2012;65:879(cid:2)884. .. 459.WengCL,ZhaoYT,LiuQH,FuCJ,SunF,MaYL,ChenYW,HeQY.Meta-
445. NieminenMS,BohmM,CowieMR,DrexlerH,FilippatosGS,JondeauG,Hasin .. analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann
.
Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, SwedbergK, PrioriSG, . InternMed2010;152:590(cid:2)600.
.
GarciaMA,BlancJJ,BudajA,CowieMR,DeanV,DeckersJ,BurgosEF,Lekakis . 460.Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR,
.
J,LindahlB,MazzottaG,MoraisJ,OtoA,SmisethOA,GarciaMA,DicksteinK, .. LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF,
Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, . McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 112 ---
3710 ESCGuidelines
.
.
Bart BA, Mascette AM, Braunwald E, O’Connor CM, Network NHFCR. . versushigh-dosefurosemidepluslow-doseisosorbidedinitrateinseverepul-
.
Diureticstrategiesinpatientswithacutedecompensatedheartfailure.NEnglJ . monaryoedema.Lancet1998;351:389(cid:2)393.
.
Med2011;364:797(cid:2)805. .. 477.LevyP,ComptonS,WelchR,DelgadoG,JennettA,PenugondaN,DunneR,
461. FelkerGM,EllisonDH,MullensW,CoxZL,TestaniJM.Diuretictherapyfor .. ZalenskiR.Treatmentofsevere decompensated heartfailurewith high-dose
.
patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol . intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med
.
2020;75:1178(cid:2)1195. .. 2007;50:144(cid:2)152.
462. BriscoMA,ZileMR,HanbergJS,WilsonFP,ParikhCR,CocaSG,TangWH, .. 478.MebazaaA,MotiejunaiteJ,GayatE,Crespo-LeiroMG,LundLH,MaggioniAP,
.
TestaniJM.Relevanceofchangesinserumcreatinineduringaheartfailuretrial . ChioncelO,AkiyamaE,HarjolaVP,SeferovicP,LarocheC,JulveMS,RoigE,
.
of decongestive strategies: insights from the DOSE trial. J Card Fail . RuschitzkaF,FilippatosG,ESCHeartFailureLong-TermRegistryInvestigators.
.
2016;22:753(cid:2)760. .. Long-term safety of intravenous cardiovascular agents in acute heart failure:
463. Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, .. resultsfromtheEuropeanSocietyofCardiologyheartfailurelong-termregis-
.
WaagsteinF,McMurrayJJ.Loopdiuretics,renalfunctionandclinicaloutcomein . try.EurJHeartFail2018;20:332(cid:2)341.
.
patients with heart failure and reduced ejection fraction. Eur J Heart Fail . 479.Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S,
.
2016;18:328(cid:2)336. .. GualandroDM,deOliveiraJuniorMT,SabtiZ,MullerB,NoveanuM,Socrates
.
464. TerMaatenJM,MartensP,DammanK,DicksteinK,PonikowskiP,LangCC,Ng . T, Ziller R, Bayes-Genis A, Sionis A, Simon P, Michou E, Gujer S, Gori T,
.
LL,AnkerSD,SamaniNJ,FilippatosG,ClelandJG,ZannadF,HillegeHL,van . Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T,
. VeldhuisenDJ,MetraM,VoorsAA,MullensW.Higherdosesofloopdiuretics .. MunzelT,ErneP,MuellerC,InvestigatorsG,MuellerC,ErneP,MullerB,Rickli
limit uptitration of angiotensin-converting enzyme inhibitors in patients with .. H, Maeder M, Tavares de Oliveira M Jr, Munzel T, Bayes-Genis A, Sionis A,
.
heart failure and reduced ejection fraction. Clin Res Cardiol . Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R,
.
2020;109:1048(cid:2)1059. . Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C,
.
465. Cubbon RM, Woolston A, Adams B, Gale CP, Gilthorpe MS, Baxter PD, .. FreeseM,VogeleJ,MeissnerK,MartinJ,StrebelI,WusslerD,SchumacherC,
KearneyLC,MercerB,RajwaniA,BatinPD,KahnM,SapsfordRJ,WitteKK, .. OsswaldS,VogtF,HiltiJ,BarataS,SchneiderD,SchwarzJ,FitzeB,Hartwiger
.
Kearney MT. Prospective development and validation of a model to predict . S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R,
.
heartfailurehospitalisation.Heart2014;100:923(cid:2)929. .. BoeddinghausJ,NestelbergerT,PuelacherC,FreeseM,VogeleJ,MeissnerK,
466. KapeliosCJ,LarocheC,Crespo-LeiroMG,AnkerSD,CoatsAJS,Diaz-Molina .. MartinJ,StrebelI,WusslerD,SchumacherC,OsswaldS,VogtF,HiltiJ,Barata
.
B,FilippatosG,LainscakM,MaggioniAP,McDonaghT,MebazaaA,MetraM, . S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S,
.
Moura B, Mullens W, Piepoli MF, Rosano GMC, Ruschitzka F, Seferovic PM, . SoeiroA,GeorgievD,JansenT,GebelG,BossardM,ChristM.Effectofastrat-
.
Lund LH, Heart Failure Long-Term Registry Investigators Group. Association .. egyofcomprehensivevasodilationvsusualcareonmortalityandheartfailure
between loop diuretic dose changes and outcomes in chronic heart failure: .. rehospitalization among patients with acute heart failure: the GALACTIC
.
observationsfromtheESC-EORPheartfailurelong-termregistry.EurJHeart . randomizedclinicaltrial.JAMA2019;322:2292(cid:2)2302.
.
Fail2020;22:1424(cid:2)1437. . 480.Freund Y, Cachanado M, Delannoy Q, Laribi S, Yordanov Y, Gorlicki J,
.
467. MebazaaA,YilmazMB,LevyP,PonikowskiP,PeacockWF,LaribiS,RisticAD, .. ChouihedT,Feral-PierssensAL,TruchotJ,DesmettreT,OccelliC,BobbiaX,
.
LambrinouE,MasipJ,RileyJP,McDonaghT,MuellerC,deFilippiC,HarjolaVP, . Khellaf M, Ganansia O, Bokobza J, Balen F, Beaune S, Bloom B, Simon T,
.
ThieleH,PiepoliMF,MetraM,MaggioniA,McMurrayJ,DicksteinK,Damman . MebazaaA.Effectofanemergencydepartmentcarebundleon30-dayhospital
.
K,SeferovicPM,RuschitzkaF,Leite-MoreiraAF,BellouA,AnkerSD,Filippatos .. discharge and survival among elderly patients with acute heart failure: the
G. Recommendations on pre-hospital & early hospital management of acute .. ELISABETHrandomizedclinicaltrial.JAMA2020;324:1948(cid:2)1956.
.
heart failure: a consensus paper from the Heart Failure Association of the . 481.Khot UN, Novaro GM, Popovic ZB, Mills RM, Thomas JD, Tuzcu EM,
.
EuropeanSocietyofCardiology,theEuropeanSocietyofEmergencyMedicine . HammerD,NissenSE,FrancisGS.Nitroprussideincriticallyillpatientswith
.
and the Society of Academic Emergency Medicine. Eur J Heart Fail .. left ventricular dysfunction and aortic stenosis. N Engl J Med
2015;17:544(cid:2)558. .. 2003;348:1756(cid:2)1763.
.
468. DammanK,TerMaatenJM,CosterJE,KrikkenJA,vanDeursenVM,Krijnen . 482.Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R,
.
HK,HofmanM,NieuwlandW,vanVeldhuisenDJ,VoorsAA,vanderMeerP. .. PadleyRJ,HuangB,Cohen-SolalA.Levosimendanvs.dobutamine:outcomes
Clinical importance of urinary sodium excretion in acute heart failure. Eur J .. foracuteheartfailurepatientsonbeta-blockersinSURVIVE.EurJHeartFail
.
HeartFail2020;22:1438(cid:2)1447. . 2009;11:304(cid:2)311.
.
469. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, . 483.MetraM,NodariS,D’AloiaA,MunerettoC,RobertsonAD,BristowMR,Dei
.
Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, .. CasL.Beta-blockertherapyinfluencesthehemodynamicresponsetoinotropic
Filippatos G, Ruschitzka F, Dupont M. Rationale and design of the ADVOR .. agentsinpatientswithheartfailure:arandomizedcomparisonofdobutamine
.
(AcetazolamideinDecompensatedHeartFailurewithVolumeOverload)trial. . andenoximonebeforeandafterchronictreatmentwithmetoprololorcarvedi-
.
EurJHeartFail2018;20:1591(cid:2)1600. . lol.JAmCollCardiol2002;40:1248(cid:2)1258. .
470. CoxZL,HungR,LenihanDJ,TestaniJM.Diureticstrategiesforloopdiuretic .. 484.Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ,
resistanceinacuteheartfailure:the3Ttrial.JACCHeartFail2020;8:157(cid:2)168. .. Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T,
.
471. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J . REVIVEHeartFailureStudyGroup.Effectoflevosimendanontheshort-term
. 2015;36:1437(cid:2)1444. .. clinicalcourseofpatientswithacutelydecompensatedheartfailure.JACCHeart
472. AmbrosyAP,PangPS,KhanS,KonstamMA,FonarowGC,TraverB,Maggioni .. Fail2013;1:103(cid:2)111.
.
AP, Cook T, Swedberg K, Burnett JC, Jr., Grinfeld L, Udelson JE, Zannad F, . 485.DeBackerD,BistonP,DevriendtJ,MadlC,ChochradD,AldecoaC,Brasseur .
Gheorghiade M, EVEREST Trial Investigators. Clinical course and predictive . A,DefranceP,GottigniesP,VincentJL,SOAPIIInvestigators.Comparisonof
.
value of congestion during hospitalization in patients admitted for worsening .. dopamine and norepinephrine in the treatment of shock. N Engl J Med
signs and symptoms of heart failure with reduced ejection fraction: findings .. 2010;362:779(cid:2)789.
.
fromtheEVERESTtrial.EurHeartJ2013;34:835(cid:2)843. . 486.LevyB,Clere-JehlR,LegrasA,Morichau-BeauchantT,LeoneM,FrederiqueG,
.
473. Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, Deedwania P, . Quenot JP, Kimmoun A, Cariou A, Lassus J, Harjola VP, Meziani F, Louis G,
.
FilippatosG,SheriffHM,ZengQ,MorganCJ,WoppererS,NguyenT,Allman .. Rossignol P, Duarte K, Girerd N, Mebazaa A, Vignon P, Collaborators.
.
RM,FonarowGC,AhmedA.Loopdiureticprescriptionand30-dayoutcomes . Epinephrineversusnorepinephrineforcardiogenicshockafteracutemyocardial
.
inolderpatientswithheartfailure.JAmCollCardiol2020;76:669(cid:2)679. . infarction.JAmCollCardiol2018;72:173(cid:2)182.
.
474. SharonA,ShpirerI,KaluskiE,MoshkovitzY,MilovanovO,PolakR,BlattA, .. 487.LeopoldV,GayatE,PirracchioR,SpinarJ,ParenicaJ,TarvasmakiT,LassusJ,
SimovitzA,ShahamO,FaigenbergZ,MetzgerM,StavD,YogevR,GolikA, .. HarjolaVP,ChampionS,ZannadF,ValenteS,UrbanP,ChuaHR,BellomoR,
.
KrakoverR,VeredZ,CotterG.High-doseintravenousisosorbide-dinitrateis . Popovic B, Ouweneel DM, Henriques JPS, Simonis G, Levy B, Kimmoun A,
.
saferandbetterthanBi-PAPventilationcombinedwithconventionaltreatment . GaudardP,BasirMB,MarkotaA,AdlerC,ReuterH,MebazaaA,ChouihedT.
.
forseverepulmonaryedema.JAmCollCardiol2000;36:832(cid:2)837. .. Epinephrine and short-term survival in cardiogenic shock: an individual data
475. Publication Committee for the VMAC Investigators (Vasodilatation in the .. meta-analysisof2583patients.IntensiveCareMed2018;44:847(cid:2)856.
.
ManagementofAcuteCHF).Intravenousnesiritidevsnitroglycerin fortreat- . 488.PeacockWF,HollanderJE,DiercksDB,LopatinM,FonarowG,EmermanCL.
.
mentofdecompensatedcongestiveheartfailure:arandomizedcontrolledtrial. .. Morphine and outcomes in acute decompensated heart failure: an ADHERE
JAMA2002;287:1531(cid:2)1540. .. analysis.EmergMedJ2008;25:205(cid:2)209.
.
476. CotterG,MetzkorE,KaluskiE,FaigenbergZ,MillerR,SimovitzA,ShahamO, . 489.GilV,Dominguez-RodriguezA,MasipJ,PeacockWF,MiroO.Morphineusein
.
Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. . thetreatmentofacutecardiogenicpulmonaryedemaanditseffectsonpatient
.
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide .. outcome:asystematicreview.CurrHeartFailRep2019;16:81(cid:2)88.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 113 ---
ESCGuidelines 3711
.
.
490. Miro O, Gil V, Martin-Sanchez FJ, Herrero-Puente P, Jacob J, Mebazaa A, . FelixSB,SiewekeJT,MollerJE,PareekN,HillJ,MacCarthyP,BergmannMW,
.
HarjolaVP,RiosJ,HollanderJE,PeacockWF,LlorensP,ICA-SEMESResearch . Henriques JPS, Mobius-Winkler S, Schulze PC, Ouarrak T, Zeymer U,
.
Group.MorphineuseintheEDandoutcomesofpatientswithacuteheartfail- .. SchneiderS,BlankenbergS,ThieleH,SchaferA,WestermannD.Impellasup-
ure:apropensityscore-matchinganalysisbasedontheEAHFEregistry.Chest .. port for acute myocardial infarction complicated by cardiogenic shock.
.
2017;152:821(cid:2)832. . Circulation2019;139:1249(cid:2)1258.
.
491. Caspi O, Naami R, Halfin E, Aronson D. Adverse dose-dependent effects of .. 506.Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP,
morphinetherapyinacuteheartfailure.IntJCardiol2019;293:131(cid:2)136. .. BerkowitzA,MasoudiFA,MessengerJC,ParzynskiCS,NguforC,GirotraS,
.
492. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for . AminAP,ShahND,DesaiNR.Associationofuseofanintravascularmicroaxial
.
atrial fibrillation and atrial flutter:a systematic review with meta-analysis and . leftventricularassistdevicevsintra-aorticballoonpumpwithin-hospitalmor-
.
trial sequential analysis of randomised clinical trials. PLoS One .. talityandmajorbleedingamongpatientswithacutemyocardialinfarctioncom-
2018;13:e0193924. .. plicatedbycardiogenicshock.JAMA2020;323:734(cid:2)745.
.
493. KhandAU,RankinAC,MartinW,TaylorJ,GemmellI,ClelandJG.Carvedilol . 507.KarB,GregoricID,BasraSS,IdelchikGM,LoyalkaP.Thepercutaneousventric-
.
aloneorincombinationwithdigoxinforthemanagementofatrialfibrillationin . ular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol
.
patientswithheartfailure?JAmCollCardiol2003;42:1944(cid:2)1951. .. 2011;57:688(cid:2)696.
.
494. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, . 508.Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand
.
Bramlage P, Riess H. Certoparin versus unfractionated heparin to prevent . WK, Cherpanath TGV, Driessen AHG, de Mol B, Henriques JPS.
. venousthromboemboliceventsinpatientshospitalizedbecauseofheartfailure: .. Extracorporeallifesupportduringcardiacarrestandcardiogenicshock:asys-
asubgroupanalysisoftherandomized,controlledCERTIFYstudy.AmHeartJ .. tematicreviewandmeta-analysis.IntensiveCareMed2016;42:1922(cid:2)1934.
.
2011;161:322(cid:2)328. . 509.CombesA,PriceS,SlutskyAS,BrodieD.Temporarycirculatorysupportfor
.
495. DentaliF,DouketisJD,GianniM,LimW,CrowtherMA.Meta-analysis:anticoa- . cardiogenicshock.Lancet2020;396:199(cid:2)212.
.
gulantprophylaxistopreventsymptomaticvenousthromboembolisminhospi- .. 510.PappalardoF, Schulte C,Pieri M,SchrageB,ContriR,Soeffker G,Greco T,
talizedmedicalpatients.AnnInternMed2007;146:278(cid:2)288. .. Lembo R, Mullerleile K, Colombo A, Sydow K, De Bonis M, Wagner F,
.
496. SeferovicPM,PiepoliMF,LopatinY,JankowskaE,PolovinaM,Anguita-Sanchez . ReichenspurnerH,BlankenbergS,ZangrilloA,WestermannD.Concomitant
.
M,StorkS,LainscakM,MilicicD,MilinkovicI,FilippatosG,CoatsAJS,Heart .. implantationofImpella((R))ontopofveno-arterialextracorporealmembrane
FailureAssociationBoardoftheEuropeanSocietyofCardiology.HeartFailure .. oxygenation may improve survival of patients with cardiogenic shock. Eur J
.
AssociationoftheEuropeanSocietyofCardiologyqualityofcarecentrespro- . HeartFail2017;19:404(cid:2)412.
.
gramme:designandaccreditationdocument.EurJHeartFail2020;22:763(cid:2)774. . 511.AndersonMB,GoldsteinJ,MilanoC,MorrisLD,KormosRL,BhamaJ,Kapur
.
497. TehraniBN,TruesdellAG,SherwoodMW,DesaiS,TranHA,EppsKC,Singh .. NK,BansalA,GarciaJ,BakerJN,SilvestryS,HolmanWL,DouglasPS,O’Neill
R, Psotka M, Shah P, Cooper LB, Rosner C, Raja A, Barnett SD, Saulino P, .. W.Benefitsofanovelpercutaneousventricularassistdeviceforrightheartfail-
.
deFilippiCR,GurbelPA,MurphyCE,O’ConnorCM.Standardizedteam-based . ure:theprospectiveRECOVERRIGHTstudyoftheImpellaRPdevice.JHeart
.
careforcardiogenicshock.JAmCollCardiol2019;73:1659(cid:2)1669. . LungTransplant2015;34:1549(cid:2)1560.
.
498. BasirMB,KapurNK,PatelK,SalamMA,SchreiberT,KakiA,HansonI,Almany .. 512.Ponikowski P,KirwanBA, Anker SD, McDonagh T, DorobantuM, Drozdz J,
.
S,TimmisS,DixonS,KolskiB,ToddJ,SenterS,MarsoS,LasordaD,Wilkins . Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H,
.
C,LalondeT,AttallahA,LarkinT,DupontA,MarshallJ,PatelN,OverlyT, . Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A,
.
GreenM,TehraniB,TruesdellAG,SharmaR,AkhtarY,McRaeT,3rd,O’Neill .. Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS,
B,FinleyJ,RahmanA,FosterM,AskariR,GoldsweigA,MartinS,BharadwajA, .. Comin-ColetJ,vonHaehlingS,Cohen-SolalA,DanchinN,DoehnerW,Dargie
.
KhuddusM,CaputoC,KorpasD,CawichI,McAllisterD,BlankN,AlraiesMC, . HJ,MotroM,ButlerJ,FriedeT,JensenKH,PocockS,JankowskaEA,AFFIRM-
.
Fisher R, Khandelwal A, Alaswad K, Lemor A, Johnson T, Hacala M, O’Neill . AHFInvestigators.Ferriccarboxymaltoseforirondeficiencyatdischargeafter
.
WW,NationalCardiogenicShockInitiativeInvestigators.Improvedoutcomes .. acute heart failure: a multicentre, double-blind, randomised, controlled trial.
associated with the use of shock protocols: updates from the National .. Lancet2020;396:1895(cid:2)1904.
.
CardiogenicShockInitiative.CatheterCardiovascInterv2019;93:1173(cid:2)1183. . 513.BhagatAA,GreeneSJ,VaduganathanM,FonarowGC,ButlerJ.Initiation,con-
.
499. TehraniBN,TruesdellAG,PsotkaMA,RosnerC,SinghR,SinhaSS,Damluji .. tinuation, switching, and withdrawal of heart failure medical therapies during
AA,BatchelorWB.Astandardizedandcomprehensiveapproachtotheman- .. hospitalization.JACCHeartFail2019;7:1(cid:2)12.
.
agementofcardiogenicshock.JACCHeartFail2020;8:879(cid:2)891. . 514.PrinsKW,NeillJM,TylerJO,EckmanPM,DuvalS.Effectsofbeta-blockerwith-
.
500. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, . drawal in acute decompensated heart failure: a systematic review and meta-
.
Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, .. analysis.JACCHeartFail2015;3:647(cid:2)653.
Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, .. 515.Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Postdischarge assessment
.
Werdan K, IABP-SHOCK II Trial Investigators. Intraaortic balloon support . after a heart failure hospitalization: the next step forward. Circulation
.
for myocardial infarction with cardiogenic shock. N Engl J Med . 2010;122:1782(cid:2)1785. .
2012;367:1287(cid:2)1296. .. 516.GreeneSJ,FonarowGC,VaduganathanM,KhanSS,ButlerJ,GheorghiadeM.
501. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de .. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol
.
WahaA,RichardtG,HennersdorfM,EmpenK,FuernauG,DeschS,EitelI, . 2015;12:220(cid:2)229.
. HambrechtR,LauerB,BohmM,EbeltH,SchneiderS,WerdanK,SchulerG, .. 517.LeeKK,YangJ,HernandezAF,SteimleAE,GoAS.Post-dischargeFollow-up
IntraaorticBalloonPumpincardiogenicshockII(IABP-SHOCKII)trialinvesti- .. characteristicsassociatedwith30-dayreadmissionafterheartfailurehospitaliza-
.
gators. Intra-aortic balloon counterpulsation in acute myocardial infarction . tion.MedCare2016;54:365(cid:2)372. .
complicatedbycardiogenicshock(IABP-SHOCKII):final12monthresultsofa . 518.Edmonston DL, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Pina IL,
.
randomised,open-labeltrial.Lancet2013;382:1638(cid:2)1645. .. HernandezA, FonarowGC, DeVoreAD.Association of post-discharge spe-
502. ThieleH,ZeymerU,ThelemannN,NeumannFJ,HausleiterJ,Abdel-WahabM, .. cialtyoutpatientvisitswithreadmissionsandmortalityinhigh-riskheartfailure
.
Meyer-SaraeiR,FuernauG,EitelI,HambrechtR,BohmM,WerdanK,FelixSB, . patients.AmHeartJ2019;212:101(cid:2)112.
.
Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S, IABP- . 519.LingLH,KistlerPM,KalmanJM,SchillingRJ,HunterRJ.Comorbidityofatrial
.
SHOCK II Trial Investigators. Intraaortic balloon pump in cardiogenic shock .. fibrillationandheartfailure.NatRevCardiol2016;13:131(cid:2)147.
.
complicating acute myocardial infarction: long-term 6-year outcome of the . 520.CarlisleMA,FudimM,DeVoreAD,PicciniJP.Heartfailureandatrialfibrillation,
.
randomizedIABP-SHOCKIITrial.Circulation2019;139:395(cid:2)403. . likefireandfury.JACCHeartFail2019;7:447(cid:2)456.
.
503. SeyfarthM,SibbingD,BauerI,FrohlichG,Bott-FlugelL,ByrneR,DirschingerJ, .. 521.GorenekB,HalvorsenS,KudaiberdievaG,BuenoH,VanGelderIC,LettinoM,
KastratiA,SchomigA.Arandomizedclinicaltrialtoevaluatethesafetyandeffi- .. MarinF,MasipJ,MuellerC,OkutucuS,PoessJ,PotparaTS,PriceS,LipGYH.
.
cacyofapercutaneousleftventricularassistdeviceversusintra-aorticballoon . Atrial fibrillation in acute heart failure: a position statement from the Acute
.
pumpingfortreatmentofcardiogenicshockcausedbymyocardialinfarction.J . Cardiovascular CareAssociation andEuropeanHeart Rhythm Association of
.
AmCollCardiol2008;52:1584(cid:2)1588. .. the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care
504. OuweneelDM,EriksenE,SjauwKD,vanDongenIM,HirschA,PackerEJ,Vis .. 2020;9:348(cid:2)357.
.
MM,WykrzykowskaJJ,KochKT,BaanJ,deWinterRJ,PiekJJ,LagrandWK,de . 522.SlawikJ,AdrianL,HohlM,LothschutzS,LaufsU,BohmM.Irregularpacingof
.
MolBA,TijssenJG,HenriquesJP.Percutaneousmechanicalcirculatorysupport .. ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine
versus intra-aortic balloon pump incardiogenic shock after acute myocardial .. effectsoftransforminggrowthfactorbetaandconnectivetissuegrowthfactor.
.
infarction.JAmCollCardiol2017;69:278(cid:2)287. . EurJHeartFail2019;21:482(cid:2)491.
.
505. SchrageB,IbrahimK,LoehnT,WernerN,SinningJM,PappalardoF,PieriM, . 523.KotechaD,LamCS,VanVeldhuisenDJ,VanGelderIC,VoorsAA,RienstraM.
.
Skurk C, Lauten A, Landmesser U, Westenfeld R, Horn P, Pauschinger M, .. Heart failure with preserved ejection fraction and atrial fibrillation: vicious
EcknerD,TwerenboldR,NordbeckP,SalingerT,AbelP,EmpenK,BuschMC, . twins.JAmCollCardiol2016;68:2217(cid:2)2228.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 114 ---
3712 ESCGuidelines
.
.
524. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, van . (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.
.
VeldhuisenDJ,VanGelderIC.Theimportanceofwhetheratrialfibrillationor .. Circulation1998;98:2574(cid:2)2579.
heartfailuredevelopsfirst.EurJHeartFail2012;14:1030(cid:2)1040. .. 542.AntiarrhythmicDrugEvaluationGroup(A.D.E.G.).Amulticentre,randomized
525. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, .. trial on the benefit/risk profile of amiodarone, flecainide and propafenone in
.
Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial . patientswithcardiacdiseaseandcomplexventriculararrhythmias.EurHeartJ
.
fibrillationinpatients withchronicheartfailureonlong-termtreatmentwith .. 1992;13:1251(cid:2)1258.
beta-blockers:resultsfromCOMET.EurHeartJ2005;26:1303(cid:2)1308. .. 543.Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D,
.
526. Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, . Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK,
.
Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV, . CommerfordP,DansA,DavyJM,DelacretazE,DiPasqualeG,DiazR,Dorian
.
PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of .. P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H,
atrialfibrillationandoutcomesinpatientswithheartfailureandreducedejec- .. KautznerJ,KimJS,LanasF,LewisBS,MerinoJL,MorilloC,MurinJ,Narasimhan
.
tionfraction.JAmCollCardiol2017;70:2490(cid:2)2500. . C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK,Tanomsup S,
.
527. HoppeUC,CasaresJM,EiskjaerH,HagemannA,ClelandJG,FreemantleN, . Toivonen L,TomcsanyiJ, Torp-PedersenC,TseHF, VardasP,VinereanuD,
.
ErdmannE.Effectofcardiacresynchronizationontheincidenceofatrialfibrilla- .. Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S,
.
tioninpatientswithsevereheartfailure.Circulation2006;114:18(cid:2)25. . ChrolaviciusS,AfzalR,HohnloserSH,PALLASInvestigators.Dronedaronein
.
528. RuffCT,GiuglianoRP,BraunwaldE,HoffmanEB,DeenadayaluN,Ezekowitz . high-riskpermanentatrialfibrillation.NEnglJMed2011;365:2268(cid:2)2276.
. MD,CammAJ,WeitzJI,LewisBS,ParkhomenkoA,YamashitaT,AntmanEM. .. 544.ChatterjeeS,GhoshJ,LichsteinE,AikatS,MukherjeeD.Meta-analysisofcardi-
Comparisonoftheefficacyandsafetyofneworalanticoagulantswithwarfarin .. ovascularoutcomeswithdronedaroneinpatientswithatrialfibrillationorheart
.
in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet . failure.AmJCardiol2012;110:607(cid:2)613.
.
2014;383:955(cid:2)962. . 545.SheltonRJ,ClarkAL,GoodeK,RigbyAS,HoughtonT,KayeGC,ClelandJG.A
.
529. ReddyVY,DoshiSK,SievertH,BuchbinderM,NeuzilP,HuberK,HalperinJL, .. randomised, controlled study of rate versus rhythm control in patients with
HolmesD,PROTECTAFInvestigators.Percutaneousleftatrialappendageclo- .. chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart
.
sureforstrokeprophylaxisinpatientswithatrialfibrillation:2.3-yearfollow-up . 2009;95:924(cid:2)930.
.
of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic .. 546.Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone
Protection in Patients with Atrial Fibrillation) trial. Circulation .. increases the efficacy of direct-current cardioversion in restoration of sinus
.
2013;127:720(cid:2)729. . rhythminpatientswithchronicatrialfibrillation.EurHeartJ2000;21:66(cid:2)73.
.
530. HolmesDR,Jr.,KarS,PriceMJ,WhisenantB,SievertH,DoshiSK,HuberK, . 547.VanGelderIC,HagensVE,BoskerHA,KingmaJH,KampO,KingmaT,SaidSA,
.
Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial .. Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus
AppendageClosuredeviceinpatients with atrialfibrillationversuslong-term .. ElectricalCardioversionforPersistentAtrialFibrillationStudyGroup.Acom-
.
warfarintherapy:thePREVAILtrial.JAmCollCardiol2014;64:1(cid:2)12. . parisonofratecontrolandrhythmcontrolinpatientswithrecurrentpersistent
.
531. VanGelderIC,WyseDG,ChandlerML,CooperHA,OlshanskyB,HagensVE, . atrialfibrillation.NEnglJMed2002;347:1834(cid:2)1840.
.
CrijnsHJ,RACEandAFFIRMInvestigators.Doesintensityofrate-controlinflu- .. 548.Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB,
.
enceoutcomeinatrialfibrillation?AnanalysisofpooleddatafromtheRACE . Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation
.
andAFFIRMstudies.Europace2006;8:935(cid:2)942. . Follow-upInvestigationofRhythmManagement(AFFIRM)Investigators.Acom-
.
532. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, .. parisonofratecontrolandrhythmcontrolinpatientswithatrialfibrillation.N
BhattDL,AllenLA,PetersonPN,HoPM,LewisWR,HernandezAF,Fonarow .. EnglJMed2002;347:1825(cid:2)1833.
.
GC, Piccini JP. Strict versus lenient versus poor rate control among patients . 549.CarlssonJ,MiketicS,WindelerJ,CuneoA,HaunS,MicusS,WalterS,Tebbe
.
withatrialfibrillationandheartfailure(fromtheGetWithTheGuidelines– . U,STAFInvestigators.Randomizedtrialofrate-controlversusrhythm-control
.
HeartFailureProgram).AmJCardiol2020;125:894(cid:2)900. .. inpersistentatrialfibrillation:theStrategiesofTreatmentofAtrialFibrillation
533. SartipyU,SavareseG,DahlstromU,FuM,LundLH.Associationofheartrate .. (STAF)study.JAmCollCardiol2003;41:1690(cid:2)1696.
.
withmortalityinsinusrhythm andatrialfibrillationinheartfailurewithpre- . 550.RoyD,TalajicM,NattelS,WyseDG,DorianP,LeeKL,BourassaMG,Arnold
.
servedejectionfraction.EurJHeartFail2019;21:471(cid:2)479. .. JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG,
534. VanGelderIC,RienstraM,CrijnsHJ,OlshanskyB.Ratecontrolinatrialfibrilla- .. HohnloserSH,LambertJ,LeHeuzeyJY,O’HaraG,PedersenOD,RouleauJL,
.
tion.Lancet2016;388:818(cid:2)828. . Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial
.
535. KotechaD,FlatherMD,AltmanDG,HolmesJ,RosanoG,WikstrandJ,Packer . FibrillationandCongestiveHeart FailureInvestigatorsRhythmcontrolversus
.
M,CoatsAJS,ManzanoL,BohmM,vanVeldhuisenDJ,AnderssonB,WedelH, .. rate control for atrial fibrillation and heart failure. N Engl J Med
vonLuederTG,RigbyAS,HjalmarsonA,KjekshusJ,ClelandJGF,Beta-Blockers .. 2008;358:2667(cid:2)2677.
.
inHeartFailureCollaborativeGroup.Heartrateandrhythmandthebenefitof . 551.KirchhofP,CammAJ,GoetteA,BrandesA,EckardtL,ElvanA,FetschT,van
.
beta-blockers in patients with heart failure. J Am Coll Cardiol . Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, .
2017;69:2885(cid:2)2896. .. KautznerJ,KuckKH,MontL,NgGA,RekoszJ,SchoenN,SchottenU,Suling
536. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, .. A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K,
.
CalvertMJ,DeeksJJ,SteedsRP,StraussVY,RahimiK,CammAJ,GriffithM,Lip . Willems S, Crijns H, Breithardt G, EAST-AFNET 4 Trial Investigators. Early
. GYH,TownendJN,KirchhofP,RateControlTherapyEvaluationinPermanent .. rhythm-control therapy in patients with atrial fibrillation. N Engl J Med
Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart .. 2020;383:1305(cid:2)1316.
.
ratecontrolinatrialfibrillationonpatient-reportedqualityoflife:theRATE-AF . 552.Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, .
randomizedclinicaltrial.JAMA2020;324:2497(cid:2)2508. . Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J,
.
537. HofmannR,SteinwenderC,KammlerJ,KyptaA,LeischF.Effectsofahighdose .. BanschD,CASTLE-AFInvestigators.Catheterablationforatrialfibrillationwith
intravenousbolusamiodaroneinpatientswithatrialfibrillationandarapidven- .. heartfailure.NEnglJMed2018;378:417(cid:2)427.
.
tricularrate.IntJCardiol2006;110:27(cid:2)32. . 553.Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE,
.
538. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes . NoseworthyPA,RosenbergYD,JeffriesN,MitchellLB,FlakerGC,Pokushalov
.
afterablationandpacingtherapyforatrialfibrillation:ameta-analysis.Circulation .. E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ,
.
2000;101:1138(cid:2)1144. . Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV,
.
539. LimKT,DavisMJ,PowellA,ArnoldaL,MouldenK,BulsaraM,WeerasooriyaR. . Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL, CABANA
.
Ablateandpacestrategyforatrialfibrillation:long-termoutcomeofAIRCRAFT .. Investigators.Effectofcatheterablationvsantiarrhythmicdrugtherapyonmor-
trial.Europace2007;9:498(cid:2)505. .. tality,stroke,bleeding,andcardiacarrestamongpatientswithatrialfibrillation:
.
540. GaspariniM,KloppeA,LunatiM,AnselmeF,LandolinaM,Martinez-FerrerJB, . theCABANArandomizedclinicaltrial.JAMA2019;321:1261(cid:2)1274.
.
Proclemer A, Morani G, Biffi M, Ricci R, Rordorf R, Mangoni L, Manotta L, . 554.PackerDL,PicciniJP,MonahanKH,Al-KhalidiHR,SilversteinAP,Noseworthy
.
GrammaticoA,LeyvaF,BorianiG.Atrioventricularjunctionablationinpatients .. PA,PooleJE,BahnsonTD,LeeKL,MarkDB,CABANAInvestigators.Ablation
with atrialfibrillation treated with cardiac resynchronization therapy:positive .. versus drug therapy for atrial fibrillation in heart failure: results from the
.
impactonventriculararrhythmias,implantablecardioverter-defibrillatorthera- . CABANAtrial.Circulation2021;143:1377(cid:2)1390.
.
piesandhospitalizations.EurJHeartFail2018;20:1472(cid:2)1481. .. 555.KuckKH,MerkelyB,ZahnR,ArentzT,SeidlK,SchluterM,TilzRR,Piorkowski
541. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. .. C,GellerL,KleemannT,HindricksG.Catheterablationversusbestmedical
.
Spontaneous conversion and maintenance of sinus rhythm by amiodarone in . therapyinpatientswithpersistentatrialfibrillationandcongestiveheartfailure:
.
patientswithheartfailureandatrialfibrillation:observationsfromtheVeterans . therandomizedAMICAtrial.CircArrhythmElectrophysiol2019;12:e007731.
.
Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy .. 556.DiBiaseL,MohantyP,MohantyS,SantangeliP,TrivediC,LakkireddyD,Reddy
. M,JaisP,ThemistoclakisS,DelloRussoA,CasellaM,PelargonioG,Narducci
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 115 ---
ESCGuidelines 3713
.
.
ML,SchweikertR,NeuzilP,SanchezJ,HortonR,BeheiryS,HongoR,HaoS, . 573.KanamasaK,HayashiT,KimuraA,IkedaA,IshikawaK.Long-term,continuous
.
Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. . treatmentwithbothoralandtransdermalnitratesincreasescardiaceventsin
.
Ablation versus amiodarone for treatment of persistent atrial fibrillation in .. healedmyocardialinfarctionpatients.Angiology2002;53:399(cid:2)408.
patientswithcongestiveheartfailureandanimplanteddevice:resultsfromthe .. 574.WilsonSR,SciricaBM,BraunwaldE,MurphySA,Karwatowska-ProkopczukE,
.
AATACmulticenterrandomizedtrial.Circulation2016;133:1637(cid:2)1644. . Buros JL, Chaitman BR, Morrow DA. Efficacy of ranolazine in patients with
.
557. Mark DB,Anstrom KJ, ShengS,Piccini JP,BalochKN, MonahanKH,Daniels .. chronicanginaobservationsfromtherandomized,double-blind,placebo-con-
MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL, CABANA .. trolledMERLIN-TIMI(MetabolicEfficiencyWithRanolazineforLessIschemiain
.
Investigators. Effect of catheter ablation vs medical therapy on quality of life . Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll
.
among patients with atrial fibrillation: the CABANA randomized clinical trial. . Cardiol2009;53:1510(cid:2)1516.
.
JAMA2019;321:1275(cid:2)1285. .. 575.GaoD,NingN,NiuX,HaoG,MengZ.Trimetazidine:ameta-analysisofrand-
558. XiongQ,LauYC,SenooK,LaneDA,HongK,LipGY.Non-vitaminKantago- .. omisedcontrolledtrialsinheartfailure.Heart2011;97:278(cid:2)286.
.
nistoralanticoagulants(NOACs)inpatientswithconcomitantatrialfibrillation . 576.VitaleC,WajngatenM,SposatoB,GebaraO,RossiniP,FiniM,VolterraniM,
.
andheartfailure:asystemicreviewandmeta-analysisofrandomizedtrials.EurJ . RosanoGM.Trimetazidineimprovesleftventricularfunctionandqualityoflife
.
HeartFail2015;17:1192(cid:2)1200. .. in elderly patients with coronary artery disease. Eur Heart J
.
559. NielsenPB,LarsenTB,SkjothF,OvervadTF,LipGY.Strokeandthromboem- . 2004;25:1814(cid:2)1821.
.
boliceventratesinatrialfibrillationaccordingtodifferentguidelinetreatment . 577.ZhangL,LuY,JiangH,ZhangL,SunA,ZouY,GeJ.Additionaluseoftrimetazi-
. thresholds:anationwidecohortstudy.SciRep2016;6:27410. .. dine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol
560. LatchamsettyR,BogunF.Prematureventricularcomplex-inducedcardiomyop- .. 2012;59:913(cid:2)922.
.
athy.JACCClinElectrophysiol2019;5:537(cid:2)550. . 578.GoldsteinRE,BoccuzziSJ,CruessD,NattelS.Diltiazemincreaseslate-onset
.
561. MondesertB,KhairyP,SchramG,ShohoudiA,TalajicM,AndradeJG,Dubuc . congestive heart failure in postinfarction patients with early reduction in
.
M,GuerraPG,MacleL,RoyD,DyrdaK,ThibaultB,BarreroM,DiazA,Kouz .. ejection fraction. The Adverse Experience Committee; and the
S,McNicollS,NowakowskaD,RivardL.Impactofrevascularizationinpatients .. Multicenter Diltiazem Postinfarction Research Group. Circulation
.
with sustained ventricular arrhythmias, prior myocardial infarction, and pre- . 1991;83:52(cid:2)60.
.
servedleftventricularejectionfraction.HeartRhythm2016;13:1221(cid:2)1227. .. 579. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam
562. YarlagaddaRK,IwaiS,SteinKM,MarkowitzSM,ShahBK,CheungJW,TanV, .. CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ,
.
Lerman BB, Mittal S. Reversal of cardiomyopathy in patients with repetitive . GreenbergB,COMMANDERHFInvestigators.Rivaroxabaninpatientswith
.
monomorphicventricularectopyoriginatingfromtherightventricularoutflow . heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379:
.
tract.Circulation2005;112:1092(cid:2)1097. .. 1332(cid:2)1342.
563. Berruezo A, Penela D, Jauregui B, Soto-Iglesias D, Aguinaga L, Ordonez A, .. 580.Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK,
.
Fernandez-ArmentaJ,MartinezM,TercedorL,BisbalF,AcostaJ,Marti-AlmorJ, . Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S.
.
Acena M, Anguera I, Rossi L, Linhart M, Borras R, Doltra A, Sanchez P, . Rivaroxabanwithorwithoutaspirininpatientswithheartfailureandchronic
.
Ortiz-Perez JT, Perea RJ, Prat-Gonzalez S, Teres C, Bosch X. Mortality and .. coronaryorperipheralarterydisease.Circulation2019;140:529(cid:2)537.
.
morbidityreductionafterfrequentprematureventricularcomplexesablationin . 581.VelazquezEJ,LeeKL,JonesRH,Al-KhalidiHR,HillJA,PanzaJA,MichlerRE,
.
patients with left ventricular systolic dysfunction. Europace 2019;21:1079(cid:2) . Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-
.
1087. .. Nickens P, Sopko G, Rouleau JL, STICHES Investigators. Coronary-artery
564. CroninEM,BogunFM,MauryP,PeichlP,ChenM,NamboodiriN,AguinagaL, .. bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med
.
LeiteLR,Al-KhatibSM,AnterE,BerruezoA,CallansDJ,ChungMK,Cuculich . 2016;374:1511(cid:2)1520.
.
P,d’AvilaA,DealBJ,DellaBellaP,DenekeT,DickfeldTM,HadidC,Haqqani . 582.PanzaJA,HollyTA,AschFM,SheL,PellikkaPA,VelazquezEJ,LeeKL,Borges-
.
HM,Kay GN, LatchamsettyR,MarchlinskiF, MillerJM, NogamiA, PatelAR, .. Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial
Pathak RK, Saenz Morales LC, Santangeli P, Sapp JL, Sarkozy A, Soejima K, .. ischemiaandoutcomesinpatientswithcoronaryarterydiseaseandleftventric-
.
StevensonWG,TedrowUB,TzouWS,VarmaN,ZeppenfeldK,ESCScientific . ulardysfunction.JAmCollCardiol2013;61:1860(cid:2)1870.
.
Document Group. 2019 HRS/EHRA/APHRS/LAHRS expert consensus state- .. 583.Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS,
ment on catheter ablation of ventricular arrhythmias. Europace .. Chattopadhyay S, Norell MS, Pennell DJ, Senior R. The Heart Failure
.
2019;21:1143(cid:2)1144. . RevascularisationTrial(HEART).EurJHeartFail2011;13:227(cid:2)233.
.
565. Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, Kim JS, Park SJ. . 584.PereraD,ClaytonT,PetrieMC,GreenwoodJP,O’KanePD,EvansR,Sculpher
.
Clinicalfeatures,predictors,andlong-termprognosisofpacing-inducedcardio- .. M,McDonaghT,GershlickA,deBelderM,RedwoodS,Carr-WhiteG,Marber
myopathy.EurJHeartFail2019;21:643(cid:2)651. .. M,REVIVEDInvestigators.Percutaneousrevascularizationforischemicventric-
.
566. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac . ulardysfunction:rationaleanddesignoftheREVIVED-BCIS2trial:percutaneous
.
resynchronizationtherapytomaximizeelectricalresynchronization:afeasibility . coronary intervention for ischemic cardiomyopathy. JACC Heart Fail .
study.CircArrhythmElectrophysiol2019;12:e006934. .. 2018;6:517(cid:2)526.
567. AbdelrahmanM,SubzposhFA,BeerD,DurrB,NaperkowskiA,SunH,Oren .. 585.BangaloreS,GuoY,SamadashviliZ,BleckerS,HannanEL.Revascularizationin
.
JW,DandamudiG,VijayaramanP.ClinicaloutcomesofHisbundlepacingcom- . patientswithmultivesselcoronaryarterydiseaseandsevereleftventricularsys-
. paredtorightventricularpacing.JAmCollCardiol2018;71:2319(cid:2)2330. .. tolicdysfunction:everolimus-elutingstentsversuscoronaryarterybypassgraft
568. ZiffOJ,SamraM,HowardJP,BromageDI,RuschitzkaF,FrancisDP,KotechaD. .. surgery.Circulation2016;133:2132(cid:2)2140.
.
Beta-blocker efficacy across different cardiovascular indications: an umbrella . 586.NagendranJ,BozsoSJ,NorrisCM,McAlisterFA,AppooJJ,MoonMC,Freed .
reviewandmeta-analyticassessment.BMCMed2020;18:103. . DH, Nagendran J. Coronary artery bypass surgery improves outcomes in
.
569. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL .. patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol
Investigators. Relationship between ivabradine treatment and cardiovascular .. 2018;71:819(cid:2)827.
.
outcomes in patients with stable coronary artery disease andleft ventricular . 587.ParkS,AhnJM,KimTO,ParkH,KangDY,LeePH,JeongYJ,HyunJ,LeeJ,Kim
.
systolicdysfunctionwithlimitingangina:asubgroupanalysisoftherandomized, . JH, Yang Y, Choe K, Park SJ, Park DW, IRIS-MAIN Registry Investigators.
.
controlledBEAUTIFULtrial.EurHeartJ2009;30:2337(cid:2)2345. .. Revascularizationinpatientswithleftmaincoronaryarterydiseaseandleftven-
.
570. PackerM,O’ConnorCM,GhaliJK,PresslerML,CarsonPE,BelkinRN,Miller . triculardysfunction.JAmCollCardiol2020;76:1395(cid:2)1406.
.
AB,NeubergGW,FridD,WertheimerJH,CroppAB,DeMetsDL.Effectof . 588.MaruiA,KimuraT,NishiwakiN,Mitsudo K,KomiyaT,HanyuM,ShiomiH,
.
amlodipine on morbidity and mortality in severe chronic heart failure. .. TanakaS,SakataR,CREDO-KyotoPCI/CABGRegistryCohort-2Investigators.
ProspectiveRandomizedAmlodipineSurvivalEvaluationStudyGroup.NEnglJ .. Comparison of five-year outcomes of coronary artery bypass grafting versus
.
Med1996;335:1107(cid:2)1114. . percutaneous coronary intervention in patients with left ventricular ejection
.
571. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, . fractions</=50%versus>50%(fromtheCREDO-KyotoPCI/CABGRegistry
.
BodenW,BaruchL,RochinP,LossL.Effectofthecalciumantagonistfelodipine .. Cohort-2).AmJCardiol2014;114:988(cid:2)996.
as supplementary vasodilator therapy in patients with chronic heart failure .. 589.WolffG,DimitroulisD,Andreotti F, KolodziejczakM, JungC,ScicchitanoP,
.
treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) . DevitoF,Zito A,OcchipintiM,Castiglioni B,CalveriG, Maisano F,Ciccone
.
StudyGroup.Circulation1997;96:856(cid:2)863. .. MM,DeServiS,NavareseEP.Survivalbenefitsofinvasiveversusconservative
572. IONAStudyGroup. Effectofnicorandil oncoronaryeventsinpatients with .. strategiesinheartfailureinpatientswithreducedejectionfractionandcoro-
.
stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. . naryarterydisease:ameta-analysis.CircHeartFail2017;10:e003255.
.
Lancet2002;359:1269(cid:2)1275. . 590.GaudinoM,HameedI,KhanFM,TamDY,RahoumaM,YongleR,NaikA,Di
.
.. Franco A, Demetres M, Petrie MC, Jolicoeur EM, Girardi LN, Fremes SE.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 116 ---
3714 ESCGuidelines
.
.
Treatmentstrategiesinischaemicleftventriculardysfunction:anetworkmeta- . 603.TornosP,SambolaA, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-
.
analysis.EurJCardiothoracSurg2021;59:293(cid:2)301. . SolerJ.Long-termoutcomeofsurgicallytreatedaorticregurgitation:influence
.
591. GenereuxP,PibarotP,RedforsB,MackMJ,MakkarRR,JaberWA,Svensson .. of guideline adherence toward early surgery. J Am Coll Cardiol
LG, Kapadia S, Tuzcu EM, Thourani VH, Babaliaros V, Herrmann HC, Szeto .. 2006;47:1012(cid:2)1017.
.
WY, Cohen DJ, Lindman BR, McAndrew T, Alu MC, Douglas PS, Hahn RT, . 604.Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ,
.
KodaliSK,SmithCR,MillerDC,WebbJG,LeonMB.Stagingclassificationof .. Yzeiraj E, Amat-Santos IJ, TchetcheD, JungC, FujitaB, Mangieri A, Deutsch
aortic stenosis based on the extent of cardiac damage. Eur Heart J .. MA,UbbenT,DeuschlF,KuwataS,DeBiaseC,WilliamsT,DhobleA,Kim
.
2017;38:3351(cid:2)3358. . WK, Ferrari E, Barbanti M, Vollema EM, Miceli A, Giannini C, Attizzani GF,
.
592. VahanianA,BeyersdorfF,PrazF,MilojevicM,BaldusS,JohannB,Capodanno . KongWKF,Gutierrez-IbanesE,JimenezDiazVA,WijeysunderaHC,KanekoH,
.
D,ConradiL,DeBonisM,DePaulisR,DelgadoV,FreemantleN,GilardM, .. ChakravartyT,MakarM,SievertH,HengstenbergC,PrendergastBD,Vincent
Haugaa KH, Jeppsson A, Ju¨ni P, Pierard L, Prendergast PD, Rafael S(cid:3)adaba J, .. F, Abdel-Wahab M, Nombela-Franco L, Silaschi M, Tarantini G, Butter C,
.
TribouilloyC,WojakowskiW;ESC/EACTSScientificDocumentGroup.2021 . EnsmingerSM,Hildick-SmithD,PetronioAS,YinWH,DeMarcoF,TestaL,
.
ESC/EACTSGuidelinesforthemanagementofvalvularheartdisease.EurHeart . Van Mieghem NM, Whisenant BK, Kuck KH, Colombo A, Kar S, Moris C,
.
J2021;doi:10.1093/eurheartj/ehab395. .. Delgado V, Maisano F, Nietlispach F, Mack MJ, Schofer J, Schaefer U, Bax JJ,
.
593. LeonMB,SmithCR,MackM,MillerDC,MosesJW,SvenssonLG,TuzcuEM, . FrerkerC,LatibA,MakkarRR.Transcatheteraorticvalvereplacementinpure
.
WebbJG,FontanaGP,MakkarRR,BrownDL,BlockPC,GuytonRA,Pichard . nativeaorticvalveregurgitation.JAmCollCardiol2017;70:2752(cid:2)2763.
. AD,BavariaJE,HerrmannHC,DouglasPS,PetersenJL,AkinJJ,AndersonWN, .. 605.FeldmanT,FosterE,GlowerDD,KarS,RinaldiMJ,FailPS,SmallingRW,Siegel
Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve .. R,RoseGA,EngeronE,LoghinC,TrentoA,SkipperER,FudgeT,LetsouGV,
.
implantationforaorticstenosisinpatientswhocannotundergosurgery.NEngl . MassaroJM,MauriL,EVERESTIIInvestigators.Percutaneousrepairorsurgery
.
JMed2010;363:1597(cid:2)1607. . formitralregurgitation.NEnglJMed2011;364:1395(cid:2)1406.
.
594. SmithCR,LeonMB,MackMJ,MillerDC,MosesJW,SvenssonLG,TuzcuEM, .. 606.TamargoM,ObokataM,ReddyYNV,PislaruSV,LinG,EgbeAC,Nishimura
WebbJG,FontanaGP,MakkarRR,WilliamsM,DeweyT,KapadiaS,Babaliaros .. RA,BorlaugBA.Functionalmitralregurgitationandleftatrialmyopathyinheart
.
V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, . failurewithpreservedejectionfraction.EurJHeartFail2020;22:489(cid:2)498.
.
Anderson WN, Wang D, Pocock SJ, PARTNER Trial Investigators. .. 607.DziadzkoV,ClavelMA,DziadzkoM,Medina-InojosaJR,MichelenaH,MaaloufJ,
Transcatheterversussurgicalaortic-valvereplacementinhigh-riskpatients.N .. NkomoV,ThapaP,Enriquez-SaranoM.Outcomeandundertreatmentofmitral
.
EnglJMed2011;364:2187(cid:2)2198. . regurgitation:acommunitycohortstudy.Lancet2018;391:960(cid:2)969.
.
595. AdamsDH,PopmaJJ,ReardonMJ,YakubovSJ,CoselliJS,DeebGM,Gleason . 608.GoliaschG,BartkoPE,PavoN,NeuholdS,WurmR,MascherbauerJ,LangIM,
.
TG,BuchbinderM,HermillerJJr,KleimanNS,ChetcutiS,HeiserJ,MerhiW, .. Strunk G, Hulsmann M. Refining the prognostic impact of functional mitral
ZornG,TadrosP,RobinsonN,PetrossianG,HughesGC,HarrisonJK,Conte .. regurgitationinchronicheartfailure.EurHeartJ2018;39:39(cid:2)46.
.
J, Maini B, Mumtaz M, Chenoweth S, Oh JK, US CoreValve Clinical . 609.BertrandPB,SchwammenthalE,LevineRA,VandervoortPM.Exercisedynam-
.
Investigators. Transcatheter aortic-valve replacement with a self-expanding . icsinsecondarymitralregurgitation:pathophysiologyandtherapeuticimplica-
.
prosthesis.NEnglJMed2014;370:1790(cid:2)1798. .. tions.Circulation2017;135:297(cid:2)314.
.
596. Popma JJ,AdamsDH,ReardonMJ, YakubovSJ,KleimanNS, HeimansohnD, . 610.ObadiaJF,Messika-ZeitounD,LeurentG,IungB,BonnetG,PiriouN,Lefevre
.
HermillerJ,Jr.,HughesGC,HarrisonJK,CoselliJ,DiezJ,KafiA,SchreiberT, . T,PiotC,RouleauF,CarrieD,NejjariM,OhlmannP,LeclercqF,SaintEtienne
.
Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, .. C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN,
Chenoweth S, Oh JK, CoreValve United States Clinical Investigators. .. Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G,
.
Transcatheteraorticvalvereplacementusingaself-expandingbioprosthesisin . GuerinP,VahanianA,MewtonN,MITRA-FRInvestigators.Percutaneousrepair
.
patientswithsevereaorticstenosisatextremeriskforsurgery.JAmCollCardiol . or medical treatment for secondary mitral regurgitation. N Engl J Med
.
2014;63:1972(cid:2)1981. .. 2018;379:2297(cid:2)2306.
597. LeonMB,SmithCR,MackMJ,MakkarRR,SvenssonLG,KodaliSK,Thourani .. 611.IungB,ArmoiryX,VahanianA,BoutitieF,MewtonN,TrochuJN,LefevreT,
.
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ,Pichard AD, . Messika-ZeitounD,GuerinP,CormierB,BrochetE,ThibaultH,HimbertD,
.
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, .. ThivoletS,LeurentG,BonnetG,DonalE,PiriouN,PiotC,HabibG,Rouleau
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, .. F, Carrie D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M,
.
Brown DL,FearonWF,PibarotP,HahnRT, JaberWA,AndersonWN,Alu . SamsonG,RioufolG,Maucort-BoulchD,ObadiaJF,MITRA-FRInvestigators.
.
MC,WebbJG,PARTNER2Investigators.Transcatheterorsurgicalaortic-valve . Percutaneous repairormedical treatment forsecondarymitralregurgitation:
.
replacementinintermediate-riskpatients.NEnglJMed2016;374:1609(cid:2)1620. .. outcomesat2years.EurJHeartFail2019;21:1619(cid:2)1627.
598. ReardonMJ,VanMieghemNM,PopmaJJ,KleimanNS,SondergaardL,Mumtaz .. 612.StoneGW,LindenfeldJ,AbrahamWT,KarS,LimDS,MishellJM,WhisenantB,
.
M,AdamsDH,DeebGM,MainiB,GadaH,ChetcutiS,GleasonT,HeiserJ, . GrayburnPA,RinaldiM,KapadiaSR,RajagopalV,SarembockIJ,BriekeA,Marx
.
Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, . SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter .
YakubovSJ,GrubeE,MakkarR,LeeJS,ConteJ,VangE,NguyenH,ChangY, .. mitral-valve repair in patients with heart failure. N Engl J Med
Mugglin AS, Serruys PW, Kappetein AP, SURTAVI Investigators. Surgical or .. 2018;379:2307(cid:2)2318.
.
transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J . 613.SenniM,AdamoM,MetraM,AlfieriO,VahanianA.Treatmentoffunctional
. Med2017;376:1321(cid:2)1331. .. mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’
599. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, .. fromtheMITRA-FRandCOAPTtrials?EurJHeartFail2019;21:852(cid:2)861.
.
Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, . 614.GrayburnPA,SanninoA,PackerM.Proportionateanddisproportionatefunc- .
Adams DH, Teirstein PS, Zorn GL, 3rd, Forrest JK, Tchetche D, Resar J, . tional mitral regurgitation: a new conceptual framework that reconciles the
.
WaltonA,PiazzaN,RamlawiB,RobinsonN,PetrossianG,GleasonTG,OhJK, .. results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging
Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial .. 2019;12:353(cid:2)362.
.
Investigators. Transcatheter aortic-valve replacement with a self-expanding . 615.CoatsAJS,AnkerSD,BaumbachA,AlfieriO,vonBardelebenRS,BauersachsJ,
.
valveinlow-riskpatients.NEnglJMed2019;380:1706(cid:2)1715. .. Bax JJ, Boveda S, Celutkiene J, Cleland JG, Dagres N, Deneke T, Farmakis D,
600. MackMJ,LeonMB,ThouraniVH,MakkarR,KodaliSK,RussoM,KapadiaSR, .. Filippatos G, Hausleiter J, HindricksG, Jankowska EA, LainscakM, Leclercq C,
.
MalaisrieSC,CohenDJ,PibarotP,LeipsicJ,HahnRT,BlankeP,WilliamsMR, . LundLH,McDonaghT,MehraMR,MetraM,MewtonN,MuellerC,MullensW,
.
McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, . MunerettoC,ObadiaJF,PonikowskiP,PrazF,RudolphV,RuschitzkaF,Vahanian
.
PershadA,PocockSJ,AluMC,WebbJG,SmithCR,PARTNER3Investigators. .. A, Windecker S, Zamorano JL, Edvardsen T, Heidbuchel H, Seferovic PM,
Transcatheteraortic-valvereplacementwithaballoon-expandablevalveinlow- .. PrendergastB.Themanagementofsecondarymitralregurgitationinpatientswith
.
riskpatients.NEnglJMed2019;380:1695(cid:2)1705. . heartfailure:ajointpositionstatementfromtheHeartFailureAssociation(HFA),
.
601. ElderDH,WeiL,SzwejkowskiBR,LibiantoR,NadirA,PauriahM,RekhrajS, . European Association of Cardiovascular Imaging (EACVI), European Heart
.
LimTK,GeorgeJ,DoneyA,Pringle SD,Choy AM,StruthersAD,LangCC. .. Rhythm Association (EHRA), and European Association of Percutaneous
Theimpactofrenin-angiotensin-aldosteronesystemblockadeonheartfailure .. Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J
.
outcomes and mortality in patients identified to have aortic regurgitation: a . 2021;42:1254(cid:2)1269.
.
largepopulationcohortstudy.JAmCollCardiol2011;58:2084(cid:2)2091. .. 616.AdamoM,FiorelliF,MelicaB,D’OrtonaR,LupiL,GianniniC,SilvaG,Fiorina
602. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, Enriquez- .. C,BrancaL,ChiariE,ChizzolaG,SpontoniP,EspadaGuerreiroC,CurelloS,
.
Sarano M. Outcomes after aortic valve replacement in patients with severe . Petronio AS, Metra M. COAPT-like profile predicts long-term outcomes in
.
aorticregurgitationandmarkedlyreducedleftventricular function. Circulation . patientswithsecondarymitralregurgitationundergoingMitraClipimplantation.
.
2002;106:2687(cid:2)2693. .. JACCCardiovascInterv2021;14:15(cid:2)25.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 117 ---
ESCGuidelines 3715
.
.
617. Godino C, Munafo A, Scotti A, Estevez-Loureiro R, Portoles Hernandez A, . 632.FagardRH,CelisH,ThijsL,WoutersS.Regressionofleftventricularmassby
.
ArzamendiD,FernandezPeregrinaE,TaramassoM,FamNP,HoEC,AsgarA, .. antihypertensivetreatment:ameta-analysisofrandomizedcomparativestudies.
VitrellaG,RaineriC,AdamoM,FiorinaC,MontaltoC,FraccaroC,GianniniC, .. Hypertension2009;54:1084(cid:2)1091.
.
Fiorelli F, Popolo Rubbio A, Ooms JF, Compagnone M, Maffeo D, Bettari L, . 633.CautelaJ,TartiereJM,Cohen-SolalA,Bellemain-AppaixA,TheronA,TibiT,
.
Furholz M, Tamburino C, Petronio AS, Grasso C, Agricola E, Van Mieghem .. Januzzi JL, Jr., Roubille F, Girerd N. Management of low blood pressure in
NM,TarantiniG,CurelloS,PrazF,PascualI,PotenaL,ColomboA,MaisanoF, .. ambulatoryheartfailurewithreducedejectionfractionpatients.EurJHeartFail
.
Metra M, Margonato A, Crimi G, Saia F. MitraClip in secondary mitral . 2020;22:1357(cid:2)1365.
.
regurgitation as a bridge to heart transplantation: 1-year outcomes from . 634.KangSH,KimJ,ParkJJ,OhIY,YoonCH,KimHJ,KimK,ChoiDJ.Riskofstroke
.
the International MitraBridge Registry. J Heart Lung Transplant .. in congestive heart failure with and without atrial fibrillation. Int J Cardiol
2020;39:1353(cid:2)1362. .. 2017;248:182(cid:2)187.
.
618. WitteKK,LipieckiJ,SiminiakT,MeredithIT,MalkinCJ,GoldbergSL,StarkMA, . 635.Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G,
.
vonBardelebenRS,CremerPC,JaberWA,CelermajerDS,KayeDM,Sievert . WikstrandJ,KjekshusJ,LipGY,MaggioniAP,TavazziL,LeesKR,McMurrayJJ,
.
H.TheREDUCEFMRtrial:arandomizedsham-controlledstudyofpercutane- .. Investigators of the Controlled Rosuvastatin Multinational Study in Heart
ous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail .. Failure (CORONA), GISSI-Heart Failure (GISSI-HF) Committees and
.
2019;7:945(cid:2)955. . Investigators.Riskofstrokeinchronicheartfailurepatientswithoutatrialfibril-
.
619. GeyerM,KellerK,SotiriouE,TammAR,RufTF,KreidelF,Beiras-FernandezA, .. lation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart
GoriT,SchulzE,MunzelT,vonBardelebenRS.Associationoftranscatheter .. Failure(CORONA)andtheGruppoItalianoperloStudiodellaSopravvivenza
.
directmitralannuloplastywithacuteanatomic,haemodynamic,andclinicalout- . nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) trials. Circulation
.
comesinseveremitralvalveregurgitation.ESCHeartFail2020;7:3336(cid:2)3344. . 2015;131:1486(cid:2)1494;discussion1494.
.
620. GiallauriaF,DiLorenzoA,ParlatoA,TestaC,BobbioE,VigoritoC,CoatsAJS. .. 636.Abdul-RahimAH,PerezAC,MacIsaacRL,JhundPS,ClaggettBL,CarsonPE,
Individual patient datameta-analysisof theeffectsofthe CARILLONVR mitral .. KomajdaM,McKelvieRS,ZileMR,SwedbergK,YusufS,PfefferMA,Solomon
. contoursystem.ESCHeartFail2020;7:3383(cid:2)3391. . SD,LipGYH,LeesKR,McMurrayJJV,CandesartaninHeartfailureAssessment
.
621. LipieckiJ,FahratH,MonzyS,CaillotN,SiminiakT,JohnsonT,VogtS,Stark . of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and
.
MA,GoldbergSL.Long-termprognosisofpatientstreatedbycoronarysinus- .. the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve)
.
based percutaneous annuloplasty: single centre experience. ESC Heart Fail . SteeringCommittees.Riskofstrokeinchronicheartfailurepatientswithpre-
.
2020;7:3329(cid:2)3335. . servedejectionfraction,butwithoutatrialfibrillation:analysisoftheCHARM-
.
622. Ruf TF, Kreidel F, Tamm AR, Geyer M, Hahad O, Zirbs JC, Schwidtal BL, .. PreservedandI-Preservetrials.EurHeartJ2017;38:742(cid:2)750.
Beiras-Fernandez A, Witte KK, Munzel T, von Bardeleben RS. Transcatheter .. 637.MehraMR, VaduganathanM, FuM, FerreiraJP, Anker SD, Cleland JGF, Lam
.
indirectmitralannuloplastyinducesannularandleftatrialremodellinginsecon- . CSP,vanVeldhuisenDJ,ByraWM,SpiroTE,DengH,ZannadF,GreenbergB.
.
darymitralregurgitation.ESCHeartFail2020;7:1400(cid:2)1408. . Acomprehensiveanalysisoftheeffectsofrivaroxabanonstrokeortransient
.
623. SorajjaP,MoatN,BadhwarV,WaltersD,PaoneG,BetheaB,BaeR,DahleG, .. ischaemicattackinpatientswithheartfailure,coronaryarterydisease,andsinus
Mumtaz M, Grayburn P, Kapadia S, Babaliaros V, Guerrero M, Satler L, .. rhythm:theCOMMANDERHFtrial.EurHeartJ2019;40:3593(cid:2)3602.
.
Thourani V, Bedogni F, Rizik D, Denti P, Dumonteil N, Modine T, Sinhal A, . 638.KotechaD,ChudasamaR,LaneDA,KirchhofP,LipGY.Atrialfibrillationand
.
ChuangML,PopmaJJ,BlankeP,LeipsicJ,MullerD.Initialfeasibilitystudyofa .. heart failure due to reduced versus preserved ejection fraction: a systematic
new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol .. review and meta-analysis of death and adverse outcomes. Int J Cardiol
.
2019;73:1250(cid:2)1260. . 2016;203:660(cid:2)666.
.
624. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, . 639.AdelborgK,SzepligetiS,SundbollJ,Horvath-PuhoE,HendersonVW,Ording
.
MillerVM,NishimuraRA.Nationaltrendsandoutcomesinisolatedtricuspid .. A, Pedersen L, Sorensen HT. Risk of stroke in patients with heart failure: a
valvesurgery.JAmCollCardiol2017;70:2953(cid:2)2960. .. population-based30-yearcohortstudy.Stroke2017;48:1161(cid:2)1168.
.
625. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, . 640.Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA,
.
Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, . Roger VL. Ischemic stroke after heart failure: a community-based study. Am
.
DeuschlF,Estevez-LoureiroR,FamN,FrerkerC,GavazzoniM,HausleiterJ, .. HeartJ2006;152:102(cid:2)109.
Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, .. 641.HommaS,ThompsonJL,PullicinoPM,LevinB,FreudenbergerRS,TeerlinkJR,
.
Lauten A, Monivas V, Mehr M, Muntane-Carol G, Nazif T, Nickening G, . AmmonSE,GrahamS,SaccoRL,MannDL,MohrJP,MassieBM,LabovitzAJ,
.
PedrazziniG,PhilipponF,PozzoliA,PrazF,PuriR,Rodes-CabauJ,SchaferU, .. AnkerSD,LokDJ,PonikowskiP,EstolCJ,LipGY,DiTullioMR,SanfordAR,
SchoferJ,SievertH,TangGHL,ThieleH,TopilskyY,RommelKP,DelgadoV, .. Mejia V, Gabriel AP, del Valle ML, Buchsbaum R, WARCEF Investigators.
.
VahanianA,VonBardelebenRS,WebbJG,WeberM,WindeckerS,WinkelM, . Warfarinandaspirininpatientswithheartfailureandsinusrhythm.NEnglJ
.
Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F. . Med2012;366:1859(cid:2)1869.
.
Transcatheter versus medical treatment of patients with symptomatic severe .. 642.HopperI,SkibaM,KrumH.Updatedmeta-analysisonantithrombotictherapy
tricuspidregurgitation.JAmCollCardiol2019;74:2998(cid:2)3008. .. inpatientswithheartfailureandsinusrhythm.EurJHeartFail2013;15:69(cid:2)78. .
626. RapsomanikiE,TimmisA,GeorgeJ,Pujades-RodriguezM,ShahAD,DenaxasS, . 643.BauersachsJ,KonigT,vanderMeerP,PetrieMC,Hilfiker-KleinerD,Mbakwem
.
White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, .. A,HamdanR,JacksonAM,ForsythP,deBoerRA,MuellerC,LyonAR,Lund
HemingwayH.Bloodpressureandincidenceoftwelvecardiovasculardiseases: .. LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Seferovic
. lifetimerisks,healthylife-yearslost,andage-specificassociationsin1.25million . PM,JohnsonMR,MebazaaA,SliwaK.Pathophysiology,diagnosisandmanage-
.
people.Lancet2014;383:1899(cid:2)1911. . ment of peripartum cardiomyopathy: a position statement from the Heart .
627. CohnJN,PfefferMA,RouleauJ,SharpeN,SwedbergK,StraubM,WiltseC, .. Failure Association of the European Society of Cardiology Study Group on
WrightTJ,MOXCONInvestigators.Adversemortalityeffectofcentralsympa- .. peripartumcardiomyopathy.EurJHeartFail2019;21:827(cid:2)843.
.
theticinhibitionwithsustained-releasemoxonidineinpatientswithheartfailure . 644.Singh DP, Patel H. Left ventricular non-compaction cardiomyopathy. In:
. (MOXCON).EurJHeartFail2003;5:659(cid:2)667. . StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021; PMID
.
628. Kato S, Onishi K, Yamanaka T, Takamura T, Dohi K, Yamada N, Wada H, .. 30725710.
Nobori T, Ito M. Exaggerated hypertensive response to exercise in patients .. 645.SubahiA,HassanAAI,AbubakarH,IbrahimW.Isolatedleftventricularnon-
.
withdiastolicheartfailure.HypertensRes2008;31:679(cid:2)684. . compaction(LVNC)andrecurrentstrokes:toanticoagulateornottoanticoa-
.
629. UijlA,SavareseG,VaartjesI,DahlstromU,BrugtsJJ,LinssenGCM,vanEmpel .. gulate,thatisthequestion.BMJCaseRep2017;2017:bcr2017220954.
V, Brunner-La Rocca HP, Asselbergs FW, Lund LH, Hoes AW, Koudstaal S. .. 646.Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J,
.
Identificationofdistinctphenotypicclustersinheartfailurewithpreservedejec- . Paulus WJ,Komajda M, Cosentino F, deBoer RA,FarmakisD, Doehner W,
.
tionfraction.EurJHeartFail2021;23:973(cid:2)982. . Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J,
.
630. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering .. Mebazaa A, Mamas MA, Tschope C, Hoes AW, Seferovic JP, Logue J,
treatmentoncardiovascularoutcomesandmortality:14-effectsofdifferent .. McDonaghT,RileyJP,MilinkovicI,PolovinaM,vanVeldhuisenDJ,LainscakM,
.
classesofantihypertensivedrugsinolderandyoungerpatients:overviewand . MaggioniAP,RuschitzkaF,McMurrayJJV.Type2diabetesmellitusandheart
.
meta-analysis.JHypertens2018;36:1637(cid:2)1647. .. failure: a position statement from the Heart Failure Association of the
631. Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sorensen T, Byrne C, .. EuropeanSocietyofCardiology.EurJHeartFail2018;20:853(cid:2)872.
.
Almarzooq Z, Olesen TB, Olsen MH, Bhatt DL. Prevention of heart failure . 647.SeferovicPM,CoatsAJS,PonikowskiP,FilippatosG,HuelsmannM,JhundPS,
.
eventswithintensiveversusstandardbloodpressureloweringacrossthespec- . PolovinaMM,KomajdaM,SeferovicJ,SariI,CosentinoF,AmbrosioG,Metra
.
trumofkidneyfunctionandalbuminuria:aSPRINTsubstudy.EurJHeartFail .. M,PiepoliM,ChioncelO,LundLH,ThumT,DeBoerRA,MullensW,Lopatin
2021;23:384(cid:2)392. . Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 118 ---
3716 ESCGuidelines
.
.
GMC.EuropeanSocietyofCardiology/HeartFailureAssociationpositionpaper . heartfailurepatientswithandwithoutdiabetes(LIVE)-amulticentre,double-
.
ontheroleandsafetyofnewglucose-loweringdrugsinpatientswithheartfail- . blind,randomised,placebo-controlledtrial.EurJHeartFail2017;19:69(cid:2)77.
.
ure.EurJHeartFail2020;22:196(cid:2)213. .. 662.MarguliesKB,HernandezAF,RedfieldMM,GivertzMM,OliveiraGH,ColeR,
648. CosentinoF, CannonCP, Cherney DZI, Masiukiewicz U,Pratley R, Dagogo- .. MannDL,WhellanDJ,KiernanMS,FelkerGM,McNultySE,AnstromKJ,Shah
.
JackS,FrederichR,CharbonnelB,MancusoJ,ShihWJ,TerraSG,CaterNB, . MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research
.
GantzI,McGuireDK,VERTISCVInvestigators.Efficacyofertugliflozinonheart .. Network.Effectsofliraglutideonclinicalstabilityamongpatientswithadvanced
failure-relatedeventsinpatientswithtype2diabetesmellitusandestablished .. heart failure and reduced ejection fraction: a randomized clinical trial. JAMA
.
atheroscleroticcardiovasculardisease:resultsoftheVERTISCVtrial.Circulation . 2016;316:500(cid:2)508.
.
2020;142:2205(cid:2)2215. . 663.Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S, ORIGIN
.
649. McGuireDK,ShihWJ,CosentinoF,CharbonnelB,CherneyDZI,Dagogo-Jack .. Investigators.Effectofbasalinsulinglargineonfirstandrecurrentepisodesof
S,PratleyR,GreenbergM,WangS,HuyckS,GantzI,TerraSG,Masiukiewicz .. heartfailurehospitalization:theORIGINtrial(OutcomeReductionWithInitial
.
U,CannonCP.AssociationofSGLT2inhibitorswithcardiovascularandkidney . GlargineIntervention).Circulation2018;137:88(cid:2)90.
.
outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol . 664.CosmiF, ShenL,MagnoliM, AbrahamWT, AnandIS,ClelandJG,CohnJN,
.
2021;6:148(cid:2)158. .. Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS,
.
650. SeferovicPM,PonikowskiP,AnkerSD,BauersachsJ,ChioncelO,ClelandJGF, . KjekshusJ,KoberL,LeporeV,LucisanoG,MaggioniAP,MassonS,McMurray
.
deBoerRA,DrexelH,BenGalT,HillL,JaarsmaT,JankowskaEA,AnkerMS, . JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R,
. LainscakM,LewisBS,McDonaghT,MetraM,MilicicD,MullensW,PiepoliMF, .. Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with
Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. .. worseoutcomeinpatientswithchronicheartfailureanddiabetes.EurJHeart
.
Clinical practice update on heart failure 2019:pharmacotherapy, procedures, . Fail2018;20:888(cid:2)895.
.
devicesandpatientmanagement.Anexpertconsensusmeetingreportofthe . 665.ShenL,RorthR,CosmiD,KristensenSL,PetrieMC,CosmiF,LatiniR,Kober
.
HeartFailureAssociationoftheEuropeanSocietyofCardiology. EurJHeart .. L,AnandIS,CarsonPE,GrangerCB,KomajdaM,McKelvieRS,SolomonSD,
Fail2019;21:1169(cid:2)1186. .. StaszewskyL,SwedbergK,HuynhT,ZileMR,JhundPS,McMurrayJJV.Insulin
.
651. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, . treatmentandclinicaloutcomesinpatientswithdiabetesandheartfailurewith
.
VanderlooSE,McAlisterFA.Comparativesafetyandeffectivenessofmetformin .. preservedejectionfraction.EurJHeartFail2019;21:974(cid:2)984.
inpatientswithdiabetesmellitusandheartfailure:systematicreviewofobser- .. 666.TzoulakiI,MolokhiaM,CurcinV,LittleMP,MillettCJ,NgA,HughesRI,Khunti
.
vationalstudiesinvolving34,000patients.CircHeartFail2013;6:395(cid:2)402. . K,WilkinsMR,MajeedA,ElliottP.Riskofcardiovasculardiseaseandallcause
.
652. AnderssonC,OlesenJB,HansenPR,WeekeP,NorgaardML,JorgensenCH, . mortality among patients with type 2 diabetes prescribed oral antidiabetes
.
Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, .. drugs:retrospectivecohortstudyusingUKgeneralpracticeresearchdatabase.
GislasonGH.Metformintreatmentisassociatedwithalowriskofmortalityin .. BMJ2009;339:b4731.
.
diabetic patients with heart failure: a retrospective nationwide cohort study. . 667.RoumieCL,MinJY,D’AgostinoMcGowanL,PresleyC,GrijalvaCG,Hackstadt
.
Diabetologia2010;53:2546(cid:2)2553. . AJ,HungAM,GreevyRA,ElasyT,GriffinMR.Comparativesafetyofsulfony-
.
653. SciricaBM,BhattDL,BraunwaldE,StegPG,DavidsonJ,HirshbergB,OhmanP, .. lureaandmetforminmonotherapyontheriskofheartfailure:acohortstudy.J
.
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, . AmHeartAssoc2017;6.
.
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 . 668.Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular
.
Steering Committee and Investigators. Saxagliptin and cardiovascular .. deathinpatientswithprediabetesandtype2diabetesgiventhiazolidinediones:
outcomes in patients with type 2 diabetes mellitus. N Engl J Med .. ameta-analysisofrandomisedclinicaltrials.Lancet2007;370:1129(cid:2)1136.
.
2013;369:1317(cid:2)1326. . 669.Vargas-UricoecheaH,Bonelo-PerdomoA.Thyroiddysfunctionandheartfail-
.
654. ZannadF,CannonCP,CushmanWC,BakrisGL,MenonV,PerezAT,FleckPR, . ure:mechanismsandassociations.CurrHeartFailRep2017;14:48(cid:2)58.
.
MehtaCR, KupferS,WilsonC,LamH,WhiteWB,EXAMINEInvestigators. .. 670.KannanL,ShawPA,MorleyMP,BrandimartoJ,FangJC,SweitzerNK,Cappola
Heart failure and mortality outcomes in patients with type 2 diabetes taking .. TP,CappolaAR.Thyroiddysfunctioninheartfailureandcardiovascularout-
.
alogliptinversusplaceboinEXAMINE:amulticentre,randomised,double-blind . comes.CircHeartFail2018;11:e005266.
.
trial.Lancet2015;385:2067(cid:2)2076. .. 671.SatoY,YoshihisaA,KimishimaY,KikoT,KannoY,YokokawaT,AbeS,Misaka
655. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, .. T,SatoT,OikawaM,KobayashiA,YamakiT,KuniiH,NakazatoK,TakeishiY.
.
KaufmanKD,KoglinJ,KornS,LachinJM,McGuireDK,PencinaMJ,StandlE, . LowT3syndromeisassociatedwithhighmortalityinhospitalizedpatientswith
.
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS . heartfailure.JCardFail2019;25:195(cid:2)203.
.
StudyGroup.Effectofsitagliptinoncardiovascularoutcomesintype2diabetes. .. 672.Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP,
NEnglJMed2015;373:232(cid:2)242. .. SattarN,AubertCE,AujeskyD,BauerDC,BaumgartnerC,BlumMR,Browne
.
656. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, . JP,ByrneS,ColletTH,DekkersOM,denElzenWPJ,DuPuyRS,EllisG,Feller
.
AlexanderJH,PencinaM,TotoRD,WannerC,ZinmanB,WoerleHJ,Baanstra . M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, .
D,PfarrE,SchnaidtS,MeinickeT,GeorgeJT,vonEynattenM,McGuireDK, .. LanghorneP,McCarthyG,McCarthyV,McConnachieA,McDadeM,Messow
CARMELINAInvestigators.Effectoflinagliptinvsplaceboonmajorcardiovas- .. M, O’Flynn A, O’Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C,
.
culareventsinadultswithtype2diabetesandhighcardiovascularandrenal . Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R,
. risk:theCARMELINArandomizedclinicaltrial.JAMA2019;321:69(cid:2)79. .. GusseklooJ,TRUSTStudyGroup.Thyroidhormonetherapyforolderadults
657. McMurrayJJV,PonikowskiP,BolliGB,LukashevichV,KozlovskiP,KothnyW, .. withsubclinicalhypothyroidism.NEnglJMed2017;376:2534(cid:2)2544.
.
LewseyJD,KrumH,VIVIDDTrialCommitteesandInvestigators.Effectsofvil- . 673.FellerM,SnelM,MoutzouriE,BauerDC,deMontmollinM,AujeskyD,FordI, .
dagliptinonventricularfunctioninpatientswithtype2diabetesmellitusand . Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R,
.
heart failure: a randomized placebo-controlled trial. JACC Heart Fail .. RodondiN,DekkersOM.Associationofthyroidhormonetherapywithquality
2018;6:8(cid:2)17. .. oflifeandthyroid-relatedsymptomsinpatientswithsubclinicalhypothyroidism:
.
658. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 . asystematicreviewandmeta-analysis.JAMA2018;320:1349(cid:2)1359.
.
inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial .. 674.PeetersRP.Subclinicalhypothyroidism.NEnglJMed2017;376:2556(cid:2)2565.
infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract .. 675.PackerM,LamCSP,LundLH,MaurerMS,BorlaugBA.Characterizationofthe
.
2019;150:8(cid:2)16. . inflammatory-metabolic phenotype of heart failure and a preserved ejection
.
659. SavareseG,D’AmoreC,FedericiM,DeMartinoF,DellegrottaglieS,Marciano . fraction:ahypothesistoexplaininfluenceofsexontheevolutionandpotential
.
C,FerrazzanoF,LoscoT,LundLH,TrimarcoB,RosanoGM,Perrone-FilardiP. .. treatmentofthedisease.EurJHeartFail2020;22:1551(cid:2)1567.
Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked .. 676.ObokataM,ReddyYNV,PislaruSV,MelenovskyV,BorlaugBA.Evidencesup-
.
cotransporter-2inhibitorsoncardiovasculareventsinpatientswithtype2dia- . portingtheexistenceofadistinctobesephenotypeofheartfailurewithpre-
.
betesmellitus:ameta-analysis.IntJCardiol2016;220:595(cid:2)601. . servedejectionfraction.Circulation2017;136:6(cid:2)19.
.
660. KristensenSL,RorthR,JhundPS,DochertyKF,SattarN,PreissD,KoberL, .. 677.Rao VN, Fudim M, Mentz RJ, MichosED, Felker GM. Regional adiposity and
PetrieMC,McMurrayJJV.Cardiovascular,mortality,andkidneyoutcomeswith .. heart failure with preserved ejection fraction. Eur J Heart Fail
.
GLP-1receptoragonistsinpatientswithtype2diabetes:asystematicreview . 2020;22:1540(cid:2)1550.
.
and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol .. 678.CarboneS,LavieCJ,ArenaR.Obesityandheartfailure:focusontheobesity
2019;7:776(cid:2)785. .. paradox.MayoClinProc2017;92:266(cid:2)279.
.
661. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, . 679.HorwichTB,FonarowGC,ClarkAL.Obesityandtheobesityparadoxinheart
.
NilssonB,MollerJE,HjortJ,RasmussenJ,BoesgaardTW,SchouM,Videbaek . failure.ProgCardiovascDis2018;61:151(cid:2)156.
.
L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a .. 680.AdamopoulosC,MeyerP,DesaiRV,KaratzidouK,OvalleF,WhiteM,AbanI,
glucagon-likepeptide-1analogue,onleftventricularfunctioninstablechronic . LoveTE,DeedwaniaP,AnkerSD,AhmedA.Absenceofobesityparadoxin
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 119 ---
ESCGuidelines 3717
.
.
patientswithchronicheartfailureanddiabetesmellitus:apropensity-matched . failure:epidemiology,clinicalimplicationsandgapsinknowledge.EurJHeartFail
.
study.EurJHeartFail2011;13:200(cid:2)206. .. 2018;20:879(cid:2)887.
681. ZamoraE,LuponJ,EnjuanesC,Pascual-FigalD,deAntonioM,DomingoM, .. 700.FonsecaG,DosSantosMR,deSouzaFR,TakayamaL,RodriguesPereiraRM,
Comin-ColetJ,VilaJ,PenafielJ,FarreN,AlonsoN,SantesmasesJ,TroyaM, .. NegraoCE,AlvesMNN.Discriminatingsarcopeniainoverweight/obesemale
.
Bayes-GenisA.Nobenefitfromtheobesityparadoxfordiabeticpatientswith . patients with heart failure: the influence of body mass index. ESC Heart Fail
.
heartfailure.EurJHeartFail2016;18:851(cid:2)858. .. 2020;7:84(cid:2)91.
682. Piepoli MF, Corra U, Veglia F, Bonomi A, Salvioni E, Cattadori G, Metra M, .. 701.Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, Loncar G,
.
LombardiC,SinagraG,LimongelliG,RaimondoR,ReF,MagriD,Belardinelli . SpringerJ,DoehnerW,LainscakM,HasenfussG,AnkerSD,vonHaehlingS.
.
R,ParatiG,MinaC,ScardoviAB,GuazziM,CicoiraM,ScrutinioD,DiLenarda . Comparison of sarcopenia and cachexia in men with chronic heart failure:
.
A, Bussotti M, Frigerio M, Correale M, Villani GQ, Paolillo S, Passino C, .. resultsfromtheStudiesInvestigatingCo-morbiditiesAggravatingHeartFailure
AgostoniP,MECKIScoreResearchGroup.Exercisetolerancecanexplainthe .. (SICA-HF).EurJHeartFail2018;20:1580(cid:2)1587.
.
obesity paradox in patients with systolic heart failure: data from the MECKI . 702.FulsterS,TackeM,SandekA,EbnerN,TschopeC,DoehnerW,AnkerSD,
.
ScoreResearchGroup.EurJHeartFail2016;18:545(cid:2)553. .. von Haehling S.Muscle wasting inpatients with chronicheartfailure: results
683. Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, .. from the studies investigating co-morbidities aggravating heart failure (SICA-
.
Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, . HF).EurHeartJ2013;34:512(cid:2)519.
.
ZwindermanAH,ZannadF,DammanK,vanderMeerP,LangCC.Waist-to- . 703.SpringerJ,SpringerJI,AnkerSD.Musclewastingandsarcopeniainheartfailure
. hipratioandmortalityinheartfailure.EurJHeartFail2018;20:1269(cid:2)1277. .. andbeyond:update2017.ESCHeartFail2017;4:492(cid:2)498.
684. CarboneS,ElagiziA,LavieCJ.Obesityandmortalityriskinheartfailure:when .. 704.vonHaehlingS,EbnerN,DosSantosMR,SpringerJ,AnkerSD.Musclewasting
.
adiposetissuedistributionmatters.EurJHeartFail2018;20:1278(cid:2)1280. . and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol
.
685. PackerM.Domostpatientswithobesityortype2diabetes,andatrialfibrilla- . 2017;14:323(cid:2)341.
.
tion,alsohaveundiagnosedheartfailure?Acriticalconceptualframeworkfor .. 705.CaminitiG,VolterraniM,IellamoF,MarazziG,MassaroR,MiceliM,MammiC,
understandingmechanismsandimprovingdiagnosisandtreatment.EurJHeart .. PiepoliM,FiniM,RosanoGM.Effectoflong-actingtestosteronetreatmenton
.
Fail2020;22:214(cid:2)227. . functionalexercisecapacity,skeletalmuscleperformance,insulinresistance,and
.
686. VitaleC,JankowskaE,HillL,PiepoliM,DoehnerW,AnkerSD,LainscakM, .. baroreflex sensitivity in elderly patients with chronic heart failure a double-
Jaarsma T, Ponikowski P, Rosano GMC, Seferovic P, Coats AJ. Heart Failure .. blind, placebo-controlled, randomized study. J Am Coll Cardiol
.
Association/EuropeanSocietyofCardiologypositionpaperonfrailtyinpatients . 2009;54:919(cid:2)927.
.
withheartfailure.EurJHeartFail2019;21:1299(cid:2)1305. . 706.AnandIS,GuptaP.Anemiaandirondeficiencyinheartfailure:currentconcepts
.
687. DenfeldQE,Winters-StoneK,MuddJO,GelowJM,KurdiS,LeeCS.Theprev- .. andemergingtherapies.Circulation2018;138:80(cid:2)98.
alence of frailty in heart failure: a systematic review and meta-analysis. Int J .. 707.IorioA,SenniM,BarbatiG,GreeneSJ,PoliS,ZambonE,DiNoraC,CioffiG,
.
Cardiol2017;236:283(cid:2)289. . Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and prognostic
.
688. Bielecka-Dabrowa A, Ebner N, Dos Santos MR, Ishida J, Hasenfuss G, von . impactofnon-cardiacco-morbiditiesinheartfailureoutpatientswithpreserved
.
HaehlingS.Cachexia,musclewasting,andfrailtyincardiovasculardisease.EurJ .. and reduced ejection fraction: a community-based study. Eur J Heart Fail
.
HeartFail2020;22:2314(cid:2)2326. . 2018;20:1257(cid:2)1266.
.
689. Khan H, Kalogeropoulos AP, Georgiopoulou VV, Newman AB, Harris TB, . 708.Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron
.
RodondiN,BauerDC,KritchevskySB,ButlerJ.Frailtyandriskforheartfailure .. homeostasisinchronicheartfailure:prevalence,predictors,andrelationtoane-
in older adults: the health, aging, and body composition study. Am Heart J .. mia,exercisecapacity,andsurvival.JAmCollCardiol2011;58:1241(cid:2)1251.
.
2013;166:887(cid:2)894. . 709.McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P,
.
690. WoodsNF,LaCroixAZ,GraySL,AragakiA,CochraneBB,BrunnerRL,Masaki . Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantahti-Maaroos H,
.
K,MurrayA,NewmanAB,Women’sHealthInitiative.Frailty:emergenceand .. TaylorJ,Comin-ColetJ.Screening,diagnosisandtreatmentofirondeficiencyin
consequencesinwomenaged65andolderintheWomen’sHealthInitiative .. chronicheartfailure: puttingthe2016EuropeanSocietyofCardiologyheart
.
ObservationalStudy.JAmGeriatrSoc2005;53:1321(cid:2)1330. . failureguidelinesintoclinicalpractice.EurJHeartFail2018;20:1664(cid:2)1672.
.
691. VidanMT,Blaya-NovakovaV,SanchezE,OrtizJ,Serra-RexachJA,BuenoH. .. 710.CappelliniMD,Comin-ColetJ,deFranciscoA,DignassA,DoehnerW,Lam
Prevalence and prognostic impact of frailty and its components in non- .. CS, Macdougall IC, Rogler G, Camaschella C, Kadir R,Kassebaum NJ, Spahn
.
dependent elderly patients with heart failure. Eur J Heart Fail . DR, Taher AT, Musallam KM, IRON CORE Group. Iron deficiency across
.
2016;18:869(cid:2)875. . chronic inflammatory conditions: international expert opinion on definition,
.
692. DewanP,JacksonA,JhundPS,ShenL,FerreiraJP,PetrieMC,AbrahamWT, .. diagnosis,andmanagement.AmJHematol2017;92:1068(cid:2)1078.
DesaiAS,DicksteinK,KoberL,PackerM,RouleauJL,SolomonSD,Swedberg .. 711.LopezA,CacoubP,MacdougallIC,Peyrin-BirouletL.Irondeficiencyanaemia.
.
K,ZileMR,McMurrayJJV.Theprevalenceandimportanceoffrailtyinheartfail- . Lancet2016;387:907(cid:2)916.
.
ure with reduced ejection fraction – an analysis of PARADIGM-HF and . 712.Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A, .
ATMOSPHERE.EurJHeartFail2020;22:2123(cid:2)2133. .. Rozentryt P, van der Meer P, Comin-Colet J, von Haehling S, Kosmala W,
693. Sanders NA, Supiano MA, Lewis EF, Liu J, Claggett B, Pfeffer MA, Desai AS, .. Przewlocka-KosmalaM,BanasiakW,NowakJ,VoorsAA,AnkerSD,Cleland
.
SweitzerNK,SolomonSD,FangJC.Thefrailtysyndromeandoutcomesinthe . JGF,PonikowskiP,JankowskaEA.Highsolubletransferrinreceptorinpatients
. TOPCATtrial.EurJHeartFail2018;20:1570(cid:2)1577. .. withheartfailure:ameasureofirondeficiencyandastrongpredictorofmor-
694. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, .. tality.EurJHeartFail2020Oct27.doi:10.1002/ejhf.2036[Epubaheadofprint].
.
Kalantar-ZadehK,LochsH,MantovaniG,MarksD,MitchWE,MuscaritoliM, . 713.RochaBML,CunhaGJL,FalcaoMenezesLF.Theburdenofirondeficiencyin .
NajandA,PonikowskiP,RossiFanelliF,SchambelanM,ScholsA,SchusterM, . heartfailure:therapeuticapproach.JAmCollCardiol2018;71:782(cid:2)793.
.
Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr .. 714.KlipIT,Comin-ColetJ,VoorsAA,PonikowskiP,EnjuanesC,BanasiakW,Lok
2008;27:793(cid:2)799. .. DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P,
.
695. LoncarG,SpringerJ,AnkerM,DoehnerW,LainscakM.Cardiaccachexia:hic . JankowskaEA.Irondeficiencyinchronicheartfailure:aninternationalpooled
.
etnunc.JCachexiaSarcopeniaMuscle2016;7:246(cid:2)260. .. analysis.AmHeartJ2013;165:575(cid:2)582.e3.
696. vonHaehlingS,LainscakM,SpringerJ,AnkerSD.Cardiaccachexia:asystematic .. 715.JankowskaEA,RozentrytP,WitkowskaA,NowakJ,HartmannO,Ponikowska
.
overview.PharmacolTher2009;121:227(cid:2)252. . B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ,
.
697. AnkerMS,HolcombR,MuscaritoliM,vonHaehlingS,HaverkampW,JatoiA, . AnkerSD,PonikowskiP.Irondeficiency:anominoussigninpatientswithsys-
.
MorleyJE,StrasserF,LandmesserU,CoatsAJS,AnkerSD.Orphandiseasesta- .. tolicchronicheartfailure.EurHeartJ2010;31:1872(cid:2)1880.
tus of cancer cachexia in the USA and in the European Union: a systematic .. 716.von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD.
.
review.JCachexiaSarcopeniaMuscle2019;10:22(cid:2)34. . Irondeficiencyandcardiovasculardisease.NatRevCardiol2015;12:659(cid:2)669.
.
698. BauerJ,MorleyJE,ScholsA,FerrucciL,Cruz-JentoftAJ,DentE,BaracosVE, . 717.StugiewiczM,TkaczyszynM,KaszturaM,BanasiakW,PonikowskiP,Jankowska
.
CrawfordJA,DoehnerW,HeymsfieldSB,JatoiA,Kalantar-ZadehK,Lainscak .. EA. The influence of iron deficiency on the functioning of skeletal muscles:
M,LandiF,LavianoA,MancusoM,MuscaritoliM,PradoCM,StrasserF,von .. experimental evidence and clinical implications. Eur J Heart Fail
.
Haehling S, Coats AJS, Anker SD. Sarcopenia: a time for action. An SCWD . 2016;18:762(cid:2)773.
.
positionpaper.JCachexiaSarcopeniaMuscle2019;10:956(cid:2)961. .. 718.Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von
699. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, .. HaehlingS,MacdougallIC,WeissG,McMurrayJJ,AnkerSD,GheorghiadeM,
.
FarmakisD,Lopez-FernandezT,LainscakM,PudilR,RuschitskaF,SeferovicP, . Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J
.
FilippatosG,CoatsA,SuterT,VonHaehlingS,CiardielloF,deBoerRA,Lyon . 2013;34:827(cid:2)834.
.
AR,TocchettiCG,HeartFailureAssociationCardio-OncologyStudyGroupof .. 719.Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP,
the European Society of Cardiology. Cancer diagnosis in patients with heart . McMurrayJJ,O’ConnorC,PfefferMA,Solomon SD,SunY,TenderaM,van
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 120 ---
3718 ESCGuidelines
.
.
VeldhuisenDJ,RED-HFCommittees,RED-HFInvestigators.Treatmentofane- . 737.Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G,
.
mia with darbepoetin alfa in systolic heart failure. N Engl J Med . HauskeSJ,BrueckmannM,PfarrE,SchneeJ,WannerC,PackerM.Cardiacand
.
2013;368:1210(cid:2)1219. .. kidneybenefitsofempagliflozininheartfailureacrossthespectrumofkidney
720. AnkerSD,CominColetJ,FilippatosG,WillenheimerR,DicksteinK,Drexler .. function:insightsfromEMPEROR-Reduced.Circulation2021;143:310(cid:2)321.
.
H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von . 738.HeerspinkHJL,StefanssonBV,Correa-RotterR,ChertowGM,GreeneT,Hou
.
EisenhartRotheB,PocockSJ,Poole-WilsonPA,PonikowskiP,FAIR-HFTrial .. FF,MannJFE,McMurrayJJV,LindbergM,RossingP,SjostromCD,TotoRD,
Investigators.Ferriccarboxymaltoseinpatientswithheartfailureandirondefi- .. LangkildeAM,WheelerDC,DAPA-CKDTrialCommitteesandInvestigators.
.
ciency.NEnglJMed2009;361:2436(cid:2)2448. . Dapagliflozin in patients with chronic kidney disease. N Engl J Med
.
721. Comin-ColetJ,LainscakM,DicksteinK,FilippatosGS,JohnsonP,LuscherTF, . 2020;383:1436(cid:2)1446.
.
MoriC,Willenheimer R, PonikowskiP,Anker SD.Theeffectof intravenous .. 739.Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B,
ferriccarboxymaltoseonhealth-relatedqualityoflifeinpatientswithchronic .. CarubelliV,BugattiS,LombardiC,CotterG,DeiCas L.Isworseningrenal
.
heartfailureandirondeficiency:asubanalysisoftheFAIR-HFstudy.EurHeartJ . functionanominousprognosticsigninpatientswithacuteheartfailure?The
.
2013;34:30(cid:2)38. .. role of congestion and its interaction with renal function. Circ Heart Fail
722. PonikowskiP,vanVeldhuisenDJ,Comin-ColetJ,ErtlG,KomajdaM,MareevV, .. 2012;5:54(cid:2)62.
.
McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, . 740.Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early
.
Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators. Beneficial . worseningrenalfunctionafterinitiationofangiotensin-convertingenzymeinhib-
. effects of long-term intravenous iron therapy with ferric carboxymaltose in .. itor therapy in patients with cardiac dysfunction. Circ Heart Fail
patients with symptomatic heart failure and iron deficiency. Eur Heart J .. 2011;4:685(cid:2)691.
.
2015;36:657(cid:2)668. . 741.DammanK,TangWH,FelkerGM,LassusJ,ZannadF,KrumH,McMurrayJJ.
.
723. vanVeldhuisenDJ,PonikowskiP,vanderMeerP,MetraM,BohmM,Doletsky . Currentevidenceontreatmentofpatientswithchronicsystolicheartfailure
.
A,VoorsAA,MacdougallIC,AnkerSD,RoubertB,ZakinL,Cohen-SolalA, .. andrenalinsufficiency:practicalconsiderationsfrompublisheddata.JAmColl
EFFECT-HFInvestigators.Effectofferriccarboxymaltoseonexercisecapacity .. Cardiol2014;63:853(cid:2)871.
.
in patients with chronic heart failure and iron deficiency. Circulation . 742.House AA. Management of heart failure in advancing CKD: core curriculum
.
2017;136:1374(cid:2)1383. .. 2018.AmJKidneyDis2018;72:284(cid:2)295.
724. JankowskaEA,TkaczyszynM,SuchockiT,DrozdM,vonHaehlingS,Doehner .. 743.Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Bohm M,
.
W,BanasiakW,FilippatosG,AnkerSD,PonikowskiP.Effectsofintravenous . McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von
.
irontherapyiniron-deficientpatientswithsystolicheartfailure:ameta-analysis . LuederTG,RigbyAS,AnderssonB,KjekshusJ,WedelH,RuschitzkaF,Cleland
.
ofrandomizedcontrolledtrials.EurJHeartFail2016;18:786(cid:2)795. .. JGF, Damman K, Redon J, Coats AJS, Beta-Blockers in Heart Failure
725. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, .. Collaborative Group. Impact of renal impairment on beta-blocker efficacy in
.
RuschitzkaF,LuscherTF,ArutyunovGP,MotroM,MoriC,RoubertB,Pocock . patientswithheartfailure.JAmCollCardiol2019;74:2893(cid:2)2904.
.
SJ,PonikowskiP.Effectsofferriccarboxymaltoseonhospitalisationsandmor- . 744.Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M,
.
tality rates in iron-deficient heart failure patients: an individual patient data .. Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O’Meara E,
.
meta-analysis.EurJHeartFail2018;20:125(cid:2)133. . ShouM,TereshchenkoS,VermaS,VinhPN,InzucchiSE,KoberL,Kosiborod
.
726. FilippatosG,FarmakisD,ColetJC,DicksteinK,LuscherTF,WillenheimerR, . MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM,
.
ParissisJ,GaudesiusG,MoriC,vonEisenhartRotheB,GreenlawN,FordI, .. SjostrandM,McMurrayJJV.Efficacyofdapagliflozinonrenalfunctionandout-
Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient .. comesinpatientswithheartfailurewithreducedejectionfraction:resultsof
.
chronic heart failure patients with and without anaemia: a subanalysis of the . DAPA-HF.Circulation2021;143:298(cid:2)309.
.
FAIR-HFtrial.EurJHeartFail2013;15:1267(cid:2)1276. . 745.BoerrigterG,Costello-BoerrigterLC,AbrahamWT,SuttonMG,HeubleinDM,
.
727. vonHaehlingS,EbnerN,EvertzR,PonikowskiP,AnkerSD.Irondeficiencyin .. KrugerKM,HillMR,McCulloughPA,BurnettJCJr.Cardiacresynchronization
heartfailure:anoverview.JACCHeartFail2019;7:36(cid:2)46. .. therapyimprovesrenalfunctioninhumanheartfailurewithreducedglomerular
.
728. LewisGD,MalhotraR,HernandezAF,McNultySE,SmithA,FelkerGM,Tang . filtrationrate.JCardFail2008;14:539(cid:2)546.
.
WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, .. 746.RoehmB,VestAR,WeinerDE.Leftventricularassistdeviceskidneydisease
WhellanD,AnstromKJ,ShahMR,Desvigne-NickensP,ButlerJ,BraunwaldE, .. anddialysis.AmJKidneyDis2018;71:257(cid:2)266.
.
NHLBIHeartFailureClinicalResearchNetwork.Effectoforalironrepletion . 747.GoldenbergI,MossAJ,McNittS,ZarebaW,AndrewsML,HallWJ,Greenberg
.
onexercisecapacityinpatientswithheartfailurewithreducedejectionfraction . H, Case RB, Multicenter Automatic Defibrillator Implantation Trial-II
.
and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA .. Investigators.Relationsamongrenalfunction,riskofsuddencardiacdeath,and
2017;317:1958(cid:2)1966. .. benefitoftheimplantedcardiacdefibrillatorinpatientswithischemicleftven-
.
729. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang . triculardysfunction.AmJCardiol2006;98:485(cid:2)490.
.
WHW,SkouriH,VerbruggeFH,OrsoF,HillL,UralD,LainscakM,Rossignol . 748.GoldenbergI,YounisA,AktasMK,McNittS,ZarebaW,KutyifaV.Competing .
P,MetraM,MebazaaA,SeferovicP,RuschitzkaF,CoatsA.Evaluationofkidney .. riskanalysisofventriculararrhythmiaeventsinheartfailurepatientswithmod-
functionthroughouttheheartfailuretrajectory–apositionstatementfromthe .. eratelycompromisedrenaldysfunction.Europace2020;22:1384(cid:2)1390.
.
HeartFailureAssociationoftheEuropeanSocietyofCardiology. EurJHeart . 749.Coiro S, Girerd N, Sharma A, Rossignol P, Tritto I, Pitt B, Pfeffer MA,
. Fail2020;22:584(cid:2)603. .. McMurrayJJV,AmbrosioG,DicksteinK,MossA,ZannadF.Associationofdia-
730. TerMaatenJM,DammanK,VerhaarMC,PaulusWJ,DunckerDJ,ChengC,van .. betesandkidneyfunctionaccordingtoageandsystolicfunctionwiththeinci-
.
HeerebeekL,HillegeHL,LamCS,NavisG,VoorsAA.Connectingheartfailure . dence of sudden cardiac death and non-sudden cardiac death in myocardial .
withpreservedejectionfractionandrenaldysfunction:theroleofendothelial . infarctionsurvivorswithheartfailure.EurJHeartFail2019;21:1248(cid:2)1258.
.
dysfunctionandinflammation.EurJHeartFail2016;18:588(cid:2)598. .. 750.TeerlinkJR,DiazR,FelkerGM,McMurrayJJV,MetraM,SolomonSD,Adams
731. vanderPolA,vanGilstWH,VoorsAA,vanderMeerP.Treatingoxidative .. KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D,
.
stress in heart failure: past, present and future. Eur J Heart Fail . ClelandJGF,CorbalanR,Crespo-LeiroMG,DahlstromU,EcheverriaCorrea
.
2019;21:425(cid:2)435. .. LE,FangJC,FilippatosG,FonsecaC,GoncalvesovaE,GoudevAR,HowlettJG,
732. Lofman I,SzummerK,DahlstromU,JernbergT,LundLH.Associationswith .. Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E,
.
andprognosticimpactofchronickidneydiseaseinheartfailurewithpreserved, . ParkhomenkoA,PonikowskiP,RamiresFJA,SerpytisP,SliwaK,SpinarJ,Suter
.
mid-range,andreducedejectionfraction.EurJHeartFail2017;19:1606(cid:2)1614. . TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB,
.
733. LofmanI,SzummerK,EvansM,CarreroJJ,LundLH,JernbergT.Incidenceof, .. Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE,
associationswith andprognostic impactof worseningrenalfunctioninheart .. GALACTIC-HFInvestigators.Omecamtivmecarbilinchronicheartfailurewith
.
failure with different ejection fraction categories. Am J Cardiol . reducedejectionfraction:GALACTIC-HFbaselinecharacteristicsandcompari-
.
2019;124:1575(cid:2)1583. . sonwithcontemporaryclinicaltrials.EurJHeartFail2020;22:2160(cid:2)2171.
.
734. SchefoldJC,FilippatosG,HasenfussG,AnkerSD,vonHaehlingS.Heartfailure .. 751.UrsoC,BrucculeriS,CaimiG.Acid-baseandelectrolyteabnormalitiesinheart
and kidney dysfunction: epidemiology, mechanismsand management. Nat Rev .. failure:pathophysiologyandimplications.HeartFailRev2015;20:493(cid:2)503.
.
Nephrol2016;12:610(cid:2)623. . 752.ButlerJ,VijayakumarS,PittB.Needtorevisitheartfailuretreatmentguidelines
.
735. DammanK,ValenteMA,VoorsAA,O’ConnorCM,vanVeldhuisenDJ,Hillege .. for hyperkalaemia management during the use of mineralocorticoid receptor
HL.Renalimpairment,worseningrenalfunction,andoutcomeinpatientswith .. antagonists.EurJHeartFail2018;20:1247(cid:2)1251.
.
heartfailure:anupdatedmeta-analysis.EurHeartJ2014;35:455(cid:2)469. . 753.Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B,
.
736. BraunwaldE.Diabetes,heartfailure,andrenaldysfunction:theviciouscircles. . Solomon SD, Randomized Aldactone Evaluation Study (RALES) Investigators.
.
ProgCardiovascDis2019;62:298(cid:2)302. .. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 121 ---
ESCGuidelines 3719
.
.
patients with severe heart failure treated with a mineralocorticoid receptor . 770.Ferreira JP, Rossello X, Pocock SJ, Rossignol P, Claggett BL, Rouleau JL,
.
antagonist.CircHeartFail2014;7:573(cid:2)579. . SolomonSD,PittB,PfefferMA,ZannadF.Spironolactonedoseinheartfailure
.
754. RossignolP,DobreD,McMurrayJJ,SwedbergK,KrumH,vanVeldhuisenDJ, .. with preserved ejection fraction: findings from TOPCAT. Eur J Heart Fail
Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, .. 2020;22:1615(cid:2)1624.
.
determinants,andprognosticsignificanceofhyperkalemiaandworseningrenal . 771.VolterraniM,PerroneV,SangiorgiD,GiacominiE,IellamoF,DegliEspostiL,
.
functioninpatientswithheartfailurereceivingthemineralocorticoidreceptor .. LHUs Study Group. Effects of hyperkalaemia and non-adherence to renin-
antagonist eplerenone or placebo in addition to optimal medical therapy: .. angiotensin-aldosteronesysteminhibitortherapyinpatientswithheartfailure
.
resultsfromtheEplerenoneinMildPatientsHospitalizationandSurvivalStudy . inItaly:apropensity-matchedstudy.EurJHeartFail2020;22:2049(cid:2)2055.
.
inHeartFailure(EMPHASIS-HF).CircHeartFail2014;7:51(cid:2)58. . 772.Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ,
.
755. NunezJ,Bayes-GenisA,ZannadF,RossignolP,NunezE,BodiV,MinanaG, .. InvestigatorsPEARL-HF.EvaluationoftheefficacyandsafetyofRLY5016,apol-
Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Lupon J, .. ymericpotassiumbinder,inadouble-blind,placebo-controlledstudyinpatients
.
HusserO,MetraM,SanchisJ.Long-termpotassiummonitoringanddynamics . withchronicheartfailure(thePEARL-HF)trial.EurHeartJ2011;32:820(cid:2)828.
.
inheartfailureandriskofmortality.Circulation2018;137:1320(cid:2)1330. .. 773.Pitt B, Bakris GL, Weir MR,Freeman MW, Lainscak M, Mayo MR, Garza D,
756. Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, .. Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for
.
BennettH,McEwanP.Serumpotassiumandclinicaloutcomesinheartfailure . hyperkalaemiatreatmentinpatientswithmildheartfailureanddiabeticnephr-
.
patients:resultsofriskcalculationsin21334patientsintheUK.ESCHeartFail . opathy on angiotensin-converting enzymes/angiotensin receptor blockers:
. 2019;6:280(cid:2)290. .. resultsfromAMETHYST-DN.ESCHeartFail2018;5:592(cid:2)602.
757. Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, .. 774.AgarwalR,RossignolP,RomeroA,GarzaD,MayoMR,WarrenS,MaJ,White
.
Dahlstrom U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH. . WB, Williams B. Patiromer versus placebo to enable spironolactone use in
.
Association between potassium level and outcomes in heart failure with . patients with resistant hypertension and chronic kidney disease (AMBER): a
.
reduced ejection fraction: a cohort study from the Swedish Heart Failure .. phase 2, randomised, double-blind, placebo-controlled trial. Lancet
Registry.EurJHeartFail2020;22:1390(cid:2)1398. .. 2019;394:1540(cid:2)1550.
.
758. RossignolP,LainscakM,Crespo-LeiroMG,LarocheC,PiepoliMF,FilippatosG, . 775.RossignolP,WilliamsB,MayoMR,WarrenS,ArthurS,AckoureyG,White
.
RosanoGMC,SavareseG,AnkerSD,SeferovicPM,RuschitzkaF,CoatsAJS, .. WB, Agarwal R. Patiromer versus placebo to enable spironolactone use in
MebazaaA,McDonaghT,SahuquilloA,PencoM,MaggioniAP,LundLH,Heart .. patients with resistant hypertension and chronic kidney disease (AMBER):
.
Failure Long-Term Registry Investigators Group. Unravelling the interplay . results in the pre-specified subgroup with heart failure. Eur J Heart Fail
.
between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and . 2020;22:1462(cid:2)1471.
.
clinicaloutcomes.Datafrom9222chronicheartfailurepatients oftheESC- .. 776.Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G,
HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail .. Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M, Patiromer
.
2020;22:1378(cid:2)1389. . Investigators.Evaluationofanindividualizeddosetitrationregimenofpatiromer
.
759. AhmedA,ZannadF,LoveTE,TallajJ,GheorghiadeM,EkundayoOJ,PittB.A . topreventhyperkalaemiainpatientswithheartfailureandchronickidneydis-
.
propensity-matchedstudyoftheassociationoflowserumpotassiumlevelsand .. ease.ESCHeartFail2018;5:257(cid:2)266.
.
mortalityinchronicheartfailure.EurHeartJ2007;28:1334(cid:2)1343. . 777.Ali W, Bakris G. Evolution of patiromer use: a review. Curr Cardiol Rep
.
760. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, . 2020;22:94.
.
Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, .. 778.Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M.
PonikowskiP,SavareseG,SchmidtTA,SeferovicP,WassmannS,WaltherT, .. Hyponatremiainheartfailure.HeartFailRev2009;14:59(cid:2)63.
.
LewisBS.Expertconsensusdocumentonthemanagementofhyperkalaemiain . 779.Rodriguez M, Hernandez M, Cheungpasitporn W, Kashani KB, Riaz I,
.
patientswithcardiovasculardiseasetreatedwithreninangiotensinaldosterone . RangaswamiJ,HerzogE,GuglinM,KrittanawongC.Hyponatremiainheartfail-
.
system inhibitors: coordinated by the Working Group on Cardiovascular .. ure:pathogenesisandmanagement.CurrCardiolRev2019;15:252(cid:2)261.
PharmacotherapyoftheEuropeanSocietyofCardiology.EurHeartJCardiovasc .. 780.AlbertNM,NutterB,ForneyJ,SlifcakE,TangWH.Arandomizedcontrolled
.
Pharmacother2018;4:180(cid:2)188. . pilot study of outcomes of strict allowance of fluid therapy in hyponatremic
.
761. FerreiraJP,MogensenUM,JhundPS,DesaiAS,RouleauJL,ZileMR,Rossignol .. heartfailure(SALT-HF).JCardFail2013;19:1(cid:2)9.
P,ZannadF,PackerM,SolomonSD, McMurrayJJV.Serum potassiuminthe .. 781.Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, 3rd, Chiong JR,
.
PARADIGM-HFtrial.EurJHeartFail2020;22:2056(cid:2)2064. . DastaJF.Currentmanagementofhyponatremiainacuteheartfailure:areport
.
762. Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, SwedbergK, van . from the Hyponatremia Registry for Patients With Euvolemic and
.
Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B. Cardiovascular risk .. HypervolemicHyponatremia(HNRegistry).JAmHeartAssoc2017;6:e005261.
associatedwithserumpotassiuminthecontextofmineralocorticoidreceptor .. 782.KonstamMA,GheorghiadeM,BurnettJCJr,GrinfeldL,MaggioniAP,Swedberg
.
antagonistuseinpatientswithheartfailureandleftventriculardysfunction.Eur . K,UdelsonJE,ZannadF,CookT,OuyangJ,ZimmerC,OrlandiC,Efficacyof
.
JHeartFail2020;22:1402(cid:2)1411. . Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan .
763. DesaiAS,LiuJ,PfefferMA,ClaggettB,FlegJ,LewisEF,McKinlayS,O’MearaE, .. (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for
ShahSJ,SweitzerNK,SolomonS,PittB.Incidenthyperkalemia,hypokalemia, .. worsening heart failure: the EVEREST Outcome Trial. JAMA
.
andclinicaloutcomesduringspironolactonetreatmentofheartfailurewithpre- . 2007;297:1319(cid:2)1331.
. served ejection fraction: analysis of the TOPCAT trial. J Card Fail .. 783.FelkerGM,MentzRJ,ColeRT,AdamsKF,EgnaczykGF,FiuzatM,PatelCB,
2018;24:313(cid:2)320. .. EcholsM, Khouri MG, TaurasJM, Gupta D, Monds P, Roberts R, O’Connor
.
764. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, . CM. Efficacyandsafetyoftolvaptaninpatients hospitalizedwith acuteheart .
andmanagement.CurrHeartFailRep2009;6:272(cid:2)280. . failure.JAmCollCardiol2017;69:1399(cid:2)1406.
.
765. Savarese G, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B, Lund LH, .. 784.MatsueY,TerMaatenJM,SuzukiM,ToriiS,YamaguchiS,FukamizuS,OnoY,
Carrero JJ. Incidence, predictors, and outcome associations of dyskalemia in .. FujiiH,KitaiT,NishiokaT,SugiK,OnishiY,NodaM,KagiyamaN,SatohY,
.
heart failure with preserved, mid-range, and reduced ejection fraction. JACC . YoshidaK,vanderMeerP,DammanK,VoorsAA,GoldsmithSR.Earlytreat-
.
HeartFail2019;7:65(cid:2)76. .. mentwithtolvaptanimprovesdiureticresponseinacuteheartfailurewithrenal
766. Rosano GMC, Spoletini I, Agewall S. Pharmacology of new treatments for .. dysfunction.ClinResCardiol2017;106:802(cid:2)812.
.
hyperkalaemia:patiromerandsodiumzirconiumcyclosilicate.EurHeartJSuppl . 785.KonstamMA,KiernanM,ChandlerA,DhingraR,ModyFV,EisenH,Haught
.
2019;21:A28(cid:2)A33. . WH,WagonerL,GuptaD,PattenR,GordonP,KorrK,FilecciaR,PresslerSJ,
.
767. AnkerSD,KosiborodM,ZannadF,PinaIL,McCulloughPA,FilippatosG,van .. Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM,
der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, .. Udelson JE, SECRET of CHF Investigators, Coordinators, and Committee
.
DeedwaniaP.Maintenanceofserumpotassiumwithsodiumzirconiumcyclosili- . Members. Short-term effectsof tolvaptan inpatients with acuteheart failure
.
cate(ZS-9)inheartfailurepatients:resultsfromaphase3randomized,double- . andvolumeoverload.JAmCollCardiol2017;69:1409(cid:2)1419.
.
blind,placebo-controlledtrial.EurJHeartFail2015;17:1050(cid:2)1056. .. 786.Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G,
768. PittB,BakrisGL,BushinskyDA,GarzaD,MayoMR,StasivY,Christ-Schmidt .. Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and
.
H,BermanL,WeirMR.Effectofpatiromeronreducingserumpotassiumand . small-volumehypertonicsalinesolutioninfusionincomparisonwithahighdose
.
preventingrecurrenthyperkalaemiainpatientswithheartfailureandchronic .. offurosemideasbolusinrefractorycongestiveheartfailure:long-termeffects.
kidneydiseaseonRAASinhibitors.EurJHeartFail2015;17:1057(cid:2)1065. .. AmHeartJ2003;145:459(cid:2)466.
.
769. Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, Barany P, . 787.Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G,
.
JernbergT,LundLH,CarreroJJ.Incidence,predictorsandclinicalmanagement . GiubilatoA,LicataG.Effectsofhigh-dosefurosemideandsmall-volumehyper-
.
ofhyperkalaemiainnewusersofmineralocorticoidreceptorantagonists.EurJ .. tonicsalinesolutioninfusionincomparisonwithahighdoseoffurosemideasa
HeartFail2018;20:1217(cid:2)1226. . bolus,inrefractorycongestiveheartfailure.EurJHeartFail2000;2:305(cid:2)313.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 122 ---
3720 ESCGuidelines
.
.
788. Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, . ventilation for central sleep apnea in systolic heart failure. N Engl J Med
.
D’Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, . 2015;373:1095(cid:2)1105.
.
TangWHW,TurnerJ,MullensW,WilsonFP,TestaniJM.Realworlduseof .. 809.CostanzoMR,PonikowskiP,JavaheriS,AugostiniR,GoldbergL,HolcombR,
hypertonicsalineinrefractoryacutedecompensatedheartfailure:aU.S.cen- .. KaoA,KhayatRN,OldenburgO,StellbrinkC,AbrahamWT,remede´System
.
ter’sexperience.JACCHeartFail2020;8:199(cid:2)208. . Pivotal Trial Study Group. Transvenous neurostimulation for central sleep
.
789. CuthbertJJ,PellicoriP,RigbyA,PanD,KazmiS,ShahP,ClarkAL.Lowserum .. apnoea:arandomisedcontrolledtrial.Lancet2016;388:974(cid:2)982.
chlorideinpatientswithchronicheartfailure:clinicalassociationsandprognos- .. 810.Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR,
.
ticsignificance.EurJHeartFail2018;20:1426(cid:2)1435. . Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, McKane S,
.
790. Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, . AbrahamWT,remede´SystemPivotalTrialStudyGroup.Phrenicnervestimu-
.
Bellumkonda L, Jacoby D, Tang WH, Parikh CR. Hypochloraemia is strongly .. lationtotreatpatientswithcentralsleepapnoeaandheartfailure.EurJHeart
andindependentlyassociatedwithmortalityinpatientswithchronicheartfail- .. Fail2018;20:1746(cid:2)1754.
.
ure.EurJHeartFail2016;18:660(cid:2)668. . 811.KjekshusJ,ApetreiE,BarriosV,Bo¨hmM,ClelandJG,CornelJH,DunselmanP,
.
791. MarchenkoR,SigalA,WasserTE,ReyerJ,GreenJ,MercoglianoC,KhanMS, . FonsecaC,GoudevA,GrandeP,GullestadL,HjalmarsonA,HradecJ,J(cid:3)anosiA,
.
Donato AA. Hypochloraemia and 30 day readmission rate in patients with .. Kamensk(cid:3)yG,KomajdaM,KorewickiJ,KuusiT,MachF,MareevV,McMurrayJJ,
.
acutedecompensatedheartfailure.ESCHeartFail2020;7:903(cid:2)907. . Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F,
.
792. GrodinJL,SimonJ,HachamovitchR,WuY,JacksonG,HalkarM,StarlingRC, . WedelH,WikstrandJ,CORONAGroup.Rosuvastatininolderpatientswith
. TestaniJM,TangWH.Prognosticroleofserumchloridelevelsinacutedecom- .. systolicheartfailure.NEnglJMed2007;357:2248(cid:2)2261.
pensatedheartfailure.JAmCollCardiol2015;66:659(cid:2)666. .. 812.TavazziL,MaggioniAP,MarchioliR,BarleraS,FranzosiMG,LatiniR,LucciD,
.
793. HanbergJS,RaoV,TerMaatenJM,LaurO,BriscoMA,PerryWilsonF,Grodin . NicolosiGL,PorcuM,TognoniG,GISSI-HFInvestigators.Effectofrosuvastatin
.
JL,AssefaM,SamuelBroughtonJ,PlanavskyNJ,AhmadT,BellumkondaL,Tang . inpatientswithchronicheartfailure(theGISSI-HFtrial):arandomised,double-
.
WH,ParikhCR,TestaniJM.Hypochloremiaanddiureticresistanceinheartfail- .. blind,placebo-controlledtrial.Lancet2008;372:1231(cid:2)1239.
ure:mechanisticinsights.CircHeartFail2016;9. .. 813.Al-GobariM,LeHH,FallM,GueyffierF,BurnandB.Nobenefitsofstatinsfor
.
794. VerbruggeFH,MartensP,AmelootK,HaemelsV,PendersJ,DupontM,Tang . suddencardiacdeathpreventioninpatientswithheartfailureandreducedejec-
.
WHW,DroogneW,MullensW.Acetazolamidetoincreasenatriuresisincon- .. tion fraction: a meta-analysis of randomized controlled trials. PLoS One
gestive heart failure at high risk for diuretic resistance. Eur J Heart Fail .. 2017;12:e0171168.
.
2019;21:1415(cid:2)1422. . 814.RogersJK,JhundPS,PerezAC,BohmM,ClelandJG,GullestadL,KjekshusJ,
.
795. Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR, . van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of
.
QuintJK.HospitalisationandmortalityinpatientswithcomorbidCOPDand .. rosuvastatin on repeat heart failure hospitalizations: the CORONA trial
heartfailure:asystematicreviewandmeta-analysis.RespirRes2020;21:54. .. (ControlledRosuvastatinMultinationalTrialinHeart Failure).JACC Heart Fail
.
796. CanepaM,Straburzynska-MigajE,DrozdzJ,Fernandez-VivancosC,PinillaJMG, . 2014;2:289(cid:2)297.
.
NyolczasN,TemporelliPL,MebazaaA,LainscakM,LarocheC,MaggioniAP, . 815.Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J,
.
PiepoliMF,CoatsAJS,FerrariR,TavazziL,ESC-HFAHeartFailureLong-Term .. TavazziL,McMurrayJ,Lloyd-JonesDM.Dostatinsreducetheriskofmyocar-
.
RegistryInvestigators.Characteristics,treatmentsand1-yearprognosisofhos- . dialinfarctioninpatientswithheartfailure?Apooledindividual-levelreanalysis
.
pitalizedandambulatoryheartfailurepatientswithchronicobstructivepulmo- . ofCORONAandGISSI-HF.EurJHeartFail2015;17:434(cid:2)441.
.
narydiseaseintheEuropeanSocietyofCardiologyHeartFailureLong-Term .. 816.ThanassoulisG,BrophyJM,RichardH,PiloteL.Gout,allopurinoluse,andheart
Registry.EurJHeartFail2018;20:100(cid:2)110. .. failureoutcomes.ArchInternMed2010;170:1358(cid:2)1364.
.
797. UijlA,KoudstaalS,DirekK,DenaxasS,GroenwoldRHH,BanerjeeA,Hoes . 817.BorghiC,PalazzuoliA,LandolfoM,CosentinoE.Hyperuricemia:anovelold
.
AW,Hemingway H,AsselbergsFW.Riskfactorsforincident heartfailure in . disorder-relationshipandpotentialmechanismsinheartfailure.HeartFailRev
.
age-andsex-specificstrata:apopulation-basedcohortusinglinkedelectronic .. 2020;25:43(cid:2)51.
healthrecords.EurJHeartFail2019;21:1197(cid:2)1206. .. 818.DoehnerW,SpringerJ,LandmesserU,StruthersAD,AnkerSD.Uricacidin
.
798. CaravitaS,VachieryJL.Obstructiveventilatorydisorderinheartfailure–caused . chronic heart failure–current pathophysiological concepts. Eur J Heart Fail
.
bytheheartorthelung?CurrHeartFailRep2016;13:310(cid:2)318. .. 2008;10:1269(cid:2)1270.
799. MagnussenH,CanepaM,ZambitoPE,BrusascoV,MeinertzT,RosenkranzS. .. 819.HuangH,HuangB,LiY,HuangY,LiJ,YaoH,JingX,ChenJ,WangJ.Uricacid
.
Whatcanwelearnfrompulmonaryfunctiontestinginheartfailure?EurJHeart . andriskofheartfailure:asystematicreviewandmeta-analysis.EurJHeartFail
.
Fail2017;19:1222(cid:2)1229. . 2014;16:15(cid:2)24.
.
800. Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, .. 820.WhiteWB,SaagKG,BeckerMA,BorerJS,GorelickPB,WheltonA,HuntB,
Rosenkranz S. Diagnostic and therapeutic gaps in patients with heart .. Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular safety of
.
failure and chronic obstructive pulmonary disease. JACC Heart Fail . febuxostat or allopurinol in patients with gout. N Engl J Med
.
2019;7:823(cid:2)833. . 2018;378:1200(cid:2)1210. .
801. GlobalInitiativeforChronicObstructiveLungDisease.Globalstrategyforthe .. 821.HareJM,MangalB,BrownJ,FisherC,Jr.,FreudenbergerR,ColucciWS,Mann
diagnosis,management,andpreventionofchronicobstructivepulmonarydis- .. DL,LiuP,GivertzMM,SchwarzRP,OPT-CHFInvestigators.Impactofoxypuri-
.
ease. 2020 report. https://goldcopd.org/wp-content/uploads/2019/12/GOLD- . nolinpatientswithsymptomaticheartfailure.ResultsoftheOPT-CHFstudy.J
. 2020-FINAL-ver1.2-03Dec19_WMV.pdf(31May2020). .. AmCollCardiol2008;51:2301(cid:2)2309.
802. Global Initiative for Asthma. Global Strategy for Asthma Management and .. 822.OginoK,KatoM,FuruseY,KinugasaY,IshidaK,OsakiS,KinugawaT,IgawaO,
.
Prevention,2019.www.ginasthma.org(28May2021). . HisatomeI,ShigemasaC,AnkerSD,DoehnerW.Uricacid-loweringtreatment .
803.BrookRD,AndersonJA,CalverleyPM,CelliBR,CrimC,DenvirMA,MagderS, . withbenzbromaroneinpatientswithheartfailure:adouble-blindplacebo-con-
.
MartinezFJ,RajagopalanS,VestboJ,YatesJ,NewbyDE,SUMMITInvestigators. .. trolledcrossoverpreliminarystudy.CircHeartFail2010;3:73(cid:2)81.
Cardiovascularoutcomeswithaninhaledbeta2-agonist/corticosteroidinpatients .. 823.Givertz MM,Anstrom KJ, Redfield MM,DeswalA, Haddad H,Butler J, Tang
.
withCOPDathighcardiovascularrisk.Heart2017;103:1536(cid:2)1542. . WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM,
.
804. VestboJ,AndersonJA,BrookRD,CalverleyPM,CelliBR,CrimC,MartinezF, . GoldsmithSR,OfiliEO,SaltzbergMT,MarguliesKB,CappolaTP,KonstamMA,
.
YatesJ,NewbyDE,SUMMITInvestigators.Fluticasone furoateandvilanterol .. Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, NHLBI Heart
.
andsurvivalinchronicobstructivepulmonarydiseasewithheightenedcardio- . Failure Clinical Research Network. Effects of xanthine oxidase inhibition in
.
vascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet . hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for
.
2016;387:1817(cid:2)1826. .. Hyperuricemic Heart Failure Patients (EXACT-HF) study. Circulation
805. HohlfeldJM, Vogel-Claussen J,BillerH, BerlinerD, Berschneider K,Tillmann .. 2015;131:1763(cid:2)1771.
.
HC,HiltlS,BauersachsJ,WelteT.Effectoflungdeflationwithindacaterolplus . 824.VermaS,EikelboomJW,NidorfSM,Al-OmranM,GuptaN,TeohH,Friedrich
.
glycopyrroniumonventricularfillinginpatientswithhyperinflationandCOPD . JO. Colchicine in cardiac disease: a systematic review and meta-analysis of
.
(CLAIM): a double-blind, randomised, crossover, placebo-controlled, single- .. randomizedcontrolledtrials.BMCCardiovascDisord2015;15:96.
centretrial.LancetRespirMed2018;6:368(cid:2)378. .. 825.Frommeyer G, Krawczyk J, Dechering DG, Kochhauser S, Leitz P, Fehr M,
.
806. PearseSG,CowieMR.Sleep-disorderedbreathinginheartfailure.EurJHeart . Eckardt L. Colchicine increases ventricular vulnerability in an experimental
.
Fail2016;18:353(cid:2)361. .. whole-heartmodel.BasicClinPharmacolToxicol2017;120:505(cid:2)508.
807. CowieMR,GallagherAM.Sleepdisorderedbreathingandheartfailure:what .. 826.ArfeA,ScottiL,Varas-LorenzoC,NicotraF,ZambonA,KollhorstB,SchinkT,
.
doesthefuturehold?JACCHeartFail2017;5:715(cid:2)723. . Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V,
.
808. CowieMR,WoehrleH,WegscheiderK,AngermannC,d’OrthoMP,Erdmann . Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G,
.
E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive servo- .. Safety of Non-steroidal Anti-inflammatory Drugs Project Consortium. Non-
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 123 ---
ESCGuidelines 3721
.
.
steroidal anti-inflammatory drugs and risk of heart failure in four European . Force for cancer treatments and cardiovascular toxicity of the European
.
countries:nestedcase-controlstudy.BMJ2016;354:i4857. .. SocietyofCardiology(ESC).EurJHeartFail2017;19:9(cid:2)42.
827. KhalidY,DasuN,ShahA,BrownK,KaellA,LevineA,DasuK,RaminfardA. .. 845.Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ,
Incidenceofcongestiveheartfailureinrheumatoidarthritis:areviewoflitera- .. CardinaleD,CardoneA,FeijenEAM,FerdinandyP,Lopez-FernandezT,Gale
.
tureandmeta-regressionanalysis.ESCHeartFail2020;7:3745(cid:2)3753. . CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM,
.
828. Mantel A, Holmqvist M, Andersson DC, Lund LH, Askling J. Association .. Minotti G. The cancer patient and cardiology. Eur J Heart Fail
betweenrheumatoidarthritisandriskofischemicandnonischemicheartfail- .. 2020;22:2290(cid:2)2309.
.
ure.JAmCollCardiol2017;69:1275(cid:2)1285. . 846.Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A,
.
829. ChungES,PackerM,LoKH,FasanmadeAA,WillersonJT,Anti-TNFTherapy . TocchettiCG,MoslehiJJ,GroarkeJD,Bergler-KleinJ,KhooV,TanLL,Anker
.
AgainstCongestiveHeartFailureInvestigators.Randomized,double-blind,pla- .. MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B,
cebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to .. Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA,
.
tumornecrosisfactor-alpha,inpatientswithmoderate-to-severeheartfailure: . MacedoAVS,ManistyC,CiardielloF,FarmakisD,deBoerRA,SkouriH,Suter
.
resultsoftheanti-TNFTherapyAgainstCongestiveHeartFailure(ATTACH) . TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF,
.
trial.Circulation2003;107:3133(cid:2)3140. .. Wechelaker A, MauroMJ, Milojkovic D, deLavallade H, Ruschitzka F, Coats
.
830. MannDL,McMurrayJJ,PackerM,SwedbergK,BorerJS,ColucciWS,DjianJ, . AJS,SeferovicPM,ChioncelO,ThumT,BauersachsJ,AndresMS,WrightDJ,
.
DrexlerH,FeldmanA,KoberL,KrumH,LiuP,NieminenM,TavazziL,van . Lopez-FernandezT,PlummerC,LenihanD.Baselinecardiovascularriskassess-
. VeldhuisenDJ,WaldenstromA,WarrenM,WestheimA,ZannadF,FlemingT. .. ment incancer patients scheduled to receive cardiotoxiccancer therapies: a
Targetedanticytokinetherapyinpatientswithchronicheartfailure:resultsof .. positionstatementandnewriskassessmenttoolsfromtheCardio-Oncology
.
the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation . Study Group of the Heart Failure Association of the European Society of
.
2004;109:1594(cid:2)1602. . Cardiology in collaboration with the International Cardio-Oncology Society.
.
831. KotylaPJ.Bimodalfunctionofanti-TNFtreatment:shallwebeconcernedabout .. EurJHeartFail2020;22:1945(cid:2)1960.
anti-TNFtreatmentinpatientswithrheumatoidarthritisandheartfailure?IntJ .. 847.Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C,
.
MolSci2018;19:1739. . MousaviN,ParkJH,PeralesMA,RyanTD,Scherrer-CrosbieM,SteingartRM,
.
832. Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Bohm M. .. YangEH,ZahaV,BaracA,LiuJE.ChimericantigenreceptorT-celltherapyfor
Cardiovascularrisk,drugsanderectilefunction–asystematicanalysis.IntJClin .. cancer and heart: JACC council perspectives. J Am Coll Cardiol
.
Pract2011;65:289(cid:2)298. . 2019;74:3153(cid:2)3163.
.
833. JaarsmaT.Sexualfunctionofpatientswithheartfailure:factsandnumbers.ESC . 848.Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of
.
HeartFail2017;4:3(cid:2)7. .. cancer-relatedtreatment.CircRes2016;118:1008(cid:2)1020.
834. LevineAB,PunihaoleD,LevineTB.Characterizationoftheroleofnitricoxide .. 849.LyonAR,YousafN,BattistiNML,MoslehiJ,LarkinJ.Immunecheckpointinhibi-
.
anditsclinicalapplications.Cardiology2012;122:55(cid:2)68. . torsandcardiovasculartoxicity.LancetOncol2018;19:e447(cid:2)e458.
.
835. GiannettaE,FeolaT,GianfrilliD,PofiR,Dall’ArmiV,BadagliaccaR,Barbagallo . 850.Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS,
.
F,LenziA,IsidoriAM.Ischronicinhibitionofphosphodiesterasetype5cardio- .. Gietema JA, Hooning MJ, Seynaeve CM, Maas A, Darby SC, Aleman BMP,
.
protectiveandsafe?Ameta-analysisofrandomizedcontrolledtrials.BMCMed . TaylorCW,vanLeeuwenFE.Heartfailureaftertreatmentforbreastcancer.
.
2014;12:185. . EurJHeartFail2020;22:366(cid:2)374.
.
836. AngermannCE,ErtlG.Depression,anxiety,andcognitiveimpairment:comor- .. 851.FarmakisD,ParissisJ,FilippatosG.Insightsintoonco-cardiology:atrialfibrilla-
bid mental health disorders in heart failure. Curr Heart Fail Rep .. tionincancer.JAmCollCardiol2014;63:945(cid:2)953.
.
2018;15:398(cid:2)410. . 852.TrompJ,BoermanLM,SamaIE,MaassS,MaduroJH,HummelYM,BergerMY,
.
837. SbolliM,FiuzatM,CaniD,O’ConnorCM.Depressionandheartfailure:the . deBockGH,GietemaJA,BerendsenAJ,vanderMeerP.Long-termsurvivors
.
lonelycomorbidity.EurJHeartFail2020;22:2007(cid:2)2017. .. ofearlybreastcancertreatedwithchemotherapyarecharacterizedbyapro-
838. JhaMK,QamarA,VaduganathanM,CharneyDS,MurroughJW.Screeningand .. inflammatorybiomarkerprofilecomparedtomatchedcontrols.EurJHeartFail
.
managementofdepressioninpatientswithcardiovasculardisease:JACCstate- . 2020;22:1239(cid:2)1246.
.
of-the-artreview.JAmCollCardiol2019;73:1827(cid:2)1845. .. 853.HasinT,GerberY,WestonSA,JiangR,KillianJM,ManemannSM,CerhanJR,
839. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, .. RogerVL.Heartfailureaftermyocardialinfarctionisassociatedwithincreased
.
CzajkowskiSM,DeBuskR,HoskingJ,JaffeA,KaufmannPG,MitchellP,Norman . riskofcancer.JAmCollCardiol2016;68:265(cid:2)271.
.
J,PowellLH,RaczynskiJM,SchneidermanN,EnhancingRecoveryinCoronary . 854.BankeA,SchouM,VidebaekL,MollerJE,Torp-PedersenC,GustafssonF,Dahl
.
HeartDiseasePatientsInvestigators.Effectsoftreatingdepressionandlowper- .. JS,KoberL,HildebrandtPR,GislasonGH.Incidenceofcancerinpatientswith
ceived social support on clinical events after myocardial infarction: the .. chronic heart failure: a long-term follow-up study. Eur J Heart Fail
.
EnhancingRecoveryinCoronaryHeartDiseasePatients(ENRICHD)random- . 2016;18:260(cid:2)266.
.
izedtrial.JAMA2003;289:3106(cid:2)3116. . 855.MeijersWC,deBoerRA.Commonriskfactorsforheartfailureandcancer. .
840. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, .. CardiovascRes2019;115:844(cid:2)853.
Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R, SADHART-CHF .. 856.de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD,
.
Investigators. Safety and efficacy of sertraline for depression in patients with . Bauersachs J, Bertero E, Coats AJS, Celutkiene J, Chioncel O, Dodion P,
. heartfailure:resultsoftheSADHART-CHF(SertralineAgainstDepressionand .. EschenhagenT,FarmakisD,Bayes-GenisA,JagerD,JankowskaEA,KitsisRN,
Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol .. KonetySH,LarkinJ,LehmannL,LenihanDJ,MaackC,MoslehiJJ,MullerOJ,
.
2010;56:692(cid:2)699. . Nowak-SliwinskaP,PiepoliMF,PonikowskiP,PudilR,RainerPP,RuschitzkaF, .
841. Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, . SawyerD,SeferovicPM,SuterT,ThumT,vanderMeerP,VanLaakeLW,von
.
Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, .. HaehlingS,HeymansS,LyonAR,BacksJ.Commonmechanisticpathwaysin
PrettinC,GottwikM,BohmM,FallerH,DeckertJ,ErtlG,MOOD-HFStudy .. cancer and heart failure. A scientific roadmap on behalf of the Translational
.
InvestigatorsandCommitteeMembers.Effectofescitalopramonall-causemor- . ResearchCommitteeoftheHeartFailureAssociation(HFA)oftheEuropean
.
tality and hospitalization in patients with heart failure and depression: the .. SocietyofCardiology(ESC).EurJHeartFail2020;22:2272(cid:2)2289.
MOOD-HFrandomizedclinicaltrial.JAMA2016;315:2683(cid:2)2693. .. 857.SelvarajS,BhattDL,ClaggettB,DjousseL,ShahSJ,ChenJ,ImranTF,QaziS,
.
842. deBoerRA,MeijersWC,vanderMeerP,vanVeldhuisenDJ.Cancerandheart . SessoHD,GazianoJM,SchragD.Lackofassociationbetweenheartfailureand
.
disease:associationsandrelations.EurJHeartFail2019;21:1515(cid:2)1525. . incidentcancer.JAmCollCardiol2018;71:1501(cid:2)1510.
.
843. FarmakisD,MantzouraniM,FilippatosG.Anthracycline-inducedcardiomyop- .. 858.MeijersWC,MaglioneM,BakkerSJL,OberhuberR,KienekerLM,deJongS,
athy:secretsandlies.EurJHeartFail2018;20:907(cid:2)909. .. Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ,
.
844. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, . WestenbrinkBD,vanderMeerP,SilljeHHW,deBoerRA.Heartfailurestimu-
.
GalderisiM,HabibG,LenihanDJ,LipGY,LyonAR,LopezFernandezT,Mohty . latestumorgrowthbycirculatingfactors.Circulation2018;138:678(cid:2)691.
.
D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, .. 859.Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der
AchenbachS,AgewallS,BadimonL,Baron-EsquiviasG,BaumgartnerH,BaxJJ, .. MeerP,CohenSolalA,ZamoranoJL,JerusalemG,MoonenM,AboyansV,Bax
.
BuenoH,CarerjS,DeanV,ErolC,FitzsimonsD,GaemperliO,KirchhofP, . JJ, AsteggianoR.Cardio-oncology services:rationale, organization, andimple-
.
Kolh P,Lancellotti P,Lip GY, Nihoyannopoulos P, Piepoli MF,Ponikowski P, .. mentation.EurHeartJ2019;40:1756(cid:2)1763.
Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force .. 860.FarmakisD,KeramidaK,FilippatosG.Howtobuildacardio-oncologyservice?
.
Members,ESCCommitteeforPracticeGuidelines,DocumentReviewers.2016 . EurJHeartFail2018;20:1732(cid:2)1734.
.
ESCPositionPaperoncancertreatmentsandcardiovasculartoxicitydeveloped . 861.CardinaleD,ColomboA,LamantiaG,ColomboN,CivelliM,DeGiacomiG,
.
undertheauspicesoftheESCCommittee forPracticeGuidelines:TheTask .. Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 124 ---
3722 ESCGuidelines
.
.
cardiomyopathy: clinical relevance and response to pharmacologic therapy. J . 876.ReyJR,Caro-CodonJ,RosilloSO,IniestaAM,Castrejon-CastrejonS,Marco-
.
AmCollCardiol2010;55:213(cid:2)220. .. ClementI,Martin-PoloL,Merino-ArgosC,Rodriguez-SoteloL,Garcia-VeasJM,
862. CardinaleD,ColomboA,BacchianiG,TedeschiI,MeroniCA,VegliaF,Civelli .. Martinez-MarinLA,Martinez-CossianiM,BunoA,Gonzalez-ValleL,HerreroA,
.
M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early . Lopez-Sendon JL, Merino JL, CARD-COVID Investigators. Heart failure in
.
detection of anthracycline cardiotoxicity and improvement with heart failure .. COVID-19 patients: prevalence, incidence and prognostic implications. Eur J
therapy.Circulation2015;131:1981(cid:2)1988. .. HeartFail2020;22:2205(cid:2)2215.
.
863. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, . 877.CannataA,BromageDI,RindIA,GregorioC,BannisterC,AlbarjasM,PiperS,
.
GravdehaugB,vonKnobelsdorff-BrenkenhoffF,BratlandA,StorasTH,Hagve . ShahAM,McDonaghTA.Temporaltrendsindecompensatedheartfailureand
.
TA,RosjoH,SteineK,GeislerJ,OmlandT.Preventionofcardiacdysfunction .. outcomes during COVID-19: a multisite report from heart failure referral
duringadjuvantbreastcancertherapy(PRADA):a2x2factorial,randomized, .. centresinLondon.EurJHeartFail2020;22:2219(cid:2)2224.
.
placebo-controlled, double-blind clinical trial of candesartan and metoprolol. . 878.KonigS,HohensteinS,Meier-HellmannA,KuhlenR,HindricksG,BollmannA,
.
EurHeartJ2016;37:1671(cid:2)1680. .. HeliosHospitalsG.In-hospitalcareinacuteheartfailureduringtheCOVID-19
864. PituskinE,MackeyJR,KoshmanS,JassalD,PitzM,HaykowskyMJ,PaganoJJ, .. pandemic:insightsfromtheGerman-wideHelioshospitalnetwork.EurJHeart
.
ChowK,ThompsonRB,VosLJ,GhoshS,OuditGY,EzekowitzJA,Paterson . Fail2020;22:2190(cid:2)2201.
.
DI.Multidisciplinaryapproachtonoveltherapiesincardio-oncologyresearch . 879.ZhangY,CoatsAJS,ZhengZ,AdamoM,AmbrosioG,AnkerSD,ButlerJ,Xu
.
(MANTICORE 101-Breast): a randomized trial for the prevention of .. D, Mao J, Khan MS, Bai L, Mebazaa A, Ponikowski P, Tang Q, Ruschitzka F,
trastuzumab-associatedcardiotoxicity.JClinOncol2017;35:870(cid:2)877. .. SeferovicP,TschopeC,ZhangS,GaoC,ZhouS,SenniM,ZhangJ,MetraM.
.
865. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, . ManagementofheartfailurepatientswithCOVID-19:ajointpositionpaperof
.
Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, . theChineseHeartFailureAssociation&NationalHeartFailureCommitteeand
.
BarberisV,FlachskampfFA,CeponieneI,Haegler-LaubeE,SuterT,Lapinskas .. the Heart Failure Association of the European Society of Cardiology. Eur J
T,PrasadS,deBoerRA,WechalekarK,AnkerMS,IakobishviliZ,Bucciarelli- .. HeartFail2020;22:941(cid:2)956.
. Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS, . 880.ModinD,JorgensenME,GislasonG,JensenJS,KoberL,ClaggettB,HegdeSM,
.
GalderisiM,LancellottiP,BaxJ,MarwickTH,ChioncelO,JaarsmaT,Mullens .. SolomonSD,Torp-PedersenC,Biering-SorensenT.Influenzavaccineinheart
W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F, .. failure.Circulation2019;139:575(cid:2)586.
.
ZamoranoJL, RosanoG,CoatsAJS,AsteggianoR,Seferovic P,EdvardsenT, . 881.Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K,
.
LyonAR.Roleofcardiovascularimagingincancerpatientsreceivingcardiotoxic . Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD, PARADIGM-HF
.
therapies: a position statement on behalf of the Heart Failure Association .. Investigators. Influenza vaccination in patients with chronic heart failure: the
(HFA),theEuropeanAssociationof CardiovascularImaging(EACVI)andthe .. PARADIGM-HFtrial.JACCHeartFail2016;4:152(cid:2)158.
.
Cardio-OncologyCounciloftheEuropeanSocietyofCardiology(ESC).EurJ . 882.GotsmanI,ShuvyM,TahirogluI,ZwasDR,KerenA.Influenzavaccinationand
.
HeartFail2020;22:1504(cid:2)1524. . outcomeinheartfailure.AmJCardiol2020;128:134(cid:2)139.
.
866. Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, .. 883.BhattAS,JeringKS,VaduganathanM,ClaggettBL,CunninghamJW,Rosenthal
Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N, .. N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD. Clinical outcomes in
.
Nihoyannopoulos P. Longitudinal changes of right ventricular deformation . patients with heart failure hospitalized with COVID-19. JACC Heart Fail
.
mechanicsduringtrastuzumabtherapyinbreastcancerpatients.EurJHeartFail .. 2021;9:65(cid:2)73.
2019;21:529(cid:2)535. .. 884.Regitz-ZagrosekV,Roos-HesselinkJW,BauersachsJ,Blomstro¨m-LundqvistC,
.
867. ThavendiranathanP,NegishiT,SomersetE,NegishiK,PenickaM,LemieuxJ, . C(cid:3)ıfkov(cid:3)aR,DeBonisM,IungB,JohnsonMR,KintscherU,KrankeP,LangIM,
.
Aakhus S, Miyazaki S, Shirazi M, Galderisi M, Marwick TH, SUCCOUR . MoraisJ,PieperPG,PresbiteroP,PriceS,RosanoGMC,SeelandU,Simoncini
.
Investigators.Strain-guidedmanagementofpotentiallycardiotoxiccancerther- .. T,SwanL,WarnesCA,ESCScientificDocumentGroup.2018ESCGuidelines
apy.JAmCollCardiol2021;77:392(cid:2)401. .. for the management of cardiovascular diseases during pregnancy. Eur Heart J
.
868. MichelL,MincuRI,MahabadiAA,SettelmeierS,Al-RashidF,RassafT,Totzeck . 2018;39:3165(cid:2)3241.
.
M.Troponinsandbrainnatriureticpeptidesforthepredictionofcardiotoxicity . 885.SliwaK,vanderMeerP,PetrieMC,FrogoudakiA,JohnsonMR,Hilfiker-Kleiner
.
incancerpatients:ameta-analysis.EurJHeartFail2020;22:350(cid:2)361. .. D, Hamdan R, Jackson AM, Ibrahim B, Mbakwem A, Tschope C, Regitz-
.
869. PudilR,MuellerC,CelutkieneJ,HenriksenPA,LenihanD,DentS,BaracA, . Zagrosek V, Omerovic E, Roos-Hesselink J, Gatzoulis M, Tutarel O, Price S,
.
StanwayS,MoslehiJ,SuterTM,KyB,SterbaM,CardinaleD,Cohen-SolalA, . HeymansS,CoatsAJS,MullerC,ChioncelO,ThumT,deBoerRA,Jankowska
.
TocchettiCG,FarmakisD,Bergler-KleinJ,AnkerMS,VonHaehlingS,Belenkov .. E,PonikowskiP,LyonAR,RosanoG,SeferovicPM,BauersachsJ.Riskstratifica-
Y,IakobishviliZ,MaackC,CiardielloF,RuschitzkaF,CoatsAJS,SeferovicP, .. tion and management of women with cardiomyopathy/heart failure planning
.
LainscakM,PiepoliMF,ChioncelO,BaxJ,HulotJS,SkouriH,Hagler-LaubeES, . pregnancyorpresentingduring/afterpregnancy:apositionstatementfromthe
.
AsteggianoR,FernandezTL,deBoerRA,LyonAR.Roleofserumbiomarkers . HeartFailureAssociationoftheEuropeanSocietyofCardiologyStudyGroup
.
incancerpatientsreceivingcardiotoxiccancertherapies:apositionstatement .. onPeripartumCardiomyopathy.EurJHeartFail2021;23:527(cid:2)540.
fromtheCardio-OncologyStudyGroupoftheHeartFailureAssociationand .. 886.SliwaK,PetrieMC,vanderMeerP,MebazaaA,Hilfiker-KleinerD,JacksonAM, .
the Cardio-Oncology Council of the European Society of Cardiology. Eur J . MaggioniAP,LarocheC,Regitz-ZagrosekV,SchaufelbergerM,TavazziL,Roos-
.
HeartFail2020;22:1966(cid:2)1983. .. HesselinkJW,SeferovicP,vanSpaendonck-ZwartsK,MbakwemA,BohmM,
870. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, .. MouquetF,PieskeB,JohnsonMR,HamdanR,PonikowskiP,VanVeldhuisen
. Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with . DJ, McMurray JJV, Bauersachs J. Clinical presentation, management, and 6-
.
immunecheckpointinhibitors.CardiovascRes2019;115:854(cid:2)868. . month outcomes in women with peripartum cardiomyopathy:an ESC EORP .
871. BankeA,FosbolEL,MollerJE,GislasonGH,AndersenM,BernsdorfM,Jensen .. registry.EurHeartJ2020;41:3787(cid:2)3797.
MB,SchouM,EjlertsenB.Long-termeffectofepirubicinonincidenceofheart .. 887.DavisMB,AranyZ,McNamaraDM,GolandS,ElkayamU.Peripartumcardio-
.
failureinwomenwithbreastcancer:insightfromarandomizedclinicaltrial.Eur . myopathy:JACCstate-of-the-artreview.JAmCollCardiol2020;75:207(cid:2)221.
. JHeartFail2018;20:1447(cid:2)1453. .. 888.MouligV,PfefferTJ,Ricke-HochM,SchlothauerS,KoenigT,SchwabJ,Berliner
872. PlatzE,JhundPS,ClaggettBL,PfefferMA,SwedbergK,GrangerCB,YusufS, .. D,PfisterR,MichelsG,HaghikiaA,FalkCS,DunckerD,VeltmannC,Hilfiker-
.
SolomonSD,McMurrayJJ.Prevalenceandprognosticimportanceofprecipitat- . Kleiner D, Bauersachs J. Long-term follow-up in peripartum cardiomyopathy
.
ingfactorsleadingtoheartfailurehospitalization:recurrenthospitalizationsand . patients with contemporary treatment: low mortality, high cardiac recovery,
.
mortality.EurJHeartFail2018;20:295(cid:2)303. .. but significant cardiovascular co-morbidities. Eur J Heart Fail
873. TomasoniD,ItaliaL,AdamoM,InciardiRM,LombardiCM,SolomonSD,Metra .. 2019;21:1534(cid:2)1542.
.
M.COVID19andheartfailure:frominfectiontoinflammationandangiotensin . 889.StapelB,KohlhaasM,Ricke-HochM,HaghikiaA,ErschowS,KnuutiJ,Silvola
.
II stimulation. Searching for evidence from a new disease. Eur J Heart Fail . JM,RoivainenA,SarasteA,NickelAG,SaarJA,SieveI,PietzschS,MullerM,
.
2020;22:957(cid:2)966;23:512(cid:2)526. .. BogeskiI,KapplR,JauhiainenM,ThackerayJT,ScherrM,BengelFM,HaglC,
874. Corrales-MedinaVF,AlvarezKN,WeissfeldLA,AngusDC,ChirinosJA,Chang .. TudoracheI,BauersachsJ,MaackC,Hilfiker-KleinerD.LowSTAT3expression
.
CC,NewmanA,LoehrL,FolsomAR,ElkindMS,LylesMF,KronmalRA,Yende . sensitizestotoxiceffectsofbeta-adrenergicreceptorstimulationinperipartum
.
S.Associationbetweenhospitalizationforpneumoniaandsubsequentriskof .. cardiomyopathy.EurHeartJ2017;38:349(cid:2)361.
cardiovasculardisease.JAMA2015;313:264(cid:2)274. .. 890.Hilfiker-KleinerD,HaghikiaA,BerlinerD,Vogel-ClaussenJ,SchwabJ,Franke
.
875. Violi F, CangemiR, Falcone M, Taliani G, Pieralli F, Vannucchi V, NozzoliC, . A,SchwarzkopfM,EhlermannP,PfisterR,MichelsG,WestenfeldR,StanglV,
.
Venditti M, Chirinos JA, Corrales-Medina VF, SIXTUS Study Group. . KindermannI,KuhlU,AngermannCE,SchlittA,FischerD,PodewskiE,Bohm
.
Cardiovascular complications and short-term mortality risk in community- .. M,SliwaK,BauersachsJ.Bromocriptineforthetreatmentofperipartumcardio-
acquiredpneumonia.ClinInfectDis2017;64:1486(cid:2)1493. . myopathy:amulticentrerandomizedstudy.EurHeartJ2017;38:2671(cid:2)2679.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 125 ---
ESCGuidelines 3723
.
.
891. SliwaK,BlauwetL,TibazarwaK,LibhaberE,SmedemaJP,BeckerA,McMurray . Titingenemutationsarecommoninfamilieswithbothperipartumcardiomyop-
.
J,YamacH,LabidiS,StrumanI,Hilfiker-KleinerD.Evaluationofbromocriptine . athyanddilatedcardiomyopathy.EurHeartJ2014;35:2165(cid:2)2173.
.
in the treatment of acute severe peripartum cardiomyopathy: a proof-of- .. 905.ChoiSH,WengLC,RoselliC,LinH,HaggertyCM,ShoemakerMB,BarnardJ,
conceptpilotstudy.Circulation2010;121:1465(cid:2)1473. .. ArkingDE,ChasmanDI,AlbertCM,ChaffinM,TuckerNR,SmithJD,GuptaN,
.
892. ArbustiniE,NarulaN,DecGW,ReddyKS,GreenbergB,KushwahaS,Marwick . GabrielS,MargolinL,SheaMA,ShafferCM,YonedaZT,BoerwinkleE,Smith
.
T,PinneyS,BellazziR,FavalliV,KramerC,RobertsR,ZoghbiWA,BonowR, .. NL,SilvermanEK,RedlineS,VasanRS,BurchardEG,GogartenSM,LaurieC,
Tavazzi L, Fuster V, Narula J. The MOGE(S) classification for a phenotype- .. Blackwell TW, Abecasis G, Carey DJ, Fornwalt BK, Smelser DT, Baras A,
.
genotype nomenclature of cardiomyopathy: endorsed by the World Heart . Dewey FE, Jaquish CE, Papanicolaou GJ, Sotoodehnia N, Van Wagoner DR,
.
Federation.JAmCollCardiol2013;62:2046(cid:2)2072. . PsatyBM,KathiresanS,DarbarD,AlonsoA,HeckbertSR,ChungMK,Roden
.
893. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC, .. DM, Benjamin EJ, Murray MF, Lunetta KL, Lubitz SA, Ellinor PT, DiscovEHR
Dennert R, Merken J, Kuznetsova T, Staessen JA, Brunner-La Rocca HP, van .. study and the NHLBI Trans-Omics for Precision Medicine (TOPMed)
.
Paassen P, Cohen Tervaert JW, Heymans S. Prevalence and prognostic rele- . Consortium.Associationbetweentitinloss-of-functionvariantsandearly-onset
.
vanceofcardiacinvolvementinANCA-associatedvasculitis:eosinophilicgranu- .. atrialfibrillation.JAMA2018;320:2354(cid:2)2364.
lomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol .. 906.HazebroekMR,KrapelsI,VerdonschotJ,vandenWijngaardA,VanhoutteE,
.
2015;199:170(cid:2)179. . HoosM,SnijdersL,vanMontfortL,WitjensM,DennertR,CrijnsH,Brunner-
.
894. PintoYM,ElliottPM,ArbustiniE,AdlerY,AnastasakisA,BohmM,DubocD, . LaRoccaHP,BrunnerHG,HeymansS.Prevalenceofpathogenicgenemuta-
. GimenoJ,deGrooteP,ImazioM,HeymansS,KlingelK,KomajdaM,Limongelli .. tionsandprognosisdonotdifferinisolatedleftventriculardysfunctioncom-
G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, .. paredwithdilatedcardiomyopathy.CircHeartFail2018;11:e004682.
.
Zamorano JL, Caforio AL, Charron P. Proposal for a revised definition of . 907.LeoneO,VeinotJP,AngeliniA,BaandrupUT,BassoC,BerryG,BrunevalP,
.
dilatedcardiomyopathy,hypokineticnon-dilatedcardiomyopathy,anditsimpli- . BurkeM,ButanyJ,CalabreseF,d’AmatiG,EdwardsWD,FallonJT,Fishbein
.
cationsforclinicalpractice:apositionstatementoftheESCworkinggroupon .. MC,GallagherPJ,HalushkaMK,McManusB,PucciA,RodriguezER,SaffitzJE,
myocardialandpericardialdiseases.EurHeartJ2016;37:1850(cid:2)1858. .. SheppardMN,SteenbergenC,StoneJR,TanC,ThieneG,vanderWalAC,
.
895. Seferovic PM, PolovinaM,BauersachsJ,AradM, GalTB, Lund LH,Felix SB, . Winters GL. 2011 consensus statement on endomyocardial biopsy from the
.
Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, .. Association for European Cardiovascular Pathology and the Society for
Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimovic R, Milicic D, .. CardiovascularPathology.CardiovascPathol2012;21:245(cid:2)274.
.
MilinkovicI,NoutsiasM,OtoA,OtoO,PavlovicSU,PiepoliMF,RisticAD, . 908.Halliday BP, Owen R, Gregson J, Vassiliou VS, Chen X, Wage R, Lota AS,
.
RosanoGMC,SeggewissH,AsaninM,SeferovicJP,RuschitzkaF,CelutkieneJ, . KhaliqueZ,TayalU,HammersleyDJ,JonesRE,BaksiAJ,CowieMR,Cleland
.
JaarsmaT,MuellerC,MouraB,HillL,VolterraniM,LopatinY,MetraM,Backs .. JGF,PennellDJ,PrasadSK.Myocardialremodellingafterwithdrawingtherapy
J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS, .. for heart failure in patients with recovered dilated cardiomyopathy: insights
.
TschopeC.Heartfailureincardiomyopathies:apositionpaperfromtheHeart . fromTRED-HF.EurJHeartFail2021;23:293(cid:2)301.
.
Failure Association of the European Society of Cardiology. Eur J Heart Fail . 909.OlivottoI,OreziakA,Barriales-VillaR,AbrahamTP,MasriA,Garcia-PaviaP,
.
2019;21:553(cid:2)576. .. SaberiS,LakdawalaNK,WheelerMT,OwensA,KubanekM,WojakowskiW,
.
896. membersAuthors/TaskForce,ElliottPM,AnastasakisA,BorgerMA,Borggrefe . Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD,
.
M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, . SehnertAJ,ZhangD,LiW,BhattacharyaM,EdelbergJM,WaldmanCB,Lester
.
McKennaWJ,MogensenJ,NihoyannopoulosP,NistriS,PieperPG,PieskeB, .. SJ, Wang A, Ho CY, Jacoby D, EXPLORER-HCM Study Investigators.
RapezziC,RuttenFH,TillmannsC,WatkinsH.2014ESCGuidelinesondiag- .. Mavacamtenfortreatmentofsymptomaticobstructivehypertrophiccardiomy-
.
nosis and management of hypertrophic cardiomyopathy: The Task Force for . opathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled,
.
the Diagnosis and Management of Hypertrophic Cardiomyopathy of the . phase3trial.Lancet2020;396:759(cid:2)769.
.
EuropeanSocietyofCardiology(ESC).EurHeartJ2014;35:2733(cid:2)2779. .. 910.Cadrin-TourignyJ,BosmanLP,NozzaA,WangW,TadrosR,BhonsaleA,Bourfiss
897. Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, .. M,FortierA,LieOH,SagunerAM,SvenssonA,AndorinA,TichnellC,MurrayB,
.
HamdaniN,Hilfiker-KleinerD,MederB,Leite-MoreiraAF,ThumT,Tocchetti . ZeppenfeldK,vandenBergMP,AsselbergsFW,WildeAAM,KrahnAD,Talajic
.
CG,VarricchiG,VanderVeldenJ,WalshR,HeymansS.Complexroadsfrom .. M,RivardL,ChelkoS,ZimmermanSL,KamelIR,CrossonJE,JudgeDP,YapSC,
genotype tophenotypeindilatedcardiomyopathy:scientificupdatefromthe .. van der Heijden JF, Tandri H, Jongbloed JDH, Guertin MC, van Tintelen JP,
.
WorkingGroupofMyocardialFunctionoftheEuropeanSocietyofCardiology. . PlatonovPG,DuruF,HaugaaKH,KhairyP,HauerRNW,CalkinsH,TeRieleA,
.
CardiovascRes2018;114:1287(cid:2)1303. . JamesCA.Anewpredictionmodelforventriculararrhythmiasinarrhythmogenic
.
898. Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, .. rightventricularcardiomyopathy.EurHeartJ2019;40:1850(cid:2)1858.
MoralesA,TaylorMRG,VattaM,WareSM.Geneticevaluationofcardiomyop- .. 911.Leren IS, Saberniak J, Haland TF, Edvardsen T, Haugaa KH. Combination of
.
athy–a Heart Failure Society of America practice guideline. J Card Fail . ECG and echocardiography for identification of arrhythmic events in early
.
2018;24:281(cid:2)302. . ARVC.JACCCardiovascImaging2017;10:503(cid:2)513. .
899. MerloM,CannataA,GobboM,StolfoD,ElliottPM,SinagraG.Evolvingcon- .. 912.TowbinJA,McKennaWJ,AbramsDJ,AckermanMJ,CalkinsH,DarrieuxFCC,
ceptsindilatedcardiomyopathy.EurJHeartFail2018;20:228(cid:2)239. .. DaubertJP,deChillouC,DePasqualeEC,DesaiMY,EstesNAM,3rd,HuaW,
.
900. LinschotenM,TeskeAJ,BaasAF,VinkA,DooijesD,BaarsHF,AsselbergsFW. . IndikJH,InglesJ,JamesCA,JohnRM,JudgeDP,KeeganR,KrahnAD,LinkMS,
. Truncating titin (TTN) variants in chemotherapy-induced cardiomyopathy. J .. MarcusFI,McLeodCJ,MestroniL,PrioriSG,SaffitzJE,SanataniS,ShimizuW,
CardFail2017;23:476(cid:2)479. .. vanTintelenJP,WildeAAM,ZarebaW.2019HRSexpertconsensusstatement
.
901. Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD, . onevaluation,riskstratification,andmanagementofarrhythmogeniccardiomy- .
PostmaA,GietemaJA,vanTintelenJP,vandenBergMP.Potentialgeneticpre- . opathy.HeartRhythm2019;16:e301(cid:2)e372.
.
dispositionforanthracycline-associatedcardiomyopathyinfamilieswithdilated .. 913.KristensenSL,LevyWC,ShadmanR,NielsenJC,HaarboJ,VidebaekL,Bruun
cardiomyopathy.OpenHeart2014;1:e000116. .. NE,EiskjaerH,WiggersH,BrandesA,ThogersenAM,HassagerC,Svendsen
.
902. WareJS,Amor-SalamancaA,TayalU,GovindR,SerranoI,Salazar-Mendiguchia . JH,HofstenDE,Torp-PedersenC,PehrsonS,SignorovitchJ,KoberL,ThuneJJ.
.
J, Garcia-Pinilla JM, Pascual-Figal DA, Nunez J, Guzzo-Merello G, Gonzalez- .. Risk models for prediction of implantable cardioverter-defibrillator benefit:
VioqueE,BardajiA,ManitoN,Lopez-GarridoMA,Padron-BartheL,Edwards .. insightsfromtheDANISHtrial.JACCHeartFail2019;7:717(cid:2)724.
.
E,WhiffinN,WalshR,BuchanRJ,MidwinterW,WilkA,PrasadS,PantazisA, . 914.CorradoD,WichterT,LinkMS,HauerR,MarchlinskiF,AnastasakisA,Bauce
.
Baski J, O’Regan DP, Alonso-Pulpon L, Cook SA, Lara-Pezzi E, Barton PJ, . B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C,
.
Garcia-PaviaP.Geneticetiologyforalcohol-inducedcardiactoxicity.JAmColl .. PellicciaA,DuruF,ProtonotariosN,EstesNA,3rd,McKennaWJ,ThieneG,
Cardiol2018;71:2293(cid:2)2302. .. MarcusFI,CalkinsH.Treatmentofarrhythmogenicrightventricularcardiomy-
.
903. WareJS,LiJ,MazaikaE,YassoCM,DeSouzaT,CappolaTP,TsaiEJ,Hilfiker- . opathy/dysplasia: aninternationaltaskforceconsensusstatement. EurHeart J
.
KleinerD,KamiyaCA,MazzarottoF,CookSA,HalderI,PrasadSK,PisarcikJ, . 2015;36:3227(cid:2)3237.
.
Hanley-YanezK,AlharethiR,DampJ,HsichE,ElkayamU,SheppardR,Kealey .. 915.ElliottPM,AnastasakisA,AsimakiA,BassoC,BauceB,BrookeMA,CalkinsH,
A,AlexisJ,RamaniG,SafirsteinJ,BoehmerJ,PaulyDF,WittsteinIS,ThohanV, .. CorradoD,DuruF,GreenKJ,JudgeDP,KelsellD,LambiasePD,McKennaWJ,
.
Zucker MJ, Liu P, Gorcsan J, 3rd, McNamara DM, Seidman CE, Seidman JG, . PilichouK,ProtonotariosA,SaffitzJE,SyrrisP,TandriH,TeRieleA,ThieneG,
.
AranyZ,IPACInvestigators,Imac.Sharedgeneticpredispositioninperipartum .. TsatsopoulouA,TintelenJP.Definitionandtreatmentofarrhythmogeniccardi-
anddilatedcardiomyopathies.NEnglJMed2016;374:233(cid:2)241. .. omyopathy:anupdatedexpertpanelreport.EurJHeartFail2019;21:955(cid:2)964.
.
904. vanSpaendonck-ZwartsKY,PosafalviA,vandenBergMP,Hilfiker-KleinerD, . 916.MazzarottoF,TayalU,BuchanRJ,MidwinterW,WilkA,WhiffinN,GovindR,
.
Bollen IA, Sliwa K, Alders M, Almomani R, van Langen IM, van der Meer P, . Mazaika E, de Marvao A, Dawes TJW, Felkin LE, Ahmad M, Theotokis PI,
.
SinkeRJ,vanderVeldenJ,VanVeldhuisenDJ,vanTintelenJP,JongbloedJD. .. Edwards E, Ing AY, Thomson KL, Chan LLH, Sim D, Baksi AJ, Pantazis A,
. RobertsAM,WatkinsH,FunkeB,O’ReganDP,OlivottoI,BartonPJR,Prasad
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 126 ---
3724 ESCGuidelines
.
.
SK,CookSA,WareJS,WalshR.Reevaluatingthegeneticcontributionofmon- . JR, Limongelli G, Omar RZ, Elliott PM. Effectiveness of the 2014 European
.
ogenicdilatedcardiomyopathy.Circulation2020;141:387(cid:2)398. . SocietyofCardiologyguidelineonsuddencardiacdeathinhypertrophiccardio-
.
917. CaforioAL,PankuweitS,ArbustiniE,BassoC,Gimeno-BlanesJ,FelixSB,FuM, .. myopathy:asystematicreviewandmeta-analysis.Heart2019;105:623(cid:2)631.
Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, .. 929.O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P,
.
MogensenJ,PintoYM,RisticA,SchultheissHP,SeggewissH,TavazziL,Thiene . Cecchi F, Olivotto I, Kitaoka H, Gotsman I, Carr-White G, Mogensen J,
.
G,YilmazA,CharronP,ElliottPM,EuropeanSocietyofCardiologyWorking .. Antoniades L, Mohiddin SA, Maurer MS, Tang HC, Geske JB, Siontis KC,
GrouponMyocardialandPericardialDiseases.Currentstateofknowledgeon .. MahmoudKD,VermeerA,WildeA,FavalliV,GuttmannOP,Gallego-Delgado
.
aetiology,diagnosis,management,andtherapyofmyocarditis:apositionstate- . M, Dominguez F, Tanini I, Kubo T, Keren A, Bueser T, Waters S, Issa IF,
.
ment of the European Society of Cardiology Working Group on Myocardial . Malcolmson J, Burns T, Sekhri N, Hoeger CW, Omar RZ, Elliott PM.
.
andPericardialDiseases.EurHeartJ2013;34:2636-2648,2648a-2648d. .. International external validation study of the 2014 European Society of
918. Heymans S, Eriksson U, Lehtonen J, Cooper LT, Jr. The quest for new .. Cardiology Guidelines on Sudden Cardiac Death Prevention inHypertrophic
.
approachesinmyocarditisandinflammatorycardiomyopathy.JAmCollCardiol . Cardiomyopathy(EVIDENCE-HCM).Circulation2018;137:1015(cid:2)1023.
.
2016;68:2348(cid:2)2364. .. 930.O’MahonyC,JichiF,PavlouM,MonserratL,AnastasakisA,RapezziC,BiaginiE,
919. TschopeC,AmmiratiE,BozkurtB,CaforioALP,CooperLT,FelixSB,HareJM, .. Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM, Hypertrophic
.
HeideckerB,HeymansS,HubnerN,KelleS,KlingelK,MaatzH,ParwaniAS, . CardiomyopathyOutcomesInvestigators.Anovelclinicalriskpredictionmodel
.
Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis . forsuddencardiacdeathinhypertrophiccardiomyopathy(HCMrisk-SCD).Eur
. andinflammatorycardiomyopathy:currentevidenceandfuturedirections.Nat .. HeartJ2014;35:2010(cid:2)2020.
RevCardiol2021;18:169(cid:2)193. .. 931.BrignoleM,MoyaA,deLangeFJ,DeharoJC,ElliottPM,FanciulliA,Fedorowski
.
920. WahbiK,BenYaouR,GandjbakhchE,AnselmeF,GossiosT,LakdawalaNK, . A,FurlanR,KennyRA,MartinA,ProbstV,ReedMJ,RiceCP,SuttonR,Ungar
.
StalensC,SacherF,BabutyD,TrochuJN,MoubarakG,SavvatisK,PorcherR, . A,vanDijkJG,ESCScientificDocumentGroup.2018ESCGuidelinesforthe
.
LaforetP,FayssoilA,MarijonE,StojkovicT,BehinA,Leonard-LouisS,SoleG, .. diagnosisandmanagementofsyncope.EurHeartJ2018;39:1883(cid:2)1948.
LabombardaF,RichardP,MetayC,Quijano-RoyS,DabajI,KlugD,Vantyghem .. 932.MarcusFI,McKennaWJ,SherrillD,BassoC,BauceB,BluemkeDA,CalkinsH,
.
MC,ChevalierP,AmbrosiP,SalortE,SadoulN,WaintraubX,ChikhaouiK, . CorradoD,CoxMG,DaubertJP,FontaineG,GearK,HauerR,NavaA,Picard
.
Mabo P, Combes N, Maury P, Sellal JM, Tedrow UB, Kalman JM, Vohra J, .. MH,ProtonotariosN,SaffitzJE,SanbornDM,SteinbergJS,TandriH,ThieneG,
AndroulakisAFA,ZeppenfeldK,ThompsonT,BarneriasC,BecaneHM,Bieth .. TowbinJA,TsatsopoulouA,WichterT,ZarebaW.Diagnosisofarrhythmo-
.
E,BoccaraF,BonnetD,BouhourF,BouleS,BrehinAC,ChaponF,CintasP, . genicrightventricularcardiomyopathy/dysplasia:proposedmodificationofthe
.
Cuisset JM, Davy JM, De Sandre-Giovannoli A, Demurger F, Desguerre I, . taskforcecriteria.Circulation2010;121:1533(cid:2)1541.
.
DieterichK,DurigneuxJ,Echaniz-LagunaA,EschalierR,FerreiroA,FerrerX, .. 933.Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A,
FrancannetC,FradinM,GaboritB,GayA,HagegeA,IsapofA,JeruI,Juntas .. Asimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, Duru F,
.
Morales R, Lagrue E, Lamblin N, Lascols O, Laugel V, Lazarus A, Leturcq F, . ElliottP,HamiltonRM,HaugaaKH,JamesCA,JudgeD,LinkMS,MarchlinskiFE,
.
LevyN,MagotA,ManelV,MartinsR,MayerM,MercierS,MeuneC,Michaud . MazzantiA,MestroniL,PantazisA,PellicciaA,MarraMP,PilichouK,Platonov
.
M,Minot-MyhieMC,MuchirA,Nadaj-PaklezaA,PereonY,PetiotP,PetitF, .. PGA,ProtonotariosA,RampazzoA,SaffitzJE,SagunerAM,SchmiedC,Sharma
.
PralineJ,RollinA,SabouraudP,SarretC,SchaefferS,TaitheF,TardC,Tiffreau . S, Tandri H, Te Riele A, Thiene G, Tsatsopoulou A, Zareba W, Zorzi A,
.
V,ToutainA,VatierC,Walther-LouvierU,EymardB,CharronP,VigourouxC, . WichterT,MarcusFI,CalkinsH,InternationalExperts.Arrhythmogenicright
.
BonneG,KumarS,ElliottP,DubocD.Developmentandvalidationofanew .. ventricularcardiomyopathy:evaluationofthecurrentdiagnosticcriteriaanddif-
riskpredictionscoreforlife-threateningventriculartachyarrhythmiasinlamino- .. ferentialdiagnosis.EurHeartJ2020;41:1414(cid:2)1429.
.
pathies.Circulation2019;140:293(cid:2)302. . 934.Reichl K, Kreykes SE, Martin CM, Shenoy C. Desmoplakin variant-associated
.
921. EcheverriaLE,MarcusR,NovickG,Sosa-EstaniS,RalstonK,ZaidelEJ,Forsyth . arrhythmogenic cardiomyopathy presenting as acute myocarditis. Circ Genom
.
C,ALPRI,MendozaI,FalconiML,MitelmanJ,MorilloCA,PereiroAC,Pinazo .. PrecisMed2018;11:e002373.
MJ,SalvatellaR,MartinezF,PerelP,LiprandiAS,PineiroDJ,MolinaGR.WHF .. 935.Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D,
.
IASCroadmaponChagasdisease.GlobHeart2020;15:26. . Sanchez-Munoz JJ, Oliva-Sandoval MJ, Gimeno JR. Genetics of myocarditis in
.
922. MartinezF,PernaE,PerroneSV,LiprandiAS.Chagasdiseaseandheartfailure: .. arrhythmogenicrightventriculardysplasia.HeartRhythm2015;12:766(cid:2)773.
anexpandingissueworldwide.EurCardiol2019;14:82(cid:2)88. .. 936.PellicciaA,SolbergEE,PapadakisM,AdamiPE,BiffiA,CaselliS,LaGercheA,
.
923. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, . Niebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,
.
HungJ,JoglarJA, KantorP,Kimmelstiel C,KittlesonM,LinkMS,MaronMS, . Borjesson M, Carre F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,
.
MartinezMW,MiyakeCY,SchaffHV,SemsarianC,SorajjaP.2020AHA/ACC .. CorradoD,SinagraG,SharmaS.Recommendationsforparticipationincom-
Guidelineforthediagnosisandtreatmentofpatientswithhypertrophiccardio- .. petitiveandleisuretimesportinathleteswithcardiomyopathies,myocarditis,
.
myopathy: executive summary: a report of the American College of . and pericarditis: position statement of the Sport Cardiology Section of the
.
Cardiology/American Heart Association Joint Committee on Clinical Practice . European Association of Preventive Cardiology (EAPC). Eur Heart J .
Guidelines.Circulation2020;142:e533(cid:2)e557. .. 2019;40:19(cid:2)33.
924. Walsh R, Mazzarotto F, Whiffin N, Buchan R, Midwinter W, Wilk A, Li N, .. 937.Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, Lai A,
.
FelkinL,IngoldN,GovindR,AhmadM,MazaikaE,AlloubaM,ZhangX,de . FreseK,Pribe-WolfertsR,AmrA,LiDT,SamaniOS,CarstensenA,Bordalo
. MarvaoA,DaySM,AshleyE,ColanSD,MichelsM,PereiraAC,JacobyD,Ho .. DM,MullerM,FischerC,ShaoJ,WangJ,NieM,YuanL,HassfeldS,Schwartz
CY, Thomson KL, Watkins H, Barton PJR, Olivotto I, Cook SA, Ware JS. .. C,ZhouM,ZhouZ,ShuY,WangM,HuangK,ZengQ,ChengL,FehlmannT,
.
Quantitativeapproachestovariantclassificationincreasetheyieldandprecision . EhlermannP,KellerA,DieterichC,Streckfuss-BomekeK,LiaoY,GotthardtM, .
ofgenetictestinginMendeliandiseases:thecaseofhypertrophiccardiomyop- . Katus HA, Meder B. Clinical genetics and outcome of left ventricular non-
.
athy.GenomeMed2019;11:5. .. compactioncardiomyopathy.EurHeartJ2017;38:3449(cid:2)3460.
925. InglesJ,GoldsteinJ,ThaxtonC,CaleshuC,CortyEW,CrowleySB,Dougherty .. 938.TowbinJA,LortsA,JefferiesJL.Leftventricularnon-compactioncardiomyop-
.
K, Harrison SM, McGlaughon J, Milko LV, Morales A, Seifert BA, Strande N, . athy.Lancet2015;386:813(cid:2)825.
.
ThomsonK, Peter van Tintelen J, Wallace K, WalshR, Wells Q, WhiffinN, .. 939.TowbinJA,JefferiesJL.Cardiomyopathiesduetoleftventricularnoncompac-
WitkowskiL,SemsarianC,WareJS,HershbergerRE,FunkeB.Evaluatingthe .. tion,mitochondrialandstoragediseases,andinbornerrorsofmetabolism.Circ
.
clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med . Res2017;121:838(cid:2)854.
.
2019;12:e002460. . 940.Shen MJ, Arora R, Jalife J. Atrial myopathy. JACC Basic Transl Sci
.
926. ThomsonKL,OrmondroydE,HarperAR,DentT,McGuireK,BaksiJ,BlairE, .. 2019;4:640(cid:2)654.
BrennanP,BuchanR,BueserT,CampbellC,Carr-WhiteG,CookS,Daniels .. 941.ReddyYNV,BorlaugBA.Leftatrialmyopathyinheartfailurewithpreserved
.
M,DeeviSVV,GoodshipJ,HayesmooreJBG,HendersonA,LambT,PrasadS, . ejectionfraction.EurJHeartFail2020;22:486(cid:2)488.
.
Rayner-MatthewsP,RobertL,SneddonL,StarkH,WalshR,WareJS,Farrall . 942.ReddyYNV,ObokataM,GershBJ,BorlaugBA.Highprevalenceofoccultheart
.
M,WatkinsHC,NIHRBioResource-RareDiseasesConsortium.Analysisof .. failure with preserved ejection fraction among patients with atrial fibrillation
51 proposed hypertrophic cardiomyopathy genes from genome sequencing .. anddyspnea.Circulation2018;137:534(cid:2)535.
.
data in sarcomere negative cases has negligible diagnostic yield. Genet Med . 943.PackerM,LamCSP,LundLH,RedfieldMM.Interdependenceofatrialfibrilla-
.
2019;21:1576(cid:2)1584. .. tion and heart failure with a preserved ejection fraction reflects a common
927. TuohyCV,KaulS,SongHK,NazerB,HeitnerSB.Hypertrophiccardiomyop- .. underlyingatrialandventricularmyopathy.Circulation2020;141:4(cid:2)6.
.
athy:thefutureoftreatment.EurJHeartFail2020;22:228(cid:2)240. . 944.ToAC,FlammSD,MarwickTH,KleinAL.ClinicalutilityofmultimodalityLA
.
928. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, . imaging: assessment of size, function, and structure. JACC Cardiovasc Imaging
.
MichelsM,MagriD,AutoreC,FernandezA,OchoaJP,LeongKMW,Varnava .. 2011;4:788(cid:2)798.
AM,MonserratL,AnastasakisA,Garcia-PaviaP,RapezziC,BiaginiE,Gimeno .
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 127 ---
ESCGuidelines 3725
.
.
945. Farmakis D, MuellerC, AppleFS.High-sensitivitycardiactroponinassaysfor . substitutionindilatedcardiomyopathy:three-monthresultsfromarandomized
.
cardiovascular risk stratification in the general population. Eur Heart J . study.JAmCollCardiol2000;35:1590(cid:2)1598.
.
2020;41:4050(cid:2)4056. .. 964.BajajNS,GuptaK,GharpureN,PateM,ChopraL,KalraR,PrabhuSD.Effect
946. Westermann D, Neumann JT, Sorensen NA, Blankenberg S. High-sensitivity .. ofimmunomodulationoncardiacremodellingandoutcomesinheartfailure:a
.
assays for troponin in patients with cardiac disease. Nat Rev Cardiol . quantitativesynthesisoftheliterature.ESCHeartFail2020;7:1319(cid:2)1330.
.
2017;14:472(cid:2)483. .. 965.Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med
947. Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, .. (Lond)2018;18:s30(cid:2)s35.
.
AnkerSD,ClelandJG,DicksteinK,FilippatosG,VanderHarstP,HillegeHL, . 966.RubergFL,GroganM,HannaM,KellyJW,MaurerMS.Transthyretinamyloid
.
TerMaatenJM,MetraM,NgLL,PonikowskiP,SamaniNJ,VanVeldhuisenDJ, . cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol
.
ZwindermanAH,ZannadF,DammanK,VanderMeerP,RienstraM,Voors .. 2019;73:2872(cid:2)2891.
AA.Comparingbiomarkerprofilesofpatientswithheartfailure:atrialfibrilla- .. 967.Gonzalez-LopezE,Gallego-DelgadoM,Guzzo-MerelloG,deHaro-DelMoral
.
tionvs.sinusrhythmandreducedvs.preservedejectionfraction.EurHeartJ . FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-
.
2018;39:3867(cid:2)3875. .. Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of
948. Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, .. heartfailurewithpreservedejectionfraction.EurHeartJ2015;36:2585(cid:2)2594.
.
MockelM,HoganC,WuAH,CloptonP,FilippatosGS,AnandI,NgL,Daniels . 968.Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR,
.
LB,NeathSX,ShahK,ChristensonR,HartmannO,AnkerSD,MaiselA.Atrial . MereutaOM,TheisJD,DoganA,EdwardsWD.Impactofincidentalamyloido-
. fibrillationimpairsthediagnosticperformanceofcardiacnatriureticpeptidesin .. sisontheprognosisofpatientswithhypertrophiccardiomyopathyundergoing
dyspneicpatients:resultsfromtheBACHStudy(BiomarkersinACuteHeart .. septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol
.
Failure).JACCHeartFail2013;1:192(cid:2)199. . 2014;114:1396(cid:2)1399.
.
949. KamelH,LongstrethWT,Jr.,TirschwellDL,KronmalRA,BroderickJP,Palesch . 969.Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR,
.
YY,MeinzerC,DillonC,EwingI,SpilkerJA,DiTullioMR,HodEA,SolimanEZ, .. RobertsN,HuttDF,RowczenioDM,WhelanCJ,AshworthMA,GillmoreJD,
Chaturvedi S, Moy CS, Janis S, Elkind MS. The AtRial Cardiopathy and .. HawkinsPN,MoonJC.Occulttransthyretincardiacamyloidinseverecalcific
.
AntithromboticDrugsInpreventionAftercryptogenicstrokerandomizedtrial: . aorticstenosis:prevalenceandprognosisinpatientsundergoingsurgicalaortic
.
rationaleandmethods.IntJStroke2019;14:207(cid:2)214. .. valvereplacement.CircCardiovascImaging2016;9.
950. ZelnikerTA,BonacaMP,FurtadoRHM,MosenzonO,KuderJF,MurphySA, .. 970.CavalcanteJL, RijalS,Abdelkarim I,AlthouseAD,SharbaughMS,Fridman Y,
.
Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, . SomanP,FormanDE,SchindlerJT,GleasonTG,LeeJS,SchelbertEB.Cardiac
.
Gause-NilssonI,LangkildeAM,RazI,SabatineMS,WiviottSD.Effectofdapa- . amyloidosisisprevalentinolderpatientswithaorticstenosisandcarriesworse
.
gliflozin on atrialfibrillation in patients with type 2 diabetesmellitus:insights .. prognosis.JCardiovascMagnReson2017;19:98.
fromtheDECLARE-TIMI58trial.Circulation2020;141:1227(cid:2)1234. .. 971.CastanoA,NarotskyDL,HamidN,KhaliqueOK,MorgensternR,DeLucaA,
.
951. Global BurdenofDiseaseStudyCollaborators.Global,regional,andnational . Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R,
.
incidence,prevalence,andyearslivedwithdisabilityfor301acuteandchronic . BokhariS,MaurerMS.Unveilingtransthyretincardiacamyloidosisanditspre-
.
diseasesandinjuriesin188countries,1990-2013:asystematicanalysisforthe .. dictorsamongelderlypatientswithsevereaorticstenosisundergoingtranscath-
.
GlobalBurdenofDiseaseStudy2013.Lancet2015;386:743(cid:2)800. . eteraorticvalvereplacement.EurHeartJ2017;38:2879(cid:2)2887.
.
952. CooperLTJr,KerenA,SliwaK,MatsumoriA,MensahGA.Theglobalburden . 972.NitscheC,AschauerS,KammerlanderAA,SchneiderM,PoschnerT,DucaF,
.
ofmyocarditis:part1:asystematicliteraturereviewfortheGlobalBurdenof .. Binder C, Koschutnik M, Stiftinger J, Goliasch G, Siller-Matula J, Winter MP,
Diseases,Injuries,andRiskFactors2010study.GlobHeart2014;9:121(cid:2)129. .. Anvari-PirschA,AndreasM,GeppertA,BeitzkeD,LoeweC,HackerM,Agis
.
953. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, . H,KainR,LangI,BondermanD,HengstenbergC,MascherbauerJ.Light-chain
.
Knackstedt C, Abdul Hamid M, Seiler M, Kolb J, Hoermann P, Ensinger C, . and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence,
.
Brunner-La Rocca HP, Poelzl G, Heymans S. Immunosuppressive therapy .. screeningpossibilities,andoutcome.EurJHeartFail2020;22:1852(cid:2)1862.
improvesbothshort-andlong-termprognosisinpatientswithvirus-negative .. 973.Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I,
.
nonfulminantinflammatorycardiomyopathy.CircHeartFail2018;11:e004228. . CaforioALP,DamyT,ErikssonU,FontanaM,GillmoreJD,Gonzalez-LopezE,
.
954. AmmiratiE,FrigerioM,AdlerED,BassoC,BirnieDH,BrambattiM,Friedrich .. GroganM,HeymansS,ImazioM,KindermannI,KristenAV,MaurerMS,Merlini
MG,KlingelK,LehtonenJ,MoslehiJJ,PedrottiP,RimoldiOE,SchultheissHP, .. G,PantazisA,PankuweitS,RigopoulosAG,LinhartA.Diagnosisandtreatment
.
TschopeC,CooperLT,Jr.,CamiciPG.Managementofacutemyocarditisand . of cardiac amyloidosis. A position statement of the European Society of
.
chronic inflammatory cardiomyopathy: an expert consensus document. Circ . CardiologyWorkingGrouponMyocardialandPericardialDiseases.EurJHeart
.
HeartFail2020;13:e007405. .. Fail2021;23:512(cid:2)526.
955. GrigoratosC,DiBellaG,AquaroGD.Diagnosticandprognosticroleofcar- .. 974.Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A,
.
diacmagneticresonanceinacutemyocarditis.HeartFailRev2019;24:81(cid:2)90. . GiannoniA,AimoA,BaggianoA,Martinez-NaharroA,WhelanC,QuartaC,
.
956. FerreiraVM,Schulz-MengerJ,HolmvangG,KramerCM,CarboneI,Sechtem . PassinoC,CastiglioneV,ChubuchnyiV,SpiniV,TaddeiC,VergaroG,PetrieA, .
U,KindermannI,GutberletM,CooperLT,LiuP,FriedrichMG.Cardiovascular .. Ruiz-Guerrero L, Monivas V, Mingo-Santos S, Mirelis JG, Dominguez F,
magnetic resonance in nonischemic myocardial inflammation: expert recom- .. Gonzalez-LopezE,PerliniS,PontoneG,GillmoreJ,HawkinsPN,Garcia-Pavia
.
mendations.JAmCollCardiol2018;72:3158(cid:2)3176. . P,EmdinM,FontanaM.Multiparametricechocardiographyscoresforthediag-
. 957. BirnieDH,NeryPB,HaAC,BeanlandsRS.Cardiacsarcoidosis.JAmCollCardiol .. nosisofcardiacamyloidosis.JACCCardiovascImaging2020;13:909(cid:2)920.
2016;68:411(cid:2)421. .. 975.Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A,
.
958. BangV,GanatraS,ShahSP,DaniSS,NeilanTG,ThavendiranathanP,ResnicFS, . Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, .
PiemonteTC,BaracA,PatelR,SharmaA,ParikhR,ChaudhryGM,VeselyM, . Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M,
.
Hayek SS, Leja M, Venesy D, Patten R, Lenihan D, Nohria A, Cooper LT. .. PalladiniG,MilaniP,GuidalottiPL,FlatmanK,LaneT,VonbergFW,WhelanCJ,
Managementofpatientswithgiantcellmyocarditis:JACCreviewtopicofthe .. MoonJC,RubergFL,MillerEJ,HuttDF,HazenbergBP,RapezziC,HawkinsPN.
.
week.JAmCollCardiol2021;77:1122(cid:2)1134. . Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation
.
959. Sinagra G, PorcariA, Gentile P, ArticoJ, Fabris E, Bussani R,Merlo M.Viral .. 2016;133:2404(cid:2)2412.
presence-guidedimmunomodulationinlymphocyticmyocarditis:anupdate.Eur .. 976.ZhaoL,TianZ,FangQ.Diagnosticaccuracyofcardiovascularmagneticreso-
.
JHeartFail2021;23:211(cid:2)216. . nanceforpatientswithsuspectedcardiacamyloidosis:asystematicreviewand
.
960. Gannon MP, Schaub E, Grines CL, Saba SG. State of the art: evaluation and . meta-analysis.BMCCardiovascDisord2016;16:129.
.
prognostication of myocarditis using cardiac MRI. J Magn Reson Imaging .. 977.Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D,
2019;49:e122(cid:2)e131. .. MaurerMS.Pressure-volumerelationshipsinpatientswithtransthyretin(ATTR)
.
961. Maisch B, Hufnagel G, Kolsch S, Funck R, Richter A, Rupp H, Herzum M, . cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin:
.
PankuweitS.Treatmentofinflammatorydilatedcardiomyopathyand(peri)myocar- . TransthyretinCardiacAmyloidStudy(TRACS).CircHeartFail2011;4:121(cid:2)128.
.
ditiswithimmunosuppressionandi.v.immunoglobulins.Herz2004;29:624(cid:2)636. .. 978.CheungCC,RostonTM,AndradeJG,BennettMT,DavisMK.Arrhythmiasin
962. KociolRD,CooperLT,FangJC,MoslehiJJ,PangPS,SabeMA,ShahRV,Sims .. cardiacamyloidosis:challengesinriskstratificationandtreatment.CanJCardiol
.
DB, Thiene G, Vardeny O, American Heart Association Heart Failure . 2020;36:416(cid:2)423.
.
TransplantationCommitteeoftheCouncilonClinicalCardiology.Recognition .. 979.MaurerMS,SchwartzJH,GundapaneniB,ElliottPM,MerliniG,Waddington-
andinitialmanagementoffulminantmyocarditis:ascientificstatementfromthe .. CruzM,KristenAV,GroganM,WittelesR,DamyT,DrachmanBM,ShahSJ,
.
AmericanHeartAssociation.Circulation2020;141:e69(cid:2)e92. . HannaM,JudgeDP,BarsdorfAI,HuberP,PattersonTA,RileyS,SchumacherJ,
.
963. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, . Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators. Tafamidis
.
MorgeraS,NeumayerHH,WerneckeKD,WallukatG,StanglK,BaumannG. .. treatmentforpatientswithtransthyretinamyloidcardiomyopathy.NEnglJMed
Hemodynamic effects of immunoadsorption and subsequent immunoglobulin . 2018;379:1007(cid:2)1016.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
--- Страница 128 ---
3726 ESCGuidelines
.
.
980. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, . 992. AppaduraiV,ThoreauJ,MalpasT,NicolaeM.Sacubitril/valsartaninadultcon-
.
PattersonTA,RileyS,SchwartzJH,SultanMB,WittelesR.Efficacyandsafety .. genitalheartdiseasepatientswithchronicheartfailure–asinglecentrecase
of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical .. seriesandcallforaninternationalregistry.HeartLungCirc2020;29:137(cid:2)141.
.
Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail . 993. MaurerSJ,PujolSalvadorC,SchieleS,HagerA,EwertP,TutarelO.Sacubitril/
.
2021;23:277(cid:2)285. .. valsartanforheartfailureinadultswithcomplexcongenitalheartdisease.IntJ
981.SolomonSD,AdamsD,KristenA,GroganM,Gonzalez-DuarteA,MaurerMS, .. Cardiol2020;300:137(cid:2)140.
MerliniG,DamyT,SlamaMS,BrannaganTH,3rd,DispenzieriA,BerkJL,Shah .. 994. VanDeBruaeneA,MeierL,DroogneW,DeMeesterP,TroostE,GewilligM,
.
AM,GargP,VaishnawA,KarstenV,ChenJ,GollobJ,VestJ,SuhrO.Effectsof . BudtsW.Managementofacuteheartfailureinadultpatientswithcongenital
.
patisiran,anRNAinterferencetherapeutic,oncardiacparametersinpatientswith .. heartdisease.HeartFailRev2018;23:1(cid:2)14.
hereditarytransthyretin-mediatedamyloidosis.Circulation2019;139:431(cid:2)443. .. 995. MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.Qualityofcarein
.
982. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, . the United Kingdom after removal of financial incentives. N Engl J Med
.
Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, . 2018;379:948(cid:2)957.
.
AdamsD.Efficacyandsafetyofpatisiranforfamilialamyloidoticpolyneurop- .. 996. SongZ,JiY,SafranDG,ChernewME.Healthcarespending,utilization,and
athy:aphaseIImulti-dosestudy.OrphanetJRareDis2015;10:109. .. quality8yearsintoglobalpayment.NEnglJMed2019;381:252(cid:2)263.
.
983. RosenblumH,CastanoA,AlvarezJ,GoldsmithJ,HelmkeS,MaurerMS.TTR . 997. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P,
.
(transthyretin)stabilizersareassociatedwithimprovedsurvivalinpatientswith .. Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of
TTRcardiacamyloidosis.CircHeartFail2018;11:e004769. .. Cardiology methodology for the development of quality indicators for the
.
984. KremastinosDT,FarmakisD.Ironoverloadcardiomyopathyinclinicalpractice. . quantificationofcardiovascularcareandoutcomes.EurHeartJQualCareClin
.
Circulation2011;124:2253(cid:2)2263. . Outcomes2020.doi:10.1093/ehjqcco/qcaa069.
.
985. FarmakisD,TriposkiadisF,LekakisJ,ParissisJ.Heartfailureinhaemoglobinopa- .. 998. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT,
thies: pathophysiology, clinical phenotypes, and management. Eur J Heart Fail .. HindricksG,KusumotoFM,LaneDA,LauDH,LettinoM,LipGYH,Lobban
. 2017;19:479(cid:2)489. . T,PakHN,PotparaT,SaenzLC,VanGelderIC,VarosyP,GaleCP,Dagres
.
986. AessoposA,FarmakisD,DeftereosS,TsironiM,TassiopoulosS,MoyssakisI, . N, Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R,
.
KaragiorgaM.Thalassemiaheartdisease:acomparativeevaluationofthalasse- .. ProvidenciaR,GuerraJM,TakahashiY,PisaniC,NavaS,SarkozyA,Glotzer
miamajorandthalassemiaintermedia.Chest2005;127:1523(cid:2)1530. .. TV,MartinsOliveiraM.Qualityindicatorsforthecareandoutcomesofadults
.
987. FarmakisD,AessoposA.Pulmonaryhypertensionassociatedwithhemoglobi- . withatrialfibrillation.Europace2021;23:494(cid:2)495.
.
nopathies:prevalentbutoverlooked.Circulation2011;123:1227(cid:2)1232. .. 999. SchieleF,AktaaS,RosselloX,AhrensI,ClaeysMJ,ColletJP,FoxKAA,Gale
988. BaumgartnerH,DeBackerJ,Babu-NarayanSV,BudtsW,ChessaM,DillerGP, .. CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M,
.
LungB,KluinJ,LangIM,MeijboomF,MoonsP,MulderBJM,OechslinE,Roos- . MasoudiFA,PriceS,QuinnT,SwahnE,ThieleH,TimmisA,TubaroM,Vrints
.
Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K, ESC Scientific . CJM, Walker D, Bueno H, Scientific Document Group ESC, Halvorsen S,
.
DocumentGroup.2020ESCGuidelinesforthemanagementofadultcongeni- .. JernbergT,JortveitJ,BlondalM,IbanezB,HassagerC.2020Updateofthe
talheartdisease.EurHeartJ2021;42:563(cid:2)645. .. quality indicators for acute myocardial infarction: a position paper of the
.
989. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, Babu- . AssociationforAcuteCardiovascularCare:thestudygroupforqualityindica-
.
NarayanS,WortSJ,DimopoulosK,GatzoulisMA.Survivalprospectsandcir- . torsfromtheACVC andtheNSTE-ACSguidelinegroup.EurHeartJAcute
.
cumstancesof deathin contemporary adult congenital heart disease patients .. CardiovascCare2021;10:224(cid:2)233.
.
underfollow-upatalargetertiarycentre.Circulation2015;132:2118(cid:2)2125. . 1000.ColletJP,ThieleH,BarbatoE,BarthelemyO,BauersachsJ,BhattDL,DendaleP,
.
990. Budts W, Roos-Hesselink J, Radle-Hurst T, Eicken A, McDonagh TA, . Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P,
.
LambrinouE,Crespo-LeiroMG,WalkerF,FrogoudakiAA.Treatmentofheart .. LambrinouE,LewisBS,MehilliJ,MeligaE,MerkelyB,MuellerC,RoffiM,Rutten
failureinadultcongenitalheartdisease:apositionpaperoftheWorkingGroup .. FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC
.
ofGrown-UpCongenitalHeartDiseaseandtheHeartFailureAssociationof . Guidelinesforthemanagementofacutecoronarysyndromesinpatientspresent-
.
theEuropeanSocietyofCardiology.EurHeartJ2016;37:1419(cid:2)1427. . ingwithoutpersistentST-segmentelevation.EurHeartJ2021;42:1289(cid:2)1367.
.
991. LluriG,LinJ,ReardonL,MinerP,WhalenK,Aboulhosn J.Earlyexperience .. 1001.WallentinL,GaleCP,MaggioniA,BardinetI,CasadeiB.EuroHeart:European
withsacubitril/valsartaninadultpatientswithcongenitalheartdisease.WorldJ .. UnifiedRegistriesOnHeartCareEvaluationandRandomizedTrials.EurHeart
.
PediatrCongenitHeartSurg2019;10:292(cid:2)295. J2019;40:2745(cid:2)2749.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
by
guest
on
22
January
2026
